<SEC-DOCUMENT>0001178913-21-000909.txt : 20210304
<SEC-HEADER>0001178913-21-000909.hdr.sgml : 20210304
<ACCEPTANCE-DATETIME>20210304074254
ACCESSION NUMBER:		0001178913-21-000909
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210304
DATE AS OF CHANGE:		20210304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sol-Gel Technologies Ltd.
		CENTRAL INDEX KEY:			0001684693
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38367
		FILM NUMBER:		21712593

	BUSINESS ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
		BUSINESS PHONE:		97289313433

	MAIL ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>zk2125664.htm
<DESCRIPTION>20-F
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="font-family: 'Times New Roman',Times,serif;" id="DSPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 20-F</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1333458b38249868555d75f46cdc044">

          <tr>
            <td style="width: 0pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#9744;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">OR</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z833bc3991d514be8a8a8ec174802f0ca">

          <tr>
            <td style="width: 0pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#9746;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
              <div>
                <div style="line-height: 1.25;">For the fiscal year ended December 31, 2020</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">OR</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5ca0d91410a747088d2fba15087af50a">

          <tr>
            <td style="width: 0pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#9744;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">OR</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z176de6e99f6f4f9d9a9eba5fdaeaa42d">

          <tr>
            <td style="width: 0pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 28.35pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#9744;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: -28.35pt; margin-left: 28.35pt; line-height: 1.25;">Date of event requiring this shell company report ________________</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Commission file number 001-38367</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="77" height="43" src="image00001.jpg"></div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0ba4fa95f2544201ab2219a4fb5eb230">

          <tr>
            <td style="width: 10.13%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.76%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Sol-Gel Technologies Ltd.</div>
            </td>
            <td style="width: 10.12%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.13%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.76%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">(Exact name of Registrant as specified in its charter)</div>
            </td>
            <td style="width: 10.12%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.13%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.76%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 10.12%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.13%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.76%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">N/A</div>
            </td>
            <td style="width: 10.12%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.13%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.76%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">(Translation of Registrant&#8217;s name into English)</div>
            </td>
            <td style="width: 10.12%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.13%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.76%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 10.12%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.13%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.76%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">Israel</div>
            </td>
            <td style="width: 10.12%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.13%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 79.76%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">(Jurisdiction of incorporation or organization)</div>
            </td>
            <td style="width: 10.12%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z9410953329414786b5e658ec9b38fe2d">

          <tr>
            <td style="width: 100%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">(Address of principal executive offices)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">Gilad Mamlok, Chief Financial Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">Tel: 972-8-9313429; Fax: 972-153-523044444</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Securities registered or to be registered pursuant to Section 12(b) of the Act.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zab310b9d70054ef69e182a2eeedb4381">

          <tr>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">Title of each class</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">Trading Symbol(s)&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">Name of each exchange on which registered</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">Ordinary Shares, par value NIS 0.1 per share</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">SLGL</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">The Nasdaq Stock Market LLC</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; line-height: 1.25;">Securities registered or to be registered pursuant to Section 12(g) of the Act:</div>
      <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc0d624d83a074534bcef07707907f267">

          <tr>
            <td style="width: 100%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">None</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">(Title of Class)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:</div>
      <div style="line-height: 1.25;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8a782e3c9b944248970846ff0e44c811">

          <tr>
            <td style="width: 100%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; line-height: 1.25;">None</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">(Title of Class)</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: 23,000,782 Ordinary
        Shares, par value NIS 0.1 per share,</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25;">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No &#9746;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities
        Exchange Act 1934.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No &#9746;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
        months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Yes &#9746; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No &#9744;</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;&#160; Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
        (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Yes &#9746; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No &#9744;</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &#8220;accelerated filer and large
        accelerated filer&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z40045ad673724de2879fcc51dc7fd354">

          <tr>
            <td style="width: 33%; vertical-align: middle;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">Large Accelerated filer &#9744;</div>
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 33%; vertical-align: middle;">
              <div style="text-align: center; line-height: 1.25;">Accelerated filer &#9744;</div>
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 33%; vertical-align: middle;">
              <div style="line-height: 1.25;">Non-accelerated filer &#9746;</div>
              <div style="line-height: 1.25;">Emerging growth company &#9746;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
        complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant has fi led a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section
        404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#9744;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">U.S. GAAP &#9746;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">International Financing Reporting Standards as issued by the International Accounting Standards Board &#9744;&#160; Other &#9744;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Item 17 &#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18 &#9744;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No &#9746;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z71fab7eece144c308f56e4e70427ad59">

          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM1">ITEM 1.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM1">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">6<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM2">ITEM 2.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM2">OFFER STATISTICS AND EXPECTED TIMETABLE</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">6<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM3">ITEM 3.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM3">KEY INFORMATION</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">6<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM4">ITEM 4.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM4">INFORMATION ON THE COMPANY</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">54<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM4A">ITEM 4A.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM4A">UNRESOLVED STAFF COMMENTS</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">87<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM5">ITEM 5.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM5">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">87<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM6">ITEM 6.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM6">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">97<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM7">ITEM 7.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM7">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">119<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM8">ITEM 8.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM8">FINANCIAL INFORMATION</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">122<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM9">ITEM 9.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM9">THE OFFER AND LISTING</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">122<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM10">ITEM 10.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM10">ADDITIONAL INFORMATION</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">123<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM11">ITEM 11.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM11">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">141<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM12">ITEM 12.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM12">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">142<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM13">ITEM 13.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM13">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">142<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM14">ITEM 14.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM14">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">142<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM15">ITEM 15.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM15">CONTROLS AND PROCEDURES</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">143<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16">ITEM 16.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16">[RESERVED]</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">144<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16A">ITEM 16A.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16A">AUDIT COMMITTEE FINANCIAL EXPERT</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">144<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16B">ITEM 16B.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16B">CODE OF ETHICS</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">144<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16C">ITEM 16C.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16C">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">145<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16D">ITEM 16D.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16D">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES.</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">145<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16E">ITEM 16E.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16E">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS.</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">145<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16F">ITEM 16F.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16F">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT.</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">145<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16G">ITEM 16G.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16G">CORPORATE GOVERNANCE</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">145<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16H">ITEM 16H.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM16H">MINE SAFETY DISCLOSURE</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">146<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM17">ITEM 17.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM17">FINANCIAL STATEMENTS</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">146<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM18">ITEM 18.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM18">FINANCIAL STATEMENTS</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">146<br>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM19">ITEM 19.</a></div>
            </td>
            <td style="width: 85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#ITEM19">EXHIBITS</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">146<br>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="#EXHIBITINDEX">EXHIBIT INDEX</a></div>
            </td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: right;">147<br>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">INTRODUCTION</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All references to &#8220;Sol-Gel,&#8221; &#8220;Sol-Gel Technologies,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; and similar designations refer to Sol-Gel Technologies Ltd. The terms &#8220;shekels,&#8221; &#8220;Israeli
        shekels&#8221; and &#8220;NIS&#8221; refer to New Israeli Shekels, the lawful currency of the State of Israel, the terms &#8220;dollar,&#8221; &#8220;US$&#8221; or &#8220;$&#8221; refer to U.S. dollars, the lawful currency of the United States. Unless derived from our financial statements or otherwise
        indicated, U.S. dollar translations of NIS amounts presented in this annual report are translated using the rate of NIS 3.215, NIS 3.456 and NIS 3.748 to $1.00, based on the exchange rates reported by the Bank of Israel on December 31, 2020,
        December&#160;31, 2019 and December&#160;31, 2018, respectively.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">
        <div style="text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">All references to the term &#8220;branded product candidates&#8221; refers to Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, a novel, once-daily, non-antibiotic topical cream that we are developing for the
          treatment of acne vulgaris, or acne; Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, a novel, once-daily topical cream containing encapsulated benzoyl peroxide that we are developing for the treatment of papulopustular (subtype II) rosacea; SGT-210 (erlotinib gel) that we
          are developing for the treatment of palmoplantar keratoderma, or PPK; erlotinib, an epidermal growth factor receptor inhibitor; tapinarof, an investigational aryl hydrocarbon receptor modulator; and roflumilast, an investigational
          phosphodiesterase 4 inhibitor. Erlotinib, tapinarof, and roflumilast are each a potential treatment of various pharmaceutical indications. All references to the term &#8220;product candidates&#8221; include both branded product candidate and generic product
          candidates.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Solely for convenience, the trademarks, service marks, and trade names referred to in this annual report are without the &#174; and &#8482; symbols, but such references are not intended to
        indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This annual report contains additional trademarks,
        service marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this annual report are, to our knowledge, the property of their respective owners. We do not
        intend our use or display of other companies&#8217; trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This annual report includes statistics and other data relating to markets, market sizes and other industry data pertaining to our business that we have obtained from industry
        publications and surveys and other information available to us. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Market data and statistics are
        inherently predictive and speculative and are not necessarily reflective of actual market conditions. Such statistics are based on market research, which itself is based on sampling and subjective judgments by both the researchers and the
        respondents, including judgments about what types of products and transactions should be included in the relevant market. In addition, the value of comparisons of statistics for different markets is limited by many factors, including that (i)&#160;the
        markets are defined differently, (ii) the underlying information was gathered by different methods, and (iii) different assumptions were applied in compiling the data. Accordingly, the market statistics included in this annual report should be
        viewed with caution. We believe that information from these industry publications included in this annual report is reliable.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We make forward-looking statements in this annual report that are subject to risks and uncertainties. These forward-looking statements include information about possible or
        assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221;
        &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management&#8217;s
        good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.
        Important factors that could cause such differences include, but are not limited to:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd05d48cb2c145f6be423f69c7cf3ea3">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze7b5f8c6e2d44d3caac2b52bee3bdbcc">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our ability to complete the development of, and obtain market approval for, our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc734fa590dab4ec286a55dff86350517">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our ability to find suitable co-development, contract manufacturing and marketing partners;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93ac4b491d5e41628c8dc30bacc128ae">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our ability to obtain and maintain regulatory approvals for our product candidates in our target markets and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is
                obtained;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zff83901f7bb14ae89f62a1f6d22de000">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our ability to commercialize and launch our pharmaceutical product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z21148e1fc35e424194c75c2783280b67">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our ability to obtain and maintain adequate protection of our intellectual property;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z179f19e4a30a44be972997d6ec87c776">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z14f18e2af9dc4761a7edf2d4d1f58a64">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our ability to establish adequate sales, marketing and distribution channels;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7023d11864bc4b56b5c565f56c1acff2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>acceptance of our product candidates by healthcare professionals and patients;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9fb8a1e9bca44b66aeef735c384aed8e">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the possibility that we may face third-party claims of intellectual property infringement;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1085a59688624a56b1ef6dcb3c2c7704">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9e03012a1bde45c29944cab79e495386">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than
                we do;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6c525aa74a8e4bba8955f76132f44896">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>potential product liability claims;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z84b52097a36b414bb2e56a616f87750a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>potential adverse federal, state and local government regulation in the United States, Europe or Israel;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7d29fbdfa5ec47d5a90388263272bf18">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the impact of pandemics such as Novel Coronavirus Disease 2019, or COVID-19, on our business and financial condition; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb47b0c9e290547b4a93169b2d8de68d2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>loss or retirement of key executives and research scientists.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in this annual report for a discussion of these and other risks that relate to our business and
        investing in our ordinary shares. The forward-looking statements contained in this annual report are expressly qualified in their entirety by this cautionary statement. Except as required by law, we undertake no obligation to update publicly any
        forward-looking statements after the date of this annual report to conform these statements to actual results or to changes in our expectations.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;"><a name="ITEM1"><!--Anchor--></a>ITEM 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">ITEM 2<a name="ITEM2"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;OFFER STATISTICS AND EXPECTED TIMETABLE</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">ITEM 3<a name="ITEM3"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;KEY INFORMATION</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Selected Financial Data </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth our selected historical financial data, which is derived from our audited financial statements, which have been prepared in accordance with U.S.
        GAAP. The selected consolidated balance sheet data as of December&#160;31, 2019 and 2020 and our selected statement of operations data for the years ended December&#160;31, 2018, 2019 and 2020 is derived from our audited consolidated financial statements
        included elsewhere in this annual report. The selected balance sheet data as of December 31, 2016, December 31, 2017 and December 31, 2018 and our selected statement of operations data for the years ended December&#160;31, 2016 and December 31, 2017
        have been derived from our audited financial statements not included in this annual report. Our historical results are not necessarily indicative of the results that should be expected in the future. You should read this selected financial data in
        conjunction with, and it is qualified in its entirety by, our historical financial information and other information provided in this annual report including &#8220;Item&#160;5. Operating and Financial Review and Prospects&#8221; and our audited consolidated
        financial statements and related notes appearing elsewhere in this annual report.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z55893dbf3c6e4bc88a60fbc169b9966e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="18" style="vertical-align: top; font-family: &#38;amp;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year Ended December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-weight: bold;"> 2016</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-weight: bold;">2017</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-weight: bold;">2018</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-weight: bold;"> 2019</div>
            </td>
            <td nowrap="nowrap" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-weight: bold;"> 2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="18" style="vertical-align: top; font-family: &#38;amp;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(in thousands, except share and per share data)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Statement of Operations Data:</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="line-height: 1.25;">Collaboration Revenues&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">174</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">129</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">22,904</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">8,771</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 40%;">
              <div style="line-height: 1.25;">Research and development expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">17,023</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">25,805</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">28,146</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">40,578</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">27,913</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="line-height: 1.25;">General and administrative expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">3,773</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">6,002</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">5,504</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">8,276</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">11,091</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 40%;">
              <div style="line-height: 1.25;">Total operating loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">20,756</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">31,633</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">33,521</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">25,950</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">30,233</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="line-height: 1.25;">Financial expenses (income), net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">15</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(65</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(1,318</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(1,374</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(943</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Loss before income taxes</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">20,771</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">31,568</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">32,203</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">24,576</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">29,290</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="line-height: 1.25;">Income taxes</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">33</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Loss for the year&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">20,771</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">31,568</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">32,203</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">24,609</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">29,290</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="line-height: 1.25;">Basic and diluted loss per ordinary share*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">3.30</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">5.02</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">1.80</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">1.26</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">1.3</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Weighted average number of ordinary shares outstanding&#8201;&#8211;&#8201;basic and diluted*</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">3,494,579</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">6,290,244</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">17,867,589</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">19,534,562</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">22,574,688</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">* On January 19, 2018, we effected a 1-for-1.8 share split of our ordinary shares by way of an issuance of bonus shares. Unless otherwise indicated, except for our authorized capital, all information in this annual
        report relating to the number of our ordinary shares and loss per ordinary share in this annual report have been adjusted, on a retroactive basis, to reflect this 1-for-1.8 share split.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z4b4259b83c18431f99d01d9fbbe51df7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; font-family: &#38;amp;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="10" style="vertical-align: top; font-family: &#38;amp;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">As of December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; font-family: &#38;amp;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2016</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2017</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2018</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2019</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp;">
              <div style="line-height: 1.25; font-weight: bold;">Balance Sheet Data:</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; font-family: &#38;amp;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="10" style="vertical-align: bottom; font-family: &#38;amp;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(in thousands)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: top; font-family: &#38;amp;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 40%;">
              <div style="line-height: 1.25;">Cash and cash equivalents&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">7,001</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">5,024</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">5,325</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">9,412</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">7,122</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="line-height: 1.25;">Total Assets&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">10,985</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">15,315</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">69,682</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">61,301</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">59,161</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 40%;">
              <div style="line-height: 1.25;">Total liabilities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">42,322</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">68,014</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">5,773</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">8,836</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">8,312</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="line-height: 1.25;">Accumulated deficit&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(63,693</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(95,261</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(127,464</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(152,073</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(181,363</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 40%;">
              <div style="line-height: 1.25;">Total shareholders&#8217; equity (capital deficiency)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(31,337</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(52,699</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">63,909</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">52,465</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">50,849</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-weight: bold;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capitalization and Indebtedness</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><font style="font-weight: bold;">C</font><font style="font-family: 'Times New Roman',Times,serif;">.<font style="font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reasons for the Offer and Use of Proceeds</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Risk Factors</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">You should carefully consider the risks we describe below, in addition to the other information set forth elsewhere in this annual report, including our
        financial statements and the related notes beginning on page F-1, before deciding to invest in our ordinary shares, or the &#8220;Ordinary Shares. The risks and uncertainties described below in this annual report on Form/ 20-F for the year ended December
        31, 2020 are not the only risks facing us. We may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial. Any of the risks described below or incorporated by reference in this Form 20-F, and any
        such additional risks, could materially adversely affect our business, financial condition or results of operations. In such case, you may lose all or part of your investment.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Summary of Risk Factors</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following is a summary of some of the principal risks we face. The list below is not exhaustive, and investors should read this &#8220;Risk factors&#8221; section in full.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z31fca747efca44f08641b993cc82ed98">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>We are a clinical-stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze63b0845fb5546228794285d5e5b882e">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>We have a limited operating history in the dermatological prescription drug space which may make it difficult to evaluate the success of our business to date and to assess our future viability.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc7a63e0c746747eba034723d8750ff20">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>We may need substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy. If we are
                successful in raising additional capital, this may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb213849b295a482db026b0ffa0111652">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>We are largely dependent on the success of our branded product candidates for the treatment of topical dermatological conditions.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z40fc2d28361845f0a5bcc6da7d3baf22">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>We currently have limited marketing capabilities. If we are unable to establish adequate sales and marketing capabilities through third parties<font style="font-weight: bold; font-style: italic;">&#160;</font>we may be required to establish
                sales and marketing capabilities on our own, or we may be unable to successfully commercialize Twyneo&#174;, Epsolay&#174; or any other of our other product candidates, if approved, or generate product revenues.&#160; In addition, establishing our own
                sales and marketing capabilities would significantly increase our expenses and require us to raise additional capital sooner that an anticipated<font style="font-weight: bold; font-style: italic;">.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zadf7c6dc1ba945378c24d40c093e17b7">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>We have not obtained regulatory approval for most of our product candidates in the United States or any other country.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e6adc1ce91b4220ae1817280f278ceb">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Our continued growth is dependent on our ability to successfully develop and commercialize new product candidates in a timely manner. We expend a significant amount of resources on research and development efforts that may not lead to
                successful product candidate introductions or the recovery of our research and development expenditures.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za8cb2cc737ce41ef8f64216a377429f0">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and clinical trials may not be predictive of future trial results, which could result in development delays or a
                failure to obtain marketing approval.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zde0ca995063949b2b1e4142ec8660344">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our
                business will be substantially harmed.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5b4f31f6751a4b289d1129950c6fad46">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon product candidates, limit the commercial profile of an
                approved label, or result in significant negative consequences following marketing approval, if any, such as the risk of product liability claims.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z056482143e4d409f9f333463acebb8c4">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Even if our branded product candidates or our other product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and market acceptance necessary for commercial success.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z10646300308a498c94f593001350f3e3">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Our product candidates, if approved, will face significant competition and our failure to compete effectively may prevent us from achieving significant market penetration and expansion.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfd91f46a30444482bb113ba993eecdb1">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>The ongoing COVID-19 pandemic may adversely affect our business, revenues, results of operations and financial condition.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3bf500585dbd4c89918d89c5cec0469b">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Any collaborative arrangements that we have or may establish in the future may not be successful or we may otherwise not realize the anticipated benefits from these collaborations.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z76dc23c2f63841349af988c2e700af53">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>We rely on third parties and consultants to assist us in conducting our clinical trials. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain
                regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb00e58667ff34ba7906717c2bdc5ed27">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>The manufacture of pharmaceutical products is complex, and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter any difficulties, our ability to provide product candidates for
                clinical trials or our product candidates to patients, once approved, and the development or commercialization of our product candidates could be delayed or stopped.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb094f58692d749b7bd1588470f2bc03a">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>We depend on our intellectual property, and our future success is dependent on our ability to protect our intellectual property and not infringe on the rights of others.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1d682a91b09e4082a461693a49333208">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>If we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6658a223d009437f981de2fc2e6a0612">

          <tr>
            <td style="width: 18.1pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>If we are not able to retain our key management, or attract and retain qualified scientific, technical and business personnel, our ability to implement our business plan may be adversely affected.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Risks Related to Our Business and Industry</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">We are a clinical-stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain
        profitability.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are a clinical-stage dermatology company with a limited operating history. We have incurred net losses since our formation in 1997. In particular, we incurred net losses
        of&#8201;$32.2 million in 2018, $24.6&#160;million in 2019, and $29.3 million in 2020. As of December 31, 2020, we had an accumulated deficit of $181.4 million. Our losses have resulted principally from expenses incurred in research and development of our
        product candidates and from general and administrative expenses that we have incurred while building our business infrastructure. We expect to continue to incur net losses for the foreseeable future as we continue to invest in research and
        development and seek to obtain regulatory approval and commercialization of our product candidates. The extent of our future operating losses and the timing of generating revenues and becoming profitable are highly uncertain, and we may never
        achieve or sustain profitability. We anticipate that our expenses will increase substantially as we:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z55887667a2f14799892e2d596e8b0fbd">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>seek marketing approval and conduct pre-commercialization and launch activities for Twyneo&#174; and Epsolay&#174;;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z113d9cc5310c4ae08428547d2b68a06a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>
                <div style="font-family: 'Times New Roman', Times, serif;">conduct Phase I proof of concept clinical studies of SGT-210, and continue the research and development of erlotinib, an epidermal growth factor receptor inhibitor, tapinarof, an
                  investigational aryl hydrocarbon receptor modulator, and roflumilast, an investigational phosphodiesterase 4 inhibitor, and other future branded product candidates;</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4cbdef0965d94179a1eec67b351a67aa">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>seek regulatory approvals for any product candidate that successfully completes clinical development;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze85b2f372a3349b5b7f1ce60a08f71c8">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>establish commercial manufacturing capabilities through one or more contract manufacturing organizations to commercialize any product candidates for which we may obtain regulatory approval;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5dc22b13059147c09298cdfcd094d2b6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>continue the development, bioequivalence and other studies required for abbreviated new drug application, or ANDA, submissions for our generic product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3854f079858a47fc8930c23b6819e821">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>seek to enhance our technology platform;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1ac2ed93496d47b4a6a3eac099f95679">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>maintain, expand and protect our intellectual property portfolio;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z71fb324b0c1e4ad8a3ffef93b0d17b90">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>seek new drug candidates and expand our disease portfolio;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf03de6f578094a1a8cf15ce65b265fba">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z90f075ab10844e1e8ccfe4eeb9541065">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have financed our operations primarily through public offerings in the U.S., private placements of equity securities and investments and loans from our controlling
        shareholder. To date, we have devoted a significant portion of our financial resources and efforts to developing the first generic version of Zovirax<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;(acyclovir) cream, 5%,&#160; developing our product candidates and conducting pre-clinical
        studies and our clinical trials for Twyneo&#174;, Epsolay&#174;, ivermectin cream, 1% and 5-fluorouracil cream, 5%. Although we are anticipating decisions from the U.S. Food and Drug Administration, or FDA, with respect to our marketing applications for
        Twyneo&#174;, Epsolay&#174; in 2021,&#160; and we are expected to launch an additional generic product in 2021 in addition to the first generic version of Zovirax<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#160;(acyclovir) cream&#160;. To become and remain profitable, we must succeed in developing and
        eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing pre-clinical studies and clinical trials for our product candidates,
        discovering and developing additional product candidates, obtaining regulatory approval for any product candidates that successfully complete clinical trials, establishing manufacturing and marketing capabilities and ultimately selling any product
        candidates for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve
        profitability.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Because of the numerous risks and uncertainties associated with pharmaceutical products, we are unable to accurately predict the timing or amount of increased expenses or when,
        or if, we will be able to achieve profitability. If we are required by the FDA or other regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials, our
        expenses could increase and revenue could be further delayed.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Even if we do generate revenue from product sales or product royalties, we may never achieve or sustain profitability on a quarterly or annual basis. Our failure to sustain
        profitability would depress the market price of our ordinary shares and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of our ordinary shares
        also could cause you to lose all or a part of your investment.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We may need substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our
        planned operations and the pursuit of our growth strategy.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Conducting pre-clinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary
        data or results required to obtain regulatory approval and achieve product sales. We expect to continue to incur significant expenses and operating losses over the next several years as we seek marketing approval and conduct pre-commercialization
        and launch activities for Twyneo&#174; and Epsolay&#174;, conduct Phase I proof of concept clinical studies of SGT-210 and advance erlotinib, tapinarof, roflumilast and our other product candidates. In addition, our product candidates, if approved, may not
        achieve commercial success. Substantial revenue, if any, will be derived from sales of products that are not yet, and may never be, commercially available. We have based this estimate on assumptions that may prove to be wrong, and we could use our
        capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7a81d72e78084578bf9a483191417a86">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the timing and success for obtaining marketing approval for Twyneo&#174; and Epsolay&#174;;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6a9c6c79d2e64049a340b4a109fa9f2c">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the progress and results of our development activities for SGT-210, erlotinib, tapinarof and roflumilast;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb36f9e5de26a4d38a406ee957e38fd1b">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the scope, progress, results and costs of development, laboratory testing and clinical trials for our generic product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z76275f4f79624bb8b0f8a28d8f26ea7e">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the cost of manufacturing clinical supplies and exhibition batches of our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zea57c6eae1154eb1b66cd5ad74ce770e">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the costs, timing and outcome of regulatory reviews of any of our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4879fb9c810249f7bd45b2be480ce668">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z67bf5d16f91d43d99a48922dc878c8e6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims by third parties that we are infringing upon
                their intellectual property rights;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z25d8aecadadb4d3ca6709e19bba2b093">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the amount of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd491f934e2ee477bb6a80f278291a4c2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the extent to which we acquire or invest in businesses, product candidates and technologies, including entering into licensing or collaboration arrangements for any of our product candidates.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In order to continue our future operations, we will need to raise additional capital until becoming profitable.&#160; If we are unable to raise sufficient additional capital, we could
        be forced to curtail our planned operations and the pursuit of our growth strategy.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We are largely dependent on the success of our branded product candidates for the treatment of topical dermatological conditions.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">We have invested a majority of our efforts and financial resources in the research and development of Twyneo&#174; for the treatment of acne and Epsolay&#174; for the treatment of papulopustular (subtype
          II) rosacea. If Twyneo&#174; and Epsolay&#174; receive regulatory approval from the FDA, we intend to market them in the United States through one or more third party collaborators that have direct sales forces and established distribution systems in lieu
          of our own sales force and distribution systems. We are currently engaged in the conduct of pre-commercialization and launch activities for Twyneo&#174; and Epsolay&#174;. The success of our business depends largely on our ability to fund, execute and
          complete the development of, obtain regulatory approval for and successfully commercialize our branded product candidates in the United States in a timely manner.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We have not obtained regulatory approval for most of our product candidates in the United States or any other country.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Other than the first generic version of Zovirax&#174;&#160;(acyclovir) cream, 5% for which Perrigo UK Finco Limited Partnership, or Perrigo, our collaborator, received final FDA approval
        in February 2019, we do not currently have any product candidates that have obtained regulatory approval for sale in the United States or any other country. Although we are expected to launch an additional generic product in 2021, we cannot
        guarantee that our other product candidates will ever obtain such approvals. Our business is substantially dependent on our ability to complete the development of, obtain regulatory approval for and successfully commercialize product candidates in
        a timely manner. We cannot commercialize our product candidates in the United States without first obtaining regulatory approval to market each product candidate from the FDA. Similarly, we cannot commercialize product candidates outside of the
        United States without obtaining regulatory approval from comparable foreign regulatory authorities.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate in pre-clinical studies and well-controlled clinical trials that
          the product candidate is safe and effective for use for its target indication and that the related manufacturing facilities, processes and controls are adequate. In the United States, we are required to submit and obtain the FDA&#8217;s approval of a
          new drug application, or NDA, before marketing our product candidates. An NDA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and efficacy for each desired indication
          and, when subject to the requirements of section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA, will allow us to rely in part on published scientific literature and/or the FDA&#8217;s prior findings of safety and efficacy in its
          approvals of similar products. The NDA must also include significant information regarding the chemistry, manufacturing and controls for the product candidate. The FDA will also inspect our manufacturing facilities to ensure that the facilities
          can manufacture each product candidate that is the subject of an NDA, in compliance with current good manufacturing practice, or cGMP requirements, and may inspect our clinical trial sites to ensure that the clinical trials conducted at the
          inspected site were performed in accordance with good clinical practices, or GCP, and our clinical protocols.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">To date, we have submitted two NDAs that were accepted for filing by the FDA, one for Twyneo&#174; with a Prescription Drug User Fee Act, or PDUFA, goal date assigned by the FDA of
        August 1, 2021 and one for Epsolay&#174; with a PDUFA goal date assigned by the FDA of April 26, 2021. In addition, in July 2020, Perrigo filed first-to-file Paragraph IV Certification for a generic version of Duobrii&#174; (halobetasol propionate and
        tazarotene) lotion, a product which is the subject of one of our collaboration agreements with Perrigo Israel, an affiliate of Perrigo Company plc. In August 2020, Bausch Health Companies, Inc. initiated a patent infringement action in the U.S.
        District Court for the District of New Jersey regarding Perrigo&#8217;s Abbreviated New Drug Application (ANDA) for this generic version of Duobrii&#174; lotion.&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Approval to market and distribute drugs that are shown to be equivalent to proprietary drugs previously approved by the FDA through its NDA process is obtained by submitting an
        ANDA to the FDA. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well
        as analytical methods, manufacturing process validation data, and quality control procedures. Premarket applications for generic drugs are termed abbreviated because they generally do not include pre-clinical and clinical data to demonstrate safety
        and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Obtaining approval of an NDA or an ANDA is a lengthy, expensive and uncertain process, and approval is never guaranteed. Upon submission of an NDA or ANDA, the FDA must make an
        initial determination that the application is sufficiently complete to accept the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA, or ultimately be approved. If the application is
        not accepted for review or approved, the FDA may require that we conduct additional clinical trials or pre-clinical studies or take other actions before it will reconsider our application. If the FDA requires us to provide additional studies or
        data to support such applications, we would incur increased costs and delays in the marketing approval process, which may require us to expend more resources than anticipated or that we have available. In addition, the FDA may not consider any
        additional information to be complete or sufficient to support approval.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Regulatory authorities outside of the United States also have requirements for approval of drugs for commercial sale with which we must comply prior to marketing in those
        countries. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates. Clinical trials conducted in one country may not be accepted by regulatory authorities in other
        countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. However, the failure to obtain regulatory approval in one jurisdiction could have a negative impact on our
        ability to obtain approval in a different jurisdiction. Approval processes vary among countries and can involve additional product candidate testing, development, validation and additional administrative review periods. Seeking regulatory approval
        outside of the United States could require additional chemical manufacturing control data, pre-clinical studies or clinical trials, which could be costly and time consuming. Obtaining regulatory approval outside of the United States may include all
        of the risks associated with obtaining FDA approval.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our business will be highly dependent on market perception of us and the safety and quality of our product candidates. Our business or products could be
        subject to negative publicity, which could have a material adverse effect on our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Market perception of our business is very important, especially market perception of the safety and quality of our product candidates. If any of our product candidates, if
        approved, or similar products that other companies distribute, or third-party products from which our product candidates are derived, are subject to market withdrawal or recall or are proven to be, or are claimed to be, harmful to consumers, it
        could have a material adverse effect on our business. Negative publicity associated with product quality, illness or other adverse effects resulting from, or perceived to result from, our product candidates could have a material adverse impact on
        our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Additionally, continuing and increasingly sophisticated studies of the proper utilization, safety and efficacy of pharmaceutical products are being conducted by the industry,
        government agencies and others which could call into question the utilization, safety and efficacy of previously marketed products. In some cases, studies have resulted, and may in the future result, in the discontinuance of product marketing or
        other costly risk management programs such as the need for a patient registry.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We have a limited operating history in the dermatological prescription drug space which may make it difficult to evaluate the success of our business to date
        and to assess our future viability.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have a limited operating history in the dermatological prescription drug space and have focused much of our efforts, to date, on the research and development of our branded
        and generic product candidates, rather than commercialization. If Twyneo&#174; and Epsolay&#174; receive regulatory approval from the FDA, we intend to market them in the United States through one or more third party collaborators that have direct sales
        forces and established distribution systems in lieu of our own sales force and distribution systems. Due to these uncertainties, we cannot provide you with any assurances as to when, if ever, we will obtain approvals or generate sufficient revenues
        to achieve sustained profitability. Our ability to successfully commercialize our product candidates and become profitable is subject to a number of challenges, including, among others, that:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za6768f00a7ee454682f7fede69fccdb7">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may not have adequate financial or other resources;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z127bf02804f94731835f6293df05c235">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may not be able to manufacture our product candidates in commercial quantities, in an adequate quality or at an acceptable cost;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z504087abede543fdb2cf044692111fc6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may not be able to establish adequate sales, marketing and distribution channels;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zea35a555c2da4ff69d30cddff32fe1f8">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may not be able to find suitable co-development, contract manufacturing or marketing partners;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z126fb7c5e0ac45b49e681d4de2051d6e">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>healthcare professionals and patients may not accept our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za3b204450b9049b99d392a9d1f359507">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may not be aware of possible complications from the continued use of our product candidates since we have limited clinical experience with respect to the actual use of our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4d44dfcab3ab4d66a36124fa22f9b70a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>changes in the market, new alliances between existing market participants and the entrance of new market participants may interfere with our market penetration efforts;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0d8671baacf44e089cfc8857910ffb1d">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>third-party payors may not agree to reimburse patients for any or all of the purchase price of our product candidates, which may adversely affect patients&#8217; willingness to purchase our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z55fed3dde39140ab8fd44d7fe3fe4531">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>uncertainty as to market demand may result in inefficient pricing of our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z961f10d44dd54957b09570e75ea90aac">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may face third-party claims of intellectual property infringement;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4afd63e7ebd54471a8b618b847d563ce">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may fail to obtain and maintain regulatory approvals for our product candidates in our target markets or may face adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z20a0bb4f178746a894036ac4b06ce072">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we are dependent upon the results of ongoing clinical trials relating to our product candidates and the products of our competitors; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z88f99c6d4a9c40e5a6788ed26c9e4ddf">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may become involved in lawsuits pertaining to our clinical trials.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The occurrence of any one or more of these events may limit our ability to successfully commercialize our product candidates, which in turn could have a material adverse effect
        on our business, financial condition and results of operations. Consequently, there can be no guaranty of the accuracy of any predictions about our future success or viability.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product
        candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings and license and
        collaboration agreements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the
        terms of these securities may include liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting
        or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish
        valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be
        required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Even if we are able to generate revenues from our operations in the future, our revenues and operating income could fluctuate significantly.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Even if we are able to generate future revenues, our operating income, and results may vary significantly from year-to-year and quarter-to-quarter. Variations may result from,
        among other factors:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z387471fb51824580bedf73d2bb988a79">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the timing of any FDA or other regulatory authority approvals;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z643e719af98d4cf5be858f7f958089bb">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the timing of process validation for particular product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5cf57498faca4c069ee834978ba2f6cc">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the timing of product launches and market acceptance of such products launched;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze23437f3d16742e3a644f5199d251034">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>changes in the amount we spend to research, develop, acquire, license or promote new product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z00efc2e255fe435287a925c06e99454a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the outcome of our research, development and clinical trial programs;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd09725ed179740c4b52e210f52ab03b1">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>serious or unexpected health or safety concerns related to our product candidates or the branded product candidates we have genericized;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5073d0e8ce024d53ba9a4479997e45f1">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the introduction of new products by others that render our product candidates obsolete or noncompetitive;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za34bea6e0b7c419aa4d8dd92a829fea6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the ability to maintain selling prices and gross margins on our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z935e644e9da84493ba181402c416e853">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the ability to comply with complex governmental regulations applicable to many aspects of our business;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zea4d13c8c07447dfa0545777a5b964d4">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>changes in coverage and reimbursement policies of health plans and other health insurers, including changes to Medicare, Medicaid and similar government healthcare programs;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zea64ba15c9fa44db998d59f30166df38">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>increases in the cost of raw materials used to manufacture our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze10352500157468e8e2716c61226948e">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>manufacturing and supply interruptions, including product rejections or recalls due to failure to comply with manufacturing specifications;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf9d90990b6cf452497a18f49498b7167">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>timing of revenue recognition related to our collaboration agreements;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd2709567422a4fdfa52fc8a1dfd68066">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the ability to protect our intellectual property and avoid infringing the intellectual property of others; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9b2434f43e0049b98fc1aadda1a5b729">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the outcome and cost of possible litigation over patents with third parties.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Risks Related to Development and Clinical Testing of Our Product Candidates</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and clinical trials may not be
        predictive of future trial results, which could result in development delays or a failure to obtain marketing approval.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Clinical testing, of both innovative and generic products, and the submission of new drug applications under the Section 505(b)(2) regulatory pathway is expensive, time consuming
        and has an inherently uncertain outcome. Failure can occur at any time during the clinical trial process, even with active ingredients that have been previously approved by the FDA as safe and effective. Favorable results in pre-clinical studies
        and early clinical trials for one or more of our product candidates may not be predictive of similar results in future clinical trials for such product candidate. Also, interim results during a clinical trial do not necessarily predict final
        results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. A number of companies in the pharmaceutical
        and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stage development. Accordingly, the results from the completed pre-clinical studies and clinical trials
        for our product candidates may not be predictive of the results we may obtain in later stage trials for such product candidates. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to
        conduct additional clinical trials. Clinical trial results may be inconclusive, or contradicted by other clinical trials, particularly larger clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses,
        and many companies that believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain FDA, or other applicable regulatory agency, approval for their products.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may experience delays in our clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be
        completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5222825af9844942a84aca1888a0eb7a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div> inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf9e19d548cc347eb8c96c0de33e80c81">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>reaching a consensus with regulatory authorities on study design or implementation of clinical trials;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z413747fc26364fdca96c8edcdb68966b">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>obtaining regulatory authorization to commence a trial;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z85a4ccec3abe471e9a87f0b71c2d3187">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and
                trial sites;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z92002b73c4b9419391427d6da1565f47">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>identifying, recruiting and training suitable clinical investigators;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9dac2238672d4729af6ce840840d8daf">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>obtaining institutional review board, or IRB, or ethics committee approval at each site;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3b982014002d47b4be29715a64fde1a7">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>recruiting suitable patients to participate in a trial;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z91bdd67a06814b25b3974c50dce0d274">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>having patients complete a trial or return for post-treatment follow-up;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8ccebab22dcc4cfa8d2594322a44efc5">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>clinical sites deviating from FDA regulations, including GCPs, or the study protocol, or dropping out of a trial;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0c5571b0f8cb4bf2b4e1fb59dd7a384a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>adding new clinical trial sites;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z54a7df995cc64ce1a40c85c57e8edb31">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits, or occurrence of adverse events in trial of the same class of agents conducted by other companies;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1d6a5b44f9d2411da91516bfce4694c2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the cost of clinical trials of our product candidates being greater than we anticipate;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z44987d40916647beb8631e47aaca20f7">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>transfer of manufacturing processes to larger-scale facilities operated by a contract manufacturing organization, or CMO, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc8db92bee86b4057b9fe0a7cbec53cad">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>third parties being unwilling or unable to satisfy their contractual obligations to us;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd1333f8b66c14479a7c7439a5a879f9c">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>manufacturing sufficient quantities of a product candidate for use in clinical trials; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze6ba295f506148b8beb49f8ee3f82ffa">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>damage to clinical supplies of a product candidate caused during storage and/or transportation.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or
        completing our planned and ongoing clinical trials. We may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by any Data Safety Monitoring Board for
        such trial, by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our
        clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a
        benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of any clinical trial for our product candidates or if
        any clinical trials are terminated, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Moreover, changes in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, as a result of which we may need to amend clinical trial
        protocols. Amendments may require us to resubmit our clinical trial protocols for review and approval, which may adversely affect the cost, timing and successful completion of a clinical trial. If we experience delays in the completion of, or if we
        terminate, any of our clinical trials, the commercial prospects for our affected product candidates would be harmed and our ability to generate product revenue would be delayed, possibly materially.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any delays in completing our clinical trials will increase our costs, slow down our product candidates&#8217; development and regulatory review and approval process and jeopardize our
        ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or
        completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are
        ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials
        and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a
        product candidate&#8217;s clinical development and may vary among jurisdictions. It is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z55d47fe0a0884913ac95c4a7b4dffbce">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3e3b0d59fcd346558d307907860e68f6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z363a99c99acb4000976426b8a84bf0fc">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd693b30e3bca4dcebdecf9784ea2f729">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze3018a3f7e494c4b8be32e9681539c84">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1a99e0984fb34cbb90cab599cd543988">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd259a341a026481b99612234b2ba3e3c">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9530a683f262497e9021f027442c337e">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product
        candidates, which would significantly harm our business, results of operations and prospects.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not
        approve the price we intend to charge for our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims
        necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have limited experience using the 505(b)(2) regulatory pathway to submit an NDA or any similar drug approval filing to the FDA, and we cannot be certain that any of our
        product candidates will receive regulatory approval. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of
        our product candidates, our revenue will be dependent, to a significant extent, upon the size of the markets in the territories for which we gain regulatory approval. If the markets for patients or indications that we are targeting are not as
        significant as we estimate, we may not generate significant revenue from sales of such products, if approved.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue
        clinical trials, abandon product candidates, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Undesirable side effects caused by our product candidates could result in the delay, suspension or termination of clinical trials by us, our collaborators, the FDA or other
        regulatory authorities for a number of reasons. For example, to date, patients treated with Twyneo&#174; and Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> have experienced drug-related side effects including moderate local site irritation such as dryness, erythema, scaling,
        pruritus, itching, stinging and burning. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our clinical trials could be suspended or terminated, and the FDA
        or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the
        ability of enrolled patients to complete the trial or result in potential product liability claims. If we elect or are required to delay, suspend or terminate any clinical trial for any product candidates that we develop, the commercial prospects
        of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or eliminated. Any of these occurrences may harm our business, prospects, financial condition and results of
        operations significantly.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of
        potentially significant negative consequences could result, including:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;regulatory authorities may withdraw approvals of such products;</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;regulatory authorities may require additional warnings on the label;</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;we may be required to create a medication guide outlining the risks of such side effects for distribution to
          patients;</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;we may be required to implement a risk evaluation and mitigation strategy, or REMS, which may include a
          medication guide or patient package insert, a communication plan to educate healthcare providers of the drug&#8217;s risks, or other elements to assure safe use;</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;we could be sued and held liable for harm caused to patients; and</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8226;<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our reputation may suffer.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business,
        results of operations and prospects. Our future clinical trial results may not be successful.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We may find it difficult to enroll patients in our clinical trials, and patients could discontinue their participation in our clinical trials, which could
        delay or prevent clinical trials for our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Identifying and qualifying patients to participate in clinical trials for our product candidates is critical to our success. The timing of our clinical trials depends on the
        speed at which we can recruit patients to participate in testing our product candidates. If patients are unwilling to participate in our clinical trials because of negative publicity from adverse events in the biotechnology or pharmaceutical
        industries or for other reasons, including competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting clinical trials and obtaining regulatory approval of potential product candidates may be
        delayed. These delays could result in increased costs, delays in advancing our product candidates development, delays in testing the effectiveness of our technology or termination of the clinical trials altogether.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">18</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Patient enrollment is a significant factor in the timing of clinical trials. We may not be able to recruit and enroll a sufficient number of patients, which would impact our
        ability to complete our clinical trials in a timely manner. Patient enrollment may be affected by numerous factors, including:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3771db61bf6b4c63a1cdb5899222800d">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>severity of the disease under investigation;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd64dd678fb494d0982b4f80dec3c8aa7">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>size and nature of the patient population;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbc8ea69a6e704ba98015fbb18d9c5d3a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>eligibility criteria for the trial;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc0a6f525381e47008fb7cbf5b326c203">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>design of the trial protocol;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze3ff58ecfcfc411abe2f2d65fbdd7050">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>perceived risks and benefits of the product candidate under study;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7fdbdaba4d3c4b43a31789022f816aaa">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>physicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any drugs that may be approved for the same indications we are investigating;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7bf2a9457f846329d9746aa7221a6b1">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>proximity to and availability of clinical trial sites for prospective patients;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2937d68db58241c3a2fea3eabde10ae2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>availability of competing therapies and clinical trials;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z129b6680985448ac85d041682b9e1aa6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>ability to monitor patients adequately during and after treatment; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd9b3dc462b5147e1a43a8ab9558ef4ad">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the effects of COVID-19</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We face intense competition with regard to patient enrollment in clinical trials from other dermatological companies which also seek to enroll subjects from the same patient
        populations. In addition, patients enrolled in our clinical trials may discontinue their participation at any time during the trial as a result of a number of factors, including withdrawing their consent or experiencing adverse clinical events,
        which may or may not be judged related to our product candidates under evaluation. For example, 104 patients, or 12.12% of patients enrolled in our Twyneo&#174; Phase 3 clinical trial, did not complete the study protocol. The most common reasons for
        subjects not completing the study were the withdrawal of informed consent (41 subjects), loss to follow-up (36 subjects) and adverse events (16 subjects). The discontinuation of patients in any one of our trials may cause us to delay or abandon our
        clinical trial or cause the results from that trial not to be positive or sufficient to support a filing for regulatory approval of the applicable product candidate.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">There is a substantial risk of product liability claims in our business. We currently do not maintain product liability insurance and a product liability
        claim against us would adversely affect our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our business exposes us to significant potential product liability risks that are inherent in the development, manufacturing and marketing of our product candidates. Product
        liability claims could delay or prevent completion of our development programs. If we succeed in commercializing our product candidates, such claims could result in a recall of our product candidates or a change in the approved indications for
        which they may be used. While we intend to purchase and maintain product liability insurance that we believe is adequate for our operations upon commercialization of our product candidates, such coverage may not be adequate to cover any incident or
        all incidents. Furthermore, product liability insurance is becoming increasingly expensive. As a result, we may be unable to maintain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect
        on our business. These liabilities could prevent or interfere with our product development and commercialization efforts.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">19</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If the FDA does not conclude that our product candidates for which we are seeking or intend to seek approval under Section 505(b)(2) of the Federal Food,
        Drug, and Cosmetic Act satisfy the requirements of the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section 505(b)(2) are not as we expect, the approval pathway for those product candidates
        will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in all cases may not be successful.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are developing product candidates for which we are seeking or intend to seek FDA approval through the Section 505(b)(2) regulatory pathway. The Drug Price Competition and
        Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section 505(b)(2) to the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that
        were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if applicable to us under the FDCA, would allow an NDA we submit to the FDA to rely in part on data in the public
        domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved drugs, which could expedite the development program for our product candidates by potentially decreasing the amount of clinical data that we would need to
        generate in order to obtain FDA approval. If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional data and information, and meet
        additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks associated with these product candidates, would likely
        substantially increase. Moreover, any inability to pursue the Section 505(b)(2) regulatory pathway may result in new competitive products reaching the market more quickly than our product candidates, which would likely materially adversely impact
        our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, our product candidates may not receive the requisite approvals for commercialization.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain brand-name pharmaceutical companies and
        others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may change its 505(b)(2) policies and practices, which could delay or even prevent the FDA
        from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of
        previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation.
        It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can
        significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are
        able to utilize the Section 505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Even if our branded product candidates or our generic product candidates receive marketing approval, we may continue to face future developmental and
        regulatory difficulties. In addition, we will be subject to ongoing obligations and continued regulatory review.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Even if we complete clinical testing and receive approval of any of our branded or generic product candidates, the FDA may grant approval contingent on the performance of
        additional post-approval clinical trials, risk mitigation requirements such as the implementation of a or REMS, and/or surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues
        or increasing expenses, and cause the approved product candidate not to be commercially viable. Absence of long-term safety data may further limit the approved uses of our product candidates, if any.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The FDA also may approve branded product candidates or any of our generic product candidates for a more limited indication or a narrower patient population than we initially
        request, or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Furthermore, any such approved product will remain subject to extensive regulatory requirements,
        including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping. These requirements include registration with the FDA, listing of our product
        candidates, payment of annual fees, as well as continued compliance with GCP requirements for any clinical trials that we conduct post-approval. Application holders must notify the FDA, and depending on the nature of the change, obtain FDA
        pre-approval for product manufacturing changes. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP
        requirements.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">20</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we fail to comply with the regulatory requirements of the FDA or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes
        are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z477de8780a3a4b06b5f922be08b95ff4">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA could suspend or impose restrictions on operations, including costly new manufacturing requirements;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7d71d02503342c0972dcb4f4f41561c">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA could refuse to approve pending applications or supplements to applications;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zba939a7b952b4157b1c8cd8994af5a71">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA could suspend any ongoing clinical trials;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcf2e9960617040ad9feb6521529383b5">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA could suspend or withdraw marketing approval;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze4fde6d2b7344d5387a6abbf5ed6e3f2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA could seek an injunction or impose civil or criminal penalties or monetary fines;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8ac4dc9d366a4f5fbe099773b7bb333d">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA could ban or restrict imports and exports;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z68142fbadb1c4e47959d7b0a31d061ae">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA could issue warning letters or untitled letters or similar enforcement actions alleging noncompliance with regulatory requirements; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z497bb4213e0d4c3a9b24210abef1504f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the FDA or other governmental authorities could take other actions, such as imposition of product seizures or detentions, clinical holds or terminations, refusals to allow the import or export of products, disgorgement, restitution, or
                exclusion from federal healthcare programs.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, if our branded product candidates or any of our other product candidates are approved, our product labeling, advertising and promotional materials would be subject
        to regulatory requirements and continuing review by the FDA. The FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as
        reflected in the product&#8217;s approved labeling, a practice known as off-label promotion. If we receive marketing approval for any of our branded product candidates or any of our generic product candidates, physicians may nevertheless prescribe the
        products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies actively
        enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal
        fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified
        promotional conduct is changed or curtailed.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Moreover, the FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval, and the sale and promotion of
        our branded product candidates or any of our other product candidates, if approved. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the
        United States or abroad. For example, the results of the 2020 U.S. Presidential Election may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders,
        that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing
        applications. It is difficult to predict whether or how these orders will be implemented, or whether they will be rescinded and replaced under the Biden administration. The policies and priorities of the new administration are unknown and could
        materially impact the regulations governing our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we
        may be subject to enforcement action and we may not achieve or sustain profitability</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">21</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Disruptions at the&#160;FDA&#160;and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or
        deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels,
        statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at
        the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
        Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.&#160; For example,
        over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the&#160;FDA, have had to furlough critical&#160;FDA&#160;employees and stop critical
        activities. &#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25;">Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing
        facilities, and subsequently, on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities and clinical trial sites. Subsequently, on July 10, 2020 the FDA announced its intention to resume
        certain on-site inspections of domestic manufacturing facilities and trial sites subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can
        occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. If a prolonged&#160;government&#160;shutdown&#160;occurs, or if global health concerns continue to prevent the FDA or other regulatory
        authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which
        could have a material adverse effect on our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Even if our branded product candidates or our other product candidates receive regulatory approval, they may fail to achieve the broad degree of physician
        adoption and market acceptance necessary for commercial success.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Even if we obtain FDA approvals for our branded product candidates or any of our generic product candidates, the commercial success of such products will depend significantly on
        their broad adoption by dermatologists, pediatricians and other physicians for approved indications and other therapeutic or aesthetic indications that we may seek to pursue if approved.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The degree and rate of physician and patient adoption of our branded product candidates and any of our generic product candidates, if approved, will depend on a number of
        factors, including:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6a09adb72dc744438ebdedb6ac9e73ff">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the clinical indications for which the product is approved;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z18a8129f385e4311b44e8d0111118e44">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the safety and efficacy of our product as compared to existing therapies for those indications;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfb32da8795904364b81716afefa982c6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the prevalence and severity of adverse side effects;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z65e18dc871704704ac9dcdf57d277524">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>patient satisfaction with the results and administration of our product and overall treatment experience, including relative convenience, ease of use and avoidance of, or reduction in, adverse side effects;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8338ae6b38a54af2a99c8d8ae6a9882c">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>patient demand for the treatment of acne and rosacea or other indications;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">22</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z89d26470b27e48749121a74f94a28ee3">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the cost of treatment in relation to alternative treatments, the extent to which these costs are reimbursed by third-party payors, and patients&#8217; willingness to pay for our product candidates; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za808bcca8f5247378a00fe6105677c2a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the effectiveness of our sales and marketing efforts, including any head-to-head studies, if conducted, especially the success of any targeted marketing efforts directed toward dermatologists, pediatricians, other physicians, clinics and
                any direct-to-consumer marketing efforts we may initiate.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We expend a significant amount of resources on research and development efforts that may not lead to successful product candidate introductions or the
        recovery of our research and development expenditures.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We conduct research and development primarily to enable us to manufacture and market topical dermatological creams containing drugs in accordance with FDA regulations as well as
        other regulatory authorities. We spent approximately $28.1 million, $40.6 million and $27.9 million on research and development activities during the years ended December&#160;31, 2018, 2019 and 2020, respectively. We are required to obtain FDA approval
        before marketing our product candidates in the United States. The FDA approval process is costly, time consuming and inherently risky.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We cannot be certain that any investment made in developing product candidates will be recovered, even if we are successful in commercialization. To the extent that we expend
        significant resources on research and development efforts and are not able to introduce successful new product candidates as a result of those efforts, we will be unable to recover those expenditures.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our clinical trials for our branded product candidates were not, and will not be, conducted head-to-head with the applicable leading products of our
        competitors, and the comparison of our results to those of existing drugs, and the conclusions we have drawn from such comparisons, may be inaccurate.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our clinical trials for branded product candidates were not, and will not be, conducted head-to-head with the drugs considered the applicable standard of care for the relevant
        indications. This means that none of the patient groups participating in these trials were, and will not in the future be, treated with the applicable standard of care drugs alongside the groups treated with our product candidates. Instead, we have
        compared and plan to continue comparing the results of our clinical trials with historical data from prior clinical trials conducted by third parties for the applicable standard of care drugs, and which results are presented in their respective
        product labels.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Direct comparison generally provides more reliable information about how two or more drugs compare, and reliance on indirect comparison for evaluating their relative efficacy or
        other qualities is problematic due to lack of objective or validated methods to assess trial similarity. For example, the various trials were likely conducted in different countries with different demographic features and in patients with different
        baseline conditions and different hygiene standards, among other relevant asymmetries. Therefore, the conclusions we have drawn from comparing the results of our clinical trials with those published in the product labels for these current standard
        of care drugs, including conclusions regarding the relative efficacy and expediency of our branded product candidates, may be distorted by the inaccurate methodology of the comparison. Moreover, the FDA generally requires head-to-head studies to
        make labeling and advertising claims regarding superiority or comparability, and our failure to collect head-to-head data may limit the types of claims we may make for our product candidates, if approved.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">We may be subject to risk as a result of international manufacturing operations</font><font style="font-family: 'Times New Roman',Times,serif;">.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">Certain of our product candidates may be manufactured, warehoused and/or tested at third-party facilities located in the U.S., Canada,&#160;New Zealand, and
        India, in addition to our facility in Israel, and therefore our operations are subject to risks inherent in doing business internationally. Such risks include the adverse effects on operations from corruption, war, public health crises, such as
        pandemics and epidemics, international terrorism, civil disturbances, political instability, governmental activities, deprivation of contract and property rights and currency valuation changes. Any of these changes could have a material adverse
        effect on our reputation, business, financial condition or results of operations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">23</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The third-party logistics providers we will rely on may be unable to warehouse, label and/or supply our products in a timely and efficient manner, which can
        adversely affect our relationship with our customers..</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.2pt; line-height: 1.25;">Our ability to timely supply our products will be dependent on the uninterrupted and efficient operations of our third-party logistics, warehousing,
        labeling and packaging providers in La Vergne, Tennessee. If for any reason such providers fail to securely warehouse, label and supply our products, our relationships with our customers could be disrupted, which could adversely our business,
        financial condition or results of operations. Further, we will rely on commercial transportation for the distribution of our products which may be negatively impacted by natural disasters or security threats.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">The ongoing COVID-19 pandemic may adversely affect our business, revenues, results of operations and financial condition</font><font style="font-family: 'Times New Roman',Times,serif;">.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">Outbreaks of epidemic, pandemic or contagious diseases, such as SARS-CoV-2, may adversely affect our business, financial condition and results of
        operations.&#160; The global spread of the SARS-CoV-2 has resulted in government-imposed quarantines, travel restrictions, stay-at-home-orders and other public health safety measures in the United States, Israel, and other affected countries. These
        precautionary measures have and may continue to have an adverse effect on the global markets and its economy and demand for pharmaceutical products, including on the availability and pricing of employees, resources, materials, manufacturing and
        delivery efforts and other aspects of the global economy. In addition, conducting clinical trials during the COVID-19 pandemic requires the adoption of special procedures and in general slows down participant enrollment. The spread of this pandemic
        has caused significant volatility and uncertainty in U.S. and international markets and has resulted in increased risks to our operations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25;">Specifically, we are monitoring several risks that have or may affect our business related to this pandemic. For example, the COVID-19 pandemic has reduced
        the revenue from sales of a generic product from the collaboration with Perrigo due to travel restrictions and stay-at-home-orders. In addition, the COVID-19 pandemic has adversely affected and may continue to adversely affect our ability to
        manufacture Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>at the times we planned to do so. An extended duration of this pandemic could adversely affect the ability of the FDA to conduct a pre-approval inspection and possibly delay the timely
        approval of Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and/or Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. Moreover, quarantines, shelter-in-place and similar government orders, travel restrictions, stay-at-home-orders and health impacts of the COVID-19 pandemic have and in the future could
        impact the availability or productivity of personnel at third-party manufacturers, distributors, freight carriers and other necessary components of our supply chain. In addition, there may be unfavorable changes in the availability or cost of raw
        materials, intermediates and other materials necessary for production, which may result in disruptions in our supply chain.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">As COVID-19 continues to spread in the United States and elsewhere, we may experience disruptions that could severely impact our preclinical studies and
          clinical trials, including:</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2f17637a001f4c4089978fed12963764">

            <tr>
              <td style="width: 18.3pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>delays or difficulties in enrolling patients in our clinical trials;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf61b62878c1d4dbbbe27662fb24105ee">

            <tr>
              <td style="width: 18.4pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc855dc085aab4e6b856264c71edcccce">

            <tr>
              <td style="width: 18.5pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc9d535408dec4ee5a73a3558147498fe">

            <tr>
              <td style="width: 18.6pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy and safety data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local
                  governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-weight: normal; font-style: normal;">24</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z66b244e0069d4ed8abe3e084a0b2745b">

            <tr>
              <td style="width: 18.7pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze02e3ceb92274f6b8ef2c94d7cd8389a">

            <tr>
              <td style="width: 18.8pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations, or CROs, and vendors;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf0188b3ce69d4a178ae5e578ae17cde7">

            <tr>
              <td style="width: 18.9pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z139845fa86844a97bb71675a99180682">

            <tr>
              <td style="width: 19pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za8e2c92dd7ff455ab73fddc9199729aa">

            <tr>
              <td style="width: 19.1pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>delays in receiving authorization from local regulatory authorities to initiate our planned clinical trials;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z841b9306add84615b5a5d003f80f1c1f">

            <tr>
              <td style="width: 19.2pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and pre-clinical work, including because of sickness of employees or their families, the desire of employees to avoid
                  travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zca6ca8bb47664d9e86c4fba5bfc80088">

            <tr>
              <td style="width: 19.3pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials
                  altogether;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcd4bbb67a4f34050bfa41c426c0da9da">

            <tr>
              <td style="width: 19.4pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z48f8d07c762c4754b0729e1f74501060">

            <tr>
              <td style="width: 19.5pt; font-family: 'Times New Roman',Times,serif;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
                <div>refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Additionally, because our corporate headquarters are in Israel while our CMOs are located in other countries, there is additional risk in our ability as a company to
          control, assist and supervise such CMOs activities.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
        <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">The COVID-19 outbreak continues to rapidly evolve, and its ultimate scope, duration and effects are unknown. The extent of the impact of the disruptions
          to our business, including commercial sales and clinical development, as a result of the pandemic, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. The continuation of the COVID-19 pandemic
          could materially disrupt our business and operations, hamper our ability to raise additional funds or sell or securities, continue to slow down the overall economy, curtail consumer spending, interrupt our sources of supply, and make it hard to
          adequately staff our operations.</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If in the future we acquire or in-license technologies or additional product candidates, we may incur various costs, may have integration difficulties and may
        experience other risks that could harm our business and results of operations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the future, we may acquire or in-license additional product candidates and technologies. Any product candidate or technologies we in-license or acquire will likely require
        additional development efforts prior to commercial sale, including extensive pre-clinical studies, clinical trials, or both, and approval by the FDA or other applicable foreign regulatory authorities, if any. All product candidates are prone to
        risks of failure inherent in pharmaceutical product development, including the possibility that the product candidate, or product developed based on in-licensed technology, will not be shown to be sufficiently safe and effective for approval by
        regulatory authorities. If intellectual property related to product candidates or technologies we in-license or our own know-how is not adequate, we may not be able to commercialize the affected product candidates even after expending resources on
        their development. In addition, we may not be able to manufacture economically or successfully commercialize any product candidate that we develop based on acquired or in-licensed technology that is granted regulatory approval, and such product
        candidates may not gain wide acceptance or be competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed product candidates could be expensive and time-consuming. If we cannot effectively manage these aspects of our
        business strategy, our business may not succeed.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">25</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The time necessary to develop generic API or drug products may adversely affect whether, and the extent to which, we receive a return on our capital.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The development process, including drug formulation where applicable, testing, and FDA review and approval for generic drug products often takes many years. This process requires
        that we expend considerable capital to pursue activities that do not yield an immediate or near-term return. Also, because of the significant time necessary to develop a generic product, the actual market for a generic product at the time it is
        available for sale may be significantly less than the originally projected market for the generic product. If this were to occur, our potential return on our investment in developing the generic product, if approved for marketing by the FDA, would
        be adversely affected and we may never receive a return on our investment in the generic product. It is also possible for the manufacturer of the brand-name product for which we are developing a generic drug to obtain approvals from the FDA to
        switch the brand-name drug from the prescription market to the over-the-counter, or OTC market. If this were to occur, we would be prohibited from marketing our generic product other than as an OTC drug, in which case our revenues could be
        significantly impacted.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Related to Regulatory Matters</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Healthcare reform in the United States may harm our future business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Healthcare costs in the United States have risen significantly over the past decade. In March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care
        and Education Reconciliation Act, collectively referred to as the Affordable Care Act, was signed into law, which, among other things, required most individuals to have health insurance, established new regulations on health plans, created
        insurance exchanges and imposed new requirements and changes in reimbursement or funding for healthcare providers, device manufacturers and pharmaceutical companies. The Affordable Care Act also included a number of changes which may impact our
        product candidates:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1786681fde6b49b1b31478dc6bc642c2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>revisions to the Medicaid rebate program by: (a) increasing the rebate percentage for branded drugs to 23.1% of the average manufacturer price, or AMP, with limited exceptions, (b) increasing the rebate for outpatient generic, multiple
                source drugs dispensed to 13% of AMP; (c) changing the definition of AMP; and (d) extending the Medicaid rebate program to Medicaid managed care plans, with limited exceptions;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf2bd562772ed4806b0eaedf8ba95dd93">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the imposition of annual fees upon manufacturers or importers of branded prescription drugs, which fees will be in amounts determined by the Secretary of Treasury based upon market share and other data;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z233d6de1e2544340a8bc1af4e38fc4f0">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>providing a discount on brand-name prescriptions filled in the Medicare Part D coverage gap as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z370e825392d44973ab11ffc02136dacb">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>imposing increased penalties for the violation of fraud and abuse laws and funding for anti-fraud activities; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z33d59e63752249bdb01c03aa490faa87">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expanding the definition of&#8201; &#8220;covered entities&#8221; that purchase certain outpatient drugs in the 340B Drug Pricing Program of Section 340B of the Public Health Service Act.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">While the Affordable Care Act may have increased the number of patients who have insurance coverage for our product candidates, if approved by the FDA, the Affordable Care Act
        also restructured payments to Medicare managed care plans and reduced reimbursement to many institutional providers. Accordingly, the change in the Medicaid rebate levels, the additional fees imposed upon us if we market branded drugs, other
        compliance obligations, and the reduced reimbursement levels to institutional providers may result in a loss of revenue and could adversely affect our business. In addition, the Affordable Care Act contemplates the promulgation of significant
        future regulatory action which may also further affect our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">26</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the Affordable Care Act. By way of example, the Tax Cuts and Jobs Act,
        or the Tax Act, was enacted, which, among other things, removed penalties for not complying with the Affordable Care Act&#8217;s individual mandate to carry health insurance. On December 14, 2018, a U.S. District Court Judge in the Northern District of
        Texas, ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. On
        December 18, 2019, the U.S. Court of Appeals for the 5<font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Circuit upheld the District Court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back
          to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule. It is also unclear
          how other efforts, if any, to challenge, repeal or replace the Affordable Care Act will impact the law, our business or financial condition.</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Moreover, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011 resulted in aggregate
        reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013, and will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless
        additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and
        cancer treatment centers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Recently there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several
        Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program
        reimbursement methodologies. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient
        reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that
        additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for
        our product candidates, if approved, or additional pricing pressure.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Related to Commercialization of Our Product Candidates</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our continued growth is dependent on our ability to successfully develop and commercialize new product candidates in a timely manner.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our financial results depend upon our ability to introduce and commercialize additional product candidates in a timely manner. Generally, revenue from new products is highest
        immediately following launch and then declines over time, as new competitors enter the market. Furthermore, the greatest revenue is generally experienced by the company that is able to bring its product to the market first. Our growth is therefore
        dependent upon our ability to successfully introduce and commercialize new product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The FDA and other regulatory authorities may not approve our product applications at all or in a timely fashion for our product candidates under development. Additionally, we may
        not successfully complete our development efforts for other reasons, such as poor results in clinical trials or a lack of funding to complete the required trials. Even if the FDA approves our product candidates, we may not be able to market them
        successfully or profitably. Our future results of operations will depend significantly upon our ability to timely develop, receive FDA approval for, and market new pharmaceutical product candidates or otherwise develop new product candidates or
        acquire the rights to other products.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">27</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our product candidates, if approved, will face significant competition and our failure to compete effectively may prevent us from achieving significant market
        penetration and expansion.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The facial aesthetic market in general, and the market for acne and rosacea treatments in particular, are highly competitive and dynamic, and characterized by rapid and
        substantial technological development and product innovations. These markets are also characterized by competitors obtaining patents to protect what they consider to be their intellectual property.<font style="font-weight: bold;">&#160;</font>We
        anticipate that Twyneo&#174; and Epsolay&#174;, if approved, will face significant competition from other approved products, including topical drugs, topical anti-acne drugs such as Acanya, Ziana, Epiduo, Epiduo Forte, Benzaclin, Aczone, Onexton, Differin,
        Arazlo, Aklief and Amzeeq, and topical drugs for the treatment of rosacea such as Metrogel, Finacea, Soolantra, Finacea and Zilxi, oral drugs such as Solodyn, Doryx, Dynacin, Oracea and Minocin. If approved, Twyneo&#174; and Epsolay&#174; may also compete
        with non-prescription anti-acne products, as well as unapproved and off-label treatments. In addition, if approved, Twyneo&#174; may compete with drug products utilizing other technologies that can separate two drug substances, such as dual chamber
        tubes, dual pouches or dual sachets. To compete successfully in the facial aesthetic market, we will have to demonstrate that our product is safe and effective for the respective treatment and has advantages over existing therapies. Competing in
        the facial aesthetic market could result in price-cutting, reduced profit margins and loss of market share, any of which would harm our business, financial condition and results of operations.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Due to less stringent regulatory requirements in certain jurisdictions outside the United States, there are many more acne products and procedures available for use in those
        international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can
        market them. As a result, we may face more competition in markets outside of the United States.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, even if we are able to commercialize our product candidates, we may not be able to price them competitively with the current standards of care or other competing
        products for their respective indications or their price may drop considerably due to factors outside our control. If this happens or the price of materials and the cost to manufacture our product candidates increases dramatically, our ability to
        continue to operate our business would be materially harmed and we may be unable to commercialize our product candidates successfully.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We believe that our principal competitors are Bausch Health Companies, Inc., Galderma S.A., Almirall, LLC, LEO Pharma A/S, VYNE Therapeutics Inc. (formerly Menlo Therapeutics
        Inc.), Dermavant Sciences and Mylan N.V. These competitors are large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing
        resources, greater brand recognition, and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to the above listed competitors, some of our product candidates might face internal competition with other product candidates of ours, for the same markets and
        patient populations, due to overlap in the required treatment and/or symptoms. For example, Epsolay&#174; may compete with ivermectin cream, 1%, for treatment of rosacea.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;"><font style="font-style: italic;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">With respect to generic pharmaceutical products, the FDA
          approval process often results in the FDA granting final approval to a number of ANDAs for a given product at the time a relevant patent for a corresponding branded product or other regulatory and/or market exclusivity expires. For example, on
          December 30, 2016, Actavis Ltd. submitted an ANDA for ivermectin, 1%, cream, and, as a potential &#8220;first applicant,&#8221; may qualify for 180-day generic marketing exclusivity. The ANDA of Actavis Ltd. was tentatively approved, and as a result&#160; the FDA
          may be prohibited from approving any other generic ivermectin, 1%, cream product for 180 days from the date of the Actavis Ltd. ANDA approval, such that we would not be able to commercialize this product until after Actavis Ltd.&#8217;s exclusivity
          period expires. Thus, we expect, in accordance with the standard practices in the industry, to face immediate competition when we introduce a generic product into the market. As competition from other manufacturers intensifies, selling prices and
          gross profit margins often decline. Accordingly, the level of market share, revenue and gross profit attributable to a particular generic product that we develop is generally related to the number of competitors in that product&#8217;s market and the
          timing of that product&#8217;s regulatory approval and launch, in relation to competing approvals and launches. Additionally, ANDA approvals often continue to be granted for a given product subsequent to the initial launch of the first generic product.
          These circumstances generally result in significantly lower prices and reduced margins for generic products compared to brand products. New generic market entrants generally cause continued price and margin erosion over the generic product life
          cycle.</font></div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">28</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to the competition we face from other generic manufacturers, we face competition from brand-name manufacturers related to our generic product candidates. Branded
        pharmaceutical companies may sell their branded products as &#8220;authorized generics,&#8221; where an approved brand name drug is marketed, either by the brand name drug company or by another company with the brand company&#8217;s permission, as a generic product
        without the brand name on its label, and potentially sold at a lower price than the brand name drug. Further, branded pharmaceutical companies may seek to delay FDA approval of our ANDAs or reduce generic competition by, for example, obtaining new
        patents on drugs whose original patent protection is about to expire, filing patent infringement suits that could delay FDA approval of generics, developing new versions of their products to obtain FDA market exclusivity, filing citizen petitions
        contesting FDA approvals of generics such as on alleged health and safety grounds, developing &#8220;next generation&#8221; versions of products that reduce demand for the generic versions we are developing, changing product claims and labeling, and seeking
        approval to market as OTC branded products.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Moreover, competitors may, upon the approval of an NDA, or an NDA supplement, obtain a three-year period of exclusivity for a particular condition of approval, or change to a
        marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by
        the applicant. Such exclusivity may prevent the FDA from approving one or more of our product candidates that are being developed, and for which we would seek the FDA&#8217;s approval under the 505(b)(2) regulatory pathway, if we were to seek approval
        for the same conditions of approval as that protected by the three-year period of exclusivity. Recent litigation against the FDA has affirmed the FDA&#8217;s interpretation of the scope of three-year exclusivity as preventing the approval of a 505(b)(2)
        NDA for the same change to a previously approved drug, regardless of whether or not the 505(b)(2) applicant relies on the competitor&#8217;s product as a listed drug in its 505(b)(2) application. Exclusivity determinations are highly fact-dependent and
        are made by the FDA on a case-by-case basis at the end of the review period for a 505(b)(2) NDA. As such, we may not know until very late in the FDA&#8217;s review of our 505(b)(2) product candidates whether or not approval may be delayed because of a
        competitor&#8217;s period of three-year exclusivity.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Other pharmaceutical companies may develop competing products for acne, rosacea and other indications we are pursuing and enter the market ahead of us.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Other pharmaceutical companies are engaged in developing, patenting, manufacturing and marketing healthcare products that compete with those that we are developing. These
        potential competitors include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition
        and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Several of these potential competitors are privately-owned companies that are not bound by public disclosure requirements and closely guard their development plans, marketing
        strategies and other trade secrets. Publicly-traded pharmaceutical companies are also able to maintain a certain degree of confidentiality over their pipeline developments and other sensitive information. As a result, we do not know whether these
        potential competitors are already developing, or plan to develop other topical treatments for acne, rosacea or other indications we are pursuing, and we will likely be unable to ascertain whether such activities are underway in the future. These
        potential competitors may therefore introduce competing products without our prior knowledge and without our ability to take preemptive measures in anticipation of their commercial launch.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">29</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Furthermore, such potential competitors may enter the market before us, and their products may be designed to circumvent our granted patents and pending patent applications. They
        may also challenge, narrow or invalidate our granted patents or our patent applications, and such patents and patent applications may fail to provide adequate protection for our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We currently have limited marketing capabilities. If we are unable to establish adequate sales and marketing capabilities through third parties, we may be
        required to establish sales and marketing capabilities on our own, or we may be unable to successfully commercialize Twyneo&#174;, Epsolay&#174; or any other of our other product candidates, if approved, or generate product revenues.&#160; In addition,
        establishing our own sales and marketing capabilities would significantly increase our expenses and require us to raise additional capital sooner that an anticipated.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We currently have limited marketing capabilities. In preparation for commercial launch of our proprietary products, we have opened a U.S. headquarters in Whippany, New Jersey. To
        commercialize Twyneo&#174;, Epsolay&#174; or any other of our other product candidates, if approved, in the United States and other jurisdictions, we expect to establish adequate sales and marketing capabilities through third parties and intend to enter into
        arrangements with third parties to perform these services and other non-technical services. For instance, if Twyneo&#174; and Epsolay&#174; receive regulatory approval from the FDA we intend to market them in the United States through one or more third party
        collaborators that have direct sales forces and established distribution systems&#160; in lieu of our own sales force and distribution systems. We are in discussions with potential partners regarding the commercialization of Twyneo&#174; and Epsolay&#174;. If we
        are unable to enter into such arrangements on acceptable terms or at all, we may be required to establish sales and marketing capabilities on our own or we may be unable to successfully commercialize Twyneo&#174;, Epsolay&#174; or any other of our other
        product candidates or generate product revenues. In addition, establishing our own sales and marketing capabilities would significantly increase our expenses and require us to raise additional capital sooner that an anticipated.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we are not successful in establishing sufficient sales and marketing capabilities to commercialize Twyneo&#174;, Epsolay&#174; or any of our other product candidates, through
        collaborations with one or more third parties, our revenues will suffer and we will incur significant additional losses.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Third-party payor coverage and adequate reimbursement may not be available for our product candidates, if approved, which could make it difficult for us to
        sell them profitably.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Sales of our product candidates, if approved, will depend, in part, on the extent to which the costs of our product candidates will be covered by third-party payors, such as
        government health programs, private health insurers and managed care organizations. Third-party payors generally decide which drugs they will cover and establish certain reimbursement levels for such drugs. In particular, in the United States,
        private health insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government (through the Medicare or Medicaid programs) provides reimbursement for such treatments. Patients
        who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our product
        candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Sales of our product candidates, and any future product candidates, will therefore depend substantially on
        the extent to which the costs of our product candidates, and any future product candidates, will be paid by third-party payors. Additionally, the market for our product candidates, and any future product candidates, will depend significantly on
        access to third-party payors&#8217; formularies without prior authorization, step therapy, or other limitations such as approved lists of treatments for which third-party payors provide coverage and reimbursement. Additionally, coverage and reimbursement
        for therapeutic products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or
        service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our product candidates to each payor separately and will
        be a time-consuming process.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">30</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs and increasingly challenging the prices charged for medical products and
        services. Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. The United States government, state legislatures and foreign governments
        have shown significant interest in implementing cost-containment programs, including price controls and transparency requirements, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and
        cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could limit our revenue and operating results. If these third-party payors do not consider our product candidates to be
        cost-effective compared to other therapies, they may not cover our product candidates once approved as a benefit under their plans or, if they do, the level of reimbursement may not be sufficient to allow us to sell our product candidates on a
        profitable basis. Decreases in third-party reimbursement for our product candidates once approved or a decision by a third-party payor to not cover our product candidates could reduce or eliminate utilization of our product candidates and have an
        adverse effect on our sales, results of operations and financial condition. In addition, state and federal healthcare reform measures have been and may be adopted in the future, any of which could limit the amounts that federal and state
        governments will pay for healthcare products and services, which could result in reduced demand for our product candidates once approved or additional pricing pressures.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Outside the United States, sales of any approved products are generally subject to extensive governmental price controls and other market regulations, and we believe the
        increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products, if any. In many countries, the prices of medical products are subject to varying price
        control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation
        could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate
        commercially reasonable revenue and profits.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our current and future relationships with investigators, health care professionals, consultants, third-party payors, and customers will be subject to
        applicable healthcare regulatory laws, which could expose us to penalties .</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly
        applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute
        our product candidates for which we obtain marketing approval. Such laws include:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za02867b50f514da3ad086ff366c1b038">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or
                reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare
                program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z404a3a9fbb25442f9492b608cde07c92">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the federal false claims laws, including the civil False Claims Act, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to
                be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or knowingly making a
                false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback
                Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">31</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze1541992d3b44fe190546ce909f6c76d">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any
                healthcare benefit program or making false or fraudulent statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to
                violate it in order to have committed a violation;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb692c792ff9a47dabdf24c27d5a01b0b">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the
                privacy, security and transmission of individually identifiable health information;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb8344d41c6d04e3c9ae7635b66c34abc">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with
                certain exceptions) to report annually to the government information related to certain payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain
                other health care providers beginning in 2022, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the physicians
                described above and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners. Covered manufacturers are required to submit reports to the government by the 90<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day of each calendar year;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e26fbfd709c479ab273d2f2684cfd86">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbb52adcf8b224dfba2a5774ec050d41d">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving
                healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and
                the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report
                information related to payments and other transfers of value to physicians and other healthcare providers or that require the reporting of pricing information and marketing expenditures; and state laws governing the privacy and security of
                health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, the California Consumer Privacy Act, or the CCPA,
                which went into effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their
                personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc1e61e1fa0794a9793995da2e6cd69be">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>similar healthcare laws and regulations in the European Union and other non-U.S. jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security
                of certain protected information, such as the General Data Protection Regulation, or GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the EU (including health
                data) and the United Kingdom until the end of the transition period on 31 December 2020 provided for in the Withdrawal Agreement between the EU and the U.K.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">32</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is
        possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in
        violation of any of these or any other health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines,
        disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to
        resolve allegations of non-compliance, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and
        our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be
        brought against us, our business may be impaired.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The illegal distribution and sale by third parties of counterfeit versions of our product candidates or of stolen products could have a negative impact on our
        reputation and a material adverse effect on our business, results of operations and financial condition.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Third parties could illegally distribute and sell counterfeit versions of our product candidates, which do not meet the rigorous manufacturing and testing standards that our
        product candidates undergo. Counterfeit products are frequently unsafe or ineffective and can be life-threatening. Counterfeit medicines may contain harmful substances, the wrong dose of the active pharmaceutical ingredient or no active
        pharmaceutical ingredient at all. However, to distributors and users, counterfeit products may be visually indistinguishable from the authentic version.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Reports of adverse reactions to counterfeit drugs similar to our product candidates or increased levels of counterfeiting such products could materially affect physician and
        patient confidence in our authentic product candidates. It is possible that adverse events caused by unsafe counterfeit products will mistakenly be attributed to our authentic product candidates. In addition, thefts of our inventory at warehouses,
        plant or while in-transit, which are not properly stored and which are sold through unauthorized channels could adversely impact patient safety, our reputation and our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Public loss of confidence in the integrity of our pharmaceutical products as a result of counterfeiting or theft could have a material adverse effect on our business, financial
        position and results of operations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Related to Dependence on Third Parties</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Any collaborative arrangements that we have or may establish in the future may not be successful or we may otherwise not realize the anticipated benefits from
        these collaborations. We do not control third parties with whom we have or may have collaborative arrangements, and we will rely on them to achieve results which may be significant to us. In addition, any current or future collaborative
        arrangements may place the development and commercialization of our product candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">We are currently party to collaborative arrangements with respect to the development, manufacture, study and commercialization of certain of our product candidates with Perrigo. In addition, if
          Twyneo&#174; and Epsolay&#174; receive regulatory approval from the FDA, we intend to market them in the United States through one or more third party collaborators that have direct sales forces and established distribution systems in lieu of our own sales
          force and distribution systems. We are in discussions with potential partners regarding the commercialization of Twyneo&#174; and Epsolay&#174;. Any current or future potential collaborative arrangements may require us to rely on external consultants,
          advisors, and experts for assistance in several key functions, including clinical development, manufacturing, regulatory, intellectual property and sales and marketing. We cannot and will not control these third parties, but we may rely on them
          to achieve results, which may be significant to us. Relying upon collaborative arrangements to develop and commercialize our product candidates subjects us to a number of risks, including:</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za40348464dcb4e459d9a5294fe3543c8">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may not be able to control the amount and timing of resources that our collaborators may devote to our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">33</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb4c6219bbe434518b816ef23d9579272">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>should a collaborator fail to comply with applicable laws, rules, or regulations when performing services for us, we could be held liable for such violations;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z25dd98e011e14cbda73209c54a8a3b03">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our current or future collaborators may fail to comply with local or any foreign health authorities&#8217; laws and regulations, and as a result, the receipt of a site manufacturing, export or import license may be delayed or withheld for an
                undefined period;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zba5cf131d09846788794f3c3d0fec08f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our current or future collaborators may experience financial difficulties or changes in business focus;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z625149d318e04c6c8263608e69f48972">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our current or future collaborators&#8217; partners may fail to secure adequate commercial supplies of our product candidates upon marketing approval, if at all;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7dcf9a0a7dfe4155a8440e324bdf7c26">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our current or future collaborators&#8217; partners may have a shortage of qualified personnel;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd5c3606951f14e41adcede73dd7c8783">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we may be required to relinquish important rights, such as marketing and distribution rights;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8471a59934824fc79c875e9468b47404">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zff85acc845384cf890694219e1cdb71a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>under certain circumstances, a collaborator could move forward with a competing product developed either independently or in collaboration with others, including our competitors;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01373ffad52942e7af4b73f615337461">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our current or future collaborators may utilize our proprietary information in a way that could expose us to competitive harm; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7c0038f38193480c8a0bade84a8343b0">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>collaborative arrangements are often terminated or allowed to expire, which could delay the development and may increase the cost of developing our product candidates.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, if disputes arise between us and our collaborators, it could result in the delay or termination of the development, manufacturing or commercialization of our product
        candidates, lead to protracted and costly legal proceedings, or cause collaborators to act in their own interest, which may not be in our interest. As a result, there can be no assurance that the collaborative arrangements that we have entered
        into, or may enter into in the future, will achieve their intended goals.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If any of these scenarios materialize, they could have an adverse effect on our business, financial condition or results of operations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We also may have other product candidates where it is desirable or essential to enter into agreements with a collaborator who has greater financial resources or different
        expertise than us, but for which we are unable to find an appropriate collaborator or are unable to do so on favorable terms. If we fail to enter into such collaborative agreements on favorable terms, it could materially delay or impair our ability
        to develop and commercialize our product candidates and increase the costs of development and commercialization of such product candidates.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">34</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We currently contract with third-party manufacturers and suppliers for certain compounds and components necessary to produce our product candidates for
        clinical trials and expect to continue to do so to support commercial scale production if any of our product candidates is approved. This increases the risk that if any of our product candidates is approved, we may not have access to sufficient
        quantities or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We currently rely on third parties for the manufacture and supply of certain compounds and components necessary to produce our product candidates for our clinical trials,
        including API&#8217;s such as benzoyl peroxide and tretinoin and other active ingredients and excipients used in the formulation of our various product candidates, as well as primary and secondary packaging and labeling materials. We lack the resources
        and the capability to manufacture any of our product candidates on a clinical or commercial scale, and we expect to continue to rely on third parties to support our commercial requirements if any of our product candidates is approved for marketing
        by the FDA or other foreign regulatory authorities.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit
        our marketing applications to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as current good manufacturing
        practices, or cGMPs, for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the
        FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality
        assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find
        alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Reliance on third-party manufacturers and suppliers entails a number of risks, including reliance on the third party for regulatory compliance and quality assurance, the possible
        breach of the manufacturing or supply agreement by the third party, the possibility that the supply is inadequate or delayed, the risk that the third party may enter the field and seek to compete and may no longer be willing to continue supplying,
        and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. If any of these risks transpire, we may be unable to timely retain an alternate manufacturer or suppliers on acceptable
        terms and with sufficient quality standards and production capacity, which may disrupt and delay our clinical trials or the manufacture and commercial sale of our product candidates, if approved.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our failure or the failure of our third-party manufacturers and suppliers to comply with applicable regulations could result in sanctions being imposed on us, including fines,
        injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of
        our product candidates that we may develop. Any failure or refusal to supply or any interruption in supply of the components for any of our product candidates could delay, prevent or impair our clinical development or commercialization efforts.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We rely on third parties and consultants to assist us in conducting our clinical trials. If these third parties or consultants do not successfully carry out
        their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We do not have the ability to independently perform all aspects of our anticipated pre-clinical studies and clinical trials. We rely on medical institutions, clinical
        investigators, contract laboratories, collaborative partners and other third parties to assist us in conducting our clinical trials and studies for our product candidates. The third parties with whom we contract for execution of our clinical trials
        play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not employees, and except for contractual duties and obligations, we have limited ability to control the
        amount or timing of resources that they devote to our programs.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">35</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, the execution of pre-clinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, require coordination among these various
        third parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another, which may prove difficult to achieve. Moreover, these third parties may also
        have relationships with other commercial entities, some of which may compete with us. Our agreement with these third parties may inevitably enable them to terminate such agreements upon reasonable prior written notice under certain circumstances.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Although we rely on these third parties to conduct certain aspects of our clinical trials and other studies and clinical trials, we remain responsible for ensuring that each of
        our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. Moreover, the FDA and foreign
        regulatory authorities require us to comply with GCPs, which are the regulations and standards for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and
        accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We also rely on our consultants to assist us in the execution, including data collection and analysis of our clinical trials.
        If we or any of our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform
        additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP
        regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the third parties or consultants that assist us in conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not
        meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols, regulatory requirements
        or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or
        terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for the product candidates being tested in such trials, and will not be able to, or may
        be delayed in our efforts to, successfully commercialize these product candidates.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The manufacture of pharmaceutical products is complex, and manufacturers often encounter difficulties in production. If we or any of our third-party
        manufacturers encounter any difficulties, our ability to provide product candidates for clinical trials or our product candidates to patients, once approved, and the development or commercialization of our product candidates could be delayed or
        stopped.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The manufacture of pharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques
        and process controls. We and our contract manufacturers must comply with cGMP requirements. Manufacturers of pharmaceutical products often encounter difficulties in production, particularly in scaling up and validating initial production and
        contamination controls. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance
        with strictly enforced federal, state and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such
        manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates will not occur in the future. Additionally, we and our
        third-party manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If we or our third-party manufacturers were to encounter any of these difficulties,
        our ability to provide any product candidates to patients in clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the initiation or completion
        of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any
        adverse developments affecting clinical or commercial manufacturing of our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product
        candidates. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures
        or difficulties faced at any level of our supply chain could materially adversely affect our business and delay or impede the development and commercialization of any of our product candidates and could have a material adverse effect on our
        business, prospects, financial condition and results of operations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">36</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Related to Our Intellectual Property</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We depend on our intellectual property, and our future success is dependent on our ability to protect our intellectual property and not infringe on the rights
        of others.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our success depends, in part, on our ability to obtain patent protection for our product candidates, maintain the confidentiality of our trade secrets and know how, operate
        without infringing on the proprietary rights of others and prevent others from infringing our proprietary rights. We try to protect our proprietary position by, among other things, filing U.S., European, and other patent applications related to our
        product candidates, inventions and improvements that may be important to the continuing development of our product candidates. While we generally apply for patents in those countries where we intend to make, have made, use, or sell patented
        products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. In addition,
        we cannot assure you that:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb40afb3e04bb417781e8edeee68e8414">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>any of our future processes or product candidates will be patentable;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z55eeebb9fefb4067b584072926908615">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our processes or product candidates will not infringe upon the patents of third parties; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5cc90db275294231a3b8eb59e5f8a289">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we will have the resources to defend against charges of patent infringement or other violation or misappropriation of intellectual property by third parties or to protect our own intellectual property rights against infringement,
                misappropriation or violation by third parties.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Because the patent position of pharmaceutical companies involves complex legal and factual questions, we cannot predict the validity and enforceability of patents with certainty.
        Changes in either the patent laws or in interpretations of patent laws may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowable or enforceable in our patents (including patents
        owned by or licensed to us). Our issued patents may not provide us with any competitive advantages, may be held invalid or unenforceable as a result of legal challenges by third parties or could be circumvented. Our competitors may also
        independently develop formulations, processes and technologies or products similar to ours or design around or otherwise circumvent patents issued to, or licensed by, us. Thus, any patents that we own or license from others may not provide any
        protection against competitors. Our pending patent applications, those we may file in the future or those we may license from third parties may not result in patents being issued. If these patents are issued, they may not be of sufficient scope to
        provide us with meaningful protection. The degree of future protection to be afforded by our proprietary rights is uncertain because legal means afford relatively limited protection and may not adequately protect our rights or permit us to gain or
        keep our competitive advantage.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Patent rights are territorial; thus, the patent protection we do have will only extend to those countries in which we have issued patents. Even so, the laws of certain countries
        do not protect our intellectual property rights to the same extent as do the laws of the United States and the European Union. Therefore, we cannot assure you that the patents issued, if any, as a result of our foreign patent applications will have
        the same scope of coverage as our U.S. patents. Competitors may successfully challenge our patents, produce similar drugs or products that do not infringe our patents, or produce drugs in countries where we have not applied for patent protection or
        that do not respect our patents. Furthermore, it is not possible to know the scope of claims that will be allowed in published applications and it is also not possible to know which claims of granted patents, if any, will be deemed enforceable in a
        court of law.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">37</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">After the completion of development and registration of our patents, third parties may still act to manufacture and/or market products in infringement of our patent protected
        rights, and we may not have adequate resources to enforce our patents. Any such manufacture and/or market of products in infringement of our patent protected rights is likely to cause us damage and lead to a reduction in the prices of our product
        candidates, thereby reducing our anticipated cash flows and profits, if any.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, due to the extensive time needed to develop, test and obtain regulatory approval for our product candidates, any patents that protect our product candidates may
        expire early during commercialization. This may reduce or eliminate any market advantages that such patents may give us. Following patent expiration, we may face increased competition through the entry of competing products into the market and a
        subsequent decline in market share and profits.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have granted, and may in the future grant, to third parties licenses to use our intellectual property. Generally, these licenses have granted rights to commercialize products
        outside the pharmaceutical field or to technology we no longer use or to otherwise use our intellectual property for a limited purpose outside the scope of our business interests. For example, in August 2013 we entered into an assignment agreement
        with Medicis Pharmaceutical Corporation (&#8220;Medicis&#8221;), according to which Medicis assigned to us its entire interest in one of the patents upon which we rely for our product candidate Twyneo&#174; for the treatment of acne . As part of this assignment
        agreement, we granted to Medicis a non-exclusive, transferable, sub-licensable, royalty-free, perpetual, license to practice the inventions claimed under the patent.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">However, our business interests may change or our licensees may disagree with the scope of our license grant. In such cases, such licensing arrangements may result in the
        development, manufacturing, marketing and sale by our licensees of products substantially similar to our products, causing us to face increased competition, which could reduce our market share and significantly harm our business, results of
        operations and prospects.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to filing patent applications, we generally try to protect our trade secrets, know-how, technology and other proprietary information by entering into confidentiality
        or non-disclosure agreements with parties that have access to it, such as our development and/or commercialization partners, employees, contractors and consultants. We also enter into agreements that purport to require the disclosure and assignment
        to us of the rights to the ideas, developments, discoveries and inventions of our employees, advisors, research collaborators, contractors and consultants while we employ or engage them. However, we cannot assure you that these agreements will
        provide meaningful protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use, misappropriation or disclosure of such trade secrets, know-how or other proprietary information because these
        agreements can be difficult and costly to enforce or may not provide adequate remedies. Any of these parties may breach the confidentiality agreements and willfully or unintentionally disclose our confidential information, or our competitors might
        learn of the information in some other way. The disclosure to, or independent development by, a competitor of any trade secret, know-how or other technology not protected by a patent could materially adversely affect any competitive advantage we
        may have over any such competitor.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">To the extent that any of our employees, advisors, research collaborators, contractors or consultants independently develop, or use independently developed, intellectual property
        in connection with any of our projects, disputes may arise as to the proprietary rights to this type of information. If a dispute arises with respect to any proprietary right, enforcement of our rights can be costly and unpredictable, and a court
        may determine that the right belongs to a third party.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">38</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Legal proceedings or third-party claims of intellectual property infringement and other challenges may require us to spend substantial time and money and
        could prevent us from developing or commercializing our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The development, manufacture, use, offer for sale, sale or importation of our product candidates may infringe on the claims of third-party patents or other intellectual property
        rights. The nature of claims contained in unpublished patent filings around the world is unknown to us and it is not possible to know which countries patent holders may choose for the extension of their filings under the Patent Cooperation Treaty,
        or other mechanisms. Therefore, there is a risk that we could adopt a technology without knowledge of a pending patent application, which technology would infringe a third-party patent once that patent is issued. We may also be subject to claims
        based on the actions of employees and consultants with respect to the usage or disclosure of intellectual property learned at other employers. The cost to us of any intellectual property litigation or other infringement proceeding, even if resolved
        in our favor, could be substantial. Any claims of patent infringement, even those without merit, could: be expensive and time consuming to defend; cause us to cease making, licensing or using products that incorporate the challenged intellectual
        property; require us to redesign, reengineer or rebrand our product candidates, if feasible; cause us to stop from engaging in normal operations and activities, including developing and marketing product candidates; and divert management&#8217;s
        attention and resources. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively because of their substantially greater financial resources. Uncertainties resulting from the initiation and
        continuation or defense of intellectual property litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Intellectual property litigation and other proceedings may also absorb significant
        management time. Consequently, we are unable to guarantee that we will be able to manufacture, use, offer for sale, sell or import our product candidates in the event of an infringement action.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the event of patent infringement claims, or to avoid potential claims, we may choose or be required to seek a license from a third party and would most likely be required to
        pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could potentially limit our competitive advantage.
        Ultimately, we could be prevented from commercializing a product or be forced to cease some aspect of our business operations if, as a result of actual or threatened patent infringement or other claims, we are unable to enter into licenses on
        acceptable terms. This inability to enter into licenses could harm our business significantly.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, because of our developmental stage, claims that our product candidates infringe on the patent rights of others are more likely to be asserted after commencement of
        commercial sales incorporating our technology.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third
        parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
        Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or
        independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees&#8217; former employers or other third parties. Litigation may be necessary
        to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in
        defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">39</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Although we believe that we take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure of confidential information
        to third parties, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them, the agreements can be
        difficult and costly to enforce. Although we seek to obtain these types of agreements from our contractors, consultants, advisors and research collaborators, to the extent that employees and consultants utilize or independently develop intellectual
        property in connection with any of our projects, disputes may arise as to the intellectual property rights associated with our product candidates. If a dispute arises, a court may determine that the right belongs to a third party. In addition,
        enforcement of our rights can be costly and unpredictable. We also rely on trade secrets and proprietary know-how that we seek to protect in part by confidentiality agreements with our employees, contractors, consultants, advisors or others.
        Despite the protective measures we employ, we still face the risk that:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0432231863a34e60bef47229dfc7f712">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>these agreements may be breached;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbe8f0d03544f4136b1701555e69f46f7">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>these agreements may not provide adequate remedies for the applicable type of breach;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z762068082c094de7a371d13cf6f32fa0">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our trade secrets or proprietary know-how will otherwise become known; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z966bbde5a2264680bb038025a2c41533">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>our competitors will independently develop similar technology or proprietary information.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">International patent protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to expend
        substantial sums and management resources.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Patent law outside the United States may be different than in the United States. Further, the laws of some foreign countries may not protect our intellectual property rights to
        the same extent as the laws of the United States, if at all. A failure to obtain sufficient intellectual property protection in any foreign country could materially and adversely affect our business, results of operations and future prospects.
        Moreover, we may participate in opposition proceedings to determine the validity of our foreign patents or our competitors&#8217; foreign patents, which could result in substantial costs and divert management&#8217;s resources and attention. Additionally, due
        to uncertainty in patent protection law, we have not filed applications in many countries where significant markets exist.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the
        review or approval of our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the United States, we have filed and may in the future file NDAs for our product candidates for approval under Section 505(b)(2) of the FDCA. Section 505(b)(2) permits the
        submission of an NDA where at least some of the information required for approval comes from studies that were not conducted by, or for, the applicant and on which the applicant has not obtained a right of reference. To date we have filed two NDAs
        for our products candidates under this section. In October 2020, we submitted an NDA for marketing approval for Twyneo, and in June 2020, we submitted an NDA for marketing approval for Epsolay.&#160; Both of these NDA&#8217;s have been accepted for filing by
        the FDA.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A 505(b)(2) application enables us to reference published literature and/or the FDA&#8217;s previous findings of safety and effectiveness for the branded reference drug. For NDAs
        submitted under Section 505(b)(2) of the FDCA, the patent certification and related provisions of the Hatch-Waxman Act apply. In accordance with the Hatch-Waxman Act, such NDAs may be required to include certifications, known as paragraph IV
        certifications, that certify that any patents listed in the Patent and Exclusivity Information Addendum of the FDA&#8217;s publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, with respect to
        any product referenced in the 505(b)(2) application, are invalid, unenforceable or will not be infringed by the manufacture, use or sale of the product that is the subject of the 505(b)(2) NDA. Applicants must also notify the holder of the approved
        NDA for any product referenced in the 505(b)(2) application, along with all patent owners, regarding submission of a paragraph IV certification with respect to applicable patents listed in the Orange Book.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">40</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Hatch-Waxman Act, the NDA holder and patent owner(s) may file a patent infringement lawsuit after receiving notice of the paragraph IV certification. Filing of a patent
        infringement lawsuit against the filer of the 505(b)(2) application within 45 days of the patent owner&#8217;s receipt of notice triggers a one-time, automatic, 30-month stay of the FDA&#8217;s ability to approve the 505(b)(2) NDA, unless patent litigation is
        resolved in the favor of the paragraph IV filer or the patent expires before that time. Accordingly, we may invest a significant amount of time and expense in the development of one or more product candidates only to be subject to significant delay
        and patent litigation before such product candidates may be commercialized, if at all. In addition, a 505(b)(2) application will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity,
        or NCE, listed in the Orange Book for the referenced product has expired. The FDA may also require us to perform one or more additional clinical trials or measurements to support the change from the branded reference drug, which could be time
        consuming and could substantially delay our achievement of regulatory approvals for such product candidates. The FDA may also reject our future 505(b)(2) submissions and require us to file such submissions under Section 505(b)(1) of the FDCA, which
        would require us to provide extensive data to establish safety and effectiveness of the drug for the proposed use and could cause delay and be considerably more expensive and time consuming. These factors, among others, may limit our ability to
        successfully commercialize our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Companies that produce branded reference drugs routinely bring litigation against ANDA or 505(b)(2) applicants that seek regulatory approval to manufacture and market generic and
        reformulated forms of their branded products. These companies often allege patent infringement or other violations of intellectual property rights as the basis for filing suit against an ANDA or 505(b)(2) applicant. Likewise, patent holders may
        bring patent infringement suits against companies that are currently marketing and selling their approved generic or reformulated products.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Litigation to enforce or defend intellectual property rights is often complex and often involves significant expense and can delay or prevent introduction or sale of our product
        candidates. If patents are held to be valid and infringed by our product candidates in a particular jurisdiction, we would, unless we could obtain a license from the patent holder, be required to cease selling in that jurisdiction and may need to
        relinquish or destroy existing stock in that jurisdiction. There may also be situations where we use our business judgment and decide to market and sell our approved product candidates, notwithstanding the fact that allegations of patent
        infringement(s) have not been finally resolved by the courts, which is known as an &#8220;at-risk launch.&#8221; The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement may include, among other
        things, damages measured by the profits lost by the patent owner and not necessarily by the profits earned by the infringer. In the case of a willful infringement, the definition of which is subjective, such damages may be increased up to three
        times. Moreover, because of the discount pricing typically involved with bioequivalent and, to a lesser extent, 505(b)(2), products, patented branded products generally realize a substantially higher profit margin than bioequivalent and, to a
        lesser extent, 505(b)(2), products, resulting in disproportionate damages compared to any profits earned by the infringer. An adverse decision in patent litigation could have a material adverse effect on our business, financial position and results
        of operations and could cause the market value of our ordinary shares to decline.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Related to Our Operations in Israel</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our headquarters, manufacturing and other significant operations are located in Israel and, therefore, our business and operations may be adversely affected
        by political, economic and military conditions in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our business and operations will be directly influenced by the political, economic and military conditions affecting Israel at any given time. A change in the security and
        political situation in Israel and in the economy could impede the raising of the funds required to finance our research and development plans and to create joint ventures with third parties and could otherwise have a material adverse effect on our
        business, operating results and financial condition. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its Arab neighbors, including Hezbollah in Lebanon (and Syria) and Hamas in
        the Gaza Strip, both of which involved missile strikes in various parts of Israel causing the disruption of economic activities. Our principal offices are located within the range of rockets that could be fired from Lebanon, Syria or the Gaza Strip
        into Israel. In addition, Israel faces many threats from more distant neighbors, in particular, Iran.&#160; Parties with whom we do business have sometimes declined to travel to Israel during periods of heightened unrest or tension, forcing us to make
        alternative arrangements when necessary. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their
        commitments under those agreements pursuant to force majeure provisions in such agreements. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could result in damage to our
        facilities and likewise have a material adverse effect on our business, operating results and financial condition.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">41</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Several countries, principally in the Middle East, restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions on doing business
        with Israel and Israeli companies if hostilities in the region continue or intensify. Such restrictions may seriously limit our ability to sell our product candidates to customers in those countries. Any hostilities involving Israel or the
        interruption or curtailment of trade between Israel and its present trading partners, or significant downturns in the economic or financial condition of Israel, could adversely affect our operations and product development, cause our revenues to
        decrease and adversely affect the share price of publicly traded companies having operations in Israel, such as us. Similarly, Israeli corporations are limited in conducting business with entities from several countries.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government
        is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, there can be no assurance that this government coverage will be maintained, or if maintained, will be sufficient to
        compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition and results of operations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Exchange rate fluctuations between the U.S. dollar, the New Israeli Shekel and other foreign currencies, may negatively affect our future revenues.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the future, we expect that a substantial portion of our revenues will be generated in U.S. dollars, Euros and other foreign currencies, although we currently incur a
        significant portion of our expenses in currencies other than U.S. dollars, and mainly in NIS. Our financial records are maintained, and will be maintained, in U.S. dollars, which is our functional currency. As a result, our financial results may be
        affected by fluctuations in the exchange rates of currencies in the countries in which our prospective product candidates may be sold.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our operations may be affected by negative labor conditions in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Strikes and work-stoppages occur relatively frequently in Israel. If Israeli trade unions threaten additional strikes or work-stoppages and such strikes or work-stoppages occur,
        those may, if prolonged, have a material adverse effect on the Israeli economy and on our business, including our ability to deliver products to our customers and to receive raw materials from our suppliers in a timely manner.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our operations could be disrupted as a result of the obligation of our personnel to perform military service.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Most of our executive officers and key employees reside in Israel and, although most of them are no longer required to perform reserve duty, some may be required to perform
        annual military reserve duty and may be called for active duty under emergency circumstances at any time. Our operations could be disrupted by the absence for a significant period of time of one or more of these officers or key employees due to
        military service. Any such disruption could adversely affect our business, results of operations and financial condition.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">42</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The termination or reduction of tax and other incentives that the Israeli Government provides to domestic companies may increase the costs involved in
        operating a company in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-align: left; line-height: 1.25;">The Israeli government currently provides tax and capital investment incentives to domestic companies, as well as grant and loan programs relating to research and development and marketing and
          export activities. In recent years, the Israeli Government has reduced the benefits available under these programs and the Israeli Governmental authorities have indicated that the government may in the future further reduce or eliminate the
          benefits of those programs. We may take advantage of these benefits and programs in the future; however, there is no assurance that such benefits and programs would continue to be available in the future to us. If such benefits and programs were
          terminated or further reduced, it could have an adverse effect on our business, operating results and financial condition.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The Israeli government grants that we have received require us to meet several conditions and may restrict our ability to manufacture some of our product
        candidates and transfer relevant know-how outside of Israel and require us to satisfy specified conditions.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have received royalty-bearing grants from the government of Israel through the National Authority for Technological Innovation, or the Israel Innovation Authority, also known
        as the IIA (formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS), for the financing of a portion of our research and development expenditures in Israel. These IIA grants relate to a peripheral
        line of product candidates which forms a negligible part of our activities. We are required to pay the IIA royalties from the revenues generated from the sale of products (and related services) or services developed (in all or in part) according
        to, or as a result of, a research and development program funded by the IIA (at rates which are determined under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984, or the Innovation Law, and
        related rules and regulations), up to the aggregate amount of the total grants received by the IIA, plus annual interest at an annual rate based on LIBOR. When know-how is developed using IIA grants, the Innovation Law, the IIA&#8217;s rules and
        guidelines as well as the terms of these grants, restrict our ability to manufacture product candidates and transfer know-how developed as a result of the IIA&#8217;s funded R&amp;D outside of Israel. Transfer of the IIA funded know-how outside of Israel
        where the transferring company remains an operating Israeli entity or where the transferring company ceases to exist as an Israeli entity, requires pre-approval by the IIA, which may, at its sole discretion, grant such approval and impose certain
        conditions, including payment of a redemption fee calculated according to the formulas provided in the IIA&#8217;s rules and guidelines, or Redemption Fee, which takes into account the consideration for such know-how paid to the transferring company in
        the transaction in which the know-how is transferred. The IIA&#8217;s rules and guidelines establish a maximum payment of the Redemption Fee under the formulas provided in the IIA&#8217;s rules and guidelines and differentiates between certain situations, as
        further detailed in such rules and guidelines (while in any event the Redemption Fee will not exceed six times the grants received). In addition, the product candidates may be manufactured outside of Israel by us or by another entity only if prior
        approval is received from the IIA (such approval is not required for the transfer of less than 10% of the manufacturing capacity in the aggregate). In addition to the obligation to receive prior approval to manufacture outside Israel, in general, a
        company that transfers manufacturing rights abroad will be required to pay royalties at an accelerated rate and will be required to pay increased royalties, as defined under the IIA&#8217;s rules and guidelines. The total amount of the increased
        royalties to be repaid to the IIA shall not exceed, in the aggregate, 300% of the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR, depending on the manufacturing volume that is performed outside Israel less
        royalties already paid to the IIA.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A company also has the option of declaring in its IIA grant application its intention to exercise a portion of the manufacturing capacity abroad, thus avoiding the need to obtain
        additional approval following the receipt of the grant and avoiding the need to pay increased royalties to the IIA.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The IIA has published certain rules and guidelines with respect to the grant to a foreign entity of the right to use know-how that was developed using the IIA&#8217;s grants, or Funded
        Know-How. According to these rules, the grant to a foreign entity of a right to use the Funded Know-How (which does not entirely prevent the IIA funded company from using the Funded Know-How) is subject to receipt of the IIA&#8217;s prior approval. This
        approval is subject to payment to the IIA in accordance with the formulas stipulated in these rules.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">43</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The abovementioned rules include a mechanism with respect to the grant of a license by a company (which is part of a multinational corporation) that received grants from the IIA
        to its group entities to use its funded Know-How. Such license is subject to the IIA&#8217;s prior approval and to the payment of 5% royalties from the income deriving from such license. Such mechanism includes certain restrictions which must be met in
        order to be able to enjoy such lower royalty payment.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to prior consent of the IIA, we may transfer Funded Know-How to another Israeli company, provided that the acquiring company assumes all of our responsibilities toward
        the IIA. In addition, such transfer will not be subject to the payment of the Redemption Fee, but there will be an obligation to pay royalties to the IIA from the income of such sale transaction as part of the royalty payment obligation.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The restrictions under the IIA&#8217;s rules and guidelines continue to apply even after payment of the full amount of royalties payable pursuant to the grants. In addition, the
        government of the State of Israel may from time to time audit sales of products which it claims incorporate Funded Know-How and this may lead to additional royalties being payable on additional product candidates. Following an audit conducted by
        the IIA, the IIA confirmed to us that products based on encapsulation technology of solid material are exempt from royalty payment obligations to the IIA. Our product candidates Twyneo&#174; and Epsolay&#174; fall within the category of products based on
        encapsulation technology of solid material. However, there can be no guarantee that the IIA will not in the future attempt to claim royalties with respect to these products, or that future products will not be subject to royalties.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">These restrictions may impair our ability to enter into agreements for Funded Know-How product candidates or technologies without the approval of the IIA. We cannot be certain
        that any approval of the IIA will be obtained on terms that are acceptable to us, or at all. Furthermore, in the event that we undertake a transaction involving the transfer to a non-Israeli entity of Funded Know-How pursuant to a merger or similar
        transaction, or in the event we undertake a transaction involving the licensing of Funded Know-How, the consideration available to our shareholders may be reduced by the amounts we are required to pay to the IIA. Any approval, if given, will
        generally be subject to additional financial obligations. Failure to comply with the requirements under the IIA&#8217;s rules and guidelines and the Innovation Law may subject us to financial sanctions, to mandatory repayment of grants received by us
        (together with interest and penalties), as well as expose us to criminal proceedings.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In August&#160;2015, an amendment to the Innovation Law was enacted, or Amendment No. 7, which came into effect on January&#160;1, 2016. Since Amendment No.&#160;7 has entered into force, the
        IIA was appointed to act as the entity which is responsible for the activity which was previously under the OCS&#8217; responsibility. The IIA was granted wide freedom of action, and among other things, the authority to amend the requirements and
        restrictions which were specified in the Innovation Law before Amendment No. 7 became effective with respect to the ownership of Funded Know-How (including with respect to the restrictions on transfer of the Funded Know-How and manufacturing
        activities outside of Israel) as well as with respect to royalty payment obligations which apply to companies that received grants from the IIA. The IIA published rules for the most part adopted the principal provisions and restrictions specified
        in the Innovation Law prior to the effectiveness of Amendment No.&#160;7. See &#8220;Item 4. Information on the Company &#8211; B. Business Overview &#8212; Government Regulation &#8212; <font style="font-style: italic;">IIA</font>.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Enforcing a U.S. judgment against us and our current executive officers and directors, or asserting U.S. securities law claims in Israel, may be difficult.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are incorporated in Israel. All of our current executive officers and directors reside in Israel (other than two of our directors and one of our executive officers who reside
        in the United States) and most of our assets reside outside of the United States. Therefore, a judgment obtained against us or any of these persons in the United States, including one based on the civil liability provisions of the U.S. federal
        securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It may also be difficult to effect service of process on these persons in the United States or to assert U.S. securities law claims in
        original actions instituted in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Even if an Israeli court agrees to hear such a claim, it may determine that Israeli, and not U.S., law is applicable to the claim. Under Israeli law, if U.S. law is found to be
        applicable to such a claim, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would be governed by Israeli law. There is little binding case law in Israel
        addressing these matters.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">44</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Provisions of our amended and restated articles of association and Israeli law and tax considerations may delay, prevent or make difficult an acquisition of
        us, which could prevent a change of control and negatively affect the price of our ordinary shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for certain transactions
        involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions. These provisions of Israeli law may delay, prevent or make difficult an acquisition of us, which could
        prevent a change of control and therefore depress the price of our ordinary shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association provide that our directors (other than external directors) are elected on a staggered basis, such that a potential acquirer
        cannot readily replace our entire board of directors at a single annual general shareholder meeting.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders, especially for those shareholders whose country of residence
        does not have a tax treaty with Israel which exempts such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows
        for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions
        of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition
        of the shares has occurred.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and
        adversely affect our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have entered into assignment of invention agreements with our employees pursuant to which such individuals agree to assign to us all rights to any inventions created during
        and as a result of their employment or engagement with us. A significant portion of our intellectual property has been developed by our employees in the course of their employment for us. Under the Israeli Patents Law, 5727-1967, or the Patents
        Law, inventions conceived by an employee during the scope of his or her employment with a company and as a result thereof are regarded as &#8220;service inventions,&#8221; which belong to the employer, absent a specific agreement between the employee and
        employer giving the employee service invention rights. The Patents Law also provides that if there is no agreement between an employer and an employee with respect to the employee&#8217;s right to receive compensation for such &#8220;service inventions,&#8221; the
        Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patents Law, shall determine whether the employee is entitled to remuneration for service inventions developed by such employee and the scope and
        conditions for such remuneration. Although our employees have agreed to assign to us service invention rights and have waived their right to receive remuneration for their service inventions, as a result of uncertainty under Israeli law with
        respect to the efficacy of waivers of service invention rights, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to
        our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The government tax benefits that we currently are entitled to receive require us to meet several conditions and may be terminated or reduced in the future.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Some of our operations in Israel may entitle us to certain tax benefits under the Law for the Encouragement of Capital Investments, 5719-1959, or the Investment Law, once we
        begin to produce revenues. If we do not meet the requirements for maintaining these benefits, they may be reduced or cancelled and the relevant operations would be subject to Israeli corporate tax at the standard rate, which is set at 23% in 2020.
        In addition to being subject to the standard corporate tax rate, we could be required to refund any tax benefits that we have already received, plus interest and penalties thereon. Even if we continue to meet the relevant requirements, the tax
        benefits that our current &#8220;Benefited Enterprise&#8221; is entitled to may not be continued in the future at their current levels or at all. If these tax benefits were reduced or eliminated, the amount of taxes that we pay would likely increase, as all of
        our operations would consequently be subject to corporate tax at the standard rate, which could adversely affect our results of operations. Additionally, if we increase our activities outside of Israel, for example, by way of acquisitions, our
        increased activities may not be eligible for inclusion in Israeli tax benefits programs. See &#8220;Item 10. Additional Information &#8212; Israeli Tax Considerations and Government Programs &#8212; Tax Benefits Under the 2011 Amendment&#8221; for additional information
        concerning these tax benefits.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">45</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and
        responsibilities of shareholders of U.S. companies.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The rights and responsibilities of the holders of our ordinary shares are governed by our amended and restated articles of association and by Israeli law. These rights and
        responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. corporations. For example, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising
        its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, voting at a general meeting of shareholders on matters such as amendments to
        a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval. In addition, a shareholder who is aware that it possesses the power to
        determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding the
        nature of these duties or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S.
        corporations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Related to Employee Matters</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If we are not able to retain our key management, or attract and retain qualified scientific, technical and business personnel, our ability to implement our
        business plan may be adversely affected.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our success largely depends on the skill, experience and effort of our senior management. The loss of the service of any of these persons, including the chairman of our board of
        directors, Mr. Moshe Arkin, and our chief executive officer, Dr. Alon Seri-Levy, would likely result in a significant loss in the knowledge and experience that we possess and could significantly delay or prevent successful product development and
        other business objectives. There is intense competition from numerous pharmaceutical and biotechnology companies, universities, governmental entities and other research institutions, seeking to employ qualified individuals in the technical fields
        in which we operate, and we may not be able to attract and retain the qualified personnel necessary for the successful development and commercialization of our product candidates.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Under applicable employment laws, we may not be able to enforce covenants not to compete.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our employment agreements generally include covenants not to compete. These agreements prohibit our employees, if they cease working for us, from competing directly with us or
        working for our competitors for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work. For example, Israeli courts have required employers seeking to enforce covenants not to
        compete to demonstrate that the competitive activities of a former employee will harm one of a limited number of material interests of the employer, such as the secrecy of a company&#8217;s confidential commercial information or the protection of its
        intellectual property. If we cannot demonstrate that such an interest will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees and our competitiveness may be diminished.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">46</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Risks Related to Our Ordinary Shares</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The controlling share ownership position of Arkin Dermatology will limit your ability to elect the members of our board of directors, may adversely affect our
        share price and will result in our non-affiliated investors having very limited, if any, influence on corporate actions.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Arkin Dermatology is currently our controlling shareholder. As of February 26, 2020, Arkin Dermatology beneficially owned approximately 62.75% of the voting power of our outstanding ordinary
          shares. Therefore, Arkin Dermatology has the ability to substantially influence us and exert significant control through this ownership position. For example, Arkin Dermatology is able to control elections of directors, amendments of our
          organizational documents, and approval of any merger, amalgamation, sale of assets or other major corporate transaction. Arkin Dermatology&#8217;s interests may not always coincide with our corporate interests or the interests of other shareholders,
          and it may exercise its voting and other rights in a manner with which you may not agree or that may not be in the best interests of our other shareholders. So long as it continues to own a significant amount of our equity, Arkin Dermatology will
          continue to be able to strongly influence and significantly control our decisions.</div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We are a &#8220;controlled company&#8221; within the meaning of Nasdaq listing standards and, as a result, will qualify for, and intend to rely on, exemptions from
        certain corporate governance requirements.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a result of the number of shares owned by Arkin Dermatology, we are a &#8220;controlled company&#8221; under the Nasdaq corporate governance rules. A &#8220;controlled company&#8221; is a company of
        which more than 50% of the voting power is held by an individual, group or another company. Pursuant to the &#8220;controlled company&#8221; exemption, we are not required to, and may not in the future comply with the requirement that a majority of our board
        of directors consist of independent directors, and we are not required to, and do not intend to comply with the requirement that we have a nominating committee composed entirely of independent directors with a written charter addressing such
        committee&#8217;s purpose and responsibilities. A majority of our board of directors currently consists of independent directors. See &#8220;Item 16G. Corporate Governance&#8212;Controlled Company.&#8221;&#160; Accordingly, you do not have the same protections afforded to
        shareholders of companies that are subject to all of the corporate governance requirements of the Nasdaq Global Market.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The market price of our ordinary shares could be negatively affected by future sales of our ordinary shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As of February 26, 2021, there were 23,000,782 ordinary shares outstanding. Future sales by us or our shareholders of a substantial number of our ordinary shares in the public
        market, or the perception that these sales might occur, could cause the market price of our ordinary shares to decline or could impair our ability to raise capital through a future sale of, or pay for acquisitions using, our equity securities. Of
        our issued and outstanding shares, all of the ordinary shares listed for trading are freely transferable, except for any shares held by our &#8220;affiliates,&#8221; as that term is defined in Rule 144 under the Securities Act of 1933, as amended, or the
        Securities Act.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, we have filed a registration statement on Form S-8 with the Securities and Exchange Commission, or the SEC, covering all of the ordinary shares issuable under our
        2014 Share Incentive Plan, and we intend to filed one or more registration statements on Form S-8 covering all of the ordinary shares issuable under&#160; any other equity incentive plans that we may adopt, and such shares will be freely transferable,
        except for any shares held by &#8220;affiliates,&#8221; as such term is defined in Rule 144 under the Securities Act. The market price of our ordinary shares may drop significantly when the restrictions on resale by our existing shareholders lapse and these
        shareholders are able to sell our ordinary shares into the market.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Upon the filing of the registration statements and following the expiration of the lock-up restrictions described above, the number of ordinary shares that are potentially
        available for sale in the open market will increase materially, which could make it harder for the value of our ordinary shares to appreciate unless there is a corresponding increase in demand for our ordinary shares. This increase in available
        shares could result in the value of your investment in our ordinary shares decreasing.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">47</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, a sale by us of additional ordinary shares or similar securities in order to raise capital might have a similar negative impact on the share price of our ordinary
        shares. A decline in the price of our ordinary shares might impede our ability to raise capital through the issuance of additional ordinary shares or other equity securities and may cause you to lose part or all of your investment in our ordinary
        shares.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Arkin Dermatology, our controlling shareholder, as holder of 14,432,266 of our ordinary shares as of February 26, 2021, is entitled to require that we register under the
        Securities Act the resale of these shares into the public markets. All shares sold pursuant to an offering covered by such registration statement will be freely transferable. See &#8220;Item 7.B&#160;&#8212;&#160;Related Party Transactions&#160;&#8212;&#160;Registration Rights
        Agreement&#8221;.</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We have broad discretion as to the use of the net proceeds from our public offerings and may not use them effectively.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We intend to use the remaining net proceeds from our public offerings in August 2019 and February 2020 (and concurrent private placement with our controlling shareholder, Arkin
        Dermatology)<font style="font-style: italic;">&#160;</font>to fund pre-commercialization and launch activities for Epsolay and Twyneo and fund development activities for our other branded product candidates. The remaining proceeds will be used for other
        research and development activities, including the development of our generic product candidates, as well as for working capital and general corporate purposes. However, our management has broad discretion in the application of the net proceeds.
        Our shareholders may not agree with the manner in which our management chooses to allocate the net proceeds from our initial public offering. The failure by our management to apply these funds effectively could have a material adverse effect on our
        business, financial condition and results of operation. Pending their use, we may invest the net proceeds from our initial public offering in a manner that does not produce income.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We do not intend to pay dividends on our ordinary shares for at least the next several years.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We do not anticipate paying any cash dividends on our ordinary shares for at least the next several years. We currently intend to retain all available funds and any future
        earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our ordinary shares will be the investors&#8217; sole source of gain for at least the next several years. In addition, Israeli law limits our
        ability to declare and pay dividends and may subject us to certain Israeli taxes. For more information, see &#8220;Item 8. Financial Information &#8211; A. Financial Statements and Other Financial Information &#8211; Dividend Policy.&#8221;</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">As a foreign private issuer whose shares are listed on The Nasdaq Global Market, we intend to follow certain home country corporate governance practices
        instead of certain Nasdaq requirements.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a foreign private issuer whose shares will be listed on The Nasdaq Global Market, we are permitted to follow certain home country corporate governance practices instead of
        certain requirements of the rules of The Nasdaq Global Market. Pursuant to the &#8220;foreign private issuer exemption&#8221;:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb60d89f8dd114f9aad9caebc283e38d9">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>
                <div style="font-family: 'Times New Roman', Times, serif;">we established a quorum requirement such that the quorum for any meeting of shareholders is two or more shareholders holding at least 33 1&#8725;3% of our voting rights, which complies
                  with Nasdaq requirements; however, if the meeting is adjourned for lack of quorum, the quorum for such adjourned meeting will be any number of shareholders, instead of 33 1&#8725;3% of our voting rights;</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5eadf30abc154a4cbf108d115cc4ab33">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we also intend to adopt and approve material changes to equity incentive plans in accordance with Israeli Companies Law, 5759-1999, or with the Companies Law, which does not impose a requirement of shareholder approval for such actions.
                In addition, we intend to follow Israeli corporate governance practice in lieu of Nasdaq Marketplace Rule 5635(c), which requires shareholder approval prior to an issuance of securities in connection with equity-based compensation of
                officers, directors, employees or consultants;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">48</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z98deae1f6ab54d8ab2c4f9bf47b33f55">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>as opposed to making periodic reports to shareholders in the manner specified by the Nasdaq corporate governance rules, the Companies Law does not require us to distribute periodic reports directly to shareholders, and the generally
                accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. We will only mail such reports to shareholders upon request; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z14c3a615ed1c4158a6a7f2fa27b04b23">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we will follow Israeli corporate governance practice instead of Nasdaq requirements to obtain shareholder approval for certain dilutive events (such as issuances that will result in a change of control, certain transactions other than a
                public offering involving issuances of a 20% or greater interest in us and certain acquisitions of the stock or assets of another company). Accordingly, our shareholders may not be afforded the same protection as provided under Nasdaq
                corporate governance rules.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Otherwise, we intend to comply with the rules generally applicable to U.S. domestic companies listed on the Nasdaq Global Market. However, we may in the future decide to use the
        foreign private issuer exemption with respect to some or all of the other Nasdaq corporate governance rules. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the
        Nasdaq Global Market may provide less protection than is accorded to investors of domestic issuers. See &#8220;Item 16G. Corporate Governance &#8211; Controlled Company".</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, as a foreign private issuer, we are exempted from the rules and regulations under the United States Securities Exchange Act of 1934, as amended, or the Exchange Act,
        related to the furnishing and content of proxy statements (including disclosures with respect to executive compensation), and our officers, directors, and principal shareholders are exempted from the reporting and short-swing profit recovery
        provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as domestic companies
        whose securities are registered under the Exchange Act.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We may lose our foreign private issuer status which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur
        significant legal, accounting and other expenses.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable
        to U.S. domestic issuers. In order to maintain our current status as a foreign private issuer, either (a) a majority of our ordinary shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a
        majority of our executive officers or directors may not be U.S. citizens or residents, (ii) more than 50 percent of our assets cannot be located in the United States and (iii) our business must be administered principally outside the United States.
        If we were to lose this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We
        may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting
        requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial
        compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive
        for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and
        retain qualified members of our supervisory board.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We are an &#8220;emerging growth company&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less
        attractive to investors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to other public
        companies that are not &#8220;emerging growth companies.&#8221; Most of such requirements relate to disclosures that we would only be required to make if we also ceased to be a foreign private issuer in the future, for example, the requirement to hold
        stockholder advisory votes on executive and severance compensation and executive compensation disclosure requirements for U.S. companies. However, as a foreign private issuer, we could still be required to comply with the auditor attestation
        requirements of Section 404 of the Sarbanes-Oxley Act. We are exempt from such requirement for as long as we remain an emerging growth company, which may be up to five fiscal years after the date of our initial public offering. We will remain an
        emerging growth company until the earliest of: (a) the last day of our fiscal year during which we have total annual gross revenues of at least $1.07 billion; (b) December 31, 2023, the last day of our fiscal year following the fifth anniversary of
        the closing of our initial public offering; (c) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (d) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under
        the Exchange Act. We may choose to take advantage of some or all of the available exemptions. When we are no longer deemed to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. We
        cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors find our ordinary shares less attractive as a result, there may be a less active trading
        market for our ordinary shares and our share price may be more volatile.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">49</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25; font-style: italic; font-weight: bold;">We may be considered to be a passive foreign investment company for U.S. federal income tax purposes for the current
        tax year and possibly thereafter, which could result in materially adverse U.S. federal income tax consequences to U.S. Holders of our ordinary shares or warrants.</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">A non-U.S. entity treated as a corporation for U.S. federal income tax purposes will be a passive foreign investment company, or PFIC,
        for any taxable year if either (i) at least 75% of its gross income for such year is passive income or (ii) at least 50% of the value of its assets (based on an average of the quarterly values of the assets) during such year is attributable to
        assets that produce passive income or are held for the production of passive income. Starting in the first quarter of 2019, we began generating revenue under our collaboration agreement with Perrigo for the development of the generic version of
        Zovirax&#174; (acyclovir) cream, 5%. We generated $8.7 million in revenue under this agreement for our 2020 taxable year, but expect to generate substantially less in future years. Though the application of the relevant rules governing the
        characterization of such revenue for purposes of the PFIC income test is uncertain, we intend to take the position that, based on our involvement and management contributions throughout the development process, such revenue is non-passive for PFIC
        purposes. As a result, based on the current and anticipated value and composition of our income and assets, we do not expect that we will be treated as a PFIC for U.S. federal income tax purposes for our current taxable year or for foreseeable
        future years. However, there are substantial factual and legal ambiguities regarding the nature of the revenue and the application of the relevant PFIC rules, and thus, the determination that such revenue is non-passive is not without doubt, and
        alternative characterizations are possible.</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A separate determination has to be made after the close of each taxable year as to whether we were a PFIC for that year. Because the value of our assets for purposes of the PFIC
        test will generally be determined by reference to the market price of our ordinary shares, our PFIC status may depend in part on the market price of our ordinary shares, which may fluctuate significantly. In addition, there are certain other
        ambiguities in applying the PFIC test to us. If we are considered a PFIC, material adverse U.S. federal income tax consequences could apply to U.S. Holders (as defined in &#8220;Item 10. Additional Information &#8211; E. Taxation &#8211; U.S. Federal Income Tax
        Considerations with respect to the Company&#8221;) of our ordinary shares or warrants with respect to any &#8220;excess distribution&#8221; received from us and any gain from a sale or other disposition of our ordinary shares or warrants.&#160; Please see &#8220;Item 10.
        Additional Information &#8211; E. Taxation &#8211; U.S. Federal Income Tax Considerations with respect to the Company.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax
        consequences.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a United States person is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary shares, such person may be
        treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group (if any).&#160; If our group includes one or more U.S. subsidiaries, under recently-enacted rules, certain of our non-U.S. subsidiaries could be
        treated as controlled foreign corporations regardless of whether we are not treated as a controlled foreign corporation (although there is currently a pending legislative proposal to significantly limit the application of these rules).&#160; A United
        States shareholder of a controlled foreign corporation may be required to report annually and include in its U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by
        controlled foreign corporations, regardless of whether we make any distributions.&#160; An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign
        tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject you to significant monetary penalties and may prevent the statute of limitations with
        respect to your U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any assurances that we will assist investors in determining whether any of our non-U.S. subsidiaries are treated as a
        controlled foreign corporation or whether such investor is treated as a United States shareholder with respect to any of such controlled foreign corporations or furnish to any United States shareholders information that may be necessary to comply
        with the aforementioned reporting and tax paying obligations.&#160; A United States investor should consult its advisors regarding the potential application of these rules to an investment in the ordinary shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">50</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">General Risk Factors</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses,
        malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our
        organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and
        sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For
        example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any
        disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, and damage to our
        reputation, and the further development of our product candidates could be delayed.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25; font-style: italic; font-weight: bold;">We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity
        plan.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">We have implemented a business continuity plan to prevent the collapse of critical business processes to a large extent or to enable the
        resumption of critical business processes in case a natural disaster, public health emergency, such as the global pandemic of Novel Coronavirus Disease 2019, or COVID-19, or other serious event occurs. However, depending on the severity of the
        situation, it may be difficult or in certain cases impossible for us to continue our business for a significant period of time. Our contingency plans for disaster recovery and business continuity may prove inadequate in the event of a serious
        disaster or similar event and we may incur substantial costs that could have a material adverse effect on our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our research and development and manufacturing involve the use of hazardous materials and chemicals and related equipment. If an accident occurs, we could be held liable for
        resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures and the handling of biohazardous materials. We do not
        maintain insurance for environmental liability claims that may be asserted against us. Moreover, additional foreign and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with
        such regulations and pay substantial fines or penalties if we violate any of these laws or regulations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">51</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">With respect to environmental, safety and health laws and regulations, we cannot accurately predict the outcome or timing of future expenditures that we may be required to make
        in order to comply with such laws as they apply to our operations and facilities. We are also subject to potential liability for the remediation of contamination associated with both present and past hazardous waste generation, handling, and
        disposal activities. We will be periodically subject to environmental compliance reviews by environmental, safety, and health regulatory agencies. Environmental laws are subject to change and we may become subject to stricter environmental
        standards in the future and face larger capital expenditures in order to comply with environmental laws which could have a material adverse effect on our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The price of our ordinary shares may be volatile and may fluctuate due to factors beyond our control.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The share price of publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the
        future. The market price of our ordinary shares may fluctuate significantly due to a variety of factors, including:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z23debcbdf946421da4680a9dc40eaa76">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>positive or negative results of testing and clinical trials by us, strategic partners and competitors;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3da227193db14d2392cee25b3f900c8f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>delays in entering into strategic relationships with respect to development and/or commercialization of our product candidates or entry into strategic relationships on terms that are not deemed to be favorable to us;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zea0e346f1fe7423bb46a96300cc7b99a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>technological innovations or commercial product introductions by us or competitors;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z478633bb41c3464b9f4073a3a7b8ef40">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>changes in government regulations;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3834167896d04f4785f47c12a01fa536">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>developments concerning proprietary rights, including patents and litigation matters;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z642914f0814c4a2f8ee474244fa5d642">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>public concern relating to the commercial value or safety of any of our product candidates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5871d43558544644b3e3d562bee69bc2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>financing or other corporate transactions;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9bdc5cb4cca14dc2ae7463d3b4849f90">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>publication of research reports or comments by securities or industry analysts;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbaf30b58e62747229269449f4d670ac6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>general market conditions in the pharmaceutical industry or in the economy as a whole; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd829909533834f8e8cec7233bb8d7e94">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>other events and factors, many of which are beyond our control.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">These and other market and industry factors may cause the market price and demand for our ordinary shares to fluctuate substantially, regardless of our actual operating
        performance, which may limit or prevent investors from readily selling their ordinary shares and may otherwise negatively affect the liquidity of our ordinary shares. In addition, the stock market in general, and biopharmaceutical companies in
        particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares,
        the price of our ordinary shares could decline.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The trading market for our ordinary shares relies in part on the research and reports that equity research analysts publish about us and our business. The price of our ordinary
        shares could decline if one or more securities analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">52</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">We have been incurring and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote
        substantial time to new compliance initiatives.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a public company whose ordinary shares are listed in the United States, and particularly after we no longer qualify as an emerging growth company, we have been incurring and
        will continue to incur accounting, legal and other expenses that we did not incur as a private company, including costs associated with our reporting requirements under the Exchange Act. We also have incurred and anticipate that we will continue to
        incur costs associated with corporate governance requirements, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules implemented by the SEC and The Nasdaq Global
        Market, and provisions of Israeli corporate law applicable to public companies. These rules and regulations increase our legal and financial compliance costs, introduce new costs such as investor relations and stock exchange listing fees, and makes
        some activities more time-consuming and costly. Our board and other personnel need to devote a substantial amount of time to these initiatives. We are currently evaluating and monitoring developments with respect to these rules, and we cannot
        predict or estimate the amount of additional costs we may incur or the timing of such costs. As an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements,
        including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act (and the rules and regulations of the SEC thereunder). When these exemptions cease to apply, we expect to
        incur additional expenses and devote increased management effort toward ensuring compliance with them. We cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing of such costs.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to Section 404 of the Sarbanes-Oxley Act and the related rules adopted by the SEC and the Public Company Accounting Oversight Board, starting with the Annual Report for
        the year ended on December 31, 2019, our management is required to report on the effectiveness of our internal control over financial reporting. In addition, once we no longer qualify as an &#8220;emerging growth company&#8221; under the JOBS Act and lose the
        ability to rely on the exemptions related thereto discussed above and depending on our status as per Rule 12b-2 of the Exchange Act, our independent registered public accounting firm may also need to attest to the effectiveness of our internal
        control over financial reporting under Section 404. The process of determining whether our existing internal controls over financial reporting systems are compliant with Section 404 and whether there are any material weaknesses or significant
        deficiencies in our existing internal controls requires the investment of substantial time and resources, including by our chief financial officer and other members of our senior management. As a result, this process may divert internal resources
        and take a significant amount of time and effort to complete. In addition, while our assessment of our internal control over financial reporting resulted in our conclusion that as of December 31, 2020, our internal control over financial reporting
        was effective, we cannot predict the outcome of this determination in future years and whether we will need to implement remedial actions in order to implement effective controls over financial reporting. The determination and any remedial actions
        required could result in us incurring additional costs that we did not anticipate, including the hiring of outside consultants. As a result, we may experience higher than anticipated operating expenses, as well as higher independent auditor fees
        during and after the implementation of these changes. If we are unable to implement any of the required changes to our internal control over financial reporting effectively or efficiently or are required to do so earlier than anticipated, it could
        adversely affect our operations, financial reporting and/or results of operations and could result in an adverse opinion on internal controls from our independent auditors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Changes in the laws and regulations affecting public companies will result in increased costs to us as we respond to their requirements. These laws and regulations could make it
        more difficult or more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same
        or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. We cannot predict or estimate
        the amount or timing of additional costs we may incur in order to comply with such requirements.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">53</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or
        prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ordinary shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports. Any failure to implement required new or improved controls, or
        difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. While our assessment of our internal control over financial reporting resulted in our conclusion that as of December 31, 2020, our internal
        control over financial reporting was effective, we cannot predict the outcome of our testing or any subsequent testing by our auditor in future periods.&#160; Any testing by us conducted in connection with Section 404, or any subsequent testing by our
        independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or
        identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information and affect our reputation, which could have a negative effect on the trading
        price of our ordinary shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our management will be required to assess the effectiveness of our internal controls and procedures and disclose changes in these controls on an annual basis. However, for as
        long as we are an &#8220;emerging growth company&#8221; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. We
        could be an &#8220;emerging growth company&#8221; for up to five years. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal
        controls could lead to financial statement restatements and require us to incur the expense of remediation.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><a name="ITEM4"><!--Anchor--></a>ITEM 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;INFORMATION ON THE COMPANY</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;History and Development of the Company</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our legal and commercial name is Sol-Gel Technologies Ltd.&#160; Our company was incorporated on October 28, 1997 and was registered as a private company limited by shares under the
        laws of the State of Israel. Our principal executive offices are located at 7&#160;Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650 Israel and our telephone number is 972-8-931 3433. Our website address is http://www.sol-gel.com. The
        information contained therein, or that can be accessed therefrom, does not constitute a part of this annual report and is not incorporated by reference herein. We have included our website address in this annual report solely for informational
        purposes. Our agent for service of process in the United States is Cogency Global Inc., located at 10 E. 40<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Street, 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor, New York, NY 10016, and its telephone number is +1 (800) 221-0102.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In February 2018 we completed our initial public offering on The Nasdaq Global Market, pursuant to which we issued 7,187,500 Ordinary Shares for aggregate gross proceeds of
        approximately $86.25 million before deducting underwriting discounts and commissions and offering expenses payable by us, including the full exercise by the underwriters of their option to purchase additional shares. Our Ordinary Shares are traded
        on The Nasdaq Global Market under the symbol "SLGL".</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our capital expenditures for the years ended December 31, 2018, 2019 and 2020 were approximately $1,052, $597 and $449, respectively. Our current capital expenditures involve
        equipment and leasehold improvements.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Business Overview</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.
        Our current product candidate pipeline consists of late-stage and early-stage branded product candidates, some of which leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across
        multiple indications.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">54</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our branded product candidate, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, is a novel, once-daily, non-antibiotic topical cream containing a fixed-dose combination of encapsulated benzoyl peroxide and
        encapsulated tretinoin, that we are developing for the treatment of acne vulgaris, or acne.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On December 30, 2019, we&#160;announced top-line results from two pivotal Phase 3 clinical trials evaluating Twyneo for the treatment of acne. Twyneo met all co-primary endpoints in
        both Phase 3 trials.&#160;The Phase 3 program enrolled an aggregate of 858 patients aged nine and older in two multicenter, randomized, double-blind, parallel group, vehicle-controlled trials at 63 sites across the United States. Twyneo demonstrated
        statistically significant improvement in each of the co-primary endpoints of&#160;(1) the proportion of patients who succeeded in achieving at least a two grade reduction from baseline and Clear (grade 0) or Almost Clear (grade 1) at Week 12 on a
        5-point Investigator Global Assessment (IGA) scale, (2) an absolute change from baseline in inflammatory lesion count at Week 12, and (3) and an absolute change from baseline in non-inflammatory lesion count at Week 12.&#160;In addition, Twyneo was
        found to be well-tolerated.<font style="font-family: 'Times New Roman',Times,serif;"> Our NDA for Twyneo&#174; was accepted for filing by the FDA, which assigned a Prescription Drug User Fee Act, or PDUFA, goal date of August 1, 2021.</font></div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our branded product candidate, Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, is a novel, once-daily topical cream containing encapsulated benzoyl peroxide, that we are developing for the treatment of
        papulopustular (subtype II) rosacea. On July 8, 2019, we announced&#160;positive top-line results from our Phase 3 program evaluating Epsolay.&#160; The program enrolled&#160;733 patients aged 18 and older in two identical, double-blind, vehicle-controlled Phase
        3 clinical trials at 54 sites across the United States. Epsolay demonstrated statistically significant improvement in both co-primary endpoints of (1) the number of patients achieving &#8220;clear&#8221; or &#8220;almost clear&#8221; in the Investigator Global Assessment
        (IGA) relative to baseline at week 12 and (2) absolute mean reduction from baseline in inflammatory lesion count at week 12. In an additional analysis, Epsolay demonstrated rapid efficacy, achieving statistically significant improvements on both
        co-primary endpoints compared with vehicle as early as Week 2. In addition, Epsolay&#174; was found to be well- tolerated. Our NDA for Epsolay&#174; was accepted for filing by the FDA, which assigned a PDUFA goal date of April 26, 2021.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Another branded product candidate is SGT-210 (erlotinib gel) that we are developing for the treatment of palmoplantar keratoderma (PPK).</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">We are also pre-clinically testing erlotinib, tapinarof and roflumilast in <font style="font-family: 'Times New Roman',Times,serif;">various








          new pharmaceutical indications.&#160;</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We designed our proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy.
        Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Our technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient
        and the skin. The resulting microcapsules are designed to allow the entrapped active ingredients to gradually migrate through the pores of the shell and deliver active ingredient doses onto the skin in a controlled manner, resulting in improved
        tolerability and stability without sacrificing efficacy. By separately encapsulating active ingredients within protective silica shells, our technology platform also enables the production of novel fixed-dose active ingredient combinations that
        otherwise would not be stable. We believe that our microencapsulation technology has the potential to be used for topical drug products to treat a variety of skin diseases. As a result of the FDA having already approved silica as a safe excipient
        for topical drug products, we expect the review process for Twyneo&#174; and Epsolay&#174; to be conducted according to the FDA&#8217;s 505(b)(2) regulatory pathway, which may provide for a more efficient regulatory process by permitting us to rely, in part, upon
        the FDA&#8217;s previous findings of safety and efficacy of an approved product.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">55</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We maintain exclusive, worldwide commercial rights for our branded product candidates, which consist of:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7bc043d405c34903a4cee60291967b13">

          <tr>
            <td style="width: 21.3pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 25.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Twyneo<font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, a novel, once-daily, non-antibiotic topical cream, which we are developing for the treatment of acne, containing a fixed-dose combination of encapsulated
                  benzoyl peroxide, or E-BPO, and encapsulated tretinoin. Acne is one of the three most prevalent skin diseases in the world and is the most commonly treated skin disease in the United States. According to the American Academy of
                  Dermatology, acne affects approximately 40 to 50 million people in the United States, of which approximately 10% are treated with prescription medications. In July 2017, we reported positive top-line results from a double-blind,
                  dose-ranging active- and placebo-controlled, six-arm, multi-center Phase II clinical trial of Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in the United States in 726 subjects, 128 of which subjects across six treatment groups did not complete the study. The
                  clinical trial evaluated the efficacy, tolerability and safety of two Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> concentrations, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Low and Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> High, each containing a lower or higher concentration, respectively, of encapsulated
                  tretinoin and an identical concentration of encapsulated benzoyl peroxide. Tretinoin and benzoyl peroxide, the two active components in Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, are both widely-used therapies for the treatment of acne that historically have
                  not been conveniently co-administered due to stability concerns. The trial also evaluated the contribution of encapsulated tretinoin and encapsulated benzoyl peroxide, in the same concentrations as those in the respective Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
                  treatment groups, to the efficacy of Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> High and Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Low. In this trial, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> showed statistically significant improvements in all pre-defined co-primary and secondary efficacy endpoints, as
                  compared to vehicle. In addition, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> was well tolerated with no treatment-related serious adverse events. Based on the efficacy data we observed in the Phase II trial, we believe Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, if approved, has the
                  potential to become a preferred treatment for acne. On December 30, 2019, we&#160;announced top-line results from two pivotal Phase 3 clinical trials evaluating Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for the treatment of acne. Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> met all
                  co-primary endpoints in both Phase 3 trials.&#160;The Phase 3 program enrolled an aggregate of 858 patients aged nine and older in two multicenter, randomized, double-blind, parallel group, vehicle-controlled trials at 63 sites across the
                  United States. Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> demonstrated statistically significant improvement in each of the co-primary endpoints of&#160;(1) the proportion of patients who succeeded in achieving at least a two grade reduction from baseline and Clear
                  (grade 0) or Almost Clear (grade 1) at Week 12 on a 5-point Investigator Global Assessment (IGA) scale, (2) an absolute change from baseline in inflammatory lesion count at Week 12, and (3) and an absolute change from baseline in
                  non-inflammatory lesion count at Week 12.&#160;In addition, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> was found to be well-tolerated. Our NDA for Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has been accepted for filing by the FDA, which assigned a PDUFA goal date of August 1, 2021. &#160;</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z19321e4aecec4ec6ba5e3d7a7e3588b7">

          <tr>
            <td style="width: 21.3pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 25.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Epsolay&#174;, a topical cream containing 5% encapsulated benzoyl peroxide, which we are developing for the treatment of papulopustular (subtype II) rosacea. Rosacea is a chronic skin disease characterized by facial redness, inflammatory
                lesions, burning and stinging. According to the U.S. National Rosacea Society, approximately 16 million people in the United States are affected by rosacea. According to a study we commissioned, approximately 4.8 million people in the
                United States experience subtype II symptoms. Subtype II rosacea is characterized by small, dome-shaped erythematous papules, tiny surmounting pustules on the central aspects of the face, solid facial erythema and edema, and
                thickening/overgrowth of skin. Subtype II rosacea resembles acne, except that comedowns are absent, and patients may report associated burning and stinging sensations. We evaluated Epsolay&#174; in a double blind, randomized, dose-ranging Phase
                II clinical trial involving 92 adult subjects at ten centers in the United States. In this trial, Epsolay&#174; showed statistically significant improvements in the Investigator Global Assessment, or IGA, pre-defined co-primary efficacy endpoint
                and in the percent change in inflammatory lesion count at week 12, as compared to vehicle. Epsolay&#174; was also well tolerated in this trial. Current topical therapies for subtype II rosacea are limited due to tolerability concerns. For
                example, BPO, a common therapy for acne, is not used for the treatment of subtype II rosacea due to side effects. As encapsulated BPO, Epsolay&#174; is designed to redefine the standard of care for the treatment of subtype II rosacea. If
                approved, we expect Epsolay&#174; to be the first product containing BPO that is marketed for the treatment of subtype II rosacea. On July 8, 2019, we announced&#160;positive top-line results from our Phase 3 program evaluating Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>.&#160;
                The program enrolled&#160;733 patients aged 18 and older in two identical, double-blind, vehicle-controlled Phase 3 clinical trials at 54 sites across the United States. Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> demonstrated statistically significant improvement in
                both co-primary endpoints of (1) the number of patients achieving &#8220;clear&#8221; or &#8220;almost clear&#8221; in the Investigator Global Assessment (IGA) relative to baseline at week 12 and (2) absolute mean reduction from baseline in inflammatory lesion
                count at week 12. In an additional analysis, Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> demonstrated rapid efficacy, achieving statistically significant improvements on both co-primary endpoints compared with vehicle as early as Week 2. In addition, Epsolay&#174; was
                found to be well-tolerated. On February 12, 2020, we announced positive topline results from our open-label, long-term safety study, evaluating Epsolay&#174; for a treatment duration up to 52 weeks.&#160; Our NDA for Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has been
                accepted for filing by the FDA, which assigned a PDUFA goal date of April 26, 2021.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">56</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfce03c61024743c19597d9b0f0a99687">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>SGT-210 (erlotinib gel) that we are developing for the treatment of palmoplantar keratoderma, or PPK, a group of skin conditions characterized by thickening of the skin on the hands and soles of the feet. SGT-210 is designed to be used
                alone or in combination for the treatment of hyperproliferation and hyperkeratinization disorders, including PPK. On January 2, 2020, we announced the initiation of a&#160;Phase 1 proof of concept clinical study of SGT-210 in patients with
                palmoplantar keratoderma. The Phase 1 proof of concept study SGT-84-01 is a single-center, single-blinded, vehicle-controlled study designed to evaluate the bioavailability, safety and tolerability of SGT-210 as well as inform on potential
                efficacy. The study is targeting enrollment of approximately 15 patients to undergo a three-month treatment period, followed by a three-month follow-up period. The enrollment of patients in the Phase 1 proof of concept study with SGT-210
                has been slowed&#160; by the COVID-19 pandemic. We expect to report top-line data in the third quarter of 2021.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><br>
        </div>
        <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2675d6c0c996411b8c3a2c62f232a3de">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">
                    <div>We are conducting pre-clinical testing to explore the possible activity of erlotinib, tapinarof (an investigational aryl hydrocarbon receptor&#160;modulator) and roflumilast (an investigational phosphodiesterase 4&#160;inhibitor) in various
                      new pharmaceutical indications. A total of 25 provisional patent applications for these project candidates have been submitted to date, including patent applications covering the use of tapinarof in ophthalmic disorders such as dry
                      eye, uveitis, and blepharitis with or without demodex involvement.</div>
                  </div>
                </div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to our branded product candidates, we have one FDA approved generic topical dermatological product, which is a generic version of Zovirax&#174;&#160;(acyclovir) cream, 5%. In
        February 2019, we announced that Perrigo received final approval from the FDA for this product.&#160; The product was developed in a collaboration between us and Perrigo in which we shared development costs with Perrigo and will equally share the gross
        profits generated from sales of the product.&#160; Following receipt by Perrigo of final approval from the FDA, we launched the product in February 2019.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are also currently developing a portfolio of 11 generic topical dermatological products in collaboration with Perrigo UK Finco Limited Partnership, or Perrigo. Perrigo has
        significant experience in the development of generic drugs.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our most advanced generic product candidate is ivermectin cream, 1%, for the treatment of inflammatory lesions associated with rosacea, which is being developed in
          collaboration with Perrigo. In March 2017, Perrigo submitted an ANDA with a Paragraph IV certification for ivermectin cream, 1% to the FDA. In January 2018, this ANDA was tentatively approved by the FDA. Final approval from the FDA is subject to
          a 30-month stay under the Hatch-Waxman Amendments. In addition, because Actavis Ltd. filed an ANDA for ivermectin cream, 1%, before us or any other generic applicants, we may be unable to obtain final approval for our ANDA until the expiration of
          Actavis Ltd.&#8217;s 180-day generic exclusivity. Ivermectin cream, 1% is the active molecule in Soolantra, which is currently marketed in the United States by Galderma Laboratories LP.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our leadership team has considerable expertise in the identification and development of generic dermatological drug products and our intellectual property and formulation teams
          continue to seek to identify new opportunities to expand our pipeline of generic product candidates.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-weight: normal; font-style: normal;">57</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In preparation for commercial launch of our proprietary products, we have opened a U.S. headquarters in Whippany, New Jersey. If Twyneo&#174; and Epsolay&#174; receive regulatory
          approval from the FDA, we intend to market them in the United States through one or more third party collaborators that have direct sales forces and established distribution systems in lieu of our own sales force and distribution systems. We are
          in discussions with potential partners regarding the commercialization of&#160; Twyneo&#174; and Epsolay&#174;.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following chart represents our current branded and generic product candidate pipeline:</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;
        <title></title>
        <div id="slide">
          <div id="frame" style="position: relative; left: 0px; top: 0px;">
            <div style="left: 0px; top: 0px;"><img src="zk2125664slide1.jpg"></div>
          </div>
          <div id="slideText">
            <div id="slideTextFrame" style="text-align: left;"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;&#160;&#160;Pipelines &amp; upcoming milestones&#160;&#160;BRANDED CANDIDATES&#160;&#160;EPSOLAY&#174;Papulopustular
                rosacea&#160;&#160;TWYNEO&#174;Acne vulgaris&#160;&#160;Research/Preclinical&#160;&#160;Phase I&#160;&#160;Phase II&#160;&#160;Phase III&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PDUFA GOAL DATEAPRIL 26, 2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PDUFA GOAL DATEAUGUST 01, 2021&#160;&#160;SGT-210Palmoplantar keratoderma&#160;&#160;Anticipated Milestones&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Data in
                1H/2021&#160;&#160;Filed&#160;&#160;SGT-310Psoriasis &amp; Other Derm. Indications&#160;&#160;SGT-510Psoriasis &amp; Other Derm. Indications&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Formulation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Formulation&#160;&#160;&#160;&#160;GENERIC PRODUCTS/CANDIDATES&#160;&#160;Halobetasol Lotion, 0.01%(RLD: Bryhali&#174;)&#160;&#160;Ivermectin cream,
                1%(RLD: Soolantra&#174;)&#160;&#160;TENTATIVE APPROVAL AS OF NOVEMBER 16, 2020&#160;&#160;TENTATIVE APPROVAL AS OF JANUARY 29, 2018&#160;&#160;&#160;&#160;&#160;&#160;Research&#160;&#160;Filed&#160;&#160;Bioequivalence&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RLD, reference listed drug.&#160;&#160;Combination of Halobetasol &amp; Tazarotene(RLD:
                Duobrii&#174;)&#160;&#160;FIRST TO FILE ANDA ON JUNE 11, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </div>
        </div>
        <div id="spaceAfterSlideText">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Our Branded Product Candidates</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Twyneo&#174; for Acne</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Using our proprietary, silica-based microencapsulation technology platform, we are developing Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> to become a preferred treatment for acne by dermatologists and
        their patients.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a novel, once-daily, non-antibiotic topical cream containing a fixed-dose combination of encapsulated benzoyl peroxide and encapsulated tretinoin that we
        are developing for the treatment of acne. Studies have shown that benzoyl peroxide and tretinoin are effective in treating acne as monotherapies; moreover, according to&#160;an article in the American Academy of Dermatology (2009), dermatologists
        recommend combining the two monotherapies as a first-line approach for acne, but a drug-drug interaction that causes the degradation of tretinoin has previously prohibited the development of a combination therapy. By encapsulating the two agents
        separately through the use of our technology platform, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is designed to be a fixed-dose combination that otherwise would not be stable. Similar to other combination drug products, such as clindamycin and benzoyl peroxide, we expect
        Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> to be kept refrigerated throughout the supply chain and then stored in ambient conditions upon its distribution to patients. Pre-clinical data suggests that Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> may be more tolerable than generic tretinoin gel 0.1%
        and Epiduo, a branded fixed-dose combination of benzoyl peroxide and adapalene, without a corresponding loss in efficacy. In addition, Epiduo and its successor Epiduo Forte contain adapalene as opposed to tretinoin, which is widely considered to be
        more effective than adapalene, but generally causes greater irritation. We expect that Twyneo&#174;, if approved, will compete directly with Epiduo and Epiduo Forte. We have utilized the FDA&#8217;s 505(b)(2) regulatory pathway in seeking approval of Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
        in the United States.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In July 2017, we reported the completion of a 726 subject, randomized, multi-center, double-blind, placebo-controlled Phase II clinical trial of Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in the United
        States that demonstrated statistically significant improvements compared to vehicle in the co-primary efficacy endpoints of &#8220;clear&#8221; or &#8220;almost clear&#8221; with a two-grade reduction in IGA and in reducing absolute inflammatory and non-inflammatory
        lesion counts at week 12. Of the 726 subjects enrolled in the trial, 128 subjects across six treatment groups did not complete the study. The most common reasons for subjects not completing the study were the withdrawal of informed consent (42
        subjects), loss to follow-up (56 subjects) and adverse events (18 subjects).</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">58</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">On December 30, 2019, we&#160;announced top-line results from two pivotal Phase 3 clinical trials evaluating Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for the treatment of acne. Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
        met all co-primary endpoints in both Phase 3 trials.&#160;The Phase 3 program enrolled an aggregate of 858 patients aged nine and older in two multicenter, randomized, double-blind, parallel group, vehicle-controlled trials at 63 sites across the United
        States. Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> demonstrated statistically significant improvement in each of the co-primary endpoints of&#160;(1) the proportion of patients who succeeded in achieving at least a two grade reduction from baseline and Clear (grade 0) or
        Almost Clear (grade 1) at Week 12 on a 5-point Investigator Global Assessment (IGA) scale, (2) an absolute change from baseline in inflammatory lesion count at Week 12, and (3) and an absolute change from baseline in non-inflammatory lesion count
        at Week 12.&#160;In addition, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> was found to be well-tolerated. Our NDA for Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has been accepted for filing by the FDA, which assigned a PDUFA goal date of August 1, 2021.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Acne Market Opportunity</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Acne is a disease characterized by areas of scaly red skin, non-inflammatory blackheads and whiteheads, inflammatory lesions, papules and pustules and occasionally boils and
        scarring that occur on the face, neck, chest, back, shoulders and upper arms. The development of acne lesions is caused by genetic and environmental factors that arise from the interplay of the following pathogenic factors:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z457c747dd28541cc9cd5022ecf4420fa">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>blockage of hair follicles through abnormal keratinization in the follicle, which narrows pores;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1ad17c52e7d548c2bf5a0aba328f11d9">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>increase in oils, or sebum production, secreted by the sebaceous gland;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z09be0e58c26141ff89f63fe5383ad67a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>overgrowth of naturally occurring bacteria caused by the colonization by the anaerobic lipohilic bacterium <font style="font-style: italic;">Propionibacterium acnes</font>, or <font style="font-style: italic;">P. acnes</font>;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zce6a3bcd4a494a72bb9e13e6d09d5b42">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>inflammatory response due to relapse of pro-inflammatory mediators into the skin.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Due to the frequency of recurrence and relapse, acne is characterized as a chronic inflammatory disease, which may require treatment over a prolonged period of time. Acne is one
        of the three most prevalent skin diseases in the world and is the most commonly treated skin disease in the United States. According to the American Academy of Dermatology, acne affects approximately 40 to 50 million people in the United States and
        approximately 85% of people between the ages of 12 and 24 experience some form of acne. Acne patients suffer from the appearance of lesions on areas of the body with a large concentration of oil glands, such as the face, chest, neck and back. These
        lesions can be inflamed (papules, pustules, nodules) or non-inflamed (comedones). Early effective treatment is recommended to lessen the overall long-term impact. For most people, acne diminishes over time and tends to disappear, or at least to
        decrease, by the age of 25. There is, however, no way to predict how long it will take for symptoms to disappear entirely, and some individuals continue to suffer from acne well into adulthood.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Current Treatment Landscape for Acne</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The treatment options for acne depend on the severity of the disease and consist of topical and oral drugs:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbe5b8107d7a044bd8f627bc0bb0417fd">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Mild acne</font><font style="font-family: 'Times New Roman',Times,serif;">: characterized by few papules or pustules (both comedonal and inflammatory); treated with an over-the-counter product or topical
                  prescription therapies.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za67a3d88364644d2acdf2b15ae047974">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>
                <div><font style="font-weight: bold;">Moderate acne</font>: characterized by multiple papules and pustules with moderate inflammation and seborrhea (scaly red skin); treated with a combination of oral antibiotics and topical therapies.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">59</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93336e5505e443d38dd31268b50e6b64">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Severe acne</font><font style="font-family: 'Times New Roman',Times,serif;">: characterized by substantial papulopustular disease, many nodules and/or cysts and significant inflammation and seborrhea;
                  treated with oral and topical combination therapies and photodynamic therapy as a third-line treatment.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Topical therapies dominate the acne market as physicians and patients often prefer therapies that act locally on the skin, while minimizing side effects. For more pronounced symptoms, patients are
        typically treated with a combination of topical and oral therapies.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The acne prescription treatment landscape is comprised of four classes of topical products and two classes of oral products:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z50957d2277e74ac8a998db1228c81979">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Topical over-the-counter monotherapies</font><font style="font-family: 'Times New Roman',Times,serif;"> such as adapalene 0.1%, benzoyl peroxide and salicylic acid, in different concentrations, are the
                  most commonly used therapies. These are generally tolerable first-line treatments for mild acne, but less efficacious than prescription therapies.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf11b68b67e89498b89fec245a6c3217b">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Topical prescription antibiotic monotherapies</font><font style="font-family: 'Times New Roman',Times,serif;"> such as clindamycin and erythromycin that are most commonly used as topical therapies in
                  cases of mild-to-moderate acne.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbee8dd6d4d8c4a8f9a1f2e7032c1d1f8">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Topical prescription retinoid monotherapies</font><font style="font-family: 'Times New Roman',Times,serif;"> such as tretinoin, adapalene 0.3% and tazarotene. Physicians view retinoids as moderately
                  efficacious, but they have high rates of skin irritation.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za859086202df445498e6f33957031fe5">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Topical prescription combination products </font><font style="font-family: 'Times New Roman',Times,serif;">such as combinations of BPO/adapalene, BPO/clindamycin, BPO/erythromycin and
                  clindamycin/tretinoin. These target multiple components that contribute to the development of acne, though topical side effects are common.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2fff643d6f624fee9362caead2b79e99">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Oral prescription antibiotics </font><font style="font-family: 'Times New Roman',Times,serif;">such as doxycycline and minocycline. These are typically used as step-up treatments for more severe cases of
                  acne, with risk of systemic side effects.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze5e5a515cc664bd6b5d50a438a1ef205">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Oral prescription isotretinoin</font><font style="font-family: 'Times New Roman',Times,serif;">, which is primarily used for severe cystic acne and acne that has not responded to other treatments. The use
                  of oral prescription isotretinoin is tightly controlled due to tolerability issues.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Twyneo&#174; for Acne</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Using our proprietary, silica-based microencapsulation technology platform, we are developing Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> to become a preferred treatment for acne by dermatologists and
        their patients. Our silica-based proprietary delivery system is designed to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high
        tolerability. Our technology platform entraps active ingredients in an inert silica shell, which creates an unnoticeable barrier between the active ingredient and the skin. The resulting microcapsules are designed to allow the entrapped active
        ingredients to gradually migrate through the pores of the shell and deliver active ingredient doses into the skin in a controlled manner, resulting in improved tolerability and stability without sacrificing efficacy.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We believe that Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, a fixed-dose combination of a cream containing encapsulated benzoyl peroxide and encapsulated tretinoin, has the potential to solve the
        industry-wide challenge of stabilizing tretinoin in the presence of benzoyl peroxide, a combination known to be effective in acne therapy, but not previously conveniently co-administered. While benzoyl peroxide slows the proliferation of P. acnes,
        tretinoin regulates hyperkeratinization and abnormal desquamation of follicular epithelium. This creates a synergistic combination which has the potential to overcome the challenges faced by currently approved products.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbda6b525beeb4cd5adff553856eaec91">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>We designed Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> to protect tretinoin from oxidative decomposition, which occurs when it is combined with benzoyl peroxide, with the goal of enhancing stability without reducing efficacy. We believe this could allow for a
                suitable clinical and commercial shelf life.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">60</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2edf4f2e1ee544329b612007feeccec8">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>The silica shell creates a barrier between the two drug substances and the skin. As a result, we believe Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> can reduce irritation typically associated with topical application of benzoyl peroxide and tretinoin, leading to
                greater tolerability to acne-affected skin.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our NDA for Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has been accepted for filing by the FDA, which assigned a PDUFA goal date of August 1, 2021.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Twyneo&#174; Phase 3 Trial Design</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">The pivotal Phase 3 clinical program evaluating the safety and efficacy of Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in subjects with acne vulgaris enrolled an aggregate of 858
        patients aged nine and older, with moderate-to-severe acne in two multicenter, randomized, double-blind, parallel group, vehicle-controlled trials at 63 sites across the United States. Patients were randomized at a 2:1 ratio to be treated
        once-daily with either Twyneo (n=571) or vehicle cream (n=287) for 12 weeks.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The primary and secondary efficacy endpoints were assessed at the end of the 12-week treatment period. Three primary efficacy endpoints were defined for this trial:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7bac6a7ffbc4284a00cef92d68d2aeb">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the proportion of subjects who achieve at least a two-grade reduction in the IGA score and either &#8220;clear&#8221; or &#8220;almost clear&#8221; at week 12;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd3a324413c204f87833b1bd730b8d14f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the mean absolute change from baseline in the number of inflammatory acne lesions at week 12; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z036d02defbd54caa83a6ccbedb3fec41">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the mean absolute change from baseline in the number of non-inflammatory acne lesions at week 12.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Twyneo&#174; Phase 3 Trial Results</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As outlined below Twyneo met all co-primary endpoints in both Phase 3 trials.&#160; Twyneo demonstrated statistically significant improvement in each of the co-primary endpoints
          described above.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In trial SGT-65-04, 38.5% of patients treated with Twyneo achieved success in IGA versus 11.5% in the vehicle treated group (P&lt;0.001) at week 12. In trial SGT-65-05,
          25.4% of patients treated with Twyneo achieved success in IGA versus 14.7% in the vehicle group (P=0.017) at week 12.&#160; In trial SGT-65-04, the absolute mean change from baseline of inflammatory lesion count for Twyneo was -21.6 versus -14.8 for
          the vehicle group (P&lt;0.001) at week 12. In trial SGT-65-05, the absolute change from baseline of inflammatory lesion count for Twyneo was -16.2 versus -14.1 for the vehicle group (P=0.021) at week 12.&#160; In trial SGT-65-04, the absolute mean
          change from baseline of non-inflammatory lesion count for Twyneo was -29.7 versus -19.8 for the vehicle group (P&lt;0.001). In trial SGT-65-05, the absolute mean change from baseline of non-inflammatory lesion count for Twyneo was -24.2 versus
          -17.4 for the vehicle group (P&lt;0.001) at week 12.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 42.55pt; line-height: 1.25;">In both trials, Twyneo appeared to be generally safe and well-tolerated and the majority of local skin reactions, when reported, were mild or moderate and improved over
          time. A total of 18 subjects discontinued treatment in both trials due to treatment emergent adverse events. There were no treatment-related serious adverse events and four unrelated serious adverse events (one Twyneo (depression), three vehicle)
          were reported across both trials.</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">61</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following chart presents the proportion of subjects in the ITT population in studies SGT 65-04 and SGT 65-05 who achieved a successful improvement in the severity of their
        disease at week 12, as assessed using the IGA:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="950" border="0" height="476" src="image2.jpg"></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following chart presents the absolute mean change from baseline in the number of inflammatory acne lesions at week 12:</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="945" border="0" height="472" src="image3.jpg"></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">62</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25;">The following chart presents the absolute mean change from baseline in the number of non-inflammatory acne lesions at week 12:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="945" border="0" height="473" src="image4.jpg"></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25;">We also assessed cutaneous tolerability by recording the erythema (redness), scaling, pigmentation, dryness, itching, burning and stinging on a four-point
          scale from 0 to 3 at baseline and at each visit. These measurements are either measured by the physician or reported by the subject.&#160; Overall, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> was generally well tolerated. The majority of cutaneous adverse events were mild.</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25;">Out of the 858 subjects who enrolled in both studies, 754 subjects were included in the safety population, and a combined total of 16 subjects discontinued
        treatment due to an adverse event across both trials. The most common reasons for subjects not completing the study in both groups (active and vehicle) were the withdrawal of informed consent (41 subjects, 4.8%), and loss to follow-up (39 subjects,
        4.5%).</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Epsolay</font><font style="font-weight: bold; font-style: italic;">&#174;</font><font style="font-weight: bold; font-style: italic;"> for Subtype II
          Rosacea</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Epsolay&#174;<font style="font-style: italic;"> Overview</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Epsolay&#174; is a once-daily topical cream containing 5% encapsulated benzoyl peroxide that we are developing for the treatment of papulopustular (subtype II) rosacea. We believe
        Epsolay&#174; has the potential to become the first product to contain&#160; encapsulated benzoyl peroxide for the treatment of subtype II rosacea and, if approved, has the potential to redefine the standard of care for the treatment of inflammatory lesions
        associated with subtype II rosacea. Subtype II rosacea is characterized by small, dome-shaped erythematous papules, tiny surmounting pustules on the central aspects of the face, solid facial erythema and edema, and thickening/overgrowth of skin.
        Subtype II rosacea resembles acne, except that comedones are absent, and patients may report associated burning and stinging sensations. In 2012, we completed a 92 subject, randomized, multi-center, double-blind, vehicle-controlled Phase II trial
        for Epsolay&#174; in the United States that demonstrated statistically significant improvements compared to vehicle in achieving the IGA success co-primary efficacy endpoint and in reducing papulopustular-lesions based on the percentage change in the
        inflammatory lesion count from baseline at week 12.&#160; In addition, the tolerability profile of Epsolay&#174; was similar to that of vehicle. We expect that Epsolay&#174;, if approved, will compete directly with Soolantra. We expect to utilize the FDA&#8217;s
        505(b)(2) regulatory pathway in seeking approval of Epsolay&#174; in the United States.<font style="font-style: italic;">&#160;</font>On July 8, 2019, we announced&#160;positive top-line results from our Phase 3 program evaluating Epsolay.&#160; The program
        enrolled&#160;733 patients aged 18 and older in two identical, double-blind, vehicle-controlled Phase 3 clinical trials at 54 sites across the United States. Epsolay demonstrated statistically significant improvement in both co-primary endpoints of (1)
        the number of patients achieving &#8220;clear&#8221; or &#8220;almost clear&#8221; in the Investigator Global Assessment (IGA) relative to baseline at week 12 and (2) absolute mean reduction from baseline in inflammatory lesion count at week 12. In an additional analysis,
        Epsolay demonstrated rapid efficacy, achieving statistically significant improvements on both co-primary endpoints compared with vehicle as early as Week 2. In addition, Epsolay&#174; was found to be well- tolerated. On February 12, 2020, we announced
        positive topline results from our open-label, long-term safety study, evaluating Epsolay&#174; for a treatment duration up to 52 weeks.&#160;&#160;Our NDA for Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has been accepted for filing by the FDA, which assigned a PDUFA goal date of April
        26, 2021.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">63</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Rosacea is a chronic skin disease characterized by persistent facial erythema (redness) and temporary inflammatory lesions (papules, pustules or both). Often misdiagnosed as acne
        vulgaris due to similarities between inflammatory acne lesions and rosacea lesions and the potential for disfigurement, rosacea is gradually increasing in visibility as a disease. The most prominent age group affected includes adults age 30 and
        above, with stronger prevalence across women and adults with fair skin.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Current Treatment Landscape for Subtype II Rosacea</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As there is no cure for rosacea, treatment is largely focused on managing the disease. We believe that a significant market opportunity exists for a subtype II rosacea treatment
        option that can provide both efficacy and higher tolerability than existing treatments. There are currently five approved drugs for the treatment of subtype II rosacea: Soolantra, Metrogel, Oracea, Zilixi and generic metronidazole. In certain
        cases, dermatologists often prescribe oral antibiotics either as monotherapies or in conjunction with approved medications.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Our Solution for Subtype II Rosacea&#8201;&#8212; Epsolay&#174;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Benzoyl peroxide is approved by the FDA for the treatment of acne and is widely considered to be safe and effective. Currently, there is no approved benzoyl peroxide product in
        the rosacea treatment landscape as a result of potential tolerability issues, despite clinical studies showing that treatment with benzoyl peroxide could be efficacious. According to a published study, benzoyl peroxide was found to be an effective
        treatment for rosacea but caused irritation. Using our proprietary, silica-based microencapsulation technology platform, we believe our Epsolay&#174; candidate for the treatment of papulopustular (subtype II) rosacea can improve on current subtype II
        rosacea treatments in the following ways:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3c2d5323c5fa44e8b500dabf7cc0247c">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Epsolay&#174; creates a silica-based barrier between benzoyl peroxide crystals and the skin and, as a result, can reduce irritation typically associated with topical application of benzoyl peroxide, increasing the potential for more tolerable
                application to rosacea-affected skin.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za141e7973c0e41e5a3deb50dd9a9a51e">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Epsolay&#174;'s release of the drug can reduce irritation while maintaining efficacy.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Epsolay&#174; is an innovative topical cream, and if approved, would be the first product containing benzoyl peroxide for the treatment of subtype II rosacea.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-style: italic;">Epsolay&#174; Phase 3 Trial Design</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In June 2018, we announced dosing of the first subject in our pivotal Phase 3 clinical program of Epsolay&#174; in subjects with papulopustular rosacea.&#160; The program enrolled&#160;733
        patients aged 18 and older in two identical, double-blind, vehicle-controlled Phase 3 clinical trials at 54 sites across the United States. Patients were randomized at a 2:1 ratio to be treated once-daily with either Epsolay (n=493) or vehicle
        cream (n=240) for 12 weeks. After the initiation of treatment, clinical and safety evaluations were performed at Weeks 2, 4, 6, 8 and 12.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The primary efficacy endpoints for both trials were success in the IGA defined as two-grade reduction in IGA on a stage of 0 to 4 with a &#8220;clear&#8221; (0) or &#8220;almost clear&#8221; (1) at week
        12, and a reduction in mean inflammatory lesion count at week 12.&#160;&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">64</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Epsolay&#174; Phase 3 Trial Results</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">As outlined below, Epsolay demonstrated statistically significant improvement in both co-primary endpoints of (1) the number of patients achieving &#8220;clear&#8221;
          or &#8220;almost clear&#8221; in the IGA relative to baseline at week 12 and (2) absolute mean reduction from baseline in inflammatory lesion count at week 12. In an additional analysis, Epsolay demonstrated rapid efficacy, achieving statistically
          significant improvements on both co-primary endpoints compared with vehicle as early as Week 2. Epsolay demonstrated a favorable safety and tolerability profile similar to vehicle.</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In study SGT 54-01, patients in the Epsolay and vehicle treatment groups had a baseline mean inflammatory lesion count of 25.7 and 26.3, respectively. The proportion of
          patients with &#8220;moderate&#8221; (3) or &#8220;severe&#8221; (4) IGA in the Epsolay treatment group was 86.4% and 13.6%, respectively, and 88.1% and 11.9%, respectively, in the vehicle treatment group.&#160; In study SGT 54-02, patients in Epsolay and vehicle treatment
          groups had a baseline mean inflammatory lesion count of 29.8 and 27.5, respectively. The proportion of patients with &#8220;moderate&#8221; (3) or &#8220;severe&#8221; (4) IGA in the Epsolay treatment group was 90.8% and 9.2%, respectively, and 91.8% and 8.2%,
          respectively, in the vehicle treatment group.</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As outlined below,&#160;Epsolay met all co-primary endpoints in both Phase 3 trials.&#160; Epsolay demonstrated statistically significant improvement in each of the co-primary endpoints
          described above.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In study SGT 54-01, 43.5% of patients treated with Epsolay achieved success in IGA versus 16.1% in the vehicle treated group (P&lt;0.001) at week 12.&#160; In Study 54-02, 50.1%
          of patients treated with Epsolay achieved success in IGA versus 25.9% in the vehicle group (P&lt;0.001) at week 12.&#160;&#160; In study SGT 54-01, the absolute change from baseline of inflammatory lesion count for Epsolay was -17.4 versus -9.5 for the
          vehicle group (P&lt;0.001) at week 12. In study SGT 54-02, the absolute change from baseline of inflammatory lesion count for Epsolay was -20.3 versus -13.3 for the vehicle group (P&lt;0.001) at week 12.</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following chart presents the proportion of subjects in the ITT population in studies SGT 54-01 and SGT 54-02 who achieved a successful improvement in the severity of their
        disease at week 12, as assessed using the IGA:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: center; text-indent: 42.55pt; line-height: 1.25;"><img width="480" border="0" height="411" src="image5.jpg"></div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-weight: normal; font-style: normal;">65</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following chart presents the absolute change from baseline in the number of inflammatory acne lesions at week 12:</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; text-indent: 42.55pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="441" border="0" height="408" src="image6.jpg"></div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following chart presents the percent change from baseline in the number of inflammatory acne lesions at week 12:</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: center; text-indent: 42.55pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="576" border="0" height="458" src="image7.jpg"></div>
        <div style="text-align: center; text-indent: 42.55pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In both studies, Epsolay&#160;demonstrated a favorable safety and tolerability profile similar to vehicle, with a low rate of cutaneous side effects (e.g., dryness, scaling,
          itching and burning/stinging) comparable to vehicle. Adverse events were primarily mild to moderate in severity with the most frequently reported adverse events across both studies being application site erythema and application site pain
          reported by less than 3.4% of subjects. There were no treatment-related serious adverse events, with a combined total of two unrelated serious adverse events (1 Epsolay, 1 vehicle) reported across both trials.</div>
        <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"> <br>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 42.55pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">Out of the 733 subjects who enrolled in both studies, 721 subjects were included in the safety population, and a combined total of
          10 subjects (9 Epsolay, 1 vehicle) discontinued treatment due to an adverse event across both trials. The most common reasons for subjects not completing the study in both groups (active and vehicle) were the withdrawal of informed consent (25
          subjects, 3.4%), and loss to follow-up (17 subjects, 2.3%).</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">66</font></div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-style: italic;">Long-Term Safety Study Results for Epsolay </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 12, 2020, we announced positive topline results from our open-label, long-term safety study, SGT -54-07, evaluating Epsolay for a treatment duration up to 52 weeks.
          The study enrolled 547 subjects, all of whom had completed 12 weeks of treatment with Epsolay or vehicle in the preceding double-blind Phase 3 studies. Patients continued onto open-label treatment with Epsolay once-daily for up to an additional
          40 weeks. The safety population of 535 subjects received Epsolay therapy for an overall period of at least 28 weeks. Of these 535 subjects, 209 subjects completed 52 weeks of treatment with Epsolay, exceeding the sample size requirements
          previously defined by the FDA for the Epsolay one-year safety evaluation.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Non-cutaneous adverse events were similar in frequency and type to those observed in the preceding Phase 3 trials. The most common adverse event reported was nasopharyngitis
          (5.4%). Less than 3% of patients experienced application site adverse events that were considered to be drug-related, and no serious drug-related adverse events were reported.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At every study visit, the investigator conducted Local Tolerability and Cutaneous Safety Assessments. At the end of 52 weeks more than 90% of subjects had &#8220;none&#8221; or &#8220;mild&#8221;
          signs or symptoms (burning or stinging, itching, dryness and scaling) and no &#8220;severe&#8221; tolerability scores were recorded.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Although the study was designed to evaluate long-term safety, subjects also continued to undergo evaluation according to the Investigator Global Assessment (IGA) 5-point scale.
          Of the 209 patients treated with Epsolay for 52 weeks, 73.2% reported an IGA score of 0 ("clear") or 1 ("almost clear") at 52 weeks.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">Our NDA for Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has been accepted for filing by the FDA, which assigned a PDUFA goal date of April 26, 2021.&#160;</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">SGT-210 for Palmoplantar Keratoderma</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">SGT-210 (erlotinib gel) that we are developing for the treatment of palmoplantar keratoderma, or PPK, a group of skin conditions characterized by thickening of the skin on the
        hands and soles of the feet. SGT-210 is designed to be used alone or in combination for the treatment of hyperproliferation and hyperkeratinization disorders, including PPK. On January 2, 2020, we announced the initiation of a&#160;Phase 1 proof of
        concept clinical study of SGT-210 in patients with palmoplantar keratoderma. The Phase 1 proof of concept study SGT-84-01 is a single-center, single-blinded, vehicle-controlled study designed to evaluate the bioavailability, safety and tolerability
        of SGT-210 as well as inform on potential efficacy. The study is targeting enrollment of approximately 15 patients to undergo a three-month treatment period, followed by a three-month follow-up period. The enrollment of patients in the Phase 1
        proof of concept study with SGT-210 has been slowed by the COVID-19 pandemic. We expect to report top-line data in the third quarter of 2021.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Erlotinib, Tapinarof and roflumilast potentially for psoriasis and other medical conditions</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">
          <div style="text-indent: 36pt; line-height: 1.25;">We are conducting pre-clinical testing to explore the possible activity of erlotinib, tapinarof (an investigational aryl hydrocarbon receptor modulator) and roflumilast (an investigational
            phosphodiesterase 4 inhibitor) in various new pharmaceutical indications. A total of 25 provisional patent applications for these project candidates have been submitted to date, including patent applications covering the use of tapinarof in
            ophthalmic disorders such as dry eye, uveitis, and blepharitis with or without demodex involvement.</div>
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Generic Drug Product Candidates</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to our branded product candidates, we have one FDA approved generic topical dermatological product, which is a generic version of Zovirax&#174;&#160;(acyclovir) cream, 5%. In
        February 2019, we announced that Perrigo received final approval from the FDA for this product.&#160; The product was developed in a collaboration between us and Perrigo in which we shared development costs with Perrigo and will equally share the gross
        profits generated from sales of the product.&#160; Following receipt by Perrigo of final approval from the FDA, we launched the product in February 2019.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">67</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are also currently developing a portfolio of 11 generic topical dermatological products, including ivermectin cream, 1%, in collaboration with Perrigo. Perrigo has significant
        experience in the development of generic drugs.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our most advanced generic product candidate is ivermectin cream, 1%, for the treatment of inflammatory lesions associated with rosacea, which we are developing in collaboration
          with Perrigo. In March 2017, Perrigo submitted an ANDA for ivermectin cream, 1% to the FDA, which was tentatively approved. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a
          patent litigation suit triggering the application of a 30-month stay on approval of the ANDA, under the Hatch-Waxman Amendments. In January 2018, this ANDA was tentatively approved by the FDA. In addition, because Actavis Ltd. filed an ANDA for
          ivermectin cream, 1%, before us or any other generic applicants, we may be unable to obtain final approval for our ANDA until the expiration of Actavis Ltd.&#8217;s 180-day generic exclusivity. Ivermectin cream, 1% is the active molecule in Soolantra
          which is currently marketed in the United States by Galderma Laboratories LP.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We previously had a collaboration arrangement with Douglas Pharmaceuticals (New Zealand) to develop an additional generic product candidate. We decided not to pursue this
          collaboration after determining that it would not be economical due to significant market competition.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Our Proprietary Silica-Based Microencapsulation Technology Platform</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Encapsulation of a drug substance can be made using a variety of techniques, such as solvent evaporation, coacervation, and interfacial polymerization. Most encapsulations
        involve organic polymers, such as poly-methyl methacrylate, chitosan and cellulose. The resultant encapsulated drug substance can be an aqueous dispersion of varying payload and volume fraction or a dried powder. Control over the encapsulation
        process when organic polymers are used is challenging and is mainly limited to shell thickness. Other properties of the organic polymer encapsulating material are hard to control.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In contrast, we use proprietary &#8216;sol-gel&#8217; processes to shape silica on site to form microcapsule shells of almost any size and release profile. Sol-gel is a chemical process
        whereby amorphous silica, or other metal oxides, are made by forming interconnections among colloidal particles (the &#8220;sol&#8221;) under increasing viscosity until a rigid silica shell (the &#8220;gel&#8221;) is formed. The drug substance that is added during the
        sol-gel reaction is encapsulated, using a patented technique, by which a core-shell structure is formed. The drug substance is in the core and the silica is the capsule shell. At the end of the process, the microcapsules are in the shape of small
        beads ranging from 1&#8201;&#8211;&#8201;50 micron in size. This process results in an aqueous suspension in which the drug substances are entrapped in silica particles.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Collaboration Agreements with Perrigo</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-style: italic;">Ivermectin cream, 1%</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On April 27, 2015, we entered into a development, manufacturing and commercialization agreement with Perrigo, as amended on October 26, 2015, to work toward the objective of
        obtaining all FDA approvals necessary for the commercialization of ivermectin cream, 1%, in the United States. Under the agreement, Perrigo will conduct all regulatory, scientific, clinical and technical activities necessary to develop ivermectin
        cream, 1%, prepare and file an ANDA with the FDA (which received tentative approval in January 2018), and is responsible for other activities to gain regulatory approval to market ivermectin cream, 1%, in the United States. We granted Perrigo the
        right, title and interest in and to ivermectin cream, 1%, and agreed on each party&#8217;s portion of the costs associated with performance under the agreement. Perrigo also owns intellectual property created in connection with the development of
        ivermectin cream, 1%. If approval by the FDA of the ANDA, Perrigo is required to use diligent efforts to commercialize ivermectin cream, 1%, in the United States. Perrigo has the sole and exclusive right to establish and control the prices and all
        other terms and conditions for the sales of ivermectin cream, 1%, in the United States and is required to do so in good faith. We will be entitled to 50% of Perrigo&#8217;s gross profits related to the sale of ivermectin cream, 1%, on a quarterly basis,
        for a period of 20 years following the first commercial sale of the ivermectin cream, 1%, in the United States. The agreement may be terminated if the gross profits relating to the sale of the product do not exceed a certain threshold or if the
        potential market for the product has been significantly reduced due to regulatory changes.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">68</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each party is responsible for its own costs in relation to performance under the agreement.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are obligated to finance all out-of-pocket trial expenses (including materials), and Perrigo UK is required to reimburse us for 40% of the out-of-pocket clinical trial
        expenses as follows (a)&#160;if we obtain FDA approval, by financing our share of the out-of-pocket litigation expenses, or (b) if FDA approval is not obtained, by reimbursing us an amount equal to 40% of our out-of-pocket expenses.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Generic version of Zovirax&#174;&#160;(acyclovir) cream</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection with the transfer of the first generic version of Zovirax&#174;&#160;(acyclovir) cream, to us by Arkin Dermatology on August&#160;22, 2017, we assumed an agreement with Perrigo
        for the development, manufacturing and commercialization of the generic version of Zovirax&#174;&#160;(acyclovir) cream. Under the terms of the agreement, Perrigo was required to conduct all regulatory, scientific, clinical and technical activities necessary
        to develop the generic version of Zovirax&#174;&#160;(acyclovir) cream, prepare and file an ANDA with the FDA, and gain regulatory approval to market the generic version of Zovirax&#174;&#160;(acyclovir) cream. The agreement provides that as soon as reasonably
        practical after final approval by the FDA of the ANDA, Perrigo is required to use diligent efforts to commercialize the product in the United States. Perrigo has the sole and exclusive right to establish and control the prices and all other terms
        and conditions for the sales of the product in the United States and is required to do so in good faith . We are responsible for 80% of all out-of-pocket clinical study costs related to the generic version of Zovirax&#174;&#160;(acyclovir) cream. We will be
        entitled to 50% of Perrigo&#8217;s gross profits related to the sale of the generic version of Zovirax&#174;&#160;(acyclovir) cream, on a quarterly basis, for a period of 20 years following the first commercial sale of the generic product. The agreement may be
        terminated if the gross profits relating to the sale of the generic version of Zovirax&#174;&#160;(acyclovir) cream do not exceed a certain threshold or if the potential market for the product has been significantly reduced to regulatory changes.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In February 2019, we announced that Perrigo received final approval from the FDA for the first generic version of Zovirax&#174;&#160;(acyclovir) cream, 5%. We launched the product in
        February 2019.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Generic version of Bryhali&#174; (halobetasol propionate) lotion, 0.01%</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are party to a collaboration agreement with Perrigo Israel, an affiliate of Perrigo Company plc, for the development, manufacturing and commercialization of a generic version
        of Bryhali&#174; (halobetasol propionate) lotion, 0.01%, for the treatment of plaque psoriasis in adults.&#160; On January 30, 2020,&#160; Perrigo filed an ANDA for such generic version of Bryhali&#174; (halobetasol propionate) lotion, 0.01%, and on May 1. 2020 Bausch
        Health Companies, Inc. (&#8220;Bausch Health&#8221;)&#160;filed a patent infringement action Perrigo&#8217;s ANDA in the US District Court for the District of New Jersey for such product.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Generic version of Duobrii<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (halobetasol propionate and tazarotene) lotion</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are also a party to a collaboration agreement with Perrigo Israel, an affiliate of Perrigo Company plc, for the development, manufacturing and commercialization of a generic
        version of Duobrii<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (halobetasol propionate and tazarotene) lotion.&#160; In July 2020, Perrigo filled first-to-file Paragraph IV Certification for such generic version of Duobrii<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> lotion asserting that certain U.S. patents, each
        of which is listed in the FDA's Orange Book for the Duobrii&#174; lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo&#8217;s generic lotion, and on August 31, 2020, Bausch Health
        initiated patent infringement action in the U.S. District Court of New Jersey regarding Perrigo&#8217;s ANDA for such product.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">69</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic;">Other generic products</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, we have entered into collaboration agreements with Perrigo Israel, an affiliate of Perrigo Company plc, for the development, manufacturing and commercialization of
        seven other generic product candidates.&#160; Under such agreements and the agreements with respect to a generic version of Bryhali&#174; (halobetasol propionate) lotion, 0.01% and a generic version of Duobrii<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (halobetasol propionate and
        tazarotene) lotion referred to above, Perrigo will conduct the regulatory (if relevant), scientific, clinical and technical activities necessary to develop the generic product candidates and seek regulatory approval with the FDA for the generic
        product candidates. If approved by the FDA, Perrigo has agreed to commercialize the generic product candidates in the United States.&#160; We and Perrigo will share the development costs and the gross profits generated from the sales of the generic
        product candidates, if approved.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Intellectual Property</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our intellectual property and proprietary technology are directed to the development, manufacture and sale of our branded product candidates, including Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,
        Epsolay&#174; and SGT-210. We seek to protect our intellectual property, core technologies and other know-how, through a combination of patents, trademarks, trade secrets, non-disclosure and confidentiality agreements, assignments of invention and other
        contractual arrangements with our employees, consultants, partners, suppliers, customers and others.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will be able to protect our technology from unauthorized use by third parties only to the extent it is covered by valid and enforceable patents or is effectively maintained as
        trade secrets. Patents and other proprietary rights are an essential element of our business. If any of the below described applications are not approved, or any of the below described patents are invalidated, deemed unenforceable or otherwise
        successfully challenged, such loss would have a material effect on the commercialization of our product candidates and our future prospects.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our patent portfolio that is directed to our branded product candidates includes 113 patents and patent applications and claims processes for manufacture (including silica
        microencapsulation platform and other technologies), formulations, composition of matter, and methods of use. Of these 113 patents and patent applications, 58 are granted patents (10 in the United States and 48 in other countries) and 55 are
        pending applications (27 in the United States and 28 in other countries).</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For our Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> product candidate, we have obtained patent protection for the composition of matter in the United States, Canada, Japan, Mexico (with a term until
        2028) and we have a pending application claiming composition of matter in the European Patent Office. There are four patent families protecting the process for the encapsulation of the active agents of our Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> product candidate (one
        patent family has patents granted in Canada, India, Mexico, Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland and the United Kingdom) and Japan (with a term until 2028) and applications pending in the United States; the
        second patent family has patents granted in Mexico, Canada and the United States (with a term until 2029) and an application pending in the United States; the third patent family has patents granted in Europe (validated in France, Germany, Ireland,
        Italy, Spain, Switzerland and the United Kingdom), China, India, Japan, Canada, Mexico and the United States (with a term until 2030) and applications pending in the United States); and the fourth patent family has patents granted in Canada, China,
        Israel, India, Mexico and the United States). We own pending patents for the formulation of our Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> product candidate in the United States (with a term until 2032) and China, and patents granted in Japan, Canada, Mexico and Europe
        (validated in France, Germany, Ireland, Italy, Spain, Switzerland, United Kingdom) (with a term until 2032). We have pending patent applications in the United States for the composition of our Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> product candidate and one patent
        granted in the United States for the method of treatment of Twyneo&#174; (with a term until 2038). We have five trademarks registered for our Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> product candidate in Israel, Europe, the United States and Canada.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">For our Epsolay&#174; product candidate, we have obtained patents in China, Canada, Japan, Europe, Mexico and the United States (with a term
        until 2032) covering the composition for topical treatment of rosacea. We have further pending applications for this composition in the United States, Canada and China. There are two patent families directed to the process for encapsulation of the
        active agents of our Epsolay&#174; product candidate (one patent family has granted patents in Canada, India, Mexico, Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland and the United Kingdom) and Japan (with a term until 2028) and
        pending applications in the United States; and the second patent family has patents granted in Canada, China, Israel, India, Mexico and the United States). We also have 16 patent applications pending covering the methods of use of Epsolay&#174; for the
        treatment of rosacea.&#160; We have four registered trademarks for our Epsolay&#174; product candidate in Israel, Europe, Canada and the United States.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">70</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have one not published application covering the compositions of Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, the processes for the encapsulation of the active agents of our
        Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> product candidates, and the methods of use.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have applied for patents covering the use of tapinarof in ophthalmic disorders including dry eye, uveitis, and blepharitis with or without demodex involvement.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">We have four registered trademarks in Europe, Canada, the United States and Israel. These registrations cover potential brand names for our Epsolay&#174; product candidate in Israel, Europe, Canada and
          the United States.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Competition</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The pharmaceutical industry is subject to intense competition as well as rapid technological changes. Our ability to compete is based on a variety of factors, including product
        efficacy, safety, cost-effectiveness, patient compliance, patent position and effective product promotion. Competition is also based upon the ability of a company to offer a broad range of other product offerings, large direct sales forces and
        long-term customer relationships with target physicians.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There are numerous companies that have branded or generic products or product candidates in the dermatology market. Among them are Aclaris Therapeutics, Inc., Akorn, Inc.,
        Almirall S.A., Aqua Pharmaceuticals LLC, Bayer HealthCare AG, Cassiopea SpA, Dermira, Inc., Vyne Pharmaceuticals Ltd., Galderma Pharma S.A., Glenmark Pharmaceuticals Ltd., G&amp;W Laboratories, Inc., LEO Pharma A/S, Mylan N.V., Novan, Inc.,
        Novartis AG, Novum Pharma, LLC, Perrigo Company plc, Pfizer, Inc., Spear Therapeutics, Ltd., Sun Pharmaceutical Industries Ltd., Teligent, Inc., Teva Pharmaceutical Industries Ltd. and Bausch Health&#160;Companies Inc.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In order for our approved product candidates, if any, to compete successfully in the dermatology market, we will have to demonstrate that their efficacy, safety and
        cost-effectiveness provide an attractive alternative to existing therapies, some of which are widely known and accepted by physicians and patients, as well as to future new therapies. Such competition could lead to reduced market share for our
        product candidates and contribute to downward pressure on the pricing of our product candidates, which could harm our business, financial condition, operating results and prospects.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Many of the companies, academic research institutions, governmental agencies and other organizations involved in the field of dermatology have substantially greater financial,
        technical and human resources than we do, and may be better equipped to discover, develop, test and obtain regulatory approvals for products that compete with ours. They may also be better equipped to manufacture, market and sell products. These
        companies, institutions, agencies and organizations may develop and introduce products and drug delivery technologies competitive with or superior to ours which could inhibit our market penetration efforts.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Twyneo<font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and Epsolay&#174; target the well-established acne and rosacea markets. If approved, we expect them to
          compete with current standard-of-care treatments, whether branded, generic or over-the-counter, as well as with new treatments to be approved in the future. The current standard-of-care for acne includes topical anti-bacterial drugs such as
          benzoyl peroxide that are broadly available over-the-counter, prescription drug products that are based on single retinoid drug products such as Differin, Atralin, Retin-A, Retin-A Micro, Tazorac and Altreno, fixed-dose combinations of benzoyl
          peroxide and adapalene such as Epiduo and Epiduo Forte, fixed-dose combinations of benzoyl peroxide and clindamycin such as Duac, Benzaclin, Onexton and Acanya, fixed-dose combinations of tretinoin and clindamycin such as Ziana and Veltin, and
          topical antibiotics such as Aczone and Amzeeq. The current standard of care for rosacea includes Metrogel, Finacea, Soolantra and the recently launched Zilxi, as well as oral Oracea (doxycycline embedded in a technology platform). As a fixed-dose
          combination product candidate, Twyneo&#174; may also compete with drug products utilizing other technologies that can separate two drug substances, such as dual chamber tubes, dual pouches or dual sachets. In addition to these products, our FDA
          approved generic version of Zovirax&#174;&#160;(acyclovir) cream, 5% and our generic drug product candidates, including ivermectin cream, 1%, are expected to face direct competition from branded drugs and authorized generics which are prescription drugs
          produced by the branded pharmaceutical companies and marketed under a private label, at generic prices. On December&#160;30, 2016, Actavis Ltd. submitted an ANDA for ivermectin, 1%, cream, and therefore we will only be able to commercialize this
          product after Actavis Ltd.'s six-month exclusivity period expires.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">71</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Marketing, Sales and Distribution</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We currently have limited sales, marketing and distribution capabilities. In order to commercialize our product candidates, if approved for commercial sale, we expect to
        collaborate with third parties that have sales and marketing experience. We intend to commercialize our late-stage branded product candidates in the United States, if approved, through one or more third party collaborators that have direct sales
        forces and established distribution systems in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize Twyneo&#174;, Epsolay&#174;
        or any of our other product candidates. In other markets, we also expect to selectively pursue strategic collaborations with third parties in order to maximize the commercial potential of our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In preparation for commercial launch of Epsolay and Twyneo, we have opened a U.S. headquarters in Whippany, New Jersey.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Manufacturing</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For the supply of current good manufacturing practice-grade, or cGMP-grade, clinical trial materials we rely on and expect to continue to rely on third-party contract
        manufacturing organizations, or CMOs, or on in-house manufacturing capabilities. As of August 2018, our in-house manufacturing operations have been audited for current good manufacturing, or cGMP, compliance, and were granted a cGMP certification
        by the Israel Ministry of Health. This certification allowed us to manufacture Twyneo&#174; and its intermediates to support Phase 3 clinical trials. This cGMP certification expired in 2020, and since no other manufacturing for Phase 3 clinical trials
        is planned at the Company during 2021, the Company and the Israel Ministry of Health have mutually concluded that the cGMP certification will be reassessed and renewed for other products as they reach relevant stages of development. ISO 14001:2015
        and OHSAS 18001:2007 certifications continue to be maintained and are due for renewal in May 2021 and March 2021, respectively. For commercial manufacturing of our products, we intend to rely solely on CMOs. It is our policy to have multiple or
        alternative sources where possible for every service and material we use in our products.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Government Regulation</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Regulation by governmental authorities in Israel, the United States and other countries is a significant factor in the development, manufacture and commercialization of our
        product candidates and in our ongoing research and development activities. Our business is subject to extensive government regulation in Israel for its manufacturing activities involving drug products, drug product intermediates, and drug product
        active substances to be used in Phase 3 clinical trials and commercial manufacturing.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Product Approval Process in the United States</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Review and approval of drugs</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act, or FDCA, and other federal and state
        statutes and implementing regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling,
        and import and export of pharmaceutical products. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant to a variety of administrative
        or judicial sanctions and enforcement actions brought by the FDA, the Department of Justice or other governmental entities. Possible sanctions may include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a
        clinical hold, issuance of warning letters or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil
        or criminal penalties.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">72</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">FDA approval of a new drug application is required before any new unapproved drug or dosage form, can be marketed in the United States. Section 505 of the FDCA describes three
        types of new drug applications: (1) an application that contains full reports of investigations of safety and effectiveness (section 505(b)(1)); (2) an application that contains full reports of investigations of safety and effectiveness but where
        at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference (section 505(b)(2)); and (3) an application that contains information
        to show that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics, and intended use, among other things, to a previously approved product (section
        505(j)). Section 505(b)(1) and 505(b)(2) new drug applications are referred to as NDAs, and section 505(j) applications are referred to as ANDAs.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In general, the process required by the FDA prior to marketing and distributing a new drug, as opposed to a generic drug subject to section 505(j), in the United States usually
        involves the following:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z96dde7f30802492eb22c4544c7849720">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>completion of pre-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practices, or GLP, requirements or other applicable regulations;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z904423032c634c85b70e1a94fb068734">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials in the United States may begin;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z31ece74b86be4cc58f7825aa3171e452">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8999e2ae13eb4762b61a61b315822e84">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb076357983e34b27a72095a1ada6b314">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>preparation and submission to the FDA of an NDA;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9070d700a4274eb8b3b54fa0d3ecfe67">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>satisfactory completion of an FDA advisory committee review, if applicable;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z316c39a371f34324a47e088bdac091e4">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product or components thereof are produced, to assess compliance with current good manufacturing practices, or cGMPs, and to
                assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaaf534e9e1734769b6625b5d18cf8a82">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7af8dc4151c5478b92e3c828fdec75f5">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>payment of user fees and FDA review and approval of the NDA.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Pre-clinical studies</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pre-clinical studies include laboratory evaluation or product chemistry, formulation and toxicity, as well as animal studies to assess the potential safety and efficacy of the
        product candidate. Pre-clinical safety tests must be conducted in compliance with the FDA regulations. The results of the pre-clinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of an
        investigational new drug application, or IND, which must become effective before clinical trials may commence. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an
        IND submission is on the general investigational plan and the protocol(s) for clinical studies.&#160; The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30- day time period, raises safety concerns or
        questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND
        therefore may or may not result in FDA authorization to begin a clinical trial. Long-term pre-clinical studies, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND application is submitted.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">73</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Clinical trials</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Clinical trials involve the administration of an investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements,
        which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among
        other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the local
        institutional review board, or IRB, and to the FDA as part of the IND.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">An IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct
          continuing review at least annually. The IRB must review and approve, among other things, the trial protocol information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations. Some studies also include oversight
          by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study&#160; may&#160; move&#160; forward&#160; at designated check points based on access
          to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Depending on its charter, this group may determine
          whether a trial may move forward at designated check points based on access to certain data from the trial. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or
          patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the
          drug has been associated with unexpected serious harm to patients.&#160; There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1f8202e17db4408fa4084fb7df9b633e">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-style: italic;">Phase 1</font><font style="font-family: 'Times New Roman',Times,serif;">: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for
                  safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4515c9102555406980be438533cf0e8c">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-style: italic;">Phase 2</font><font style="font-family: 'Times New Roman',Times,serif;">: The drug is administered to a limited patient population to identify possible short-term adverse effects and safety risks, to
                  preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0944c9f5a3a64c45b4a75a6f0f3b5a4f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-style: italic;">Phase 3</font><font style="font-family: 'Times New Roman',Times,serif;">: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in
                  well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for
                  the labeling of the product.</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">74</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These
        so-called Phase 4 studies, may be conducted after initial marketing approval, and may be used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the
        performance of Phase 4 clinical trials as a condition of approval of an NDA.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about
        the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
        batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability
        studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies
        performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies
        suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <font style="font-style: italic;">in vitro </font>testing suggesting a significant risk to humans, and any clinically important increased
        incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 0.1pt; margin-left: 0.1pt; line-height: 1.25;">In addition, during the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points
        may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date,
        for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the
        pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unlike NDA products which must be shown to be safe and effective for their intended use, ANDA products must be shown to be the same as, and bioequivalent to, a reference listed
        drug, or RLD, and superior over the vehicle. A product is considered bioequivalent if there is no significant difference in the rate and extent to which the active ingredient in the generic product and in the RLD becomes available at the site of
        drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Accordingly, an applicant typically compares the systemic exposure profile of the generic test drug product to that of the RLD at the
        same regimen and exposure period as the RLD to demonstrate bioequivalence. For most ANDAs, bioequivalence must be shown in human clinical trials, but in some cases, FDA will accept in vitro data. Specific requirements are typically outlined by FDA
        in product-specific bioequivalence guidance.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Submission of an NDA to the FDA</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Assuming successful completion of all required testing with all applicable regulatory requirements, the results of the pre-clinical studies and clinical trials, together with
        other detailed information, including information on the manufacture, control and composition of the product, are submitted to the FDA as part of an NDA requesting approval to market the product candidate for a proposed indication. Under the
        Prescription Drug User Fee Act, as amended, applicants are required to pay fees to the FDA for reviewing an NDA. These application user fees, as well as the annual program fees required for approved products, can be substantial. The NDA application
        review fee alone can exceed $2.5 million, subject to certain limited deferrals, waivers and reductions that may be available.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is
        sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information and is subject to payment of additional
        user fees. The resubmitted application is also subject to review before the FDA accepts it for filing. If found complete, the FDA will accept the NDA for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive
        review.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">75</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the PDUFA, the FDA has agreed to certain performance goals in the review of NDAs through a two-tiered classification system, Standard Review and Priority Review. An NDA is
        eligible for Priority Review if the product candidate is designed to treat serious or life-threatening disease or condition, and if approved, would provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or
        condition compared to marketed products. For non-new molecular entities, such as those typically submitted in 505(b)(2) applications, the FDA endeavors to review applications subject to Standard Review within approximately 10 months of receipt,
        whereas the FDA&#8217;s goal is to review Priority Review applications within approximately six months of receipt. The FDA, however, may not approve a drug within these established goals, as the review process is often significantly extended by FDA
        requests for additional information or clarification, and its review goals are subject to change from time to time.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Before approving an NDA, the FDA inspects the facilities at which the product is manufactured or facilities that are significantly involved in the product development and
        distribution process and will not approve the product unless cGMP compliance is satisfactory. Additionally, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. The FDA may also refer applications
        for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. The FDA
        is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the
          product with specific prescribing information for specific indications. A complete response letter indicates that the review cycle for an application is complete and that the application is not ready for approval. A complete response letter
          generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA may ultimately
          decide that an application does not satisfy the regulatory criteria for approval. If, or when, the deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.</div>
      </div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a product is approved, the approval will impose limitations on the indicated uses for which the product may be marketed, may require that warning statements be included in the
        product labeling, may require that additional studies or trials be conducted following approval as a condition of the approval, may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a risk
        management plan, or impose other limitations. For example, as a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to ensure that the benefits of the drug outweigh the potential risks. If the FDA
        determines a REMS is necessary during review of the application, the drug sponsor must agree to the REMS plan at the time of approval. A REMS may be required to include various elements, such as a medication guide or patient package insert, a
        communication plan to educate healthcare providers of the drug&#8217;s risks, limitations on who may prescribe or dispense the drug, or other elements to assure safe use, such as special training or certification for prescribing or dispensing, dispensing
        only under certain circumstances, special monitoring and the use of patient registries. In addition, the REMS must include a timetable to periodically assess the strategy. The requirement for a REMS can materially affect the potential market and
        profitability of a drug.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Further changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require
        submission and FDA approval of a new NDA or NDA supplement before the change can be implemented, which may require manufacturers to develop additional data or conduct additional pre-clinical studies and clinical trials. An NDA supplement for a new
        indication typically requires clinical data similar to that in the original application, and the FDA uses the similar procedures in reviewing NDA supplements as it does in reviewing NDAs.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">76</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Post-Approval Requirements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any drug products receiving FDA approval will be subject to continuing regulation by the FDA. Certain requirements include, among other things, record-keeping requirements,
        reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information on an annual basis or more frequently for specific events, product sampling and distribution requirements, complying with certain
        electronic records and signature requirements and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include standards for direct-to-consumer advertising, prohibitions against promoting drugs for
        uses or patient populations that are not described in the drug&#8217;s approved labeling, known as &#8220;off-label use,&#8221; and other promotional activities, such as those considered to be false or misleading.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not encourage, market or promote such off-label uses. As a result, &#8220;off-label
        promotion&#8221; has formed the basis for litigation under the Federal False Claims Act, violations of which are subject to significant civil fines and penalties. In addition, manufacturers of prescription products are required to disclose annually to
        the Center for Medicaid and Medicare any payments made to physicians in the United States under the Sunshine Act of 2012. These payments could be in cash or kind, could be for any reason, and are required to be disclosed even if the payments are
        not related to the approved product. A failure to fully disclose or not report in time could lead to penalties of up to $1 million per year.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The manufacturing of any drug products must comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s cGMP regulations. The FDA&#8217;s cGMP regulations require,
        among other things, quality control and quality assurance, as well as the corresponding maintenance of comprehensive records and documentation. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are
        also required to register their establishments and list any products they make with the FDA and to comply with related requirements in certain states. Changes to the manufacturing process are strictly regulated and often require prior FDA approval
        before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may
        decide to use. These entities are further subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the
        area of production and quality control to maintain cGMP compliance.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Discovery of problems with a product after approval may result in serious and extensive restrictions on a product, manufacturer or holder of an approved NDA, as well as lead to
        potential market disruptions. These restrictions may include recalls, suspension of a product until the FDA is assured that quality standards can be met, and continuing oversight of manufacturing by the FDA under a &#8220;consent decree,&#8221; which
        frequently includes the imposition of costs and continuing inspections over a period of many years, as well as possible withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA
        approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. There also are continuing, annual program user
        fee requirements for any approved products, as well as new application fees for supplemental applications with clinical data.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The FDA also may require post-marketing testing, or Phase IV testing, as well as risk minimization action plans and surveillance to monitor the effects of an approved product or
        place conditions on an approval that could otherwise restrict the distribution or use of our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">77</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Once approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
        reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in
        mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential
        consequences include, among other things:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze38ec621434446129a106d40858f2985">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd4800fe9e9884c4ba9b67880b750c3ff">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>fines, warning letters or holds on post-approval clinical trials;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7c000b0569884dabaf88a25458512706">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z38b8dd36a0954d15bb3f53acf5f8de71">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>product seizure or detention, or refusal to permit the import or export of products; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaeab36ace0b1423fb67596f7fc6782a2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>injunctions or the imposition of civil or criminal penalties.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Pediatric trials and exclusivity</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Even when not pursuing a pediatric indication, under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that is adequate to assess the
        safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must
        also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric trials the applicant plans to conduct, including trial objectives and design, any deferral or waiver requests, and other
        information required by the statute. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment
        to the plan at any time.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The FDA may also, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for
        use in adults, or full or partial waivers from the pediatric data requirements.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Separately, in the event the FDA makes a written request for pediatric data relating to a drug product, an NDA sponsor who submits such data may be entitled to pediatric
        exclusivity. Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing non-patent
        exclusivity.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">The Hatch-Waxman Amendments</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">ANDA Approval Process</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Hatch-Waxman Amendments established abbreviated FDA approval procedures for drugs that are shown to be equivalent to proprietary drugs previously approved by the FDA through
        the NDA process. Approval to market and distribute these drugs is obtained by submitting an ANDA to the FDA. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical
        ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data, and quality control procedures. Premarket applications for generic drugs are termed
        abbreviated because they generally do not include pre-clinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug. In certain situations,
        an applicant may obtain ANDA approval of a generic product with a strength or dosage form that differs from a referenced innovator drug pursuant to the filing and approval of an ANDA Suitability Petition. The FDA will approve the generic product as
        suitable for an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product. A product is not eligible for ANDA approval if the FDA determines that it is not
        bioequivalent to the referenced innovator drug, if it is intended for a different use, or if it is not subject to an approved Suitability Petition. However, such a product might be approved under an NDA, with supportive data from clinical trials.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">78</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">505(b)(2) NDAs</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendment, and permits the filing of an NDA where at least some of the information required for approval comes from
        studies or trials not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2) typically serves as an alternative path to FDA approval for modifications to formulations or uses of
        products previously approved by the FDA. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain pre-clinical
        studies or clinical trials for the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved branded reference drug. The FDA may then approve
        the new product candidate for all, or some, of the labeled indications for which the branded reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Orange Book Listing</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant&#8217;s product
        or method of using the product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Publication of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the
        &#8220;Orange Book.&#8221; Any applicant who submits an ANDA seeking approval of a generic equivalent of a drug listed in the Orange Book or a Section 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA (1) that no patent
        information on the drug product that is the subject of the application has been submitted to the FDA; (2) that such patent has expired; (3) the date on which such patent expires; or (4) that such patent is invalid or will not be infringed upon by
        the manufacture, use, or sale of the drug product for which the application is submitted. This last certification is known as a Paragraph IV certification. The applicant may also elect to submit a &#8220;section viii&#8221; statement certifying that its
        proposed label does not contain (or carves out) any language regarding a patented method-of-use rather than certify to a listed method-of-use patent.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the applicant does not challenge one or more listed patents through a Paragraph IV certification, the FDA will not approve the ANDA or Section 505(b)(2) NDA until all the
        listed patents claiming the referenced product have expired. Further, the FDA will also not approve, as applicable, an ANDA or Section 505(b)(2) NDA until any non-patent exclusivity, as described in greater detail below, has expired.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the ANDA or Section 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the
        owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the ANDA or Section 505(b)(2) NDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent
        infringement suit against the ANDA or Section 505(b)(2) applicant. Under the FDCA, the filing of a patent infringement lawsuit within 45 days of receipt of the notification regarding a Paragraph IV certification automatically prevents the FDA from
        approving the ANDA or Section 505(b)(2) NDA until the earliest to occur of 30 months beginning on the date the patent holder receives notice, expiration of the patent, settlement of the lawsuit, or until a court deems the patent unenforceable,
        invalid or not infringed. Even if a patent infringement claim is not brought within the 45-day period, a patent infringement claim may be brought under traditional patent law, but it does not invoke the 30-month stay.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Moreover, in cases where an ANDA or Section 505(b)(2) application containing a Paragraph IV certification is submitted after the fourth year of a previously approved drug&#8217;s
        five-year NCE exclusivity period, as described more fully below, and the patent holder brings suit within 45 days of notice of the Paragraph IV certification, the 30-month period is automatically extended to prevent approval of the Section
        505(b)(2) application until the date that is seven and one-half years after approval of the previously approved reference product that has the five-year NCE exclusivity. The court also has the ability to shorten or lengthen either the 30-month or
        the seven and one-half year period if either party is found not to be reasonably cooperating in expediting the litigation.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">79</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Notwithstanding the approval of many products by the FDA pursuant to Section 505(b)(2), over the last few years, some pharmaceutical companies and others have objected to the
        FDA&#8217;s interpretation of Section 505(b)(2). If the FDA changes its interpretation of Section 505(b)(2), or if the FDA&#8217;s interpretation is successfully challenged in court, this could delay or even prevent the FDA from approving any Section 505(b)(2)
        NDA that we submit.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Non-Patent Exclusivity</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to patent exclusivity, NDA holders may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA or 505(b)(2) application that
        relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity upon NDA approval of a new chemical entity, or NCE, which is a drug that contains an active moiety that has not been approved by
        FDA in any other NDA. An &#8220;active moiety&#8221; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological or pharmacologic action. During the five year exclusivity period, the FDA cannot accept for filing any ANDA seeking
        approval of a generic version of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA&#8217;s findings regarding that drug, except that FDA may accept an application for filing after four years if the follow-on applicant
        makes a Paragraph IV certification.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Another form of non-patent exclusivity is clinical investigation exclusivity. A drug, including one approved under Section 505(b)(2), may obtain a three-year period of
        exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or bioequivalence studies) was
        essential to the approval of the application and was conducted or sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or 505(b)(2) application for the protected modification until after that three-year
        exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the exclusivity period.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Review and Approval of Drug Products Outside the United States</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to regulations in the United States, if we target non-U.S. markets, we will be subject to a variety of foreign regulations governing manufacturing, clinical trials,
        commercial sales and distribution of our future product candidates. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before
        commencing clinical trials or marketing in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials,
        product licensing, pricing and reimbursement vary greatly from country to country.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under European Union regulatory systems, marketing authorizations may be submitted either under a centralized, decentralized or mutual recognition procedure. The centralized
        procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure includes selecting one &#8220;reference member state,&#8221; or RMS, and submitting to more than one-member
        state at the same time. The RMS National Competent Authority conducts a detailed review and prepares an assessment report, to which concerned member states provide comment. The mutual recognition procedure provides for mutual recognition of
        national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states post-initial approval. Within 90 days of receiving the applications and assessment report,
        each member state must decide whether to recognize the approval.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 0.2pt; margin-left: 0.2pt; line-height: 1.25; font-style: italic; font-weight: bold;">Pharmaceutical Coverage, Pricing and Reimbursement</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and other
        markets, sales of any product candidates for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government health
        administrative authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or
        reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a particular
        indication.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">80</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety
        and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of Epsolay&#174; and Twyneo&#174;, in addition to the costs required to obtain the FDA approvals. For example,
        Epsolay&#174; and Twyneo&#174; may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may
        not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement
        price has been agreed. Some countries may require the completion of additional studies or trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides
        options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a
        specific price for a drug product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug
        products but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, there are increasingly high barriers to entry for new products. In addition,
        in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable
        reimbursement and pricing arrangements.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;Healthcare Reform</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In March&#160;2010, the President of the United States signed the Affordable Care Act, one of the most significant healthcare reform measures in decades. The Affordable Care Act
        substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the pharmaceutical industry. The Affordable Care Act contained a number of provisions, including those governing enrollment
        in federal healthcare programs, reimbursement changes and fraud and abuse, which impacted existing government healthcare programs and will result in the development of new programs, including Medicare payment for performance initiatives and
        improvements to the physician quality reporting system and feedback program.&#160; Additionally, the Affordable Care Act increased the minimum level of rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1%, and imposed a
        non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the Affordable Care Act. By way of example, the Tax Act was enacted,
        which, among other things, removes penalties for not complying with the Affordable Care Act&#8217;s individual mandate to carry health insurance. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the
        individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. On December 18, 2019, the
        U.S. Court of Appeals for the 5th Circuit upheld the District Court's decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care
        Act are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court the rule. It is also unclear how other efforts, if any, to challenge, repeal or replace the Affordable Care Act will
        impact the law or our business.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">81</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011 resulted in aggregate
        reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2030, with the exception of a temporary suspension
        from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. Additionally, in January&#160;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to
        several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Recently there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several
        Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program
        reimbursement methodologies. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient
        reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that
        additional state and federal healthcare initiatives will be adopted in the future, any of which could impact the coverage and reimbursement for drugs, including our product candidates, if approved.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Healthcare Laws and Regulations</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Although we do not currently have any product candidates on the market, other than the first generic version of Zovirax&#174;&#160;(acyclovir) cream, 5% for which Perrigo, our
        collaborator, received final FDA approval in February 2019, our current and future business operations may be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign
        jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, price reporting and physician and other healthcare provider payment
        transparency laws. Some of our pre-commercial activities are subject to some of these laws.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer or a party acting on its behalf to knowingly and
        willfully, directly or indirectly solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, lease of any good, facility, item or service for which payment may be made under
        a federal healthcare program, such as Medicare or Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical
        manufacturers on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the
        exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe
        harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be
        evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to
        induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed
        a violation.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by,
        federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed, knowingly making, using or causing to be made or used, a false record or statement material
        to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to a federal program. Persons and entities can be held liable under these laws if they are deemed to &#8220;cause&#8221; the
        submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated
        retail prices for our product candidates, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our product candidates, and the sale and marketing of
        our product candidates, are subject to scrutiny under this law. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil
        False Claims Act.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">82</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">HIPAA created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
        benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying,
        concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, a person
        or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to
        a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Affordable Care Act imposed, among other things, new annual reporting requirements for covered manufacturers for certain payments and other transfers of value provided to
        physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other health care providers beginning in 2022, and teaching hospitals, as well as certain ownership and investment interests held by physicians
        as defined by statute and their immediate family members.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services
        reimbursed under Medicaid and other state programs. Additionally, to the extent that any of our product candidates are sold in a foreign country, we may be subject to similar foreign laws. Certain states also mandate implementation of compliance
        programs, impose restrictions on drug manufacturer marketing practices, require reporting of marketing expenditures and pricing information and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without
        limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation
        in federal and state healthcare programs or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations, and imprisonment, any of which could adversely affect our ability to operate our business and our
        financial results.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Data Privacy and Security</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The collection and use of personal health data in the European Union, previously governed by the provisions of the Data Protection Directive, is now governed by the GDPR, which
        became effective on May 25, 2018. While the Data Protection Directive did not apply to organizations based outside the EU, the GDPR has expanded its reach to include any business, regardless of its location, that provides goods or services to
        residents in the EU. This expansion would incorporate any clinical trial activities in EU members states. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;sensitive information&#8221;
        which includes health and genetic information of data subjects residing in the EU. GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain
        circumstances, and provides the individual with an express right to seek legal remedies in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules on the transfer of personal data out of the
        European Union to the United States or other regions that have not been deemed to offer &#8220;adequate&#8221; privacy protections. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member
        States, which may deviate slightly from the GDPR, may result in fines of up to 4% of global revenues, or &#8364; 20,000,000, whichever is greater. Additionally, following the United Kingdom&#8217;s withdrawal from the European Union, we will have to comply
        with the GDPR and the United Kingdom GDPR, each regime having the ability to fine up to the greater of &#8364;20 million/ &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain
        aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">83</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">HIPAA, as amended by HITECH, and their implementing regulations, including the final omnibus rule published on January&#160;25, 2013, mandates, among other things, the adoption of
        uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative,
        physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as independent contractors or agents of covered entities that create,
        receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates,
        and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition,
        certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus
        complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties. By way of example, California enacted the California Consumer Privacy Act, or CCPA,
        on June 28, 2018, which went into effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information
        about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance
        costs and potential liability.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Innovation Authority</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have received royalty-bearing grants from the government of Israel through the IIA, for the financing of a portion of our research and development expenditures in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Innovation Law and the IIA&#8217;s rules and guidelines, recipients of grants, or Recipient Company(ies), are subject to certain obligations including, the following:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9ac4a71002434b1f94f30a4f80598e8a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>In general, the Recipient Company is obligated to pay the IIA royalties from the revenues generated from the sale of products (and related services) developed (in all or in part) as a result of, a research and development program funded
                by the IIA at rates which are determined under the IIA&#8217;s rules and guidelines (currently a yearly rate of 1.3% to 5% on sales of products or services developed under the approved programs, depending on the type of the Recipient
                Company&#8201;&#8212;&#8201;i.e., whether it is a &#8220;Small Company,&#8221; a &#8220;Large Company&#8221; or a &#8220;Traditional Industrial Company&#8221; as such terms are defined in the IIA&#8217;s rules and guidelines), up to the aggregate amount of the total grants received by the IIA, plus
                annual interest (as determined in the IIA&#8217;s rules and guidelines);</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">84</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5d41fef8b56f4fb294e263bd53264e71">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Products developed as a result of the IIA funded R&amp;D must, as a general matter, be manufactured in Israel. The Recipient Company is prohibited from manufacturing products developed using these IIA grants outside of the State of
                Israel without receiving prior approval from the IIA (except for the transfer of less than 10% of the manufacturing capacity in the aggregate which requires only a notice). If the Recipient Company receives approval to manufacture products
                developed with government grants outside of Israel, it will be required to pay increased royalties to the IIA, up to 300% of the grant amount plus interest, depending on the manufacturing volume that is performed outside of Israel. The
                Recipient Company may also be subject to an accelerated royalty repayment rate. A Recipient Company also has the option of declaring in its IIA grant application its intention to exercise a portion of the manufacturing capacity abroad, thus
                avoiding the need to obtain additional approval following the receipt of the grant; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf806977478574c21ba6755a9591e6f6a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Under the IIA&#8217;s rules and guidelines, a Recipient Company is prohibited from transferring the IIA-financed know-how and related intellectual property rights outside of Israel except under limited circumstances, and only with the approval
                of the Research Committee and subject to certain payments to the IIA calculated according to formulas provided under the IIA&#8217;s rules and guidelines (which are capped to amounts specified under such rules and guidelines).</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have received grants from the IIA in connection with our research and development of a peripheral line of product candidates, which forms a negligible part of our activities,
        and therefore, we are subject to the aforementioned restrictions with respect to such product candidates. Such restrictions continue to apply even after payment of the full amount of royalties payable pursuant to the grants.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Even if our IIA funded know-how is transferred to another Israeli entity, the transfer would require the IIA&#8217;s approval but will not be subject to the payment of a redemption fee
        (we note that there will be an obligation to pay royalties to the IIA from the income of such sale transaction as part of the royalty payment obligation). In such case, the acquiring company would have to assume all of our responsibilities towards
        the IIA as a condition to the IIA&#8217;s approval.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The government of Israel does not own intellectual property rights in technology developed with IIA funding and there is no restriction on the export of products manufactured
        using technology developed with IIA funding. However, the know-how is subject to transfer of know-how and manufacturing rights restrictions as described above. The IIA&#8217;s approval is not required for the export of any products resulting from the IIA
        research or development grants. In addition, the IIA has recently published new rules and guidelines for the granting of licenses to use know-how developed as a result of research financed by the IIA to foreign entities. According to such rules, we
        will be required to receive the IIA&#8217;s prior approval for the grant of such use rights, and we will be subject to the IIA in accordance with the formula stipulated under these rules and guidelines.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to Amendment No. 7 of the Innovation Law, the IIA is authorized to change the restrictions imposed on the recipients of grants that were stipulated under the
          Innovation Law prior to the effectiveness of Amendment No.&#160;7 with a new set of arrangements in connection with ownership obligations of know-how (including with respect to restrictions on transfer of know-how and manufacturing activities outside
          of Israel), as well as royalties obligations associated with approved programs. Amendment No. 7 also includes provisions with respect to sanctions imposed for violations of the Innovation Law. The IIA published rules for the most part adopted the
          principal provisions and restrictions specified in the Innovation Law prior to the effectiveness of Amendment No. 7.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may not receive the required approvals for any actual proposed transfer and, if received, we may be required to pay the IIA a portion of the consideration that we receive upon
        any sale of the IIA funded know-how to a non-Israeli entity. The scope of the support received, the royalties that we have already paid to the IIA, the amount of time that has elapsed between the date on which the know-how was transferred and the
        date on which the IIA grants were received and the sale price and the form of transaction will be taken into account in calculating the amount of the payment to the IIA.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">85</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Environmental, Health and Safety Matters</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are subject to extensive environmental, health and safety laws and regulations in a number of jurisdictions including Israel. These laws and regulations govern, among other
        things, (i) the use, storage, registration, handling, emission and disposal of chemicals, waste materials and sewage and (ii) chemical, air, water and ground contamination, air emissions and the cleanup of contaminated sites, including any
        contamination that results from spills due to our failure to properly dispose of chemicals, waste materials and sewage. Our operations at our Ness Ziona facility use chemicals and produce waste materials and sewage. Our activities require permits
        from various governmental authorities, including local municipal authorities, the Ministry of Environmental Protection and the Ministry of Health. The Ministry of Environmental Protection and the Ministry of Health, local authorities and the
        municipal water and sewage company conduct periodic inspections in order to review and ensure our compliance with the various regulations. Our business permit is currently in effect until December 31, 2026.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">These laws, regulations and permits could potentially require the expenditure by us of significant amounts for compliance or remediation. If we fail to comply with such laws,
        regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the revocation of permits and licenses necessary to continue our business activities. In addition, we may be required to pay damages
        or civil judgments in respect of third-party claims, including those relating to personal injury (including exposure to hazardous substances we use, store, handle, transport, manufacture or dispose of), property damage or contribution claims. Some
        environmental, health and safety laws allow for strict, joint and several liability for remediation costs, regardless of comparative fault. We may be identified as a responsible party under such laws. Such developments could have a material adverse
        effect on our business, financial condition and results of operations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, laws and regulations relating to environmental, health and safety matters are often subject to change. In the event of any changes or new laws or regulations, we
        could be subject to new compliance measures or to penalties for activities which were previously permitted.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The operations of our subcontractors and suppliers are also subject to various Israeli and foreign laws and regulations relating to environmental, health and safety matters, and
        their failure to comply with such laws and regulations could have a material adverse effect on our business and reputation, result in an interruption or delay in the development or manufacture of our product candidates, or increase the costs for
        the development or manufacture of our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Properties</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our principal executive offices are located in a leased facility in Weizmann Science Park, Ness Ziona 7403650, Israel. The facility is 2,040 square meters, and houses our
        offices, warehouse, laboratories and production area. Our lease will expire on December&#160;31, 2023.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have a U.S. headquarters in Whippany, New Jersey. The facility is 3,361 square feet and houses our U.S. marketing and sales team. Our lease will expire on October 1, 2023.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Legal Proceedings</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We are not subject to any material legal proceedings.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Organizational Structure</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Properties&#8221;.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">86</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><a name="ITEM4A"><!--Anchor--></a>ITEM 4A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">None.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><a name="ITEM5"><!--Anchor--></a>ITEM 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;OPERATING AND FINANCIAL REVIEW AND PROSPECTS</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">You should read the following discussion of our financial condition and results of operations in conjunction with the</font>&#160;<font style="font-style: italic;">consolidated








          financial statements and the notes thereto included elsewhere in this annual report.&#160;&#160;The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs.&#160;&#160;Our actual results could differ materially from
          those discussed in the forward-looking statements.&#160;Factors that could cause or contribute to these differences include those discussed below and elsewhere in this annual report, particularly those in &#8220;Item 3. Key Information</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-style: italic;">&#8211;</font>&#160;<font style="font-style: italic;">D. Risk Factors.&#8221;</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Overview</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.
        Our current product candidate pipeline consists of late-stage and early-stage branded product candidates, some of which leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across
        multiple indications. Our branded product candidate, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, is a novel, once-daily, non-antibiotic topical cream that we are developing for the treatment of acne vulgaris, or acne. We completed a 726 subject, double-blind,
        placebo-controlled, six-arm, multi-center Phase II clinical trial designed to assess the safety and efficacy of Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in subjects with facial acne. In this trial, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> demonstrated statistically significant improvements
        in all pre-defined co-primary and secondary efficacy&#160;&#160; endpoints, as compared to vehicle.</div>
      <br>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.2pt; line-height: 1.25;">On December 30, 2019, we&#160;announced top-line results from two pivotal Phase 3 clinical trials evaluating Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for the treatment of acne. Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
        met all co-primary endpoints in both Phase 3 trials.&#160;The Phase 3 program enrolled an aggregate of 858 patients aged nine and older in two multicenter, randomized, double-blind, parallel group, vehicle-controlled trials at 63 sites across the United
        States. Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> demonstrated statistically significant improvement in each of the co-primary endpoints of&#160;(1) the proportion of patients who succeeded in achieving at least a two grade reduction from baseline and Clear (grade 0) or
        Almost Clear (grade 1) at Week 12 on a 5-point Investigator Global Assessment (IGA) scale, (2) an absolute change from baseline in inflammatory lesion count at Week 12, and (3) and an absolute change from baseline in non-inflammatory lesion count
        at Week 12.&#160;In addition, Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> was found to be well-tolerated. Our NDA for Twyneo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has been accepted for filing by the FDA, which assigned a PDUFA goal date of August 1, 2021.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Our branded product candidate, Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, is a novel, once-daily topical cream containing encapsulated benzoyl peroxide that we are developing for the treatment of papulopustular (subtype
          II) rosacea. On July 8, 2019, we announced&#160;positive top-line results from our Phase 3 program evaluating Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>.&#160; The program enrolled&#160;733 patients aged 18 and older in two identical, double-blind, vehicle-controlled Phase 3 clinical
          trials at 54 sites across the United States. Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> demonstrated statistically significant improvement in both co-primary endpoints of (1) the number of patients achieving &#8220;clear&#8221; or &#8220;almost clear&#8221; in the Investigator Global
          Assessment, or IGA, relative to baseline at week 12 and (2) absolute mean reduction from baseline in inflammatory lesion count at week 12. In an additional analysis, Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> demonstrated rapid efficacy, achieving statistically
          significant improvements on both co-primary endpoints compared with vehicle as early as Week 2. In addition, Epsolay&#174; was found to be well-tolerated.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">On February 12, 2020, we announced positive topline results from our open-label, long-term safety study, evaluating Epsolay&#174; for a treatment duration up to
        52 weeks. The study enrolled 547 subjects, all of whom had completed 12 weeks of treatment with Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> or vehicle in the preceding double-blind Phase 3 studies. Patients continued onto open-label treatment with Epsolay once-daily for
        up to an additional 40 weeks. The safety population of 535 subjects received Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> therapy for an overall period of at least 28 weeks. Of these 535 subjects, 209 subjects completed 52 weeks of treatment with Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,
        exceeding the sample size requirements previously defined by the FDA for the Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> one-year safety evaluation. Our NDA for Epsolay<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> has been accepted for filing by the FDA, which assigned a PDUFA goal date of April 26,
        2021.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">87</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our other branded product candidates are SGT-210 (erlotinib gel) that we are developing for the treatment of palmoplantar keratoderma (PPK), and erlotinib, tapinarof and
        roflumilast, each a potential treatment of various pharmaceutical indications.&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">We designed our proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while
        maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Our technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier
        between the active ingredient and the skin. The resulting microcapsules are designed to allow the entrapped active ingredients to gradually migrate through the pores of the shell and deliver active ingredient doses onto the skin in a controlled
        manner, resulting in improved tolerability and stability without sacrificing efficacy. By separately encapsulating active ingredients within protective silica shells, our technology platform also enables the production of novel fixed-dose active
        ingredient combinations that otherwise would not be stable. We believe that our microencapsulation technology has the potential to be used for topical drug products to treat a variety of skin diseases. As a result of the FDA having already approved
        silica as a safe excipient for topical drug products, we have submitted NDAs for Twyneo and Epsolay under the FDA&#8217;s 505(b)(2) regulatory pathway, which may provide for a more efficient regulatory process by permitting us to rely, in part, upon the
        FDA&#8217;s previous findings of safety and efficacy of an approved product.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">In order to commercialize our product candidates, if approved for commercial sale, we expect to collaborate with third parties that have sales and marketing
        experience. We intend to commercialize our late-stage branded product candidates in the United States, if approved, through one or more third party collaborators that have direct sales forces and established distribution systems in lieu of our own
        sales force and distribution systems. We are in discussions with potential partners regarding the commercialization of&#160; Twyneo&#174; and Epsolay&#174;. In other markets, we also expect to selectively pursue strategic collaborations with third parties in
        order to maximize the commercial potential of our product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Since our inception, we have incurred significant operating losses. We incurred net losses of $32.2 million, $24.6 million and $29.3 million for the years ended December&#160;31,
        2018, 2019 and 2020, respectively. As of December 31, 2020, we had an accumulated deficit of&#8201;$181.4 million. We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates from
        formulation development through pre-clinical development and clinical trials, seek regulatory approval and pursue commercialization of any approved product candidate. In addition, we may incur expenses in connection with the in-license or
        acquisition of additional product candidates.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In February 2018 we closed our initial public offering, at which time we sold a total of 7,187,500 ordinary shares in the offering and received net proceeds of approximately
        $78.8 million, after deducting underwriting discounts and commissions and without deducting other offering expenses.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On August 12, 2019, the Company completed an underwritten public offering, in which it issued 1,437,500 ordinary shares, including the full exercise by the underwriters of their
        option to purchase 187,500 additional ordinary shares, at a public offering price of $8.00 per ordinary share. The total proceeds received from the offering were approximately $10.8 million net of underwriting discounts and commissions and without
        deducting other offering expenses.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 19, 2020 the Company completed an underwritten public offering in which it issued 2,091,907 ordinary shares together with ordinary share warrants to purchase
        1,673,525 ordinary shares.&#160; The ordinary shares and warrants were sold together at a combined public offering price of $11.00 per ordinary share and accompanying warrant to purchase 0.80 of an ordinary share.&#160; The warrants have an initial exercise
        price of&#160;$14.00&#160;per share, subject to certain adjustments, and will expire on&#160;February 19, 2023. The total proceeds received from the offering were approximately $21.6 million net of underwriting discounts and commissions and without deducting
        other offering expenses.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">In addition, following the approval of the Company&#8217;s shareholders,&#160; M. Arkin Dermatology Ltd., the controlling shareholder of the Company, purchased 454,628
        ordinary shares and warrants to purchase up to 363,702 ordinary shares in a concurrent private placement, exempt from the registration of the Securities Act of 1933, as amended, at a price equal to the public offering price of the ordinary shares
        and accompanying warrants in the February 2020 public offering. The private placement, which closed on April 13, 2020,&#160; generated proceeds of approximately $5 million.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">88</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Collaboration Agreements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For a description of our collaboration agreements, please see &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Collaboration Agreements with Perrigo.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating Results</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Collaboration Revenues</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">From 2013 until December 31, 2018, other than revenues of approximately $0.2 million and $0.1 million on royalties generated in 2017 and 2018, respectively, pursuant to sales of
        products overseas under past collaboration agreements with Merck, we did not recognize any revenue. In 2019, we generated approximately $0.1 million in revenues under such past collaboration agreements with Merck.&#160;In addition, in February 2019 we
        announced that Perrigo had received final approval from the FDA for of the first generic version of Zovirax&#174;&#160;(acyclovir) cream, 5% .&#160;The product was developed in a collaboration between us and Perrigo in which we shared development costs with
        Perrigo and are sharing equally the gross profits generated from sales of the product.&#160;During the years ended December 31, 2019 and December 31, 2020, the Company recognized revenues from royalties related to sales of this product in the amount of
        $22.8 million and $8.7 million, respectively.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Operating expenses</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our current operating expenses consist primarily of research and development as well as general and administrative expenses.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Research and development expenses</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25;">Research and development expenses consist principally of:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z735e4f7d68e846b8aa18b1272eaefed1">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>salaries for research and development staff and related expenses, including employee benefits and share-based compensation expenses;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8d5b125e899e45fab52391bac99bd5d7">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expenses paid to suppliers of disposables and raw materials, including drug substances, and related expenses, such as, external laboratory testing and development of analytical methods;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z50184d73041d43998368596bded3f546">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expenses for production of our product candidates both in-house and by contract manufacturers;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9d33c4317df4e9eae82dca5675eb246">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expenses paid to contract research organizations and other third parties in connection with the performance of pre-clinical studies, clinical trials and related expenses;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z558037afa6374662b7245d82ce174932">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expenses incurred under agreements with other third parties, including subcontractors, suppliers and consultants that conduct formulation development, regulatory activities and pre-clinical studies;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd3d5c1fad5a94fa2bc258b78ac0d0fbf">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expenses incurred to acquire, develop and manufacture materials for use in pre-clinical and other studies;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5e9de8b274634ac79b1cd128f7e67af2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expenses incurred from the purchase and transfer of product candidates; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze79c86637e3f43e0988c8a593bcf4c63">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>facilities, depreciation of fixed assets used to develop our product candidates, maintenance of equipment used to develop our product candidates and other expenses, including direct and allocated expenses for rent, maintenance of
                facilities, insurance and other operating expenses.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">89</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development expenses than
        those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.&#160;&#160; We expect to continue to incur research and development expenses over the next several years as we conduct
        pre-clinical studies and clinical trials and prepare regulatory filings for our product candidates.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Due to the inherently unpredictable and highly uncertain nature of clinical development processes, we cannot reasonably estimate the nature, timing and expenses of the efforts
        that will be necessary to complete the remainder of the development of our product candidates, or when, if ever, material net cash inflows may commence from any of our product candidates. Clinical development timelines, the probability of success
        and development expenses can differ materially from expectations. This is due to numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4d7e17375a5843729352dfeb68e51b81">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the scope, rate of progress and expense of our research and development activities;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z512a9192c836422690876ddd9362881b">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>clinical trials and early-stage results;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc49ae9e490d447679a41e896c3fd1733">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the terms and timing of regulatory requirements and approvals;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1efe31ee5e8f4902a54bdd937e727f85">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6f3e259a08e541a580ef57ddcc1c5f1a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the ability to market, commercialize and achieve market acceptance of any product candidate that we are developing or may develop in the future.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">While we are currently focused on advancing our product development, our future research and development expenses will depend on the clinical success of our product candidates,
        as well as ongoing assessments of the candidates&#8217; commercial potential. As we obtain results from clinical trials, we may elect to discontinue or delay clinical trials for one or more of our product candidates in certain indications in order to
        focus our resources on more promising product candidates. Completion of clinical trials may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The lengthy process of completing clinical trials and seeking regulatory approval for our product candidates requires the expenditure of substantial resources. Any failure or
        delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">General and administrative expenses</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our general and administrative expenses consist primarily of salaries and related expenses, including employee benefits and share-based compensation expenses, legal expenses and
        professional fees for auditors and other expenses not related to research and development activities.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As we are in discussions with potential partners regarding the commercialization of&#160; Twyneo&#174; and Epsolay&#174;&#160;to occur if the product candidates receive regulatory approval from the
        FDA, we do not currently anticipate an increase in general and administrative expenses. However, if we are unable to enter into such arrangements on acceptable terms or at all, we may look to directly commercialize Twyneo&#174; and Epsolay&#174; on our own.
        In such case, our expenses related to product sales, marketing and distribution would increase significantly and we may be forced to raise additional capital sooner than anticipated.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">90</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Financial income, net</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our financial income, net&#160; consists primarily of income generated on our marketable securities&#160;and bank deposits net of expenses related to bank charges and foreign currency
        exchange transactions.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Results of operations</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table summarizes our results of operations for the indicated periods:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="z6fc51a8db6764a79ac7d6e25150c0c85" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;quot; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="10" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year ended December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;quot; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2018</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: bold;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: bold;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2019</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: bold;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: bold;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;quot; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="10" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(in thousands)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%;">
              <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">Collaboration Revenues</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">129</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">22,904</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">8,771</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">Research and development</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">28,146</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">40,578</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">27,913</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">General and administrative</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">5,504</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">8,276</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">11,091</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 64%;">
              <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">Total operating loss</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">33,521</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">25,950</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">30,233</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">Financial income, net</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">(1.318</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">(1,374</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">)</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">943</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">Loss before income taxes</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">32,203</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">24,576</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">29,290</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">Income taxes</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">33</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;">
              <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">Loss for the year</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">32,203</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">24,609</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">29,290</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; clear: both;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Year ended December 31, 2019 compared to year ended December 31, 2020</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Collaboration Revenues</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Revenues are comprised mainly of royalties earned under a collaboration agreement with Perrigo related to the first generic version of Zovirax&#174;&#160;(acyclovir) cream, 5%, which
        generated$8.7 million in 2020, compared with $22.8 million in 2019. The decrease in revenues in 2020 resulted mainly from the entrance of an additional generic version of this product into the market and to a certain extent the impact of COVID-19.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Research and development expenses</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table describes the breakdown of our research and development expenses for the indicated periods:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="zc46ef226f8cd4fd180b08122a61901e9" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;quot; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="6" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year Ended December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;quot; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;quot; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="6" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(in thousands)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%;">
              <div style="line-height: 1.25;">Payroll and related expenses</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">6,001</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">6,194</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="line-height: 1.25;">Clinical trial expenses</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">23,037</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">5,179</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%;">
              <div style="line-height: 1.25;">Professional consulting and subcontracted work</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">7,425</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">12,855</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Other</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">4,115</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">3,685</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%; padding-bottom: 4px;">
              <div style="line-height: 1.25;">Total research and development expenses</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">40,578</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">27,913</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; clear: both;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Our research and development expenses were $40.6 million for the year ended December 31, 2019, compared to $27.9 million for the year ended December 31, 2020. The decrease of $12.7 million was
          mainly attributed to a decrease of $17.9 million in clinical trial expenses, mainly related to the completion of the clinical trials of Epsolay and Twyneo, towards the end of 2019, a decrease of $0.4 million in other expenses, mainly purchase of
          raw material for manufacturing, partially offset by an increase of $5.4 million in manufacturing expenses.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">91</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">General and administrative expenses</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Our general and administrative expenses were $8.3 million for the year ended December 31, 2019, compared to $11.1 million for the year ended December 31, 2020. The increase of $2.8 million was
          mainly attributed to an increase of $3.0 million in commercialization expenses and an increase of $0.4 million in patent related expenses, partially offset by a decrease of $0.7 million in stock based compensation expenses.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Financial income, net</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our financial income, net, was $1.4 million for the year ended December 31, 2019 compared to $0.9 million for the year ended December 31, 2020.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Year ended December 31, 2018 compared to year ended December&#160;31, 2019</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">This analysis can be found in Item&#160;5 of the Company&#8217;s Annual Report on Form&#160;20&#8209;F for the&#160;year ended December&#160;31, 2019.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Significant Accounting Policies and Estimates</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We prepare our consolidated financial statements in conformity with U.S. GAAP. We describe our significant accounting policies and estimates more fully in Note 2 to our
        consolidated financial statements as of and for the year ended December&#160;31, 2020, included elsewhere in this annual report. We believe that the accounting policies and estimates below are critical in order to fully understand and evaluate our
        financial condition and results of operations. In preparing these consolidated financial statements, our management has made estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets
        and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods recognized in our financial statements. Actual results may differ from these estimates. As applicable to the consolidated
        financial statements included in this annual report, the most significant estimates and assumptions relate to the fair value of share-based compensation.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Share-based Compensation</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Share-based compensation reflects the compensation expense of our share option programs granted to employees which compensation expense is measured at the grant date fair value
        of the options. The grant date fair value of share-based compensation is recognized as an expense over the requisite service period, net of estimated forfeitures. We recognize compensation expense for awards conditioned only on continued service
        that have a graded vesting schedule using the accelerated method based on the multiple-option award approach, and classify these amounts in our statement of operations based on the department to which the related employee reports.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Options Valuation</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value of the shared based compensation.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For the purpose of the evaluation of the fair value and the manner of the recognition of share-based compensation, our management is required to estimate, among others, various
        subjective and complex parameters that are included in the calculation of the fair value of the option. These parameters include the expected volatility of our share price over the expected term of the options, the risk-free interest rate
        assumption, and the term the that options are expected to remain outstanding.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">&#160;<font style="font-weight: bold;">JOBS Act</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On April&#160;5, 2012, the JOBS Act was signed into law. Subject to certain conditions set forth in the JOBS Act, as an &#8220;emerging growth company,&#8221; we elected or may elect to rely on
        certain exemptions, including without limitation, not (i)&#160;providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section 404 and (ii) complying with any requirement that may be adopted by
        the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). These
        exemptions will apply until the earliest of&#8201; (a) the last day of our fiscal year during which we have total annual gross revenues of at least $1.07 billion; (b) December 31, 2023, the last day of our fiscal year following the fifth anniversary of
        the closing of our initial public offering; (c) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (d) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under
        the Exchange Act.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">92</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Liquidity and Capital Resources</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Overview</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Since our inception, we have devoted substantially all of our resources to developing our product candidates, building our intellectual property portfolio, developing our supply
        chain, business planning, raising capital and providing for general and administrative support for these operations. Although we are expected to launch an additional generic product in 2021, we do not currently have any approved products other than
        the first generic version of Zovirax&#174;&#160;(acyclovir) cream, 5% for which Perrigo, our collaborator, received final FDA approval in February 2019.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">From inception through December 31, 2020, we have funded our operations primarily through proceeds from our public offerings, the issuance of equity securities to and loans and
        investments from our controlling shareholder, funding received from the IIA and from amounts received pursuant to past and current collaboration agreements. We automatically converted our outstanding promissory note between us and our controlling
        shareholder into an aggregate of 5,444,825 ordinary shares immediately prior to the closing of our initial public offering. For a description of the conversion of our shareholder loan agreement, see &#8220;Item 7. Major Shareholders and Related Party
        Transactions &#8211; B. Related Party Transactions &#8212; Loan Agreements with Our Controlling Shareholder.&#8221; As of December 31, 2020, our cash and cash equivalents, bank deposits and marketable securities were $50.2 million.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;On February 5, 2018, we announced the closing of our initial public offering of 7,187,500 ordinary shares at a public offering price of $12.00 per ordinary share, which included
        the exercise in full by the underwriters of their option to purchase up to 937,500 additional shares. The aggregate net proceeds to us from the offering were approximately $78.8 million, after deducting underwriting discounts and commissions and
        before deducting other offering expenses.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On August 12, 2019, the Company completed an underwritten public offering in which it issued 1,437,500 ordinary shares, including the full exercise by the underwriters of their
        option to purchase 187,500 additional ordinary shares, at a public offering price of $8.00 per ordinary share.&#160; The total proceeds received from the offering were approximately $10.8 million net of underwriting discounts and commissions and without
        deducting other offering expenses.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 19, 2020 the Company completed an underwritten public offering in which it issued 2,091,907 ordinary shares together with ordinary share warrants to purchase
        1,673,525 ordinary shares. The ordinary shares and accompanying warrants were sold together at a combined public offering price of $11.00 per ordinary share and accompanying warrant. Each warrant sold in the underwritten public offering is
        exercisable for 0.80 of an ordinary share&#160;and has an initial exercise price of $14.00 per share, subject to certain adjustments. The warrants are immediately exercisable and will expire on February 19, 2023. The total proceeds received from the
        offering were approximately $21.6 million net of underwriting discounts and commissions and without deducting other offering expenses.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition M. Arkin Dermatology Ltd., the controlling shareholder of the Company, has purchased 454,628 ordinary shares and warrants to purchase up to 363,702 ordinary shares in
        a concurrent private placement, exempt from the registration of the Securities Act of 1933, as amended, at a price equal to the public offering price of the ordinary shares and accompanying warrants in the underwritten public offering. The private
        placement has generated proceeds of approximately $5 million.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Company was informed by its collaboration partner that the launch of an FDA-approved generic drug is expected in the second quarter of 2021. Annual sales of the brand name
        exceed $180 million in the United States in 2019.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">93</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div>
        <div style="text-align: justify; line-height: 1.25;">The table below summarizes our cash flow activities for the indicated periods:</div>
      </div>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="ze312a516ed4e4c3fa79207409844ce2d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: &#38;amp; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year Ended</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: &#38;amp; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;amp; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2018</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;amp; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2019</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;amp; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: &#38;amp; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="10" style="vertical-align: bottom; font-family: &#38;amp; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(in thousands)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%;">Net cash used in operating activities</td>
            <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" rowspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(23,467</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" rowspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">)</td>
            <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" rowspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(22,500</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" rowspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">)</td>
            <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" rowspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(25,241</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" rowspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;">)</td>
          </tr>
          <tr>
            <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; width: 64%;">
              <div style="text-align: justify; line-height: 1.25;">Net cash provided by (used in) investing activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
              </div>
            </td>
            <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(54,735</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%;">)</td>
            <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">16,024</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">(2,694</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 64%; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25;">Net cash provided by financing activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">78,819</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">10,613</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">26,457</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;">
              <div style="text-align: justify; line-height: 1.25;">Increase (decrease) in cash and cash equivalents</div>
            </td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">617</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">4,137</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">(1,478</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">
              <div style="line-height: 1.25;">)</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Operating Activities</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">Net cash used in operating activities was $22.5 million during the year ended December 31, 2019, compared to $25.2 million during the year ended December 31, 2020.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">Net cash used in operating activities in the year ended December 31, 2020 primarily resulted from our loss of&#8201;$29.3 million during the period,&#160; $1.6 million of net changes in working capital and
        non-cash expenses of $1.2 million share-based compensation expenses and $0.9 million of depreciation of property and equipment.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">Net cash used in operating activities in the year ended December 31, 2019 primarily resulted from our loss of&#8201;$24.6 million during the period, a net increase of $1.5 million in working capital, net
        of non-cash expenses of $2.6 million share-based compensation expenses and $0.9 million of depreciation of property and equipment.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; line-height: 1.25;">Net cash used in operating activities was $23.5 million during the year ended December 31, 2018, compared to $22.5 million during the year ended December 31, 2019.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-indent: 36pt;">Net cash used in operating activities in the year ended December 31, 2018 primarily resulted from our loss of&#8201;$32.2 million during the period, $3.2 million
        of net changes in working capital and non- cash expenses of $4.7 million share-based compensation expenses and $0.8 million of depreciation of property and equipment.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Investing Activities</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25;">Net cash provided by investing activities was $16.0 million during the year ended December 31, 2019, compared to net cash used in investing activities of&#8201;$2.7 million during the year ended December 31, 2020.&#160; The
          2019 net cash provided by investing activities resulted mainly from $15.6 million proceeds from marketable securities, net, and $1.0 million proceeds from bank deposits offset by investment of $0.6 million in property and equipment. The 2020 net
          cash used in investing activities resulted mainly from $19.2 million proceeds from marketable securities, net, offset by investment of $0.5 million in property and equipment and investment of $21.4 million in bank deposits.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Net cash used in investing activities was $54.7 million during the year ended December 31, 2018, compared to net cash provided by investing activities of $16.0 million during
          the year ended December 31, 2019. The 2018 net cash used in investing activities resulted mainly from $56.7 million investment in marketable securities, net, and investment of $1.0 million in property and equipment offset by $3.0 million proceeds
          from bank deposits.</div>
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
        </div>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">94</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <br>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Financing Activities</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Net cash from financing activities was $10.6 million during the year ended December 31, 2019, compared to $26.4 million during the year ended December 31, 2020. The increase was principally due to
          our underwritten public offering in 2019, net of issuance cost, of $10.6 million, compared to our underwritten public offering and private placement in 2020, net of issuance cost, of $26.3 million.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Net cash from financing activities was $78.8 million during the year ended December 31, 2018, compared to $10.6 million during the year ended December 31, 2019. The decrease was
        due to our initial public offering in 2018, net of issuance cost, of $78.9 million, compared to our underwritten public offering in 2019, net of issuance cost, of $10.6 million.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Funding Requirements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our primary uses of cash have been to fund working capital requirements and research and development. We expect to continue to incur net losses for the foreseeable future as we
        continue to invest in research and development and seek to obtain regulatory approval for and commercialize our product candidates. We believe that our existing cash resources will be sufficient to enable us to fund our operating expenses and
        capital expenditure requirements into the third quarter of 2022. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our ability to continue as a going
        concern will depend on our ability to generate positive cash flow from operations and obtain additional financing, both of which are uncertain.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Developing drugs, conducting clinical trials, obtaining commercial manufacturing capabilities and commercializing products is expensive and we will need to raise substantial
        additional funds to achieve our strategic objectives. We will require significant additional financing in the future to fund our operations, including if and when we progress into additional clinical trials for our product candidates, obtain
        regulatory approval for one or more of our product candidates, obtain commercial manufacturing capabilities and commercialize one or more of our product candidates. Our future funding requirements will depend on many factors, including, but not
        limited to:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfab404480ce846f79941d4f777e336b4">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the progress and expenses of our pre-clinical studies, clinical trials and other research and development activities;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z98192ece017a482082a1da1a1950c9a7">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the scope, prioritization and number of our clinical trials and other research and development programs;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5f9dab98db8941c9b5c689de7381f1d4">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the expenses and timing of obtaining regulatory approval, if any, for our product candidates;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9c274b3d5115497c956be8f637752f52">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the expenses of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9f2daf394e114177adf90248b0480ba6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the expenses of, and timing for, expanding our manufacturing agreements for production of sufficient clinical and commercial quantities of our product candidates; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zffaca35dba8b4eb5a96a3c7e6893cf5c">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the potential expenses of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Other than revenue that we expect to generate from a collaboration between us and Perrigo with respect to the first generic version of Zovirax&#174;&#160;(acyclovir) cream, 5% and from a
        second partnered generic dermatology product with an anticipated launched date in the second quarter of 2021, until we can generate recurring revenues, we expect to satisfy our future cash needs through existing cash resources, additional debt or
        equity financings or by entering into collaborations with third parties in connection with one or more of our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. In addition, the
        terms of any securities we issue in future financings may be more favorable to new investors and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect
        on the holders of any of our securities then outstanding. If we raise additional funds through collaborations with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or
        product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to obtain adequate funds on reasonable terms, we will need to curtail operations significantly, including possibly postponing anticipated clinical
        trials or entering into financing agreements with unattractive terms.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">95</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Research and Development, Patents and Licenses</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For a description of our research and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see &#8220;Item 5. Operating
        and Financial Review and Prospects &#8212; A. Operating Results &#8212; Research and Development Expenses&#8221;; and &#8220;Item 5. Operating and Financial Review and Prospects &#8212; A. Operating Results &#8212; Year Ended December 31, 2019 compared to Year ended December 31, 2020
        - Research and Development Expenses.&#8221;; and &#8220;Item 5. Operating and Financial Review and Prospects &#8212; A. Operating Results &#8212; Year Ended December 31, 2018 compared to Year ended December 31, 2019 - Research and Development Expenses.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trend Information</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2020 to
        December 31, 2020 that are reasonably likely to have a material adverse effect on our revenue, income, profitability, liquidity or capital resources, or that caused that disclosed financial information to be not necessarily indicative of future
        operating results or financial condition.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">E.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Off-Balance Sheet Arrangements </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We do not have any, and during the periods presented we did not have any, off-balance sheet arrangements as defined in the rules and regulations of the SEC.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">F.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Tabular Disclosure of Contractual Obligations</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The following table summarizes our contractual obligations as of December&#160;31, 2020:</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z496c3f7b21c5496c8957e3a70ee900dc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: &#38;quot; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Total</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Less than</div>
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">1 year</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">1&#8201;&#8211;&#8201;3 years</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;quot; border-bottom: #000000 solid 2px;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">3&#8201;&#8211;&#8201;5 years</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: &#38;quot; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">More than</div>
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">5 years</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="18" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(in thousands)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 40%; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25;">Operating lease obligations (1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">2,140</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">778</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">1,362</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px;">
              <div style="text-align: justify; line-height: 1.25;">Total&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">2,140</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">778</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">1,362</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
              <div style="line-height: 1.25;">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z00aa42b62a5b44d99aac595b2cfac936">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Operating lease obligations consist of payments pursuant to several lease agreements that are scheduled to expire on December&#160;31, 2023.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">96</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><a name="ITEM6"><!--Anchor--></a>ITEM 6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors and Senior Management</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth information concerning our directors and senior management, which includes members of our administrative, supervisory and management bodies,
        including their ages, as of the date of this annual report:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd3be502e949f4827b56285dadbaa556d">

          <tr>
            <td style="width: 29.79%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Name</div>
            </td>
            <td style="width: 1.27%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; text-align: center;">
              <div style="line-height: 1.25; font-weight: bold;">Age</div>
            </td>
            <td style="width: 1.27%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Position</div>
            </td>
            <td style="width: 1.27%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Moshe Arkin</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">68</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Chairman of the Board of Directors</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Alon Seri-Levy</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center;">
              <div style="line-height: 1.25;">59</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Chief Executive Officer and Director</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Gilad Mamlok</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">52</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Chief Financial Officer</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Ofer Toledano</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center;">
              <div style="line-height: 1.25;">55</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Vice President Research and Development</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Ofra Levy-Hacham</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">54</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Vice President Clinical and Regulatory Affairs</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Karine Neimann</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center;">
              <div style="line-height: 1.25;">49</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Vice President Projects and Planning, Chief Chemist</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Itzik Yosef</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">44</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Vice President Operations</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Dov Zamir</div>
            </td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center;">
              <div style="line-height: 1.25;">67</div>
            </td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Vice President Special Projects</div>
            </td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Nissim Bilman</div>
            </td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">&#160;</td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">&#160;</td>
            <td rowspan="1" style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">59</div>
            </td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">&#160;</td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">&#160;</td>
            <td rowspan="1" style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Vice President&#160; Quality</div>
            </td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">John Vieira</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; text-align: center;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">51</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">U.S. Head of Commercialization</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Itai Arkin</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">32</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Director</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Shmuel Ben Zvi</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center;">
              <div style="line-height: 1.25;">60</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Director</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Hani Lerman</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">48</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Director</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Yaffa Krindel-Sieradzki</div>
            </td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center;">
              <div style="line-height: 1.25;">66</div>
            </td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;Director</td>
            <td rowspan="1" style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Jonathan B. Siegel</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">47</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">Director</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">Ran Gottfried</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center;">
              <div style="line-height: 1.25;">76</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">External Director</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 29.79%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">Jerrold S. Gattegno</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4.56%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">68</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 59.28%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; line-height: 1.25;">External Director</div>
            </td>
            <td style="width: 1.27%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Mr. Moshe Arkin </font>has served as chairman of our board of directors since 2014. Mr. Moshe Arkin currently sits on the
        board of directors of several private pharmaceutical and medical device companies including Exalenz Bioscience Ltd., a developer of advanced systems for gastrointestinal and liver disorders since 2006, SoniVie Ltd., a company developing systems for
        the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve
        devices. From 2005 to 2008, Mr. Moshe Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining us, Mr. Moshe Arkin served as a director of cCAM Biotherapeutics
        Ltd., a company focused on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck &amp; Co., Inc. Mr. Moshe Arkin served as chairman of Agis Industries Ltd. from its inception in 1972
        until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel&#160;Aviv University, Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Dr. Alon Seri-Levy </font><font style="font-family: 'Times New Roman',Times,serif;">co-founded Sol-Gel and has served as our
          chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Dr. Seri-Levy established the computer-aided drug design department at Peptor Ltd., an Israeli research and
          development company that specialized in the development of peptide-based drug products. Dr.&#160;Seri-Levy holds a Ph.D. in Chemistry (summa cum laude) from The Hebrew University of Jerusalem, Israel, and conducted his post-doctoral studies at Oxford
          University, United Kingdom. Dr. Seri-Levy was appointed to our board of directors immediately following the pricing of our initial public offering.</font></div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Mr. Gilad Mamlok</font><font style="font-family: 'Times New Roman',Times,serif;"> has served as our chief financial officer
          since February 2017. From August 2015 to January 2017, Mr.&#160;Mamlok served as the chief financial officer for Medigus Ltd., a medical device company dual listed on Nasdaq and the Tel Aviv Stock Exchange, or the TASE. From September 2005 to March
          2015, Mr.&#160;Mamlok served as senior vice president, global finance and accounting of Given Imaging Ltd., a medical device company dual listed on Nasdaq and TASE, acquired by Covidien plc in February 2014. From January 2002 to September 2005,
          Mr.&#160;Mamlok served as chief financial officer of two other medical device companies. Mr.&#160;Mamlok holds a Master&#8217;s degree in business economics from Tel-Aviv University and a B.A. in economics (magna cum laude) from Tel-Aviv University, Israel.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">97</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Dr. Ofer Toledano </font><font style="font-family: 'Times New Roman',Times,serif;">has served as our vice president of
          research and development since 2004. Prior to joining Sol-Gel, Dr. Toledano served as manager of the formulation department at ADAMA Agricultural Solutions Ltd. (formerly known as Makhteshim Agan Industries Ltd.), an Israeli manufacturer and
          distributor of crop protection products from 1998 until 2004. Dr. Toledano holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Dr. Ofra Levy-Hacham</font><font style="font-family: 'Times New Roman',Times,serif;"> has served as our vice president of
          clinical and regulatory affairs since 2018, and as our vice president of quality and regulatory affairs from 2011 to 2018. Prior to joining Sol-Gel, Dr. Levy-Hacham served as a scientific specialist and project manager at Biotechnology General
          Ltd., a wholly owned subsidiary of Ferring Pharmaceuticals Ltd., and a fully integrated biopharmaceutical services private company from 2010 until 2011. From 2005 until 2010, Dr. Levy-Hacham served as vice president chemistry, manufacturing and
          controls at HealOr Ltd., a private company engaging in the development of therapeutics for the treatment of various skin disorders. Dr.&#160;Levy-Hacham holds a Ph.D. in chemistry from The Technion &#8211; Israel Institute of Technology, Israel.</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Dr. Karine Neimann</font><font style="font-family: 'Times New Roman',Times,serif;"> has served as our vice president of
          projects and planning and chief chemist since September 2016. Since joining us in 2008, Dr. Neimann held various positions, including as chief chemist and laboratory manager. Dr. Neimann holds a Ph.D. in chemistry from The Hebrew University of
          Jerusalem, Israel.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Dr. Itzik Yosef</font><font style="font-family: 'Times New Roman',Times,serif;"> has served as our vice president of
          operations since August&#160;2016. Since joining us in 2010, Dr. Yosef held various positions including as head of operations. Dr. Yosef holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Dr. Dubi Zamir</font><font style="font-family: 'Times New Roman',Times,serif;"> has served as our vice president special
          projects since August&#160;2016. Prior to joining us, Dr. Zamir lead the R&amp;D group in Cima NanoTech Ltd., a private company developing sophisticated nanotechnology-based coating formulations from 2007 until 2016. From 2004 to 2007, Dr. Zamir was
          VP of Pharma and Analytical R&amp;D at Taro Pharmaceutical Industries in Haifa, and for three years prior to that he managed its Analytical R&amp;D lab. Dr. Zamir holds a Ph.D. in organic chemistry from Tel-Aviv University, Israel.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Mr. Nissim Bilman</font><font style="font-family: 'Times New Roman',Times,serif;"> became Vice President Quality of Sol-Gel
          on the August 15, 2018. From 2004 until 2018, Mr. Bilman served as CEO of QPRO Pharma, a project management and consulting company offering services related to the pharmaceutical industry.&#160; From 2011 until 2018, he served as the Vice President
          Drug Development of Exalenz Bioscience. From 2007 until 2010, Mr. Bilman served as VP R&amp;D and Manufacturing and Site Manager for Gelesis Inc./Gelesis R&amp;D Ltd. Mr. Bilman holds a Bachelor Degree in Chemistry and Meteorology, as well as a
          Master of Science in Applied Chemistry, both from the Hebrew University in Israel.</font></div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Mr. John Vieira</font><font style="font-family: 'Times New Roman',Times,serif;"> has served as our U.S. head of
          commercialization since January 2019. Prior to joining Sol-Gel, Mr. Vieira served in U.S. and Global Marketing roles at Leo Pharmaceuticals. Prior to Leo Pharmaceuticals, Mr. Vieira was Executive Director, Thrombosis, at Daiichi Sankyo, where he
          led the global launch of a major anti-coagulant, following various senior leadership roles in the U.S. commercial operations. Prior to Daiichi Sankyo, Mr. Vieira held leadership positions at several healthcare companies, including Organon
          Biopharmaceuticals and GlaxoSmithKline, successfully launching over six new global and U.S. products in diverse therapeutic areas. Mr. Vieira holds an M.B.A. degree from Rutgers University and a B.A. degree from York University in Toronto,
          Canada.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Mr. Itai Arkin </font><font style="font-family: 'Times New Roman',Times,serif;">became a member of our board of directors
          immediately following the pricing of our initial public offering. Mr. Itai Arkin currently serves as Investment Manager at Arkin Holdings Ltd. and as an investment committee member of Accelmed, a leading Israeli MedTech investment firm since
          March&#160;2014. Mr. Itai Arkin holds a B.A. in business administration (cum laude) from Interdisciplinary Center, Herzliya, Israel, and an MBA (cum laude) from Tel Aviv University. Mr. Itai Arkin is the son of Mr. Moshe Arkin, the chairman of our
          board of directors and sole beneficial owner of Arkin Dermatology, our controlling shareholder.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">98</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Dr. Shmuel (Muli) Ben Zvi</font><font style="font-family: 'Times New Roman',Times,serif;"> became a member of our board of
          directors immediately following pricing of our initial public offering. Dr. Ben Zvi is currently a board member and member of the risk management, technology, investment and strategy committees at Bank Leumi, and a board member and member of the
          audit committee and compensation committee of VBL Therapeutics. From 2004 to 2014, Dr. Ben Zvi held various managerial positions at Teva Pharmaceuticals Industries Ltd., including Vice President of Finance and Vice President of Strategy. From
          2000 to 2004, Dr. Ben Zvi was the financial advisor to the Chief of General Staff of the Israel Defense Forces and head of the Defense Ministry budget department. Dr. Ben Zvi holds a Ph.D. in economics from Tel-Aviv University, Israel and
          participated in the Harvard Business School Advanced Management Program (AMP).</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Ms. Hani Lerman</font><font style="font-family: 'Times New Roman',Times,serif;"> became a member of our board of directors
          immediately following pricing of our initial public offering. Ms. Lerman has served as chief financial officer at Arkin Holdings since 2015. From 2010 until 2014, Ms. Lerman served as chief financial officer of Sansa Security (f/k/a Discretix
          Technologies), and from 2006 until 2010, she served as chief financial officer of Storwize, which was acquired by IBM in 2010. She holds a Master's degree in business administration with a major in finance from Tel-Aviv University, Israel, and a
          B.A. in economics and accounting from Tel-Aviv University, Israel.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Ms. Yaffa Krindel</font><font style="font-family: 'Times New Roman',Times,serif;">-<font style="font-weight: bold; font-style: italic;">Sieradzki</font> became a member of our board of directors on February 23, 2018. Ms. Krindel-Sieradzki currently serves on the board of Itamar Medical Ltd., a medical device company publicly traded on both Nasdaq and the
          Tel Aviv Stock Exchange ("TASE"), BGN Technologies Ltd., the technology transfer company of Ben Gurion University, and three private medical device companies, as follows: EZbra Advanced Wound Care Ltd., Theranica Bio Electronics Ltd. and Trisol
          Medical Ltd. Ms. Krindel-Sieradzki has served on the board of directors of numerous companies publicly traded on Nasdaq. From 1997 until 2007, Ms. Krindel-Sieradzki served as Partner and Managing Partner of Star Ventures, a private venture
          capital fund headquartered in Munich, Germany. Before joining Star Ventures, Ms. Krindel served from 1992 to 1996 as CFO and VP Finance of Lannet Data Communications Ltd., an Israeli telecommunications company publicly traded on Nasdaq which is
          now part of Avaya Inc. From 1993 to 1997, she served as CFO and later as director of BreezeCOM Ltd., an Israeli telecommunications company which traded on Nasdaq and TASE. Ms. Krindel-Sieradzki has earned an M.B.A. from Tel Aviv University and a
          B.A. in Economics and Japanese Studies from the Hebrew University in Jerusalem, both with honors.</font></div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Jonathan B. Siegel</font><font style="font-family: 'Times New Roman',Times,serif;"> became a member of our board of directors
          on September 13, 2018. Mr. Siegel is the founder and CEO of JBS Healthcare Ventures since formation in 2017. Previously, he was a partner and healthcare sector head at Kingdon Capital Management from 2011 until 2017. Prior to joining Kingdon, Mr.
          Siegel was a healthcare portfolio manager at SAC Capital Advisors from 2005 until 2011; an associate director of pharmaceutical and specialty pharmaceutical research at Bear, Stearns &amp; Co.; a pharmaceuticals research associate at Dresdner
          Kleinwort Wasserstein; and a consultant to the Life Sciences Division of Computer Sciences Corporation. Mr. Siegel has worked as a research associate at the Novartis Center for Immunobiology at Harvard Medical School and as a research assistant
          at Tufts University School of Medicine. He is also a director at Jaguar Health, Inc., a Nasdaq listed company, and has served on the board of advisors of Vitalis LLC, a private pharmaceutical company, since March 2019. Mr. Siegel received a BS in
          Psychology from Tufts University in 1995 and an MBA from Columbia Business School in 1999.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Mr. Ran Gottfried</font><font style="font-family: 'Times New Roman',Times,serif;"> became a member of our board of directors
          immediately following the pricing of our initial public offering and serves as an external director under the Companies Law. Since 1975, Mr.&#160;Gottfried has served as a chief executive officer, consultant and director of private companies in Israel
          and Europe in the areas of retail and distribution of pharmaceuticals, consumer and household products. Mr. Gottfried served as a director of Perrigo Company from 2006 until 2015. From 2006 until 2008, Mr. Gottfried served as chairman and chief
          executive officer of Powerpaper Ltd., a leading developer and manufacturer of micro electrical cosmetic and pharmaceutical patches. From 2005 until 2010, Mr. Gottfried served as a director of Bezeq, Israel&#8217;s leading telecommunications provider
          and from 2003 until its acquisition by Perrigo Company in 2005, Mr. Gottfried served as a director of Agis Industries Ltd. He is currently a board member and member of the audit and investment, technology and innovation and risk management
          committees at Shufersal Ltd.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">99</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Mr. Jerrold S. Gattegno</font><font style="font-family: 'Times New Roman',Times,serif;"> became a member of our board of
          directors immediately following the pricing of&#160; our initial public offering and serves as an external director under the Companies Law. Mr. Gattegno worked in the New York, Washington D.C. and London offices of Deloitte Touche Tohmatsu Limited, a
          public accounting firm, from 1973 until 2015, where he served in various senior positions, including as the partner-in-charge and founding partner of Deloitte&#8217;s multistate tax practice and as a managing partner in Deloitte&#8217;s Washington National
          Tax Office, and as managing director and principal of Deloitte Tax Overseas Services LLC. Mr.&#160;Gattegno served as a governing board member of the Hispanic Association of Colleges and Universities and a member of its finance and audit committee,
          from 2012 until 2015. Mr. Gattegno is a certified public accountant and holds a B.S. in accounting (cum laude) from the City University of New York and an M.B.A. in taxation (with honors) from Pace University, New York.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Compensation</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The aggregate compensation paid by us to our executive officers and directors for the year ended December&#160;31, 2020 was approximately $3.2 million. This amount includes
        approximately $0.4 million set aside or accrued to provide pension, severance, retirement or similar benefits or expenses, but does not include business travel, relocation, professional and business association dues and expenses reimbursed to
        officers, and other benefits commonly reimbursed or paid by companies in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The table and summary below outline the compensation granted to our five highest compensated directors and officers during the year ended December&#160;31, 2020. The compensation
        detailed in the table below refers to actual compensation granted or paid to the director or officer during the year 2020.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zb37eb6525c614bd1849e2c217ff07fe5">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Name and Position of director or officer</div>
            </td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Base Salary or</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Other</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Payment (1)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Value of</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Social</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Benefits (2)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Value of Equity Based</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compensation</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Granted (3)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">All Other</div>
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compensation (4)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;"> </font></div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="20">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Amounts in U.S. dollars are based on 2020 monthly average representative U.S. dollar &#8211; NIS rate of exchange)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 40%;">
              <div style="text-align: justify; line-height: 1.25;">Alon Seri-Levy / CEO</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">314</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">61</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">239</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">22</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">636</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 40%;">
              <div style="text-align: justify; line-height: 1.25;">Gilad Mamlok / CFO</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">262</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">54</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">137</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">48</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">501</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 40%;">
              <div style="text-align: justify; line-height: 1.25;">John Vieira / U.S. Head of Commercialization</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">241</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">17</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">113</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">26</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">398</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; width: 40%;">
              <div style="text-align: justify; line-height: 1.25;">Ofer Toledano / VP R&amp;D</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">206</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">57</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">79</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">24</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">366</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 40%;">
              <div style="text-align: justify; line-height: 1.25;">Ofra Levy-Hacham / VP Clinical &amp; RA</div>
            </td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">152</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">45</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">63</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">21</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">280</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          </tr>

      </table>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4a239b3d4f5a4aa8970d0ab52d4ce872">

          <tr>
            <td style="width: 26.95pt; vertical-align: top; align: right;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>&#8220;Base Salary or Other Payment&#8221; means the aggregate yearly gross monthly salaries or other payments with respect to the Company's Executive Officers and members of the board of directors for the year 2020.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc0ca9f66c9dc42eebe48eff70305e386">

          <tr>
            <td style="width: 26.95pt; vertical-align: top; align: right;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>&#8220;Social Benefits&#8221; include payments to the National Insurance Institute, advanced education funds, managers&#8217; insurance and pension funds; vacation pay; and recuperation pay as mandated by Israeli law.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8088210bf0dc42298ceb88b455d03c61">

          <tr>
            <td style="width: 26.95pt; vertical-align: top; align: right;">(3)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Consists of the fair value of the equity-based compensation granted during 2020 in exchange for the directors and officers services recognized as an expense in profit or loss and is carried to the accumulated deficit under equity. The
                total amount recognized as an expense over the vesting period of the options.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z88b56e6d350646c29bc159436c595d3b">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">(4)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">&#8220;All Other Compensation&#8221; includes, among&#160;other things, car-related expenses, communication expenses, basic health insurance, holiday
              presents, and 2018, 2019 and 2020 special bonuses that officers received. </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">In addition, all of our directors and executive officers are covered under our directors&#8217; and executive officers&#8217; liability insurance policies and were granted letters of indemnification by us.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">100</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Employment Agreements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have entered into written employment agreements with each of our executive officers. These agreements provide for notice periods of varying duration for termination of the
        agreement by us or by the relevant executive officer, during which time the executive officer will continue to receive base salary and benefits. These agreements also contain customary provisions regarding noncompetition, confidentiality of
        information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. See &#8220;Item 3. Key Information &#8211; D. Risk Factors &#8212; Risks Related to Employee Matters &#8212; Under applicable
        employment laws, we may not be able to enforce covenants not to compete&#8221; for a further description of the enforceability of non-competition clauses.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For information on exemption and indemnification letters granted to our directors and officers, please see &#8220; &#8211;&#160; C. Board Practices &#8211; Exculpation, Insurance and Indemnification of
        Directors and Officers&#8221;.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Director Compensation</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; We currently pay our external directors and our other independent directors:&#160; (i) $35,000 annually in cash; (ii) $5,000 annually in cash for service on each of the Audit Committee and/or
        Compensation Committee (as the case may be) and (iii) $10,000 annually in cash for service as chairman of the Audit Committee and/or Compensation Committee (as the case may be), which includes amounts payable under clause (ii) (all cash amounts to
        be paid quarterly).</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There shall be no limit regarding the number and/or hours of meetings, and it includes all meetings of the Board and any Board&#8217;s committees.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In addition, each of our external directors and our other independent directors has received 11,500 Restricted Share Units ("RSU's") for the first three years of their service as a
        director, with a three-year vesting, one-third of the RSU's to vest after each year (if they continue to serve as directors), and otherwise in accordance with the Company's 2014 Share Incentive Plan.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; We do not pay compensation to the other directors of the Company in their capacity as directors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Compensation Policy</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our compensation policy, which became effective immediately after the pricing of our initial public offering, is designed to promote retention and motivation of directors and
        executive officers, incentivize superior individual excellence, align the interests of our directors and executive officers with our long-term performance and provide a risk management tool. To that end, a portion of an executive officer
        compensation package is targeted to reflect our short and long-term goals, as well as the executive officer&#8217;s individual performance. On the other hand, our compensation policy includes measures designed to reduce the executive officer&#8217;s incentives
        to take excessive risks that may harm us in the long-term, such as limits on the value of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive officer and minimum
        vesting periods for equity-based compensation.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our compensation policy also addresses our executive officer&#8217;s individual characteristics (such as his or her respective position, education, scope of responsibilities and
        contribution to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers the internal ratios between compensation of our executive officers and directors and other employees. Pursuant to our
        compensation policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses and other cash bonuses (such as a signing bonus and special bonuses with respect to any special achievements, such as
        outstanding personal achievement, outstanding personal effort or outstanding company performance), equity-based compensation, benefits and retirement and termination of service arrangements. All cash bonuses are limited to a maximum amount linked
        to the executive officer&#8217;s base salary. In addition, the total variable compensation components (cash bonuses and equity-based compensation) may not exceed 85% of each executive officer&#8217;s total compensation package with respect to any given
        calendar year.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">101</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">An annual cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be granted to
        our executive officers other than our chief executive officer will be based on performance objectives and a discretionary evaluation of the executive officer&#8217;s overall performance by our chief executive officer and subject to minimum thresholds.
        The annual cash bonus that may be granted to executive officers other than our chief executive officer may be based entirely on a discretionary evaluation. Furthermore, our chief executive officer will be entitled to recommend performance
        objectives, and such performance objectives will be approved by our compensation committee (and, if required by law, by our board of directors).</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The performance measurable objectives of our chief executive officer will be determined annually by our compensation committee and board of directors, will include the weight to
        be assigned to each achievement in the overall evaluation. A less significant portion of the chief executive officer&#8217;s annual cash bonus may be based on a discretionary evaluation of the chief executive officer&#8217;s overall performance by the
        compensation committee and the board of directors based on quantitative and qualitative criteria.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The equity-based compensation under our compensation policy for our executive officers (including members of our board of directors) is designed in a manner consistent with the
        underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the alignment between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to
        strengthen the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation in the form of share options or other equity-based awards, such as restricted shares and
        restricted share units, in accordance with our share incentive plan then in place. All equity-based incentives granted to executive officers shall be subject to vesting periods in order to promote long-term retention of the awarded executive
        officers. The equity-based compensation shall be granted from time to time and be individually determined and awarded according to the performance, educational background, prior business experience, qualifications, role and the personal
        responsibilities of the executive officer.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, our compensation policy contains compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, enables our chief
        executive officer to approve an immaterial change in the terms of employment of an executive officer (provided that the changes of the terms of employment are in accordance our compensation policy) and allows us to exculpate, indemnify and insure
        our executive officers and directors subject to certain limitations set forth thereto.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our compensation policy also provides for compensation to the members of our board of directors either (i) in accordance with the amounts provided in the Companies Regulations
        (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time
        to time, or (ii) in accordance with the amounts determined in our compensation policy.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our compensation policy, which was approved by our board of directors and our controlling shareholder on October&#160;2, 2017, became effective upon the pricing of our initial public
        offering.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Board Practices</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Appointment of Directors and Terms of Officers</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our board of directors consists of eight directors, including two external directors, and appointment fulfills the requirements of the Companies Law for the company to have two
        external directors (see &#8220; &#8211; External Directors&#8221;). These two directors, as well as three additional directors, qualify as independent directors under the corporate governance standards of the Nasdaq corporate governance rules and the independence
        requirements of Rule 10A-3 of the Exchange Act.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">102</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Under our amended and restated articles of association, the number of directors on our board of directors will be no less than five (5) and no more than nine (9), including any external directors
          required to be appointed under the Companies Law. The minimum and maximum number of directors may be changed, at any time and from time to time, by a special 66 2&#8725;3% majority shareholder vote.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Other than external directors, for whom special election requirements apply under the Companies Law, as detailed below, our directors are divided into three classes with
        staggered three-year terms. Each class of directors consists, as nearly as possible, of one-third of the total number of directors constituting the entire board of directors (other than the external directors). At each annual general meeting of our
        shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class of directors will be for a term of office that expires on the third annual general meeting following such election
        or re-election, such that from 2019 and after, at each annual general meeting the term of office of only one class of directors will expire. Each director holds office until the third annual general meeting of our shareholders and until his or her
        successor is duly appointed, unless the tenure of such director expires earlier pursuant to the Companies Law or unless removed from office as described below, except that our external directors have a term of office of three years under Israeli
        law. See &#8220;&#8212;&#160;External directors &#8212; Election and Dismissal of External Directors&#8221;.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our directors who are not external directors are divided among the three classes as follows:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93a7f9e2713a40e2a8696b8f4e03944f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Class I directors consist of Ms. Yaffa Krindel-Sieradzki, Dr. Shmuel Ben Zvi and Mr. Jonathan B. Siegel, who are all independent directors, and their term will expire at our annual general meeting of our shareholders to be held in 2022;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zff205785495744838af24b5dd9cbcb5f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Class II directors consist of Ms. Hani Lerman and Dr. Alon Seri-Levy, and their term will expire at our annual general meeting of our shareholders to be held in 2023; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e8b324107214fc8a7cd86a6b38db437">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Class III directors consist of Mr. Itai Arkin and Mr. Moshe Arkin, and their term will expire at our annual general meeting of our shareholders to be held in 2021.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Mr. Ran Gattegno and Mr. Jerrold S. Gottfried serve as our external directors and will each have a term of three years.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under our amended and restated articles of association, our board of directors may elect new directors if the number of directors is below the maximum provided therein. External
        directors are elected for an initial term of three years and may be elected for up to two additional three-year terms (or more) under the circumstances described below. External directors may be removed from office only under the limited
        circumstances set forth in the Companies Law. See &#8220;&#8212;&#160;External Directors&#8212; Election and Dismissal of External Directors&#8221; for a description of the procedure for the election of external directors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, the chief executive officer of a public company may not serve as the chairman of the board of directors of the company unless approved by a special majority of
        our shareholders as required under the Companies Law.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, under the Companies Law, our board of directors must determine the minimum number of directors who are required to have financial and accounting expertise. Under
        applicable regulations, a director with financial and accounting expertise is a director who, by reason of his or her education, professional experience and skill, has a high level of proficiency in and understanding of business accounting matters
        and financial statements. See &#8220;&#8212; External Directors&#160;&#8212; Qualifications of External Directors.&#8221; He or she must be able to thoroughly comprehend the financial statements of the company and initiate debate regarding the manner in which financial
        information is presented. In determining the number of directors required to have such expertise, the board of directors must consider, among other things, the type and size of the company and the scope and complexity of its operations. Our board
        of directors has determined that we require at least one director with the requisite financial and accounting expertise and that has such expertise.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There are no family relationships among any of our office holders (including directors), other than Mr. Itai Arkin who is the son of Mr. Moshe Arkin.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">103</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Alternate Directors</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association provide, as allowed by the Companies Law, that any director may, by written notice to us, appoint another person who is qualified
        to serve as a director to serve as an alternate director. The alternate director will be regarded as a director. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as a director or
        a person who is already serving as an alternate director for another director, may not be appointed as an alternate director. Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a
        committee of the board of directors as long as he or she is not already serving as a member of such committee, and if the alternate director is to replace an external director, he or she is required to be an external director and to have either
        &#8220;financial and accounting expertise&#8221; or &#8220;professional expertise,&#8221; depending on the qualifications of the external director he or she is replacing. The term of appointment of an alternate director may be for one meeting of the board of directors or
        until notice is given of the cancellation of the appointment. A person who does not have the requisite &#8220;financial and accounting experience&#8221; or the &#8220;professional expertise,&#8221; depending on the qualifications of the external director he or she is
        replacing, may not be appointed as an alternate director for an external director.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">External Directors</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Qualifications of External Directors</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, companies incorporated under the laws of the State of Israel that are &#8220;public companies,&#8221; including companies with shares listed on The Nasdaq Global
        Market, are generally required to appoint at least two external directors who meet the qualification requirements set forth in the Companies Law.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A person may not be appointed as an external director if the person is a relative of a controlling shareholder or if on the date of the person&#8217;s appointment or within the
        preceding two years the person or his or her relatives, partners, employers or anyone to whom that person is subordinate, whether directly or indirectly, or entities under the person&#8217;s control have or had any affiliation with any of&#8201; (each an
        &#8220;Affiliated Party&#8221;): (1) us; (2) any person or entity controlling us on the date of such appointment; (3) any relative of a controlling shareholder; or (4) any entity controlled, on the date of such appointment or within the preceding two years, by
        us or by a controlling shareholder. If there is no controlling shareholder or any shareholder holding 25% or more of voting rights in the company, a person may not be appointed as an external director if the person has any affiliation to the
        chairman of the board of directors, the general manager (chief executive officer), any shareholder holding 5% or more of the company&#8217;s shares or voting rights or the senior financial officer as of the date of the person&#8217;s appointment.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The term &#8220;controlling shareholder&#8221; means a shareholder with the ability to direct the activities of the company, other than by virtue of being an office holder. A shareholder is
        presumed to have &#8220;control&#8221; of the company and thus to be a controlling shareholder of the company if the shareholder holds 50% or more of the &#8220;means of control&#8221; of the company. &#8220;Means of control&#8221; is defined as (1) the right to vote at a general
        meeting of a company or a corresponding body of another corporation; or (2) the right to appoint directors of the corporation or its general manager. For the purpose of approving related-party transactions, the term also includes any shareholder
        that holds 25% or more of the voting rights of the company if the company has no shareholder that owns more than 50% of its voting rights. For the purpose of determining the holding percentage stated above, two or more shareholders who have a
        personal interest in a transaction that is brought for the company&#8217;s approval are deemed as joint holders.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">104</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 20.25pt; margin-left: 0.1pt; line-height: 1.25;">The term affiliation includes:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcdcceec22dc842b8bfcb124f2a709780">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>an employment relationship;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8467b709f030409f9180e07c15219c14">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a business or professional relationship maintained on a regular basis;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze62b71cbba1b44a5b0b491c49de040d5">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>control; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze7e4f9042e4d4848a34b39a68b290f59">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>service as an office holder, excluding service as a director in a private company prior to the first offering of its shares to the public if such director was appointed as a director of the private company in order to serve as an
                external director following the initial public offering.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The term &#8220;relative&#8221; is defined as a spouse, sibling, parent, grandparent, descendant, spouse&#8217;s descendant, sibling and parent and the spouse of each of the foregoing.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The term &#8220;office holder&#8221; is defined as a general manager, chief business manager, deputy general manager, vice general manager, director or manager directly subordinate to the
        general manager or any other person assuming the responsibilities of any of the foregoing positions, without regard to such person&#8217;s title.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A person may not serve as an external director if that person or that person&#8217;s relative, partner, employer, a person to whom such person is subordinate (directly or indirectly)
        or any entity under the person&#8217;s control has a business or professional relationship with any entity that has an affiliation with any Affiliated Party, even if such relationship is intermittent (excluding insignificant relationships). Additionally,
        any person who has received compensation intermittently (excluding insignificant relationships) other than compensation permitted under the Companies Law may not continue to serve as an external director.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">No person can serve as an external director if the person&#8217;s position or other affairs create, or may create, a conflict of interest with the person&#8217;s responsibilities as a
        director or may otherwise interfere with the person&#8217;s ability to serve as a director or if such a person is an employee of the Israeli Securities Authority or of an Israeli stock exchange. If at the time an external director is appointed all
        current members of the board of directors, who are not controlling shareholders or relatives of controlling shareholders, are of the same gender, then the external director to be appointed must be of the other gender. In addition, a person who is a
        director of a company may not be elected as an external director of another company if, at that time, a director of the other company is acting as an external director of the first company.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law provides that an external director must meet certain professional qualifications or have financial and accounting expertise and that at least one external
        director must have financial and accounting expertise. However, if at least one of our other directors (1)&#160;meets the independence requirements of the Exchange Act, (2) meets the standards of the Nasdaq corporate governance rules for membership on
        the audit committee and (3) has financial and accounting expertise as defined in the Companies Law and applicable regulations, then neither of our external directors is required to possess financial and accounting expertise as long as both possess
        other requisite professional qualifications. The determination of whether a director possesses financial and accounting expertise is made by the board of directors. A director with financial and accounting expertise is a director who by virtue of
        his or her education, professional experience and skill, has a high level of proficiency in and understanding of business accounting matters and financial statements so that he or she is able to fully understand our financial statements and
        initiate debate regarding the manner in which the financial information is presented.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The regulations promulgated under the Companies Law define an external director with requisite professional qualifications as a director who satisfies one of the following
        requirements: (1) the director holds an academic degree in either economics, business administration, accounting, law or public administration, (2) the director either holds an academic degree in any other field or has completed another form of
        higher education in the company&#8217;s primary field of business or in an area which is relevant to his or her office as an external director in the company, or (3) the director has at least five years of experience serving in any one of the following,
        or at least five years of cumulative experience serving in two or more of the following capacities: (a) a senior business management position in a company with a substantial scope of business, (b) a senior position in the company&#8217;s primary field of
        business or (c) a senior position in public administration.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">105</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Until the lapse of a two-year period from the date that an external director of a company ceases to act in such capacity, the company in which such external director served, and
        its controlling shareholder or any entity under control of such controlling shareholder may not, directly or indirectly, grant such former external director, or his or her spouse or child, any benefit, including via (i) the appointment of such
        former director or his or her spouse or his child as an officer in the company or in an entity controlled by the company&#8217;s controlling shareholder, (ii) the employment of such former director, and (iii) the engagement, directly or indirectly, of
        such former director as a provider of professional services for compensation, directly or indirectly, including via an entity under his or her control. With respect to a relative who is not a spouse or a child, such limitations shall only apply for
        one year from the date such external director ceased to be engaged in such capacity.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Election and Dismissal of External Directors</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, external directors are elected by a majority vote at a shareholders&#8217; meeting, provided that either:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6c7b1893e1b54cee94f765d6cd50c239">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the majority of the shares that are voted at the meeting in favor of the election of the external director, excluding abstentions, include at least a majority of the votes of shareholders who are not controlling shareholders and do not
                have a personal interest in the appointment (excluding a personal interest that did not result from the shareholder&#8217;s relationship with the controlling shareholder); or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z915de01370a04db28fdc97332ffee933">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the total number of shares held by non-controlling shareholders or any one on their behalf that are voted against the election of the external director does not exceed two percent of the aggregate voting rights in the company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, the initial term of an external director of an Israeli public company is three years. The external director may be re-elected, subject to certain circumstances
        and conditions, for up to two additional terms of three years each, and thereafter, subject to conditions set out in the regulations promulgated under the Companies Law, to further three year terms, each re-election subject to one of the following:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc00eb9de13d44eab931514f66db046db">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>his or her service for each such additional term is recommended by one or more shareholders holding at least 1% of the company&#8217;s voting rights and is approved at a shareholders meeting by a disinterested majority, where the total number
                of shares held by non-controlling, disinterested shareholders voting for such reelection exceeds 2% of the aggregate voting rights in the company and subject to additional restrictions set forth in the Companies Law with respect to the
                affiliation of the external director nominee;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z76b321bd88454a5d89fef637f34b67bb">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the external director proposed his or her own nomination, and such nomination was approved in accordance with the requirements described in the paragraph above; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1a6627441e244ac6b2adb976ac8227e2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>his or her service for each such additional term is recommended by the board of directors and is approved at a meeting of shareholders by the same majority required for the initial election of an external director (as described above).</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">An external director may be removed by the same special majority of the shareholders required for his or her election, if he or she ceases to meet the statutory qualifications
        for appointment or if he or she violates his or her fiduciary duty to the company. An external director may also be removed by order of an Israeli court if the court finds that the external director is permanently unable to exercise his or her
        office, has ceased to meet the statutory qualifications for his or her appointment, has violated his or her fiduciary duty to the company, or has been convicted by a court outside Israel of certain offenses detailed in the Companies Law.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">106</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the vacancy of an external directorship causes a company to have fewer than two external directors, the company&#8217;s board of directors is required under the Companies Law to
        call a special general meeting of the company&#8217;s shareholders as soon as possible to appoint such number of new external directors so that the company thereafter has two external directors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Additional Provisions</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, each committee authorized to exercise any of the powers of the board of directors is required to include at least one external director and its audit and
        compensation committees are required to include all of the external directors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">An external director is entitled to compensation and reimbursement of expenses in accordance with regulations promulgated under the Companies Law and is prohibited from receiving
        any other compensation, directly or indirectly, in connection with serving as a director except for certain exculpation, indemnification and insurance provided by the company, as specifically allowed by the Companies Law.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Audit Committee</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Companies Law Requirements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, the board of directors of any public company must also appoint an audit committee comprised of at least three directors, including all of the external
        directors. The audit committee may not include:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd2d9ac64306a4bf89b06847977557797">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the chairman of the board of directors;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd05f1f8e6ab43329e2d74dc0cc34e96">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a controlling shareholder or a relative of a controlling shareholder;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd6c6caa90da94518bde1dd832242e017">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>any director employed by us or by one of our controlling shareholders or by an entity controlled by our controlling shareholders (other than as a member of the board of directors); or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zba36bad871e84ad19e822e5904d93b0a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>any director who regularly provides services to us, to one of our controlling shareholders or to an entity controlled by our controlling shareholders.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">According to the Companies Law, the majority of the members of the audit committee, as well as the majority of members present at audit committee meetings, will be required to be
        &#8220;independent&#8221; (as defined below) and the chairman of the audit committee will be required to be an external director. Any persons disqualified from serving as a member of the audit committee may not be present at the audit committee meetings,
        unless the chairman of the audit committee has determined that such person is required to be present at the meeting or if such person qualifies under one of the exemptions of the Companies Law.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The term &#8220;independent director&#8221; is defined under the Companies Law as an external director or a director who meets the following conditions and who is appointed or classified as
        such according to the Companies Law: (1) the conditions for his or her appointment as an external director (as described above) are satisfied and the audit committee approves the director having met such conditions and (2) he or she has not served
        as a director of the company for over nine consecutive years with any interruption of up to two years of his or her service not being deemed a disruption to the continuity of his or her service.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Nasdaq Listing Requirements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Nasdaq corporate governance rules, we are required to maintain an audit committee consisting of at least three independent directors, all of whom are financially
        literate and one of whom has accounting or related financial management expertise.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">Our audit committee consists of Ran Gottfried, Jerrold S. Gattegno, Shmuel Ben Zvi and Yaffa Krindel-Sieradzki. Jerrold S. Gattegno serves as Chairman of
        the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq corporate governance rules. Our board of directors has determined that Jerrold S.
        Gattegno is an audit committee financial expert as defined by SEC rules and has the requisite financial experience as defined by the Nasdaq corporate governance rules.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">107</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each of the members of the audit committee is &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Approval of Transactions with Related Parties</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The approval of the audit committee is required to effect specified actions and transactions with office holders and controlling shareholders and their relatives, or in which
        they have a personal interest. See &#8220;&#8212; Duties of Directors and Officers and Approval of Specified Related Party Transactions under the Israeli Companies Law &#8211; Fiduciary Duties of Office Holders.&#8221; The audit committee may not approve an action or a
        transaction with a controlling shareholder or with an office holder unless at the time of approval the audit committee meets the composition requirements under the Companies Law.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Audit Committee Role</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our board of directors has adopted an audit committee charter effective immediately after the pricing of&#160; our initial public offering setting forth the responsibilities of the
        audit committee consistent with the rules of the SEC and the Nasdaq corporate governance rules, which include:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z71a9ca9f1ed04efea2ed7875a2ad74e9">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>retaining and terminating our independent auditors, subject to board of directors and shareholder ratification;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7757ee690b924f0481222022c2db2762">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>overseeing the independence, compensation and performance of the Company&#8217;s independent auditors;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd78fb4c8617f41c6b04ef506766a69c8">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit services;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd875c495b16d4540a894ca75b0bc2cdb">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>pre-approval of audit and non-audit services to be provided by the independent auditors;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf516cfaa87144250ad4525782de1977a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>reviewing with management and our independent directors our financial statements prior to their submission to the SEC; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4cadd71f84ed4be49e5d45e39fe6f0f1">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>approval of certain transactions with office holders and controlling shareholders, as described below, and other related party transactions.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Additionally, under the Companies Law, the role of the audit committee includes the identification of irregularities in our business management, among other things, by consulting
        with the internal auditor or our independent auditors and suggesting an appropriate course of action to the board of directors. In addition, the audit committee or the board of directors, as set forth in the articles of association of the company,
        is required to approve the yearly or periodic work plan proposed by the internal auditor. The audit committee is required to assess the company&#8217;s internal audit system and the performance of its internal auditor. The Companies Law also requires
        that the audit committee assess the scope of the work and compensation of the company&#8217;s external auditor. In addition, the audit committee is required to determine whether certain related party actions and transactions are &#8220;material&#8221; or
        &#8220;extraordinary&#8221; for the purpose of the requisite approval procedures under the Companies Law and whether certain transactions with a controlling shareholder will be subject to a competitive procedure. The audit committee charter states that in
        fulfilling its role the committee is empowered to conduct or authorize investigations into any matters within its scope of responsibilities. A company whose audit committee&#8217;s composition also meets the requirements set for the composition of a
        compensation committee (as further detailed below) may have one committee acting as both audit and compensation committees.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">108</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Compensation Committee</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, public companies are required to appoint a compensation committee in accordance with the guidelines set forth thereunder.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The compensation committee must consist of at least three members. All of the external directors must serve on the committee and constitute a majority of its members. The
        chairman of the compensation committee must be an external director. The remaining members are not required to be external directors, but must be directors who qualify to serve as members of the audit committee (as described above).</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The compensation committee, which consists of Ran Gottfried, Jerrold S. Gattegno, Shmuel&#160;Ben Zvi and Jonathan B. Siegel, assists the board of directors in determining
        compensation for our directors and officers. Ran Gottfried serves as Chairman of the committee. Under SEC and Nasdaq rules, there are heightened independence standards for members of the compensation committee, including a prohibition against the
        receipt of any compensation from us other than standard supervisory board member fees. Although foreign private issuers are not required to meet this heightened standard, our board of directors has determined that all of our expected compensation
        committee members meet this heightened standard.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with the Companies Law, the roles of the compensation committee are, among others, as follows:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2796710637b54058a08493133d635f48">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>to recommend to the board of directors the compensation policy for directors and officers, and to recommend to the board of directors once every three years whether the compensation policy that had been approved should be extended for a
                period of more than three years;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za8fd4fe97f2c4131b531671db64bbeb3">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>to recommend to the board of directors updates to the compensation policy, from time to time, and examine its implementation;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5267078fa7d94077bd1dc093e92cf61f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">(3)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>to decide whether to approve the terms of office and employment of directors and officers that require approval of the compensation committee; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z482e81a206504dbdb3800d9611b6ef31">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">(4)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>to decide whether the compensation terms of the chief executive officer, which were determined pursuant to the compensation policy, will be exempted from approval by the shareholders because such approval would harm the ability to engage
                the chief executive officer.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to the roles mentioned above our compensation committee also makes recommendations to our board of directors regarding the awarding of employee equity grants.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In general, under the Companies Law, a public company must have a compensation policy approved by the board of directors after receiving and considering the recommendations of
        the compensation committee. In addition, the compensation policy requires the approval of the general meeting of the shareholders. In public companies such as our company, shareholder approval requires one of the following: (i) the majority of
        shareholder votes counted at a general meeting including the majority of all of the votes of those shareholders who are non-controlling shareholders and do not have a personal interest in the approval of the compensation policy, who vote at the
        meeting (excluding abstentions) or (ii) the total number of votes against the proposal among the shareholders mentioned in paragraph (i) does exceed two percent (2%) of the voting rights in the company. Under special circumstances, the board of
        directors may approve the compensation policy despite the objection of the shareholders on the condition that the compensation committee and then the board of directors decide, on the basis of detailed arguments and after discussing again the
        compensation policy, that approval of the compensation policy, despite the objection of the meeting of shareholders, is for the benefit of the company.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If a company initially offer its securities to the public, like we recently did, adopts a compensation policy in advance of its initial public offering, and describes it in its
        prospectus, then such compensation policy shall be deemed a validly adopted policy in accordance with the Companies Law requirements described above. Furthermore, if the compensation policy is set in accordance with the aforementioned relief, then
        it will remain in effect for term of five years from the date such company has become a public company.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">109</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The compensation policy must be based on certain considerations, include certain provisions and needs to reference certain matters as set forth in the Companies Law.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance,
        indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company&#8217;s objectives, business plan and long-term
        strategy, and creation of appropriate incentives for office holders. It must also consider, among other things, the company&#8217;s risk management, size and the nature of its operations. The compensation policy must furthermore consider the following
        additional factors:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd144eb514d30442daa5a1d4d2b4d66ab">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the education, skills, experience, expertise and accomplishments of the relevant office holder;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z17dd98a899d14d1980760eccd22d0588">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the office holder&#8217;s position, responsibilities and prior compensation agreements with him or her;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze499d9feef8c4cf3ae405d62975471bf">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the company, including employees employed through contractors who provide services to the company, in
                particular the ratio between such cost, the average and median salary of the employees of the company, as well as the impact of such disparities on the work relationships in the company;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf484cc08ed464e87890a4641215f107a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>if the terms of employment include variable components &#8212; the possibility of reducing variable components at the discretion of the board of directors and the possibility of setting a limit on the value of non-cash variable equity-based
                components; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6101225d52d6414abf3c90d91a0d7150">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>if the terms of employment include severance compensation &#8212; the term of employment or office of the office holder, the terms of his or her compensation during such period, the company&#8217;s performance during the such period, his or her
                individual contribution to the achievement of the company goals and the maximization of its profits and the circumstances under which he or she is leaving the company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The compensation policy must also include, among others:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z12153ee4bbed4736afc6492954c0d7d2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>with regards to variable components:</div>
            </td>
          </tr>

      </table>
      <br>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z32c71629b8fc47889570accc779d5a97">

          <tr>
            <td style="width: 47.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8201;&#8211;&#8201;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>
                <div style="font-family: 'Times New Roman', Times, serif;">with the exception of office holders who report directly to the chief executive officer, determining the variable components on long-term performance basis and on measurable
                  criteria; however, the company may determine that an immaterial part of the variable components of the compensation package of an office holder&#8217;s shall be awarded based on non-measurable criteria, if such amount is not higher than three
                  monthly salaries per annum, while taking into account such office holder contribution to the company;</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze5139643a887428b8cc4dd9ec2e75faa">

          <tr>
            <td style="width: 47.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8201;&#8211;&#8201;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>
                <div style="font-family: 'Times New Roman', Times, serif;">the ratio between variable and fixed components, as well as the limit of the values of variable components at the time of their grant.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z48827398e9e545efb3a0db84a6daae23">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a condition under which the office holder will return to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part of his or her terms of employment, if such amounts were paid based on
                information later to be discovered to be wrong, and such information was restated in the company&#8217;s financial statements;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb6a679bd72504b63a881daa04fdab8e0">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the minimum holding or vesting period of variable equity-based components to be set in the terms of office or employment, as applicable, while taking into consideration long-term incentives; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc0986af66bcc42d78ee3dc84f07e63fc">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a limit to retirement grants.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">110</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Corporate Governance Practices</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Internal Auditor</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, the board of directors of a public company must appoint an internal auditor based on the recommendation of the audit committee. The role of the internal
        auditor is, among other things, to examine whether a company&#8217;s actions comply with applicable law and orderly business procedure. Under the Companies Law, the internal auditor may not be an interested party or an office holder or a relative of an
        interested party or of an office holder, nor may the internal auditor be the company&#8217;s independent auditor or the representative of the same.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">An &#8220;interested party&#8221; is defined in the Companies Law as (i) a holder of 5% or more of the issued share capital or voting power in a company, (ii) any person or entity who has
        the right to designate one or more directors or to designate the chief executive officer of the company, or (iii)&#160;any person who serves as a director or as a chief executive officer of the company. As of the date of this annual report, we have not
        yet appointed our internal auditor.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Duties of Directors and Officers and Approval of Specified Related Party Transactions under the Israeli Companies Law</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Fiduciary Duties of Office Holders</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law imposes a duty of care and a fiduciary duty on all office holders of a company. The duty of care of an office holder is based on the duty of care set forth in
        connection with the tort of negligence under the Israeli Torts Ordinance (New Version) 5728-1968. This duty of care requires an office holder to act with the degree of proficiency with which a reasonable office holder in the same position would
        have acted under the same circumstances. The duty of care includes, among other things, a duty to use reasonable means, in light of the circumstances, to obtain:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc373b6e006bc48c3a8033aae555aafcc">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>information on the business advisability of a given action brought for his or her approval or performed by virtue of his or her position; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4d9aad63d7184706869a3a0bb3185461">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>all other important information pertaining to such action.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The fiduciary duty incumbent on an office holder requires him or her to act in good faith and for the benefit of the company, and includes, among other things, the duty to:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z39ee9e148175466f85559f436418c8cb">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>refrain from any act involving a conflict of interest between the performance of his or her duties in the company and his or her other duties or personal affairs;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfbd9705005fb43c5a7de9e34fbb43cd8">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>refrain from any activity that is competitive with the business of the company;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z04336ef8f37343faa134f21d36fecd63">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>refrain from exploiting any business opportunity of the company for the purpose of gaining a personal advantage for himself or herself or others; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze8e49c033abd47eca6ca567ddd7ce0ea">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder received as a result of his or her position as an office holder.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may approve an act specified above which would otherwise constitute a breach of the office holder&#8217;s fiduciary duty, provided that the office holder acted in good faith, the
        act or its approval does not harm the company, and the office holder discloses his or her personal interest a sufficient time before the approval of such act. Any such approval is subject to the terms of the Companies Law, setting forth, among
        other things, the appropriate bodies of the company entitled to provide such approval, and the methods of obtaining such approval.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">111</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Disclosure of Personal Interests of an Office Holder and Approval of Transactions</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law requires that an office holder promptly disclose to the company any personal interest that he or she may have and all related material information or documents
        relating to any existing or proposed transaction by the company. An interested office holder&#8217;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. An
        office holder is not obliged to disclose such information if the personal interest of the office holder derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, once an office holder has complied with the above disclosure requirement, a company may approve a transaction between the company and the office holder
        or a third party in which the office holder has a personal interest. However, a company may not approve a transaction or action that is not to the company&#8217;s benefit.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, unless the articles of association of a company provide otherwise, a transaction with an office holder or with a third party in which the office holder
        has a personal interest, which is not an extraordinary transaction, requires approval by the board of directors. Our amended and restated articles of association provide that such a transaction, which is not an extraordinary transaction, shall be
        approved by the board of directors or a committee of the board of directors or any other body or person (which has no personal interest in the transaction) authorized by the board of directors. If the transaction considered is an extraordinary
        transaction with an office holder or third party in which the office holder has a personal interest, then audit committee approval is required prior to approval by the board of directors. For the approval of compensation arrangements with directors
        and executive officers, see &#8220; &#8211; Duties of Directors and Officers and Approval of Specified Related Party Transactions under the Israeli Companies Law &#8211;&#160; Fiduciary Duties of Office Holders.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Any persons who have a personal interest in the approval of a transaction that is brought before a meeting of the board of directors or the audit committee may not be present at
        the meeting or vote on the matter. However, if the chairman of the board of directors or the chairman of the audit committee has determined that the presence of an office holder with a personal interest is required, such office holder may be
        present at the meeting for the purpose of presenting the matter. Notwithstanding the foregoing, a director who has a personal interest may be present at the meeting and vote on the matter if a majority of the directors or members of the audit
        committee have a personal interest in the approval of such transaction. If a majority of the directors at a board of directors meeting have a personal interest in the transaction, such transaction also requires approval of the shareholders of the
        company.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A &#8220;personal interest&#8221; is defined under the Companies Law as the personal interest of a person in an action or in a transaction of the company, including the personal interest of
        such person&#8217;s relative or the interest of any other corporate body in which the person and/or such person&#8217;s relative is a director or general manager, a 5% shareholder or holds 5% or more of the voting rights, or has the right to appoint at least
        one director or the general manager, but excluding a personal interest stemming solely from the fact of holding shares in the company. A personal interest also includes (1) a personal interest of a person who votes according to a proxy of another
        person, including in the event that the other person has no personal interest, and (2) a personal interest of a person who gave a proxy to another person to vote on his or her behalf regardless of whether or not the discretion of how to vote lies
        with the person voting.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">An &#8220;extraordinary transaction&#8221; is defined under the Companies Law as any of the following:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd49dc4f9a1447d6b1e20885fa7edf24">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a transaction other than in the ordinary course of business;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf4862c52f97b4382bc5e881ac1e0b340">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a transaction that is not on market terms; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z38a581686041489f852f57f62f0e388d">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a transaction that may have a material impact on the company&#8217;s profitability, assets or liabilities.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">112</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Disclosure of Personal Interests of a Controlling Shareholder and Approval of Transactions</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law also requires that a controlling shareholder promptly disclose to the company any personal interest that he or she may have and all related material information
        or documents relating to any existing or proposed transaction by the company. A controlling shareholder&#8217;s disclosure must be made promptly and, in any event, no later than the first meeting of the board of directors at which the transaction is
        considered. Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest, and the terms of
        engagement of the company, directly or indirectly, with a controlling shareholder or a controlling shareholder&#8217;s relative (including through a corporation controlled by a controlling shareholder), regarding the company&#8217;s receipt of services from
        the controlling shareholder, and if such controlling shareholder is also an office holder or employee of the company, regarding his or her terms of employment, require the approval of each of&#8201; (i) the audit committee or the compensation committee
        with respect to the terms of the engagement of the company, (ii) the board of directors and (iii) the shareholders, in that order. In addition, the shareholder approval must fulfill one of the following requirements:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2413ed95145c437abc44177294f4bc04">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8a8a34dce5a842e7b0196d6e8f6b90f1">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than two percent (2%) of the voting rights in the company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, an extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest, and an engagement of the company, directly
        or indirectly, with a controlling shareholder or a controlling shareholder&#8217;s relative (including through a corporation controlled by a controlling shareholder), regarding the company&#8217;s receipt of services from the controlling shareholder, and if
        such controlling shareholder is also an office holder or employee of the company, regarding his or her terms of employment, in each case with a term of more than three years requires the abovementioned approval every three years, however,
        transactions not involving the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances. In addition, transactions with a
        controlling shareholder or a controlling shareholder&#8217;s relative who serves as an officer in a company, directly or indirectly (including through a corporation under his control), involving the receipt of services by a company or their compensation
        can have a term of five years from the company's initial public offering under certain circumstances.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling
        shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question. Failure to so indicate will result in the invalidation of that shareholder&#8217;s vote.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Disclosure of Compensation of Executive Officers</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement
        applicable to emerging growth companies to disclose the compensation of our chief executive officer and other two most highly compensated executive officers on an individual, rather than an aggregate, basis. Nevertheless, regulations promulgated
        under the Companies Law will require us, after we became a public company, to disclose the annual compensation of our five most highly compensated office holders on an individual basis, rather than on an aggregate basis. This disclosure will not be
        as extensive as that required of a U.S. domestic issuer.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">113</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Compensation of Directors and Executive Officers</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25;"><font style="font-style: italic;">Directors</font><font style="font-family: 'Times New Roman',Times,serif;">. Under the Companies Law, the compensation of
          our directors requires the approval of our compensation committee, the subsequent approval of the board of directors and, unless exempted under regulations promulgated under the Companies Law, the approval of the shareholders at a general
          meeting. If the compensation of our directors is inconsistent with our stated compensation policy, then, those provisions that must be included in the compensation policy according to the Companies Law must have been considered by the
          compensation committee and board of directors, and shareholder approval will also be required, provided that:</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01b1e0a6b7aa42569190c7fdb8a5c673">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such matter, present and voting at such meeting, are voted in favor of the compensation package,
                excluding abstentions; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zef2a12ed17214a7bb128645910c4910a">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter voting against the compensation package does not exceed two percent (2%) of the aggregate voting rights in the
                company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.8pt; margin-left: 0.2pt; line-height: 1.25;"><font style="font-style: italic;">Executive officers other than the chief executive officer.</font><font style="font-family: 'Times New Roman',Times,serif;">
          The Companies Law requires the approval of the compensation of a public company&#8217;s executive officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&#8217;s board of directors, and (iii)
          if such compensation arrangement is inconsistent with the company&#8217;s stated compensation policy, the company&#8217;s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation). However, if the
          shareholders of the company do not approve a compensation arrangement with an executive officer that is inconsistent with the company&#8217;s stated compensation policy, the compensation committee and board of directors may override the shareholders&#8217;
          decision if each of the compensation committee and the board of directors provide detailed reasons for their decision.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;"><font style="font-style: italic;">Chief executive officer.</font><font style="font-family: 'Times New Roman',Times,serif;"> Under the Companies Law, the
          compensation of a public company&#8217;s chief executive officer is required to be approved by: (i) the company&#8217;s compensation committee; (ii) the company&#8217;s board of directors, and (iii) the company&#8217;s shareholders (by a special majority vote as
          discussed above with respect to the approval of director compensation). However, if the shareholders of the company do not approve the compensation arrangement with the chief executive officer, the compensation committee and board of directors
          may override the shareholders&#8217; decision if each of the compensation committee and the board of directors provide a detailed report for their decision. The approval of each of the compensation committee and the board of directors should be in
          accordance with the company&#8217;s stated compensation policy; however, in special circumstances, they may approve compensation terms of a chief executive officer that are inconsistent with such policy provided that they have considered those
          provisions that must be included in the compensation policy according to the Companies Law and that shareholder approval was obtained (by a special majority vote as discussed above with respect to the approval of director compensation). In
          addition, the compensation committee may waive the shareholder approval requirement with regards to the approval of the engagement terms of a candidate for the chief executive officer position, if they determine that the compensation arrangement
          is consistent with the company&#8217;s stated compensation policy, and that the chief executive officer did not have a prior business relationship with the company or a controlling shareholder of the company and that subjecting the approval of the
          engagement to a shareholder vote would impede the company&#8217;s ability to employ the chief executive officer candidate.</font></div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Duties of Shareholders</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in exercising its rights
        and performing its obligations to the company and other shareholders, including, among other things, when voting at meetings of shareholders on the following matters:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z52ece37e241d43e99fb897f6a80c09dd">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>an amendment to the articles of association;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdbb3e1937e4f466899a660aba202521d">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>an increase in the company&#8217;s authorized share capital;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4a6ad18270744cbc8d917824918a9dcd">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a merger; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">114</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zac7bb5b0285643a9bc98a3aedb4ab293">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the approval of related party transactions and acts of office holders that require shareholder approval.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A shareholder also has a general duty to refrain from discriminating against other shareholders.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The remedies generally available upon a breach of contract will also apply to a breach of the shareholder duties mentioned above, and in the event of discrimination against other
        shareholders, additional remedies may be available to the injured shareholder.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under a company&#8217;s
        articles of association, has the power to appoint or prevent the appointment of an office holder, or any other power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe the
        substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Approval of Private Placements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and the regulations promulgated thereunder, a private placement of securities does not require approval at a general meeting of the shareholders of a
        company; provided however, that in special circumstances, such as a private placement which is intended to obviate the need to conduct a special tender offer (see &#8220;Item 10. Additional Information&#8212; Memorandum of Association &#8211; Acquisitions under
        Israeli Law&#8221;) or a private placement which qualifies as a related party transaction (see &#8220;&#8212; Duties of Directors and Officers and Approval of Specified Related Party Transactions under the Israeli Companies Law &#8211;&#160; Fiduciary Duties of Office
        Holders&#8221;), approval at a general meeting of the shareholders of a company is required.</div>
      <div style="line-height: 1.25; font-weight: bold;"><br>
        Exculpation, Insurance and Indemnification of Directors and Officers</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the fiduciary duty. An Israeli company may exculpate an office holder in
        advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and
        restated articles of association include such a provision. The company may not exculpate in advance a director from liability arising due to the breach of his or her duty of care in the event of a prohibited dividend or distribution to
        shareholders.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and the Israeli Securities Law, 5728-1968, or the Securities Law, a company may indemnify an office holder in respect of the following liabilities,
        payments and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z988ae7a9f28f45b99b68bcc2efac3d33">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator&#8217;s decision approved by a competent court.
                However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the
                company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned
                foreseen events and amount or criteria;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8989b4816b6242cfb00d047fe5e93b0f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>reasonable litigation expenses, including reasonable attorneys&#8217; fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such
                investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a
                criminal proceeding; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require
                proof of criminal intent; or (iii) in connection with a monetary sanction;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">115</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8b698ac047364872a2c486840047de18">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9bd816fb95424b539e8e7f78a213dd2f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0af51ab37d1641a69968d8137f7b4c39">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third
                party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z570065aa68fd4f6c8861e94ce560c1b5">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures
        of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and the Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office
        holder if and to the extent provided in the company&#8217;s articles of association:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcb29ca1a4fde443cb87f19410944d327">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a breach of the fiduciary duty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z79a2f1227d7a48058e5618836d67f2c2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd36c707509b4108b052c1dd3730f6cc">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a monetary liability imposed on the office holder in favor of a third party;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd869b5ea7604db3be8ae0742da8e1c8">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z578c907e458243ecae41045e9508dd85">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys&#8217; fees.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf399cc13cd4b4a5ba1651a8735d59c12">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a breach of the fiduciary duty, except for indemnification and insurance for a breach of the fiduciary duty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would
                not prejudice the company;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcbcce88e6e504e02b984701fcf175c09">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">116</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5c47b5602bd245b2a3d3aa900d82259f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>an act or omission committed with intent to derive illegal personal benefit; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ad5f84423384614b30fdb0d433a3948">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a fine or forfeit levied against the office holder.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors and, with respect
        to directors or controlling shareholders, their relatives and third parties in which controlling shareholders have a personal interest, also by the shareholders.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. Our
        office holders are currently covered by a directors&#8217; and officers&#8217; liability insurance policy. As of the date of this annual report, no claims for directors&#8217; and officers&#8217; liability insurance have been filed under this policy and we are not aware
        of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification is sought.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">See "Item 7. Major Shareholders and Related Party Transactions &#8211; B. Related Party Transactions - Directors and Officers Insurance Policy and Indemnification
        Agreements" for information regarding letters of indemnification to directors and officers of the Company.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Employees</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As of December 31, 2020, we had 65 employees, all of whom except 3 are located in Israel.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z51a1358a0df245c39147d20580df9918">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="22">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">As of December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2018</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2019</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Company</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Company</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Company</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Employees</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Consultants</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Employees</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Consultants</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Employees</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Consultants</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 28%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">Management</div>
            </td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">8</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><br>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">9</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><br>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">9</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><br>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman',Times,serif; width: 28%;">
              <div style="text-align: justify; text-indent: -7.2pt; margin-left: 7.2pt; line-height: 1.25;">Research and development and other</div>
            </td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">48</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">52</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="line-height: 1.25;">56</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
            <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; clear: both;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">While none of our employees are party to a collective bargaining agreement, certain provisions of the collective bargaining agreements between the Histadrut (General Federation
        of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the Industrialists&#8217; Associations) are applicable to our employees by order of the Israel Ministry of Labor. These provisions primarily concern the length of the
        workday, minimum daily wages for professional workers, pension fund benefits for all employees, insurance for work-related accidents, procedures for dismissing employees, determination of severance pay and other conditions of employment. We
        generally provide our employees with benefits and working conditions beyond the required minimums.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have never experienced any employment-related work stoppages and believe our relationship with our employees is good.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">E.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Share Ownership</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For information regarding the share ownership of our directors and executive officers, please see &#8220;Item 7.A. Major Shareholders.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Award Plans</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">2014 Share Incentive Plan</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On December&#160;2, 2014, we adopted the 2014 Share Incentive Plan, or the Plan, and, in connection with&#160;our initial public offering, we amended and restated the Plan which became
        effective immediately after the pricing of our initial public offering. The Plan is intended to afford an incentive to our and any of our affiliate&#8217;s employees, directors, officers, consultants, advisors and any other person or entity who provides
        services to the Company, to continue as service providers, to increase their efforts on our and our affiliates behalf and to promote our success, by providing such persons with opportunities to acquire a proprietary interest in us.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">117</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">The number of shares that may be issued under the Plan is subject to adjustment if particular capital changes affect our share
          capital or such other number as our board of directors may determine from time to time. Ordinary shares subject to outstanding awards under the Plan that subsequently expire, are cancelled, forfeited or terminated for any reason before being
          exercised will be automatically, and without any further action, returned to the &#8220;pool&#8221; of reserved shares and will again be available for grant under the Plan.&#160; As of February 26, 2021, we had an aggregate of 929,415&#160;ordinary shares available
          for issuance under the Plan (including ordinary shares underlying outstanding options and restricted share units).</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A share option is the right to purchase a specified number of ordinary shares in the future at a specified exercise price and subject to the other terms and conditions specified
        in the option agreement and the Plan. The exercise price of each share option granted under the Plan will be determined in accordance with the limitations set forth under the Plan. The exercise price of any share options granted under the Plan may
        be paid in cash, through the surrender of ordinary shares by the option holder or any other method that may be approved by our compensation committee, which may include procedures for cashless exercise.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our compensation committee may also grant, or recommend that our board of directors grant, other forms of equity incentive awards under the Plan, such as restricted shares,
        restricted share units, and other forms of share-based compensation.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Israeli participants in the Plan may be granted options subject to Section 102 of the Israeli Income Tax Ordinance (New Version), 1961, or the Israeli Tax Ordinance. Section 102
        of the Israeli Tax Ordinance allows employees, directors and officers who are not controlling shareholders (as defined for those purposes under the Israeli Tax Ordinance) and are considered Israeli residents to receive favorable tax treatment for
        compensation in the form of shares or options. Our non-employee service providers and controlling shareholders may only be granted options under another section of the Israeli Tax Ordinance, which does not provide for similar tax benefits. Section
        102 includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of options or shares directly to the grantee. The
        most favorable tax treatment for the grantees is under Section 102(b)(2) of the Israeli Tax Ordinance, the issuance to a trustee under the &#8220;capital gain track.&#8221; However, under this track we are not allowed to deduct an expense with respect to the
        issuance of the options or shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, any options granted under the Plan to participants in the United States will be either &#8220;incentive stock options,&#8221; which may be eligible for special tax treatment
        under the Code, or options other than incentive stock options (referred to as &#8220;nonqualified stock options&#8221; under the Plan). The type of option granted under the Plan and specific terms and conditions are, in each case, determined by our
        compensation committee or our board of directors and set forth in the applicable option agreement.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our compensation committee will administer the Plan, or if determined otherwise by our board of directors, the Plan will be administered by our board of directors or other
        designated committee on its behalf. Even if the compensation committee or any other committee was appointed by our board of directors in order to administrate the Plan, our board of directors may, subject to any legal limitations, exercise any
        powers or duties of the compensation committee or any other committee concerning the Plan. The compensation committee will, among others, select which eligible persons will receive options or other awards under the Plan and will determine, or
        recommend to our board of directors, the number of ordinary shares covered by those options or other awards, the terms under which such options or other awards may be exercised (however, options generally may not be exercised later than ten years
        from the grant date of an option) or may be settled or paid, and the other terms and conditions of such options and other awards under the Plan. All awards granted under the Plan shall not be transferable other than by will or by the laws of
        descent and distribution, unless otherwise determined by our compensation committee.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">118</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">To the extent permitted under applicable law, our compensation committee will have the authority to accelerate the vesting of any outstanding awards at such time and under such
        circumstances as it, in its sole discretion, deems appropriate. In the event of a change of control, as defined in the Plan, any award then outstanding shall be assumed or an equivalent award shall be substituted by the successor corporation of the
        merger or sale or any parent or affiliate thereof as determined by our board of directors. In the event that the awards are not assumed or substituted, our compensation committee may, in its discretion, accelerate the vesting, exercisability of the
        outstanding award, or provide for the cancellation of such award and payment of cash, as determined to be fair in the circumstances.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to particular limitations specified in the Plan and under applicable law, our board of directors may amend or terminate the Plan, and the compensation committee may amend
        awards outstanding under the Plan. In addition, an amendment to the Plan that requires shareholder approval under applicable law will not be effective unless approved by the requisite vote of shareholders. In addition, in general, no suspension,
        termination, modification or amendment of the Plan may adversely affect any award previously granted without the written consent of grantees holding a majority in interest of the awards so affected. The Plan will continue in effect until all
        ordinary shares available under the Plan are delivered and all restrictions on those shares have lapsed, unless the Plan is terminated earlier by our board of directors. No awards may be granted under the Plan on or after the tenth anniversary of
        the date of adoption of the plan unless our board of directors chooses to extend the term.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">Any equity award to an office holder, director or controlling shareholder, whether under the Plan or otherwise, may be subject to further approvals in
        addition to the approval of the compensation committee as described above. As of December&#160;31, 2020, options to purchase 1,199,469 ordinary shares, at a weighted average exercise price of&#8201;$5.08 per share, were outstanding under our Plan.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><a name="ITEM7"><!--Anchor--></a>ITEM 7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Major Shareholders</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of February 26, 2021 by:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z27ddb365f7c846e19ff6f96ab844024d">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>each person or entity known by us to own beneficially 5% or more of our outstanding ordinary shares;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z123454c47eac4737ba227e2afa66d40e">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>each of our directors, executive officers and director nominees; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2bc4e29c81034e3a88b7240a10c941ce">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>all of our executive officers, directors and director nominees as a group.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The beneficial ownership of our ordinary shares is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a
        security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security. For purposes of
        the table below, we deem ordinary shares issuable pursuant to options that are currently exercisable or exercisable within 60 days as of February 26, 2021, if any, to be outstanding and to be beneficially owned by the person holding the options or
        warrants for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. The percentage of ordinary shares beneficially owned
        is based on 23,000,782 ordinary shares outstanding as of February 26, 2021.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole
        investment and voting power with respect to such shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">119</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">None of our shareholders has different voting rights from other shareholders. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of
        our company.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Unless otherwise noted below, the address for each beneficial owner is c/o Sol-Gel Technologies Ltd., 7&#160;Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650 Israel.</div>
      <div style="line-height: 1.25;"> <br>
        <table cellspacing="0" cellpadding="0" id="z35f33387594d45ceb6ea5ad82264c194" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

            <tr>
              <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: justify; line-height: 1.25;">&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Shares Beneficially</div>
                <div style="text-align: center; line-height: 1.25; font-weight: bold;">Owned</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Name of Beneficial Owner</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Number</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Percentage</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">5% or greater shareholders</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25;">M. Arkin Dermatology Ltd. (1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">14,432,266</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">62.75</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">%</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-align: justify; line-height: 1.25;">The Phoenix Holding Ltd. (2)</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">2,672,944</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">11.62</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">%</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Directors, director nominees and executive officers</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Moshe Arkin (1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">14,518,266</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">63.12</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">%</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25;">Alon Seri-Levy (3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">285,188</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">1.23</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">
                <div style="line-height: 1.25;">%</div>
              </td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Gilad Mamlok&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25;">Ofer Toledano&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Ofra Levy-Hacham&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25;">Karine Neimann&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Itzik Yosef&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25;">Dubi Zamir&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Nissim Bilman</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25;">John Vieira</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Itai Arkin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25;">Ran Gottfried&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Jerrold S. Gattegno&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25;">Shmuel Ben Zvi&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Hani Lerman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="line-height: 1.25;">Yaffa Krindel Sieradzki&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">Jonathan Siegel&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="line-height: 1.25;">*</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            </tr>
            <tr>
              <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                <div style="line-height: 1.25; font-style: italic; font-weight: bold;">All directors, director nominees and executive officers as a group (17 persons) (1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
              </td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                <div style="line-height: 1.25;">15,292,379</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>
              <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                <div style="line-height: 1.25;">64.49</div>
              </td>
              <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;">
                <div style="line-height: 1.25;">%</div>
              </td>
            </tr>

        </table>
        <u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
        </u></div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zac1edf7292b547e6907da6bf95658f35">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">*</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Less than 1%.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z44494c153aad4a188e8cd296effdc882">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Based on the Schedule 13D/A filed with the SEC on April 20, 2020, Arkin Dermatology directly owns 14,432,266 ordinary shares. Mr. Moshe Arkin, the chairman of our board of directors, is the sole shareholder and sole director of Arkin
                Dermatology and may therefore be deemed to be the indirect beneficial owner of the ordinary shares owned directly by Arkin Dermatology. In addition, Mr. Moshe Arkin directly owns 86,000 ordinary shares.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7493584563d640cda06da922ebab4427">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Based on the Schedule 13G/A filed with the SEC on February 11, 2021, the ordinary shares are beneficially owned by various&#160;direct or indirect, majority or wholly-owned subsidiaries of the Phoenix Holding Ltd., or the Subsidiaries.&#160; The
                Subsidiaries manage their own funds and/or the funds of others, including for holders of exchange-traded notes or various insurance policies, members of pension or provident funds, unit holders of mutual funds, and portfolio management
                clients. Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1407219ed6324224aac707918acbd8fe">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">(3)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;"> <a name="_Hlk65701876">Consists of </a>options to purchase 285,188 ordinary shares exercisable within 60&#160;days of February&#160;26,
              2021. The exercise price of these options ranges between $1.59 and $11.21 per share and the options expire between March 2025 and May 2028.</td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">120</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Record Holders</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As of February 26, 2021, we had one holder of record of our ordinary shares in the United States, consisting of Cede &amp; Co., the nominee of The Depository Trust Company. That
        shareholder held, in the aggregate, 10,811,084 ordinary shares, representing 47.0% of the outstanding ordinary shares as of February 26, 2021. The number of record holders in the United States is not representative of the number of beneficial
        holders nor is it representative of where such beneficial holders are resident since many of these ordinary shares were held by brokers or other nominees.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Related Party Transactions</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Private Placement with Our Controlling Shareholder</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">On April 13, 2020, we closed a $5.0 million private placement with our controlling shareholder, Arkin Dermatology, which agreed to make this private
        investment concurrently with the&#160;February 2020&#160; public offering. In the private placement, we issued to Arkin Dermatology&#160;454,628 ordinary shares and warrants to purchase up to 363,702 ordinary shares at a combined price of&#160;$11.00&#160;per ordinary
        share and accompanying warrant to purchase 0.80 of an ordinary share, which is the same price as the public offering price of the ordinary shares and accompanying warrants issued in the Company&#8217;s February 2020 public offering.&#160;The warrants issued
        to&#160;Arkin Dermatology&#160;have an initial exercise price of&#160;$14.00&#160;per share, subject to certain adjustments, and will expire on&#160;February 19, 2023, which are on the same terms as the warrants issued in the February 2020&#160; public offering.&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Participation in Our Initial Public Offering</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">According to Form 13D filed by it on February 12, 2018, our controlling shareholder, Arkin Dermatology, which is wholly-owned by the chairman of our board of directors, purchased
        1,833,333 of our ordinary shares in our initial public offering in consideration for $22.0 million, on the same terms as the other purchasers in the offering.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Directors and Officers Insurance Policy and Indemnification Agreements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association permit us to exculpate, indemnify and insure each of our directors and officers to the fullest extent permitted by the Companies
        Law. We have obtained Directors and Officers insurance for each of our executive officers and directors. For further information, see</div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Item 6 C. &#8211; Board Practices &#8211; Exculpation, Insurance and Indemnification of Directors and Officers&#8221;.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We entered into agreements with each of our current directors and officers exculpating them from a breach of their duty of care to us to the fullest extent permitted by law,
        subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, subject to limited exceptions, including, with respect to liabilities resulting from our initial public offering, to the extent that these
        liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum
        aggregate amount of indemnification that we may pay to our directors and officers based on such indemnification agreement is the greater of (1) 25% of our shareholders&#8217; equity pursuant to our audited financial statements for the year preceding the
        year in which the event in connection of which indemnification is sought occurred, and (2) $40 million (as may be increased from time to time by shareholders&#8217; approval). Such indemnification amounts are in addition to any insurance amounts. Each
        director or officer who agrees to receive this letter of indemnification also gives his approval to the termination of all previous letters of indemnification that we have provided to him or her in the past, if any.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Registration Rights Agreement</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We entered into a registration rights agreement, pursuant to which we granted demand registration rights, short-form registration rights and piggyback registration rights to
        Arkin Dermatology, our controlling shareholder. All fees, costs and expenses of underwritten registrations are expected to be borne by us. No registration rights to be granted pursuant to this registration rights agreement shall be exercisable
        until expiration of the 180-day lock-up agreement entered into by Arkin Dermatology with the underwriters in connection with our initial public offering.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">121</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Interests of Experts and Counsel</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><a name="ITEM8"><!--Anchor--></a>ITEM 8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements and Other Financial Information</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The financial statements required by this item are found at the end of this annual report, beginning on page F-2.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Legal Proceedings</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We are not currently a party to any material legal proceedings.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Dividend Policy</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have never declared or paid any cash dividends on our ordinary shares and we anticipate that, for the foreseeable future, we will retain any future earnings to support
        operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends for at least the next several years.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The distribution of dividends may also be limited by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived over the two
        most recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will prevent a company from satisfying its existing and foreseeable obligations as they become due. Our amended and restated
        articles of association provide that dividends will be paid at the discretion of, and upon resolution by, our board of directors, subject to the provisions of the Companies Law.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Significant Changes</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Except as otherwise disclosed in this annual report, no significant change has occurred since December 31, 2020.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><a name="ITEM9"><!--Anchor--></a>ITEM 9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;THE OFFER AND LISTING</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Offer and Listing Details</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Ordinary Shares have been trading on The Nasdaq Global Market under the symbol &#8220;SLGL&#8221; since February 1, 2018. Prior to that date, there was no public trading market for our
        Ordinary Shares. Our initial public offering was priced at $12.00 per share on January 31, 2018.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 26, 2021, the last reported closing price of our Ordinary Shares on The Nasdaq Global Market was $8.90 per share.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Plan of Distribution</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">122</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Markets</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Our Ordinary Shares are listed and traded on The Nasdaq Global Market under the symbol &#8220;SLGL&#8221;.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Selling Shareholders</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">E.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dilution</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">F.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Expenses of the Issue</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><a name="ITEM10"><!--Anchor--></a>ITEM 10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ADDITIONAL INFORMATION</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Share Capital</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Memorandum and Articles of Association</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Registration Number and Purposes of the Company</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our registration number with the Israeli Registrar of Companies is 51-254469-3. Our purpose as set forth in our amended and restated articles of association is to engage in any
        lawful activity.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Voting Rights and Conversion</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">All ordinary shares will have identical voting and other rights in all respects.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Transfer of Shares</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer is
        restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our
        amended and restated articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Liability to Further Capital Calls</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our board of directors may make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by such
        shareholders which is not payable at a fixed time. Such shareholder shall pay the amount of every call so made upon him. Unless otherwise stipulated by the board of directors, each payment in response to a call shall be deemed to constitute a pro
        rata payment on account of all shares with respect to which such call was made. A shareholder shall not be entitled to his rights as shareholder, including the right to dividends, unless such shareholder has fully paid all the notices of call
        delivered to him, or which according to our amended and restated articles of association are deemed to have been delivered to him, together with interest, linkage and expenses, if any, unless otherwise determined by the board of directors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">123</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Election of Directors</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our ordinary shares do not have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders
        meeting have the power to elect all of our directors, subject to the special approval requirements for external directors under the Companies Law described under &#8220;Management &#8212; External Directors.&#8221;</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under our amended and restated articles of association, our board of directors must consist of not less than five (5) but no more than nine (9) directors, including any external
        directors required to be appointed by the Companies Law. Pursuant to our amended and restated articles of association, other than the external directors, for whom special election requirements apply under the Companies Law, the vote required to
        appoint a director is a simple majority vote of holders of our voting shares participating and voting at the relevant meeting. In addition, our amended and restated articles of association allow our board of directors to appoint new directors to
        fill vacancies on the board of directors if the number of directors is below the maximum number provided in our amended and restated articles. Furthermore, under our amended and restated articles of association our directors other than external
        directors are divided into three classes with staggered three-year terms. For a more detailed description on the composition of our board of election procedures of our directors, other than our external directors, see &#8220;Item 6. Directors, Senior
        Management and Employees &#8212; C. Board Practices &#8212; Appointment of Directors and Terms of Officers.&#8221; External directors are elected for an initial term of three years, may be elected for additional terms of three years each under certain circumstances,
        and may be removed from office pursuant to the terms of the Companies Law. For further information on the election and removal of external directors, see &#8220;Item 6. Directors, Senior Management and Employees &#8212; C. Board Practices &#8212; External Directors
        &#8212; Election and Dismissal of External Directors.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Dividend and Liquidation Rights</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are
        determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our amended and restated articles of association do not require shareholder
        approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to our then
        last reviewed or audited financial statements, provided that the date of the financial statements is not more than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with court
        approval. In each case, we are only permitted to distribute a dividend if our board of directors and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing
        and foreseeable obligations as they become due.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in
        proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be
        authorized in the future.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Shareholder Meetings</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the
        previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred to in our amended and restated articles of association as special meetings. Our board of directors may call special meetings whenever
        it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene a special meeting upon the written request of&#8201; (i) any two of our
        directors or one-quarter of the members of our board of directors or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 5% or more of
        our outstanding voting power. This is different from the Delaware General Corporation Law, or the DGCL, which allows such right of shareholders to be denied by a provision in a company&#8217;s certificate of incorporation.</div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">124</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include a matter in the agenda
        of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the general meeting.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders
        of record on a date to be decided by the board of directors, which may be between four and 40 days prior to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a
        general meeting of our shareholders:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zad5366c9ebed4f8fb868bbec39744f05">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>amendments to our amended and restated articles of association;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd297cc4f17d944d39b569624f15e782c">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>appointment or termination of our auditors;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2ddfbe62049f4b90bc690851bd26cccb">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>appointment of external directors;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zff14e5d8eec64f49b0f48ba090542af2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>approval of certain related party transactions;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7035a2ef22c4300be2197321bfdb133">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>increases or reductions of our authorized share capital;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3e46d3e7e83a47e98e06dcdf47efb766">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>mergers; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z20c1c6475ff842cab32bdcb35895fde6">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the exercise of our board of director&#8217;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under our amended and restated articles of association, we are not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required
        by law. The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal of
        directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, or as otherwise required under applicable law, notice must be provided at least 35 days prior to the meeting. Under the
        Companies Law, shareholders are not permitted to take action by written consent in lieu of a meeting. Our amended and restated articles of association provide that a notice of general meeting shall be published by us on Form 6-K at a date prior to
        the meeting as required by law.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Voting Rights</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Quorum Requirements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at
          a general meeting. Under our amended and restated articles of association, the quorum required for general meetings of shareholders must consist of at least two shareholders present in person or by proxy (including by voting deed) holding 33 1&#8725;3%
          or more of the voting rights in the Company, which complies with the quorum requirements for general meetings under the Nasdaq Marketplace Rules. A meeting adjourned for lack of a quorum will generally be adjourned to the same day of the
          following week at the same time and place, or to such other day, time or place as indicated by our board of directors if so specified in the notice of the meeting. At the reconvened meeting, any number of shareholders present in person or by
          proxy shall constitute a lawful quorum, instead of 33 1&#8725;3% of the issued share capital as required under the Nasdaq Marketplace Rules.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">125</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Vote Requirements</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law
        or by our amended and restated articles of association. Pursuant to our amended and restated articles of association, an amendment to our amended and restated articles of association regarding any change of the composition or election procedures of
        our directors will require a special majority vote (662&#8725;3%). Under the Companies Law, each of&#8201; (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling
        shareholder of the company or such controlling shareholder&#8217;s relative (even if not extraordinary) requires the approval described above under &#8220;Management &#8212; Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation under
        Israeli Law &#8212; Disclosure of Personal Interests of a Controlling Shareholder and Approval of Transactions.&#8221; Certain transactions with respect to remuneration of our office holders and directors require further approvals described above under
        &#8220;Management &#8212; Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation under Israeli Law &#8212; Compensation of Directors and Executive Officers.&#8221; Under our amended and restated articles of association, any change to the
        rights and privileges of the holders of any class of our shares requires a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the governing documents relevant to such class), in
        addition to the ordinary majority vote of all classes of shares voting together as a single class at a shareholder meeting. Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a
        scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, which requires the approval of holders of 75% of the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on
        the resolution.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Access to Corporate Records</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, shareholders are provided access to minutes of our general meetings, our shareholders register and principal shareholders register, our amended and
        restated articles of association, our financial statements and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be provided
        with any document related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe it has not been made in good faith or if such denial is
        necessary to protect our interest or protect a trade secret or patent.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Modification of Class Rights</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation and dividend rights, may be
        amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance with the rights attached to such class of shares, in addition to the ordinary majority vote
        of all classes of shares voting together as a single class at a shareholder meeting, as set forth in our amended and restated articles of association.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Registration Rights</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For a discussion of registration rights we granted to our controlling shareholder in connection with the closing of our initial public offering, please see &#8220;Item 7. Major
        Shareholders and Related Party Transactions &#8211; Related Party Transactions &#8212; Registration Rights Agreement.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Acquisitions under Israeli Law</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Full Tender Offer</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&#8217;s issued and outstanding share capital is required
        by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result
        hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares
        of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in
        the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less
        than 2% of the issued and outstanding share capital of the company or of the applicable class of shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">126</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not,
        may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under
        certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If&#8201; (a) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the applicable class or
        the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold 2% or more of the
        issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s issued and outstanding share capital or of the
        applicable class from shareholders who accepted the tender offer.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Special Tender Offer</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the
        purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies Law provides that
        an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other
        shareholder of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A special tender offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting power attached
        to the company&#8217;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated only if&#8201; (i) at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by
        the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser and its controlling shareholder, holders of 25% or more of the voting rights in the company or
        any person having a personal interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such person&#8217;s control). If a special tender offer is accepted, then the purchaser or any
        person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target
        company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Under the DGCL there are no provisions relating to mandatory tender offers.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Merger</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under the Companies Law are met, by a
        majority vote of each party&#8217;s shares, and, in the case of the target company, a majority vote of each class of its shares voted on the proposed merger at a shareholders meeting.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">127</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at the
        shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or
        more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is
        instead subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders (as described under &#8220;Management &#8212; Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation
        under Israeli Law &#8212; Disclosure of Personal Interests of a Controlling Shareholder and Approval of Transactions&#8221;).</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain
        shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value to the
        parties to the merger and the consideration offered to the shareholders of the company.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a
        result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the
        Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Anti-Takeover Measures under Israeli Law</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights
        with respect to voting, distributions or other matters and shares having preemptive rights. As of the date of this annual report, no preferred shares are authorized under our amended and restated articles of association. In the future, if we do
        authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from
        realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and restated articles of association, which requires the prior
        approval of the holders of a majority of the voting power attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained at
        such a meeting will be subject to the requirements set forth in the Companies Law as described above in &#8220;&#8212; Voting Rights.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As an Israeli company we are not subject to the provisions of Section 203 of the DGCL, which in general prohibits a publicly held Delaware corporation from engaging in a
        &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. For
        purposes of Section 203, a &#8220;business combination&#8221; includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder, and an &#8220;interested stockholder&#8221; is a person who, together with affiliates and
        associates, owns, or within three years prior did own, 15% or more of the voting stock of a corporation.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Borrowing Powers</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take all actions that are not required
        under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">128</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Changes in Capital</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must
        be approved by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings
        or profits, require the approval of both our board of directors and an Israeli court.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Transfer Agent and Registrar</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The transfer agent and registrar for our ordinary shares is American Stock Transfer &amp; Trust Company, LLC.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">C.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Material Contracts</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For a description of other material agreements, please see "Item 4. Information on the Company &#8211; B. Business Overview."</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">D.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#160; <font style="font-weight: bold;">Exchange Controls</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other
        payments to non-residents of Israel, except for shareholders who are subjects of certain countries that are considered to be in a state of war with Israel at such time.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">E.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-weight: bold;">Taxation</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Israeli Tax Considerations and Government Programs</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">General</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following is a summary of the material Israeli tax laws applicable to us, and some Israeli Government programs benefiting us. This section also contains a discussion of some
        Israeli tax consequences to persons owning our ordinary shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types
        of investors subject to special treatment under Israeli law. Examples of this kind of investor include traders in securities or persons that own, directly or indirectly, 10% or more of our outstanding voting capital, all of whom are subject to
        special tax regimes not covered in this discussion. Some parts of this discussion are based on new tax legislation which has not been subject to judicial or administrative interpretation. The discussion should not be construed as legal or
        professional tax advice and does not cover all possible tax considerations.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">SHAREHOLDERS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS AS TO THE ISRAELI OR OTHER TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES, INCLUDING,
        IN PARTICULAR, THE EFFECT OF ANY FOREIGN, STATE OR LOCAL TAXES.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">General Corporate Tax Structure in Israel</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Israeli resident companies are generally subject to corporate tax at the rate of 23% in 2020. However, the effective tax rate payable by a company that derives income from a
        Benefited Enterprise or a Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli resident company are subject to tax at the prevailing corporate tax rate.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">129</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli tax legislation, a corporation will be considered as an &#8220;Israeli resident company&#8221; if it meets one of the following: (i) it was incorporated in Israel; or (ii) the
        control and management of its business are exercised in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Law for the Encouragement of Industry (Taxes), 5729-1969</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for &#8220;Industrial Companies.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as a company resident in Israel and which was incorporated in Israel of which 90% or more of its income in any tax
        year, other than income from defense loans, is derived from an &#8220;Industrial Enterprise&#8221; owned by it and which is located in Israel. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose principal activity in a given tax year is industrial
        production.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following corporate tax benefits, among others, are available to Industrial Companies:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3df6842d57a2406cb8e5bac9d5edb1a4">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>amortization over an eight-year period of the cost of purchased know-how and patents and rights to use a patent and know-how which are used for the development or advancement of the Industrial Enterprise;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zacbaa4cdc00e4fa1b5d0fc5dd2acf0a0">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze7f225efc4d34cd2b59d64c5708589de">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>expenses related to a public offering are deductible in equal amounts over three years.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Although as of the date of this annual report, we do not have industrial production activities, we may qualify as an Industrial Company in the future and may be eligible for the
        benefits described above.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Tax Benefits and Grants for Research and Development</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Israeli tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which they are incurred. Expenditures are
        deemed related to scientific research and development projects, if:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaaec3826b42d4c50bd37fc52cd20f434">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>The expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z472ed63929994b8a99a4988bf88a4c7f">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>The research and development must be for the promotion of the company; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za351d0f7fe9b4d6ebc706d4bff65bcf2">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>The research and development are carried out by or on behalf of the company seeking such tax deduction.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The amount of such deductible expenses is reduced by the sum of any funds received through government grants for the financing of such scientific research and development
        projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested in an asset depreciable under the general depreciation rules of the Israeli Tax Ordinance, 1961. Expenditures
        not so approved are deductible in equal amounts over three years.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">From time to time we may apply to the IIA for approval to allow a tax deduction for all research and development expenses during the year incurred. There can be no assurance that
        such application will be accepted.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">130</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Law for the Encouragement of Capital Investments, 5719-1959</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in production
        facilities (or other eligible assets) by &#8220;Industrial Enterprises&#8221; (as defined under the Investment Law).</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Tax Benefits Prior to the 2005 Amendment</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">An investment program that is implemented in accordance with the provisions of the Investment Law prior to an amendment that became effective in April 2005, or the 2005
        Amendment, referred to as an &#8220;Approved Enterprise,&#8221; is entitled to certain benefits. A company that wished to receive benefits as an Approved Enterprise must have received approval from the Investment Center of the Israeli Ministry of Economy and
        Industry, or the Investment Center. Each certificate of approval for an Approved Enterprise relates to a specific investment program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical
        characteristics of the facility or the asset.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In general, an Approved Enterprise is entitled to receive a grant from the Government of Israel or an alternative package of tax benefits, known as the alternative benefits
        track. The tax benefits from any certificate of approval relate only to taxable profits attributable to the specific Approved Enterprise. Income derived from activity that is not integral to the activity of the Approved Enterprise does not enjoy
        tax benefits.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, a company that has an Approved Enterprise program is eligible for further tax benefits if it qualifies as a Foreign Investors&#8217; Company, or FIC, which is a company
        with a level of foreign investment, as defined in the Investment Law, of more than 25%. The level of foreign investment is measured as the percentage of rights in the company (in terms of shares, rights to profits, voting and appointment of
        directors), and of combined share and loan capital, that are owned, directly or indirectly, by persons who are not residents of Israel. The determination as to whether a company qualifies as an FIC is made on an annual basis. We are currently not
        entitled to tax benefits for Approved Enterprise.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Tax Benefits Subsequent to the 2005 Amendment</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The 2005 Amendment applies to new investment programs and investment programs commencing after 2004, but does not apply to investment programs approved prior to April&#160;1, 2005.
        The 2005 Amendment provides that terms and benefits included in any certificate of approval that was granted before the 2005 Amendment became effective (April&#160;1, 2005) will remain subject to the provisions of the Investment Law as in effect on the
        date of such approval. Pursuant to the 2005 Amendment, the Investment Center will continue to grant Approved Enterprise status to qualifying investments. The 2005 Amendment, however, limits the scope of enterprises that may be approved by the
        Investment Center by setting criteria for the approval of a facility as an Approved Enterprise, such as provisions generally requiring that at least 25% of the Approved Enterprise&#8217;s income be derived from exports.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The 2005 Amendment provides that Approved Enterprise status will only be necessary for receiving cash grants. As a result, it was no longer necessary for a company to obtain
        Approved Enterprise status in order to receive the tax benefits previously available under the alternative benefits track. Rather, a company may claim the tax benefits offered by the Investment Law directly in its tax returns, provided that its
        facilities meet the criteria for tax benefits set forth in the amendment. Companies are entitled to approach the Israeli Tax Authority for a pre-ruling regarding their eligibility for benefits under the Investment Law, as amended.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In order to receive the tax benefits, the 2005 Amendment states that a company must make an investment which meets all of the conditions, including exceeding a minimum investment
        amount specified in the Investment Law. Such investment allows a company to receive &#8220;Benefited Enterprise&#8221; status, and may be made over a period of no more than three years from the end of the year in which the company requested to have the tax
        benefits apply to its Benefited Enterprise. Where the company requests to apply the tax benefits to an expansion of existing facilities, only the expansion will be considered to be a Benefited Enterprise and the company&#8217;s effective tax rate will be
        the weighted average of the applicable rates. In this case, the minimum investment required in order to qualify as a Benefited Enterprise is required to exceed a certain percentage of the value of the company&#8217;s production assets before the
        expansion.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">131</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The extent of the tax benefits available under the 2005 Amendment to qualifying income of a Benefited Enterprise depend on, among other things, the geographic location in Israel
        of the Benefited Enterprise. The location will also determine the period for which tax benefits are available. Such tax benefits include an exemption from corporate tax on undistributed income for a period of between two to 10 years, depending on
        the geographic location of the Benefited Enterprise in Israel, and a reduced corporate tax rate of between 10% and the applicable corporate tax for the remainder of the benefits period, depending on the level of foreign investment in the company in
        each year. A company qualifying for tax benefits under the 2005 Amendment which pays a dividend out of income derived by its Benefited Enterprise during the tax exemption period will be subject to corporate tax in respect of the gross amount of the
        dividend at the otherwise applicable corporate tax rate or a lower rate in the case of a qualified FIC which is at least 49% owned by non-Israeli residents. Dividends paid out of income attributed to a Benefited Enterprise are generally subject to
        withholding tax at source at the rate of 20% or such lower rate as may be provided in an applicable tax treaty.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">The benefits available to a Benefited Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations. If a company does not meet these conditions, it may
        be required to refund the amount of tax benefits, as adjusted by the Israeli consumer price index, and interest, or other monetary penalties.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We applied for tax benefits as a &#8220;Benefited Enterprise&#8221; with 2012 as a &#8220;Year of Election.&#8221; We may be entitled to tax benefits under this regime once we are profitable for tax
        purposes and subject to the fulfillment of all the relevant conditions. If we do not meet these conditions, the tax benefits may not be applicable which would result in adverse tax consequences to us. Alternatively, and subject to the fulfillment
        of all the relevant conditions, we may elect in the future to irrevocably waive the tax benefits available for Benefited Enterprise and claim the tax benefits available to Preferred Enterprise under the 2011 Amendment (as detailed below).</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Tax Benefits Under the 2011 Amendment</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Investment Law was significantly amended as of January&#160;1, 2011, or the 2011 Amendment. The 2011 Amendment introduced new benefits to replace those granted in accordance with
        the provisions of the Investment Law in effect prior to the 2011 Amendment.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The 2011 Amendment introduced new tax benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise,&#8221; in accordance with the definition of such term in
        the Investment Law, which generally means that a &#8220;Preferred Company&#8221; is an industrial company meeting certain conditions (including a minimum threshold of 25% export).</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A Preferred Company is entitled to a reduced flat tax rate with respect to the income attributed to the Preferred Enterprise, at the following rates:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z787f946395f442a19a015e6ac63d71d9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Tax Year</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
              <div style="line-height: 1.25; font-weight: bold;">Development Region &#8220;A&#8221;</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
              <div style="line-height: 1.25; font-weight: bold;">Other Areas within Israel</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 76%;">
              <div style="line-height: 1.25;">2011 &#8211; 2012&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
              </div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">10</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">15</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; width: 76%;">
              <div style="text-align: justify; line-height: 1.25;">2013&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
              </div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">7</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">12.5</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 76%;">
              <div style="text-align: justify; line-height: 1.25;">2014&#8201;&#8211;&#8201;2016&#160;&#160;&#160;&#160;&#160;&#160; <br>
              </div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">9</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">16</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; width: 76%;">
              <div style="line-height: 1.25;">2017 and thereafter&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">7.5</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">16</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">
              <div style="line-height: 1.25;">%</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Dividends distributed from income which is attributed to a &#8220;Preferred Enterprise&#8221; will be subject to withholding tax at source at the following rates: (i) Israeli resident
        corporations &#8212; 0%, (ii) Israeli resident individuals &#8212; 20% in 2020 (iii) non-Israeli residents &#8212; may be reduced down to 4% in 2020, subject to certain conditions under the Investment Law and to a reduced tax rate under the provisions of an
        applicable double tax treaty.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">132</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the 2011 Amendment, a company located in Development Region &#8220;A&#8221; may be entitled to cash grants and the provision of loans under certain conditions, if approved. The rates
        for grants and loans shall not be fixed, but up to 20% of the amount of the approved investment (may be increased by an additional 4%). In addition, a company owning a Preferred Enterprise under the Grant Track may be entitled also to the tax
        benefits which are prescribed for a Preferred Company.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The termination or substantial reduction of any of the benefits available under the Investment Law could materially increase our tax liabilities.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">We are currently not entitled to tax benefits for a Preferred Enterprise.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">Taxation of Our Shareholders</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Capital Gains</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Capital gain tax is imposed on the disposition of capital assets by an Israeli resident, and on the disposition of such assets by a non-Israeli resident if those assets are
        either (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly or indirectly, rights to assets located in Israel. The Israeli Tax Ordinance distinguishes between &#8220;Real Gain&#8221; and
        the &#8220;Inflationary Surplus.&#8221; Real Gain is the excess of the total capital gain over Inflationary Surplus computed generally on the basis of the increase in the Israeli consumer price index between the date of purchase and the date of disposition.
        Inflationary Surplus is not currently subject to tax in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Real Gain accrued by individuals on the sale of our ordinary shares will be taxed at the rate of 25%. However, if the individual shareholder is a &#8220;Controlling Shareholder&#8221; (i.e.,
        a person who holds, directly or indirectly, alone or together with another, 10% or more of one of the Israeli resident company&#8217;s means of control) at the time of sale or at any time during the preceding 12-month period, such gain will be taxed at
        the rate of 30%.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Real Gain derived by corporations will be generally subject to the corporate tax rate of 23% in 2020.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Individual and corporate shareholder dealing in securities in Israel are taxed at the tax rates applicable to business income &#8212;23% for corporations in 2020, and a marginal tax
        rate of up to 50% for individuals, including an excess tax.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Notwithstanding the foregoing, capital gain derived from the sale of our ordinary shares by a non-Israeli shareholder may be exempt under the Israeli Tax Ordinance from Israeli
        capital gain tax provided that the seller does not have a permanent establishment in Israel to which the derived capital gain is attributed. However, non-Israeli corporations will not be entitled to the foregoing exemption if more than 25% of its
        means of control are held, directly and indirectly, by Israeli residents, and Israeli residents are entitled to 25% or more of the revenues or profits of the corporation, directly or indirectly. In addition, such exemption would not be available to
        a person whose gains from selling or otherwise disposing of the securities are deemed to be business income.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, the sale of shares may be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty. For example, the U.S.-Israel Double Tax Treaty
        exempts U.S. residents from Israeli capital gain tax in connection with such sale, provided (i) the U.S. resident owned, directly or indirectly, less than 10% of an Israeli resident company&#8217;s voting power at any time within the 12-month period
        preceding such sale; (ii) the seller, being an individual, is present in Israel for a period or periods of less than 183 days during the taxable year; and (iii) the capital gain from the sale was not derived through a permanent establishment of the
        U.S. resident in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In some instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the withholding of
        Israeli tax at source at a rate of 25% if the seller is an individual and at the corporate tax rate (23% in 2020) if the seller is a corporation. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in
        order to avoid withholding at source at the time of sale.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">133</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At the sale of securities traded on a stock exchange a detailed return, including a computation of the tax due, must be filed and an advanced payment must be paid on January&#160;31
        and July 31 of every tax year in respect of sales of securities made within the previous six months. However, if all tax due was withheld at source according to applicable provisions of the Israeli Tax Ordinance and regulations promulgated
        thereunder, the aforementioned return need not be filed and no advance payment must be paid. Capital gain is also reportable on the annual income tax return.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Dividends</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have never paid cash dividends. A distribution of a dividend by our company from income attributed to a Benefited Enterprise will generally be subject to withholding tax in
        Israel at a rate of 20% unless a reduced tax rate is provided under an applicable tax treaty. A distribution of a dividend by our company from income attributed to a Preferred Enterprise will generally be subject to withholding tax in Israel at the
        following tax rates: Israeli resident individuals &#8212; 20%; Israeli resident companies &#8212; 0% for a Preferred Enterprise; Non-Israeli residents &#8212; 20%, subject to a reduced rate under the provisions of any applicable double tax treaty. A distribution of
        dividends from income, which is not attributed to a Preferred Enterprise to an Israeli resident individual, will generally be subject to withholding tax at a rate of 25%, or 30% if the dividend recipient is a &#8220;Controlling Shareholder&#8221; (as defined
        above) at the time of distribution or at any time during the preceding 12-month period. If the recipient of the dividend is an Israeli resident corporation, such dividend will not be subject to Israeli tax provided the income from which such
        dividend is distributed was derived or accrued within Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Israeli Tax Ordinance provides that a non-Israeli resident (either individual or corporation) is generally subject to Israeli withholding tax on the receipt of dividends at
        the rate of 25% (30% if the dividends recipient is a &#8220;Controlling Shareholder&#8221; (as defined above), at the time of distribution or at any time during the preceding 12-month period); those rates may be subject to a reduced rate under the provisions
        of an applicable double tax treaty. Under the U.S.-Israel Double Tax Treaty, the following withholding rates will apply in respect of dividends distributed by an Israeli resident company to a U.S. resident: (i) if the U.S. resident is a corporation
        which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding shares of the voting share capital of the Israeli
        resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain type of interest or dividends &#8212; the rate is 12.5%, (ii) if both the conditions
        mentioned in clause (i) above are met and the dividend is paid from an Israeli resident company&#8217;s income which was entitled to a reduced tax rate applicable to an Approved Enterprise &#8212; the rate is 15% and (iii)&#160;in all other cases, the rate is 25%.
        The aforementioned rates under the Israel U.S. Double Tax Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A non-Israeli resident who receives dividends from which tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to such income,
        provided that (i) such income was not generated from a business conducted in Israel by the taxpayer, and (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Dividends are generally subject to Israeli withholding tax at a rate of 25% so long as the shares are registered with a nominee company (whether or not the recipient is a
        &#8220;Controlling Shareholder,&#8221; as defined above), unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence and provided that a certificate from the Israel Tax Authority allowing for a reduced withholding tax rate
        is obtained in advance.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Excess Tax</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Individuals who are subject to tax in Israel are also subject to an additional tax at a rate of 3% on annual income exceeding NIS 651,600 for 2020, linked to the annual change in
        the Israeli consumer price index, including, but not limited to income derived from, dividends, interest and capital gains.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">134</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Foreign Exchange Regulations</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Non-residents of Israel who hold our ordinary shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up of our affairs,
        repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income tax is generally required to have been paid or withheld on these amounts. In addition, the statutory framework for the potential
        imposition of currency exchange control has not been eliminated and may be restored at any time by administrative action.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Estate and Gift Tax</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Israeli law presently does not impose estate or gift taxes.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">U.S. Federal Income Tax Considerations with respect to the Company</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 10.2pt; margin-left: 5.45pt; line-height: 1.25;">The following discussion describes certain material U.S. federal income tax consequences to U.S. Holders (as defined below) under
        present law of an investment in our ordinary shares or warrants. This discussion applies only to U.S. Holders that hold our ordinary shares or warrants as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as
        amended, or (the Code, and that have the U.S. dollar as their functional currency.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 4.35pt; margin-left: 5.45pt; line-height: 1.25;">This discussion is based on the tax laws of the United States, including the Code, as in effect on the date hereof and on U.S. Treasury
        regulations as in effect or, in some cases, as proposed, on the date hereof, as well as judicial and administrative interpretations thereof available on or before such date. All of the foregoing authorities are subject to change, which change could
        apply retroactively and could affect the tax consequences described below. This summary does not address any estate or gift tax consequences, the alternative minimum tax, the Medicare tax on net investment income or any state, local, or non-U.S.
        tax consequences. The following discussion neither deals with the tax consequences to any particular investor nor describes all of the tax consequences applicable to persons in special tax situations such as:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0c6447e365e645f184811521e8b81954">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>banks;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zca90a13ac3c8411db19d90e94368431f">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>certain financial institutions;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze3499cf7d4db4e8c9706938295399ce1">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>insurance companies;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z265ba2f529724db982aed42493d3199d">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>regulated investment companies;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb7adf43837df454ba87fbecf308bb76c">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>real estate investment trusts;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z176bc4e17e8848a3892ea60f7b0d8007">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>broker-dealers;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd8df535cfbce4c50bc270d7fce30fa91">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>traders that elect to mark to market;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z75fe5247625f46fe9373e3420e02492f">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>U.S. expatriates;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6c9d575104704963b5dfd8a85e248ec2">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>tax-exempt entities;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5d729659c60f4d338a0108f75b44605a">

          <tr>
            <td style="width: 23.55pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>persons holding our ordinary shares or warrants as part of a straddle, hedging, constructive sale, conversion or integrated transaction;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zec9b02d429f54ba3a4312aefa5ee1377">

          <tr>
            <td style="width: 23.5pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>persons that actually or constructively (including through the ownership of our warrants) own 10% or more of our share capital (by vote or value);</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3d420e6063ea4560b7215682763e88fc">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>persons that are resident or ordinarily resident in or have a permanent establishment in a jurisdiction outside the United States;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z55b048e10e444b229828bdd1e295c73b">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>persons who acquired our ordinary shares or warrants pursuant to the exercise of any employee share option or otherwise as compensation;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">135</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3aa36b75b2834c62bed14a828ef7309f">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>persons subject to special tax accounting rules as a result of any item of gross income with respect to our ordinary shares or warrants being taken into account in an applicable financial statement; or</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8540685657684314a7d4c0f2b439f332">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>pass-through entities, or persons holding our ordinary shares or warrants through pass-through entities.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.6pt; margin-right: 6.75pt; margin-left: 0.4pt; line-height: 1.25;">INVESTORS ARE URGED TO CONSULT THEIR TAX ADVISORS ABOUT THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR
        CIRCUMSTANCES AS WELL AS THE STATE, LOCAL, NON-U.S. AND OTHER TAX CONSEQUENCES TO THEM OF AN INVESTMENT IN OUR ORDINARY SHARES OR WARRANTS.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 12.35pt; margin-left: 5.5pt; line-height: 1.25;">The discussion below of the U.S. federal income tax consequences to &#8220;U.S. Holders&#8221; will apply to you if you are the beneficial owner of
        our ordinary shares or warrants and you are, for U.S. federal income tax purposes,</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1ae6f71ab21e4e38b2423fe98b6921fd">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>an individual who is a citizen or resident of the United States;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z69d3ad474f304f9a8c2cca122837fa37">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in the United States or under the laws of the United States, any state thereof or the District of Columbia;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf5c296a86f694e1e865a0295fce9da3a">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z69cd4150f3ba4baf9a623888829e83da">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>a trust that (i) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (ii) has a valid election in effect under applicable U.S. Treasury
                regulations to be treated as a U.S. person.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 10.65pt; margin-left: 5.45pt; line-height: 1.25;">If an entity or other arrangement treated as a partnership for U.S. federal income tax purposes holds our ordinary shares or warrants,
        the tax treatment of a partner will generally depend upon the status of the partner and the activities of the partnership. A person that would be a U.S. Holder if it held our ordinary shares or warrants directly and that is a partner of a
        partnership holding our ordinary shares or warrants is urged to consult its own tax advisor.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; margin-left: 5.45pt; line-height: 1.25; font-style: italic; font-weight: bold;">Passive Foreign Investment Company</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 24.4pt; margin-left: 5.45pt; line-height: 1.25;">A non-U.S. entity treated as a corporation for U.S. federal income tax purposes will generally be a passive foreign investment company
        (&#8220;PFIC&#8221;) for U.S. federal income tax purposes for any taxable year if either:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd37c01e32a4c4c828bab24bdc744c016">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>at least 75% of its gross income for such year is passive income (such as interest income); or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z14ce0021779c41d683a17fc9d937e056">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>at least 50% of the value of its assets (based on an average of the quarterly values of the assets) during such year is attributable to assets that produce passive income or are held for the production of passive income.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 19.75pt; margin-left: 5.45pt; line-height: 1.25;">For this purpose, we will be treated as owning our proportionate share of the assets and earning our proportionate share of the income
        of any other entity treated as a corporation for U.S. federal income tax purposes in which we own, directly or indirectly, 25% or more (by value) of the stock.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 5.4pt; margin-left: 5.45pt; line-height: 1.25;">Starting in the first quarter of 2019, we began generating revenue under a collaboration agreement with Perrigo for the development of
        the generic version of Zovirax&#174; (acyclovir) cream, 5%. We generated $8.7 in revenue under such agreement for our 2020 taxable year, but expect to generate substantially less in future years.&#160; Though the application of the relevant rules governing
        the characterization of such revenue for purposes of the PFIC income test is uncertain, we intend to take the position that, based on our involvement and management contributions throughout the development process, such revenue is non-passive for
        PFIC purposes. As a result, assuming we continue to earn substantial revenue from such agreement as anticipated and based on the current and anticipated value and composition of our income and assets, we do not expect that we will be treated as a
        PFIC for U.S. federal income tax purposes for our current taxable year or for foreseeable future years. However, there are substantial factual and legal ambiguities regarding the nature of the revenue and the application of the relevant PFIC rules,
        and thus, the determination that such revenue is non-passive is not without doubt, and alternative characterizations are possible.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">136</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 9.65pt; margin-left: 5.5pt; line-height: 1.25;">A separate determination must be made after the close of each taxable year as to whether we were a PFIC for that year. Because the value
        of our assets for purposes of the PFIC test will generally be determined by reference to the market price of our ordinary shares, our PFIC status may depend in part on the market price of our ordinary shares, which may fluctuate significantly. In
        addition, there may be certain other ambiguities in applying the PFIC test to us. No rulings from the U.S. Internal Revenue Service, or the IRS, however, have been or will be sought with respect to our status as a PFIC. If the IRS were to assert
        that, contrary to our expectation, we are a PFIC in the current taxable year or a future year, there would be adverse tax consequences to investors, including those described below. Potential investors are strongly advised to consult their own
        advisors regarding the consequences to them if we were to be considered a PFIC.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 19.2pt; margin-left: 5.5pt; line-height: 1.25;">If we are a PFIC for any taxable year during your holding period for our ordinary shares (or under proposed Regulations, our warrants),
        we generally will continue to be treated as a PFIC with respect to your investment in our ordinary shares or warrants for all succeeding years during which you hold our ordinary shares or warrants, and, although subject to uncertainty, potentially
        our ordinary shares received upon exercise of such warrants. Certain elections (such as a deemed sale election) may be available under certain circumstances.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 10.35pt; margin-left: 5.5pt; line-height: 1.25;">For each taxable year that we are treated as a PFIC with respect to you, you will be subject to special tax rules with respect to any
        &#8220;excess distribution&#8221; (as defined below) you receive and any gain you realize from a sale or other disposition (including a pledge) of our ordinary shares or warrants, unless you make a valid &#8220;mark-to-market&#8221; election as discussed below, which may
        not be available for the warrants. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable years or your holding period will be
        treated as an excess distribution. Under these special tax rules:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z338b34f93c5b4a1ab47643711b08665b">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the excess distribution or gain will be allocated ratably over your holding period;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1feec4ed68664dee96479bcbdb8571a6">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the amount allocated to the current taxable year, and any taxable years in your holding period prior to the first taxable year in which we were a PFIC, will be treated as ordinary income; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9ace7874625140e5bc6c972f5597c997">

          <tr>
            <td style="width: 23.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 17.9pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the amount allocated to each other taxable year will be subject to the highest tax rate in effect for individuals or corporations, as applicable, for each such year and the interest charge generally applicable to underpayments&#160; of tax
                will be imposed on the resulting tax attributable to each such year.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 9.65pt; margin-left: 5.5pt; line-height: 1.25;">The tax liability for amounts allocated to taxable years prior to the year of disposition or excess distribution cannot be offset by
        any net operating losses, and gains (but not losses) realized on the sale of our ordinary shares or warrants cannot be treated as capital gains, even if you hold our ordinary shares or warrants as capital assets.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 7.4pt; margin-left: 5.45pt; line-height: 1.25;">If we are treated as a PFIC with respect to you for any taxable year, to the extent any of our subsidiaries are also PFICs, you may
        be deemed to own a proportionate interest in such lower-tier PFICs that are directly or indirectly owned by us, and you may be subject to the adverse tax consequences described above with respect to the shares of such lower-tier PFICs you would be
        deemed to own. As a result, you may incur liability for any excess distribution described above if we receive a distribution from our lower-tier PFICs or if any shares in such lower-tier PFICs are disposed of (or deemed disposed of). You should
        consult your tax advisor regarding the application of the PFIC rules to any of our subsidiaries.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 7.4pt; margin-left: 5.45pt; line-height: 1.25;">A U.S. Holder of &#8220;marketable stock&#8221; (as defined below) in a PFIC may make a mark-to-market election for such stock to elect out of
        the tax treatment discussed above. If you make a valid mark-to-market election for our ordinary shares, you will include in income for each year that we are treated as a PFIC with respect to you an amount equal to the excess, if any, of the fair
        market value of our ordinary shares as of the close of your taxable year over your adjusted basis in such ordinary shares. You will be allowed a deduction for the excess, if any, of the adjusted basis of our ordinary shares over their fair market
        value as of the close of the taxable year. However, deductions will be allowable only to the extent of any net mark-to-market gains on our ordinary shares included in your income for prior taxable years. Amounts included in your income under a
        mark-to-market election, as well as gain on the actual sale or other disposition of our ordinary shares, will be treated as ordinary income. Ordinary loss treatment will also apply to the deductible portion of any mark-to-market loss on our
        ordinary shares, as well as to any loss realized on the actual sale or disposition of our ordinary shares, to the extent the amount of such loss does not exceed the net mark-to-market gains for such ordinary shares previously included in income.
        Your basis in our ordinary shares will be adjusted to reflect any such income or loss amounts. If you make a mark-to-market election, any distributions we make would generally be subject to the rules discussed below under &#8220;&#8212; Taxation of Dividends
        and Other Distributions on our Ordinary Shares,&#8221; except the lower rates applicable to qualified dividend income would not apply.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">137</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 4.3pt; margin-left: 5.45pt; line-height: 1.25;">The mark-to-market election is available only for &#8220;marketable stock,&#8221; which is stock that is regularly traded on a qualified exchange
        or other market, as defined in applicable U.S. Treasury regulations, and may not include our warrants. Our ordinary shares are listed on the Nasdaq Global Market. Because a mark-to-market election cannot be made for equity interests in any
        lower-tier PFICs we own, you generally will continue to be subject to the PFIC rules with respect to your indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. The
        Nasdaq Global Market is a qualified exchange, but there can be no assurance that the trading in our ordinary shares will be sufficiently regular to qualify our ordinary shares as marketable stock. You should consult your tax advisor as to the
        availability and desirability of a mark-to-market election, as well as the impact of such election on interests in any lower-tier PFICs. </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 6.6pt; margin-left: 5.45pt; line-height: 1.25;">Alternatively, if a non-U.S. entity treated as a corporation is a PFIC, a holder of shares in that entity may avoid taxation under
        the PFIC rules described above regarding excess distributions and recognized gains by making a &#8220;qualified electing fund&#8221; election to include in income its share of the entity&#8217;s income on a current basis. However, you may make a qualified electing
        fund election with respect to your ordinary shares only if we furnish you annually with certain tax information, and we currently do not intend to prepare or provide such information. A qualified electing fund election may not be available for our
        warrants regardless of whether we provide such information.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 7.65pt; margin-left: 5.45pt; line-height: 1.25;">A U.S. Holder of a PFIC may be required to file an IRS Form 8621. If we are a PFIC, you should consult your tax advisor regarding
        any reporting requirements that may apply to you. You are urged to consult your tax advisor regarding the application of the PFIC rules to an investment in ordinary shares or warrants.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 5.5pt; margin-left: 5.45pt; line-height: 1.25;">YOU ARE STRONGLY URGED TO CONSULT YOUR TAX ADVISOR REGARDING THE IMPACT ON YOUR INVESTMENT IN OUR ORDINARY SHARES OR WARRANTS IF WE
        WERE TO BE CONSIDERED A PFIC AS WELL AS THE APPLICATION OF THE PFIC RULES AND THE POSSIBILITY OF MAKING A MARK-TO-MARKET ELECTION.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; margin-left: 5.45pt; line-height: 1.25; font-style: italic; font-weight: bold;">Taxation of Dividends and Other Distributions on our Ordinary Shares</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 7.25pt; margin-left: 5.45pt; line-height: 1.25;">Subject to the PFIC rules discussed above, the gross amount of any distributions we make to you (including the amount of any tax
        withheld) with respect to our ordinary shares generally will be includible in your gross income as dividend income on the date of receipt by the holder, but only to the extent the distribution is paid out of our current or accumulated earnings and
        profits (as determined under U.S. federal income tax principles). The dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations. To the extent the
        amount of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles), such excess amount will be treated first as a tax-free return of your tax basis in your ordinary shares,
        and then, to the extent such excess amount exceeds your tax basis in your ordinary shares, as capital gain. We currently do not, and we do not intend to, calculate our earnings and profits under U.S. federal income tax principles. Therefore, you
        should expect that a distribution will generally be reported as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 6.55pt; margin-left: 5.5pt; line-height: 1.25;">With respect to certain non-corporate U.S. Holders, including individual U.S. Holders, dividends may be taxed at the lower capital gain
        rates applicable to &#8220;qualified dividend income,&#8221; provided (i) our ordinary shares are readily tradable on an established securities market in the United States (such as the Nasdaq Global Market), (ii) we are neither a PFIC nor treated as such with
        respect to you (as discussed above) for either the taxable year in which the dividend was paid or the preceding taxable year, (iii) certain holding period requirements are met and (iv) you are not under an obligation to make related payments with
        respect to positions in substantially similar or related property.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">138</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 8.45pt; margin-left: 5.5pt; line-height: 1.25;">The amount of any distribution paid in a currency other than U.S. dollars will be equal to the U.S. dollar value of such currency on the
        date such distribution is includible in your income, regardless of whether the payment is in fact converted into U.S. dollars at that time. The amount of any distribution of property other than cash will be the fair market value of such property on
        the date of distribution.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 4.25pt; margin-left: 5.5pt; line-height: 1.25;">Any dividends will constitute foreign source income for foreign tax credit limitation purposes. If the dividends are taxed as qualified
        dividend income (as discussed above), the amount of the dividend taken into account for purposes of calculating the foreign tax credit limitation will in general be limited to the gross amount of the dividend, multiplied by the reduced tax rate
        applicable to qualified dividend income and divided by the highest tax rate normally applicable to dividends. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose,
        dividends distributed by us with respect to our ordinary shares will generally constitute &#8220;passive category income.&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 5.95pt; margin-left: 5.5pt; line-height: 1.25;">If Israeli withholding taxes apply to any dividends paid to you with respect to our ordinary shares, subject to certain conditions and
        limitations, such withholding taxes may be treated as foreign taxes eligible for credit against your U.S. federal income tax liability. Instead of claiming a credit, you may elect to deduct such taxes in computing taxable income, subject to
        applicable limitations. If a refund of the tax withheld is available under the applicable laws of Israel or under the Israel-U.S. income tax treaty, or the Treaty, the amount of tax withheld that is refundable will not be eligible for such credit
        against your U.S. federal income tax liability (and will not be eligible for the deduction against your U.S. federal taxable income). The rules relating to the determination of the foreign tax credit are complex, and you should consult your tax
        advisor regarding the availability of a foreign tax credit in your particular circumstances, including the effects of the Treaty.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Constructive Dividends on our Ordinary Shares or Warrants</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 6.95pt; margin-left: 5.5pt; line-height: 1.25;">If the exercise price of our warrants is adjusted in certain circumstances (or in certain circumstances, there is a failure to make
        adjustments or a failure to make adequate adjustments), that adjustment (or failure to adjust) may result in the deemed payment of a taxable dividend to a U.S. Holder of the warrants or our ordinary shares. Any such constructive dividend will be
        taxable generally as described above under &#8220;Taxation of Dividends and Other Distributions on our Ordinary Shares.&#8221; Generally, a U.S. Holder&#8217;s tax basis in our ordinary shares or the warrants will be increased to the extent of any such constructive
        dividend. It is not entirely clear whether a constructive dividend deemed paid to a non-corporate U.S. Holder could be &#8220;qualified dividend income&#8221; as discussed above under &#8220;Taxation of Dividends and Other Distributions on our Ordinary Shares.&#8221; U.S.
        Holders should consult their tax advisers regarding the proper U.S. federal income tax treatment of any adjustments to (or failure to adjust or adjust adequately) the exercise price of the warrants.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 5.2pt; margin-left: 5.5pt; line-height: 1.25;">We are currently required to report the amount of any constructive dividends on our website or to the IRS and to holders not exempt from
        reporting. The IRS has proposed regulations addressing the amount and timing of constructive dividends, as well as, obligations of withholding agents and filing and notice obligations of issuers in respect of such constructive dividends. If adopted
        as proposed, the regulations would generally provide that (i) the amount of a constructive dividend is the excess of the fair market value of the right to acquire stock immediately after the exercise price adjustment over the fair market value of
        the right to acquire stock (after the exercise price adjustment) without the adjustment, (ii) the constructive dividend occurs at the earlier of the date the adjustment occurs under the terms of the instrument and the date of the actual
        distribution of cash or property that results in the constructive dividend and (iii) we are required to report the amount of any constructive dividends on our website or to the IRS and to all holders (including holders that would otherwise be
        exempt from reporting). The final regulations will be effective for constructive dividends occurring on or after the date of adoption, but holders and withholding agents may rely on them prior to that date under certain circumstances.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">139</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 5.45pt; line-height: 1.25; font-style: italic; font-weight: bold;">Taxation of Disposition of our Ordinary Shares or Warrants</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 6.2pt; margin-left: 5.45pt; line-height: 1.25;">Subject to the PFIC rules discussed above, upon a sale or other disposition of our ordinary shares or warrants, you will generally
        recognize capital gain or loss for U.S. federal income tax purposes in an amount equal to the difference between the amount realized (including the amount of any tax withheld) and your tax basis in such ordinary shares or warrants. If the
        consideration you receive for our ordinary shares or warrants is not paid in U.S. dollars, the amount realized will be the U.S. dollar value of the payment received determined by reference to the spot rate of exchange on the date of the sale or
        other disposition. However, if our ordinary shares or warrants are treated as traded on an &#8220;established securities market&#8221; and you are either a cash basis taxpayer or an accrual basis taxpayer that has made a special election (which must be applied
        consistently from year to year and cannot be changed without the consent of the IRS), you will determine the U.S. dollar value of the amount realized in a non-U.S. dollar currency by translating the amount received at the spot rate of exchange on
        the settlement date of the sale. If you are an accrual basis taxpayer that is not eligible to or does not elect to determine the amount realized using the spot rate on the settlement date, you will recognize foreign currency gain or loss to the
        extent of any difference between the U.S. dollar amount realized on the date of sale or disposition and the U.S. dollar value of the currency received at the spot rate on the settlement date.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 30pt; margin-right: 5.7pt; margin-left: 5.5pt; line-height: 1.25;">Any gain or loss on the sale or other disposition of our ordinary shares or warrants will generally be treated as U.S. source income or
        loss and treated as long-term capital gain or loss if your holding period in our ordinary shares or warrants at the time of the disposition exceeds one year. Accordingly, in the event any Israeli tax (including withholding tax) is imposed upon the
        sale or other disposition, you may not be able to utilize foreign tax credit unless you have foreign source income or gain in the same category from other sources. Long-term capital gain of non-corporate U.S. Holders generally will be subject to
        U.S. federal income tax at reduced tax rates. The deductibility of capital losses is subject to significant limitations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; margin-left: 5.5pt; line-height: 1.25; font-style: italic; font-weight: bold;">Taxation of Exercise or Expiration of our Warrants</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 6.15pt; margin-left: 5.5pt; line-height: 1.25;">In general, you will not be required to recognize income, gain or loss upon exercise of our warrants by payment of the exercise
        price. Your tax basis in our ordinary shares received upon exercise of our warrants will be equal to the sum of (1) your tax basis in the warrants exchanged therefor and (2) the exercise price of the warrants. Your holding period in our ordinary
        shares received upon exercise will commence on the day after you exercise the warrants.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 9.2pt; margin-left: 5.5pt; line-height: 1.25;">If the warrants expire without being exercised, you will recognize a capital loss in an amount equal to your tax basis in the
        warrants. Such loss will be long-term capital loss if, at the time of the expiration, your holding period in the warrants is more than one year. The deductibility of capital losses is subject to limitations.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; margin-left: 5.5pt; line-height: 1.25; font-style: italic; font-weight: bold;">Information Reporting and Backup Withholding</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 5.4pt; margin-left: 5.5pt; line-height: 1.25;">Dividend payments (including constructive dividends) with respect to our ordinary shares or warrants and proceeds from the sale,
        exchange or redemption of our ordinary shares or warrants may be subject to information reporting to the IRS and possible U.S. backup withholding. Backup withholding will not apply, however, to a U.S. Holder that furnishes a correct taxpayer
        identification number and makes any other required certification or that is otherwise exempt from backup withholding. U.S. Holders that are required to establish their exempt status generally must provide such certification on IRS Form W-9. You
        should consult your tax advisor regarding the application of the U.S. information reporting and backup withholding rules.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 6.1pt; margin-left: 5.5pt; line-height: 1.25;">Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal income
        tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the IRS and furnishing any required information in a timely manner.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; margin-left: 5.5pt; line-height: 1.25; font-style: italic; font-weight: bold;">Information with respect to Foreign Financial Assets</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 0.95pt; margin-left: 5.5pt; line-height: 1.25;">Certain U.S. Holders may be required to report information relating to an interest in our ordinary shares or warrants, subject to
        certain exceptions (including an exception for ordinary shares held in accounts maintained by certain financial institutions). Penalties can apply if U.S. Holders fail to satisfy such reporting requirements. You should consult your tax advisor
        regarding the effect, if any, of this requirement on your ownership and disposition of our ordinary shares.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 29.95pt; margin-right: 18.8pt; margin-left: 5.5pt; line-height: 1.25;">THE SUMMARY OF U.S. FEDERAL INCOME TAX CONSEQUENCES SET OUT ABOVE IS FOR GENERAL INFORMATIONAL PURPOSES ONLY. INVESTORS ARE URGED TO
        CONSULT THEIR TAX ADVISORS ABOUT THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE STATE, LOCAL, NON-U.S. AND OTHER TAX CONSEQUENCES TO THEM OF AN INVESTMENT IN OUR ORDINARY SHARES OR WARRANTS.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">140</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">F.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; Dividends and Paying Agents</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">G.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; Statement by Experts</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">H.&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; Documents on Display</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are subject to the information reporting requirements of the Exchange Act, applicable to foreign private issuers, and under those requirements, we file reports with the SEC.
        Our filings with the SEC are available to the public through the SEC&#8217;s website at <font style="font-style: italic;"><u>http://www.sec.gov</u></font>.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a foreign private issuer, we are exempt from the rules under the Exchange Act, related to the furnishing and content of proxy statements, and our officers, directors and
        principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act, to file annual, quarterly and current reports and
        financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we are required to comply with the informational requirements of the Exchange Act, and, accordingly,
        file current reports on Form 6-K, annual reports on Form 20-F and other information with the SEC.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">I.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160;&#160; <font style="font-weight: bold;">Subsidiary Information</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><a name="ITEM11"><!--Anchor--></a>ITEM 11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in
        financial market prices and rates. Our market risk exposure is primarily a result of foreign currency exchange rates, which is discussed in detail below.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Interest Rate Risk</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We do not anticipate undertaking any significant long-term borrowings.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At present, our investments consist primarily of marketable securities and bank deposits. We may be exposed to market price risk because of investments in tradable securities,
        mainly corporate bonds, held by us and classified in our financial statements as financial assets at fair value through profit or loss. To manage the price risk arising from investments in tradable securities, we invest in marketable securities
        with high ratings and diversify our investment portfolio. Our investments may also be exposed to market risk due to fluctuation in interest rates, which may affect our interest income and the fair market value of our investments, if any.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">141</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Foreign Currency Exchange Risk</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The U.S. dollar is our functional and reporting currency. Although a substantial portion of our expenses (mainly salaries and related costs) are denominated in NIS, accounting
        for almost half of our expenses in the year ended December&#160;31, 2020, all of our financing has been in U.S. dollars and the vast majority of our liquid assets are held in U.S. dollars.&#160; Furthermore, while we anticipate that a portion of our
        expenses, principally salaries and related personnel expenses in Israel, will continue to be denominated in NIS, we expect to incur an increasing amount of expenses in U.S. dollars as we progress in the development and the regulatory processes of
        our product candidates. Changes of 5% in the U.S. dollar/NIS exchange rate would have increased/decreased operating expenses by approximately 2% during the fiscal year ended on December&#160;31, 2020. We also have expenses, although to a much lesser
        extent, in other non-U.S. dollar currencies, in particular the Euro.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Moreover, for the next few years we expect that the substantial majority of our revenues from the sale of our products in the United States, if any, will be denominated in U.S.
        dollars. Since a portion of our expenses is denominated in NIS and other non-U.S. currencies, we are exposed to risk associated with exchange rate fluctuations vis-&#224;-vis the non-U.S. currencies. See &#8220;Item 3 &#8211; D. Risk Factors&#160;&#8212; Exchange rate
        fluctuations between the U.S. dollar, the New Israeli Shekel and other foreign currencies, may negatively affect our future revenues.&#8221; If the NIS fluctuates significantly against the U.S. dollar it may have a negative impact on our results of
        operations. As of the date of this annual report and for the periods under review, fluctuations in the currencies exchange rates have not materially affected our results of operations or financial condition.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Company carries out transactions involving foreign currency exchange derivative financial instruments. The transactions are designed to hedge the Company&#8217;s exposure in
        currencies other than the U.S. dollar. The derivative does not meet the definition of a cash flow accounting hedge, and therefore the changes in the fair value are included in financial expense (income), net.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Inflation-related risks</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We do not believe that the rate of inflation in Israel has had a material impact on our business to date, however, our costs in Israel will increase if the inflation rate in
        Israel exceeds the devaluation of the NIS against the U.S. dollar or if the timing of such devaluation lags behind inflation in Israel.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">ITEM 12<a name="ITEM12"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt Securities</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">B.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold;">Warrants and Rights</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">C.&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160;&#160; Other Securities</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">D.&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160;&#160; American Depositary Shares</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">ITEM 13<a name="ITEM13"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">ITEM 14<a name="ITEM14"><!--Anchor--></a>.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">MATERIAL
            MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 35.9pt; margin-left: 0.1pt; line-height: 1.25;">All proceeds have been applied from our initial public offering on Nasdaq on February 5, 2018.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">142</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">ITEM 15<a name="ITEM15"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">(a)</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold;"><u>Disclosure Controls and Procedures</u></font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We performed an evaluation of the effectiveness of our disclosure controls and procedures that are designed to ensure that information required to be disclosed and filed with the
        SEC is recorded, processed, summarized and reported timely within the time period specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information
        required to be disclosed by us in the reports that we file or submit under the Exchange Act, is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar
        functions, as appropriate to allow timely decisions regarding required disclosure. There can be no assurance that our disclosure controls and procedures will detect or uncover all failures of persons within the company to disclose information
        otherwise required to be set forth in our reports. Nevertheless, our disclosure controls and procedures are designed to provide reasonable assurance of achieving the desired control objectives. Based on our evaluation, our management, including our
        Chief Executive Officer and Chief Financial Officer, have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this report are effective at
        such reasonable assurance level.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">(b)</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;"><u>Management&#8217;s Annual Report on Internal Control
              over Financial Reporting</u></font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our management, under the supervision of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over
        our financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act of 1934, as amended. The Company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
        financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes policies and procedures that:</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7156ad5364ed456caccf36e1e53d43be">

          <tr>
            <td style="width: 3.58%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.37%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 0.58%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 92.48%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and asset dispositions;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.58%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.37%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 0.58%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 92.48%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">provide reasonable assurance that transactions are recorded as necessary to permit the preparation of our financial statements in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.58%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.37%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 0.58%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 92.48%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">provide reasonable assurance that receipts and expenditures are made only in accordance with authorizations of our management and board of directors (as appropriate); and</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.58%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.37%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 0.58%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 92.48%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial
                statements.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness to
        future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we assessed the effectiveness of our
        internal control over financial reporting as of December 31, 2020 based on the framework for Internal Control-Integrated Framework set forth by The Committee of Sponsoring Organizations of the Treadway Commission (COSO) (2013).</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Based on our assessment and this framework, our management concluded that the Company&#8217;s internal control over financial reporting was effective as of December 31, 2020.&#160;&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">(c)</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Attestation Report of Registered Public
              Accounting Firm</u></font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">143</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">(d)</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Changes in Internal Controls Over Financial
              Reporting</u></font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">There were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2020 that have materially affected or are reasonably
        likely to materially affect our internal control over financial reporting.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">ITEM16<a name="ITEM16"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[RESERVED]</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">ITEM 16A<a name="ITEM16A"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;AUDIT COMMITTEE FINANCIAL EXPERT</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our board of directors has determined that Mr. Jerrold S. Gattegno is an audit committee financial expert. Mr. Gattegno is an independent director for the purposes of the Nasdaq
        Listing Rules.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">ITEM 16B<a name="ITEM16B"><!--Anchor--></a>.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">CODE OF ETHICS</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have adopted a code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing
        similar functions.&#160;&#160;This code of ethics is posted on our website, http://ir.sol-gel.com/corporate-governance/governance-overview.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">144</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">ITEM 16C<a name="ITEM16C"><!--Anchor--></a>.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">PRINCIPAL
            ACCOUNTANT FEES AND SERVICES</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Fees Paid to Independent Registered Public Accounting Firm</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth, for each of the years indicated, the aggregate fees billed by our independent registered public accounting firm for professional services.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z19ef638aa9cf4f28b00768987c47ef66" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
              <div style="line-height: 1.25; font-weight: bold;">Year Ended December 31,</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Services Rendered</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
              <div style="line-height: 1.25; font-weight: bold;">2020</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
              <div style="line-height: 1.25; font-weight: bold;">2019</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;">&#160;</td>
            <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; text-align: center;">
              <div style="line-height: 1.25; font-weight: bold;">(U.S. dollars in thousands)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 76%;">
              <div style="text-align: justify; line-height: 1.25;">Audit Fees (1)</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">187</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;">
              <div style="line-height: 1.25;">164</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman',Times,serif; width: 76%; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25;">Tax (2)</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">29</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">37</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 76%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;Total</div>
            </td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">216</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" colspan="1" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td valign="bottom" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">201</div>
            </td>
            <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z54c1a9a894f9494ea4295edb48b218d0">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Audit Fees consist of professional services rendered in connection with the audit of our consolidated financial statements, review of our consolidated quarterly financial statements, issuance of comfort letters, consents and assistance
                with review of documents filed with the SEC.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc8f6d4f391134995b9c9fc471baef45e">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Tax fees relate to tax compliance, planning and advice.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Audit Committee Pre-Approval Policies and Procedures</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our audit committee&#8217;s specific responsibilities in carrying out its oversight of the quality and integrity of the accounting, auditing and reporting practices of the Company
        include the approval of audit and non-audit services to be provided by the external auditor. The audit committee approves in advance the particular services or categories of services to be provided to the Company during the following yearly period
        and also sets forth a specific budget for such audit and non-audit services. Additional non-audit services may be pre-approved by the audit committee.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">ITEM 16D<a name="ITEM16D"><!--Anchor--></a>.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">EXEMPTIONS FROM
            THE LISTING STANDARDS FOR AUDIT COMMITTEES</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">ITEM 16E<a name="ITEM16E"><!--Anchor--></a>.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">PURCHASES OF
            EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">ITEM 16F<a name="ITEM16F"><!--Anchor--></a>.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">CHANGE IN
            REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">ITEM 16G<a name="ITEM16G"><!--Anchor--></a>.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">CORPORATE
            GOVERNANCE</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Nasdaq Stock Listing</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-weight: bold;">Rules and Home Country Practices</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and
        principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Also, we are not required to comply with Regulation FD, which restricts the selective disclosure of
        material information. However, we intend to file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an
        independent registered public accounting firm, and we intend to submit to the SEC from time to time, on Form 6-K, reports of information that would likely be material to an investment decision in our securities.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">145</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a foreign private issuer, we are permitted to follow certain Israeli corporate governance practices instead of the Nasdaq corporate governance rules, provided that we disclose
        which requirements we are not following and the equivalent Israeli requirement. Pursuant to the &#8220;foreign private issuer exemption&#8221;:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8f20bc375bcf44cdac58adf128b0a0a1">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>the quorum for any meeting of shareholders is two or more shareholders holding at least 33-1&#8725;3% of our voting rights, which complies with Nasdaq requirements; however, if the meeting is adjourned for lack of quorum, the quorum for such
                adjourned meeting will be any number of shareholders, instead of 33-1&#8725;3% of our voting rights;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc8142a9ab64a443f95be2f82fbb74985">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we adopt and approve material changes to equity incentive plans in accordance with the Companies Law, which does not impose a requirement of shareholder approval for such actions. In addition, we intend to follow Israeli corporate
                governance practice in lieu of Nasdaq Marketplace Rule 5635(c), which requires shareholder approval prior to an issuance of securities in connection with equity based compensation of officers, directors, employees or consultants;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z78099da8ba5a402dacdd5e0960dbd2f7">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>as opposed to making periodic reports to shareholders and proxy solicitation materials available to shareholders in the manner specified by the Nasdaq corporate governance rules, the Companies Law does not require us to distribute
                periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. We only mail such reports to
                shareholders upon request; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3047de1d9a9f4a1b9b7f9302c18ccbae">

          <tr>
            <td style="width: 20.25pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>we follow Israeli corporate governance practice instead of Nasdaq requirements to obtain shareholder approval for certain dilutive events (such as issuances that will result in a change of control, certain transactions other than a
                public offering involving issuances of a 20% or greater interest in us and certain acquisitions of the stock or assets of another company).</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Otherwise, we intend to comply with the rules generally applicable to U.S. domestic companies listed on the Nasdaq Global Market. We may in the future decide to use the foreign
        private issuer exemption with respect to some or all of the other Nasdaq corporate governance rules. We also intend to comply with Israeli corporate governance requirements under the Companies Law applicable to public companies.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Controlled Company</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">As a result of the number of shares owned by Arkin Dermatology, as of the date of this annual report, we are a &#8220;controlled company&#8221; under the Nasdaq corporate governance rules. A
        &#8220;controlled company&#8221; is a company of which more than 50% of the voting power is held by an individual, group or another company. Pursuant to the &#8220;controlled company&#8221; exemption, we are not required to, and may not in the future comply with the
        requirement that a majority of our board of directors consist of independent directors, and we are not required to, and do not intend to comply with the requirement that we have a nominating committee composed entirely of independent directors with
        a written charter addressing such committee&#8217;s purpose and responsibilities. A majority of our board of directors currently consists of independent directors.<u>&#160;</u>See &#8220;Item 6. Directors, Senior Management and Employees &#8212; C. Board Practices."</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">ITEM 16H<a name="ITEM16H"><!--Anchor--></a>.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">MINE SAFETY
            DISCLOSURE</font></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">ITEM 17<a name="ITEM17"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; FINANCIAL STATEMENTS</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Not applicable.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">ITEM 18<a name="ITEM18"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; FINANCIAL STATEMENTS</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The financial statements required by this item are found at the end of this annual report, beginning on page F-1.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">ITEM 19<a name="ITEM19"><!--Anchor--></a>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXHIBITS</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">See Exhibit Index on page [___].</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">146</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXHIBIT INDEX<a name="EXHIBITINDEX"><!--Anchor--></a></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The exhibits filed with or incorporated into this Registration Statement are listed in the index of exhibits below.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z54eda2e11160456390366f4400d6c3e8">

          <tr>
            <td style="width: 8.24%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Exhibit Number</div>
            </td>
            <td style="width: 1.74%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;&#160;&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Exhibit Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000114420418003151/tv482396_ex3-1.htm">1.1</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000114420418003151/tv482396_ex3-1.htm">Amended and Restated Memorandum of Association (incorporated by reference to Exhibit 3.1 of the Registration
                  Statement on Form F-1/A filed with the Securities and Exchange Commission on January 23, 2018).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891318002424/exhibit_99-1.htm">1.2</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891318002424/exhibit_99-1.htm">Amended and Restated Articles of Association (incorporated by reference to Exhibit 99.1 of Form
                  6-K/A filed with the Securities and Exchange Commission on August 20, 2018).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007981/t1702540_ex4-1.htm">2.1</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90.02%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007981/t1702540_ex4-1.htm">Form of Specimen Share Certificate (incorporated by reference to Exhibit 4.1 of the
                  Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on September 20, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891320000911/exhibit_2-2.htm">2.2</a></div>
            </td>
            <td rowspan="1" style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td rowspan="1" style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891320000911/exhibit_2-2.htm">Description of Share Capital (incorporated by reference to Exhibit 2.2 of the Annual Report on
                  Form 20-F filed with the Securities and Exchange Commission on March 24, 2020).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007780/t1702477_ex10-3.htm">4.1&#8224;</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007780/t1702477_ex10-3.htm">Development, Manufacturing and Commercialization Agreement between Perrigo UK Finco Limited Partnership and
                  Sol-Gel Technologies Ltd., dated as of April 27, 2015 (incorporated by reference to Exhibit 10.3 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on September 20, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007780/t1702477_ex10-4.htm">4.2&#8224;</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007780/t1702477_ex10-4.htm">Amendment to the Development, Manufacturing and Commercialization Agreement between the Registrant and Perrigo UK
                  Finco Limited Partnership, dated as of October 26, 2015 (incorporated by reference to Exhibit 10.4 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on September 6, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007981/t1702540_ex10-5.htm">4.3</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007981/t1702540_ex10-5.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.5 of the
                  Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on September 20, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007981/t1702540_ex10-1.htm">4.4</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007981/t1702540_ex10-1.htm">2014 Share Incentive Plan (incorporated by reference to Exhibit 4.4 of the Annual Report on
                  Form 20-F filed with the Securities and Exchange Commission on March 24, 2020)</a><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007981/t1702540_ex10-1.htm">.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_4-5.htm">4.5</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_4-5.htm">Compensation Policy.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000114420418005995/tv484898_ex99-2.htm">4.6</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000114420418005995/tv484898_ex99-2.htm">Registration Rights Agreement (incorporated by reference to Exhibit 99.2 of Form 6-K filed
                  with the Securities and Exchange Commission on February 6, 2018).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-7.htm">4.7&#8734;</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-7.htm">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of October 10, 2007 (incorporated by
                  reference to Exhibit 10.7 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on August 29, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-8.htm">4.8&#8734;</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-8.htm">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of September 29, 2014 (incorporated by
                  reference to Exhibit 10.8 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on August 29, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.24%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-9.htm">4.9&#8734;</a></div>
            </td>
            <td style="width: 1.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90.02%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-9.htm">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of March 30, 2016 (incorporated by
                  reference to Exhibit 10.9 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on August 29, 2017).</a></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">147</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc44f01cb435643c9ab222e6117a455ba">

          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-10.htm">4.10&#8734;</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-10.htm">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of September 20, 2016 (incorporated by
                  reference to Exhibit 10.10 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on August 29, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-11.htm">4.11&#8734;</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-11.htm">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of January 30,
                  2017 (incorporated by reference to Exhibit 10.11 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on August 29, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891319000896/exhibit_4-12.htm">4.12&#8734;</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"> <br>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891319000896/exhibit_4-12.htm">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of September 25,&#160;2017 (incorporated by
                  reference to Exhibit 4.12 of the Annual on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891319000896/exhibit_4-13.htm">4.13&#8734;</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891319000896/exhibit_4-13.htm">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of July 3, 2018 (incorporated by reference
                  to Exhibit 4.13 of the Annual on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891319000896/exhibit_4-14.htm">4.14&#8734;</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891319000896/exhibit_4-14.htm">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of August 14, 2018 (incorporated by
                  reference to Exhibit 4.14 of the Annual on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891320000911/exhibit_4-15.htm">4.15&#8734;</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"> <br>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000117891320000911/exhibit_4-15.htm">&#160;Lease Agreement by and between the Registrant and Rachel Zacks, dated as of November 12, 2019 (incorporated by
                  reference to Exhibit 4.15 of the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 24, 2020).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-12.htm">4.16</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-12.htm">Promissory Note by and between the Registrant and Moshe Arkin, dated as of August 2, 2016 (incorporated by
                  reference to Exhibit 10.12 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on August 29, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-13.htm">4.17</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-13.htm">Schedule A, as amended, of Promissory Note by and between the Registrant and Moshe Arkin, dated as of June 28,
                  2017 (incorporated by reference to Exhibit 10.13 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on August 29, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-14.htm">4.18</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-14.htm">Instrument of Conversion of Promissory Note by and between the Registrant and Moshe Arkin,
                  dated as of August 22, 2017 (incorporated by reference to Exhibit 10.14 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on August 29, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-15.htm">4.19</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000157104917007701/t1702381_ex10-15.htm">Assignment Agreement between the Registrant and Medicis Pharmaceutical Corporation, dated August 16, 2013
                  (incorporated by reference to Exhibit 10.15 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on August 29, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000114420418004431/tv483839_ex10-16.htm">4.20&#8734;</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="https://www.sec.gov/Archives/edgar/data/1684693/000114420418004431/tv483839_ex10-16.htm">Asset Transfer Agreement and Assignment Deed between Sol-Gel Technologies Ltd. and M. Arkin Dermatology Ltd.,
                  dated August 22, 2017 (incorporated by reference to Exhibit 10.16 of the Registration Statement on Form F-1/A filed with the Securities and Exchange Commission on January 30, 2017).</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_12-1.htm">12.1</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"> <br>
            </td>
            <td style="width: 90%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_12-1.htm">Certification by Chief Executive Officer pursuant to Section 302 of
                  the Sarbanes-Oxley Act of 2002.</a></div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            <td rowspan="1" style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_12-2.htm">12.2</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"> <br>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_12-2.htm">Certification by Chief Financial Officer pursuant to Section 302 of
                  the Sarbanes-Oxley Act of 2002.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"> <br>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_13.htm">13</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"> <br>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_13.htm">Certification by Chief Executive Officer and Chief Financial Officer
                  pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="exhibit_15-1.htm">15.1</a></div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"> <br>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;"><a href="exhibit_15-1.htm">Consent of Independent Registered Public Accounting Firm</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">101</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">The following financial statements from the Company&#8217;s 20-F for the fiscal year ended December 31, 2020 formatted in XBRL: (i)&#160;Consolidated Statements of Comprehensive Loss, (ii)
                Consolidated Statements of Financial Position, (iii) Consolidated Statements of Changes in Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">&#8224;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Confidential treatment granted with respect to certain portions of this Exhibit.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8.38%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#8734;</div>
            </td>
            <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">Informal translation of the original Hebrew document.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">148</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%149%%%-->
      <div style="text-align: center; line-height: 1.25;"><u>SIGNATURE</u></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zfd7992475b1645d897cca56dede1def6">

          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="3" style="vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">SOL-GEL TECHNOLOGIES LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td colspan="3" style="vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">By:</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">/s/ Alon Seri-Levy</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Name:</div>
            </td>
            <td style="width: 43%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Alon Seri-Levy</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Title:</div>
            </td>
            <td style="width: 43%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Chief Executive Officer and Director</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 43%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">By:</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">/s/ Gilad Mamlok</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Name:</div>
            </td>
            <td style="width: 43%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Gilad Mamlok</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Title:</div>
            </td>
            <td style="width: 43%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify; line-height: 1.25;">Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Date:&#160;&#160;March 4, 2021</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">149</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONSOLIDATED FINANCIAL STATEMENTS</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS OF DECEMBER 31, 2020</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONSOLIDATED FINANCIAL STATEMENTS</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS OF DECEMBER 31, 2020</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="2" border="0" id="z2e79ff35778b4abd8454e527a84bc380" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 92.42%; vertical-align: top;">&#160;</td>
                <td style="width: 7.58%; vertical-align: top; border-bottom: #000000 2px solid;">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Page</div>
                </td>
              </tr>
              <tr>
                <td style="width: 92.42%; vertical-align: top;">
                  <div style="line-height: 1.25; font-weight: bold;"><a href="#Report">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></div>
                </td>
                <td style="width: 7.58%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">F-2</div>
                </td>
              </tr>
              <tr>
                <td style="width: 92.42%; vertical-align: top;">
                  <div style="line-height: 1.25; font-weight: bold;">CONSOLIDATED FINANCIAL STATEMENTS:</div>
                </td>
                <td style="width: 7.58%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 92.42%; vertical-align: top;">
                  <div style="margin-left: 9pt; line-height: 1.25;"><a href="#BALANCE">Balance Sheets</a></div>
                </td>
                <td style="width: 7.58%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">F-3</div>
                </td>
              </tr>
              <tr>
                <td style="width: 92.42%; vertical-align: top;">
                  <div style="margin-left: 9pt; line-height: 1.25;"><a href="#OPERATIONS">Statements of Operations</a></div>
                </td>
                <td style="width: 7.58%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">F-4</div>
                </td>
              </tr>
              <tr>
                <td style="width: 92.42%; vertical-align: top;">
                  <div style="margin-left: 9pt; line-height: 1.25;"><a href="#EQUITY">Statements of Changes in Shareholders' Equity</a></div>
                </td>
                <td style="width: 7.58%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">F-5</div>
                </td>
              </tr>
              <tr>
                <td style="width: 92.42%; vertical-align: top;">
                  <div style="margin-left: 9pt; line-height: 1.25;"><a href="#CASH">Statements of Cash Flows</a></div>
                </td>
                <td style="width: 7.58%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">F-6</div>
                </td>
              </tr>
              <tr>
                <td style="width: 92.42%; vertical-align: top;">
                  <div style="margin-left: 9pt; line-height: 1.25;"><a href="#NOTES">Notes to the Financial Statements</a></div>
                </td>
                <td style="width: 7.58%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">F-7</div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%2%F - %%-->
          <div id="DSPFPageHeader">
            <div style="line-height: 1.25;"><img width="152" height="129" src="image0.jpg"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="Report"><!--Anchor--></a>Report of Independent Registered Public Accounting Firm</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">To<font style="font-weight: bold;">&#160;</font>the board of directors and shareholders of<font style="font-weight: bold;">&#160;</font>Sol-Gel Technologies Ltd.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Opinion on the Financial Statements</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">We have audited the accompanying consolidated<font style="font-weight: bold;">&#160;</font>balance sheets of Sol-Gel Technologies Ltd<font style="font-weight: bold;">.</font>&#160;and its subsidiary (the
            &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related consolidated statements of operations, of changes in shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2020, including the related
            notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the<font style="font-weight: bold;">&#160;</font>consolidated financial statements present fairly, in all material respects, the financial position of the
            Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of
            America.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: justify; line-height: 1.25; font-style: italic;">Change in Accounting Principle</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">As discussed in Note 2(o) to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.</div>
            </div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Basis for Opinion</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">These consolidated<font style="font-weight: bold;">&#160;</font>financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
            consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in
            accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">We conducted our audits of these consolidated<font style="font-weight: bold;">&#160;</font>financial statements in accordance with the standards of the PCAOB. Those standards require that we plan
            and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an
            audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
            Company's internal control over financial reporting. Accordingly, we express no such opinion.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that
            respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and
            significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" border="0" id="z8569f296335340bb91f3a15c07e6444f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">Tel-Aviv, Israel</div>
                </td>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">/s/ Kesselman &amp; Kesselman</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">March 4, 2021</div>
                </td>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">Certified Public Accountants (Isr.)</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 50%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">A member firm of PricewaterhouseCoopers International Limited</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">We have served as the Company's auditor since 2000.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">
            <hr align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25; font-style: italic;">Kesselman &amp; Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103, Israel,</div>
            <div style="line-height: 1.25; font-style: italic;">P.O Box 7187 Tel-Aviv 6107120, Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 2</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
          </div>
          <div id="DSPFPageHeader">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONSOLIDATED <a name="BALANCE"><!--Anchor--></a>BALANCE SHEETS</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share data)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z1cef303708014acbbd04aa2e2e8252f7">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Assets</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom;">
                  <div style="line-height: 1.25; font-weight: bold;">CURRENT ASSETS:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Cash and cash equivalents</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">9,412</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">7,122</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Bank deposits</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">21,400</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Marketable securities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">40,966</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">21,652</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Receivables from collaborative arrangements</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">4,120</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">2,153</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Prepaid expenses and other current assets</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">1,293</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">1,074</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="line-height: 1.25; font-weight: bold;">TOTAL CURRENT ASSETS</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">55,791</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">53,401</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-weight: bold;">NON-CURRENT ASSETS:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Restricted long-term deposits and cash</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">472</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">1,293</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Property and equipment, net</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">2,314</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">1,817</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Operating lease right-of-use assets</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">2,040</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">1,896</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Funds in respect of employee rights upon retirement</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">684</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">754</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="line-height: 1.25; font-weight: bold;">TOTAL NON-CURRENT ASSETS</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">5,510</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">5,760</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-weight: bold;">TOTAL ASSETS</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">61,301</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">59,161</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Liabilities and shareholders' equity</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-weight: bold;">CURRENT LIABILITIES:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Accounts payable</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">1,710</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">1,203</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Other accounts payable</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">4,123</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">4,088</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Current maturities of operating leases</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">672</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">673</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-weight: bold;">TOTAL CURRENT LIABILITIES</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">6,505</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">5,964</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="line-height: 1.25; font-weight: bold;">LONG-TERM LIABILITIES:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;">&#160;&#160;&#160;Operating leases liabilities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">1,373</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">1,299</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Liability for employee rights upon retirement</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">958</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">1,049</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-weight: bold;">TOTAL LONG-TERM LIABILITIES</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">2,331</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">2,348</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="line-height: 1.25; font-weight: bold;">COMMITMENTS</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-weight: bold;">TOTAL LIABILITIES</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">8,836</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">8,312</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="line-height: 1.25; font-weight: bold;">SHAREHOLDERS' EQUITY:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 36pt; text-indent: -27pt;">Ordinary shares, NIS 0.1 par value &#8211; authorized: 50,000,000 as of December 31, 2019 and 2020, respectively; issued and
                    outstanding: 20,402,800 and 23,000,782 as of December 31, 2019 and December 31, 2020, respectively</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">561</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">635</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Additional paid-in capital</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">203,977</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">231,577</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 9pt;">Accumulated deficit</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(152,073</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(181,363</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="line-height: 1.25; font-weight: bold;">TOTAL SHAREHOLDERS' EQUITY</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">52,465</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">50,849</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-weight: bold;">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">61,301</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">59,161</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">The accompanying notes are an integral part of these consolidated financial statements.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 3</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONSOLIDATED STATEMENTS OF <a name="OPERATIONS"><!--Anchor--></a>OPERATIONS</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share data)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="za22f9fe8d41549d593c632826ce8063a">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-left: 9pt; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="10">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year ended December 31,</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25;"> 2018</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">2019</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2020</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25; font-weight: bold;">COLLABORATION REVENUES</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">129</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">22,904</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">8,771</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25; font-weight: bold;">OPERATING EXPENSES</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">&#160;&#160;&#160;&#160;Research and Development</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">28,146</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">40,578</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">27,913</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25;">&#160;&#160;&#160;&#160;General and Administrative</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">5,504</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">8,276</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">11,091</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25; font-weight: bold;">TOTAL OPERATING LOSS</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">33,521</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">25,950</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">30,233</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25; font-weight: bold;">FINANCIAL INCOME, net</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">(1,318</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">)</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">(1,374</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">)</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">(943</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">)</div>
                  </div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25; font-weight: bold;">LOSS BEFORE INCOME TAXES</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">32,203</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">24,576</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">29,290</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25; font-weight: bold;">INCOME TAXES</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">33</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25; font-weight: bold;">LOSS FOR THE YEAR</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">32,203</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">24,609</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">29,290</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25; font-weight: bold;">BASIC AND DILUTED LOSS PER ORDINARY SHARE</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">$</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">1.80</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">1.26</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">1.30</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="text-indent: -14.2pt; margin-left: 14.2pt; line-height: 1.25; font-weight: bold;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">17,867,589</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">19,534,562</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">22,574,688</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br>
          </div>
          <div style="line-height: 1.25;">The accompanying notes are an integral part of these consolidated financial statement.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 4</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' <a name="EQUITY"><!--Anchor--></a>EQUITY</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share data)</div>
          <div style="text-align: center; line-height: 1.25;"> <br>
          </div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z421d4b99096c4458a721852a3a22a4f6">

                <tr>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ordinary shares</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Additional</font> <font style="font-weight: bold;">paid-in</font><br>
                      <font style="font-weight: bold;">capital</font></div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Accumulated</div>
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">deficit</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">&#160;</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number</div>
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">of shares</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amounts</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="10">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amounts</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-weight: bold;">BALANCE AS OF JANUARY 1, 2018</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">6,290,244</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">82</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">42,480</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(95,261</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(52,699</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CHANGES DURING 2018:</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Loss for the year</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(32,203</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(32,203</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Stock split</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">66</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">(66</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Conversion of loans from the Controlling shareholder</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">5,444,825</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">160</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">65,178</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">65,338</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Issuance of shares through an initial public offering, net of issuance costs</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">7,187,500</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">211</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">78,564</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">78,775</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Exercise of options granted to employee</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">27,399</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">1</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">43</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">44</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Share-based compensation</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">4,654</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">4,654</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-weight: bold;">BALANCE AS OF DECEMBER 31, 2018</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">18,949,968</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">520</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">190,853</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(127,464</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">63,909</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CHANGES DURING 2019:</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Loss for the year</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(24,609</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(24,609</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">
                      <div style="line-height: 1.25;">Vesting of restricted share units</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">15,332</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Issuance of shares through public offering, net of issuance costs</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">1,437,500</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">41</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">10,572</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">10,613</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Share-based compensation</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">2,552</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">2,552</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-weight: bold;">BALANCE AS OF DECEMBER 31, 2019</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">20,402,800</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">561</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">203,977</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">(152,073</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">)</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">52,465</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CHANGES DURING 2020:</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Loss for the year</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(29,290</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(29,290</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Issuance of shares and warrants through public offering, net of issuance costs</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">2,091,907</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">61</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">21,245</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">21,306</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Issuance of shares and warrants through private placement from the controlling shareholder</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">454,628</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">13</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">4,987</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">5,000</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">
                      <div style="line-height: 1.25;">Vesting of restricted share units</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">23,000</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Exercise of options</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">28,447</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">*</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">151</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">151</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
                    <div style="margin-left: 12.5pt; line-height: 1.25;">Share-based compensation</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">1,217</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">1,217</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-weight: bold;">BALANCE AS OF DECEMBER 31, 2020</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">23,000,782</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">635</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">231,577</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(181,363</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">50,849</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"> <br>
          </div>
          <div style="line-height: 1.25;">* Less than 1,000.</div>
          <div style="line-height: 1.25;"> <br>
          </div>
          <div style="line-height: 1.25;">The accompanying notes are an integral part of these consolidated financial statements.</div>
          <div id="DSPFPageHeader">
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 5</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">CONSOLIDATED STATEMENTS OF <a name="CASH"><!--Anchor--></a>CASH FLOWS</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands)</div>
          <div style="text-align: center; line-height: 1.25;"> <br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z0f4c11b6b9a5407d9fe88d6a180edaca">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-left: 9pt; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="10">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year ended December 31,</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2018</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2020</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25; font-weight: bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Loss</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(32,203</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(24,609</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(29,290</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Adjustments required to reconcile loss to net cash used in operating activities:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Depreciation</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">762</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">887</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">946</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Changes in accrued liability for employee rights upon retirement</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">106</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">38</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">21</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Share-based compensation expenses</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">4,654</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">2,552</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">1,217</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Net changes in operating leases</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">5</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">71</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Changes in fair value of marketable securities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">29</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">65</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">138</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Finance expenses, net</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(34</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">50</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">12</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Changes in operating asset and liabilities:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Receivables from collaborative arrangements</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(4,120</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">1,967</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Prepaid expenses and other current assets</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(1,463</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">1,694</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">219</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Accounts payable, accrued expenses and other</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">3,029</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">938</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(542</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" colspan="1">
                  <div style="margin-left: 18.2pt; line-height: 1.25;">Long term receivables</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">1,653</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Net cash used in operating activities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(23,467</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(22,500</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(25,241</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="line-height: 1.25; font-weight: bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Purchase of property and equipment</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(1,052</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(597</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(449</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Bank deposits</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">3,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">1,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(21,400</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Restricted long-term deposits</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">8</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(10</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(21</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Investments in marketable securities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(71,783</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(38,702</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(32,322</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Proceeds from sales and maturity of marketable securities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">15,092</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">54,333</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">51,498</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Net cash provided by (used in) investing activities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">(54,735</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">16,024</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">(2,694</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25; font-weight: bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Proceeds from exercise of options granted to employees</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">44</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">151</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">&#160;&#160;&#160;Proceeds from issuance of shares and warrants through public offering, net of issuance costs</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">78,775</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">10,613</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">21,306</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Net proceeds from issuance of shares and warrants to the controlling shareholder through private placement<br>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">5,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="margin-left: 8.4pt; line-height: 1.25;">Net cash provided by financing activities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">78,819</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">10,613</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">26,457</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="text-indent: -8.4pt; margin-left: 8.4pt; line-height: 1.25; font-weight: bold;">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">34</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(50</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">(12</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="text-indent: -8.4pt; margin-left: 8.4pt; line-height: 1.25; font-weight: bold;">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">651</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">4,087</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(1,490</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">
                  <div style="text-indent: -8.4pt; margin-left: 8.4pt; line-height: 1.25; font-weight: bold;">CASH AND CASH EQUIVALENTS AND RESRICTED CASH AT BEGINNING OF THE YEAR</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">5,024</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">5,675</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">9,762</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="text-indent: -8.4pt; margin-left: 8.4pt; line-height: 1.25; font-weight: bold;">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">5,675</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">9,762</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">8,272</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">Cash and Cash equivalents</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">5,325</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">9,412</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">7,122</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;" colspan="1">
                  <div style="text-indent: -8.4pt; margin-left: 8.4pt; line-height: 1.25;">Restricted cash</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">350</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">350</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">1,150</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="text-indent: -8.4pt; margin-left: 8.4pt; line-height: 1.25; font-weight: bold;">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">5,675</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">9,762</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">8,272</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zfc6148ffcc22497292ce84a2ff50ab5a">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -8.4pt; margin-left: 8.4pt; line-height: 1.25; font-weight: bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="margin-left: 9.8pt; line-height: 1.25;">Recognition of new operating lease ROU and liabilities</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">1,329</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">378</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px;">
                  <div style="margin-left: 9.8pt; line-height: 1.25;">Conversion of loans from the controlling shareholder</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">65,338</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -8.4pt; margin-left: 8.4pt; line-height: 1.25; font-weight: bold;">SUPPLEMENTARY INFORMATION:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%;">
                  <div style="text-indent: -8.4pt; margin-left: 8.4pt; line-height: 1.25;">&#160;&#160;&#160;&#160;Income taxes paid</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">7</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="margin-left: 9.8pt; line-height: 1.25;">Interest received</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">1,477</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">1,600</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">770</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25;"> <br>
          </div>
          <div style="line-height: 1.25;">The accompanying notes are an integral part of these consolidated financial statements.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 6</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="NOTES"><!--Anchor--></a>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">NOTE 1&#8201;&#8212;&#8201;NATURE OF OPERATIONS</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Sol-Gel Technologies Ltd. (collectively with its subsidiary, the Company) is an Israeli Company incorporated in&#160; 1997.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">
            <div style="line-height: 1.25;">The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. The Company&#8217;s lead product candidates are based upon its
              proprietary microencapsulation delivery system, consisting of microcapsules made of precipitated silica. The most advanced investigational drugs in the Company's product pipeline are: (i) Twyneo<sup style="font-family: 'Times New Roman',serif; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, which is developed for the treatment of acne vulgaris. The New Drug Application ("NDA") for Twyneo&#174; was accepted by the U.S.&#160;Food and Drug Administration
              (the &#8220;FDA&#8221;), which assigned a Prescription Drug User Fee Act ("PDUFA") goal date of August 1, 2021; and (ii) Epsolay<sup style="font-family: 'Times New Roman',serif; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, a
              potential treatment for subtype II rosacea. The NDA for Epsolay&#174; was accepted by the FDA, which assigned a PDUFA goal date of April 26, 2021. In addition to the novel product candidates, the Company&#8217;s products include the generic product
              Acyclovir and other generic product candidates.</div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regard to marketing, regulatory affairs and business
            development relating to its products and technology in the U.S.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Since incorporation through December 31, 2020, the Company has an accumulated deficit of approximately $181,363 thousand and its activities have been funded mainly by its shareholders and
            collaboration revenues. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations and in order to continue its future operations, the Company will need to obtain additional
            funding until becoming profitable.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 7</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; margin-left: 20pt; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 1&#8201;</font><font style="font-weight: bold;">-</font><font style="font-weight: bold;">&#8201;NATURE OF OPERATIONS </font>(continued)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Management is considering raising additional funding from different sources, such as corporate collaborations, licensing of its branded products or similar arrangements, public or private equity
            offerings and/or debt financings, and/or selling shares under the Company's Open Market Sale Agreement with Jefferies LLC. Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of December 31,
            2020 will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">In December 2019, COVID-19 was identified in Wuhan, China. This virus continues to spread globally and, as of December 2020, has spread to over 50 countries, including the United States and
            Israel. The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">As of December 31, 2020, the main impact on the Company's operations resulting from COVID-19 was the decline in revenues of Acyclovir in the second quarter.&#160; Management believes that such decline
            was mainly attributed to travel restrictions and stay-at-home-orders.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues from collaboration
            arrangements, expenses, reserves and allowances, manufacturing, supply, regulatory approvals, clinical trials, commercial launch of branded and generic product candidates,&#160; research and development costs and employee-related amounts, will
            depend on future developments that are highly uncertain and cannot be predicted. The Company continues to monitor and assess new information related to the COVID-19 pandemic, the actions taken to contain or treat COVID-19, as well as the
            economic impact on the different markets.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Furthermore, the estimation process required to prepare the Company&#8217;s consolidated financial statements requires assumptions to be made about future events and conditions and the impact of
            COVID-19 on its financial results, and while management believes such assumptions are reasonable, they are inherently subjective and uncertain. The Company&#8217;s actual results could differ materially from those estimates.</div>
          <div style="line-height: 1.25; font-weight: bold;"><br>
            NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Basis of presentation</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z79ce61c58f764cd4a9fa64fe81b14829" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">a.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Use of estimates in the preparation of financial statements</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the
            disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 8</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </font>(continued)<font style="font-weight: bold;">:</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the fair value of share-based compensation and the incremental borrowing rate
            for leases.<br>
            <br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z324b2b78394744a6be48487dc70d4003" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">b.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Functional and presentation currency</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The U.S. dollar (&#8220;dollar&#8221;) is the currency of the primary economic environment in which the operations of the Company and its subsidiary are conducted. The Company&#8217;s financing has been provided
            in dollars, revenues are primarily in dollars and a significant part of expenses are incurred in dollars. The financial statements are presented in dollars, which is the Company&#8217;s functional and presentation currency.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current
            exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (I) for transactions &#8212; exchange rates at
            transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) &#8212; historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses,
            as appropriate.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z6c9ffab81e864a618ac4edfe4b6d9c74" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">c.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Cash and cash equivalents</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of
            purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z7f1b6911715048f48107b0c09a6d1af5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right;">d.</td>
                <td style="width: auto; vertical-align: top;">
                  <div><font style="font-weight: bold;">Bank deposits</font><br>
                    <br>
                    Bank deposits with original maturity dates of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an average annual rate of approximately 0.71%-1.87% in 2020.
                    Interest accrued on bank deposits was recorded as interest receivable as part of "Prepaid expenses and other current assets" in the company&#8217;s balance sheet. </div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"> <br>
          </div>
          <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bank deposits with maturity of more than one year are considered long-term.<br>
            <br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="zc761d232035445b7b04ae0b4702e8c23" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">e.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Marketable securities</div>
                </td>
              </tr>

          </table>
          <div style="margin-left: 20.15pt; line-height: 1.25;"><br>
            Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825,&#160;Financial Instruments as the Company manages its portfolio and
            evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z5ee031687b39499782a8e3367f82326a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">f.</td>
                <td style="width: auto; vertical-align: top;">
                  <div><font style="font-weight: bold;">Derivatives and hedging</font><br>
                    <br>
                    The Company carries out transactions involving foreign currency exchange derivative financial instruments. The transactions are designed to hedge the Company&#8217;s exposure in currencies other than the U.S. dollar. The derivative does not
                    meet the definition of a cash flow accounting hedge, therefore the changes in the fair value are included in financial expense (income), net.</div>
                  <div><br>
                    The currency hedged items are denominated in New Israeli Shekel (NIS).&#160; The counterparties to the derivatives are major banks in Israel.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 9</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </font>(continued)<font style="font-weight: bold;">:</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20.15pt; line-height: 1.25;">As of December 31, 2020, the Company has $1,150 on the Company&#8217;s bank account that is restricted in order to secure the hedging transactions. This amount is presented among Restricted
            long-term deposits and cash.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="za932c38e076d43c9b7a8bedb2974ffe4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">g.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Trade receivables:</div>
                </td>
              </tr>

          </table>
          <div style="margin-left: 20.15pt; line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; margin-left: 20.15pt; line-height: 1.25;">Trade receivables are initially recognized at the transaction price and subsequently measured at amortized cost less any allowance for expected credit losses.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; margin-left: 20.15pt; line-height: 1.25;">&#160;Starting from January 1, 2020, the Company applies ASU 2016-13 &#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;the
            Standard&#8221;).</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z109d213175f74f7a8c8ca1b35225a9f2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">h.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Property and equipment:</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z59a5ed342ee546a4bd32f4e6f1249a3a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt;"><br>
                </td>
                <td style="width: 20.15pt; vertical-align: top; align: right;">1)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Property and equipment are stated at cost, net of accumulated depreciation and amortization.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z6147f6baec204641b7d368d9e11bcc9b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt;"><br>
                </td>
                <td style="width: 20.15pt; vertical-align: top; align: right;">2)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>The Company&#8217;s property and equipment are depreciated utilizing the straight-line method on the basis of their estimated useful life.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20.15pt; line-height: 1.25;">Annual rates of depreciation are as follows:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table align="center" cellspacing="0" cellpadding="0" border="0" id="z8b2cd7cdce7d403380565b5c928b1fed" style="width: 85%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

              <tr>
                <td style="width: 72.22%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td style="width: 27.78%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">%&#8201;&#8199;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;">Laboratory equipment</div>
                </td>
                <td style="width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="text-align: center; line-height: 1.25;">10 &#8211; 33 (mainly 15 &#8211; 25)</div>
                </td>
              </tr>
              <tr>
                <td style="width: 72.22%; vertical-align: top;">
                  <div style="line-height: 1.25;">Office equipment and furniture</div>
                </td>
                <td style="width: 27.78%; vertical-align: top;">
                  <div style="text-align: center; line-height: 1.25;">7 &#8211; 15</div>
                </td>
              </tr>
              <tr>
                <td style="width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;">Computers and related equipment</div>
                </td>
                <td style="width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255);">
                  <div style="text-align: center; line-height: 1.25;">33</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Leasehold improvements are amortized utilizing the straight-line method over the shorter of the expected lease term or the estimated useful life of the improvements.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="zf29af5ff7e744ab7a318efd9f9ceb0f7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">i.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Impairment of long-lived assets</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without
            interest charges) of the assets is less than the carrying amount of such assets, an impairment loss would be recognized. The assets would then be written down to their estimated fair values.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">For the three years ended December&#160;31, 2020, the Company did not recognize an impairment loss for its long-lived assets.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="za27b9bfab8074ad4ac5345b539fb50df" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">j.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Share-based compensation</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company accounts for employees&#8217; share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized
            as an expense over the requisite service period.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option
            award approach.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">On January 1, 2019 the Company adopted ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees.
            Under the provision of the amendment, the Company measures share-based compensation to non-employees in the same manner (except for certain exceptions) as share-based compensation to employees.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 10</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </font>(continued)<font style="font-weight: bold;">:</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Prior to January 1, 2019, when options were granted as consideration for services provided by consultants and other non-employees, the grant was accounted for based on the fair value of the
            consideration received or the fair value of the options issued, whichever is more reliably measurable. The fair value of the options granted was measured on a final basis at the end of the related service period and recognized over the related
            service period using the graded vesting schedule method.</div>
          <div style="margin-left: 15.7pt; line-height: 1.25;"> <br>
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company has elected to recognize forfeitures as they occur.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="zf8bf3f8a3cc54154a9fe73d9f16a6983" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">k.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Research and development expenses</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses,
            payroll taxes and other employee benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Acquisitions of in-process research and development product candidate, which are not part of business combination, are recognized as an expense as research and development expenses as incurred.<br>
            <br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Grants received from Israel Innovation Authority (hereafter &#8212; &#8220;IIA&#8221;), formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS are recognized when
            the grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research
            and development expenses as the applicable costs are incurred. See note 6a(1).</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources its clinical trial
            activities utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs
            are expensed as incurred.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="zb6c579e0afcb47cf80a2422f09d1b739" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">l.<br>
                </td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Revenue recognition</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20.15pt; line-height: 1.25;">The Company applies ASC 606, Revenue from Contracts with Customers. According to the standard, an entity recognizes revenue when its customer obtains control of promised goods or services, in
            an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity
            performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
            obligations in the contract; and (v) recognize revenue when (or as) the performance obligation is satisfied.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20.15pt; line-height: 1.25;">An entity only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers
            to the customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the entity assesses the goods or services promised within each contract and determines those that are
            performance obligations and assesses whether each promised good or service is distinct. The entity then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the
            performance obligation is satisfied.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 11</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </font>(continued)<font style="font-weight: bold;">:</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin: 0px 0px 0px 20pt; line-height: 1.25;"><font style="font-style: italic;">Collaborative Arrangements</font><br>
            <br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20.15pt; line-height: 1.25;">The Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). While these arrangements are in the scope of
            ASC 808, the Company may analogize to ASC 606 for some aspects of the arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account)
            that is part of its ongoing major or central operations. Revenue recognized by analogizing to ASC 606 is recorded as &#8220;collaboration revenues&#8221;.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20.15pt; line-height: 1.25;">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) royalties on net sales of licensed products; (ii) reimbursements or cost-sharing of
            R&amp;D expenses. Each of these payments results in collaboration revenues or an offset against R&amp;D expense.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20.15pt; line-height: 1.25;">Royalties: For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes collaboration revenue
            at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20.15pt; line-height: 1.25;">Under certain collaborative arrangements, the Company has been reimbursed for a portion of its R&amp;D expenses or participates in the cost-sharing of such R&amp;D expenses. Such
            reimbursements and cost-sharing arrangements have been reflected as a reduction of R&amp;D expense in the Company&#8217;s consolidated statements of operations, as the Company does not consider performing research and development services for
            reimbursement to be a part of its ongoing major or central operations.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z0812def152d54fdb9f01feeecdb9dedc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">m.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Income taxes:</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z7defb31d969c43c8980ae9f04b65e866" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt;"><br>
                </td>
                <td style="width: 20.15pt; vertical-align: top; align: right;">1)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Deferred taxes</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC&#160;740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset
            and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are
            expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be
            realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">Uncertainty in income taxes</div>
          <div style="text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 36pt; line-height: 1.25;">The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available
            evidence indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood
            of being realized upon ultimate settlement.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 12</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </font>(continued)<font style="font-weight: bold;">:</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z7945dbca9614463db051890512fb5a4a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">n.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Leases</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">As of January 1, 2019, the Company adopted ASU No. 2016-02, &#8220;Leases (Topic 842)". The Company adopted the standard using the modified retrospective approach with an effective date as of the
            beginning of the Company's fiscal year, January 1, 2019. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts
            are or contain leases, (2) lease classification and (3) initial direct costs.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Right of Use ("ROU") assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising
            from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when
            it is reasonably certain that the Company will exercise that option.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company uses the implicit rate when readily determinable. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the
            information available at commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to not separate lease and non-lease
            components for the leases. The Company elected the practical expedient of the short-term lease recognition exemption for all leases with a term shorter than 12 months.</div>
          <div style="margin-left: 20pt; line-height: 1.25;"> <br>
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Additionally, the company applies the portfolio approach to account for operating lease ROU asset and liabilities for certain car leases and incremental borrowing rates.<br>
            <br>
            <div style="line-height: 1.25;">Upon adoption, the standard resulted in an increase of $1,200 in operating lease ROU assets and corresponding liabilities on the Company&#8217;s consolidated balance sheet and did not have a material impact on the
              Company&#8217;s consolidated statements of operations or consolidated statements of cash flows.&#160; See also note 6b.</div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z27d5f92405494446b69a4061f09c078a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">o.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Loss per share</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is
            based upon the weighted average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options, restricted shares and warrants, which are included under the
            treasury stock method when dilutive. The calculation of diluted loss per share does not include 1,119,310, 1,260,984 and 3,271,507 options, restricted shares and warrants for the years ended December&#160;31, 2018, 2019 and 2020, respectively,
            because their effect would be anti-dilutive.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z4d42a1eac37e418b92c66e4e364bc26f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">p.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Fair value measurement</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the
            measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad
            levels, which are described as follows:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 13</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </font>(continued)<font style="font-weight: bold;">:</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers
            counterparty credit risk in its assessment of fair value.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The carrying amount of the cash and cash equivalents, bank deposits, restricted cash, receivables from collaborative arrangements, restricted long-term deposits, accrued expenses (under other
            account payable), operating leases liabilities and other liabilities approximates their fair value.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="zf24ba24f57404740917d2ca20a147269" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">q.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Concentration of credit risks</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, bank deposits and marketable securities and certain
            receivables. The Company deposits cash and cash equivalents with highly rated financial institutions (Israeli banks). In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced any
            material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z339fd1fa884f49f086d0c0eb4212cb95" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">r.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Newly issued and recently adopted accounting pronouncements</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25; font-style: italic; font-weight: bold;">Recently adopted accounting pronouncements:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">In June 2016, the FASB issued ASU 2016-13 &#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&#8221;. This guidance replaces the current incurred loss impairment
            methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance became effective for the fiscal year
            beginning on January 1, 2020, including interim periods within that year. This guidance did not have significant impact on the Company&#8217;s financial statements.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">NOTE 3&#8201;&#8212;&#8201;MARKETABLE SECURITIES</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The following table sets forth the Company&#8217;s marketable securities for the indicated period:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z9e4af40726134ff29da35241ab772cb6">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-left: 9pt; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25;">December 31,</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; padding-left: 9pt; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25;"> 2019</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25;">2020</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: middle; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">Level 2 securities:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="6">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: middle; width: 76%;" colspan="1">
                  <div style="line-height: 1.25;">U.S government and agency bonds</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">2,499</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">4,192</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">Canada government bonds</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">999</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">-</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: middle; width: 76%;" colspan="1">
                  <div style="line-height: 1.25;">Other foreign government bonds</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">3,521</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">2,006</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: middle; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">Corporate bonds*</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">33,947</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">15,454</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: middle; width: 76%; padding-bottom: 4px;" colspan="1">
                  <div style="line-height: 1.25;">Total</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">$</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">40,966</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">$</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">21,652</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
              </tr>

          </table>
          <div style="margin-right: 1.95pt; margin-left: 36pt; line-height: 1.25; clear: both;"> <br>
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">* Investments in Corporate bonds rated A or higher.<br>
            <br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 14</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 3&#8201;&#8212;&#8201;MARKETABLE SECURITIES </font>(continued)<font style="font-weight: bold;">:</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company&#8217;s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their
            fair value.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The table below sets forth a summary of the changes in the fair value of the Company&#8217;s marketable securities for the years ended December 31, 2019 and 2020:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z7ff47d7add744957b075a599acb90947">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25;">December 31,</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25;"> 2019</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25;">2020</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;">Balance at beginning of the year</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">56,662</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">40,966</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 76%;">
                  <div style="line-height: 1.25;">Additions</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">38,702</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">32,322</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;">Sale or maturity</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(54,333</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">(51,498</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                  <div style="text-align: justify; line-height: 1.25;">Changes in fair value during the year</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">(65</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">)</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">(138</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">)</div>
                  </div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="text-align: justify; line-height: 1.25;">Balance at end of the year</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">$</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">40,966</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">$</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">21,652</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">As of December 31, 2020, the Company&#8217;s debt securities had the following maturity dates:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="zf17a4cc52f0946eb8e8223ee2e133e79">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 7pt;">Market value</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 7pt;">December 31,</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="line-height: 1.25;">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 7pt;"> 2020</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: &#38;quot;">Due within one year</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">21,652</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: middle; width: 88%; padding-bottom: 2px;">
                  <div style="line-height: 1.25; font-family: &#38;quot;">1 to 2 years</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">-</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: middle; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25; font-family: &#38;quot;">Total</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">21,652</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">NOTE 4&#8201;&#8212;&#8201;PROPERTY AND EQUIPMENT</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z5b8c8feb5b8048ae96207a1f12d10a94">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;">Cost:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="margin-left: 9pt; line-height: 1.25;">Laboratory equipment</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">3,242</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">3,644</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="margin-left: 9pt; line-height: 1.25;">Office equipment and furniture</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">265</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">265</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="margin-left: 9pt; line-height: 1.25;">Computers and software</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">490</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">530</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="margin-left: 9pt; line-height: 1.25;">Leasehold improvements</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">1,946</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">1,953</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">5,943</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="line-height: 1.25;">6,392</div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="line-height: 1.25;">Less:</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="margin-left: 9pt; line-height: 1.25;">Accumulated depreciation and amortization</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">(3,629</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">)</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">(4,575</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">)</div>
                  </div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="margin-left: 9pt; line-height: 1.25;">Property and equipment, net</div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">$</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">2,314</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">$</div>
                  </div>
                </td>
                <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25;">1,817</div>
                  </div>
                </td>
                <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">Depreciation and amortization expense totaled $762, $887 and 946$ for the years ended December&#160;31, 2018, 2019 and 2020, respectively.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">NOTE 5&#8201;&#8212;&#8201;EMPLOYEE SEVERANCE BENEFITS</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company is required to make severance payments upon dismissal of an employee or upon termination of employment in certain circumstances. The severance payment liability to the employees
            (based upon length of service and the latest monthly salary &#8212; one month&#8217;s salary for each year employed) is recorded on the Company&#8217;s balance sheet under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it was
            payable at each balance sheet date on an undiscounted basis.</div>
          <div style="margin-left: 20pt; line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 15</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 5&#8201;&#8212;&#8201;EMPLOYEE SEVERANCE BENEFITS </font>(continued)<font style="font-weight: bold;">:</font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">In accordance with the current employment terms starting in August&#160;2014 with all of its employees (Section 14 of the Israeli Severance Pay Law, 1963), the Company makes regular deposits with
            certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s retirement benefit obligation. The Company is fully relieved from any severance pay liability with respect to each such employee
            after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company balance sheet, as the amounts</div>
          <div style="margin-left: 20pt; line-height: 1.25;">funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution
            Plan&#8221;).</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">With regard to the period before August&#160;2014, the liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the
            funds. The amounts used to fund these liabilities are included in the balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s assets.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The amounts of severance payment expenses were $431, $402 and $428 for the years ended December&#160;31, 2018, 2019 and 2020, respectively, of which $292, $363 and $408 in the years ended December
            2018, 2019 and 2020, respectively, were in respect of the Contribution Plan.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 20pt; line-height: 1.25;">The Company expects to contribute approximately $408 in the year ending December&#160;31, 2021 to insurance companies in connection with its expected severance liabilities for that year.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">NOTE 6&#8201;&#8212;&#8201;COMMITMENTS:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z2206b0aec79c40bb963978da84db12f6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 20pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; align: right;">a.</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Royalty Commitments:</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z96799f1a692b43d0a6f3b5be12a526fa" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 38pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; align: right;">1)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>The Company is obligated to pay royalties to the IIA on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from the IIA.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="margin-left: 56pt; line-height: 1.25;">Under the specific terms of the funding arrangements with the IIA, royalties of 3.5% to 25% are payable on the sale of products developed with funding received from the IIA, which payments shall
            not exceed, in the aggregate, 300% of the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.<br>
            <br>
            Up to December&#160;31, 2020, the Company had recognized and received grants from the IIA in the aggregate amount of $1,431 (no grants were received in the last three years.). Through December&#160;31, 2020, the Company recorded an accumulated royalty
            expense of&#8201;$2,086 as royalties to the IIA with respect to revenue recognized through December 31, 2020 ($32, $32 and $25 were recorded in 2018, 2019 and 2020 accordingly, as an expense in the consolidated statements of operations).<br>
            <br>
            The Company did not receive any grants from the IIA for the years ended December&#160;31, 2018, 2019 and 2020.<br>
            <br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="zbf7a8e9a9ae249baa013c9d81cb75b17" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; align: right;">2)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>The Company has an agreement, that was amended several times (hereafter &#8212; the agreements) with Yissum Research Development Company (hereafter &#8212; &#8220;Yissum&#8221;), the technology-licensing arm of the Hebrew University of Jerusalem.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 16</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
          <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 6&#8201;&#8212;&#8201;COMMITMENTS&#8201;</font>(continued):</div>
          <div><br>
            <div style="margin-left: 56.7pt; line-height: 1.25;">According to the agreements, the Company received from Yissum an exclusive and a non-exclusive license for the commercialization of certain Yissum patents. According to the agreements the
              Company shall pay Yissum:</div>
            <div style="margin-left: 56.7pt; line-height: 1.25;"> <br>
            </div>
            <div style="margin-left: 56.7pt; line-height: 1.25;">Royalties of 1.5% of net sales related to certain patents.</div>
            <div style="margin-left: 56.7pt; line-height: 1.25;"> <br>
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="zc1742217551248ed9b7f4429a64baf29" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 72pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">i.</td>
                    <td style="width: auto; vertical-align: top;">
                      <div>1.5%&#8201;&#8211;&#8201;8% of proceeds received by the Company for the sub-license or license of certain patents.<br>
                      </div>
                    </td>
                  </tr>

              </table>
              <div><br>
              </div>
              <div>
                <div style="margin-right: 1.7pt; margin-left: 56.7pt; line-height: 1.25;">Royalty expenses in immaterial amounts were recorded in 2018, 2019 and 2020 in respect of these agreements</div>
              </div>
              <br style="line-height: 1.25;">
            </div>
            <div style="margin-right: 1.7pt; margin-left: 56.7pt; line-height: 1.25;">According to the agreements, the Company may continue commercial use of certain Yissum&#8217;s patents in connection with the products and subject to the obligation to pay
              Yissum the royalties and the sub-license fees.<br>
              <br>
              The Company granted rights to a third party for use and commercialization of certain Yissum patents.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="z905397d8e1d84d10b0626edcd3bfaa66" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 20pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">b.</td>
                    <td style="width: auto; vertical-align: top;">
                      <div><font style="font-weight: bold;">Lease Agreements</font><br>
                      </div>
                    </td>
                  </tr>

              </table>
              <br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 38pt; line-height: 1.25;">
              <div style="line-height: 1.25;">The Company leases offices and vehicles under operating leases. For leases with terms greater than 12 months, the Company records right of use assets and lease liabilities at the present value of lease payments
                over the leases term.</div>
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
              <div style="margin-left: 38pt; line-height: 1.25;"><u>Offices</u></div>
              <div style="margin-left: 38pt; line-height: 1.25;">The Company leases office spaces and research and development facilities under several agreements. These agreements are linked to the change in the Israeli consumer price index and expire in
                December 2023. These agreements are considered as operating leases and presented under operating lease right-of-use assets and operating leases liabilities.&#160;A restricted deposit of $143 has been made in order to secure the agreement. <br>
                <br style="line-height: 1.25;">
              </div>
              <div style="margin-left: 38pt; line-height: 1.25;"><u>Vehicles</u></div>
              <div style="margin-left: 38pt; line-height: 1.25;">The Company has entered into operating lease agreements for vehicles used by its employees for a period of 3 years. These contracts are considered as operating leases and presented under
                operating lease right-of-use assets and operating leases liabilities.</div>
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 17</font></div>
                <div style="page-break-after: always;" id="DSPFPageBreak">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
            </div>
            <div style="text-align: center; margin-left: 20pt; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; margin-left: 20pt; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; margin-left: 20pt; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 6&#8201;&#8212;&#8201;COMMITMENTS&#8201;</font>(continued):</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <div style="margin-left: 38pt; line-height: 1.25;"><u>Lease Position</u></div>
              <div style="margin-left: 38pt; line-height: 1.25;"><br>
                The table below presents the lease-related assets and liabilities recorded on the consolidated balance sheet:</div>
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 93%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="za98baf96df3e480f81f6a0b47af646c1">

                <tr>
                  <td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="6">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">As of<br>
                      December 31,</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2020</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; background-color: rgb(204, 238, 255);">
                    <div style="margin-right: 2.55pt; line-height: 1.25; font-weight: bold;">Assets</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle;">
                    <div style="margin-right: 2.55pt; line-height: 1.25; font-weight: bold;">Operating Leases</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Operating lease right-of-use assets</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">2,040</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">1,896</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="margin-right: 2.55pt; line-height: 1.25; font-weight: bold;">Liabilities</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%;">
                    <div style="margin-right: 2.55pt; line-height: 1.25; font-weight: bold;">Current liabilities</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Current maturities of operating leases</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">672</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">673</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%;">
                    <div style="margin-right: 2.55pt; line-height: 1.25; font-weight: bold;">Long-term liabilities</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Non-current operating leases</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">1,373</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">1,299</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Weighted Average Remaining Lease Term</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%;">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Operating leases</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">1.66</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">1.29</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%;">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Weighted Average Discount Rate</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Operating leases</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">7.44</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">6.25</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">%</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 38pt; line-height: 1.25;"><u>Lease Costs</u></div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="line-height: 1.25;">
              <div style="margin-left: 38pt; line-height: 1.25;">The table below present certain information related to lease costs of operating leases the year ended December 31, 2020:</div>
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 93%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z189bca4764724745a014e2f7301a4530">

                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="6">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year</div>
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ended</div>
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31,</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2020</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Operating lease cost:</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">643</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">685</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25; clear: both;">
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <div style="line-height: 1.25;">
              <div style="margin-left: 38pt; line-height: 1.25;">The table below presents supplemental cash flow information related to leases for the year ended December 31, 2020:</div>
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 93%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="zcf28705bc8f54985bc6fdc8eeb00706b">

                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="6">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year</div>
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ended</div>
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31,</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2020</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Cash paid for amounts included in the measurement of leases liabilities:</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: middle; width: 76%;" colspan="1">
                    <div style="margin-right: 2.55pt; line-height: 1.25;">Operating cash flows from operating leases</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">807</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">735</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 18</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: center; margin-left: 20pt; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; margin-left: 20pt; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; margin-left: 20pt; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 6&#8201;&#8212;&#8201;COMMITMENTS&#8201;</font>(continued):</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <div style="text-indent: 36pt; line-height: 1.25;"><u>Undiscounted Cash Flows</u><br>
                <br style="line-height: 1.25;">
              </div>
            </div>
            <div style="line-height: 1.25;">
              <div style="margin-left: 36pt; line-height: 1.25;">The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities recorded on the consolidated
                balance sheet:</div>
            </div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"><br style="line-height: 1.25;">
              </div>
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="zd3bb0ab18d5d49dc9dada56d56d1d045">

                <tr>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Operating</div>
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Leases</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="text-indent: -8.5pt; margin-left: 11.35pt; line-height: 1.25;">&#160;For the year ended December 31, 2020</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%;">
                    <div style="margin-left: 8.15pt; line-height: 1.25;">2021</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">778</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
                    <div style="margin-left: 8.15pt; line-height: 1.25;">2022</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">714</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                    <div style="margin-left: 8.15pt; line-height: 1.25;">2023</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">648</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Total minimum lease payments</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">2,140</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%;" rowspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" rowspan="1">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" rowspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Less: amount of lease payments representing interest</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(168</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">Present value of future minimum lease payments</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">1,972</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Less:&#160; Current maturities of operating leases</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">673</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">Long-term operating leases liabilities</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">1,299</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">1,972</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z770f468da62e42938aa55590c6d29e43" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">c.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>
                      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In June&#160;2008, the Company entered into a Master Clinical Trial Services Agreement with a third party, which was later amended in April&#160;2017, to retain its
                        services as a clinical research organization for certain product candidate subject to task work orders to be issued by the Company. During 2018, the Company entered into six additional task orders. As consideration for its services
                        the Company will pay a total amount of approximately $14,425 during the term of the engagement and based on achievement of certain milestones, out of which $14,354 were recognized as an expense until December&#160;31, 2020.</div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="margin-left: 38pt; line-height: 1.25;"><br>
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="zc6c20d410f8f48c7a282d50dec86fcf9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 20pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">d.</td>
                    <td style="width: auto; vertical-align: top;">
                      <div>In 2016 through 2020, the Company entered into twelve collaboration agreements with two third parties for the development, manufacturing and commercialization of ten product candidates (including an agreement assumed by the
                        Company in August 2018, following the transfer of an in-process research and development product candidate from a related party). See detailed information in note 7b.<br>
                      </div>
                    </td>
                  </tr>

              </table>
              <div><br>
              </div>
            </div>
            <table cellspacing="0" cellpadding="0" id="z35b3af3e3b604c0f917e16d36a6c38b1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">e.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>
                      <div style="line-height: 1.25;">In October&#160;2017, the Company entered into a Clinical Development Master Services Agreement with a third party, to retain it as clinical research organization for certain product candidate, subject to
                        task work orders to be issued by the Company. As consideration for its services the Company will pay a total amount of approximately $13,955 during the term of the engagement and based on achievement of certain milestones, out of
                        which $13,801 were recognized as an expense until December&#160;31, 2020.</div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 19</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: center; margin-left: 20pt; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; margin-left: 20pt; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; margin-left: 20pt; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 6&#8201;&#8212;&#8201;COMMITMENTS&#8201;</font>(continued):</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"> </div>
            <table cellspacing="0" cellpadding="0" id="z62610358882041928953182433291290" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">f.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>
                      <div style="line-height: 1.25;">In July&#160;2018, the Company signed on a Master Services Agreement to receive certain clinical research services for certain product candidate subject to task work orders to be issued by the Company. As
                        consideration for the services in the first work order the Company will pay a total amount of approximately $2,234 during the term of the engagement and based on achievement of certain milestones, out of which $2,099 were recognized
                        as an expense until December&#160;31, 2020.</div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 7&#8201;&#8212;&#8201;COLLABORATION AGREEMENTS<br>
              </font><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z69f6c9ad58d04439a6a2789d55e7fe8f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">a.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales,
                      royalties are not material.</div>
                  </td>
                </tr>

            </table>
            <div><br>
            </div>
            <table cellspacing="0" cellpadding="0" id="z27cd88c288d14dcba4faaa3dbbfb4ac5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">b.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>
                      <div style="line-height: 1.25;">In 2016 through 2020, the Company entered into several collaboration agreements with two third parties for the development, manufacturing and commercialization of several generic product candidates.
                        Under the agreements, the third parties are obligated to conduct regulatory, scientific, clinical and technical activities necessary to develop the product and prepare and file ANDA, with the FDA and gain regulatory approval. The
                        Company participates in the development of the product candidates, including participation in joint steering committees and is obligated for sourcing the active pharmaceutical ingredient (API) during the development phase.</div>
                    </div>
                    <div><br>
                      <div style="line-height: 1.25;">Upon FDA approval, the third parties have exclusive rights and are required to use diligent efforts to commercialize these products in territories defined under the agreements, including all required
                        sales, marketing and distributing activities associated with the agreements. The Company is entitled to 50% of the third parties&#8217; gross profits related to the sale of these products, as such term is defined in the agreements.</div>
                      <br>
                      As of December 31, 2020, the Company decided not to pursue one of the agreements with one of the third parties collaborators.<br>
                      <br>
                      In February 2019, the Company announced that a third party has received final approval from the FDA for the first generic version of a drug product.&#160; During the years ended December 31, 2019 and 2020, the Company recognized
                      collaboration revenues related to sales of products in the U.S. under this agreement in the amounts of $22,775 and $8,673, respectively.<br>
                    </div>
                    <div>
                      <div style="line-height: 1.25;"><br>
                        This Agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative activity.<br>
                        <br style="line-height: 1.25;">
                      </div>
                      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Company recognizes collaboration revenues when the related sales occur<font style="font-family: 'Times New Roman', Times, serif;">.</font><font style="font-family: 'Times New Roman', Times, serif;"> </font> </div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; font-weight: bold;">NOTE 8&#8212;&#8201;SHARE CAPITAL</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="z8fa77ab4ec544cda8510b95deb82eef6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 18pt; vertical-align: top; align: right; font-weight: bold;">a.</td>
                    <td style="width: auto; vertical-align: top;">
                      <div style="font-weight: bold;">Ordinary shares<br>
                      </div>
                    </td>
                  </tr>

              </table>
              <br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="z8eb2dd07038b4695834632dcacda22be" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 20pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">1)</td>
                    <td style="width: auto; vertical-align: top;">
                      <div><font style="font-weight: bold;">Rights of the Company&#8217;s ordinary shares</font><br>
                        <br>
                        Each ordinary share is entitled to one vote. The holder of the ordinary shares is also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the
                        Company has not declared any dividends.<br>
                      </div>
                    </td>
                  </tr>

              </table>
              <br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 20</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="text-align: center; margin-left: 38pt; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 8&#8201;&#8212;&#8201;SHARE CAPITAL (</font>continued):</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="zfcc58fdf7aa343d4b9e4a0c228b544d7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">2)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>On January&#160;19, 2018, the Company executed a 1-for-1.8 share split of the Company&#8217;s shares by way of an issuance of bonus shares for each share. Upon the effectiveness of the share split, (i)&#160;0.8 bonus shares were issued for each
                      outstanding share, (ii)&#160;the number of ordinary shares into which each outstanding option to purchase ordinary shares is exercisable was proportionally increased, and (iii)&#160;the exercise price of each outstanding option to purchase
                      ordinary shares was proportionately decreased. Unless otherwise indicated, and except for authorized capital, all of the share numbers, loss per share amounts, share prices and option exercise prices in these financial statements have
                      been adjusted, on a retroactive basis, to reflect this 1-for-1.8 share split.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z60c56e9853dd4a50928dbc17e985ab49" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">3)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>In January 2018, the Company completed an Initial Public Offering ("IPO") on the NASDAQ Stock Market, in which it issued 6,250,000 Ordinary shares at a price per share of $12. During February 2018 the underwriters exercised their
                      green shoe option and purchased additional 937,500 ordinary shares at the same price per share.&#160;The total proceeds received from the IPO, net of issuance costs, were $78,775.<br>
                      <br>
                    </div>
                    <div style="font-family: 'Times New Roman',Times,serif;">
                      <div style="line-height: 1.25;">Immediately prior to the closing of the IPO, the outstanding promissory note received from its current controlling shareholder (the "Controlling Shareholder") were automatically converted into 5,444,825
                        Ordinary shares of the Company based on the IPO price of&#8201;$12 per ordinary share.</div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z4fd0d1b03c6b4f5b9bee3db9b6a2fce7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">4)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>On August 12, 2019, the Company completed an underwritten follow-on public offering, in which it issued 1,437,500&#160;ordinary shares,&#160;including the full exercise by the underwriters of their option to purchase&#160;187,500 additional
                      ordinary shares,&#160;at a&#160;public offering&#160;price of $8.00&#160;per ordinary share.<br>
                      The total proceeds received from the offering, net of issuance costs, were approximately $10,613.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="ze94b55ad01934790acb357e2db6b9a1b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">5)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>On February 19, 2020, the Company completed an underwritten public offering, in which it issued 2,091,907 ordinary shares and 2,091,907 warrants to purchase up to 1,673,525 ordinary shares, at a public offering price of $11.00 per
                      ordinary shares. The warrants are exercisable over a three-years period from the date of issuance at a per share exercise price of $14, subject to certain adjustments as defined in the agreement.&#160;The total proceeds received from the
                      offering, net of&#160;issuance costs, were approximately $21,306.</div>
                  </td>
                </tr>

            </table>
            <div style="margin-left: 38pt; line-height: 1.25;"> <br>
            </div>
            <div style="margin-left: 38pt; line-height: 1.25;">In addition and in parallel to the public offering, the Company signed an agreement for a private placement with its controlling shareholder for an additional investment of approximately $5,000
              in consideration of 454,628 ordinary shares and 454,628 warrants to purchase up to 363,702 ordinary shares, at the same terms of the underwritten public offering mentioned above. The private placement agreement was contingent on certain
              conditions and was approved by the company&#8217;s shareholders on April 8, 2020.&#160; The total proceeds of $5,000 were received&#160;in April 2020.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="zfda0292c5dc449c5a54c23cb1aeb159c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt; vertical-align: top; align: right; font-weight: bold;">b.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Share-based compensation:</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="z0b21a8a2fdcb4a3083fe3032d3d5a858" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 20.15pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">1)</td>
                    <td style="width: auto; vertical-align: top;">
                      <div><font style="font-weight: bold;">Option plan</font><br>
                      </div>
                    </td>
                  </tr>

              </table>
              <br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; margin-left: 38pt; line-height: 1.25;">In December, 2014, the Company&#8217;s Board of Directors approved a Share Incentive Plan (hereafter &#8212; the Plan) and reserved a pool of 629,025 ordinary shares, par value NIS 0.1
              each, or such other number as the Board may determine, subject to certain terms and conditions as defined in the Plan. According to the Plan, the Company may issue shares or restricted shares, may grant options or restricted share units and
              other share-based awards (hereafter &#8212; the awards) to the Company employees, consultants, directors and other service providers.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; margin-left: 38pt; line-height: 1.25;">The Plan is designed to enable the Company to grant awards to purchase Ordinary Shares under various and different tax regimes including, without limitation: pursuant and
              subject to Section 102 of the Israeli Tax Ordinance and pursuant and subject to Section 3(i) of the Israeli Tax Ordinance and under Internal revenue Code Section 422.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 21</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 8&#8201;&#8212;&#8201;SHARE CAPITAL (</font>continued):</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; margin-left: 38pt; line-height: 1.25;">The awards may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of
              the awards is 10 years. The fair value of each option granted under this Plan is estimated using the Black-Scholes option pricing method. Expected volatility is based on the historical volatility of comparable peer companies.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 38pt; line-height: 1.25;">The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted in dollar terms. <font style="font-family: 'Times New Roman', Times, serif;">The expected term of the options is estimated based on the simplified method, as its historical experience for options grants as a public company is insufficient.</font><font style="font-family: 'Times New Roman', Times, serif;"><br>
              </font><font style="font-family: 'Times New Roman', Times, serif;"><br>
              </font>In December 2019, the Company&#8217;s Board of Directors approved an increase of the ordinary shares that may be issued under the Company&#8217;s Plan by reserving an additional amount of 912,230 ordinary shares.</div>
            <div style="margin-left: 38pt; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: justify; margin-left: 38pt; line-height: 1.25;">As of December 31, 2020, 949,415 ordinary shares remain available for future grants under the Plan.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="z93a633ddd1db481aacea15e042b9702e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 20.15pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">2)</td>
                    <td style="width: auto; vertical-align: top;">
                      <div><font style="font-weight: bold;">Options grants</font><br>
                      </div>
                    </td>
                  </tr>

              </table>
              <br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z9005236ad7ae411793e0a26cda0d10a0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 54pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">a.</td>
                  <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>Option granted to employees and directors</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z1b8ebecfd9ec453881039d2deb7ffa3e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 85.05pt;"><br>
                  </td>
                  <td style="width: 21.3pt; vertical-align: top; align: right;">i.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>In January 2019, the Company granted a total of 80,000 options to an executive officer to purchase ordinary shares at an exercise price of $5.95 per share.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="za7081ac888d64c28b3e7464a194600e7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 85.05pt;"><br>
                  </td>
                  <td style="width: 21.3pt; vertical-align: top; align: right;">ii.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>In May 2019, the Company granted a total of 9,000 options to several employees to purchase ordinary shares at an exercise price of $7.32 per share.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z3c0e048d8d7a4f5d9e71d3c3b4b6923c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 85.05pt;"><br>
                  </td>
                  <td style="width: 21.3pt; vertical-align: top; align: right;">iii.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>In December 2019, the Company granted a total of 6,300 options to several employees to purchase ordinary shares at an exercise price of $8.32 per share.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 72pt; line-height: 1.25;">The options vest over a period of 4 years; 25% of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over
              the following three years. The options expire on the tenth anniversary of their grant date.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 72pt; line-height: 1.25;">The fair value of options granted to employees and directors in 2018 and 2019 were $878 and $485 respectively. The underlying data used for computing the fair value of the options are as
              follows:</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" id="zd132b3fd475547dba6e7e8ceae2bfccd" style="width: 90%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

                <tr>
                  <td style="width: 46.21%; vertical-align: top;">&#160;</td>
                  <td style="width: 25.06%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2018</div>
                  </td>
                  <td style="width: 1.83%; vertical-align: top;">&#160;</td>
                  <td style="width: 25.12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2019</div>
                  </td>
                  <td style="width: 1.78%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Value of one ordinary share</div>
                  </td>
                  <td style="width: 25.06%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">$6.24-$10.40</div>
                  </td>
                  <td style="width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td style="width: 25.12%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">$6.08-$8.59</div>
                  </td>
                  <td style="width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 46.21%; vertical-align: top;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Dividend yield</div>
                  </td>
                  <td style="width: 25.06%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">0%</div>
                  </td>
                  <td style="width: 1.83%; vertical-align: top;">&#160;</td>
                  <td style="width: 25.12%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">0%</div>
                  </td>
                  <td style="width: 1.78%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Expected volatility</div>
                  </td>
                  <td style="width: 25.06%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">70.43 %-73.35%</div>
                  </td>
                  <td style="width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td style="width: 25.12%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">74.87%-77.83 %</div>
                  </td>
                  <td style="width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 46.21%; vertical-align: top;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Risk-free interest rate</div>
                  </td>
                  <td style="width: 25.06%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.67%-2.83%</div>
                  </td>
                  <td style="width: 1.83%; vertical-align: top;">&#160;</td>
                  <td style="width: 25.12%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1.82%-2.75%</div>
                  </td>
                  <td style="width: 1.78%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Expected term</div>
                  </td>
                  <td style="width: 25.06%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">5.50-7 years</div>
                  </td>
                  <td style="width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td style="width: 25.12%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">6.11 years</div>
                  </td>
                  <td style="width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 22</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 8&#8201;&#8212;&#8201;SHARE CAPITAL (</font>continued)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 72pt; line-height: 1.25;">The total unrecognized compensation cost of employee options at December&#160;31, 2020 is $271, which is expected to be recognized over a period of 2.96 years.</div>
            <div style="margin-left: 72pt; line-height: 1.25;"><br>
              The following table summarizes the number of options granted to employees under the Plan for the years ended December&#160;31, 2019 and 2020, and related information:</div>
            <div style="margin-left: 76.3pt; line-height: 1.25;"> <br>
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 90%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z8504eda92ce2497294e9b56e1f571d96">

                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="22">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year ended December 31</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="10">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="10">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of options</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Weighted average exercise price</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Weighted average remaining contractual life</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of options</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Weighted average exercise price</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Weighted average remaining contractual life</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt;">Options outstanding at the beginning of the year</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">938,090</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">4.47</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">7.89</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">1,031,591</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">4.74</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">7.25</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%;">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Granted</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">95,300</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">6.24</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">9.17</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Exercised</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(28,447</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">5.27</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%;">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Expired</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">(563</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">5.57</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">-</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Forfeited</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">(1,238</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">)</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">5.57</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">-</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">(2,250</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">)</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">7.77</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">-</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%; padding-bottom: 4px;">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Options outstanding at the end of the year</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">1,031,591</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">4.74</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">7.25</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">1,000,894</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">4.63</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">6.05</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Options exercisable at the end of the year</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">683,979</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">3.60</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">6.56</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">900,687</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">4.08</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">5.67</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>

            </table>
            <div style="margin-left: 76.3pt; line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="z060c11d49c1742b1bab4681a407a72f5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 54pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">b.</td>
                    <td style="width: auto; vertical-align: top;">
                      <div>Option granted to non-employees<br>
                      </div>
                    </td>
                  </tr>

              </table>
              <br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 72pt; line-height: 1.25;">In March 2018, the Company granted a total of 76,895 options to several consultants to purchase ordinary shares at an exercise price of $11.21 per share.<br>
              <br>
              The options vest over a period of 4 years; 25% of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over the following three years. The options expire on
              the tenth anniversary of their grant date.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 72pt; line-height: 1.25;">The fair value of options granted to non-employees in 2018 was $648. The underlying data used for computing the fair value of the options are as follows:</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table align="center" cellspacing="0" cellpadding="0" border="0" id="zb5166ac1be864ad599232c6ce037f683" style="width: 80%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

                <tr>
                  <td style="width: 71%; vertical-align: top;">&#160;</td>
                  <td style="width: 2.5%; vertical-align: top;">&#160;</td>
                  <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2018</div>
                  </td>
                  <td style="width: 2.42%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Value of one ordinary share</div>
                  </td>
                  <td style="width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td style="width: 25%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">$ 10.40</div>
                  </td>
                  <td style="width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 71%; vertical-align: top;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Dividend yield</div>
                  </td>
                  <td style="width: 2.5%; vertical-align: top;">&#160;</td>
                  <td style="width: 25%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">0%</div>
                  </td>
                  <td style="width: 2.42%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Expected volatility</div>
                  </td>
                  <td style="width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td style="width: 25%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">79.07%</div>
                  </td>
                  <td style="width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 71%; vertical-align: top;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Risk-free interest rate</div>
                  </td>
                  <td style="width: 2.5%; vertical-align: top;">&#160;</td>
                  <td style="width: 25%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2.86%</div>
                  </td>
                  <td style="width: 2.42%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Expected term</div>
                  </td>
                  <td style="width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td style="width: 25%; vertical-align: top; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">10 years</div>
                  </td>
                  <td style="width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 72pt; line-height: 1.25;">The total unrecognized compensation cost of non-employees' options at December&#160;31, 2020 is $25, which is expected to be recognized over a period of 1.23&#160;years.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 23</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 8&#8201;&#8212;&#8201;SHARE CAPITAL&#8201;</font>(continued)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 70.9pt; line-height: 1.25;">The following table summarizes the number of options granted to non-employees under the Plan for the year ended December&#160;31, 2019 and 2020, and related information:</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 90%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="zb2de4e2f65a649efac2a1f4896b9f69f">

                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="22" rowspan="1">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year ended December 31</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="10">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="10">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;"><font style="line-height: 1.25;"> </font></div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of options</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Weighted average exercise price</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Weighted average remaining contractual life</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of options</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Weighted average exercise price</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="line-height: 1.25;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Weighted average remaining contractual life</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; text-indent: -9pt; margin-left: 9pt;">Options outstanding at the beginning of the year</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">198,575</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">7.48</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">8.81</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">198,575</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">7.48</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">7.84</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%; padding-bottom: 2px;">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Granted</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">-</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">-</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">-</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">-</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">-</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">-</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Options outstanding at the end of the year</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">198,575</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">7.48</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">7.84</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">198,575</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">7.70</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">6.84</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 28%; padding-bottom: 4px;">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Options exercisable at the end of the year</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">96,588</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">6.97</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">7.78</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">137,771</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">7.34</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">6.8</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                </tr>

            </table>
            <div style="margin-left: 70.9pt; line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="zb5378c024eca4291a968ee7fce692323" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 54pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">c.</td>
                    <td style="width: auto; vertical-align: top;">
                      <div>The aggregate intrinsic value of the total outstanding and of total exercisable options as of December 31, 2020 is approximately $482 and $413, respectively.<br>
                      </div>
                    </td>
                  </tr>

              </table>
              <div><br>
              </div>
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="z6bdd89df0c0d4d09a2903226774a5021" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 54pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; align: right;">d.</td>
                    <td style="width: auto; vertical-align: top;">
                      <div>Restricted Share Units (RSUs) granted to Directors<br>
                        <br>
                        In February 2018 and September 2018, the board of directors approved and recommended the Company shareholders to approve a total grant of 46,000 and 11,500 RSUs, respectively, to its independent and external directors that vest
                        annually in equal portions over a three-year period. The fair value of shares as of the date of grant was $495 and $105 respectively. As of December 31, 2020, 38,332 RSUs were vested.<br>
                      </div>
                    </td>
                  </tr>

              </table>
              <br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="zaf6f739ae1274c2497a12e2429df894b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 54pt;"><br>
                    </td>
                    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">e.</td>
                    <td style="width: auto; vertical-align: top;">
                      <div>The following table illustrates the effect of share-based compensation on the statements of operations:<br>
                      </div>
                    </td>
                  </tr>

              </table>
              <br style="line-height: 1.25;">
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 90%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z242876e0ae6a4d3180613b645b513bc5">

                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="10">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year ended<br>
                      December 31</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2018</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">2019</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Research and development expenses</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">2,708</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">1,028</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">431</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">General and administrative expenses</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">1,946</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">1,524</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">786</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">4,654</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">2,552</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">1,217</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 24</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; font-weight: bold;">NOTE 9&#8201;&#8212;&#8201;TAXES ON INCOME</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="zafcb5a0dbf77404cbc014740969eb7b3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">a.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Tax rates in Israel</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">The Company is taxed in accordance with Israeli tax laws. The corporate tax rates applicable to 2018, 2019 and 2020 is 23%. Capital gain is subject to capital gain tax according to the
              corporate tax rate in the year the assets are sold.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z9f68172d194443cf92430c81892fb78e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">b.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Tax rates for the U.S Subsidiary</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">The subsidiary is taxed according to U.S. tax laws. The Company&#8217;s income is taxed in the United States at the federal rate of 21%.<br>
              <br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z7f798157ebb3419994c9166d9fb8fb9f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">c.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;)</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">Under the Investment Law, including Amendment No. 60 to the Investment Law that was published in April&#160;2005, by virtue of the Benefited Enterprise program for certain of its facilities; the
              Company may be entitled to various tax benefits.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">The main benefit arising from such status is the reduction in tax rates on income derived from a Benefited Enterprise. The extent of such benefits depends on the location of the enterprise.
              Since the Company&#8217;s facilities are not located in &#8220;national development zone A,&#8221; income derived from Benefited Enterprises will be tax exempt for a period of two years and then have a reduced tax rate for a period of up to an additional eight
              years.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">The period of tax benefits, as described above, is limited to 12 years from the beginning of the Benefited Enterprise election year (2012). As of December&#160;31, 2020, the period of benefits has
              not yet commenced.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">In the event of distribution of cash dividends from income, which was tax exempt as above, the amount distributed will be subject to the tax rate it was exempted from. The Company is entitled
              to claim accelerated depreciation in respect of equipment used by the approved enterprises during five tax years.</div>
            <div style="margin-left: 20pt; line-height: 1.25;"> <br>
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">Entitlement to the above benefits is conditioned upon the Company fulfilling the conditions stipulated by the Investment Law and regulations published thereunder.</div>
            <div style="margin-left: 20pt; line-height: 1.25;"> <br>
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">In the event of failure to comply with these conditions, the benefits may be canceled and the Company may be required to refund the amount of the benefits, in whole or in part, with the
              addition of linkage differences to the Israeli consumer price index and interest.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">The Investment Law was amended as part of the Economic Policy Law for the years 2011&#160;&#8211;&#160;2012 (the &#8220;Amendment&#8221;), which became effective on January&#160;1, 2011 and was further amended in August 2013
              and January 2017.<br>
              <br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">Under the 2017 Amendment, and provided the conditions stipulated therein are met, income derived by Preferred Companies from &#8216;Preferred Technological Enterprises&#8217; (&#8220;PTE&#8221;) (as defined in the
              2017 Amendment), would be subject to reduced corporate tax rates of 7.5% in Development Zone &#8220;A&#8221; and 12% elsewhere, or 6% in case of a &#8216;Special Preferred Technological Enterprise&#8217; (&#8220;SPTE&#8221;) as defined in the 2017 Amendment) regardless of the
              company&#8217;s geographical location within Israel. A Preferred Company distributing dividends from income derived from its PTE or SPTE, would subject the recipient to a 20% tax (or lower, if so provided under an applicable tax treaty). The 2017
              Amendment further provides that, in certain circumstances, a dividend distributed to a corporate shareholder who is not an Israeli resident for tax purposes would be subject to a 4% tax (inter alia, if the amount of foreign investors in the
              distributing company exceeds 90%). Such taxes would generally be withheld at source by the distributing company.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 25</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 9&#8201;&#8212;&#8201;TAXES ON INCOME </font><font style="font-weight: bold;">(</font>continued)</div>
            <div style="margin-left: 20pt; line-height: 1.25;"><br>
              On June 14, 2017, the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017 (the &#8220;Regulations&#8221;) were published, which adopted Action 5 under the base erosion
              and profit shifting (&#8220;BEPS&#8221;) regulations. The Regulations describe, inter alia, the mechanism used to determine the calculation of the benefits under the PTE and under the SPTE Regime and determine certain requirements relating to
              documentation of intellectual property for the purpose of the PTE. According to these provisions, a company that complies with the terms under the PTE regime may be entitled to certain tax benefits with respect to income generated during the
              company&#8217;s regular course of business and derived from the preferred intangible asset (as determined in the Investments Law), excluding income derived from intangible assets used for marketing and income attributed to production activity. In
              the event that intangible assets used for marketing purposes generate over 10% of the PTE&#8217;s income, the relevant portion, calculated using a transfer pricing study, would be subject to regular corporate income tax. If such income does not
              exceed 10%, the PTE will not be required to exclude the marketing income from the PTE&#8217;s total income. The Regulations set a presumption of direct production expenses plus 10% with respect to income related to production, which can be
              countered by the results of a supporting transfer pricing study. Tax rates applicable to such production income expenses will be similar to the tax rates under the Preferred Enterprise regime, to the extent such income would be considered as
              eligible. In order to calculate the preferred income, the PTE is required to take into account the income and the research and development expenses that are attributed to each single preferred intangible asset. Nevertheless, it should be
              noted that the transitional provisions allow companies to take into account the income and research and development expenses attributed to all of the preferred intangible assets they have.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">Under the transitional provisions of the law, a company is allowed to continue to enjoy the tax benefits available under the law prior to its amendment until the end of the period of benefits,
              as defined in the law. In each year during the period of benefits as a Benefited Enterprise, the Company will be able to opt for application of the amendment, thereby making available the tax rates discussed above. The Company&#8217;s election to
              apply the amendment is irrecoverable.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">As of December&#160;31, 2020, the Company&#8217;s management decided not to adopt the application of the Amendment.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">There is no assurance that future taxable income of the Company will qualify as Benefited or Preferred income or that the benefits described above will be available to the Company in the
              future.</div>
            <div style="margin-left: 20pt; line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="za6788c86eeaa4adda5a5cca049c2b07d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">d.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Tax assessments</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">Tax assessments filed by the Company through the year 2015 are considered to be final.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 26</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;"><font style="font-weight: bold;">NOTE 9&#8201;&#8212;&#8201;TAXES ON INCOME </font><font style="font-weight: bold;">(</font>continued)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="zadebd1412dd84e49ac50920812a568ad" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">e.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Losses for tax purposes carried forward to future years</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">As of December&#160;31, 2020, the Company had approximately $151.4 million of net carry forward tax losses which are available to reduce future taxable income with no limited period of use.<br>
              <br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z0356fe2a933a4536a0e14eecb1af6ec9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">f.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Deferred income taxes:</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z48e34922d0dc4e97a12bd3715a9a8159">

                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">December, 31</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">In respect of:</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%;">
                    <div style="line-height: 1.25;">Net operating loss carry forward</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">25,879</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">34,835</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25; font-family: &#38;quot;">Research and development expenses</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">7,842</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">7,133</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%;">
                    <div style="line-height: 1.25;">Other</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">1,226</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">1,085</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Less&#8201;&#8211;&#8201;valuation allowance</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(34,947</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">(43,053</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">)</div>
                  </td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                    <div style="line-height: 1.25;">Net deferred tax assets</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">&#8212;</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">&#8212;</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z3d861b0c288b4988b8d969b13b072614" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">g.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Reconciliation of theoretical tax expenses to actual expenses</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">Actual tax expenses are in respect of the U.S. subsidiary. The primary reconciling items between the statutory tax rate of the Company and the effective rate are the full valuation allowance of
              deferred tax assets and nondeductible expenses in relation to the operations in Israel.<br>
              <br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z46e47d0cd1f6456f88d75a17f843be40" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">h.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Roll forward of valuation allowance</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z7da7b359ed9d4f239f9f2621cf1bb85b">

                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Balance at January 1, 2018</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">21,982</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">Additions</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">4,184</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Balance at December 31, 2018</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">26,166</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">Additions</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">8,781</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Balance at December 31, 2019</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">34,947</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                    <div style="line-height: 1.25;">Additions</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">8,106</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Balance at December 31, 2020</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">$</div>
                    </div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">43,053</div>
                    </div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z30097f43e4894caf9a50737470e45e3d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 20.15pt; vertical-align: top; align: right; font-weight: bold;">i.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">Provision for uncertain tax positions</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-left: 20pt; line-height: 1.25;">As of December&#160;31, 2019, and 2020, the Company does not have a provision for uncertain tax positions.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
              <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 27</font></div>
              <div style="page-break-after: always;" id="DSPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
            <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</font>&#8201;(continued)</div>
            <div style="text-align: center; line-height: 1.25;">(U.S. dollars in thousands, except share and per share amounts)</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; font-weight: bold;">NOTE 10&#8201;&#8212;&#8201; &#160;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-indent: -21.3pt; margin-left: 39.3pt; line-height: 1.25;">Other accounts payables and accruals</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table align="right" cellspacing="0" cellpadding="0" border="0" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="za1f580f57fe44685a5e67f5546f31902">

                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">December, 31</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> 2019</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; line-height: 1.25; font-weight: bold;">2020</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Accrued expenses</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">3,249</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">3,250</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%;">
                    <div style="line-height: 1.25;">Employees payables</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">841</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                    <div style="line-height: 1.25;">812</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                    <div style="line-height: 1.25;">Other</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">33</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1">
                    <div style="line-height: 1.25;">26</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
                </tr>
                <tr>
                  <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">4,123</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                  <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">$</div>
                  </td>
                  <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
                    <div style="line-height: 1.25;">4,088</div>
                  </td>
                  <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; font-weight: bold;">NOTE 11&#8201;&#8212;&#8201;RELATED PARTIES</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="zf003d7e6af31422597f9239a41dc021d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">a.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>Related parties include the Controlling Shareholder and companies under his control, the Board of Directors and the Executive Officers of the Company.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="z66b62cc7c3624fe7a98fdf038818bee0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">b.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>As to options and restricted shares granted to directors and executive officers, see note 8b.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" id="zb5477391df374a25a6630398886bec9d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">c.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>As to issuance of shares and warranted to the controlling shareholder in a private placement for a total consideration of $5,000, see note 8a (4).</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <br>
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">F - 28<br>
          </font>
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber"> </font></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>exhibit_4-5.htm
<DESCRIPTION>EXHIBIT 4.5
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 4.5</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">COMPENSATION POLICY</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Compensation Policy for Executive Officers and Directors</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">ADOPTED: October 2, 2017</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%A - %%-->
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;<u>Table of Contents</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="z88ca091fcd9c45fbb68aca4a99dd2adc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1"><font style="font-family: 'Times New Roman', Times, serif;"><u>Page</u></font></td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">A.</td>
                <td style="width: 92%; vertical-align: top;">Overview and Objectives</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman', Times, serif;">A -</font><font style="font-family: 'Times New Roman', Times, serif;"> 3</font></td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" border="0" id="z48006960c9784b10831c2e4fb17ac78c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">B.</td>
                <td style="width: 92%; vertical-align: top;">Base Salary and Benefits</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman', Times, serif;">A -</font><font style="font-family: 'Times New Roman', Times, serif;"> 5</font></td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="zdc45a2a943ab45f7a76b789b0f875175" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 3%; vertical-align: top;">C.</td>
                <td style="width: 92%; vertical-align: top;">Cash Bonuses&#160;(Excluding Directors)</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">A - 6</td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="z46a5b6e9662b46c287b0bf31ebca7d41" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">D.</td>
                <td style="width: 92%; vertical-align: top;">Equity-Based Compensation</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman', Times, serif;">A -</font><font style="font-family: 'Times New Roman', Times, serif;"> 8</font></td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">E.</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">
                  <div>Retirement and Termination of Service Arrangements (Excluding Directors)</div>
                </td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1"><font style="font-family: 'Times New Roman', Times, serif;">A -</font><font style="font-family: 'Times New Roman', Times, serif;"> 9<br>
                  </font></td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="zc61c628796bf4cf9ae40acb79ebf703e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">F.</td>
                <td style="width: 92%; vertical-align: top;">Exemption, Indemnification and Insurance</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman', Times, serif;">A -</font><font style="font-family: 'Times New Roman', Times, serif;"> 10</font></td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="ze65c468aa131487291095cf57316764a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 3%; vertical-align: top;">G.</td>
                <td style="width: 92%; vertical-align: top;">Arrangements upon Change of Control</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">A - 11</td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="z979397b8bbab4222afa11b2b99c9abfd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">H.</td>
                <td style="width: 92%; vertical-align: top;">Board of Directors Compensation</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman', Times, serif;">A -</font><font style="font-family: 'Times New Roman', Times, serif;"> 11</font></td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 92%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="z94c000a9b71b4a0eb58c05a81f6251ae" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 3%; vertical-align: top;">I.</td>
                <td style="width: 92%; vertical-align: top;">Miscellaneous</td>
                <td style="width: 5%; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">A - 12</td>
              </tr>

          </table>
        </div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 2</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">A. <u>Overview and Objectives</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zbdf5ff7e2f7443a4b56655660627abb5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Introduction</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="6eedd2b67cc24fb3b364709caf92bc09" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This document sets forth the
                  compensation policy for executive officers (this "<font style="font-weight: bold;">Compensation Policy</font>"<font style="font-weight: bold;">&#160;</font>or "<font style="font-weight: bold;">Policy</font>")<font style="font-weight: bold;">&#160;</font>of Sol-Gel Technologies Ltd. ("<font style="font-weight: bold;">Sol-Gel" </font>or the "<font style="font-weight: bold;">Company</font>" and "<font style="font-weight: bold;">Executive Officers</font>", accordingly),<font style="font-weight: bold;">&#160;</font>in accordance with the requirements of the Companies Law 5759-1999 (the "<font style="font-weight: bold;">Companies Law</font>").</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Compensation is a key component of Sol-Gel's overall human capital strategy to attract, retain, reward, and motivate
                highly skilled individuals that will enhance Sol-Gel's value and otherwise assist Sol-Gel to reach its business and financial short and long term goals. Accordingly, the structure of this Policy was established to tie the compensation of
                each Executive Officer to Sol-Gel's goals and performance.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">For purposes of this Policy, "<font style="font-weight: bold;">Executive Officers</font>" shall mean "Office Holders" as such term is defined in Section 1 of the Companies Law.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This Compensation Policy shall apply to compensation agreements and arrangements which will be approved after the date
                on which this Compensation Policy is approved by the general meeting of Sol-Gel's shareholders and shall serve as Sol-Gel&#8217;s Compensation Policy for the maximum period of time permitted by any applicable law.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Compensation Committee (upon its appointment in accordance with the applicable law) and the Board of Directors of
                Sol-Gel (the "<font style="font-weight: bold;">Compensation Committee</font>" and "<font style="font-weight: bold;">Board</font>", respectively) shall review and reassess the adequacy of this Policy from time to time, as required by the Companies Law.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">It should be clarified, that wherever reference is made to the required approvals in this Compensation Policy, such
                reference relates to the applicable law as of the date of approval of this Compensation Policy and in any case is subject to the provisions of sections 32 and 34 below.</div>
            </td>
          </tr>

      </table>
      <br>
      <table cellspacing="0" cellpadding="0" id="z708f4565a3a84926acc04dfd9014a581" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Objectives</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="f1fde3996a374059959889552e691531" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Sol-Gel's objectives and goals in setting this Compensation Policy are to attract, motivate and retain highly
                experienced personnel who will provide leadership for Sol-Gel's success and enhance the Company's shareholders' value, while supporting a performance culture that is based on merit, and rewards excellent performance in the short and long
                term, while recognizing Sol-Gel's core values. To that end, this Policy is designed, among others:</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zf78f1aa282e04ba4830757ecddc83868" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">2.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To closely align the interests of the Executive Officers with those of Sol-Gel's shareholders in order to enhance shareholder value;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z12cde6a8adf044f8af0828d94a55439c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">2.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To provide the Executive Officers with a structured compensation package, while creating a balance between the fixed components, <font style="font-style: italic;">i.e.</font>, the base salaries and benefits, and the variable compensation, such as bonuses and equity-based compensation in order to minimize potential conflicts between
                the interests of Executive Officers and those of Sol-Gel;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z61f7cbbfbc0643e18361244ca7ec6c45" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">2.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To strengthen the retention and the motivation of Executive Officers in the short and long term.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z21ad111fae544ead8f747515b7df4e48" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">2.4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>This Compensation Policy was prepared taking into account the Company's nature, size and business and financial characteristics.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z56fa3e1cb3b843138d5d3d720787bc8a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Compensation structure and instruments</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ae26f479d4384154b2922497bbff4f66" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">29.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Compensation instruments under this Compensation Policy may include the following:</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z728e1dff084c478a9c86d1b75f4cfa58" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Base salary;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 3</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="ze0debd32a9fd44128675b0e3fe3b8638" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Benefits and perquisites;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0924219e443e457686623d4bb3f9390e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Cash bonuses (short-to-medium term incentive);</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf6f28138560e48059d5878f5f4d93a82" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Equity based compensation (medium-to-long term incentive); and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd3f6293077dd4cf8be8d05160c29aae4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Retirement and termination of service arrangements payments.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="2e01418379a24156a22ebd72038125b2" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">For the purpose of this Compensation Policy:</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
              </div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">"Base Salary" shall mean: gross salary, before contributions to social benefits ("<font style="font-weight: bold;">Base Salary</font>"); "Employment Cost" shall mean: any payment for the
                employment, including contributions to social benefits, car and expenses of the use thereof, bonuses and any other benefit or payment ("<font style="font-weight: bold;">Employment</font>&#160;<font style="font-weight: bold;">Cost</font>").</div>
            </td>
          </tr>

      </table>
      <br>
      <table cellspacing="0" cellpadding="0" id="z01263e1b0a8743b28dbfe6f6d6c8edb5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Overall Compensation - Ratio Between Fixed and Variable Compensation</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="cf3dc65d105d4b31afaeb29d23afa8f2" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This Policy aims to balance the
                  mix of "fixed compensation", comprised of base salary&#160;and benefits ("<font style="font-weight: bold;">Fixed Compensation</font>") and "variable compensation", comprised of cash bonuses and equity based compensation<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> (excluding
                  adjustment period/retirement bonuses, granted in accordance with section 21 below) ("<font style="font-weight: bold;">Variable Compensation</font>") in order to, among other things, appropriately incentivize Executive Officers to meet Sol-Gel's short and long term goals while taking into consideration
                  the Company&#8217;s need to manage a variety of business risks.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The total Variable Compensation of each Executive Officer shall not exceed 85% of the total compensation package of
                such an Executive Officer on an annual basis. The Board believes that such range expresses the appropriate compensation mix in the event that all performance objectives are achieved and assumes that all compensation elements are granted
                with respect to a given year.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">It should be clarified, that the Fixed Compensation may constitute 100% of the total compensation package for an
                Executive Officer in any year (under circumstances in which a variable component will not be approved for that year and/or in the event of a failure to meet the set goals, if and when determined).</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z0d18912b42b24c9992390e9c74c0b23b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Intra-Company Compensation Ratio</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="1f96dd8e419d472794a2349f99729f4e" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">29.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In the process of drafting this
                  Policy, Sol-Gel&#8217;s Board has examined the ratio between employer cost, as such term is defined in the Companies Law, associated with the
                  engagement of the Executive Officers (the "<font style="font-weight: bold;">Executive Officers Cost</font>") and the average and median employer cost associated with the engagement of the other employees of Sol-Gel (the "<font style="font-weight: bold;">Other Employees Cost</font>" and the "<font style="font-weight: bold;">Ratio</font>", respectively). The Board
                  believes that the current Ratio does not adversely impact the work environment in Sol-Gel. The following are the ratios as of the date of the approval of this Compensation Policy:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="2" border="0" align="center" id="z1d3d8946f4ff427b8e339aac872d0fce" style="width: 80%; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: left;">

          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Position</div>
            </td>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ratio between the Executive Officers Cost and the average Other Employees Cost</div>
            </td>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ratio between the Executive Officers Cost and the median Other Employees Cost</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CEO</div>
            </td>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">8.12</div>
            </td>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">10.64</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Other Executive Officers</div>
            </td>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">3.12</div>
            </td>
            <td style="width: 33%; vertical-align: middle; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">4.16</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;<br>
        <hr noshade="noshade" align="left" style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 28.35pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Based on the fair value on the date of grant, calculated annually, on a linear basis.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 4</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">B. </font><font style="font-weight: bold;"><u>Base Salary</u></font><font style="font-weight: bold;"><u>&#160;</u></font><font style="font-weight: bold;"><u>and</u></font><u>&#160;</u><font style="font-weight: bold;"><u>Benefits</u></font></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb76451b63c4f47b98ea82988e735c903" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">6.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Base Salary</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z249f2bfffb4b465f91ce1f63d9f58e5e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">6.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Base Salary varies between Executive Officers, is individually determined by the Company (subject to the approvals of the Compensation Committee and the Board,
                and with respect to the CEO, also the Company's general meeting of shareholders) and may be considered and adjusted by the Company (subject to the approvals of the abovementioned organs) on a periodically basis, according<font style="font-weight: bold;">&#160;</font>to, among others, the educational background, prior vocational experience, expertise and qualifications, role, business authorities and
                responsibilities, past performance and previous compensation arrangements of such Executive Officer, as well as the Company's financial state and cash position and any requirements or restrictions prescribed by any applicable legislation,
                from time to time. When determining the Base Salary, the Company may also decide to consider, at the sole discretion of the Compensation Committee and the Board and as required, the prevailing pay levels in the relevant market, Base Salary
                and the total compensation package of comparable Executive Officers in the Company, the proportion between the Executive Officer's compensation package and the salaries of other employees in the Company and specifically the median and
                average salaries and the effect of such proportions on the work relations in the Company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z5be054105d0f4f05bfbf5903804ee10a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">7.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Benefits</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z1c3ee2e7fa0b412fbde9592a32d28d02" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">7.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In addition to the Base Salary, the following benefits may be granted to the Executive Officers (subject to the approvals of the Compensation Committee and the Board,
                and with respect to the CEO- also the Company's general meeting pf shareholders), in order, among other things, to comply with legal requirements. It shall be clarified, that the list below is an open list and Sol-Gel (subject to the
                abovementioned required approvals) may grant to its Executive Officers other similar, comparable or customary benefits, subject to the applicable law. In addition, Executive Officers employed outside of Israel may receive other similar,
                comparable or customary benefits as applicable in the relevant jurisdiction in which they are employed.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z2622e5cca3834187acb22720c7e8a249" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Vacation days in accordance with market practice and the applicable law, up to a cap of 30 days per annum;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf9e764a29c594ebab0e345ba200d8ddd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Sick days in accordance with market practice and the applicable law; However, the Company may decide to cover sick days from the first day;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8cb623ba0d4f44d88cfd66934e3a21d8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Convalescence pay according to the applicable law;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z642d2a938e4a406fa06348a87675ef04" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Medical Insurance in accordance with market practice and the applicable law;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd862f77e0c6f479bad5ceeea3a06d5c6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>With respect to Executive Officers employed in Israel: monthly remuneration for a study fund ("Keren Hishtalmut"), as allowed by applicable tax law and with reference
                to Sol-Gel&#8217;s practice and common market practice;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd3cbabce22f64a478393cffb9a468b59" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Pension and savings &#8211; according to local market practices and legislation;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z855a968e556d4253b635002dad082d83" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disability insurance &#8211; the Company may purchase disability insurance, according to applicable legislation.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z5fcae0e5808d4eb8a2dbbd16d6cc8186" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">7.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Sol-Gel may offer additional benefits to its Executive Officers, including but not
                  limited to: communication, company car and travel benefits, insurances and other benefits<font style="font-weight: bold;">&#160;</font>(such as newspaper subscriptions,
                academic and professional studies), etc., including their gross up.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z20ee82a18f79443c87ce656a0a57a2f9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">7.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Sol-Gel may reimburse its Executive Officers for reasonable work-related expenses incurred as part of their activities, including without limitations, meeting
                participation expenses, reimbursement of business travel, including a daily stipend when traveling and accommodation expenses. Sol-Gel may provide advance payments to its Executive Officers in connection with work-related expenses.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 5</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="zaddb736b681d432ba69de7d3824b817f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">8.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Signing Bonus</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="2191a52d8c9443ef985995a0987404bd" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">At the discretion of the Compensation Committee and the Board (and with respect to the CEO- also the Company's general
                meeting of shareholders), Sol-Gel may grant a newly recruited Executive Officer a signing bonus. Such bonus may be granted in cash, equity or a combination of both. The signing bonus will not exceed: (1) 50% of such Executive Officer's
                annual Base Salary, if the signing bonus is granted in cash; (2) 100% of such Executive Officer's annual Base Salary, if the signing bonus is granted by equity; (3) In case the signing bonus is a combination of cash and equity, its ceiling
                shall be proportional to the cash and equity components, calculated in accordance with the ratios mentioned in sections (1) and (2) above.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">C. <u>Cash Bonuses (Excluding
            Directors)</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25;">The Company (subject to the approvals of the Compensation Committee and the Board, and with respect to the CEO- also the Company's
          general meeting of shareholders) may grant cash bonuses to its Executive Officers (excluding directors) on a quarterly or annually basis, or on a shorter or longer period basis, in accordance with the principles detailed below.</div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze3fffbe772f942d9b042e7a00e947df6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">9.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Annual Bonuses</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze6ac6f4392714a53a73eef303a2a158a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">9.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The annual bonus that may be paid to the Executive Officers for any fiscal year shall not exceed twelve (12) monthly Base Salaries to the CEO, and six (6) monthly
                Base Salaries to any other Executive Officer.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6724ef04acce4cbc8193513f0b5b2c0f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">9.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>CEO</u></div>
              <div><u> <br>
                </u></div>
              <div style="font-family: 'Times New Roman',Times,serif;">
                <div style="line-height: 1.25;">The annual bonus to the CEO will be based mainly on measurable criteria, and with respect to its less significant
                  part shall be determined at the discretion of the Compensation Committee and the Board, in accordance with the following:</div>
                <u> </u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="2" border="0" align="center" id="zfe126d891c0e4be6b5249d083e0af23e" style="width: 80%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Position</div>
            </td>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Company/Individual<br>
                Performance Measures</div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Company's Discretion</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25;">CEO</div>
            </td>
            <td style="width: 33%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25;">75%-100%</div>
            </td>
            <td style="width: 33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25;">0%-25%</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="555cf70be35c443387ac734b5f6cd851" class="DSPFListTable">

          <tr>
            <td style="width: 45.35pt;"></td>
            <td style="width: 26.65pt; vertical-align: top; align: right;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The measurable criteria and their relative weight shall be determined by the Compensation Committee and the Board in
                respect of each calendar year. These measurable criteria will include, <font style="font-style: italic;">inter alia</font>, objectives relating to compliance with the
                Company's work plans and with various budget objectives, including, <font style="font-style: italic;">inter alia</font>, compliance with objectives relating to
                revenues, expenses, investments, etc., meeting various financial objectives, such as objectives relating to the annual profit (net profit, pre-tax profit, etc.) and the Company's EBITDA, objectives relating to the recruitment and
                development of professional personnel, objectives relating to raising investments, debt, etc., objectives relating to the Company's business operations and the Company's operations as a company traded on NASDAQ, objectives relating to the
                realization of the Company's assets, the acquisition of new activities and/or companies and objectives relating to an increase of the return on the Company's assets.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z29ec3fa0b8cc4742b3aad2d7bf709f6b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; align: right;">9.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Other Executive Officers (Excluding CEO and Directors)</u></div>
              <div><u> <br>
                </u></div>
              <div style="font-family: 'Times New Roman',Times,serif;">
                <div style="line-height: 1.25;">The Company may also award (subject to the approvals of the Compensation Committee and the Board) an annual bonus to
                  its Executive Officers, due to their unique contribution to the Company. Such grant will be based, <font style="font-style: italic;">inter alia</font>, on measurable
                  criteria, based on the Company's financial results, the scope of the Company's business activity, the CEO's opinion on the contribution of the Executive Officer to the Company, the distribution of the annual bonus over the year, etc. It
                  should be clarified, that the annual bonus may be based in whole or in part on discretion, provided that it does not exceed the ceiling specified in section 9.1 above. The CEO of the Company shall be entitled to determine the
                  abovementioned targets for each such an Executive Officer. Notwithstanding the foregoing, it is hereby clarified, that the grant of annual bonus to an Executive Officer, of up to three Base Salaries, shall be approved by the CEO of the
                  Company.</div>
                <u> </u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 6</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z82689676ad4e44a38864d3f15aead14c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">10.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Special Bonuses</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="1c3f79076050439abe6adf17edc104e5" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In addition to the annual bonus,
                  Sol-Gel may grant Executive Officers a special bonus as an award for special achievements (outstanding personal achievement, outstanding personal effort or outstanding Company's performance, such as in connection with mergers and
                  acquisitions, offerings, achieving target budget or business plan under exceptional circumstances and special recognition in case of retirement),
                  at the discretion of the Compensation Committee and the Board (and with respect to the CEO- also the Company's general meeting of shareholders) which shall not exceed six (6) monthly Base Salaries.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z59fdb1831f8d4898acb8724ce1c68972" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">11.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Additional Provisions Relating to Cash Bonuses</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zcdd29a0a76a04e38a2ce787043118dfd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">11.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Pro Rata Payment</u></div>
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> </u><br>
                <div style="line-height: 1.25; font-weight: normal;">Should the employment or service of the Executive Officer terminate prior to the end of a fiscal year, Sol-Gel may pay the Executive Officer his/her pro-rata share of that fiscal year&#8217;s bonus, based on the period such Executive Officer
                  was employed by the Company or has served in the Company.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9aa458cd0d9c477489d4bffc40d27b69" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">11.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Compensation Recovery ("Clawback")</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z1c367031c99143469cafff37c4a73cd2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 74.7pt;"><br>
            </td>
            <td style="width: 42.55pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">11.2.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the event of an accounting restatement, Sol-Gel shall be entitled to recover from its Executive Officers the bonus compensation in the amount in which such bonus
                exceeded what would have been paid under the financial statements, as restated ("<font style="font-weight: bold;">Compensation Recovery</font>"), provided that a claim is made
                by Sol-Gel prior to the third anniversary of fiscal year end of the restated financial statements.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc679237058b84c6a87d3cc3cb36c3413" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 74.7pt;"><br>
            </td>
            <td style="width: 42.55pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">11.2.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Notwithstanding the aforesaid, the Compensation Recovery will not be triggered in the following events:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd07326096ca949258e61796795a5ec05" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 120.5pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The financial restatement is required due to changes in the applicable financial reporting standards; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb1b90712eb1f412e88f04494d047d429" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 120.5pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Company (subject to any required approval by the applicable law) has determined that clawback proceedings in the specific case would be impossible, impractical or
                not commercially or legally efficient; or</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z7404ca91307c4e11b11056d9e61d6329" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 120.5pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The amount to be paid under the clawback proceedings is less than 10% of the relevant bonus received by the Executive Officer.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z29c17b20a4f64b63bea0619e51eeca72" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 74.7pt;"><br>
            </td>
            <td style="width: 42.55pt; vertical-align: top; align: right;">11.2.4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>It shall be clarified, that Sol-Gel shall not be entitled to Compensation Recovery with respect to equity-based compensation granted to its Executive Officers.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9a0bc185d14f4018911e9340ace79767" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">11.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Reduction or Postponement</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="12c6b40b1e2047b28897ed8c4b7b5685" class="DSPFListTable">

          <tr>
            <td style="width: 45.35pt;"></td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In the event of the termination of office of an Executive Officer under circumstances in which he/she will not be
                entitled to severance pay, the Company (subject to the approvals of the Compensation Committee and the Board) may revoke the entitlement of such an Executive Officer to an annual bonus and to all parts of the annual bonus which have not yet
                been paid to him.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 7</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">D. <u>Equity-Based Compensation</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zdc7b30ca3d104e4d9199dfc85990c6f6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">12.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>General and Objectives</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z4f1fbb1c901d47a69e3c73337b211042" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">12.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Company (subject to the approvals of the Compensation Committee and the Board, and with respect to the Company's directors and CEO- also the Company's general
                meeting of shareholders) may grant from time to time equity-based compensation which will be individually determined and awarded according to, <font style="font-style: italic;">inter
                  alia</font>, the performance, educational background, prior business experience, qualifications, role and the personal responsibilities of the Executive Officer. Equity-based compensation may also be awarded to the Company's directors,
                including, for the avoidance of doubt, the Executive Chairman, provided that such directors do not also serve as officers in the Company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z619b9538ac104f438e668d08491a9892" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">12.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The main objectives of the equity-based compensation is to enhance the alignment between the Executive Officers' and directors' interests with the long term interests
                of Sol-Gel and its shareholders, and to strengthen the retention and the motivation of Executive Officers in the medium-to-long term. In addition, since equity-based awards are structured to vest over several years, their incentive value to
                recipients is aligned with longer-term strategic plans.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf17bd592a8574a54ab802fc497a0b7d7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">12.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The equity based compensation offered by Sol-Gel is intended to be in a form of options exercisable into shares, restricted shares and/or other equity based awards,
                such as restricted share units (RSUs), in accordance with the Company's incentive plan in place as may be updated from time to time.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc97410a7b2974906a625c490c7c6115e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">13.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Fair Market Value</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="dcce685522a54e51b163907307701c60" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The fair market value of the equity-based compensation for each Executive Officer during a fiscal year, shall not
                exceed 200% of his/her annual Base Salary, as shall be determined according to acceptable valuation practices at the time of grant.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb817ca6860664253b8f7d2560fde4376" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">14.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;"><u>Taxation Regime</u></font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="50766dff4c4643018aaaae13fe32f82b" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Subject to any applicable law, Sol-Gel may determine, at the discretion of the Compensation Committee and the Board
                (and with respect to the Company's directors and CEO- also the Company's general meeting of shareholders), the tax regime under which equity-based compensation may be granted, including a tax regime which will maximize the benefit to the
                Executive Officers.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z255b0cfa542649bb9df21be1b85925ba" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">15.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Exercise Period</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="5438728cce56418e813233431417c4cd" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The exercise price for each option shall not be less than the average closing Company's share price on NASDAQ over the
                30 trading days preceding the Board&#8217;s decision on the grant of the relevant option.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">It is hereby clarified, that unless otherwise determined by the Company (subject to the approvals of the Compensation
                Committee and the Board, and with respect to the Company's directors and CEO- also the Company's general meeting of shareholders), and subject to the provisions of any applicable law, the exercise price of restricted shares and restricted
                share units (RSUs) is zero. In addition, it shall be clarified, that the exercise of restricted shares and RSUs may be subject to the achievement of goals set in advance and approved in accordance with the applicable law.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Options, restricted shares and restricted share units (RSUs) may also be exercised by a method of "Cashless" exercise.</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Board considered the possibility of determining a ceiling for the exercise value of the variable equity components
                and decided, taking into account the purpose of the equity-based compensation, not to set such a ceiling in this Policy.</div>
            </td>
          </tr>

      </table>
      &#160;<br>
      <div style="line-height: 1.25">
        <hr noshade="noshade" align="left" style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 28.35pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The equity based compensation is based on the fair value on the date of grant, calculated annually, on a linear basis.</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 28.35pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup></td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Calculated annually, on a linear basis.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 8</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z2e69314ac0c94aef9a8ba111aa90f0a5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">16.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Vesting</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="095e020393b848069aaa7b08c927765d" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">All equity-based incentives granted to Executive Officers and directors shall be subject to vesting periods in order
                to promote long-term retention of such recipients. Grants to Executive Officers (excluding directors) shall vest gradually over a period of at least two years, while grants to directors shall vest over a period of at least one year. Such
                grants may be vested on a quarterly, semi-annual or an annual basis, or based on other time periods (which may not be necessarily equal), as determined by the Company (subject to the approvals of the Compensation Committee and the Board,
                and with respect to the Company's directors and CEO- also the Company's general meeting of shareholders). The Company (subject to the abovementioned required approvals) may condition the vesting of part or all of the equity-based
                incentives, for some or all of its Executive Officers, upon the achievement of predetermined performance goals. The Company (subject to the abovementioned required approvals) may also set terms relating to vesting in connection with an
                Executive Officer leaving the Company (due to a dismissal, resignation, death or disability).</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="za94f5c2686c6498a81b54c3017e0f774" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">17.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>For details regarding ceilings with respect to director's equity-based compensation see section 29 below.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z059e8ac4b8884418bf51b8d24ad12835" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">18.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>General</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="d400e11480f94cb6b9126a452c47c820" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">All other terms of the equity awards shall be in accordance with Sol-Gel's incentive plans and other related practices
                and policies. Accordingly, the Company may (subject to the approvals of the Compensation Committee and the Board, and with respect to the Company's directors and CEO- also the Company's general meeting of shareholders) extend the period of
                time for which an award is to remain exercisable and make provisions with respect to the acceleration of the vesting period of any Executive Officer's awards, including, without limitation, in connection with a corporate transaction
                involving a change of control, subject to any additional approval as may be required by the Companies Law.</div>
            </td>
          </tr>

      </table>
      <br>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">E. <u>Retirement and Termination of
            Service Arrangements (Excluding Directors)</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z43a8378c05114200be8c10569b99f207" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">19.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Advanced Notice Period</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0f642cc1e7d447249be85c4a2a1cb173" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">19.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Sol-Gel (subject to the approvals of the Compensation Committee and the Board, and with respect to the CEO- also the Company's general meeting of shareholders) may
                provide each Executive Officer (excluding directors), pursuant to an Executive Officer's employment agreement and according to the Company's decision per each case, a prior notice of termination of up to six (6) months, except for the CEO
                whose prior notice may be of up to twelve (12) months (the "<font style="font-weight: bold;">Advance Notice Period</font>"). During the Advance Notice Period, the Executive
                Officer may be entitled to all of the compensation elements, and to the continuation of vesting of his/her options, restricted shares, RSUs and/or any other equity based awards.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9a7da1351e5847f7855a6791bb13ddc0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">19.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>During the Advance Notice Period, an Executive Officer will be required to keep performing his/her duties pursuant to his/her agreement with the Company, unless the
                Company (subject to the approvals of the Compensation Committee and the Board, and with respect to the CEO- also the Company's general meeting of shareholders) has waived the Executive Officer&#8217;s services to the Company during the Advance
                Notice Period and pay the amount payable in lieu of notice, plus the value of benefits.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8e65f7936ce245c587532518661ff722" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">19.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the event of a change of control in the Company, the Company (subject to the approvals of the Compensation Committee and the Board, and with respect to the CEO-
                also the Company's general meeting of shareholders) may decide to extend the Advance Notice Period as provided in section 19.1 above (and the compensation paid for such Advance Notice Period, accordingly) to up to two times the original
                Advance Notice Period of the Executive Officer, in accordance with the applicable law as of that time.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 9</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z87fbe1657e0a409c972e86f2eb95a619" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">20.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Adjustment Period/Retirement Bonus</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="f2b68ac9d76c4454b2ce440248a168a9" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In addition to the Advance Notice
                  Period, the Company (subject to the approvals of the Compensation Committee and the Board, and with respect to the CEO- also the Company's general meeting of shareholders) may provide an additional adjustment period/retirement payment
                  that will be determined, among other things, taking into consideration the Executive Officer's seniority in the Company, performance during employment, contribution to Sol-Gel achieving its goals and the circumstances of
                retirement or termination. The maximum adjustment period/retirement bonus that may be paid to each Executive Officer shall be up to six (6) month Base Salaries and may only be granted to Executive Officers who have served in the Company for
                at least one year.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z046cd6426dda489c88ca3d259a2fdef6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">21.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Additional Retirement and Termination Benefits</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="816ee3a5ec1b445ea39ed851c53e7326" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Sol-Gel may provide additional retirement and terminations benefits and payments as may be required by applicable law
                (e.g., mandatory severance pay under Israeli labor laws- unless employment/term of service was terminated for cause), or which will be comparable to customary market practices.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">F. <u>Exemption, Indemnification and
            Insurance</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zefbd537b6d584ae2ab1b92e33b503e04" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">22.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Exemption</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="62a20f08e01e4b5b9b8af511ba593965" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Sol-Gel (subject to the approvals of the Compensation Committee and the Board, and with respect to the Company's
                directors and CEO- also the Company's general meeting of shareholders) may exempt in advance and retroactively its Executive Officers, from any liability to the Company, in whole or in part, for damages in consequence of his or her duty of
                care vis-a-vis the Company, to the fullest extent permitted by law and subject to the provisions of the Company&#8217;s Articles of Association.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6ba6ce960aa5465d8ffe82bf7c6f4a79" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">23.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Indemnification</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="bfb6cff6f4584c2db62c58dea1251a6b" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Sol-Gel (subject to the approvals of the Compensation Committee and the Board, and with respect to the Company's
                directors and CEO- also the Company's general meeting of shareholders) may indemnify its Executive Officers to the fullest extent permitted by applicable law and the Company's Articles of Association, for any liability and expense that may
                be imposed on the Executive Officer, as provided in the Indemnity Agreement between such individuals and Sol-Gel, all subject to applicable law and the Company&#8217;s Articles of Association.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z5a4fffe87c8444fb9057f850bc987cae" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">24.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;"><u>Insurance</u></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z42dece0873064758b0f7e2eb2208baa5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">24.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Sol-Gel (subject to the approvals of the Compensation Committee and the Board, and with respect to the Company's directors and CEO- also the Company's general meeting
                of shareholders) will provide "Directors&#8217; and Officers&#8217; Liability Insurance" (the "<font style="font-weight: bold;">Insurance Policy</font>"), as well as a "run off" insurance
                policy<font style="font-weight: bold;">&#160;</font>for its Executive Officers as follows:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z66bdc6cadc454693954e07e2030b563a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The annual premium to be paid by Sol-Gel shall not exceed $1.5 million of the aggregate coverage of the Insurance Policy;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z93a407880de24637a7862fab9cd199f5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The limit of liability of the insurer shall be up to $75 million per event and in the aggregate in the insurance period.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6b26fed289fa4724a7438a7460dfc67a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 102.9pt;"><br>
            </td>
            <td style="width: 17.85pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The deductible amount per each claim shall not exceed $5 million.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9aa860d5d1454fdcb3aa42259bf30044" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Insurance Policy, as well as the limit of liability and the premium for each extension or renewal shall be approved by the Company, which shall determine (subject to the approvals of the Compensation Committee and the Board, and with respect to the Company's directors and CEO- also the Company's general meeting of
                  shareholders) that the sums are reasonable considering Sol-Gel's exposures, the scope of coverage and the market conditions and that the Insurance Policy reflects the current market conditions, and it shall not materially affect
                the Company's profitability, assets or liabilities.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6af20f2ec03b4699883cd8d2223b1f90" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 103.05pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The policy will also cover the liability of the controlling shareholders due to their positions as Executive Officers in the Company, from time to time, provided that
                the coverage terms in this respect do not exceed those of the other Executive Officers in the Company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 10</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">G. </font><font style="font-weight: bold;"><u>Arrangements upon Change of Control</u></font></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb88a1388647e45aaa201b4142065a211" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">25.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The following benefits may be granted to the Executive Officers in addition to the benefits applicable in the case of any retirement or termination of
                  service upon a "Change of Control" following of which the employment
                  of the Executive Officer is terminated or adversely adjusted in a material way:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zbea48b3defef41a49ac3e251acff6590" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">25.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Vesting acceleration of outstanding options, restricted shares, restricted share units (RSUs) and/or other equity based awards.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6e2ebe9e063c47d48bc0a83fa10ac1cd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">25.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Extension of the exercising period of options, restricted shares, restricted share units (RSUs) and/or other equity based awards for Sol-Gel&#8217;s Executive Officers for
                a period of up to five (5) years, following the date of termination of employment.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0f54b0741f5a4fd3813fe5d9c3cf25b9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">25.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>An Advance Notice Period, in accordance with section 19.3 above.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6c0a8e7b28fa40fa8cc48c0ab7fda6b6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">25.4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>An Adjustment period/retirement bonus in accordance with section 20 above, of up to
                  twelve (12) months of Employment Cost.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">H. <u>Board of Directors Compensation</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc24fe861ef144c829354c18e3627ea37" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">26.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The compensation of the Company's directors shall be in accordance with the amounts
                  provided in the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of
                  2000, as such regulations may be amended from time to time, or in accordance with section 27 below, subject to any required approvals by the applicable law.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z59f05754e1ba409ca8dce7fdccc44d6c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">27.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The compensation of the Company's directors (including external directors and independent directors) shall not exceed the following:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z7d670d673abb4d0ba00495dd7b120d7e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">27.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Base payment of $45,000 per year (the "<font style="font-weight: bold;">Base Payment</font>");</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z059da787f31b43ad86e0ab0f51adfc60" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">27.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Chairman of the Board- an additional amount of $25,000 per year to the Base Payment;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z4789f7e38b4348ad920b28ff5e0cc216" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">27.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Committee Chairman- an additional amount of $10,000 per year to the Base Payment;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6050c450a3ea46618aa55eb29b912715" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">27.4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Committee member- an additional amount of $5,000 per year to the Base Payment;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z26fdc9208c3a44afabd80833566e8dab" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">28.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In addition, the Company may engage with its directors (excluding external and independent directors) for the receipt of consulting services and/or other special
                services, for a consideration of up to $1,000 per day, plus reasonable expense reimbursement. Such compensation shall be paid for a maximum of 6 days per year for each director.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 11</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="zb4b2598bed574bfdad412c68ca809b02" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">29.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Directors may be granted equity-based compensation in accordance with the applicable principles detailed in section D of this Policy, and subject to the provisions of
                the Companies Law and the regulations thereunder.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="47928bb5555444b9b690b38777e2e45f" class="DSPFListTable">

          <tr>
            <td style="width: 18.35pt;"></td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Equity based-compensation granted to the Company's directors, shall not exceed the following amounts (subject to any
                applicable law):<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5</sup></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9e2fb3340d674a62bdf9a695bc6e50b2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">29.1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Director: $55,000 per year (the "<font style="font-weight: bold;">Equity Compensation</font>");</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zdf54ddcf5cb04fcab3017e691426e85d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">29.2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Chairman of the Board- an additional amount of $55,000 per year to the Equity Compensation;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z7ee15c848d8f4ea08880899c56a74df8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">29.3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Committee Chairman- an additional amount of $10,000 per year per year to the Equity Compensation;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z23acb67d5cf94f429d936970d14bed75" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45.35pt;"><br>
            </td>
            <td style="width: 26.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">29.4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Committee member- an additional amount of $5,000 per year to the Equity Compensation;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z2dd8b07e6a004a949f7b02b9a2dc85f4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">30.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Sol-Gel's external and independent directors may be entitled to reimbursement of expenses
                in accordance with the Companies Law and the regulations thereunder.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; margin-left: 8.5pt; line-height: 1.25; font-weight: bold;">I. <u>Miscellaneous</u></div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z70c6eeb316e84dbab47a60cf4da3e3e1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">31.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>This Policy is designed solely for the benefit of Sol-Gel. Nothing in this Compensation Policy shall be deemed to grant any of Sol-Gel&#8217;s Executive Officers or
                employees or any third party any right or privilege in connection with their employment by the Company and their compensation thereof. Such rights and privileges, to which Executive Officers or employees serving in the Company or that will
                serve in the Company in the future, are entitled for, shall be governed by the respective personal employment agreements.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za74928cecba74eb2bf2222d6bb7534da" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">32.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>This Policy is subject to applicable law and is not intended, and should not be interpreted as limiting or derogating from, provisions of applicable law to the extent
                not permitted, nor should it be interpreted as limiting or derogating from the Company&#8217;s Articles of Association.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z76d676cd887347aa9229a8af86b5b044" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">33.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>This Policy is not intended to affect current agreements nor affect obligating customs (if applicable) between the Company and its Executive Officers as such may
                exist prior to the approval of this Compensation Policy, subject to any applicable law.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z61bf1b0dbcc04fa2ac029cac7c1fda4d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">34.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the event of amendments made to the Companies Law or any regulations promulgated thereunder providing relief in connection with Sol-Gel&#8217;s compensation to its
                Executive Officers, Sol-Gel may elect to act pursuant to such relief without regard to any contradiction with this Policy.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z670839378c63464da235fb1c2cd321a0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">35.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Company (subject to any required approvals by the applicable law) may determine that none or only part of the payments, benefits and perquisites shall be granted,
                and is authorized to cancel or suspend a compensation package or part of it.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zcdafe3980c26499c917b838045847749" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">36.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>An immaterial change in the terms of office of Executive Officers (excluding directors, a controlling shareholder or a controlling shareholder's relative) during the
                term of this Compensation Policy, will be subject to the approval of the Company's CEO only (changes in the terms of office of the CEO shall be approved in accordance with the Companies Law). An immaterial change in this matter shall be
                deemed to be a change that does not exceed 5% of the annual Employment Cost with respect to the employment of such an Executive Officer in the Company, subject to the conditions prescribed in this Compensation Policy.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd4b26fa1869d4506aad3bc7a94c2f9c6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.35pt;"><br>
            </td>
            <td style="width: 25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">37.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>It should be clarified, that the compensation components detailed in this Policy do not relate to various components that the Company may provide to all or part of
                its employees and/or its Executive Officers, such as: parking spaces, entry permits for its assets, reimbursement for meals and accommodation expenses, vacations, company events, etc.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">*********************</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <hr noshade="noshade" align="left" style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
      <div> </div>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z8ad998a56e5c45578e64a004b2d8b403" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The equity based compensation is based on the fair value on the date of grant, calculated annually, on a linear basis.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zc57f9bccc95e48769a0d055b981e39c6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt; vertical-align: top; align: right;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5</sup></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on the fair value on the date of grant, calculated annually, on a linear basis.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
  </div>
  <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">A - 12</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>exhibit_12-1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 12.1</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 <br>
        OF THE&#160;SARBANES-OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="margin-right: 7.05pt; line-height: 1.25;">I, Alon Seri-Levy, certify
        that:</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z312d9dcb55524886ad26ab4721476442" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">1.</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -18pt; margin-left: 187.2pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3f51f580e54f47228897dd843950605b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">2.</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
                necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -18pt; margin-left: 187.2pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z06027eefc8504d5e85e832dd933f319f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">3.</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
                all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -18pt; margin-left: 187.2pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6ba2165b1cb948dfabc80c1e8af53a03" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">4.</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
                procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -18pt; margin-left: 187.2pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="zf3e53f8200c943d2b75df4b0701451a1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 6%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">&#160;<font style="font-family: 'Times New Roman',Times,serif;">a)</font></td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
                  be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this
                  report is being prepared;</font></div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -21.3pt; margin-left: 187.2pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze9ea2cefeb9e4dd4a1d82561a952c013" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 6%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">&#160;<font style="font-family: 'Times New Roman',Times,serif;">b)</font></td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Designed such internal control over financial reporting, or caused such internal control over financial
                  reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
                  accounting principles;</font></div>
              <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">&#160;<font style="font-family: 'Times New Roman',Times,serif;">c)</font></td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this
                  report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z146561d5e09848cfb511a3889bb7f688" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 6%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">d)</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; margin-right: 43.2pt; line-height: 1.25;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that
                occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -18pt; margin-left: 187.2pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0961934c71c74b9998d1edb517e9db68" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">5.</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 95%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
                financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -18pt; margin-left: 187.2pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zfb4530171bdf44caa33ddec5639b7ca8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 6%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">a)</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
                which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -18pt; margin-left: 187.2pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze3aa2a1f2c5d4f45b6a8772b7ae9d41a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 6%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">b)</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s
                internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Date: March 4, 2021</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z2c689bd84a674ace8960aed210650035">

            <tr>
              <td style="width: 25%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>/s/ Alon Seri-Levy</div>
              </td>
              <td style="width: 75%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%;">
                <div>
                  <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">Alon Seri-Levy</div>
                </div>
              </td>
              <td style="width: 75%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%;">
                <div>
                  <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">Chief Executive Officer</div>
                </div>
              </td>
              <td style="width: 75%;">
                <div>&#160;</div>
              </td>
            </tr>

        </table>
      </div>
      <br>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>exhibit_12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 12.2</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">OF THE&#160;SARBANES&#8209;OXLEY ACT OF 2002</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="margin-right: 7.05pt; line-height: 1.25;">I,&#160;Gilad Mamlok, certify that:</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -154.65pt; margin-left: 183pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
                light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
                condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
                13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-left: 28.35pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 56.7pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
                information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -14.2pt; margin-left: 70.9pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 56.7pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
                reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -14.2pt; margin-left: 70.9pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 56.7pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
                controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -14.2pt; margin-left: 70.9pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 56.7pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has
                materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -154.65pt; margin-left: 183pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s
                auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -154.65pt; margin-left: 183pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 63.8pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
                affect the company&#8217;s ability to record, process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -119.2pt; margin-left: 183pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 63.8pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial
                reporting.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: -154.65pt; margin-left: 183pt; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">Date: March 4, 2021</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z023e75d7d95948648dabc380b1f539b3">

            <tr>
              <td style="width: 25%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>
                  <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">/s/ Gilad Mamlok</div>
                </div>
              </td>
              <td style="width: 75%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%;">
                <div>
                  <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">Gilad Mamlok</div>
                </div>
              </td>
              <td style="width: 75%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%;">
                <div>
                  <div style="text-align: left; line-height: 1.25;">Chief&#160;Financial&#160;Officer</div>
                </div>
              </td>
              <td style="width: 75%;">
                <div>&#160;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>5
<FILENAME>exhibit_13.htm
<DESCRIPTION>EXHIBIT 13
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; text-indent: 7.05pt; margin-left: 7.05pt; line-height: 1.25; font-weight: bold;"><u>Exhibit 13</u></div>
      <div style="text-align: right; margin-right: 7.05pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; margin-right: 7.05pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">CERTIFICATION BY CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL </div>
      <div style="text-align: center; margin-right: 7.05pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">OFFICER PURSUAN&#160;TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002&#160;</div>
      <div style="text-align: justify; margin-right: 7.05pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; margin-right: 7.05pt; line-height: 1.25;">In connection with the Annual Report of Sol-Gel Technologies Ltd. (the &#8220;Company&#8221;) on Form 20-F for the period
        ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the
        Sarbanes-Oxley Act of 2002, that to such officer's knowledge:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; margin-right: 7.05pt; line-height: 1.25;">&#160;&#160;</div>
      <div style="margin-right: 7.05pt; line-height: 1.25;">Dated: March 4, 2021</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z5b298678967241ba8cc8f38b7a6794a9">

            <tr>
              <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>
                  <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">/s/ Alon Seri-Levy</div>
                </div>
              </td>
              <td style="width: 50%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div>
                  <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">Alon Seri-Levy</div>
                </div>
              </td>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div>
                  <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">Chief Executive Officer</div>
                </div>
              </td>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;" rowspan="1">&#160;</td>
              <td style="width: 50.00%;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">
                <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">/s/ Gilad Mamlok</div>
              </td>
              <td style="width: 50%; padding-bottom: 2px;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50.00%;" rowspan="1">
                <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">Gilad Mamlok</div>
              </td>
              <td style="width: 50.00%;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50.00%;" rowspan="1">
                <div style="text-align: left; margin-right: 7.05pt; line-height: 1.25;">Chief&#160;Financial&#160;Officer</div>
              </td>
              <td style="width: 50.00%;" rowspan="1">&#160;</td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>6
<FILENAME>exhibit_15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 15.1</u></div>
    </div>
    <div> <br>
      </div>
    <div>
      <div id="DSPFPageHeader">
        <div style="line-height: 1.25;"><img width="152" height="129" src="image0.jpg"></div>
      </div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">We hereby consent to the incorporation by reference in the Registration Statements on Form&#160;S-8 (No. 333-223915) and Form F-3 (No.
        333-230564) of Sol-Gel Technologies Ltd. of our report dated March 4, 2021 relating to the financial statements, which appears in this Form 20-F.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za5928250de3448a5872de62b58ed0a99" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 30%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Tel-Aviv, Israel</div>
            </td>
            <td style="width: 70%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">/s/Kesselman &amp; Kesselman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">March 4, 2021</div>
            </td>
            <td style="width: 70%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Certified Public Accountants (Isr.)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 70%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">A member firm of PricewaterhouseCoopers International Limited</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z4de38aa5fa2740ac9075bcaba13d69e5">

            <tr>
              <td style="border-left: 2px dotted #000000; border-top: 2px dotted #000000; width: 100%;">
                <div>
                  <div style="text-align: left; line-height: 1.25; font-style: italic;">Kesselman &amp; Kesselman, Derech Menachem Begin 146, Tel-Aviv 6492103, Israel,</div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div>
                  <div style="text-align: left; line-height: 1.25; font-style: italic;">P.O Box 7187 Tel-Aviv 6107120, Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il</div>
                </div>
              </td>
            </tr>

        </table>
        <br>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-style: italic;">
          <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      </div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>slgl-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: SLGL 1220 20F.xfr; Date: 2021%2D03%2D03T12:57:40Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x800F0000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:SLGL="http://sol-gel.com/20201231">
    <link:schemaRef xlink:href="slgl-20201231.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2007-01-01to2007-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2007-01-01</xbrli:startDate>
        <xbrli:endDate>2007-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2007-01-01to2007-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2007-01-01</xbrli:startDate>
        <xbrli:endDate>2007-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-01-19_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-01-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_EmployeesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_EmployeesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_EmployeesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_EmployeesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_NonEmployeesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:NonEmployeesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ForeignGovernmentDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_OtherForeignGovernmentBondsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">SLGL:OtherForeignGovernmentBondsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AllOtherCorporateBondsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_EmployeesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_EmployeesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_EmployeesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_EmployeesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_EmployeesMember1112152093">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-01-31_srt_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-31_srt_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-01to2019-05-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-31_custom_FPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SLGL:FPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-31_custom_FPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SLGL:FPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-02-01to2018-02-28_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-02-01</xbrli:startDate>
        <xbrli:endDate>2018-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-01to2018-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:LaboratoryEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:LaboratoryEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember_srt_MinimumMember_custom_MainlyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:LaboratoryEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SLGL:MainlyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember_srt_MaximumMember_custom_MainlyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:LaboratoryEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SLGL:MainlyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_OfficeFurnitureAndEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_OfficeFurnitureAndEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ForeignGovernmentDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OtherForeignGovernmentBondsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">SLGL:OtherForeignGovernmentBondsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AllOtherCorporateBondsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">SLGL:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_MinimumMember_custom_IsraelInnovationAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SLGL:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_MaximumMember_custom_IsraelInnovationAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SLGL:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_IsraelInnovationAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SLGL:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_IsraelInnovationAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SLGL:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_YissumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SLGL:YissumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_YissumMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SLGL:YissumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_YissumMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SLGL:YissumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MasterClinicalTrialServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">SLGL:MasterClinicalTrialServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_MasterClinicalTrialServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">SLGL:MasterClinicalTrialServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ClinicalDevelopmentMasterServicesAgreementMember_custom_AgreementOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">SLGL:ClinicalDevelopmentMasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SLGL:AgreementOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ClinicalDevelopmentMasterServicesAgreementMember_custom_AgreementOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">SLGL:ClinicalDevelopmentMasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SLGL:AgreementOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ClinicalDevelopmentMasterServicesAgreementMember_custom_AgreementTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">SLGL:ClinicalDevelopmentMasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SLGL:AgreementTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ClinicalDevelopmentMasterServicesAgreementMember_custom_AgreementTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">SLGL:ClinicalDevelopmentMasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SLGL:AgreementTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_EmployeesMember247647703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_NonEmployeesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:NonEmployeesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NonEmployeesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:NonEmployeesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeesMember248115000">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SLGL:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_SubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-01to2021-12-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-19_custom_FPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SLGL:FPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-01to2020-02-19_custom_FPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SLGL:FPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-01to2020-02-19_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-19_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-04-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-01to2019-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SLGL:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-31_custom_FPOMember_custom_UnderwriterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SLGL:FPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SLGL:UnderwriterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-19_custom_FPOMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SLGL:FPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-01to2020-02-19_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-02-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001684693</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="usd">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="ILSPerShare">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:ILS</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6290244</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">18949968</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">20402800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">20402800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">23000782</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">23000782</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">-52699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">42480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-95261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">63909000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">520000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">190853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-127464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">52465000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">561000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">203977000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-152073000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">50849000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">635000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">231577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-181363000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-32203000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-32203000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-24609000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-24609000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-29290000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-29290000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">4654000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">4654000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">2708000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">1946000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">2552000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">2552000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">1028000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">1524000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">1217000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">1217000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">431000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">786000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">55791000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">53401000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">5510000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">5760000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">61301000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">59161000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">1710000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1203000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">2331000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">2348000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">8836000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">8312000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">561000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">635000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">203977000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">231577000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">-152073000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">-181363000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">61301000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">59161000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2019-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">1293000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1074000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InterestBearingDepositsInBanks contextRef="AsOf2019-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:InterestBearingDepositsInBanks contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">21400000</us-gaap:InterestBearingDepositsInBanks>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">472000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1293000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">2314000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1817000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">684000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">754000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">958000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1049000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-12-31_us-gaap_BoardOfDirectorsChairmanMember" unitRef="ILSPerShare" decimals="INF">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="ILSPerShare" decimals="INF">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="ILSPerShare" decimals="INF">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">28146000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">40578000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">27913000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">5504000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">8276000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">11091000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">17867589</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">19534562</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">22574688</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-01-01to2018-12-31" unitRef="USDPShares" decimals="INF">1.80</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="USDPShares" decimals="INF">1.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="USDPShares" decimals="INF">1.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:Depreciation contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">762000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">887000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">946000</us-gaap:Depreciation>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-54735000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">16024000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-2694000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">78819000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">10613000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">26457000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">34000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-50000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-12000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">651000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">4087000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-1490000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-23467000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-22500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-25241000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">3029000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">938000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-542000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">1052000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">597000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">449000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <SLGL:FinanceExpensesNet contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-34000</SLGL:FinanceExpensesNet>
    <SLGL:FinanceExpensesNet contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">50000</SLGL:FinanceExpensesNet>
    <SLGL:FinanceExpensesNet contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">12000</SLGL:FinanceExpensesNet>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">1463000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-1694000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-219000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <SLGL:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-106000</SLGL:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement>
    <SLGL:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-38000</SLGL:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement>
    <SLGL:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-21000</SLGL:ChangesInAccruedLiabilityForEmployeeRightsUponRetirement>
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-32203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-24609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-29290000</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-33521000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-25950000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-30233000</us-gaap:OperatingIncomeLoss>
    <SLGL:FinancialIncomeExpensesNet contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">1318000</SLGL:FinancialIncomeExpensesNet>
    <SLGL:FinancialIncomeExpensesNet contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">1374000</SLGL:FinancialIncomeExpensesNet>
    <SLGL:FinancialIncomeExpensesNet contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">943000</SLGL:FinancialIncomeExpensesNet>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2018-01-01to2018-12-31_us-gaap_IPOMember" unitRef="Shares" decimals="INF">5444825</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">1119310</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-01-01to2019-12-31" unitRef="Shares" decimals="INF">1260984</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-01-01to2020-12-31" unitRef="Shares" decimals="INF">3271507</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">5943000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_custom_LaboratoryEquipmentMember" unitRef="usd" decimals="-3">3242000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_custom_OfficeFurnitureAndEquipmentMember" unitRef="usd" decimals="-3">265000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3">490000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3">1946000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">6392000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31_custom_LaboratoryEquipmentMember" unitRef="usd" decimals="-3">3644000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31_custom_OfficeFurnitureAndEquipmentMember" unitRef="usd" decimals="-3">265000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3">530000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3">1953000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">3629000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">4575000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;The fair value of options granted to employees and directors in 2018 and 2019 were $878 and $485 respectively. The&#13;        underlying data used for computing the fair value of the options are as follows:&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="zd132b3fd475547dba6e7e8ceae2bfccd" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Value of one ordinary share&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;$6.24-$10.40&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;$6.08-$8.59&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Dividend yield&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;0%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;0%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expected volatility&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;70.43 %-73.35%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;74.87%-77.83 %&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2.67%-2.83%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;1.82%-2.75%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expected term&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;5.50-7 years&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;6.11 years&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-12-31_custom_NonEmployeesMember">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;The fair value of options granted to non-employees in 2018 was $648. The underlying data used for computing the fair&#13;        value of the options are as follows:&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="center" cellspacing="0" cellpadding="0" border="0" id="zb5166ac1be864ad599232c6ce037f683" style="font: 10pt Times New Roman, Times, Serif; width: 80%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Value of one ordinary share&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;$ 10.40&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Dividend yield&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;0%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expected volatility&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;79.07%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2.86%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expected term&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;10 years&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;The following table summarizes the number of options granted to employees under the Plan for the years ended December&amp;#160;31, 2019 and 2020, and related information:&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 76.3pt"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z8504eda92ce2497294e9b56e1f571d96" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="22" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;font style="line-height: 1.25"&gt; &lt;/font&gt;&lt;/div&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -9pt; margin-left: 9pt"&gt;Options outstanding at the beginning of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;938,090&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.47&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.89&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,031,591&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.74&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.25&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Granted&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;95,300&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.24&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;9.17&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Exercised&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(28,447&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5.27&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expired&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(563&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5.57&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Forfeited&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(1,238&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5.57&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(2,250&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.77&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Options outstanding at the end of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,031,591&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.74&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.25&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,000,894&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.63&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.05&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Options exercisable at the end of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;683,979&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3.60&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.56&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;900,687&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.08&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5.67&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-12-31_custom_NonEmployeesMember">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 70.9pt"&gt;The following table summarizes the number of options granted to non-employees under the Plan for the year ended&#13;        December&amp;#160;31, 2019 and 2020, and related information:&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="zb2de4e2f65a649efac2a1f4896b9f69f" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="22" rowspan="1" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;font style="line-height: 1.25"&gt; &lt;/font&gt;&lt;/div&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -9pt; margin-left: 9pt"&gt;Options outstanding at the beginning of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;198,575&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.48&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;8.81&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;198,575&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.48&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.84&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Granted&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Options outstanding at the end of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;198,575&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.48&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.84&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;198,575&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.70&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.84&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Options exercisable at the end of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;96,588&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.97&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.78&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;137,771&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.34&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.8&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:DepreciationAndAmortization contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">762000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">887000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">946000</us-gaap:DepreciationAndAmortization>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-12-31">SOL-GEL TECHNOLOGIES LTD.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-12-31">0001684693</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2020-01-01to2020-12-31">20-F</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2020-01-01to2020-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2020-01-01to2020-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-12-31">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:Revenues contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">129000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">22904000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">8771000</us-gaap:Revenues>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityShellCompany>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">6505000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">5964000</us-gaap:LiabilitiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">56662000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">40966000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" decimals="-3">2499000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-12-31_us-gaap_ForeignGovernmentDebtMember" unitRef="usd" decimals="-3">999000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-12-31_custom_OtherForeignGovernmentBondsMember" unitRef="usd" decimals="-3">3521000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2019-12-31_us-gaap_AllOtherCorporateBondsMember" unitRef="usd" id="Foot-00-0" decimals="-3">33947000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">21652000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2020-12-31_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" unitRef="usd" decimals="-3">4192000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2020-12-31_us-gaap_ForeignGovernmentDebtMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2020-12-31_custom_OtherForeignGovernmentBondsMember" unitRef="usd" decimals="-3">2006000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2020-12-31_us-gaap_AllOtherCorporateBondsMember" unitRef="usd" id="Foot-00-1" decimals="-3">15454000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2018-12-31_us-gaap_IPOMember" unitRef="USDPShares" decimals="INF">12</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2019-08-31_custom_FPOMember" unitRef="USDPShares" decimals="INF">8.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2020-02-19_custom_FPOMember" unitRef="USDPShares" decimals="INF">11.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">78775000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2018-01-01to2018-12-31_us-gaap_IPOMember" unitRef="usd" decimals="-3">78775000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">10613000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">21306000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" id="Foot-01-0" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit contextRef="From2018-01-01to2018-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">66000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">-66000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">65338000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">160000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">65178000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5444825</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <SLGL:IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">78775000</SLGL:IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts>
    <SLGL:IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">211000</SLGL:IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts>
    <SLGL:IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">78564000</SLGL:IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts>
    <SLGL:IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7187500</SLGL:IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">44000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">43000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">27399</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <SLGL:ChangesInFairValueOfMarketableSecurities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-29000</SLGL:ChangesInFairValueOfMarketableSecurities>
    <SLGL:ChangesInFairValueOfMarketableSecurities contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-65000</SLGL:ChangesInFairValueOfMarketableSecurities>
    <SLGL:ChangesInFairValueOfMarketableSecurities contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-138000</SLGL:ChangesInFairValueOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">71783000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">38702000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">32322000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">15092000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">54333000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">51498000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <SLGL:BankDeposits contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-3000000</SLGL:BankDeposits>
    <SLGL:BankDeposits contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-1000000</SLGL:BankDeposits>
    <SLGL:BankDeposits contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">21400000</SLGL:BankDeposits>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">44000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2019-01-01to2019-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">151000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromInterestReceived contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">1477000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">1600000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">770000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">65338000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="From2019-01-01to2019-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="From2020-01-01to2020-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">5024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">5675000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">9762000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">8272000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">5325000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">9412000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">7122000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">350000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">350000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1150000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2020-12-31_srt_OfficerMember" unitRef="usd" decimals="-3">143000</us-gaap:RestrictedCash>
    <SLGL:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1 contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">5675000</SLGL:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1>
    <SLGL:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1 contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">9762000</SLGL:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1>
    <SLGL:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1 contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">8272000</SLGL:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">21652000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <SLGL:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue contextRef="AsOf2020-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">28447</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">28447</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">4123000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">4088000</us-gaap:AccountsPayableOtherCurrent>
    <SLGL:RestrictedBankDeposit contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1150000</SLGL:RestrictedBankDeposit>
    <dei:EntityExTransitionPeriod contextRef="From2020-01-01to2020-12-31">false</dei:EntityExTransitionPeriod>
    <us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-8000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
    <us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">10000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
    <us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">21000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-12-31">IL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <SLGL:PropertyAndEquipmentDepreciationPercentage contextRef="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.10</SLGL:PropertyAndEquipmentDepreciationPercentage>
    <SLGL:PropertyAndEquipmentDepreciationPercentage contextRef="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.33</SLGL:PropertyAndEquipmentDepreciationPercentage>
    <SLGL:PropertyAndEquipmentDepreciationPercentage contextRef="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember_srt_MinimumMember_custom_MainlyMember" unitRef="pure" decimals="INF">0.15</SLGL:PropertyAndEquipmentDepreciationPercentage>
    <SLGL:PropertyAndEquipmentDepreciationPercentage contextRef="From2020-01-01to2020-12-31_custom_LaboratoryEquipmentMember_srt_MaximumMember_custom_MainlyMember" unitRef="pure" decimals="INF">0.25</SLGL:PropertyAndEquipmentDepreciationPercentage>
    <SLGL:PropertyAndEquipmentDepreciationPercentage contextRef="From2020-01-01to2020-12-31_custom_OfficeFurnitureAndEquipmentMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.07</SLGL:PropertyAndEquipmentDepreciationPercentage>
    <SLGL:PropertyAndEquipmentDepreciationPercentage contextRef="From2020-01-01to2020-12-31_custom_OfficeFurnitureAndEquipmentMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.15</SLGL:PropertyAndEquipmentDepreciationPercentage>
    <SLGL:PropertyAndEquipmentDepreciationPercentage contextRef="From2020-01-01to2020-12-31_us-gaap_ComputerEquipmentMember" unitRef="pure" decimals="INF">0.33</SLGL:PropertyAndEquipmentDepreciationPercentage>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">2040000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1896000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">1373000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1299000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ReceivablesNetCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">4120000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">2153000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-1653000</us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent contextRef="From2019-01-01to2019-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent contextRef="From2020-01-01to2020-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2018-01-01to2018-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">4120000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-1967000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2018-01-01to2018-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-12-31" unitRef="usd" xsi:nil="true" />
    <SLGL:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities contextRef="From2018-01-01to2018-12-31" unitRef="usd" xsi:nil="true" />
    <SLGL:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">1329000</SLGL:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities>
    <SLGL:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">378000</SLGL:RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">10613000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">41000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">10572000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1437500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-02-01to2020-02-19_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">454628</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-02-01to2020-02-19_us-gaap_PrivatePlacementMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">454628</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-01-1" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" id="Foot-01-2" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2020-01-01to2020-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-01-3" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">15332</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">23000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">672000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">673000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-32203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-24576000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-29290000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <dei:DocumentAnnualReport contextRef="From2020-01-01to2020-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentTransitionReport contextRef="From2020-01-01to2020-12-31">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="From2020-01-01to2020-12-31">false</dei:DocumentShellCompanyReport>
    <us-gaap:SharesIssued contextRef="AsOf2018-12-31_us-gaap_IPOMember" unitRef="Shares" decimals="INF">6250000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2019-08-31_custom_FPOMember" unitRef="Shares" decimals="INF">1437500</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2020-02-19_custom_FPOMember" unitRef="Shares" decimals="INF">2091907</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2020-02-19_custom_FPOMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2091907</us-gaap:SharesIssued>
    <SLGL:IncreaseInOperatingLeaseRouAssetsAndLiabilities contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">1200000</SLGL:IncreaseInOperatingLeaseRouAssetsAndLiabilities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-08-01to2019-08-31_custom_FPOMember" unitRef="usd" decimals="-3">10613000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-02-01to2020-02-19_custom_FPOMember" unitRef="usd" decimals="-3">21306000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-02-01to2020-02-19_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-04-01to2020-04-30_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <SLGL:NetChangesInOperatingLeases contextRef="From2018-01-01to2018-12-31" unitRef="usd" xsi:nil="true" />
    <SLGL:NetChangesInOperatingLeases contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">-5000</SLGL:NetChangesInOperatingLeases>
    <SLGL:NetChangesInOperatingLeases contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">-71000</SLGL:NetChangesInOperatingLeases>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;/div&gt;&#13;    &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;NOTE 3&amp;#8201;&amp;#8212;&amp;#8201;MARKETABLE SECURITIES&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The following table sets forth the Company&amp;#8217;s marketable securities for the indicated period:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z9e4af40726134ff29da35241ab772cb6" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-left: 9pt; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-left: 9pt; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Level 2 securities:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;U.S government and agency bonds&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,499&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,192&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Canada government bonds&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;999&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Other foreign government bonds&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,521&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,006&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Corporate bonds*&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;33,947&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;15,454&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 4px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Total&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;40,966&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;21,652&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 1.95pt; margin-left: 36pt; clear: both"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;&lt;font style="font-family: Times New Roman,Times,serif"&gt;* Investments in Corporate bonds&#13;        rated A or higher.&lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;&lt;font style="font-family: Times New Roman,Times,serif"&gt;&amp;#160;&lt;/font&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company&amp;#8217;s debt securities are classified&#13;      within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The table below sets forth a summary of the changes in the fair value of the Company&amp;#8217;s marketable securities for the&#13;      years ended December 31, 2019 and 2020:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z7ff47d7add744957b075a599acb90947" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Balance at beginning of the year&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;56,662&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;40,966&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Additions&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;38,702&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;32,322&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Sale or maturity&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(54,333&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(51,498&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify"&gt;Changes in fair value during the year&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(65&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(138&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify"&gt;Balance at end of the year&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;40,966&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;21,652&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;As of December 31, 2020, the Company&amp;#8217;s debt securities had the following maturity dates:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="zf17a4cc52f0946eb8e8223ee2e133e79" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center; text-indent: 7pt"&gt;Market value&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center; text-indent: 7pt"&gt;December 31,&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center; text-indent: 7pt"&gt; 2020&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Due within one year&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;21,652&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 88%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1 to 2 years&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Total&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;21,652&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;/div&gt;&#13;    &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;NOTE 4&amp;#8201;&amp;#8212;&amp;#8201;PROPERTY AND EQUIPMENT&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z5b8c8feb5b8048ae96207a1f12d10a94" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December 31&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Cost:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Laboratory equipment&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,242&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,644&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Office equipment and furniture&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;265&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;265&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Computers and software&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;490&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;530&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Leasehold improvements&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,946&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,953&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5,943&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6,392&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Less:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Accumulated depreciation and amortization&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(3,629&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(4,575&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Property and equipment, net&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,314&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,817&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Depreciation and amortization expense&#13;        totaled $762, $887 and 946$ for the years ended December&amp;#160;31, 2018, 2019 and 2020, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;/div&gt;&#13;    &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;NOTE 5&amp;#8201;&amp;#8212;&amp;#8201;EMPLOYEE SEVERANCE BENEFITS&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company is required to make severance payments upon dismissal of an employee or upon termination of employment in&#13;      certain circumstances. The severance payment liability to the employees (based upon length of service and the latest monthly salary &amp;#8212; one month&amp;#8217;s salary for each year employed) is recorded on the Company&amp;#8217;s balance sheet under &amp;#8220;Liability for employee&#13;      rights upon retirement.&amp;#8221; The liability is recorded as if it was payable at each balance sheet date on an undiscounted basis.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;In accordance with the current employment terms starting in August&amp;#160;2014 with all of its employees (Section 14 of the&#13;      Israeli Severance Pay Law, 1963), the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&amp;#8217;s retirement benefit obligation. The Company is fully relieved&#13;      from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not&#13;      reflected in the Company balance sheet, as the amounts&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;funded are not under the control and management of the Company and the pension or severance pay risks have been&#13;      irrevocably transferred to the applicable insurance companies (the &amp;#8220;Contribution Plan&amp;#8221;).&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;With regard to the period before August&amp;#160;2014, the liability is funded in part from the purchase of insurance policies or&#13;      by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the balance sheets under &amp;#8220;Funds in respect of employee rights upon retirement.&amp;#8221; These policies are the Company&amp;#8217;s&#13;      assets.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The amounts of severance payment expenses were $431, $402 and $428 for the years ended December&amp;#160;31, 2018, 2019 and 2020,&#13;      respectively, of which $292, $363 and $408 in the years ended December 2018, 2019 and 2020, respectively, were in respect of the Contribution Plan.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company expects to contribute approximately $408 in the year ending December&amp;#160;31, 2021 to insurance companies in&#13;      connection with its expected severance liabilities for that year.&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;      &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;NOTE 8&amp;#8212;&amp;#8201;SHARE CAPITAL&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" id="z8fa77ab4ec544cda8510b95deb82eef6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;a.&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Ordinary shares&lt;br /&gt;&#13;                  &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" id="z8eb2dd07038b4695834632dcacda22be" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;1)&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: bold"&gt;Rights of the Company&amp;#8217;s ordinary shares&lt;/font&gt;&lt;br /&gt;&#13;                  &lt;br /&gt;&#13;                  Each ordinary share is entitled to one vote. The holder of the ordinary shares is also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the&#13;                  Company has not declared any dividends.&lt;br /&gt;&#13;                  &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="zfcc58fdf7aa343d4b9e4a0c228b544d7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;2)&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;On January&amp;#160;19, 2018, the Company executed a 1-for-1.8 share split of the Company&amp;#8217;s shares by way of an issuance of bonus shares for each share. Upon the effectiveness&#13;                of the share split, (i)&amp;#160;0.8 bonus shares were issued for each outstanding share, (ii)&amp;#160;the number of ordinary shares into which each outstanding option to purchase ordinary shares is exercisable was proportionally increased, and (iii)&amp;#160;the&#13;                exercise price of each outstanding option to purchase ordinary shares was proportionately decreased. Unless otherwise indicated, and except for authorized capital, all of the share numbers, loss per share amounts, share prices and option&#13;                exercise prices in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-1.8 share split.&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z60c56e9853dd4a50928dbc17e985ab49" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;3)&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;In January 2018, the Company completed an Initial Public Offering ("IPO") on the NASDAQ&#13;                  Stock Market, in which it issued 6,250,000 Ordinary shares at a price per share of $12. During February 2018 the underwriters exercised their green shoe option and purchased additional 937,500 ordinary shares at the same price per share.&amp;#160;The total proceeds received from the IPO, net of issuance costs, were $78,775.&lt;br /&gt;&#13;                  &lt;br /&gt;&#13;                &lt;/div&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Immediately prior to the closing of the IPO, the outstanding promissory note received from its current controlling&#13;                  shareholder (the "Controlling Shareholder") were automatically converted into 5,444,825 Ordinary shares of the Company based on the IPO price of&amp;#8201;$12 per ordinary share.&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z4fd0d1b03c6b4f5b9bee3db9b6a2fce7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;4)&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;On August 12, 2019, the Company completed an underwritten follow-on public offering, in which it issued 1,437,500&amp;#160;ordinary shares,&amp;#160;including the full exercise by the&#13;                underwriters of their option to purchase&amp;#160;187,500 additional ordinary shares,&amp;#160;at a&amp;#160;public offering&amp;#160;price of $8.00&amp;#160;per ordinary share.&lt;br /&gt;&#13;                The total proceeds received from the offering, net of issuance costs, were approximately $10,613.&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="ze94b55ad01934790acb357e2db6b9a1b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;5)&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;On February 19, 2020, the Company completed an underwritten public offering, in which it issued 2,091,907 ordinary shares and 2,091,907 warrants to purchase up to&#13;                1,673,525 ordinary shares, at a public offering price of $11.00 per ordinary shares. The warrants are exercisable over a three-years period from the date of&#13;                issuance at a per share exercise price of $14, subject to certain adjustments as defined in the agreement.&amp;#160;The total proceeds received from the offering, net of&amp;#160;issuance costs, were approximately $21,306.&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;In addition and in parallel to the public offering, the Company signed an agreement for a private placement with its&#13;        controlling shareholder for an additional investment of approximately $5,000 in consideration of 454,628 ordinary shares and 454,628 warrants to purchase up to 363,702 ordinary shares, at the same terms of the underwritten public offering mentioned&#13;        above. The private placement agreement was contingent on certain conditions and was approved by the company&amp;#8217;s shareholders on April 8, 2020.&amp;#160; The total proceeds of $5,000 were received&amp;#160;in April 2020.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="zfda0292c5dc449c5a54c23cb1aeb159c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;b.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Share-based compensation:&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" id="z0b21a8a2fdcb4a3083fe3032d3d5a858" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;1)&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: bold"&gt;Option plan&lt;/font&gt;&lt;br /&gt;&#13;                  &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 38pt"&gt;In December, 2014, the Company&amp;#8217;s Board of Directors approved a Share Incentive Plan (hereafter &amp;#8212; the Plan)&#13;        and reserved a pool of 629,025 ordinary shares, par value NIS 0.1 each, or such other number as the Board may determine, subject to certain terms and conditions as defined in the Plan. According to the Plan, the Company may issue shares or&#13;        restricted shares, may grant options or restricted share units and other share-based awards (hereafter &amp;#8212; the awards) to the Company employees, consultants, directors and other service providers.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 38pt"&gt;The Plan is designed to enable the Company to grant awards to purchase Ordinary Shares under various and&#13;        different tax regimes including, without limitation: pursuant and subject to Section 102 of the Israeli Tax Ordinance and pursuant and subject to Section 3(i) of the Israeli Tax Ordinance and under Internal revenue Code Section 422.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 38pt"&gt;The awards may be exercised after vesting and in accordance with vesting schedules which will be determined&#13;        by the Board of Directors for each grant. The maximum term of the awards is 10 years. The fair value of each option granted under this Plan is estimated using the Black-Scholes option pricing method. Expected volatility is based on the historical&#13;        volatility of comparable peer companies.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term&#13;        of the options granted in dollar terms. &lt;font style="font-family: Times New Roman, Times, serif"&gt;The expected term of the options is estimated based on the simplified method, as its historical experience for options grants as a&#13;          public company is insufficient.&lt;/font&gt;&lt;font style="font-family: Times New Roman, Times, serif"&gt;&lt;br /&gt;&#13;        &lt;/font&gt;&lt;font style="font-family: Times New Roman, Times, serif"&gt;&lt;br /&gt;&#13;        &lt;/font&gt;In December 2019, the Company&amp;#8217;s Board of Directors approved an increase of the ordinary shares that may be issued under the Company&amp;#8217;s Plan by reserving an additional amount of 912,230 ordinary shares.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 38pt"&gt;As of December 31, 2020, 949,415 ordinary shares remain available for future grants under the Plan.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" id="z93a633ddd1db481aacea15e042b9702e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;2)&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: bold"&gt;Options grants&lt;/font&gt;&lt;br /&gt;&#13;                  &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z9005236ad7ae411793e0a26cda0d10a0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;a.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top; text-align: justify"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;Option granted to employees and directors&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z1b8ebecfd9ec453881039d2deb7ffa3e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 85.05pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 21.3pt; vertical-align: top"&gt;i.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;In January 2019, the Company granted a total of 80,000 options to an executive officer to purchase ordinary shares at an exercise price of $5.95 per share.&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="za7081ac888d64c28b3e7464a194600e7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 85.05pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 21.3pt; vertical-align: top"&gt;ii.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;In May 2019, the Company granted a total of 9,000 options to several employees to purchase ordinary shares at an exercise price of $7.32 per share.&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z3c0e048d8d7a4f5d9e71d3c3b4b6923c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 85.05pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 21.3pt; vertical-align: top"&gt;iii.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;In December 2019, the Company granted a total of 6,300 options to several employees to purchase ordinary shares at an exercise price of $8.32 per share.&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;The options vest over a period of 4 years; 25% of the options vest on the first anniversary of the vesting&#13;        commencement date (as described in each agreement) and the rest vest quarterly over the following three years. The options expire on the tenth anniversary of their grant date.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;The fair value of options granted to employees and directors in 2018 and 2019 were $878 and $485 respectively. The&#13;        underlying data used for computing the fair value of the options are as follows:&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="zd132b3fd475547dba6e7e8ceae2bfccd" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Value of one ordinary share&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;$6.24-$10.40&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;$6.08-$8.59&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Dividend yield&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;0%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;0%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expected volatility&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;70.43 %-73.35%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;74.87%-77.83 %&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2.67%-2.83%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;1.82%-2.75%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expected term&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;5.50-7 years&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;6.11 years&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;The total unrecognized compensation cost of employee options at December&amp;#160;31, 2020 is $271, which is expected to be&#13;        recognized over a period of 2.96 years.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;&lt;br /&gt;&#13;        The following table summarizes the number of options granted to employees under the Plan for the years ended December&amp;#160;31, 2019 and 2020, and related information:&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 76.3pt"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z8504eda92ce2497294e9b56e1f571d96" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="22" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;font style="line-height: 1.25"&gt; &lt;/font&gt;&lt;/div&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -9pt; margin-left: 9pt"&gt;Options outstanding at the beginning of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;938,090&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.47&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.89&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,031,591&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.74&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.25&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Granted&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;95,300&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.24&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;9.17&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Exercised&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(28,447&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5.27&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expired&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(563&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5.57&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Forfeited&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(1,238&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5.57&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(2,250&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.77&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Options outstanding at the end of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,031,591&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.74&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.25&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,000,894&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.63&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.05&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Options exercisable at the end of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;683,979&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3.60&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.56&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;900,687&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4.08&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5.67&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 76.3pt; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" id="z060c11d49c1742b1bab4681a407a72f5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;b.&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;Option granted to non-employees&lt;br /&gt;&#13;                  &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;In March 2018, the Company granted a total of 76,895 options to several consultants to purchase ordinary shares at an&#13;        exercise price of $11.21 per share.&lt;br /&gt;&#13;        &lt;br /&gt;&#13;        The options vest over a period of 4 years; 25% of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over the following three years. The options expire on&#13;        the tenth anniversary of their grant date.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;The fair value of options granted to non-employees in 2018 was $648. The underlying data used for computing the fair&#13;        value of the options are as follows:&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="center" cellspacing="0" cellpadding="0" border="0" id="zb5166ac1be864ad599232c6ce037f683" style="font: 10pt Times New Roman, Times, Serif; width: 80%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Value of one ordinary share&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;$ 10.40&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Dividend yield&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;0%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expected volatility&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;79.07%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2.86%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Expected term&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;10 years&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"&gt;The total unrecognized compensation cost of non-employees' options at December&amp;#160;31, 2020 is $25, which is expected to&#13;        be recognized over a period of 1.23&amp;#160;years.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 70.9pt"&gt;The following table summarizes the number of options granted to non-employees under the Plan for the year ended&#13;        December&amp;#160;31, 2019 and 2020, and related information:&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="zb2de4e2f65a649efac2a1f4896b9f69f" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="22" rowspan="1" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year ended December 31&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;font style="line-height: 1.25"&gt; &lt;/font&gt;&lt;/div&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average exercise price&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -9pt; margin-left: 9pt"&gt;Options outstanding at the beginning of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;198,575&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.48&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;8.81&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;198,575&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.48&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.84&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Granted&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Options outstanding at the end of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;198,575&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.48&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.84&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;198,575&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.70&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.84&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Options exercisable at the end of the year&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;96,588&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.97&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.78&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;137,771&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.34&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.8&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 70.9pt; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" id="zb5378c024eca4291a968ee7fce692323" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;c.&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;The aggregate intrinsic value of the total outstanding and of total exercisable options as of December 31, 2020 is approximately $482 and $413, respectively.&lt;br /&gt;&#13;                  &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" id="z6bdd89df0c0d4d09a2903226774a5021" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;d.&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted Share Units (RSUs) granted to Directors&lt;br /&gt;&#13;                  &lt;br /&gt;&#13;                  In February 2018 and September 2018, the board of directors approved and recommended the Company shareholders to approve a total grant of 46,000 and 11,500 RSUs, respectively, to its independent and&#13;                  external directors that vest annually in equal portions over a three-year period. The fair value of shares as of the date of grant was $495 and $105 respectively. As of December 31, 2020, 38,332 RSUs were vested.&lt;br /&gt;&#13;                  &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" id="zaf6f739ae1274c2497a12e2429df894b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;e.&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;The following table illustrates the effect of share-based compensation on the statements of operations:&lt;br /&gt;&#13;                  &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z242876e0ae6a4d3180613b645b513bc5" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year ended&lt;br /&gt;&#13;                December 31&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,708&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,028&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;431&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;General and administrative expenses&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,946&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,524&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;786&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,654&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,552&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,217&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;/div&gt;&#13;      &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;NOTE 9&amp;#8201;&amp;#8212;&amp;#8201;TAXES ON INCOME&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="zafcb5a0dbf77404cbc014740969eb7b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;a.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Tax rates in Israel&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company is taxed in accordance with Israeli tax laws. The corporate tax rates applicable to 2018, 2019 and 2020 is&#13;        23%. Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z9f68172d194443cf92430c81892fb78e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;b.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Tax rates for the U.S Subsidiary&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The subsidiary is taxed according to U.S. tax laws. The Company&amp;#8217;s income is taxed in the United States&#13;          at the federal rate of 21%.&lt;br /&gt;&#13;          &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z7f798157ebb3419994c9166d9fb8fb9f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;c.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the &amp;#8220;Investment Law&amp;#8221;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Under the Investment Law, including Amendment No. 60 to the Investment Law that was published in April&amp;#160;2005, by virtue&#13;        of the Benefited Enterprise program for certain of its facilities; the Company may be entitled to various tax benefits.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The main benefit arising from such status is the reduction in tax rates on income derived from a Benefited Enterprise.&#13;        The extent of such benefits depends on the location of the enterprise. Since the Company&amp;#8217;s facilities are not located in &amp;#8220;national development zone A,&amp;#8221; income derived from Benefited Enterprises will be tax exempt for a period of two years and then&#13;        have a reduced tax rate for a period of up to an additional eight years.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The period of tax benefits, as described above, is limited to 12 years from the beginning of the Benefited Enterprise&#13;        election year (2012). As of December&amp;#160;31, 2020, the period of benefits has not yet commenced.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;In the event of distribution of cash dividends from income, which was tax exempt as above, the amount distributed will&#13;        be subject to the tax rate it was exempted from. The Company is entitled to claim accelerated depreciation in respect of equipment used by the approved enterprises during five tax years.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Entitlement to the above benefits is conditioned upon the Company fulfilling the conditions stipulated by the&#13;        Investment Law and regulations published thereunder.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;In the event of failure to comply with these conditions, the benefits may be canceled and the Company may be required&#13;        to refund the amount of the benefits, in whole or in part, with the addition of linkage differences to the Israeli consumer price index and interest.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Investment Law was amended as part of the Economic Policy Law for the years 2011&amp;#160;&amp;#8211;&amp;#160;2012 (the&#13;          &amp;#8220;Amendment&amp;#8221;), which became effective on January&amp;#160;1, 2011 and was further amended in August 2013 and January 2017.&lt;br /&gt;&#13;          &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Under the 2017 Amendment, and provided the conditions stipulated therein are met, income derived by Preferred&#13;        Companies from &amp;#8216;Preferred Technological Enterprises&amp;#8217; (&amp;#8220;PTE&amp;#8221;) (as defined in the 2017 Amendment), would be subject to reduced corporate tax rates of 7.5% in Development Zone &amp;#8220;A&amp;#8221; and 12% elsewhere, or 6% in case of a &amp;#8216;Special Preferred Technological&#13;        Enterprise&amp;#8217; (&amp;#8220;SPTE&amp;#8221;) as defined in the 2017 Amendment) regardless of the company&amp;#8217;s geographical location within Israel. A Preferred Company distributing dividends from income derived from its PTE or SPTE, would subject the recipient to a 20% tax&#13;        (or lower, if so provided under an applicable tax treaty). The 2017 Amendment further provides that, in certain circumstances, a dividend distributed to a corporate shareholder who is not an Israeli resident for tax purposes would be subject to a&#13;        4% tax (inter alia, if the amount of foreign investors in the distributing company exceeds 90%). Such taxes would generally be withheld at source by the distributing company.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;&lt;br /&gt;&#13;        On June 14, 2017, the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017 (the &amp;#8220;Regulations&amp;#8221;) were published, which adopted Action 5 under the base erosion&#13;        and profit shifting (&amp;#8220;BEPS&amp;#8221;) regulations. The Regulations describe, inter alia, the mechanism used to determine the calculation of the benefits under the PTE and under the SPTE Regime and determine certain requirements relating to documentation of&#13;        intellectual property for the purpose of the PTE. According to these provisions, a company that complies with the terms under the PTE regime may be entitled to certain tax benefits with respect to income generated during the company&amp;#8217;s regular&#13;        course of business and derived from the preferred intangible asset (as determined in the Investments Law), excluding income derived from intangible assets used for marketing and income attributed to production activity. In the event that intangible&#13;        assets used for marketing purposes generate over 10% of the PTE&amp;#8217;s income, the relevant portion, calculated using a transfer pricing study, would be subject to regular corporate income tax. If such income does not exceed 10%, the PTE will not be&#13;        required to exclude the marketing income from the PTE&amp;#8217;s total income. The Regulations set a presumption of direct production expenses plus 10% with respect to income related to production, which can be countered by the results of a supporting&#13;        transfer pricing study. Tax rates applicable to such production income expenses will be similar to the tax rates under the Preferred Enterprise regime, to the extent such income would be considered as eligible. In order to calculate the preferred&#13;        income, the PTE is required to take into account the income and the research and development expenses that are attributed to each single preferred intangible asset. Nevertheless, it should be noted that the transitional provisions allow companies&#13;        to take into account the income and research and development expenses attributed to all of the preferred intangible assets they have.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Under the transitional provisions of the law, a company is allowed to continue to enjoy the tax benefits available&#13;        under the law prior to its amendment until the end of the period of benefits, as defined in the law. In each year during the period of benefits as a Benefited Enterprise, the Company will be able to opt for application of the amendment, thereby&#13;        making available the tax rates discussed above. The Company&amp;#8217;s election to apply the amendment is irrecoverable.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;As of December&amp;#160;31, 2020, the Company&amp;#8217;s management decided not to adopt the application of the Amendment.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;There is no assurance that future taxable income of the Company will qualify as Benefited or Preferred income or that&#13;        the benefits described above will be available to the Company in the future.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="za6788c86eeaa4adda5a5cca049c2b07d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;d.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Tax assessments&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Tax assessments filed by the Company through the year 2015 are considered to be final.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="zadebd1412dd84e49ac50920812a568ad" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;e.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Losses for tax purposes carried forward to future years&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;As of December&amp;#160;31, 2020, the Company had approximately $151.4 million of net carry forward tax losses&#13;          which are available to reduce future taxable income with no limited period of use.&lt;br /&gt;&#13;          &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z0356fe2a933a4536a0e14eecb1af6ec9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;f.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Deferred income taxes:&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z48e34922d0dc4e97a12bd3715a9a8159" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December, 31&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;In respect of:&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Net operating loss carry forward&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;25,879&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;34,835&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7,842&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7,133&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Other&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,226&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,085&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Less&amp;#8201;&amp;#8211;&amp;#8201;valuation allowance&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(34,947&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(43,053&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Net deferred tax assets&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z3d861b0c288b4988b8d969b13b072614" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;g.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Reconciliation of theoretical tax expenses to actual expenses&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Actual tax expenses are in respect of the U.S. subsidiary. The primary reconciling items between the&#13;          statutory tax rate of the Company and the effective rate are the full valuation allowance of deferred tax assets and nondeductible expenses in relation to the operations in Israel.&lt;br /&gt;&#13;          &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z46e47d0cd1f6456f88d75a17f843be40" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;h.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Roll forward of valuation allowance&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z7da7b359ed9d4f239f9f2621cf1bb85b" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Balance at January 1, 2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;21,982&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Additions&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,184&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Balance at December 31, 2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;26,166&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Additions&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;8,781&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Balance at December 31, 2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;34,947&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Additions&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;8,106&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Balance at December 31, 2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;43,053&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z30097f43e4894caf9a50737470e45e3d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;i.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Provision for uncertain tax positions&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;As of December&amp;#160;31, 2019, and 2020, the Company does not have a provision for uncertain tax positions.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;/div&gt;&#13;      &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;NOTE 10&amp;#8201;&amp;#8212;&amp;#8201; &amp;#160;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -21.3pt; margin-left: 39.3pt"&gt;Other accounts payables and accruals&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="za1f580f57fe44685a5e67f5546f31902" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December, 31&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,249&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,250&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Employees payables&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;841&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;812&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Other&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;33&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;26&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,123&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,088&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <SLGL:ScheduleOfDepreciationRatesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;Annual rates of depreciation are as follows:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table align="center" cellspacing="0" cellpadding="0" border="0" id="z8b2cd7cdce7d403380565b5c928b1fed" style="font: 10pt Times New Roman, Times, Serif; width: 85%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;%&amp;#8201;&amp;#8199;&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Laboratory equipment&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;10 &amp;#8211; 33 (mainly 15 &amp;#8211; 25)&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Office equipment and furniture&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;7 &amp;#8211; 15&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Computers and related equipment&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;33&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</SLGL:ScheduleOfDepreciationRatesTableTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The following table sets forth the Company&amp;#8217;s marketable securities for the indicated period:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z9e4af40726134ff29da35241ab772cb6" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-left: 9pt; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-left: 9pt; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Level 2 securities:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;U.S government and agency bonds&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,499&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,192&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Canada government bonds&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;999&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;-&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Other foreign government bonds&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,521&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,006&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Corporate bonds*&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;33,947&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;15,454&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 4px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Total&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;40,966&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;21,652&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 1.95pt; margin-left: 36pt; clear: both"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;&lt;font style="font-family: Times New Roman,Times,serif"&gt;* Investments in Corporate bonds&#13;        rated A or higher.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div&gt;&lt;div style="margin-left: 20pt; line-height: 1.25"&gt;The table below sets forth a summary of the changes in the fair value of the Company&amp;#8217;s marketable securities for the&#13;      years ended December 31, 2019 and 2020:&lt;/div&gt;&#13;    &lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z7ff47d7add744957b075a599acb90947" style="font: 10pt Times New Roman, Times, serif; width: 95%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="text-align: center; line-height: 1.25"&gt;December 31,&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="text-align: center; line-height: 1.25"&gt; 2019&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="text-align: center; line-height: 1.25"&gt;2020&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;Balance at beginning of the year&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;56,662&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;40,966&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: top; width: 76%"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;Additions&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;38,702&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;32,322&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;Sale or maturity&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;(54,333&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;)&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;(51,498&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;)&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px"&gt;&#13;            &lt;div style="text-align: justify; line-height: 1.25"&gt;Changes in fair value during the year&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;(65&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;)&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;(138&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;)&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="text-align: justify; line-height: 1.25"&gt;Balance at end of the year&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;40,966&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;21,652&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div&gt;&lt;div style="margin-left: 20pt; line-height: 1.25"&gt;As of December 31, 2020, the Company&amp;#8217;s debt securities had the following maturity dates:&lt;/div&gt;&#13;    &lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="zf17a4cc52f0946eb8e8223ee2e133e79" style="font: 10pt Times New Roman, Times, serif; width: 95%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 7pt"&gt;Market value&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 7pt"&gt;December 31,&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 7pt"&gt; 2020&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25; font-family: &amp;#38;quot"&gt;Due within one year&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;21,652&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: middle; width: 88%; padding-bottom: 2px"&gt;&#13;            &lt;div style="line-height: 1.25; font-family: &amp;#38;quot"&gt;1 to 2 years&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;-&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr&gt;&#13;          &lt;td style="vertical-align: bottom; vertical-align: middle; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25; font-family: &amp;#38;quot"&gt;Total&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="line-height: 1.25"&gt;&#13;              &lt;div style="line-height: 1.25"&gt;21,652&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z5b8c8feb5b8048ae96207a1f12d10a94" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December 31&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Cost:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Laboratory equipment&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,242&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,644&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Office equipment and furniture&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;265&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;265&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Computers and software&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;490&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;530&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Leasehold improvements&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,946&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,953&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;5,943&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6,392&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Less:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Accumulated depreciation and amortization&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(3,629&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(4,575&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt"&gt;Property and equipment, net&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,314&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,817&lt;/div&gt;&#13;            &lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <SLGL:ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;The table below presents the lease-related assets and liabilities recorded on the consolidated balance sheet:&lt;/div&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="za98baf96df3e480f81f6a0b47af646c1" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;As of&lt;br /&gt;&#13;                December 31,&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2020&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Assets&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating Leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating lease right-of-use assets&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,040&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,896&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Liabilities&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Current liabilities&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Current maturities of operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;672&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;673&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Long-term liabilities&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Non-current operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,373&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,299&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Weighted Average Remaining Lease Term&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1.66&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1.29&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Weighted Average Discount Rate&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.44&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.25&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</SLGL:ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z189bca4764724745a014e2f7301a4530" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year&lt;/div&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Ended&lt;/div&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating lease cost:&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;643&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;685&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <SLGL:ScheduleOfSupplementalCashFlowInformationRelatedToLeases contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;The table below presents supplemental cash flow information related to leases for the year ended December 31, 2020:&lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="zcf28705bc8f54985bc6fdc8eeb00706b" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year&lt;/div&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Ended&lt;/div&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2020&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Cash paid for amounts included in the measurement of leases liabilities:&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating cash flows from operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;807&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;735&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;/div&gt;&lt;/div&gt;</SLGL:ScheduleOfSupplementalCashFlowInformationRelatedToLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 36pt"&gt;The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining&#13;          years to the operating lease liabilities recorded on the consolidated balance sheet:&lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="zd3bb0ab18d5d49dc9dada56d56d1d045" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Operating&lt;/div&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -8.5pt; margin-left: 11.35pt"&gt;&amp;#160;For the year ended December 31, 2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt"&gt;2021&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;778&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt"&gt;2022&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;714&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt"&gt;2023&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;648&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,140&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Less: amount of lease payments representing interest&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(168&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Present value of future minimum lease payments&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,972&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Less:&amp;#160; Current maturities of operating&#13;                leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;673&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Long-term operating leases liabilities&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,299&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,972&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z48e34922d0dc4e97a12bd3715a9a8159" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December, 31&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;In respect of:&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Net operating loss carry forward&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;25,879&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;34,835&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7,842&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7,133&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Other&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,226&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,085&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Less&amp;#8201;&amp;#8211;&amp;#8201;valuation allowance&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(34,947&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(43,053&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Net deferred tax assets&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#8212;&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z7da7b359ed9d4f239f9f2621cf1bb85b" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Balance at January 1, 2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;21,982&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Additions&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,184&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Balance at December 31, 2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;26,166&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Additions&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;8,781&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Balance at December 31, 2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;34,947&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Additions&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;8,106&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Balance at December 31, 2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;43,053&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="za1f580f57fe44685a5e67f5546f31902" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December, 31&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,249&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;3,250&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Employees payables&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;841&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;812&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Other&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;33&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;26&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,123&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,088&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">20402800</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">23000782</us-gaap:CommonStockSharesIssued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;/div&gt;&#13;      &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;NOTE 11&amp;#8201;&amp;#8212;&amp;#8201;RELATED PARTIES&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="zf003d7e6af31422597f9239a41dc021d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;a.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;Related parties include the Controlling Shareholder and companies under his control, the Board of Directors and the Executive Officers of the Company.&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="z66b62cc7c3624fe7a98fdf038818bee0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;b.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;As to options and restricted shares granted to directors and executive officers, see note 8b.&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" id="zb5477391df374a25a6630398886bec9d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;c.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;As to issuance of shares and warranted to the controlling shareholder in a private placement for a total consideration of $5,000, see note 8a (4).&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">23000782</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">151000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-01-4" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">151000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <SLGL:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">21306000</SLGL:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts>
    <SLGL:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">61000</SLGL:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts>
    <SLGL:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">21245000</SLGL:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts>
    <SLGL:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2091907</SLGL:IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares>
    <SLGL:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">5000000</SLGL:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder>
    <SLGL:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="usd" decimals="-3">13000</SLGL:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder>
    <SLGL:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">4987000</SLGL:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder>
    <SLGL:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">454628</SLGL:IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares>
    <us-gaap:SeveranceCosts1 contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">431000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">402000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">428000</us-gaap:SeveranceCosts1>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">292000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">363000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">408000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="From2021-12-01to2021-12-31_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-3">408000</us-gaap:DefinedContributionPlanCostRecognized>
    <SLGL:RoyaltiesPayableOnSaleOfProductsDeveloped contextRef="From2020-01-01to2020-12-31_srt_MinimumMember_custom_IsraelInnovationAuthorityMember" unitRef="pure" decimals="INF">0.035</SLGL:RoyaltiesPayableOnSaleOfProductsDeveloped>
    <SLGL:RoyaltiesPayableOnSaleOfProductsDeveloped contextRef="From2020-01-01to2020-12-31_srt_MaximumMember_custom_IsraelInnovationAuthorityMember" unitRef="pure" decimals="INF">0.25</SLGL:RoyaltiesPayableOnSaleOfProductsDeveloped>
    <SLGL:PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived contextRef="From2020-01-01to2020-12-31_custom_IsraelInnovationAuthorityMember" unitRef="pure" decimals="INF">3.00</SLGL:PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived>
    <us-gaap:GrantsReceivable contextRef="AsOf2020-12-31_custom_IsraelInnovationAuthorityMember" unitRef="usd" decimals="-3">1431000</us-gaap:GrantsReceivable>
    <us-gaap:RoyaltyExpense contextRef="From2020-01-01to2020-12-31_custom_IsraelInnovationAuthorityMember" unitRef="usd" decimals="-3">2086000</us-gaap:RoyaltyExpense>
    <SLGL:RoyaltiesPayForNetSalesRelatedToPatents contextRef="From2020-01-01to2020-12-31_custom_YissumMember" unitRef="pure" decimals="INF">0.015</SLGL:RoyaltiesPayForNetSalesRelatedToPatents>
    <SLGL:PercentageOfProceedsReceivedForSubLicence contextRef="From2020-01-01to2020-12-31_custom_YissumMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.015</SLGL:PercentageOfProceedsReceivedForSubLicence>
    <SLGL:PercentageOfProceedsReceivedForSubLicence contextRef="From2020-01-01to2020-12-31_custom_YissumMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.08</SLGL:PercentageOfProceedsReceivedForSubLicence>
    <us-gaap:LeaseExpirationDate1 contextRef="From2020-01-01to2020-12-31">2020-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-12-31_us-gaap_VehiclesMember">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="AsOf2020-12-31_custom_MasterClinicalTrialServicesAgreementMember" unitRef="usd" decimals="-3">14425000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="AsOf2020-12-31_custom_ClinicalDevelopmentMasterServicesAgreementMember_custom_AgreementOneMember" unitRef="usd" decimals="-3">13955000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="AsOf2020-12-31_custom_ClinicalDevelopmentMasterServicesAgreementMember_custom_AgreementTwoMember" unitRef="usd" decimals="-3">2234000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <us-gaap:SellingExpense contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">32000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">32000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">25000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="From2020-01-01to2020-12-31_custom_MasterClinicalTrialServicesAgreementMember" unitRef="usd" decimals="-3">14354000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="From2020-01-01to2020-12-31_custom_ClinicalDevelopmentMasterServicesAgreementMember_custom_AgreementOneMember" unitRef="usd" decimals="-3">13801000</us-gaap:SellingExpense>
    <us-gaap:SellingExpense contextRef="From2020-01-01to2020-12-31_custom_ClinicalDevelopmentMasterServicesAgreementMember_custom_AgreementTwoMember" unitRef="usd" decimals="-3">2099000</us-gaap:SellingExpense>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">1373000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1299000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-12-31">P1Y7M28D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-12-31">P1Y3M15D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2019-12-31" unitRef="pure" decimals="INF">0.0744</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2020-12-31" unitRef="pure" decimals="INF">0.0625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">643000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">685000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">807000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">735000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">778000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">714000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">648000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">2140000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <SLGL:AmountOfLeasePaymentsRepresentingInterest contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">168000</SLGL:AmountOfLeasePaymentsRepresentingInterest>
    <SLGL:PresentValueOfFutureMinimumLeasePayments contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1972000</SLGL:PresentValueOfFutureMinimumLeasePayments>
    <SLGL:RoyaltiesMaturity contextRef="From2007-01-01to2007-12-31_us-gaap_MinimumMember">2016</SLGL:RoyaltiesMaturity>
    <SLGL:RoyaltiesMaturity contextRef="From2007-01-01to2007-12-31_us-gaap_MaximumMember">2024</SLGL:RoyaltiesMaturity>
    <SLGL:PercentageOfGrossProfitsRelatedToSaleProducts contextRef="From2020-01-01to2020-12-31" unitRef="pure" decimals="INF">0.50</SLGL:PercentageOfGrossProfitsRelatedToSaleProducts>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">22775000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">8673000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2014-01-01to2014-12-31_us-gaap_BoardOfDirectorsChairmanMember" unitRef="Shares" decimals="INF">629025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2019-01-01to2019-12-31_srt_BoardOfDirectorsChairmanMember" unitRef="Shares" decimals="INF">912230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_custom_NonEmployeesMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_custom_EmployeesMember_srt_MinimumMember">P5Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_custom_EmployeesMember_srt_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember247647703">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2020-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">949415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-03-01to2018-03-31_custom_ConsultantMember" unitRef="Shares" decimals="INF">76895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">95300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-01-01to2019-12-31_custom_NonEmployeesMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-01-01to2019-01-31_srt_ExecutiveOfficerMember" unitRef="Shares" decimals="INF">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-05-01to2019-05-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-02-01to2018-02-28_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">46000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-09-01to2018-09-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">11500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-12-31_custom_NonEmployeesMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-12-01to2019-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">6300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31_custom_NonEmployeesMember" unitRef="USDPShares" decimals="INF">7.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">4.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-03-31_custom_ConsultantMember" unitRef="USDPShares" decimals="INF">11.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_NonEmployeesMember" unitRef="USDPShares" decimals="INF">7.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_EmployeesMember1112152093" unitRef="USDPShares" decimals="INF">8.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-01-31_srt_ExecutiveOfficerMember" unitRef="USDPShares" decimals="INF">5.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-05-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_EmployeesMember248115000" unitRef="USDPShares" decimals="INF">4.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_NonEmployeesMember" unitRef="USDPShares" decimals="INF">7.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-02-19_custom_FPOMember" unitRef="USDPShares" decimals="INF">14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember247647703">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2020-01-01to2020-12-31_custom_NonEmployeesOneMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember247647703" unitRef="pure" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2020-01-01to2020-12-31_custom_NonEmployeesOneMember" unitRef="pure" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">878000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2018-01-01to2018-12-31_custom_NonEmployeesOneMember" unitRef="usd" decimals="-3">648000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">485000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2018-02-01to2018-02-28_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3">495000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="From2018-09-01to2018-09-30_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3">105000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2020-12-31_custom_EmployeesMember" unitRef="usd" decimals="-3">271000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2020-12-31_custom_NonEmployeesOneMember" unitRef="usd" decimals="-3">25000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <SLGL:ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember247647703">P2Y11M15D</SLGL:ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition>
    <SLGL:ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition contextRef="From2020-01-01to2020-12-31_custom_NonEmployeesOneMember">P1Y2M23D</SLGL:ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-12-31_custom_NonEmployeesOneMember" unitRef="usd" decimals="-3">482000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2020-12-31_custom_NonEmployeesOneMember" unitRef="usd" decimals="-3">413000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharePrice contextRef="AsOf2018-12-31_custom_EmployeesMember_srt_MinimumMember" unitRef="USDPShares" decimals="INF">6.24</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2018-12-31_custom_EmployeesMember_srt_MaximumMember" unitRef="USDPShares" decimals="INF">10.40</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2018-12-31_custom_NonEmployeesMember" unitRef="USDPShares" decimals="INF">10.40</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2019-12-31_custom_EmployeesMember_srt_MinimumMember" unitRef="USDPShares" decimals="INF">6.08</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2019-12-31_custom_EmployeesMember_srt_MaximumMember" unitRef="USDPShares" decimals="INF">8.59</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-01-01to2018-12-31_custom_EmployeesMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-01-01to2018-12-31_custom_NonEmployeesMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember" unitRef="pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_custom_NonEmployeesMember" unitRef="pure" decimals="INF">0.7907</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_custom_EmployeesMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.7043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_custom_EmployeesMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.7335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.7487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.7783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-01-01to2018-12-31_custom_NonEmployeesMember" unitRef="pure" decimals="INF">0.0286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-01-01to2018-12-31_custom_EmployeesMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-01-01to2018-12-31_custom_EmployeesMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31_custom_NonEmployeesMember" unitRef="Shares" decimals="INF">198575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">938090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_NonEmployeesMember" unitRef="Shares" decimals="INF">198575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">1031591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_custom_EmployeesMember248115000" unitRef="Shares" decimals="INF">1000894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_custom_NonEmployeesMember" unitRef="Shares" decimals="INF">198575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">1238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">2250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2019-12-31_custom_NonEmployeesMember" unitRef="Shares" decimals="INF">96588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2019-12-31_custom_EmployeesMember" unitRef="Shares" decimals="INF">683979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-12-31_custom_EmployeesMember248115000" unitRef="Shares" decimals="INF">900687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-12-31_custom_NonEmployeesMember" unitRef="Shares" decimals="INF">137771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">6.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31_custom_NonEmployeesMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_custom_NonEmployeesMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">5.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">5.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">5.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">7.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_NonEmployeesMember" unitRef="USDPShares" decimals="INF">6.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_EmployeesMember" unitRef="USDPShares" decimals="INF">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_EmployeesMember248115000" unitRef="USDPShares" decimals="INF">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_NonEmployeesMember" unitRef="USDPShares" decimals="INF">7.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-01-01to2018-12-31_custom_EmployeesMember">P7Y10M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-01-01to2018-12-31_custom_NonEmployeesMember">P8Y9M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember">P7Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-01to2019-12-31_custom_NonEmployeesMember">P7Y10M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember">P6Y0M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-12-31_custom_NonEmployeesMember">P6Y10M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <SLGL:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember">P9Y2M1D</SLGL:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2019-01-01to2019-12-31_custom_EmployeesMember">P6Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2019-01-01to2019-12-31_custom_NonEmployeesMember">P7Y9M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-12-31_custom_EmployeesMember">P5Y8M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-12-31_custom_NonEmployeesMember">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-01-01to2018-12-31" unitRef="pure" decimals="INF">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2019-01-01to2019-12-31" unitRef="pure" decimals="INF">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2020-01-01to2020-12-31" unitRef="pure" decimals="INF">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2020-01-01to2020-12-31_srt_SubsidiariesMember" unitRef="pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <SLGL:TaxBenefitPeriod contextRef="From2020-01-01to2020-12-31">P12Y</SLGL:TaxBenefitPeriod>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">151400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">25879000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">34835000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">7842000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">7133000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">1226000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">1085000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">21982000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">26166000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">34947000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">43053000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2019-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="AsOf2020-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">4184000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2019-01-01to2019-12-31" unitRef="usd" decimals="-3">8781000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">8106000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">3249000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">3250000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">841000</us-gaap:AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent>
    <us-gaap:AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">812000</us-gaap:AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="usd" decimals="-3">33000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="usd" decimals="-3">26000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-02-19_custom_FPOMember" unitRef="Shares" decimals="INF">1673525</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-02-19_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">363702</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2019-08-31_custom_FPOMember_custom_UnderwriterMember" unitRef="Shares" decimals="INF">187500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">38332</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">5000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2018-01-01to2018-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaidNet contextRef="From2019-01-01to2019-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaidNet contextRef="From2020-01-01to2020-12-31" unitRef="usd" decimals="-3">7000</us-gaap:IncomeTaxesPaidNet>
    <SLGL:ShorttermDepositsBearInterest contextRef="From2020-01-01to2020-12-31_srt_MinimumMember" unitRef="pure" decimals="INF">0.0071</SLGL:ShorttermDepositsBearInterest>
    <SLGL:ShorttermDepositsBearInterest contextRef="From2020-01-01to2020-12-31_srt_MaximumMember" unitRef="pure" decimals="INF">0.0187</SLGL:ShorttermDepositsBearInterest>
    <SLGL:AdditionalOrdinarySharesPurchased contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">937500</SLGL:AdditionalOrdinarySharesPurchased>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2018-12-31_us-gaap_IPOMember" unitRef="USDPShares" decimals="INF">12</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;table cellspacing="0" cellpadding="0" id="zaf6f739ae1274c2497a12e2429df894b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;The following table illustrates the effect of share-based compensation on the statements of operations:&lt;br /&gt;&#13;                  &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table align="right" cellspacing="0" cellpadding="0" border="0" id="z242876e0ae6a4d3180613b645b513bc5" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year ended&lt;br /&gt;&#13;                December 31&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2018&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2019&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,708&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,028&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;431&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;General and administrative expenses&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,946&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,524&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;786&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;4,654&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,552&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,217&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="From2018-01-01to2018-01-19_us-gaap_SubsequentEventMember">1-for-1.8</us-gaap:StockholdersEquityNoteStockSplit>
    <SLGL:BonusShare contextRef="From2018-01-01to2018-01-19_us-gaap_SubsequentEventMember" unitRef="USDPShares" decimals="INF">0.8</SLGL:BonusShare>
    <us-gaap:NatureOfOperations contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;NOTE 1&amp;#8201;&amp;#8212;&amp;#8201;NATURE OF OPERATIONS&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Sol-Gel Technologies Ltd. (collectively with its subsidiary, the Company) is an Israeli Company incorporated in&amp;#160; 1997.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;The Company is a clinical stage specialty&#13;          pharmaceutical company focused on developing and commercializing topical dermatological drug products. The Company&amp;#8217;s lead product candidates are based upon its proprietary microencapsulation delivery system, consisting of microcapsules made of&#13;          precipitated silica. The most advanced investigational drugs in the Company's product pipeline are: (i) Twyneo&lt;sup style="font: smaller/1 Times New Roman,serif; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt;, which is developed for the treatment of acne vulgaris. The New Drug Application ("NDA") for Twyneo&amp;#174; was accepted by&#13;          the U.S.&amp;#160;Food and Drug Administration (the &amp;#8220;FDA&amp;#8221;), which&#13;          assigned a Prescription Drug User Fee Act ("PDUFA") goal date of August 1, 2021; and (ii) Epsolay&lt;sup style="font: smaller/1 Times New Roman,serif; vertical-align: text-top"&gt;&amp;#174;&lt;/sup&gt;, a potential treatment for subtype II rosacea. The NDA for Epsolay&amp;#174; was accepted by the FDA, which assigned a PDUFA goal date of April 26, 2021.  In addition to the novel product candidates, the Company&amp;#8217;s products include the generic product Acyclovir and other generic product candidates.&lt;/div&gt;&#13;    &lt;/div&gt;&#13;  &#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regard to marketing, regulatory affairs and business development&#13;      relating to its products and technology in the U.S.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Since incorporation through December 31, 2020, the Company has an accumulated deficit of approximately $181,363 thousand and its activities have been funded mainly by its shareholders and collaboration&#13;      revenues. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations and in order to continue its future operations, the Company will need to obtain additional funding until&#13;      becoming profitable.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Management is considering raising additional funding from different sources, such as corporate collaborations, licensing of its branded products or similar arrangements, public or private equity&#13;      offerings and/or debt financings, and/or selling shares under the Company's Open Market Sale Agreement with Jefferies LLC. Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of December 31, 2020&#13;      will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;In December 2019, COVID-19 was identified in Wuhan, China. This virus continues to spread globally and, as of December 2020, has spread to over 50 countries, including the United States and Israel. The&#13;      Company is subject to risks and uncertainties as a result of the COVID-19 pandemic.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;As of December 31, 2020, the main impact on the Company's operations resulting from COVID-19 was the decline in revenues of Acyclovir in the second quarter.&amp;#160; Management believes that such decline was&#13;      mainly attributed to travel restrictions and stay-at-home-orders.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues from collaboration&#13;      arrangements, expenses, reserves and allowances, manufacturing, supply, regulatory approvals, clinical trials, commercial launch of branded and generic product candidates,&amp;#160; research and development costs and employee-related amounts, will depend on&#13;      future developments that are highly uncertain and cannot be predicted. The Company continues to monitor and assess new information related to the COVID-19 pandemic, the actions taken to contain or treat COVID-19, as well as the economic impact on the&#13;      different markets.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Furthermore, the estimation process required to prepare the Company&amp;#8217;s consolidated financial statements requires assumptions to be made about future events and conditions and the impact of COVID-19 on&#13;      its financial results, and while management believes such assumptions are reasonable, they are inherently subjective and uncertain. The Company&amp;#8217;s actual results could differ materially from those estimates.&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;NOTE 6&amp;#8201;&amp;#8212;&amp;#8201;COMMITMENTS:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2206b0aec79c40bb963978da84db12f6" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;a.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Royalty Commitments:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z96799f1a692b43d0a6f3b5be12a526fa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 38pt"&gt;&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;1)&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;The Company is obligated to pay royalties to the IIA on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from the IIA.&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56pt"&gt;Under the specific terms of the funding arrangements with the IIA, royalties of 3.5% to 25% are payable on the sale of products developed with funding received from the IIA, which payments shall not&#13;      exceed, in the aggregate, 300% of the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.&lt;br /&gt;&#13;      &lt;br /&gt;&#13;      Up to December&amp;#160;31, 2020, the Company had recognized and received grants from the IIA in the aggregate amount of $1,431 (no grants were received in the last three years.). Through December&amp;#160;31, 2020, the Company recorded an accumulated royalty expense&#13;      of&amp;#8201;$2,086 as royalties to the IIA with respect to revenue recognized through December 31, 2020 ($32, $32 and $25 were recorded in 2018, 2019 and 2020 accordingly, as an expense in the consolidated statements of operations).&lt;br /&gt;&#13;      &lt;br /&gt;&#13;      The Company did not receive any grants from the IIA for the years ended December&amp;#160;31, 2018, 2019 and 2020.&lt;br /&gt;&#13;      &lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbf7a8e9a9ae249baa013c9d81cb75b17" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"&gt;&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;2)&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;The Company has an agreement, that was amended several times (hereafter &amp;#8212; the agreements) with Yissum Research Development Company (hereafter &amp;#8212; &amp;#8220;Yissum&amp;#8221;), the technology-licensing arm of the Hebrew University of Jerusalem.&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;&#13;    &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56.7pt"&gt;According to the agreements, the Company received from Yissum an exclusive and a non-exclusive license for the commercialization of certain Yissum patents. According to the agreements the Company&#13;        shall pay Yissum:&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56.7pt"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56.7pt"&gt;Royalties of 1.5% of net sales related to certain patents.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56.7pt"&gt; &lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc1742217551248ed9b7f4429a64baf29" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;i.&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;1.5%&amp;#8201;&amp;#8211;&amp;#8201;8% of proceeds received by the Company for the sub-license or license of certain patents.&lt;br /&gt;&#13;                &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;br /&gt;&#13;        &lt;/div&gt;&#13;        &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 1.7pt; margin-left: 56.7pt"&gt;Royalty expenses in immaterial amounts were recorded in 2018, 2019 and 2020 in respect of&#13;            these agreements&lt;/div&gt;&#13;        &lt;/div&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 1.7pt; margin-left: 56.7pt"&gt;According to the agreements, the Company may continue commercial use of certain Yissum&amp;#8217;s patents in connection with the products and subject to the obligation to pay Yissum the&#13;        royalties and the sub-license fees.&lt;br /&gt;&#13;        &lt;br /&gt;&#13;        The Company granted rights to a third party for use and commercialization of certain Yissum patents.&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z905397d8e1d84d10b0626edcd3bfaa66" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;b.&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: bold"&gt;Lease Agreements&lt;/font&gt;&lt;br /&gt;&#13;                &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;The Company leases offices and vehicles under operating leases. For leases with terms greater than 12 months, the Company&#13;          records right of use assets and lease liabilities at the present value of lease payments over the leases term.&lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;&lt;u&gt;Offices&lt;/u&gt;&lt;/div&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;The Company leases office spaces and research and development facilities under several agreements. These agreements are linked to the change in the Israeli consumer price index and expire in&#13;          December 2023. These agreements are considered as operating leases and presented under operating lease right-of-use assets and operating leases liabilities.&amp;#160;A restricted deposit of $143 has been made in order to secure the agreement. &lt;br /&gt;&#13;          &lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;&lt;u&gt;Vehicles&lt;/u&gt;&lt;/div&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;The Company has entered into operating lease agreements for vehicles used by its employees for a period of 3 years. These contracts are considered as operating leases and presented under operating&#13;          lease right-of-use assets and operating leases liabilities.&lt;/div&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;&lt;u&gt;Lease Position&lt;/u&gt;&lt;/div&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;&lt;br /&gt;&#13;          The table below presents the lease-related assets and liabilities recorded on the consolidated balance sheet:&lt;/div&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" border="0" align="right" id="za98baf96df3e480f81f6a0b47af646c1" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;As of&lt;br /&gt;&#13;                December 31,&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2020&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Assets&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating Leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating lease right-of-use assets&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,040&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,896&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Liabilities&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Current liabilities&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Current maturities of operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;672&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;673&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Long-term liabilities&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Non-current operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,373&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,299&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Weighted Average Remaining Lease Term&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1.66&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1.29&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Weighted Average Discount Rate&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;7.44&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;6.25&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;%&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;&lt;font style="font-family: Times New Roman,Times,serif"&gt;&lt;u&gt;Lease Costs&lt;/u&gt;&lt;/font&gt;&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;The table below present certain information related to lease costs of operating leases the year ended December 31, 2020:&lt;/div&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" border="0" align="right" id="z189bca4764724745a014e2f7301a4530" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year&lt;/div&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Ended&lt;/div&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating lease cost:&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;643&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;685&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;The table below presents supplemental cash flow information related to leases for the year ended December 31, 2020:&lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" border="0" align="right" id="zcf28705bc8f54985bc6fdc8eeb00706b" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Year&lt;/div&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Ended&lt;/div&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2019&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt; 2020&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Cash paid for amounts included in the measurement of leases liabilities:&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt"&gt;Operating cash flows from operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;807&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;735&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt"&gt;&lt;u&gt;Undiscounted Cash Flows&lt;/u&gt;&lt;br /&gt;&#13;          &lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 36pt"&gt;The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities recorded on the consolidated balance&#13;          sheet:&lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" border="0" align="right" id="zd3bb0ab18d5d49dc9dada56d56d1d045" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom"&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Operating&lt;/div&gt;&#13;              &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;Leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -8.5pt; margin-left: 11.35pt"&gt;&amp;#160;For the year ended December 31, 2020&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt"&gt;2021&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;778&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt"&gt;2022&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;714&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt"&gt;2023&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;648&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;2,140&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Less: amount of lease payments representing interest&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;(168&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;)&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Present value of future minimum lease payments&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,972&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Less:&amp;#160; Current maturities of operating leases&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;673&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Long-term operating leases liabilities&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,299&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;$&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)"&gt;&#13;              &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;1,972&lt;/div&gt;&#13;            &lt;/td&gt;&#13;            &lt;td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z770f468da62e42938aa55590c6d29e43" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;c.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;In June&amp;#160;2008, the Company entered into a Master Clinical Trial Services Agreement with a third party, which was later&#13;                  amended in April&amp;#160;2017, to retain its services as a clinical research organization for certain product candidate subject to task work orders to be issued by the Company. During 2018, the Company entered into six additional task orders. As consideration for its services the Company will pay a total amount of approximately $14,425 during the term of the engagement and based on&#13;                  achievement of certain milestones, out of which $14,354 were recognized as an expense until December&amp;#160;31, 2020.&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"&gt;&lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&#13;        &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc6c20d410f8f48c7a282d50dec86fcf9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;          &#13;            &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;              &lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;d.&lt;/td&gt;&#13;              &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;                &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;In 2016 through 2020, the Company entered into twelve collaboration agreements with two third parties for the development, manufacturing and commercialization of ten product candidates (including an agreement assumed by the Company in&#13;                  August 2018, following the transfer of an in-process research and development product candidate from a related party). See detailed information in note 7b.&lt;br /&gt;&#13;                &lt;/div&gt;&#13;              &lt;/td&gt;&#13;            &lt;/tr&gt;&#13;          &#13;        &lt;/table&gt;&#13;        &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;br /&gt;&#13;        &lt;/div&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z35b3af3e3b604c0f917e16d36a6c38b1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;e.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;In October&amp;#160;2017, the Company entered into a Clinical Development Master Services Agreement with a third party, to retain it as&#13;                  clinical research organization for certain product candidate, subject to task work orders to be issued by the Company. As consideration for its services the Company will pay a total amount of approximately $13,955 during the term of the engagement and based on achievement of certain milestones, out of which $13,801 were recognized as an expense until December&amp;#160;31, 2020.&lt;/div&gt;&#13;              &lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;&#13;      &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z62610358882041928953182433291290" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;f.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top; text-align: justify"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;In July&amp;#160;2018, the Company signed on a Master Services Agreement to receive certain clinical research services for certain&#13;                  product candidate subject to task work orders to be issued by the Company. As consideration for the services in the first work order the Company will pay a total amount of approximately $2,234 during the term of the engagement and based&#13;                  on achievement of certain milestones, out of which $2,099 were recognized as an expense until December&amp;#160;31, 2020.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: bold"&gt;NOTE 7&amp;#8201;&amp;#8212;&amp;#8201;COLLABORATION AGREEMENTS&lt;br /&gt;&#13;        &lt;/font&gt;&lt;br style="line-height: 1.25" /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z69f6c9ad58d04439a6a2789d55e7fe8f" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;a.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales,&#13;                royalties are not material.&lt;/div&gt;&#13;            &lt;/td&gt;&#13;          &lt;/tr&gt;&#13;        &#13;      &lt;/table&gt;&#13;      &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;br /&gt;&#13;      &lt;/div&gt;&#13;      &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z27cd88c288d14dcba4faaa3dbbfb4ac5" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;        &#13;          &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"&gt;&lt;br /&gt;&#13;            &lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top"&gt;b.&lt;/td&gt;&#13;            &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;In 2016 through 2020, the Company entered into several collaboration agreements with two third parties for the development,&#13;                  manufacturing and commercialization of several generic product candidates. Under the agreements, the third parties are obligated to conduct regulatory, scientific, clinical and technical activities necessary to develop the product and&#13;                  prepare and file ANDA, with the FDA and gain regulatory approval. The Company participates in the development of the product candidates, including participation in joint steering committees and is obligated for sourcing the active&#13;                  pharmaceutical ingredient (API) during the development phase.&lt;/div&gt;&#13;              &lt;/div&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;br /&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Upon FDA approval, the third parties have exclusive rights and are required to use diligent efforts to commercialize these&#13;                  products in territories defined under the agreements, including all required sales, marketing and distributing activities associated with the agreements. The Company is entitled to 50% of the third parties&amp;#8217; gross profits related to the&#13;                  sale of these products, as such term is defined in the agreements.&lt;/div&gt;&#13;                &lt;br /&gt;&#13;                As of December 31, 2020, the Company decided not to pursue one of the agreements with one of the third parties collaborators.&lt;br /&gt;&#13;                &lt;br /&gt;&#13;                In February 2019, the Company announced that a third party has received final approval from the FDA for the first generic version of a drug product.&amp;#160; During&#13;                  the years ended December 31, 2019 and 2020, the Company&#13;                  recognized collaboration revenues related to sales of products in the U.S. under this agreement in the amounts of $22,775 and $8,673, respectively.&lt;br /&gt;&#13;              &lt;/div&gt;&#13;              &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br /&gt;&#13;                  This Agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative&#13;                    activity.&lt;br /&gt;&#13;                    &lt;br style="line-height: 1.25" /&gt;&#13;                &lt;/div&gt;&#13;                &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;The Company recognizes collaboration revenues when the related sales occur&lt;font style="font-family: Times New Roman, Times, serif"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;Basis of presentation&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company&amp;#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;).&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z79ce61c58f764cd4a9fa64fe81b14829" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;a.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Use of estimates in the preparation of financial statements&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of&#13;      contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the fair value of share-based compensation and the incremental borrowing rate for&#13;      leases.&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z324b2b78394744a6be48487dc70d4003" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;b.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Functional and presentation currency&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The U.S. dollar (&amp;#8220;dollar&amp;#8221;) is the currency of the primary economic environment in which the operations of the Company and its subsidiary are conducted. The Company&amp;#8217;s financing has been provided in&#13;      dollars, revenues are primarily in dollars and a significant part of expenses are incurred in dollars. The financial statements are presented in dollars, which is the Company&amp;#8217;s functional and presentation currency.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange&#13;      rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (I) for transactions &amp;#8212; exchange rates at transaction&#13;      dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) &amp;#8212; historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6c9ffab81e864a618ac4edfe4b6d9c74" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;c.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase&#13;      that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <SLGL:BankDepositsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7f1b6911715048f48107b0c09a6d1af5" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;d.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: bold"&gt;Bank deposits&lt;/font&gt;&lt;br /&gt;&#13;              &lt;br /&gt;&#13;              Bank deposits with original maturity dates of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an average annual rate of approximately 0.71%-1.87% in 2020. Interest&#13;              accrued on bank deposits was recorded as interest receivable as part of "Prepaid expenses and other current assets" in the company&amp;#8217;s balance sheet. &lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt; &lt;br /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Bank deposits with maturity of more than one year are considered long-term.&lt;/div&gt;&lt;/div&gt;</SLGL:BankDepositsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc761d232035445b7b04ae0b4702e8c23" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;e.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Marketable securities&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;&lt;br /&gt;&#13;      Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825,&amp;#160;Financial Instruments as the Company manages its portfolio and&#13;      evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z109d213175f74f7a8c8ca1b35225a9f2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;h.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Property and equipment:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z59a5ed342ee546a4bd32f4e6f1249a3a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"&gt;&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;1)&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6147f6baec204641b7d368d9e11bcc9b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"&gt;&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;2)&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;The Company&amp;#8217;s property and equipment are depreciated utilizing the straight-line method on the basis of their estimated useful life.&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;Annual rates of depreciation are as follows:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" border="0" align="center" id="z8b2cd7cdce7d403380565b5c928b1fed" style="font: 10pt Times New Roman, Times, Serif; width: 85%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;%&amp;#8201;&amp;#8199;&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Laboratory equipment&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;10 &amp;#8211; 33 (mainly 15 &amp;#8211; 25)&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Office equipment and furniture&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;7 &amp;#8211; 15&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Computers and related equipment&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;33&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Leasehold improvements are amortized utilizing the straight-line method over the shorter of the expected lease term or the estimated useful life of the improvements.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf29af5ff7e744ab7a318efd9f9ceb0f7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;i.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Impairment of long-lived assets&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest&#13;      charges) of the assets is less than the carrying amount of such assets, an impairment loss would be recognized. The assets would then be written down to their estimated fair values.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;For the three years ended December&amp;#160;31, 2020, the Company did not recognize an impairment loss for its long-lived assets.&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za27b9bfab8074ad4ac5345b539fb50df" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;j.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Share-based compensation&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company accounts for employees&amp;#8217; share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an&#13;      expense over the requisite service period.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option award&#13;      approach.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;On January 1, 2019 the Company adopted ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Under&#13;      the provision of the amendment, the Company measures share-based compensation to non-employees in the same manner (except for certain exceptions) as share-based compensation to employees.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Prior to January 1, 2019, when options were granted as consideration for services provided by consultants and other non-employees, the grant was accounted for based on the fair value of the&#13;      consideration received or the fair value of the options issued, whichever is more reliably measurable. The fair value of the options granted was measured on a final basis at the end of the related service period and recognized over the related&#13;      service period using the graded vesting schedule method.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 15.7pt"&gt; &lt;br /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company has elected to recognize forfeitures as they occur.&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf8bf3f8a3cc54154a9fe73d9f16a6983" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;k.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll&#13;      taxes and other employee benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Acquisitions of in-process research and development product candidate, which are not part of business combination, are recognized as an expense as research and development expenses as incurred.&lt;br /&gt;&#13;      &lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Grants received from Israel Innovation Authority (hereafter &amp;#8212; &amp;#8220;IIA&amp;#8221;), formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS are recognized when the&#13;      grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and&#13;      development expenses as the applicable costs are incurred. See note 6a(1).&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources its clinical trial activities&#13;      utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs are expensed as&#13;      incurred.&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb6c579e0afcb47cf80a2422f09d1b739" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;l.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Revenue recognition&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;The Company applies ASC 606, Revenue from Contracts with Customers. According to the standard, an entity recognizes revenue when its customer obtains control of promised goods or services, in an&#13;      amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the&#13;      following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;&#13;      and (v) recognize revenue when (or as) the performance obligation is satisfied.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;An entity only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the&#13;      customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the entity assesses the goods or services promised within each contract and determines those that are performance&#13;      obligations and assesses whether each promised good or service is distinct. The entity then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation&#13;      is satisfied.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin: 0px 0px 0px 20pt"&gt;&lt;font style="font-family: Times New Roman,Times,serif"&gt;&lt;font style="font-style: italic"&gt;Collaborative Arrangements&lt;/font&gt;&lt;br /&gt;&#13;      &lt;/font&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;The Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, Collaborative Arrangements (&amp;#8220;ASC 808&amp;#8221;). While these arrangements are in the scope of ASC&#13;      808, the Company may analogize to ASC 606 for some aspects of the arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part&#13;      of its ongoing major or central operations. Revenue recognized by analogizing to ASC 606 is recorded as &amp;#8220;collaboration revenues&amp;#8221;.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;The terms of the Company&amp;#8217;s collaborative arrangements typically include one or more of the following: (i) royalties on net sales of licensed products; (ii) reimbursements or cost-sharing of R&amp;#38;D&#13;      expenses. Each of these payments results in collaboration revenues or an offset against R&amp;#38;D expense.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;Royalties: For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes collaboration revenue at the&#13;      later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;Under certain collaborative arrangements, the Company has been reimbursed for a portion of its R&amp;#38;D expenses or participates in the cost-sharing of such R&amp;#38;D expenses. Such reimbursements and&#13;      cost-sharing arrangements have been reflected as a reduction of R&amp;#38;D expense in the Company&amp;#8217;s consolidated statements of operations, as the Company does not consider performing research and development services for reimbursement to be a part of&#13;      its ongoing major or central operations.&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0812def152d54fdb9f01feeecdb9dedc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;m.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Income taxes:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7defb31d969c43c8980ae9f04b65e866" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"&gt;&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;1)&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred taxes&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 36pt"&gt;The Company accounts for income taxes in accordance with ASC 740, &amp;#8220;Income Taxes&amp;#8221; (&amp;#8220;ASC&amp;#160;740&amp;#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and&#13;      liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to&#13;      reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the&#13;      weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt"&gt;Uncertainty in income taxes&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 36pt"&gt;The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence&#13;      indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being&#13;      realized upon ultimate settlement.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7945dbca9614463db051890512fb5a4a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;n.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Leases&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;As of January 1, 2019, the Company adopted ASU No. 2016-02, &amp;#8220;Leases (Topic 842)". The Company adopted the standard using the modified retrospective approach with an effective date as of the beginning&#13;      of the Company's fiscal year, January 1, 2019. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts are or contain&#13;      leases, (2) lease classification and (3) initial direct costs.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Right of Use ("ROU") assets represent the Company&amp;#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&amp;#8217;s obligation to make lease payments arising from the&#13;      lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company&amp;#8217;s lease terms may include options to extend or terminate the lease when it is&#13;      reasonably certain that the Company will exercise that option.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company uses the implicit rate when readily determinable. As the Company&amp;#8217;s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information&#13;      available at commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to not separate lease and non-lease components for the&#13;      leases. The Company elected the practical expedient of the short-term lease recognition exemption for all leases with a term shorter than 12 months.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt; &lt;br /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Additionally, the company applies the portfolio approach to account for operating lease ROU asset and liabilities for certain car leases and incremental borrowing rates.&lt;br /&gt;&#13;      &lt;br /&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Upon adoption, the standard resulted in an increase of $1,200 in operating lease ROU assets and corresponding liabilities on the&#13;        Company&amp;#8217;s consolidated balance sheet and did not have a material impact on the Company&amp;#8217;s consolidated statements of operations or consolidated statements of cash flows.&amp;#160; See also note 6b.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z27d5f92405494446b69a4061f09c078a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;o.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Loss per share&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is based&#13;      upon the weighted average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options, restricted shares and warrants, which are included under the treasury&#13;      stock method when dilutive. The calculation of diluted loss per share does not include 1,119,310, 1,260,984 and 3,271,507 options, restricted shares and warrants for the years ended December&amp;#160;31, 2018, 2019 and 2020, respectively, because their effect&#13;      would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4d42a1eac37e418b92c66e4e364bc26f" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;p.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Fair value measurement&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement&#13;      date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are&#13;      described as follows:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers&#13;      counterparty credit risk in its assessment of fair value.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The carrying amount of the cash and cash equivalents, bank deposits, restricted cash, receivables from collaborative arrangements, restricted long-term deposits, accrued expenses (under other account&#13;      payable), operating leases liabilities and other liabilities approximates their fair value.&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf24ba24f57404740917d2ca20a147269" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;q.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Concentration of credit risks&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, bank deposits and marketable securities and certain&#13;      receivables. The Company deposits cash and cash equivalents with highly rated financial institutions (Israeli banks). In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced any material&#13;      credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z339fd1fa884f49f086d0c0eb4212cb95" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;r.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Newly issued and recently adopted accounting pronouncements&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: italic bold 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Recently adopted accounting pronouncements:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;In June 2016, the FASB issued ASU 2016-13 &amp;#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&amp;#8221;. This guidance replaces the current incurred loss impairment&#13;      methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance became effective for the fiscal year beginning&#13;      on January 1, 2020, including interim periods within that year. This guidance did not have significant impact on the Company&amp;#8217;s financial statements.&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br /&gt;&#13;      NOTE 2&amp;#8201;&amp;#8212;&amp;#8201;SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"&gt;Basis of presentation&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company&amp;#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;).&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;&amp;#160;&lt;br style="line-height: 1.25" /&gt;&lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z79ce61c58f764cd4a9fa64fe81b14829" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;a.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Use of estimates in the preparation of financial statements&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of&#13;      contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the fair value of share-based&#13;compensation and the incremental borrowing rate for leases.&amp;#160;&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &#13;    &lt;table cellspacing="0" cellpadding="0" id="z324b2b78394744a6be48487dc70d4003" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;b.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Functional and presentation currency&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The U.S. dollar (&amp;#8220;dollar&amp;#8221;) is the currency of the primary economic environment in which the operations of the Company and its subsidiary are conducted. The Company&amp;#8217;s financing has been provided in&#13;      dollars, revenues are primarily in dollars and a significant part of expenses are incurred in dollars. The financial statements are presented in dollars, which is the Company&amp;#8217;s functional and presentation currency.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange&#13;      rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (I) for transactions &amp;#8212; exchange rates at transaction&#13;      dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) &amp;#8212; historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z6c9ffab81e864a618ac4edfe4b6d9c74" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;c.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase&#13;      that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z7f1b6911715048f48107b0c09a6d1af5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;d.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: bold"&gt;Bank deposits&lt;/font&gt;&lt;br /&gt;&#13;              &lt;br /&gt;&#13;              Bank deposits with original maturity dates of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an average annual rate of approximately 0.71%-1.87% in 2020. Interest&#13;              accrued on bank deposits was recorded as interest receivable as part of "Prepaid expenses and other current assets" in the company&amp;#8217;s balance sheet. &lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt; &lt;br /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Bank deposits with maturity of more than one year are considered long-term.&lt;br /&gt;&#13;      &lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="zc761d232035445b7b04ae0b4702e8c23" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;e.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Marketable securities&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;&lt;br /&gt;&#13;      Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825,&amp;#160;Financial Instruments as the Company manages its portfolio and&#13;      evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z5ee031687b39499782a8e3367f82326a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;f.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: bold"&gt;Derivatives and hedging&lt;/font&gt;&lt;br /&gt;&#13;              &lt;br /&gt;&#13;              The Company carries out transactions involving foreign currency exchange derivative financial instruments. The transactions are designed to hedge the Company&amp;#8217;s exposure in currencies other than the U.S. dollar. The derivative does not meet&#13;              the definition of a cash flow accounting hedge, therefore the changes in the fair value are included in financial expense (income), net.&lt;/div&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;br /&gt;&#13;              The currency hedged items are denominated in New Israeli Shekel (NIS).&amp;#160; The counterparties to the derivatives are major banks in Israel.&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;    &lt;div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt"&gt;&#13;      &#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;As of December 31, 2020, the Company has $1,150 on the Company&amp;#8217;s bank account that is restricted in order to secure the hedging transactions. This amount is presented among Restricted long-term&#13;      deposits and cash.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="za932c38e076d43c9b7a8bedb2974ffe4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;g.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Trade receivables:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 20.15pt"&gt;Trade receivables are initially recognized at the transaction price and subsequently measured at amortized cost less any allowance for expected credit losses.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 20.15pt"&gt;&amp;#160;Starting from January 1, 2020, the Company applies ASU 2016-13 &amp;#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&amp;#8221; (&amp;#8220;the Standard&amp;#8221;).&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z109d213175f74f7a8c8ca1b35225a9f2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;h.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Property and equipment:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z59a5ed342ee546a4bd32f4e6f1249a3a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"&gt;&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;1)&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z6147f6baec204641b7d368d9e11bcc9b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"&gt;&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;2)&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;The Company&amp;#8217;s property and equipment are depreciated utilizing the straight-line method on the basis of their estimated useful life.&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;Annual rates of depreciation are as follows:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" border="0" align="center" id="z8b2cd7cdce7d403380565b5c928b1fed" style="font: 10pt Times New Roman, Times, Serif; width: 85%; color: #000000; text-align: left"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: bottom; padding-bottom: 2px"&gt;&amp;#160;&lt;/td&gt;&#13;          &lt;td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: bottom"&gt;&#13;            &lt;div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;%&amp;#8201;&amp;#8199;&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Laboratory equipment&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;10 &amp;#8211; 33 (mainly 15 &amp;#8211; 25)&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Office equipment and furniture&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;7 &amp;#8211; 15&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Computers and related equipment&lt;/div&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)"&gt;&#13;            &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"&gt;33&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Leasehold improvements are amortized utilizing the straight-line method over the shorter of the expected lease term or the estimated useful life of the improvements.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="zf29af5ff7e744ab7a318efd9f9ceb0f7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;i.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Impairment of long-lived assets&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest&#13;      charges) of the assets is less than the carrying amount of such assets, an impairment loss would be recognized. The assets would then be written down to their estimated fair values.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;For the three years ended December&amp;#160;31, 2020, the Company did not recognize an impairment loss for its long-lived assets.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="za27b9bfab8074ad4ac5345b539fb50df" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;j.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Share-based compensation&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company accounts for employees&amp;#8217; share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an&#13;      expense over the requisite service period.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option award&#13;      approach.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;On January 1, 2019 the Company adopted ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Under&#13;      the provision of the amendment, the Company measures share-based compensation to non-employees in the same manner (except for certain exceptions) as share-based compensation to employees.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;    &lt;div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt"&gt;&#13;      &#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Prior to January 1, 2019, when options were granted as consideration for services provided by consultants and other non-employees, the grant was accounted for based on the fair value of the&#13;      consideration received or the fair value of the options issued, whichever is more reliably measurable. The fair value of the options granted was measured on a final basis at the end of the related service period and recognized over the related&#13;      service period using the graded vesting schedule method.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 15.7pt"&gt; &lt;br /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company has elected to recognize forfeitures as they occur.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="zf8bf3f8a3cc54154a9fe73d9f16a6983" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;k.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Research and development expenses&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll&#13;      taxes and other employee benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Acquisitions of in-process research and development product candidate, which are not part of business combination, are recognized as an expense as research and development expenses as incurred.&lt;br /&gt;&#13;      &lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Grants received from Israel Innovation Authority (hereafter &amp;#8212; &amp;#8220;IIA&amp;#8221;), formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS are recognized when the&#13;      grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and&#13;      development expenses as the applicable costs are incurred. See note 6a(1).&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources its clinical trial activities&#13;      utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs are expensed as&#13;      incurred.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="zb6c579e0afcb47cf80a2422f09d1b739" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;l.&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Revenue recognition&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;The Company applies ASC 606, Revenue from Contracts with Customers. According to the standard, an entity recognizes revenue when its customer obtains control of promised goods or services, in an&#13;      amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the&#13;      following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;&#13;      and (v) recognize revenue when (or as) the performance obligation is satisfied.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;An entity only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the&#13;      customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the entity assesses the goods or services promised within each contract and determines those that are performance&#13;      obligations and assesses whether each promised good or service is distinct. The entity then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation&#13;      is satisfied.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt"&gt;&#13;      &#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin: 0px 0px 0px 20pt"&gt;&lt;font style="font-family: Times New Roman,Times,serif"&gt;&lt;font style="font-style: italic"&gt;Collaborative Arrangements&lt;/font&gt;&lt;br /&gt;&#13;      &lt;/font&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;The Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, Collaborative Arrangements (&amp;#8220;ASC 808&amp;#8221;). While these arrangements are in the scope of ASC&#13;      808, the Company may analogize to ASC 606 for some aspects of the arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part&#13;      of its ongoing major or central operations. Revenue recognized by analogizing to ASC 606 is recorded as &amp;#8220;collaboration revenues&amp;#8221;.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;The terms of the Company&amp;#8217;s collaborative arrangements typically include one or more of the following: (i) royalties on net sales of licensed products; (ii) reimbursements or cost-sharing of R&amp;#38;D&#13;      expenses. Each of these payments results in collaboration revenues or an offset against R&amp;#38;D expense.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;Royalties: For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes collaboration revenue at the&#13;      later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;Under certain collaborative arrangements, the Company has been reimbursed for a portion of its R&amp;#38;D expenses or participates in the cost-sharing of such R&amp;#38;D expenses. Such reimbursements and&#13;      cost-sharing arrangements have been reflected as a reduction of R&amp;#38;D expense in the Company&amp;#8217;s consolidated statements of operations, as the Company does not consider performing research and development services for reimbursement to be a part of&#13;      its ongoing major or central operations.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z0812def152d54fdb9f01feeecdb9dedc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;m.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Income taxes:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z7defb31d969c43c8980ae9f04b65e866" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"&gt;&lt;br /&gt;&#13;          &lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;1)&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred taxes&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 36pt"&gt;The Company accounts for income taxes in accordance with ASC 740, &amp;#8220;Income Taxes&amp;#8221; (&amp;#8220;ASC&amp;#160;740&amp;#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and&#13;      liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to&#13;      reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the&#13;      weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt"&gt;Uncertainty in income taxes&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 36pt"&gt;The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence&#13;      indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being&#13;      realized upon ultimate settlement.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt"&gt;&#13;      &#13;    &lt;table cellspacing="0" cellpadding="0" id="z7945dbca9614463db051890512fb5a4a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;n.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Leases&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;As of January 1, 2019, the Company adopted ASU No. 2016-02, &amp;#8220;Leases (Topic 842)". The Company adopted the standard using the modified retrospective approach with an effective date as of the beginning&#13;      of the Company's fiscal year, January 1, 2019. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts are or contain&#13;      leases, (2) lease classification and (3) initial direct costs.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Right of Use ("ROU") assets represent the Company&amp;#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&amp;#8217;s obligation to make lease payments arising from the&#13;      lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company&amp;#8217;s lease terms may include options to extend or terminate the lease when it is&#13;      reasonably certain that the Company will exercise that option.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The Company uses the implicit rate when readily determinable. As the Company&amp;#8217;s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information&#13;      available at commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to not separate lease and non-lease components for the&#13;      leases. The Company elected the practical expedient of the short-term lease recognition exemption for all leases with a term shorter than 12 months.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt; &lt;br /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Additionally, the company applies the portfolio approach to account for operating lease ROU asset and liabilities for certain car leases and incremental borrowing rates.&lt;br /&gt;&#13;      &lt;br /&gt;&#13;      &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;Upon adoption, the standard resulted in an increase of $1,200 in operating lease ROU assets and corresponding liabilities on the Company&amp;#8217;s consolidated balance sheet and did&#13;        not have a material impact on the Company&amp;#8217;s consolidated statements of operations or consolidated statements of cash flows.&amp;#160; See also note 6b.&lt;/div&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z27d5f92405494446b69a4061f09c078a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;o.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Loss per share&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is based&#13;      upon the weighted average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options, restricted shares and warrants, which are included under the treasury&#13;      stock method when dilutive. The calculation of diluted loss per share does not include 1,119,310, 1,260,984 and 3,271,507 options, restricted shares and warrants for the years ended December&amp;#160;31, 2018, 2019 and 2020, respectively, because their effect&#13;      would be anti-dilutive.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z4d42a1eac37e418b92c66e4e364bc26f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;p.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Fair value measurement&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement&#13;      date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are&#13;      described as follows:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt"&gt;&#13;      &#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers&#13;      counterparty credit risk in its assessment of fair value.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;The carrying amount of the cash and cash equivalents, bank deposits, restricted cash, receivables from collaborative arrangements, restricted long-term deposits, accrued expenses (under other account&#13;      payable), operating leases liabilities and other liabilities approximates their fair value.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="zf24ba24f57404740917d2ca20a147269" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;q.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Concentration of credit risks&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, bank deposits and marketable securities and certain&#13;      receivables. The Company deposits cash and cash equivalents with highly rated financial institutions (Israeli banks). In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced any material&#13;      credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z339fd1fa884f49f086d0c0eb4212cb95" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;r.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Newly issued and recently adopted accounting pronouncements&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: italic bold 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;Recently adopted accounting pronouncements:&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"&gt;In June 2016, the FASB issued ASU 2016-13 &amp;#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&amp;#8221;. This guidance replaces the current incurred loss impairment&#13;      methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance became effective for the fiscal year beginning&#13;      on January 1, 2020, including interim periods within that year. This guidance did not have significant impact on the Company&amp;#8217;s financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="z5ee031687b39499782a8e3367f82326a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;f.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: bold"&gt;Derivatives and hedging&lt;/font&gt;&lt;br /&gt;&#13;              &lt;br /&gt;&#13;              The Company carries out transactions involving foreign currency exchange derivative financial instruments. The transactions are designed to hedge the Company&amp;#8217;s exposure in currencies other than the U.S. dollar. The derivative does not meet&#13;              the definition of a cash flow accounting hedge, therefore the changes in the fair value are included in financial expense (income), net.&lt;/div&gt;&#13;            &lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;br /&gt;&#13;              The currency hedged items are denominated in New Israeli Shekel (NIS).&amp;#160; The counterparties to the derivatives are major banks in Israel.&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt;&#13;    &#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;As of December 31, 2020, the Company has $1,150 on the Company&amp;#8217;s bank account that is restricted in order to secure the hedging transactions. This amount is presented among Restricted long-term&#13;      deposits and cash.&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy contextRef="From2020-01-01to2020-12-31">&lt;div style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;/div&gt;&#13;    &lt;table cellspacing="0" cellpadding="0" id="za932c38e076d43c9b7a8bedb2974ffe4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"&gt;&#13;      &#13;        &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;&#13;          &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top"&gt;g.&lt;/td&gt;&#13;          &lt;td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"&gt;&#13;            &lt;div style="font: bold 10pt Times New Roman, Times, Serif"&gt;Trade receivables:&lt;/div&gt;&#13;          &lt;/td&gt;&#13;        &lt;/tr&gt;&#13;      &#13;    &lt;/table&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 20.15pt"&gt;Trade receivables are initially recognized at the transaction price and subsequently measured at amortized cost less any allowance for expected credit losses.&lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;    &lt;/div&gt;&#13;    &lt;div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 20.15pt"&gt;&amp;#160;Starting from January 1, 2020, the Company applies ASU 2016-13 &amp;#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&amp;#8221; (&amp;#8220;the Standard&amp;#8221;).&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-02" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-1" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-2" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-3" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-4" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Less than 1,000.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">Investments in Corporate bonds rated A or higher.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>slgl-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: SLGL 1220 20F.xfr; Date: 2021%2D03%2D03T12:57:40Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x800F0000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /apZo7xRiXgOn8uHanFcWaeBibPty5t7+Zkxu2h+fQl6byEgiNGbCyiqRximwbYP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:SLGL="http://sol-gel.com/20201231" elementFormDefault="qualified" targetNamespace="http://sol-gel.com/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://sol-gel.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" id="ConsolidatedStatementsOfChangesInShareholdersEquity">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/NatureOfOperations" id="NatureOfOperations">
	  <link:definition>00000007 - Disclosure - NATURE OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/MarketableSecurities" id="MarketableSecurities">
	  <link:definition>00000009 - Disclosure - MARKETABLE SECURITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000010 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/EmployeeSeveranceBenefits" id="EmployeeSeveranceBenefits">
	  <link:definition>00000011 - Disclosure - EMPLOYEE SEVERANCE BENEFITS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/Commitments" id="Commitments">
	  <link:definition>00000012 - Disclosure - COMMITMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/CollaborationAgreements" id="CollaborationAgreements">
	  <link:definition>00000013 - Disclosure - COLLABORATION AGREEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ShareCapital" id="ShareCapital">
	  <link:definition>00000014 - Disclosure - SHARE CAPITAL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/TaxesOnIncome" id="TaxesOnIncome">
	  <link:definition>00000015 - Disclosure - TAXES ON INCOME</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformation" id="SupplementaryFinancialStatementInformation">
	  <link:definition>00000016 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000017 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000018 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/MarketableSecuritiesTables" id="MarketableSecuritiesTables">
	  <link:definition>00000021 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/CommitmentsTables" id="CommitmentsTables">
	  <link:definition>00000023 - Disclosure - COMMITMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ShareCapitalTables" id="ShareCapitalTables">
	  <link:definition>00000024 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/TaxesOnIncomeTables" id="TaxesOnIncomeTables">
	  <link:definition>00000025 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformationTables" id="SupplementaryFinancialStatementInformationTables">
	  <link:definition>00000026 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/NatureOfOperationsDetails" id="NatureOfOperationsDetails">
	  <link:definition>00000027 - Disclosure - NATURE OF OPERATIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesNarrativeDetails" id="SignificantAccountingPoliciesNarrativeDetails">
	  <link:definition>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" id="SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails">
	  <link:definition>00000029 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Annual Depreciation Rates) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" id="MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails">
	  <link:definition>00000030 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" id="MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails">
	  <link:definition>00000031 - Disclosure - MARKETABLE SECURITIES (Summary of Changes in Fair Value of Company's Marketable Securities) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" id="MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails">
	  <link:definition>00000032 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/PropertyAndEquipmentNarrativeDetails" id="PropertyAndEquipmentNarrativeDetails">
	  <link:definition>00000033 - Disclosure - PROPERTY AND EQUIPMENT (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
	  <link:definition>00000034 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/EmployeeSeveranceBenefitsDetails" id="EmployeeSeveranceBenefitsDetails">
	  <link:definition>00000035 - Disclosure - EMPLOYEE SEVERANCE BENEFITS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/CommitmentsNarrativeDetails" id="CommitmentsNarrativeDetails">
	  <link:definition>00000036 - Disclosure - COMMITMENTS (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" id="CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails">
	  <link:definition>00000037 - Disclosure - COMMITMENTS (Schedule of Lease-related Assets And Liabilities) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/CommitmentsScheduleOfLeaseCostsDetails" id="CommitmentsScheduleOfLeaseCostsDetails">
	  <link:definition>00000038 - Disclosure - COMMITMENTS (Schedule of Lease Costs) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" id="CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails">
	  <link:definition>00000039 - Disclosure - COMMITMENTS (Schedule of Supplemental Cash Flow Information Related to Leases) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" id="CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails">
	  <link:definition>00000040 - Disclosure - COMMITMENTS ( Schedule of Reconciles Undiscounted Cash Flows) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/CollaborationAgreementsDetails" id="CollaborationAgreementsDetails">
	  <link:definition>00000041 - Disclosure - COLLABORATION AGREEMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ShareCapitalNarrativeDetails" id="ShareCapitalNarrativeDetails">
	  <link:definition>00000042 - Disclosure - SHARE CAPITAL (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" id="ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails">
	  <link:definition>00000043 - Disclosure - SHARE CAPITAL (Schedule of Assumptions Used to Estimate Fair Value) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfStockOptionActivityDetails" id="ShareCapitalScheduleOfStockOptionActivityDetails">
	  <link:definition>00000044 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Activity) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" id="ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails">
	  <link:definition>00000045 - Disclosure - SHARE CAPITAL (Schedule of Effect of Share-based Compensation Statements of Operations) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/TaxesOnIncomeNarrativeDetails" id="TaxesOnIncomeNarrativeDetails">
	  <link:definition>00000046 - Disclosure - TAXES ON INCOME (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" id="TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails">
	  <link:definition>00000047 - Disclosure - TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/TaxesOnIncomeRollForwardOfValuationAllowanceDetails" id="TaxesOnIncomeRollForwardOfValuationAllowanceDetails">
	  <link:definition>00000048 - Disclosure - TAXES ON INCOME (Roll Forward of Valuation Allowance) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" id="SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails">
	  <link:definition>00000049 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Accounts Payables and Accruals) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://sol-gel.com/role/RelatedPartiesDetails" id="RelatedPartiesDetails">
	  <link:definition>00000050 - Disclosure - RELATED PARTIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="slgl-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="slgl-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="slgl-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="slgl-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="SLGL_FinanceExpensesNet" name="FinanceExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" name="ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_FinancialIncomeExpensesNet" name="FinancialIncomeExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" name="IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" name="IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ChangesInFairValueOfMarketableSecurities" name="ChangesInFairValueOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_BankDeposits" name="BankDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_RestrictedBankDeposit" name="RestrictedBankDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PropertyAndEquipmentDepreciationPercentage" name="PropertyAndEquipmentDepreciationPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" name="RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities" name="IncreaseInOperatingLeaseRouAssetsAndLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_NetChangesInOperatingLeases" name="NetChangesInOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ScheduleOfDepreciationRatesTableTextBlock" name="ScheduleOfDepreciationRatesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" name="ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeases" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" name="IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" name="IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" name="IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" name="IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped" name="RoyaltiesPayableOnSaleOfProductsDeveloped" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" name="PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_RoyaltiesPayForNetSalesRelatedToPatents" name="RoyaltiesPayForNetSalesRelatedToPatents" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PercentageOfProceedsReceivedForSubLicence" name="PercentageOfProceedsReceivedForSubLicence" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_AmountOfLeasePaymentsRepresentingInterest" name="AmountOfLeasePaymentsRepresentingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PresentValueOfFutureMinimumLeasePayments" name="PresentValueOfFutureMinimumLeasePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_RoyaltiesMaturity" name="RoyaltiesMaturity" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PercentageOfGrossProfitsRelatedToSaleProducts" name="PercentageOfGrossProfitsRelatedToSaleProducts" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" name="ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_TaxBenefitPeriod" name="TaxBenefitPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ShorttermDepositsBearInterest" name="ShorttermDepositsBearInterest" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_AdditionalOrdinarySharesPurchased" name="AdditionalOrdinarySharesPurchased" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_BonusShare" name="BonusShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_BankDepositsPolicyTextBlock" name="BankDepositsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_OfficeFurnitureAndEquipmentMember" name="OfficeFurnitureAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_BuildingsAndLandMember" name="BuildingsAndLandMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_NationalAuthorityForTechnologicalInnovationMember" name="NationalAuthorityForTechnologicalInnovationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_YissumMember" name="YissumMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_EmployeeMember" name="EmployeeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_NonEmployeesMember" name="NonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_NonEmployeesOneMember" name="NonEmployeesOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PreferredEnterpriseMember" name="PreferredEnterpriseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_MainlyMember" name="MainlyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_IsraelInnovationAuthorityMember" name="IsraelInnovationAuthorityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_OtherForeignGovernmentBondsMember" name="OtherForeignGovernmentBondsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ClinicalDevelopmentMasterServicesAgreementMember" name="ClinicalDevelopmentMasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_AgreementOneMember" name="AgreementOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_AgreementTwoMember" name="AgreementTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_MasterClinicalTrialServicesAgreementMember" name="MasterClinicalTrialServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_FPOMember" name="FPOMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_UnderwriterMember" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" name="IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate" name="ShorttermDepositsBearInterestAtAverageAnnualRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_DecreaseInNetCashUsedInInvestingActivities" name="DecreaseInNetCashUsedInInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct" name="PercentageOfGrossProfitsRelatedToSaleOfProduct" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_TermOfCommericalSaleOfProduct" name="TermOfCommericalSaleOfProduct" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PercentageOfReimburseOutofpocketExpense" name="PercentageOfReimburseOutofpocketExpense" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_TotalConsideration" name="TotalConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PercentageOfExpenseRecognized" name="PercentageOfExpenseRecognized" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct" name="AmountPayToThirdPartyUponNdaSubmissionOfProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct" name="AmountPayToApprovalOfFdaOnFirstNdaProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_PercentageOfFutureGrossProfitProductSold" name="PercentageOfFutureGrossProfitProductSold" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_SharesIssuedInPublicOffering" name="SharesIssuedInPublicOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract" name="TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>slgl-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: SLGL 1220 20F.xfr; Date: 2021%2D03%2D03T12:57:40Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x800F0000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sol-gel.com/role/DocumentAndEntityInformation" xlink:href="slgl-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedBalanceSheets" xlink:href="slgl-20201231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="slgl-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfOperations" xlink:href="slgl-20201231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" xlink:href="slgl-20201231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="slgl-20201231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/NatureOfOperations" xlink:href="slgl-20201231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPolicies" xlink:href="slgl-20201231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecurities" xlink:href="slgl-20201231.xsd#MarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipment" xlink:href="slgl-20201231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/EmployeeSeveranceBenefits" xlink:href="slgl-20201231.xsd#EmployeeSeveranceBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/Commitments" xlink:href="slgl-20201231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CollaborationAgreements" xlink:href="slgl-20201231.xsd#CollaborationAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapital" xlink:href="slgl-20201231.xsd#ShareCapital" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncome" xlink:href="slgl-20201231.xsd#TaxesOnIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformation" xlink:href="slgl-20201231.xsd#SupplementaryFinancialStatementInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/RelatedParties" xlink:href="slgl-20201231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SubsequentEvents" xlink:href="slgl-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesPolicies" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesTables" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesTables" xlink:href="slgl-20201231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipmentTables" xlink:href="slgl-20201231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsTables" xlink:href="slgl-20201231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalTables" xlink:href="slgl-20201231.xsd#ShareCapitalTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeTables" xlink:href="slgl-20201231.xsd#TaxesOnIncomeTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformationTables" xlink:href="slgl-20201231.xsd#SupplementaryFinancialStatementInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/NatureOfOperationsDetails" xlink:href="slgl-20201231.xsd#NatureOfOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" xlink:href="slgl-20201231.xsd#MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" xlink:href="slgl-20201231.xsd#MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" xlink:href="slgl-20201231.xsd#MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="slgl-20201231.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="slgl-20201231.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/EmployeeSeveranceBenefitsDetails" xlink:href="slgl-20201231.xsd#EmployeeSeveranceBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsNarrativeDetails" xlink:href="slgl-20201231.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfLeaseCostsDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CollaborationAgreementsDetails" xlink:href="slgl-20201231.xsd#CollaborationAgreementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalNarrativeDetails" xlink:href="slgl-20201231.xsd#ShareCapitalNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" xlink:href="slgl-20201231.xsd#ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfStockOptionActivityDetails" xlink:href="slgl-20201231.xsd#ShareCapitalScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" xlink:href="slgl-20201231.xsd#ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeNarrativeDetails" xlink:href="slgl-20201231.xsd#TaxesOnIncomeNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:href="slgl-20201231.xsd#TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeRollForwardOfValuationAllowanceDetails" xlink:href="slgl-20201231.xsd#TaxesOnIncomeRollForwardOfValuationAllowanceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" xlink:href="slgl-20201231.xsd#SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/RelatedPartiesDetails" xlink:href="slgl-20201231.xsd#RelatedPartiesDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestBearingDepositsInBanks" xlink:label="loc_us-gaapInterestBearingDepositsInBanks" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInterestBearingDepositsInBanks" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaapDefinedBenefitPlanFairValueOfPlanAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaapDefinedBenefitPlanBenefitObligation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDefinedBenefitPlanBenefitObligation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_FinancialIncomeExpensesNet" xlink:label="loc_SLGLFinancialIncomeExpensesNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_SLGLFinancialIncomeExpensesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_FinanceExpensesNet" xlink:label="loc_SLGLFinanceExpensesNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SLGLFinanceExpensesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:label="loc_SLGLChangesInAccruedLiabilityForEmployeeRightsUponRetirement" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SLGLChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ChangesInFairValueOfMarketableSecurities" xlink:label="loc_SLGLChangesInFairValueOfMarketableSecurities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SLGLChangesInFairValueOfMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NetChangesInOperatingLeases" xlink:label="loc_SLGLNetChangesInOperatingLeases" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SLGLNetChangesInOperatingLeases" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInLongTermReceivablesCurrent" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInLongTermReceivablesCurrent" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_BankDeposits" xlink:label="loc_SLGLBankDeposits" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SLGLBankDeposits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCashAndInvestments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCashAndInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/NatureOfOperations" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecurities" xlink:title="00000009 - Disclosure - MARKETABLE SECURITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/EmployeeSeveranceBenefits" xlink:title="00000011 - Disclosure - EMPLOYEE SEVERANCE BENEFITS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/Commitments" xlink:title="00000012 - Disclosure - COMMITMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CollaborationAgreements" xlink:title="00000013 - Disclosure - COLLABORATION AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapital" xlink:title="00000014 - Disclosure - SHARE CAPITAL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncome" xlink:title="00000015 - Disclosure - TAXES ON INCOME" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SupplementaryFinancialStatementInformation" xlink:title="00000016 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/RelatedParties" xlink:title="00000017 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesTables" xlink:title="00000021 - Disclosure - MARKETABLE SECURITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipmentTables" xlink:title="00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsTables" xlink:title="00000023 - Disclosure - COMMITMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalTables" xlink:title="00000024 - Disclosure - SHARE CAPITAL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeTables" xlink:title="00000025 - Disclosure - TAXES ON INCOME (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SupplementaryFinancialStatementInformationTables" xlink:title="00000026 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/NatureOfOperationsDetails" xlink:title="00000027 - Disclosure - NATURE OF OPERATIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" xlink:title="00000029 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Annual Depreciation Rates) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" xlink:title="00000030 - Disclosure - MARKETABLE SECURITIES (Schedule of Company&apos;s Marketable Securities) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" xlink:title="00000031 - Disclosure - MARKETABLE SECURITIES (Summary of Changes in Fair Value of Company&apos;s Marketable Securities) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" xlink:title="00000032 - Disclosure - MARKETABLE SECURITIES (Schedule of Company&apos;s debt marketable securities) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipmentNarrativeDetails" xlink:title="00000033 - Disclosure - PROPERTY AND EQUIPMENT (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/EmployeeSeveranceBenefitsDetails" xlink:title="00000035 - Disclosure - EMPLOYEE SEVERANCE BENEFITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsNarrativeDetails" xlink:title="00000036 - Disclosure - COMMITMENTS (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:title="00000037 - Disclosure - COMMITMENTS (Schedule of Lease-related Assets And Liabilities) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfLeaseCostsDetails" xlink:title="00000038 - Disclosure - COMMITMENTS (Schedule of Lease Costs) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="00000039 - Disclosure - COMMITMENTS (Schedule of Supplemental Cash Flow Information Related to Leases) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" xlink:title="00000040 - Disclosure - COMMITMENTS ( Schedule of Reconciles Undiscounted Cash Flows) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PresentValueOfFutureMinimumLeasePayments" xlink:label="loc_SLGLPresentValueOfFutureMinimumLeasePayments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SLGLPresentValueOfFutureMinimumLeasePayments" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AmountOfLeasePaymentsRepresentingInterest" xlink:label="loc_SLGLAmountOfLeasePaymentsRepresentingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SLGLPresentValueOfFutureMinimumLeasePayments" xlink:to="loc_SLGLAmountOfLeasePaymentsRepresentingInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:to="loc_SLGLPresentValueOfFutureMinimumLeasePayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CollaborationAgreementsDetails" xlink:title="00000041 - Disclosure - COLLABORATION AGREEMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalNarrativeDetails" xlink:title="00000042 - Disclosure - SHARE CAPITAL (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" xlink:title="00000043 - Disclosure - SHARE CAPITAL (Schedule of Assumptions Used to Estimate Fair Value) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalScheduleOfStockOptionActivityDetails" xlink:title="00000044 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Activity) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" xlink:title="00000045 - Disclosure - SHARE CAPITAL (Schedule of Effect of Share-based Compensation Statements of Operations) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeNarrativeDetails" xlink:title="00000046 - Disclosure - TAXES ON INCOME (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:title="00000047 - Disclosure - TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeRollForwardOfValuationAllowanceDetails" xlink:title="00000048 - Disclosure - TAXES ON INCOME (Roll Forward of Valuation Allowance) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" xlink:title="00000049 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Accounts Payables and Accruals) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableOtherCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent" xlink:label="loc_us-gaapAccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableOtherCurrent" xlink:to="loc_us-gaapAccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableOtherCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/RelatedPartiesDetails" xlink:title="00000050 - Disclosure - RELATED PARTIES (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>slgl-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: SLGL 1220 20F.xfr; Date: 2021%2D03%2D03T12:57:40Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x800F0000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sol-gel.com/role/DocumentAndEntityInformation" xlink:href="slgl-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedBalanceSheets" xlink:href="slgl-20201231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="slgl-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfOperations" xlink:href="slgl-20201231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" xlink:href="slgl-20201231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="slgl-20201231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/NatureOfOperations" xlink:href="slgl-20201231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPolicies" xlink:href="slgl-20201231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecurities" xlink:href="slgl-20201231.xsd#MarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipment" xlink:href="slgl-20201231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/EmployeeSeveranceBenefits" xlink:href="slgl-20201231.xsd#EmployeeSeveranceBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/Commitments" xlink:href="slgl-20201231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CollaborationAgreements" xlink:href="slgl-20201231.xsd#CollaborationAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapital" xlink:href="slgl-20201231.xsd#ShareCapital" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncome" xlink:href="slgl-20201231.xsd#TaxesOnIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformation" xlink:href="slgl-20201231.xsd#SupplementaryFinancialStatementInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/RelatedParties" xlink:href="slgl-20201231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SubsequentEvents" xlink:href="slgl-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesPolicies" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesTables" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesTables" xlink:href="slgl-20201231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipmentTables" xlink:href="slgl-20201231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsTables" xlink:href="slgl-20201231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalTables" xlink:href="slgl-20201231.xsd#ShareCapitalTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeTables" xlink:href="slgl-20201231.xsd#TaxesOnIncomeTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformationTables" xlink:href="slgl-20201231.xsd#SupplementaryFinancialStatementInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/NatureOfOperationsDetails" xlink:href="slgl-20201231.xsd#NatureOfOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" xlink:href="slgl-20201231.xsd#MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" xlink:href="slgl-20201231.xsd#MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" xlink:href="slgl-20201231.xsd#MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="slgl-20201231.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="slgl-20201231.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/EmployeeSeveranceBenefitsDetails" xlink:href="slgl-20201231.xsd#EmployeeSeveranceBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsNarrativeDetails" xlink:href="slgl-20201231.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfLeaseCostsDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CollaborationAgreementsDetails" xlink:href="slgl-20201231.xsd#CollaborationAgreementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalNarrativeDetails" xlink:href="slgl-20201231.xsd#ShareCapitalNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" xlink:href="slgl-20201231.xsd#ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfStockOptionActivityDetails" xlink:href="slgl-20201231.xsd#ShareCapitalScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" xlink:href="slgl-20201231.xsd#ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeNarrativeDetails" xlink:href="slgl-20201231.xsd#TaxesOnIncomeNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:href="slgl-20201231.xsd#TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeRollForwardOfValuationAllowanceDetails" xlink:href="slgl-20201231.xsd#TaxesOnIncomeRollForwardOfValuationAllowanceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" xlink:href="slgl-20201231.xsd#SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/RelatedPartiesDetails" xlink:href="slgl-20201231.xsd#RelatedPartiesDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:label="loc_SLGLIssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_SLGLIssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:label="loc_SLGLIssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:label="loc_SLGLIssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockSplits_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockSplits_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" xlink:label="loc_SLGLIssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" xlink:label="loc_SLGLIssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_SLGLIssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/NatureOfOperations" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecurities" xlink:title="00000009 - Disclosure - MARKETABLE SECURITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/EmployeeSeveranceBenefits" xlink:title="00000011 - Disclosure - EMPLOYEE SEVERANCE BENEFITS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/Commitments" xlink:title="00000012 - Disclosure - COMMITMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CollaborationAgreements" xlink:title="00000013 - Disclosure - COLLABORATION AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapital" xlink:title="00000014 - Disclosure - SHARE CAPITAL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncome" xlink:title="00000015 - Disclosure - TAXES ON INCOME" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SupplementaryFinancialStatementInformation" xlink:title="00000016 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/RelatedParties" xlink:title="00000017 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesTables" xlink:title="00000021 - Disclosure - MARKETABLE SECURITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipmentTables" xlink:title="00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsTables" xlink:title="00000023 - Disclosure - COMMITMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalTables" xlink:title="00000024 - Disclosure - SHARE CAPITAL (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeesMember" xlink:label="loc_SLGLEmployeesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLEmployeesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesMember" xlink:label="loc_SLGLNonEmployeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLNonEmployeesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeTables" xlink:title="00000025 - Disclosure - TAXES ON INCOME (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SupplementaryFinancialStatementInformationTables" xlink:title="00000026 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/NatureOfOperationsDetails" xlink:title="00000027 - Disclosure - NATURE OF OPERATIONS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate" xlink:label="loc_SLGLShorttermDepositsBearInterestAtAverageAnnualRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLShorttermDepositsBearInterestAtAverageAnnualRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_DecreaseInNetCashUsedInInvestingActivities" xlink:label="loc_SLGLDecreaseInNetCashUsedInInvestingActivities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLDecreaseInNetCashUsedInInvestingActivities_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAmountOfHedgedItem" xlink:label="loc_us-gaapDerivativeAmountOfHedgedItem_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeAmountOfHedgedItem_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RestrictedBankDeposit" xlink:label="loc_SLGLRestrictedBankDeposit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLRestrictedBankDeposit_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ShorttermDepositsBearInterest" xlink:label="loc_SLGLShorttermDepositsBearInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLShorttermDepositsBearInterest_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities" xlink:label="loc_SLGLIncreaseInOperatingLeaseRouAssetsAndLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIncreaseInOperatingLeaseRouAssetsAndLiabilities_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" xlink:title="00000029 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Annual Depreciation Rates) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_LaboratoryEquipmentMember" xlink:label="loc_SLGLLaboratoryEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SLGLLaboratoryEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_OfficeFurnitureAndEquipmentMember" xlink:label="loc_SLGLOfficeFurnitureAndEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SLGLOfficeFurnitureAndEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_MainlyMember" xlink:label="loc_SLGLMainlyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SLGLMainlyMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PropertyAndEquipmentDepreciationPercentage" xlink:label="loc_SLGLPropertyAndEquipmentDepreciationPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_SLGLPropertyAndEquipmentDepreciationPercentage_80" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" xlink:title="00000030 - Disclosure - MARKETABLE SECURITIES (Schedule of Company&apos;s Marketable Securities) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:label="loc_us-gaapForeignGovernmentDebtMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapForeignGovernmentDebtMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_OtherForeignGovernmentBondsMember" xlink:label="loc_SLGLOtherForeignGovernmentBondsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_SLGLOtherForeignGovernmentBondsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaapAllOtherCorporateBondsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapAllOtherCorporateBondsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaapMarketableSecuritiesAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesAbstract_110" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" xlink:title="00000031 - Disclosure - MARKETABLE SECURITIES (Summary of Changes in Fair Value of Company&apos;s Marketable Securities) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" xlink:title="00000032 - Disclosure - MARKETABLE SECURITIES (Schedule of Company&apos;s debt marketable securities) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipmentNarrativeDetails" xlink:title="00000033 - Disclosure - PROPERTY AND EQUIPMENT (Narrative) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_LaboratoryEquipmentMember" xlink:label="loc_SLGLLaboratoryEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SLGLLaboratoryEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_OfficeFurnitureAndEquipmentMember" xlink:label="loc_SLGLOfficeFurnitureAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SLGLOfficeFurnitureAndEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/EmployeeSeveranceBenefitsDetails" xlink:title="00000035 - Disclosure - EMPLOYEE SEVERANCE BENEFITS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedContributionPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaapDefinedContributionPlanTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedContributionPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDefinedContributionPlanTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedContributionPlanDisclosureLineItems" xlink:to="loc_us-gaapSeveranceCosts1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedContributionPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsNarrativeDetails" xlink:title="00000036 - Disclosure - COMMITMENTS (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IsraelInnovationAuthorityMember" xlink:label="loc_SLGLIsraelInnovationAuthorityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SLGLIsraelInnovationAuthorityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_YissumMember" xlink:label="loc_SLGLYissumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SLGLYissumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_MasterClinicalTrialServicesAgreementMember" xlink:label="loc_SLGLMasterClinicalTrialServicesAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_SLGLMasterClinicalTrialServicesAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ClinicalDevelopmentMasterServicesAgreementMember" xlink:label="loc_SLGLClinicalDevelopmentMasterServicesAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_SLGLClinicalDevelopmentMasterServicesAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AgreementOneMember" xlink:label="loc_SLGLAgreementOneMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SLGLAgreementOneMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AgreementTwoMember" xlink:label="loc_SLGLAgreementTwoMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SLGLAgreementTwoMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped" xlink:label="loc_SLGLRoyaltiesPayableOnSaleOfProductsDeveloped_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLRoyaltiesPayableOnSaleOfProductsDeveloped_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" xlink:label="loc_SLGLPercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapGrantsReceivable_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RoyaltiesPayForNetSalesRelatedToPatents" xlink:label="loc_SLGLRoyaltiesPayForNetSalesRelatedToPatents_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLRoyaltiesPayForNetSalesRelatedToPatents_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfProceedsReceivedForSubLicence" xlink:label="loc_SLGLPercentageOfProceedsReceivedForSubLicence_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfProceedsReceivedForSubLicence_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSecurityDeposit_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:label="loc_us-gaapRegistrationPaymentArrangementMaximumPotentialConsideration_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRegistrationPaymentArrangementMaximumPotentialConsideration_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSellingExpense_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRestrictedCash_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct" xlink:label="loc_SLGLPercentageOfGrossProfitsRelatedToSaleOfProduct_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfGrossProfitsRelatedToSaleOfProduct_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TermOfCommericalSaleOfProduct" xlink:label="loc_SLGLTermOfCommericalSaleOfProduct_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLTermOfCommericalSaleOfProduct_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfReimburseOutofpocketExpense" xlink:label="loc_SLGLPercentageOfReimburseOutofpocketExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfReimburseOutofpocketExpense_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaapAccountsReceivableNetNoncurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccountsReceivableNetNoncurrent_190" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TotalConsideration" xlink:label="loc_SLGLTotalConsideration_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLTotalConsideration_190" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfExpenseRecognized" xlink:label="loc_SLGLPercentageOfExpenseRecognized_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfExpenseRecognized_190" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct" xlink:label="loc_SLGLAmountPayToThirdPartyUponNdaSubmissionOfProduct_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLAmountPayToThirdPartyUponNdaSubmissionOfProduct_190" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct" xlink:label="loc_SLGLAmountPayToApprovalOfFdaOnFirstNdaProduct_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLAmountPayToApprovalOfFdaOnFirstNdaProduct_190" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfFutureGrossProfitProductSold" xlink:label="loc_SLGLPercentageOfFutureGrossProfitProductSold_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfFutureGrossProfitProductSold_190" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:title="00000037 - Disclosure - COMMITMENTS (Schedule of Lease-related Assets And Liabilities) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfLeaseCostsDetails" xlink:title="00000038 - Disclosure - COMMITMENTS (Schedule of Lease Costs) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="00000039 - Disclosure - COMMITMENTS (Schedule of Supplemental Cash Flow Information Related to Leases) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" xlink:title="00000040 - Disclosure - COMMITMENTS ( Schedule of Reconciles Undiscounted Cash Flows) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CollaborationAgreementsDetails" xlink:title="00000041 - Disclosure - COLLABORATION AGREEMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RoyaltiesMaturity" xlink:label="loc_SLGLRoyaltiesMaturity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLRoyaltiesMaturity_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfGrossProfitsRelatedToSaleProducts" xlink:label="loc_SLGLPercentageOfGrossProfitsRelatedToSaleProducts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLPercentageOfGrossProfitsRelatedToSaleProducts_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalNarrativeDetails" xlink:title="00000042 - Disclosure - SHARE CAPITAL (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeesMember" xlink:label="loc_SLGLEmployeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SLGLEmployeesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srtExecutiveOfficerMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtExecutiveOfficerMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ConsultantMember" xlink:label="loc_SLGLConsultantMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SLGLConsultantMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesOneMember" xlink:label="loc_SLGLNonEmployeesOneMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SLGLNonEmployeesOneMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_FPOMember" xlink:label="loc_SLGLFPOMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SLGLFPOMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_UnderwriterMember" xlink:label="loc_SLGLUnderwriterMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SLGLUnderwriterMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_350" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_350" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_350" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_350" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_350" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_350" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_350" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_350" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_350" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_350" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_350" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_350" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" xlink:label="loc_SLGLShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SLGLShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition_350" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_350" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_350" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssued_350" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_350" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AdditionalOrdinarySharesPurchased" xlink:label="loc_SLGLAdditionalOrdinarySharesPurchased_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SLGLAdditionalOrdinarySharesPurchased_350" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_350" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_350" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_SharesIssuedInPublicOffering" xlink:label="loc_SLGLSharesIssuedInPublicOffering_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SLGLSharesIssuedInPublicOffering_350" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_350" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_350" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_350" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_350" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit_350" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_BonusShare" xlink:label="loc_SLGLBonusShare_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SLGLBonusShare_350" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" xlink:title="00000043 - Disclosure - SHARE CAPITAL (Schedule of Assumptions Used to Estimate Fair Value) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeesMember" xlink:label="loc_SLGLEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesMember" xlink:label="loc_SLGLNonEmployeesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLNonEmployeesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalScheduleOfStockOptionActivityDetails" xlink:title="00000044 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Activity) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeesMember" xlink:label="loc_SLGLEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesMember" xlink:label="loc_SLGLNonEmployeesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLNonEmployeesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" xlink:label="loc_SLGLSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_SLGLSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" xlink:label="loc_SLGLSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_SLGLSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" xlink:title="00000045 - Disclosure - SHARE CAPITAL (Schedule of Effect of Share-based Compensation Statements of Operations) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeNarrativeDetails" xlink:title="00000046 - Disclosure - TAXES ON INCOME (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaapTaxCreditCarryforwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaapIncomeTaxContingencyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardLineItems" xlink:to="loc_us-gaapIncomeTaxContingencyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIncomeTaxContingencyTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srtSubsidiariesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtSubsidiariesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TaxBenefitPeriod" xlink:label="loc_SLGLTaxBenefitPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardLineItems" xlink:to="loc_SLGLTaxBenefitPeriod_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:title="00000047 - Disclosure - TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeRollForwardOfValuationAllowanceDetails" xlink:title="00000048 - Disclosure - TAXES ON INCOME (Roll Forward of Valuation Allowance) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" xlink:title="00000049 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Accounts Payables and Accruals) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sol-gel.com/role/RelatedPartiesDetails" xlink:title="00000050 - Disclosure - RELATED PARTIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_20" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>slgl-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: SLGL 1220 20F.xfr; Date: 2021%2D03%2D03T12:57:40Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x800F0000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeesMember" xlink:label="SLGL_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_EmployeesMember" xlink:to="SLGL_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesMember" xlink:label="SLGL_NonEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_NonEmployeesMember" xlink:to="SLGL_NonEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_NonEmployeesMember_lbl" xml:lang="en-US">Non Employees Member [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesOneMember" xlink:label="SLGL_NonEmployeesOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_NonEmployeesOneMember" xlink:to="SLGL_NonEmployeesOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SLGL_NonEmployeesOneMember_lbl" xml:lang="en-US">Non Employees Member [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Subsidiary Sale Of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ConsultantMember" xlink:label="SLGL_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ConsultantMember" xlink:to="SLGL_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ConsultantMember_lbl" xml:lang="en-US">Consultant Member [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xml:lang="en-US">U.S government and agency bonds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignGovernmentDebtMember" xlink:to="us-gaap_ForeignGovernmentDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignGovernmentDebtMember_lbl" xml:lang="en-US">Canada government bonds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_OtherForeignGovernmentBondsMember" xlink:label="SLGL_OtherForeignGovernmentBondsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_OtherForeignGovernmentBondsMember" xlink:to="SLGL_OtherForeignGovernmentBondsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_OtherForeignGovernmentBondsMember_lbl" xml:lang="en-US">Other foreign government bonds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherCorporateBondsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xml:lang="en-US">Corporate bonds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_LaboratoryEquipmentMember" xlink:label="SLGL_LaboratoryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_LaboratoryEquipmentMember" xlink:to="SLGL_LaboratoryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_OfficeFurnitureAndEquipmentMember" xlink:label="SLGL_OfficeFurnitureAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_OfficeFurnitureAndEquipmentMember" xlink:to="SLGL_OfficeFurnitureAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_OfficeFurnitureAndEquipmentMember_lbl" xml:lang="en-US">Office equipment and furniture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers and software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_FPOMember" xlink:label="SLGL_FPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_FPOMember" xlink:to="SLGL_FPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_FPOMember_lbl" xml:lang="en-US">FPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_MainlyMember" xlink:label="SLGL_MainlyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_MainlyMember" xlink:to="SLGL_MainlyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_MainlyMember_lbl" xml:lang="en-US">Mainly [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IsraelInnovationAuthorityMember" xlink:label="SLGL_IsraelInnovationAuthorityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IsraelInnovationAuthorityMember" xlink:to="SLGL_IsraelInnovationAuthorityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_IsraelInnovationAuthorityMember_lbl" xml:lang="en-US">IIA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_YissumMember" xlink:label="SLGL_YissumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_YissumMember" xlink:to="SLGL_YissumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_YissumMember_lbl" xml:lang="en-US">Yissum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegistrationPaymentArrangementByArrangementAxis_lbl" xml:lang="en-US">Registration Payment Arrangement by Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_MasterClinicalTrialServicesAgreementMember" xlink:label="SLGL_MasterClinicalTrialServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_MasterClinicalTrialServicesAgreementMember" xlink:to="SLGL_MasterClinicalTrialServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_MasterClinicalTrialServicesAgreementMember_lbl" xml:lang="en-US">Master Clinical Trial Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ClinicalDevelopmentMasterServicesAgreementMember" xlink:label="SLGL_ClinicalDevelopmentMasterServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ClinicalDevelopmentMasterServicesAgreementMember" xlink:to="SLGL_ClinicalDevelopmentMasterServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ClinicalDevelopmentMasterServicesAgreementMember_lbl" xml:lang="en-US">Clinical Development Master Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AgreementOneMember" xlink:label="SLGL_AgreementOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AgreementOneMember" xlink:to="SLGL_AgreementOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_AgreementOneMember_lbl" xml:lang="en-US">Agreement One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AgreementTwoMember" xlink:label="SLGL_AgreementTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AgreementTwoMember" xlink:to="SLGL_AgreementTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_AgreementTwoMember_lbl" xml:lang="en-US">Agreement Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SubsidiariesMember_lbl" xml:lang="en-US">Subsidiaries [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_2_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_UnderwriterMember" xlink:label="SLGL_UnderwriterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_UnderwriterMember" xlink:to="SLGL_UnderwriterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_UnderwriterMember_lbl" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_DocumentAndEntityInformationAbstract" xlink:label="SLGL_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_DocumentAndEntityInformationAbstract" xlink:to="SLGL_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestBearingDepositsInBanks" xlink:label="us-gaap_InterestBearingDepositsInBanks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDepositsInBanks" xlink:to="us-gaap_InterestBearingDepositsInBanks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestBearingDepositsInBanks_lbl" xml:lang="en-US">Bank deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivables from collaborative arrangements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xml:lang="en-US">Restricted long-term deposits and cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="us-gaap_DefinedBenefitPlanBenefitObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanBenefitObligation_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">TOTAL LONG-TERM LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS' EQUITY:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, NIS 0.1 par value - authorized: 50,000,000 as of December 31, 2019 and 2020, respectively; issued and outstanding: 20,402,800 and 23,000,782 as of December 31, 2019 and December 31, 2020, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">COLLABORATION REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">TOTAL OPERATING LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_FinancialIncomeExpensesNet" xlink:label="SLGL_FinancialIncomeExpensesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_FinancialIncomeExpensesNet" xlink:to="SLGL_FinancialIncomeExpensesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SLGL_FinancialIncomeExpensesNet_lbl" xml:lang="en-US">FINANCIAL INCOME, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">LOSS FOR THE YEAR</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">BASIC AND DILUTED LOSS PER ORDINARY SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Loss for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:to="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of shares and warrants through public offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:to="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of shares and warrants through public offering, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:to="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_lbl" xml:lang="en-US">Issuance of shares and warrants through private placement from the controlling shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:to="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_lbl" xml:lang="en-US">Issuance of shares and warrants through private placement from the controlling shareholder, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xml:lang="en-US">Stock split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of loans from the Controlling shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of loans from the Controlling shareholder, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of shares due to in- process research and development acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" xlink:label="SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" xlink:to="SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares_lbl" xml:lang="en-US">Issuance of shares due to in- process research and development acquired, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" xlink:label="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" xlink:to="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of shares through an initial public offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" xlink:label="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" xlink:to="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of shares through an initial public offering, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">Exercise of options granted to employee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Exercise of options granted to employee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of restricted share units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of restricted share units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of shares through public offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares through public offering, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:label="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:to="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based compensation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NetChangesInOperatingLeases" xlink:label="SLGL_NetChangesInOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_NetChangesInOperatingLeases" xlink:to="SLGL_NetChangesInOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SLGL_NetChangesInOperatingLeases_lbl" xml:lang="en-US">Net changes in operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ChangesInFairValueOfMarketableSecurities" xlink:label="SLGL_ChangesInFairValueOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ChangesInFairValueOfMarketableSecurities" xlink:to="SLGL_ChangesInFairValueOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SLGL_ChangesInFairValueOfMarketableSecurities_lbl" xml:lang="en-US">Changes in fair value of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_FinanceExpensesNet" xlink:label="SLGL_FinanceExpensesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_FinanceExpensesNet" xlink:to="SLGL_FinanceExpensesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_FinanceExpensesNet_lbl" xml:lang="en-US">Finance expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating asset and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Receivables from collaborative arrangements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable, accrued expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:to="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_lbl" xml:lang="en-US">Long term receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_BankDeposits" xlink:label="SLGL_BankDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_BankDeposits" xlink:to="SLGL_BankDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SLGL_BankDeposits_lbl" xml:lang="en-US">Bank deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_lbl" xml:lang="en-US">Restricted long-term deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Investments in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from sales and maturity of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options granted to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from issuance of shares and warrants through public offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds from issuance of shares and warrants to the controlling shareholder through private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESRICTED CASH AT BEGINNING OF THE YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:label="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:to="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:to="SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">Recognition of new operating lease ROU and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Conversion of loans from the controlling shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromInterestReceived_lbl" xml:lang="en-US">Interest received</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">MARKETABLE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE SEVERANCE BENEFITS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">COLLABORATION AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHARE CAPITAL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in the preparation of financial statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional and presentation currency</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_BankDepositsPolicyTextBlock" xlink:label="SLGL_BankDepositsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_BankDepositsPolicyTextBlock" xlink:to="SLGL_BankDepositsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SLGL_BankDepositsPolicyTextBlock_lbl" xml:lang="en-US">Bank deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivatives and hedging</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xml:lang="en-US">Trade receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risks</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Newly issued and recently adopted accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ScheduleOfDepreciationRatesTableTextBlock" xlink:label="SLGL_ScheduleOfDepreciationRatesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ScheduleOfDepreciationRatesTableTextBlock" xlink:to="SLGL_ScheduleOfDepreciationRatesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ScheduleOfDepreciationRatesTableTextBlock_lbl" xml:lang="en-US">Schedule of Annual Depreciation Rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_lbl" xml:lang="en-US">Summary of Changes in Fair Value of Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Schedule of Debt Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:label="SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:to="SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease-related Assets And Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases" xlink:label="SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases" xlink:to="SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases_lbl" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciles Undiscounted Cash Flows</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments Under Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions Used to Estimate Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Effect of Share-based Compensation Statements of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Roll Forward of Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accounts Payables and Accruals</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RangeAxis_2_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate" xlink:label="SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate" xlink:to="SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate_lbl" xml:lang="en-US">Short-term deposits bear interest at an average annual rate</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_DecreaseInNetCashUsedInInvestingActivities" xlink:label="SLGL_DecreaseInNetCashUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_DecreaseInNetCashUsedInInvestingActivities" xlink:to="SLGL_DecreaseInNetCashUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_DecreaseInNetCashUsedInInvestingActivities_lbl" xml:lang="en-US">Decrease in net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAmountOfHedgedItem" xlink:label="us-gaap_DerivativeAmountOfHedgedItem" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAmountOfHedgedItem" xlink:to="us-gaap_DerivativeAmountOfHedgedItem_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAmountOfHedgedItem_lbl" xml:lang="en-US">Total hedged amount</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RestrictedBankDeposit" xlink:label="SLGL_RestrictedBankDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RestrictedBankDeposit" xlink:to="SLGL_RestrictedBankDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_RestrictedBankDeposit_lbl" xml:lang="en-US">Restricted bank deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ShorttermDepositsBearInterest" xlink:label="SLGL_ShorttermDepositsBearInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ShorttermDepositsBearInterest" xlink:to="SLGL_ShorttermDepositsBearInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ShorttermDepositsBearInterest_lbl" xml:lang="en-US">Short-term deposits bear interest</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities" xlink:label="SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities" xlink:to="SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities_lbl" xml:lang="en-US">Increase in Operating lease ROU assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PropertyAndEquipmentDepreciationPercentage" xlink:label="SLGL_PropertyAndEquipmentDepreciationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PropertyAndEquipmentDepreciationPercentage" xlink:to="SLGL_PropertyAndEquipmentDepreciationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_PropertyAndEquipmentDepreciationPercentage_lbl" xml:lang="en-US">Annual rate of depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US">Level 2 securities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Balance at beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Additions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2_lbl" xml:lang="en-US">Sale or maturity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ChangesInFairValueOfMarketableSecurities" xlink:to="SLGL_ChangesInFairValueOfMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ChangesInFairValueOfMarketableSecurities_2_lbl" xml:lang="en-US">Changes in fair value during the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_3_lbl" xml:lang="en-US">Balance at end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US">Due within one year</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xml:lang="en-US">1 to 2 years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_4_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Amount of severance payment expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Contribution Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped" xlink:label="SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped" xlink:to="SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped_lbl" xml:lang="en-US">Royalties payable on the sale of products developed</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" xlink:label="SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" xlink:to="SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived_lbl" xml:lang="en-US">Percentage of royalties payments shall not exceed aggregate rant received</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grant received</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Accumulated royalty expense</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RoyaltiesPayForNetSalesRelatedToPatents" xlink:label="SLGL_RoyaltiesPayForNetSalesRelatedToPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RoyaltiesPayForNetSalesRelatedToPatents" xlink:to="SLGL_RoyaltiesPayForNetSalesRelatedToPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_RoyaltiesPayForNetSalesRelatedToPatents_lbl" xml:lang="en-US">Royalties pay for net sales related to patents</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfProceedsReceivedForSubLicence" xlink:label="SLGL_PercentageOfProceedsReceivedForSubLicence" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfProceedsReceivedForSubLicence" xlink:to="SLGL_PercentageOfProceedsReceivedForSubLicence_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_PercentageOfProceedsReceivedForSubLicence_lbl" xml:lang="en-US">Percentage of proceeds received for sub licence</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expire</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Operating lease agreements period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit obligation under lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Bonus paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:to="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl" xml:lang="en-US">Consideration for services payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingExpense" xlink:label="us-gaap_SellingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Expense recognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct" xlink:label="SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct" xlink:to="SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct_lbl" xml:lang="en-US">Percentage of gross profits related to sale of product</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TermOfCommericalSaleOfProduct" xlink:label="SLGL_TermOfCommericalSaleOfProduct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_TermOfCommericalSaleOfProduct" xlink:to="SLGL_TermOfCommericalSaleOfProduct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_TermOfCommericalSaleOfProduct_lbl" xml:lang="en-US">Term of commercial sale of product</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfReimburseOutofpocketExpense" xlink:label="SLGL_PercentageOfReimburseOutofpocketExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfReimburseOutofpocketExpense" xlink:to="SLGL_PercentageOfReimburseOutofpocketExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_PercentageOfReimburseOutofpocketExpense_lbl" xml:lang="en-US">Percentage of reimburse out-of-pocket expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="us-gaap_AccountsReceivableNetNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetNoncurrent" xlink:to="us-gaap_AccountsReceivableNetNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetNoncurrent_lbl" xml:lang="en-US">Long term receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TotalConsideration" xlink:label="SLGL_TotalConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_TotalConsideration" xlink:to="SLGL_TotalConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_TotalConsideration_lbl" xml:lang="en-US">Total consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfExpenseRecognized" xlink:label="SLGL_PercentageOfExpenseRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfExpenseRecognized" xlink:to="SLGL_PercentageOfExpenseRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_PercentageOfExpenseRecognized_lbl" xml:lang="en-US">Percentage of expense recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct" xlink:label="SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct" xlink:to="SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct_lbl" xml:lang="en-US">Amount pay to third party upon NDA submission of product</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct" xlink:label="SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct" xlink:to="SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct_lbl" xml:lang="en-US">Amount pay to approval of FDA on the first NDA product</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfFutureGrossProfitProductSold" xlink:label="SLGL_PercentageOfFutureGrossProfitProductSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfFutureGrossProfitProductSold" xlink:to="SLGL_PercentageOfFutureGrossProfitProductSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_PercentageOfFutureGrossProfitProductSold_lbl" xml:lang="en-US">Percentage of future gross profit product sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_2_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_2_lbl" xml:lang="en-US">Long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted Average Discount Rate Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of leases liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">For the year ended December 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AmountOfLeasePaymentsRepresentingInterest" xlink:label="SLGL_AmountOfLeasePaymentsRepresentingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AmountOfLeasePaymentsRepresentingInterest" xlink:to="SLGL_AmountOfLeasePaymentsRepresentingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SLGL_AmountOfLeasePaymentsRepresentingInterest_lbl" xml:lang="en-US">Less: amount of lease payments representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PresentValueOfFutureMinimumLeasePayments" xlink:label="SLGL_PresentValueOfFutureMinimumLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PresentValueOfFutureMinimumLeasePayments" xlink:to="SLGL_PresentValueOfFutureMinimumLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="SLGL_PresentValueOfFutureMinimumLeasePayments_lbl" xml:lang="en-US">Present value of future minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: Current maturities of operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long-term operating leases liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PresentValueOfFutureMinimumLeasePayments" xlink:to="SLGL_PresentValueOfFutureMinimumLeasePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_PresentValueOfFutureMinimumLeasePayments_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RoyaltiesMaturity" xlink:label="SLGL_RoyaltiesMaturity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RoyaltiesMaturity" xlink:to="SLGL_RoyaltiesMaturity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_RoyaltiesMaturity_lbl" xml:lang="en-US">Royalties Maturity</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfGrossProfitsRelatedToSaleProducts" xlink:label="SLGL_PercentageOfGrossProfitsRelatedToSaleProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfGrossProfitsRelatedToSaleProducts" xlink:to="SLGL_PercentageOfGrossProfitsRelatedToSaleProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_PercentageOfGrossProfitsRelatedToSaleProducts_lbl" xml:lang="en-US">Percentage of gross profits related to sale products</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenues recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Odinary share issued under share incentive plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Maximum term of awards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for future grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Option grants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Option vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Option vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Percentage of option vesting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" xlink:label="SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" xlink:to="SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition_lbl" xml:lang="en-US">Compensation costs weighted average period to be recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value outstanding option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value exercisable option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Ordinary shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Per share price</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AdditionalOrdinarySharesPurchased" xlink:label="SLGL_AdditionalOrdinarySharesPurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AdditionalOrdinarySharesPurchased" xlink:to="SLGL_AdditionalOrdinarySharesPurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_AdditionalOrdinarySharesPurchased_lbl" xml:lang="en-US">Additional ordinary shares purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Procceds from Initial public offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_SharesIssuedInPublicOffering" xlink:label="SLGL_SharesIssuedInPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_SharesIssuedInPublicOffering" xlink:to="SLGL_SharesIssuedInPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_SharesIssuedInPublicOffering_lbl" xml:lang="en-US">Shares issued in public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Outstanding promissory note converted into ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Promissory note conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Share split</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_BonusShare" xlink:label="SLGL_BonusShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_BonusShare" xlink:to="SLGL_BonusShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_BonusShare_lbl" xml:lang="en-US">Bonus share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Value of one ordinary share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted-average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options Outstanding at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted-average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" xlink:label="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" xlink:to="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" xlink:label="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" xlink:to="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options exercisable at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Corporate tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TaxBenefitPeriod" xlink:label="SLGL_TaxBenefitPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_TaxBenefitPeriod" xlink:to="SLGL_TaxBenefitPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_TaxBenefitPeriod_lbl" xml:lang="en-US">Tax benefit period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net carry forward tax losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">In respect of:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less - valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract" xlink:label="SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract" xlink:to="SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract_lbl" xml:lang="en-US">Taxes On Income Roll Forward Of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent" xlink:label="us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent" xlink:to="us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent_lbl" xml:lang="en-US">Employees payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_2_lbl" xml:lang="en-US">Other accounts payables and accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AdditionalOrdinarySharesPurchased" xlink:to="SLGL_AdditionalOrdinarySharesPurchased_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_AdditionalOrdinarySharesPurchased_doc" xml:lang="en-US">Additional ordinary shares purchased.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AgreementOneMember" xlink:to="SLGL_AgreementOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_AgreementOneMember_doc" xml:lang="en-US">Agreement One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AgreementTwoMember" xlink:to="SLGL_AgreementTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_AgreementTwoMember_doc" xml:lang="en-US">Agreement Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AmountOfLeasePaymentsRepresentingInterest" xlink:to="SLGL_AmountOfLeasePaymentsRepresentingInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_AmountOfLeasePaymentsRepresentingInterest_doc" xml:lang="en-US">Amount of lease payments representing interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct" xlink:to="SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct_doc" xml:lang="en-US">Amount pay to approval of FDA on the first NDA product.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct" xlink:to="SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct_doc" xml:lang="en-US">Amount pay to third party upon NDA submission of product.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_doc" xml:lang="en-US">Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in two fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_BankDeposits" xlink:to="SLGL_BankDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_BankDeposits_doc" xml:lang="en-US">Cash inflow and outflow from bank deposits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_BankDepositsPolicyTextBlock" xlink:to="SLGL_BankDepositsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_BankDepositsPolicyTextBlock_doc" xml:lang="en-US">Bank deposits [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_BuildingsAndLandMember" xlink:label="SLGL_BuildingsAndLandMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_BuildingsAndLandMember" xlink:to="SLGL_BuildingsAndLandMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_BuildingsAndLandMember_doc" xml:lang="en-US">Buildings And Land Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:to="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1_doc" xml:lang="en-US">Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:to="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_doc" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ChangesInFairValueOfMarketableSecurities" xlink:to="SLGL_ChangesInFairValueOfMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ChangesInFairValueOfMarketableSecurities_doc" xml:lang="en-US">Cash inflow from changes in fair value of marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ClinicalDevelopmentMasterServicesAgreementMember" xlink:to="SLGL_ClinicalDevelopmentMasterServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ClinicalDevelopmentMasterServicesAgreementMember_doc" xml:lang="en-US">Clinical Development Master Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ConsultantMember" xlink:to="SLGL_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ConsultantMember_doc" xml:lang="en-US">Consultant Member [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_DecreaseInNetCashUsedInInvestingActivities" xlink:to="SLGL_DecreaseInNetCashUsedInInvestingActivities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_DecreaseInNetCashUsedInInvestingActivities_doc" xml:lang="en-US">Decrease in net cash used in investing activities.</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeeMember" xlink:label="SLGL_EmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_EmployeeMember" xlink:to="SLGL_EmployeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_EmployeeMember_doc" xml:lang="en-US">Employee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_EmployeesMember" xlink:to="SLGL_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_EmployeesMember_doc" xml:lang="en-US">Employees Member [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_FPOMember" xlink:to="SLGL_FPOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_FPOMember_doc" xml:lang="en-US">FPO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_FinanceExpensesNet" xlink:to="SLGL_FinanceExpensesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_FinanceExpensesNet_doc" xml:lang="en-US">Finance expenses, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_FinancialIncomeExpensesNet" xlink:to="SLGL_FinancialIncomeExpensesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_FinancialIncomeExpensesNet_doc" xml:lang="en-US">Financial expenses (income), net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities" xlink:to="SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities_doc" xml:lang="en-US">Increase in Operating lease ROU assets and liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IsraelInnovationAuthorityMember" xlink:to="SLGL_IsraelInnovationAuthorityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_IsraelInnovationAuthorityMember_doc" xml:lang="en-US">IIA [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" xlink:to="SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares_doc" xml:lang="en-US">Issuance of shares due to in- process research and development acquired, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" xlink:to="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts_doc" xml:lang="en-US">Issuance of shares through an initial public offering, net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" xlink:to="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares_doc" xml:lang="en-US">Issuance of shares through an initial public offering, net of issuance costs, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_LaboratoryEquipmentMember" xlink:to="SLGL_LaboratoryEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_LaboratoryEquipmentMember_doc" xml:lang="en-US">Laboratory equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_MainlyMember" xlink:to="SLGL_MainlyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_MainlyMember_doc" xml:lang="en-US">Mainly [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_MasterClinicalTrialServicesAgreementMember" xlink:to="SLGL_MasterClinicalTrialServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_MasterClinicalTrialServicesAgreementMember_doc" xml:lang="en-US">Master Clinical Trial Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NationalAuthorityForTechnologicalInnovationMember" xlink:label="SLGL_NationalAuthorityForTechnologicalInnovationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_NationalAuthorityForTechnologicalInnovationMember" xlink:to="SLGL_NationalAuthorityForTechnologicalInnovationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_NationalAuthorityForTechnologicalInnovationMember_doc" xml:lang="en-US">NATI [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_NetChangesInOperatingLeases" xlink:to="SLGL_NetChangesInOperatingLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_NetChangesInOperatingLeases_doc" xml:lang="en-US">Net changes in operating leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_NonEmployeesMember" xlink:to="SLGL_NonEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_NonEmployeesMember_doc" xml:lang="en-US">Non Employees Member [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_NonEmployeesOneMember" xlink:to="SLGL_NonEmployeesOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_NonEmployeesOneMember_doc" xml:lang="en-US">Non Employees Member [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_OfficeFurnitureAndEquipmentMember" xlink:to="SLGL_OfficeFurnitureAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_OfficeFurnitureAndEquipmentMember_doc" xml:lang="en-US">Office Furniture And Equipment Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_OtherForeignGovernmentBondsMember" xlink:to="SLGL_OtherForeignGovernmentBondsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_OtherForeignGovernmentBondsMember_doc" xml:lang="en-US">Other foreign government bonds [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfExpenseRecognized" xlink:to="SLGL_PercentageOfExpenseRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PercentageOfExpenseRecognized_doc" xml:lang="en-US">Percentage of expense recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfFutureGrossProfitProductSold" xlink:to="SLGL_PercentageOfFutureGrossProfitProductSold_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PercentageOfFutureGrossProfitProductSold_doc" xml:lang="en-US">Percentage of future gross profit product sold.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct" xlink:to="SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct_doc" xml:lang="en-US">Percentage of gross profits related to sale of product.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfGrossProfitsRelatedToSaleProducts" xlink:to="SLGL_PercentageOfGrossProfitsRelatedToSaleProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PercentageOfGrossProfitsRelatedToSaleProducts_doc" xml:lang="en-US">Percentage of gross profits related to sale products.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfProceedsReceivedForSubLicence" xlink:to="SLGL_PercentageOfProceedsReceivedForSubLicence_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PercentageOfProceedsReceivedForSubLicence_doc" xml:lang="en-US">Percentage of proceeds received for sub licence.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfReimburseOutofpocketExpense" xlink:to="SLGL_PercentageOfReimburseOutofpocketExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PercentageOfReimburseOutofpocketExpense_doc" xml:lang="en-US">Percentage of reimburse out-of-pocket expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" xlink:to="SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived_doc" xml:lang="en-US">Percentage of royalties payments shall not exceed aggregate rant received.</link:label>
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PreferredEnterpriseMember" xlink:label="SLGL_PreferredEnterpriseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PreferredEnterpriseMember" xlink:to="SLGL_PreferredEnterpriseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PreferredEnterpriseMember_doc" xml:lang="en-US">Preferred Enterprise [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PresentValueOfFutureMinimumLeasePayments" xlink:to="SLGL_PresentValueOfFutureMinimumLeasePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PresentValueOfFutureMinimumLeasePayments_doc" xml:lang="en-US">Present value of future minimum lease payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_PropertyAndEquipmentDepreciationPercentage" xlink:to="SLGL_PropertyAndEquipmentDepreciationPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_PropertyAndEquipmentDepreciationPercentage_doc" xml:lang="en-US">The annual rate by which the asset depreciates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:to="SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities_doc" xml:lang="en-US">Recognition of operating lease ROU and liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RestrictedBankDeposit" xlink:to="SLGL_RestrictedBankDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_RestrictedBankDeposit_doc" xml:lang="en-US">Restricted bank deposit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RoyaltiesMaturity" xlink:to="SLGL_RoyaltiesMaturity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_RoyaltiesMaturity_doc" xml:lang="en-US">Royalties Maturity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RoyaltiesPayForNetSalesRelatedToPatents" xlink:to="SLGL_RoyaltiesPayForNetSalesRelatedToPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_RoyaltiesPayForNetSalesRelatedToPatents_doc" xml:lang="en-US">Royalties pay for net sales related to patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped" xlink:to="SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped_doc" xml:lang="en-US">Royalties payable on the sale of products developed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ScheduleOfDepreciationRatesTableTextBlock" xlink:to="SLGL_ScheduleOfDepreciationRatesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ScheduleOfDepreciationRatesTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of annual depreciation rates for property, plant and equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:to="SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of lease-related assets and liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases" xlink:to="SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases_doc" xml:lang="en-US">Schedule of supplemental cash flow information related to leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" xlink:to="SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition_doc" xml:lang="en-US">Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" xlink:to="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Weighted average remaining contractual term for option Forfeited awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" xlink:to="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Weighted average remaining contractual term for option grant awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate" xlink:to="SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate_doc" xml:lang="en-US">Short-term deposits bear interest at an average annual rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_TaxBenefitPeriod" xlink:to="SLGL_TaxBenefitPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_TaxBenefitPeriod_doc" xml:lang="en-US">Tax benefit period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_TermOfCommericalSaleOfProduct" xlink:to="SLGL_TermOfCommericalSaleOfProduct_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_TermOfCommericalSaleOfProduct_doc" xml:lang="en-US">Term of commercial sale of product.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_TotalConsideration" xlink:to="SLGL_TotalConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_TotalConsideration_doc" xml:lang="en-US">Total consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_YissumMember" xlink:to="SLGL_YissumMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_YissumMember_doc" xml:lang="en-US">Yissum [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:to="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts_doc" xml:lang="en-US">Issuance of shares and warrants through public offering, net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:to="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares_doc" xml:lang="en-US">Issuance of shares and warrants through public offering, net of issuance costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:to="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder_doc" xml:lang="en-US">Issuance of shares and warrants through private placement from the controlling shareholder.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:to="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares_doc" xml:lang="en-US">Issuance of shares and warrants through private placement from the controlling shareholder, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_SharesIssuedInPublicOffering" xlink:to="SLGL_SharesIssuedInPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_SharesIssuedInPublicOffering_doc" xml:lang="en-US">Number of shares issued in public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_UnderwriterMember" xlink:to="SLGL_UnderwriterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_UnderwriterMember_doc" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ShorttermDepositsBearInterest" xlink:to="SLGL_ShorttermDepositsBearInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_ShorttermDepositsBearInterest_doc" xml:lang="en-US">Short-term deposits bear interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_BonusShare" xlink:to="SLGL_BonusShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SLGL_BonusShare_doc" xml:lang="en-US">Bonus share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_NonEmployeesOneMember" xlink:to="SLGL_NonEmployeesOneMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_NonEmployeesOneMember_3_lbl" xml:lang="en-US">Employee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_FinancialIncomeExpensesNet" xlink:to="SLGL_FinancialIncomeExpensesNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_FinancialIncomeExpensesNet_3_lbl" xml:lang="en-US">Financial Income Expenses Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:to="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement_3_lbl" xml:lang="en-US">ChangesInAccruedLiabilityForEmployeeRightsUponRetirement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_NetChangesInOperatingLeases" xlink:to="SLGL_NetChangesInOperatingLeases_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_NetChangesInOperatingLeases_3_lbl" xml:lang="en-US">Office Furniture And Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:to="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_2_lbl" xml:lang="en-US">Increase (Decrease) in Long-term Receivables, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_BankDeposits" xlink:to="SLGL_BankDeposits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_BankDeposits_3_lbl" xml:lang="en-US">Office Furniture And Equipment [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_2_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash and Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:to="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1_3_lbl" xml:lang="en-US">Employee [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_2_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_BankDepositsPolicyTextBlock" xlink:to="SLGL_BankDepositsPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_BankDepositsPolicyTextBlock_3_lbl" xml:lang="en-US">BankDepositsPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_2_lbl" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Director [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_AmountOfLeasePaymentsRepresentingInterest" xlink:to="SLGL_AmountOfLeasePaymentsRepresentingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_AmountOfLeasePaymentsRepresentingInterest_3_lbl" xml:lang="en-US">AmountOfLeasePaymentsRepresentingInterest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" xlink:to="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" xlink:to="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2_lbl" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>slgl-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: SLGL 1220 20F.xfr; Date: 2021%2D03%2D03T12:57:40Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x800F0000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sol-gel.com/role/DocumentAndEntityInformation" xlink:href="slgl-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedBalanceSheets" xlink:href="slgl-20201231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="slgl-20201231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfOperations" xlink:href="slgl-20201231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" xlink:href="slgl-20201231.xsd#ConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="slgl-20201231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/NatureOfOperations" xlink:href="slgl-20201231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPolicies" xlink:href="slgl-20201231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecurities" xlink:href="slgl-20201231.xsd#MarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipment" xlink:href="slgl-20201231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/EmployeeSeveranceBenefits" xlink:href="slgl-20201231.xsd#EmployeeSeveranceBenefits" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/Commitments" xlink:href="slgl-20201231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CollaborationAgreements" xlink:href="slgl-20201231.xsd#CollaborationAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapital" xlink:href="slgl-20201231.xsd#ShareCapital" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncome" xlink:href="slgl-20201231.xsd#TaxesOnIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformation" xlink:href="slgl-20201231.xsd#SupplementaryFinancialStatementInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/RelatedParties" xlink:href="slgl-20201231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SubsequentEvents" xlink:href="slgl-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesPolicies" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesTables" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesTables" xlink:href="slgl-20201231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipmentTables" xlink:href="slgl-20201231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsTables" xlink:href="slgl-20201231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalTables" xlink:href="slgl-20201231.xsd#ShareCapitalTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeTables" xlink:href="slgl-20201231.xsd#TaxesOnIncomeTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformationTables" xlink:href="slgl-20201231.xsd#SupplementaryFinancialStatementInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/NatureOfOperationsDetails" xlink:href="slgl-20201231.xsd#NatureOfOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" xlink:href="slgl-20201231.xsd#SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" xlink:href="slgl-20201231.xsd#MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" xlink:href="slgl-20201231.xsd#MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" xlink:href="slgl-20201231.xsd#MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="slgl-20201231.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="slgl-20201231.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/EmployeeSeveranceBenefitsDetails" xlink:href="slgl-20201231.xsd#EmployeeSeveranceBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsNarrativeDetails" xlink:href="slgl-20201231.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfLeaseCostsDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" xlink:href="slgl-20201231.xsd#CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/CollaborationAgreementsDetails" xlink:href="slgl-20201231.xsd#CollaborationAgreementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalNarrativeDetails" xlink:href="slgl-20201231.xsd#ShareCapitalNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" xlink:href="slgl-20201231.xsd#ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfStockOptionActivityDetails" xlink:href="slgl-20201231.xsd#ShareCapitalScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" xlink:href="slgl-20201231.xsd#ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeNarrativeDetails" xlink:href="slgl-20201231.xsd#TaxesOnIncomeNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:href="slgl-20201231.xsd#TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/TaxesOnIncomeRollForwardOfValuationAllowanceDetails" xlink:href="slgl-20201231.xsd#TaxesOnIncomeRollForwardOfValuationAllowanceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" xlink:href="slgl-20201231.xsd#SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sol-gel.com/role/RelatedPartiesDetails" xlink:href="slgl-20201231.xsd#RelatedPartiesDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_DocumentAndEntityInformationAbstract" xlink:label="loc_SLGLDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestBearingDepositsInBanks" xlink:label="loc_us-gaapInterestBearingDepositsInBanks" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInterestBearingDepositsInBanks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaapReceivablesNetCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapRestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaapDefinedBenefitPlanFairValueOfPlanAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaapDefinedBenefitPlanBenefitObligation" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDefinedBenefitPlanBenefitObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_FinancialIncomeExpensesNet" xlink:label="loc_SLGLFinancialIncomeExpensesNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_SLGLFinancialIncomeExpensesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:label="loc_SLGLIssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_SLGLIssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:label="loc_SLGLIssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:label="loc_SLGLIssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockSplits" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" xlink:label="loc_SLGLIssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesDueToInProcessResearchAndDevelopmentAcquiredShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" xlink:label="loc_SLGLIssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" xlink:label="loc_SLGLIssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:label="loc_SLGLChangesInAccruedLiabilityForEmployeeRightsUponRetirement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SLGLChangesInAccruedLiabilityForEmployeeRightsUponRetirement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NetChangesInOperatingLeases" xlink:label="loc_SLGLNetChangesInOperatingLeases" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SLGLNetChangesInOperatingLeases" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ChangesInFairValueOfMarketableSecurities" xlink:label="loc_SLGLChangesInFairValueOfMarketableSecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SLGLChangesInFairValueOfMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_FinanceExpensesNet" xlink:label="loc_SLGLFinanceExpensesNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SLGLFinanceExpensesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInLongTermReceivablesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInLongTermReceivablesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_BankDeposits" xlink:label="loc_SLGLBankDeposits" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_SLGLBankDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCashAndInvestments" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCashAndInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:label="loc_SLGLCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SLGLCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="loc_SLGLRecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_SLGLRecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaapProceedsFromInterestReceived" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapProceedsFromInterestReceived" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/NatureOfOperations" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecurities" xlink:title="00000009 - Disclosure - MARKETABLE SECURITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/EmployeeSeveranceBenefits" xlink:title="00000011 - Disclosure - EMPLOYEE SEVERANCE BENEFITS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/Commitments" xlink:title="00000012 - Disclosure - COMMITMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CollaborationAgreements" xlink:title="00000013 - Disclosure - COLLABORATION AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapital" xlink:title="00000014 - Disclosure - SHARE CAPITAL">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncome" xlink:title="00000015 - Disclosure - TAXES ON INCOME">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SupplementaryFinancialStatementInformation" xlink:title="00000016 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/RelatedParties" xlink:title="00000017 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_BankDepositsPolicyTextBlock" xlink:label="loc_SLGLBankDepositsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SLGLBankDepositsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ScheduleOfDepreciationRatesTableTextBlock" xlink:label="loc_SLGLScheduleOfDepreciationRatesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SLGLScheduleOfDepreciationRatesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesTables" xlink:title="00000021 - Disclosure - MARKETABLE SECURITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaapMarketableSecuritiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeAssetsAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaapInvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipmentTables" xlink:title="00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsTables" xlink:title="00000023 - Disclosure - COMMITMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_SLGLScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_SLGLScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases" xlink:label="loc_SLGLScheduleOfSupplementalCashFlowInformationRelatedToLeases" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_SLGLScheduleOfSupplementalCashFlowInformationRelatedToLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalTables" xlink:title="00000024 - Disclosure - SHARE CAPITAL (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeesMember" xlink:label="loc_SLGLEmployeesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesMember" xlink:label="loc_SLGLNonEmployeesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeTables" xlink:title="00000025 - Disclosure - TAXES ON INCOME (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaapSummaryOfValuationAllowanceTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfValuationAllowanceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SupplementaryFinancialStatementInformationTables" xlink:title="00000026 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/NatureOfOperationsDetails" xlink:title="00000027 - Disclosure - NATURE OF OPERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ShorttermDepositsBearInterestAtAverageAnnualRate" xlink:label="loc_SLGLShorttermDepositsBearInterestAtAverageAnnualRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLShorttermDepositsBearInterestAtAverageAnnualRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_DecreaseInNetCashUsedInInvestingActivities" xlink:label="loc_SLGLDecreaseInNetCashUsedInInvestingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLDecreaseInNetCashUsedInInvestingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAmountOfHedgedItem" xlink:label="loc_us-gaapDerivativeAmountOfHedgedItem" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeAmountOfHedgedItem" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RestrictedBankDeposit" xlink:label="loc_SLGLRestrictedBankDeposit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLRestrictedBankDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ShorttermDepositsBearInterest" xlink:label="loc_SLGLShorttermDepositsBearInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLShorttermDepositsBearInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities" xlink:label="loc_SLGLIncreaseInOperatingLeaseRouAssetsAndLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLIncreaseInOperatingLeaseRouAssetsAndLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails" xlink:title="00000029 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Annual Depreciation Rates) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_LaboratoryEquipmentMember" xlink:label="loc_SLGLLaboratoryEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SLGLLaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_OfficeFurnitureAndEquipmentMember" xlink:label="loc_SLGLOfficeFurnitureAndEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SLGLOfficeFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_MainlyMember" xlink:label="loc_SLGLMainlyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SLGLMainlyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PropertyAndEquipmentDepreciationPercentage" xlink:label="loc_SLGLPropertyAndEquipmentDepreciationPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_SLGLPropertyAndEquipmentDepreciationPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails" xlink:title="00000030 - Disclosure - MARKETABLE SECURITIES (Schedule of Company&apos;s Marketable Securities) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapUSGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:label="loc_us-gaapForeignGovernmentDebtMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapForeignGovernmentDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_OtherForeignGovernmentBondsMember" xlink:label="loc_SLGLOtherForeignGovernmentBondsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_SLGLOtherForeignGovernmentBondsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaapAllOtherCorporateBondsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapAllOtherCorporateBondsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaapMarketableSecuritiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails" xlink:title="00000031 - Disclosure - MARKETABLE SECURITIES (Summary of Changes in Fair Value of Company&apos;s Marketable Securities) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ChangesInFairValueOfMarketableSecurities" xlink:label="loc_SLGLChangesInFairValueOfMarketableSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_SLGLChangesInFairValueOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails" xlink:title="00000032 - Disclosure - MARKETABLE SECURITIES (Schedule of Company&apos;s debt marketable securities) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="loc_SLGLAvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_SLGLAvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipmentNarrativeDetails" xlink:title="00000033 - Disclosure - PROPERTY AND EQUIPMENT (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_LaboratoryEquipmentMember" xlink:label="loc_SLGLLaboratoryEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SLGLLaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_OfficeFurnitureAndEquipmentMember" xlink:label="loc_SLGLOfficeFurnitureAndEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_SLGLOfficeFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/EmployeeSeveranceBenefitsDetails" xlink:title="00000035 - Disclosure - EMPLOYEE SEVERANCE BENEFITS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaapDefinedContributionPlanTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedContributionPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedContributionPlanTable" xlink:to="loc_us-gaapDefinedContributionPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedContributionPlanTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedContributionPlanDisclosureLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaapDefinedContributionPlanCostRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedContributionPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanCostRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsNarrativeDetails" xlink:title="00000036 - Disclosure - COMMITMENTS (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_IsraelInnovationAuthorityMember" xlink:label="loc_SLGLIsraelInnovationAuthorityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SLGLIsraelInnovationAuthorityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_YissumMember" xlink:label="loc_SLGLYissumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SLGLYissumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_MasterClinicalTrialServicesAgreementMember" xlink:label="loc_SLGLMasterClinicalTrialServicesAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_SLGLMasterClinicalTrialServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ClinicalDevelopmentMasterServicesAgreementMember" xlink:label="loc_SLGLClinicalDevelopmentMasterServicesAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRegistrationPaymentArrangementArrangementDomain" xlink:to="loc_SLGLClinicalDevelopmentMasterServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AgreementOneMember" xlink:label="loc_SLGLAgreementOneMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SLGLAgreementOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AgreementTwoMember" xlink:label="loc_SLGLAgreementTwoMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SLGLAgreementTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped" xlink:label="loc_SLGLRoyaltiesPayableOnSaleOfProductsDeveloped" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLRoyaltiesPayableOnSaleOfProductsDeveloped" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" xlink:label="loc_SLGLPercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="loc_us-gaapGrantsReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapGrantsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RoyaltiesPayForNetSalesRelatedToPatents" xlink:label="loc_SLGLRoyaltiesPayForNetSalesRelatedToPatents" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLRoyaltiesPayForNetSalesRelatedToPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfProceedsReceivedForSubLicence" xlink:label="loc_SLGLPercentageOfProceedsReceivedForSubLicence" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfProceedsReceivedForSubLicence" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:label="loc_us-gaapRegistrationPaymentArrangementMaximumPotentialConsideration" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRegistrationPaymentArrangementMaximumPotentialConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfGrossProfitsRelatedToSaleOfProduct" xlink:label="loc_SLGLPercentageOfGrossProfitsRelatedToSaleOfProduct" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfGrossProfitsRelatedToSaleOfProduct" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TermOfCommericalSaleOfProduct" xlink:label="loc_SLGLTermOfCommericalSaleOfProduct" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLTermOfCommericalSaleOfProduct" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfReimburseOutofpocketExpense" xlink:label="loc_SLGLPercentageOfReimburseOutofpocketExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfReimburseOutofpocketExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetNoncurrent" xlink:label="loc_us-gaapAccountsReceivableNetNoncurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccountsReceivableNetNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TotalConsideration" xlink:label="loc_SLGLTotalConsideration" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLTotalConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfExpenseRecognized" xlink:label="loc_SLGLPercentageOfExpenseRecognized" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfExpenseRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AmountPayToThirdPartyUponNdaSubmissionOfProduct" xlink:label="loc_SLGLAmountPayToThirdPartyUponNdaSubmissionOfProduct" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLAmountPayToThirdPartyUponNdaSubmissionOfProduct" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AmountPayToApprovalOfFdaOnFirstNdaProduct" xlink:label="loc_SLGLAmountPayToApprovalOfFdaOnFirstNdaProduct" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLAmountPayToApprovalOfFdaOnFirstNdaProduct" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfFutureGrossProfitProductSold" xlink:label="loc_SLGLPercentageOfFutureGrossProfitProductSold" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_SLGLPercentageOfFutureGrossProfitProductSold" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails" xlink:title="00000037 - Disclosure - COMMITMENTS (Schedule of Lease-related Assets And Liabilities) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaapLeasesOperatingAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapLeasesOperatingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfLeaseCostsDetails" xlink:title="00000038 - Disclosure - COMMITMENTS (Schedule of Lease Costs) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="00000039 - Disclosure - COMMITMENTS (Schedule of Supplemental Cash Flow Information Related to Leases) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowOperatingActivitiesLesseeAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails" xlink:title="00000040 - Disclosure - COMMITMENTS ( Schedule of Reconciles Undiscounted Cash Flows) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AmountOfLeasePaymentsRepresentingInterest" xlink:label="loc_SLGLAmountOfLeasePaymentsRepresentingInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_SLGLAmountOfLeasePaymentsRepresentingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PresentValueOfFutureMinimumLeasePayments" xlink:label="loc_SLGLPresentValueOfFutureMinimumLeasePayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_SLGLPresentValueOfFutureMinimumLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PresentValueOfFutureMinimumLeasePayments" xlink:label="loc_SLGLPresentValueOfFutureMinimumLeasePayments_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_SLGLPresentValueOfFutureMinimumLeasePayments_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/CollaborationAgreementsDetails" xlink:title="00000041 - Disclosure - COLLABORATION AGREEMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_RoyaltiesMaturity" xlink:label="loc_SLGLRoyaltiesMaturity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLRoyaltiesMaturity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_PercentageOfGrossProfitsRelatedToSaleProducts" xlink:label="loc_SLGLPercentageOfGrossProfitsRelatedToSaleProducts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SLGLPercentageOfGrossProfitsRelatedToSaleProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalNarrativeDetails" xlink:title="00000042 - Disclosure - SHARE CAPITAL (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeesMember" xlink:label="loc_SLGLEmployeesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SLGLEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srtExecutiveOfficerMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ConsultantMember" xlink:label="loc_SLGLConsultantMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SLGLConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesOneMember" xlink:label="loc_SLGLNonEmployeesOneMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SLGLNonEmployeesOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_FPOMember" xlink:label="loc_SLGLFPOMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SLGLFPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_UnderwriterMember" xlink:label="loc_SLGLUnderwriterMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SLGLUnderwriterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" xlink:label="loc_SLGLShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SLGLShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_AdditionalOrdinarySharesPurchased" xlink:label="loc_SLGLAdditionalOrdinarySharesPurchased" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SLGLAdditionalOrdinarySharesPurchased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_SharesIssuedInPublicOffering" xlink:label="loc_SLGLSharesIssuedInPublicOffering" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SLGLSharesIssuedInPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_BonusShare" xlink:label="loc_SLGLBonusShare" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SLGLBonusShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails" xlink:title="00000043 - Disclosure - SHARE CAPITAL (Schedule of Assumptions Used to Estimate Fair Value) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeesMember" xlink:label="loc_SLGLEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesMember" xlink:label="loc_SLGLNonEmployeesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalScheduleOfStockOptionActivityDetails" xlink:title="00000044 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Activity) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_EmployeesMember" xlink:label="loc_SLGLEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_NonEmployeesMember" xlink:label="loc_SLGLNonEmployeesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SLGLNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" xlink:label="loc_SLGLSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_SLGLSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" xlink:label="loc_SLGLSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_SLGLSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingForfeitedWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails" xlink:title="00000045 - Disclosure - SHARE CAPITAL (Schedule of Effect of Share-based Compensation Statements of Operations) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeNarrativeDetails" xlink:title="00000046 - Disclosure - TAXES ON INCOME (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaapIncomeTaxContingencyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxContingencyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaapTaxCreditCarryforwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxContingencyTable" xlink:to="loc_us-gaapTaxCreditCarryforwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxContingencyTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SubsidiariesMember" xlink:label="loc_srtSubsidiariesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtSubsidiariesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TaxBenefitPeriod" xlink:label="loc_SLGLTaxBenefitPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardLineItems" xlink:to="loc_SLGLTaxBenefitPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:title="00000047 - Disclosure - TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/TaxesOnIncomeRollForwardOfValuationAllowanceDetails" xlink:title="00000048 - Disclosure - TAXES ON INCOME (Roll Forward of Valuation Allowance) (Details)">
      <link:loc xlink:type="locator" xlink:href="slgl-20201231.xsd#SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract" xlink:label="loc_SLGLTaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLTaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SLGLTaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails" xlink:title="00000049 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Accounts Payables and Accruals) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent" xlink:label="loc_us-gaapAccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sol-gel.com/role/RelatedPartiesDetails" xlink:title="00000050 - Disclosure - RELATED PARTIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +J W(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **KWUY'86<ES*K%$QD(.>2!_6L?\
MX3#3_P#GC=?]\K_\56%7$TJ3Y9RLS6%"I45XJYT%%<__ ,)AI_\ SQNO^^5_
M^*H_X3#3_P#GC=?]\K_\56?U[#?SHOZI6_E.@HKG_P#A,-/_ .>-U_WRO_Q5
M'_"8:?\ \\;K_OE?_BJ/KV&_G0?5*W\IT%%<_P#\)AI__/&Z_P"^5_\ BJ/^
M$PT__GC=?]\K_P#%4?7L-_.@^J5OY3H**Y__ (3#3_\ GC=?]\K_ /%4?\)A
MI_\ SQNO^^5_^*H^O8;^=!]4K?RG045S_P#PF&G_ //&Z_[Y7_XJC_A,-/\
M^>-U_P!\K_\ %4?7L-_.@^J5OY3H**Y__A,-/_YXW7_?*_\ Q5'_  F&G_\
M/&Z_[Y7_ .*H^O8;^=!]4K?RG04445UG.%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 97B7_D7[K_@
M'_H8KSZO0?$O_(OW7_ /_0Q7GU?-9S_'7I^K/;RW^$_7]$%%%%>2>B%%%% !
M1110 4444 %%%% !1110!ZM1117W9\F%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^>G_ (Z*/MMQ_P ]/_'14%%%@Y8]CTG^V+__ )[_ /CB_P"%']L7_P#SW_\
M'%_PJC17N>VJ?S/[SPO94_Y4;VCW]S=7;I-+N41D@;0.<CTK;KF_#_\ Q_R?
M]<C_ #%=)7IX63E3NV>=B8I5+(****Z3G"BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-/\ E7W&C_;FH_\ /S_XXO\ A72Z5/)<Z;#-,VZ1LY.,=R*XFNQT/_D#P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.>/"!X+U D@#]
MWU_ZZ+7BOF1_WU_.O9OB'_R(NI?]LO\ T:E>$5\_FL;UEZ?JSZ?)7;#OU_1&
MCYD?]]?SH\R/^^OYUG45YGLT>OS&CYD?]]?SH\R/^^OYUG44>S0<QH^9'_?7
M\Z/,C_OK^=9U%'LT',:/F1_WU_.G5F5IU,HV&G<****@84444 =-1117&<)=
MTS_CY;_</\Q6M63IG_'RW^X?YBM:LI[G)6^(****@S"BBB@ KL=#_P"0/!_P
M+_T(UQU=CH?_ "!X/^!?^A&O=X?_ -YE_A?YHXL?_#7K_F:-%%%?7GDA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S'Q#_Y$74O^V7_H
MU*\(KW?XA_\ (BZE_P!LO_1J5X17A9I_&7I^K/ILF_@/U_1!1117FGK!1110
M 4444 %:=9E:=95.A40HHHK,H**** .FHHHKC.$NZ9_Q\M_N'^8K6K)TS_CY
M;_</\Q6M64]SDK?$%%%%09A1110 5V.A_P#('@_X%_Z$:XZNQT/_ ) \'_ O
M_0C7N\/_ .\R_P +_-'%C_X:]?\ ,T:***^O/)"BBB@ HHHH **** "BBB@
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MG_HN2HJSY(.78WPU)5JT:;ZG7_\ "5^'/^@_I7_@9'_C1_PE?AS_ *#^E?\
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MZ .E_P#@''_A6O11R1[![:I_,_O,C_A%?#O_ $ =+_\  ./_  H_X17P[_T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7Z "HYIX;:)I9Y4BC7J[L% _$UXO\=_&WB'PO=Z59Z+J+6<5U#(\IC1=Q((
MPQ&1U[5\]:EK6J:Q+YNI:C=WCYSF>9G_ )F@#Z]UCXL>"-%W+/KUO-(O_+.U
MS,?_ !W(_,UP.L?M):9%N31M#N;D]I+J01#\AN/\J^<J* /3]8^/7C74]RVT
M]KIL9[6T(+8_WGS^F*Y-_'_C"1R[>)]6R3DXNW']:YRB@#H?^$\\7?\ 0S:O
M_P"!C_XU]E>&I9)_"NCS32-)+)90L[L<EB4!))]:^%*^Z/"O_(GZ)_UX0?\
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M[?POIJHG07=Z,D^X0' _$GZ5XQKWB+5?$^IOJ&L7LEU</T+'A!Z*.BCV%9=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^'_A:7QCXSL-*528"_F7+#^&)>6/X]![D5]IR206-F\LC+%;P1EF/0(JC^0
MH XGXI?$&+P'X=WPE)-6N\I:1-R!ZNP]!G\3@>M?(5[>W.HWLUY>3O/<S.7D
MED.69CU)-;_CWQ;/XT\77FK2%A 6\NUC/_+.(?='U/4^Y-<S0 4444 %?3WP
M=^%4'A^Q@\0ZU;A]8G4/!%(.+53TX_OD=3VZ>M>1_!GPJGBCQ_;&YCWV6GK]
MKF!'#$$;%/U8CCT!KZ]H *\L_:!_Y)DW_7[%_P"S5ZG7EG[0/_),F_Z_8O\
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M!M=2M;E3@Q3)(#]"#0!][44@.0#ZTM !7PAKO_(PZG_U]R_^AFON^OA#7?\
MD8=3_P"ON7_T,T 9]%%% !7W1X5_Y$_1/^O"#_T6M?"]?='A7_D3]$_Z\(/_
M $6M &O7GOQ?\<CP9X1=+67;JM_F&UP>4'\4GX \>Y%=[=7,%E:375S*L4$*
M&221C@*H&23^%?%_Q"\8S^-_%MSJCEEM5/E6D1_@B!X_$\D^YH Y8DDDDDD]
M2:2BNJUKP=-H7@;1-<O R7&K32-'$?X85"[2?=LD_3% '*T444 %>V?LV?\
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ME_\ 0S0!GT444 %?='A7_D3]$_Z\(/\ T6M?"]?9DOB:T\(?"BPUF[P1#IL
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M+2"3X2Z)C^$2J?PE>N^KRG]GR_6Z^&YMMWSVEY)&1Z!L./\ T(UZM0 4444
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MLWNC;A_Z&?RKZ+KSKXV>'&\0?#F[>&/?<Z<PO(P!R0N0X_[Y)/X4 ?(M%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU.[NDUC3%6:9Y #YF0"Q/]WWH \-HKVC_AF[Q'_T&M*_\B?_ !-'_#-WB/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7-?$+_DG/B/\ [!T__H!KI:X?XE^(]$L_ ^NV
M-QJUE'=SV,L<4!F7S'8J0 %ZT ?'%%%% !1110!]4?L]?\DU?_K_ )?_ $%*
M]7KQ3X">)=#L?!#Z9>:M96]Z;V1Q!-,J,5(7! /7H:]I1UD0.C!E/(*G(- #
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0A!V@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHICM@4 .W49JJ9AGK4L;@]ZJPKDU%%%2,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ JI=R;%-6ZSM0^X::W%)Z&-+?XEQFM.QN?, YKE;K(
MGS[UH6%WY>,FM6M#G4]3KU.13JSK>[#@<U?4Y%9-&\97'4444B@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 0UGWW*&KCN%K-O9E*GFKBM3"I.QS-Z/G-54D96XJW=G+&J@7YJZN70XG
M5U-W39&)&:Z2$_(*YC32%(S720R+L'-<\XV.NE*Z+%+30<TM9'0F+1110,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I">*"<"J\LN!32)<DBG?7'E@\USMQ?EF(S6AJ,FX&N>D4F0UVT:=SS<14UT
M)6?>:55IB# I^[%=:@CSY5-2S%/Y?>M2TOBQ S7/DYJ]8 [Q6-6FK'30JN]C
MK[=]RYJQ5.S^X*MUYTMSV(.Z%HHHJ2PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV: H-,S2[L5?)8CVC)-BXII&#2;Z,YI6)YKCA2D4W-*#F@5A.]/ H IU ,3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&^]<T 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%(>E "TF15"[O!"#DUE/KJJV-U '032!4)S6!?:GY1
M/-5Y]<5HR-U<SJ5\92<-0!N'7>?O4JZYG^*N+\UL]33UE;U-,I([3^V^/O4T
M:Y\V-U<AY[8ZFFB9MW6D#1Z387_G8YK95@5ZUYSIVI>5C+5OIKZA1\U K'4Y
M%+7.PZVLC8W5L6UP)1G- BU1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5N9?+6L.YU3R
MV(S6GJ380UPVI3$.>: -A]<P?O4Y-;S_ !5QDDS9ZFB.=AWI%=#MSK/'WJC;
M6\?Q5R9N3CK4+SMZTR3KAKOS8W5IV>I^;CFO.!,V\<FNETF0G'-(M6.ZBFW
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M$KCBNEC^Z*\>N]3Z##?"/HHHK Z@HHHH **** "BBB@ HHHH **** "BBB@
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M[GYJF(XJ%AEJ0'0Z"?G6O0[+_4BO/="7YUKT.R_U(IDEJBBB@ HHHH ****
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MNT/RBM2/[M A]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,G%<'JBA9#]:1:9DD4X49&:6BX[BTAZ4M% $8'S5T6D7(C(YKG^]6H)BA&*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%4[_ /U)JY5._P#]2U 'GFN'YVK 4\UNZY]]JP5ZTBT2$\4PN:DQD4FR@:&;
MN*C)^:IBM1$?-3!G1Z#]]:]#LO\ 4K7GN@CYUKT.R_U(H(+5%%% @HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IC]*?3'Z4 9MT?E-<;K
M!ZUVETORFN.UA?O4B[G+$?/3L<4K##4O:J07(RV#3@<T%,TN,4FQZD4E7])_
MUP^M4F%:6DK^]'UH(9Z)I'^J'TK7K*TD?NA]*U:!!1110 4444 (>E<SK_\
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M2!5Z"I0,5QSFY'J4Z:B@  I:**@T"BBB@ HHHH **** "BBB@ HHHH ****
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MM3FQ?TJ6VLF$HXH$V=GH/W5KJU^[7,Z)$45<UTR_=ID"T444 %%%% !1110
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MB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&Z4M(WW:
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M7F^C:EY6W<U=E::FLH !%,AHUZ*8C[ES3Z!!1110 53O_P#4FKE4[_\ U+4
M>=ZY]]JP%ZUNZZWSM6"AYI%HF[4F*<.E% [B=JA;[U3FH&/S4"W.BT$?.M>A
MV7^I%>>:"?G6O0[+_4BF2T6Z***!!1110 4444 %%%% !1110 4444 %%%%
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M^*Z72>U,FQV%H?E%:D?W:R;0<"M:/I0Q,?1112$%%%% !1110 4444 %%%%
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M9F<5+%/L/6@EW._L+[Y0,UNP2;Q7GNFWF7 S7;Z:^Y!3)-.BBB@#)U4_NS7
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M,8_.:<.E(I"XHHH[4#&-6GI./-'UK*<UH:23YP^M,AGI.E?ZH?2M3M65I/\
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M0!Q6O_Q5Q$I_>'ZUV^O_ ,5<1(N9#]:1:!6J9>:8D52CBA#0AIC#-/-1LV*
M9?TQ/WHKT32!B,?2O.M,D_?#ZUZ+HYS$/I0B6C9HHHIDF3JH_=GZ5P&II^\-
M=_JA_=GZ5P.IM^\-(I&4>*,9H)S0#BFF4@VTAIVZFFAC8U1\XKI-).,5S:GY
MQ71Z5VID,["S;Y16M']VL>S' K7B^[2))**** "BBB@ HHHH **** "BBB@
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MK4LKDQD<UG$5)&V#0#.VTZ_+8&:Z>V?<F:X+27RZUW-B?W0ID%VD/2EI#TH
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MM>AV7^I%")9:HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\]T$?.M>AV7^I%,DM4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$='H(^=:]$LO]2*\[T$_.M>AV7^I%,ELMT444""BBB@ HHHH **** "BBB@
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M]*18M':BB@"&49J[I*_OA]:J/5BQF$4@- 'IND<1"MBN,TS6%4!=U=):W@F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 84!IA@7TJ:BBXK$(@4=JD"@4M%+F'86BDI,U/,
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M6NPD**!IGG!'EG!IP;-6]3M'CD.%[U00%>M(JY94TXL,56,@Q2!R30,F-)2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !24A8"HS*!64II#)<TQGQ4+7"CO4$ERN.M<E;$**'8EDN0O>J[7R^M9
MMW<GG!K+:Y?=UKSIX\#?EO 1UK,GG+$\U2\]C2[B:X9XRXFA'=L]:BWMZU*:
M8PKEEB&R;#=Y/>DY)I,<U(N*YYSN4"BAEIU%8-@0%:2IFQ46.::  *7%2+BD
M;%4@(S3>:<:*JQ+04QA2THH3!,CQ2U)BFXJ[DR5QM%.HI$\I&13=M38HP*=K
MCL1XIC"I<4F*5B!BTK=*#252'8B*G-/45)@4A%4I#0PTE*:3O3$Q#TJ,J:F
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M *UI);(/X14J1!1@4\"F)L:L:KT%/HHH$%%%% !1110 4444 %%%% !1110
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M/2IX[4)VJ[BB@!BK@4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% !112,<"@!:*JR72IU-5GU2->XH TZ*SHM2CD. :O(X<9% #Z***
M"BJ\MPL?4U4.JQ@XR* -.BLT:G&>]!U./UH TJ*S/[4C]:7^U(_6@#2HJ@NH
M(QZU:CF#]* ):*** "BBB@ HHHH **** "BBB@ HIK-MJ![I4ZF@"S16:VJ1
MJ<9J6&^27H: +M%(#D9I: "BBB@ HHHH **** "BBB@ HHHH ***BEF$8YH
MEHK..I1AL9JS%<+)T- %BBDS2T %%(3BHFF"T 3451>_1.IJ+^U(_44 :=%9
MW]IQ^M-.J1^M &G169_:L?J*GBO4DZ&@"Y14#SA5S54ZE&&QD4 :-%017 DZ
M5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !2$XH)J":3:M9U)J*&D+)* #S65=7.,X-,N;O!(S5!I?,KQ,5B
M[%J(YK@DTPL30J9IY3 KY_$8IMC2(MM/4"F,<&@/7G2K-E$NT&F%!2;Z-V:B
MXAI%)BG&HF;%5$;0IXI <TW=F@'%6-;$H HZ5'OI"U40T*QIE,=J:&R:=[ D
M2XS33'3@:6A,+#-N*,4ZD-.Y+1&13<U(::5JDR10,TC"DSBE'-6@& 4_'%!%
M-)ILEB&E44VE!I6&.(IM+FD-4A(2DHS15 PQ1BBC-*X;!24&F%J9(,:0')II
M;-(.M7$1-@8IC"E#4[&:UL!&!2D8IQXIF<U#):&YIVT&C;1NQ23$,88J/-2G
MFHGXK>.HT1R=.*AA5_.'!ZU9A7S&Q6W9:4'(;%=U"BVRDKFAH@.U<UTJ]*S;
M*T\D#BM,=*^@H*T;%I"T445T#"BBB@ HHHH **** "J=Y)L0FKE9FJ-B(_2@
M#F]0U$QL>:R'UAMWWJKZO<8D//>L(SDOUH ] TF_,K#FNNMVW1@UYWX?<EEK
MT&T_U0^E %BBBB@ HHHH I7\FR(FN"U;57CE(!/6NYU3_4&O,=<'[YOK0!;M
M=7=CU-=-IMXTA&37"6*_,*[+25^[3L.QV%NVY!4]5[7_ %8JQ2$%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBN-NO#S-*3MKTYHE;J*JRVD?7:* /,&T)HQG;526W\@XQ7H][;QK&>!7#ZN
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MP]#4I1);6S55!Q5]$VBB-=JT^O:IQ218M%%%;B"BBB@ HHHH **** "BBB@
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M$')K-L[K?!NSVK%UC5##D;J!$^KZB%#;6KCY]5D\TX)J.ZU-IR1G-9Y5G;-
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M1110 4444 %%%% !1110 4C?=I:1ONF@#D_$!^1JX3&ZZ/UKN?$7W&KAH_\
MC\.?6I8['4Z79JZCBNAAT]-G2LW1R@09-= LJ!.HJA'(:[:HBM@5S^G+BZ_&
MNG\02*0V#7,Z?_Q]?C0!WEO_ ,>?X5QFOCYVKM+;_CS_  KD->'S-04CE0/F
MKH]# WK]:YUN&K>T-OWB_6D4SNV_X\OPK@M;_P!<WUKO#_QY?A7!ZW_KC]:=
MR45[ \BNNTQ=VW-<C8=178Z5_#0-FC>P+]FSCM7"7RXNOQKT*\_X]OPK@]0
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M /5"@DQ?$)^4USNEG_2OQK?\1'Y6KF]+)^U?C18I'IFEC, JZ]LK]15/2?\
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M4#EKS\: :.KTNP5@IQ746=N(P,"LS1(MT:UT2)@4"'CI2T44 %%%% !1110
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M=43[U<C?+@FNFU>Z"EN:Y.ZG#F@#0T3_ %J_6O2-._U(KS?1/]:OUKTC3O\
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M!O\ AZ>1G7)KJ=1.;3\*Y[0;5D*Y%=%J0Q:_A0!P5Q_Q^?C77Z"/E6N/N/\
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M7)VU/IVF^41D4R1NGZ.(P#MKHK>+RTQ3XD"J!BI* (I_]6?I7 ^(3RU=]/\
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M110 4444 %1M"K=14E% $'V6/^Z*<($'85+10 @4#I2T44 -* TPP(>U2T4
M0?9DS]T5(L:KT%/HH 8T2MU%,^S)_=%344 0_9T]!2?9D_NBIZ* (A @[4X(
M!VI]% !2$9I:* (FA5NHH6%5Z"I:* $ Q2T44 %,:)6ZBGT4 1"! >@I^P8Q
M3J* (C AZBE6)5Z"I** $*@TPQ*>U244 0_9T]!3UC5>@I]% #&C5NHIGV9/
M[HJ:B@"(0*.U/"@4ZB@ IK(&ZTZB@"$VZ'L*/LR>@J:B@!BQJO04^BB@ HZT
M44 1M"K=131;H.U344 ,$:CM3@,4M% !3&C#=13Z* (?LR'^$4?9D_NBIJ*
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M.D^]7RN+CJ:(510W%(&Q2,<UX]0VB,)I,<TN*!6*0VAP6G>6#2 TADQ5)$V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!AC4]13?(3T%2T4 1B%1V%/  I:* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ II0'J*=10!&(4'84\ "EHH **** "D(S2T4 ,,:GM2A .U.HH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@!*8:?337-65T-%68<5FRKS6I,.*SY!S7S^,@;1
M97Z4X<T[;1C%?-8C1FR&L.*B-3GFF%:Y$RB*ES013@,TP <T$4I&*C+5+9#$
M-)3L9IRI5*+ CR12AC4C)41&*WC"YFQU1M2YYJ14W5V4L.Y!<IOFI;=26Z5=
M6UW=JLPV>WM7IT< V2V+##E>E2BU![58CCVBI0*]6A@^7<ER(HX0M3@4 4ZO
M5ITTD0V)BEHHK>P@HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!#4;C(J6FL*PK1NAHSIH\U69=M:4BU0GXK
MY7'4M6;Q9#G--9::&YJ3.17@U(69LF5V.#3EYH9,FE7Y:=.%V-V)%2I5CS1'
MS5N..O9PN%NS&3&)![5:CCQ3T45*!7T>'PRBC%L0"EI:*[U&Q 44458!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EI#4RV A<<
M5FW(K58<50N$SFO%QE&ZN:Q9E\[JD7-/\OFE*X%?+XB%F;(!C%,89Z4QG(-6
M8$WU6#I<T@DQ;=#FM.->*CCAQ5E1@5];A:"BCGDQ0*6BEKTHQL2%%%%6(***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBDP
M&FJTB9JU3"*Y*\.9%)F;(FVJSMVK0N!P:S'Y:OFL9AGS&JD,VY:M"U3%5XHL
MUH0QXJ\#AVI!)Z%E1Q3Z0#BG5]33C9&+"BBBM1!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$4M%)JX%.X7B
MLXQG?6Q(N:K>5S7GUZ";+3&P1]*MHH%,1<5,*5"DHL&QU%%%>BB HHHI@%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "$9IFRI**EQ3 8%IU+124$AW"BBBK$%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,:!C # 2(  A$! Q$!_\0
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M%%% "TX4VE![4 244T&E)H 1J8:<33: $HQ12T (!1BG8I<4 -HIP7%+CVH
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M<95E.0:Y3N)***IV.J6FHO.EK+O,#;).",'G_ T 7***R+OQ-I-E=&WFN@)
M<-M!(7ZXH UZ*9%*DT2RQ.KQN,JRG((IQ( )/04 +15+3M4M=4CD>U<NL;[&
MR".:NT %%%% !6'%P\J]ED8#\":W*PD.;JY_ZZM_.@":BBB@84444 :E%%%
M@HHHH **** $-%+VI*8!1110(**** "BBB@ HHHH :>M%*:2@ HHHH ****
M"BBB@ HHHH 2B@T4AA1110 4444 %%%% !1110 444G>@!:*** "BBB@ I#2
MT4 -H[4&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:>M.IM !111
M0 4444 %%%% "BEI.U. H 0"G8HIV* &X]J0BGXI"* &4VI"*:: &44M)0 4
M444 %%%% !1110 4444 )WHHHH **** "BBB@ HHHH 7M112B@!P%.%(*<M
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M_IL__H1K>9@J%F. !DFN=T_+6X=OO-\Q^IYH N4444#"BBB@#4HHHH$%%%%
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MBB@ HHHH **** "D-+10 VBBB@ HHHH **** "BBB@ I#2T4 )1112&%%%%
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M:8?Z7=GSIB>O/0?E6)\5O^/?1?\ KZ/]*[^+_4Q_[@_E2CI'\!R^+\1]%%%
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MKS 2'QW\1(;BWC+:7I^,R,.& .?U/04X_&O(;TBSU$UYS\5V"0:,YZ+<%C^
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M=O#J/XE[B@#?HID4J3PK+$P9'&013Z *5[8+=S0L> IPWN*M1Q1PH%C0*H[
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M4M% '(:A\-O#U],94BGM&)R1;2  _@P('X8J72_AYX?TR99O(DNI4.5:Y?<
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MFBG4 %%%% !2TG>G#O0 ZBBB@ HHHH **** $-,-24P]: (S3:>:90 E%%%
M!1110 448HQ0 M%)29H =1FDHS0 M%-S29H 7.*2BB@8E%+2"@ HHHH ****
M "BBEH 2D-.I<4 1T4_%&*!#**?BDQ0 VBEQ24 %**2B@!X-.S4>:7- R3-+
MFH]U&XT"'YII.:3-% PIV*0"G@4"$ IV*=BEH ;BC'M3Z3% #,4A%28I,4 1
M$5&14Y'-,(H BI*<1BDH 2BBB@ I*6@T )1110 4444 %%%% !1110 444M
M!1BE IZK0 S%+BI0*7;0!"1334Y6F%: (J3O3R*;0 E%%% !VIPIM.% $JGB
MI :A4XJ0&@"6BF@\4Z@ HHHH *J7=FEPA! JW29H YR.6\T64^4/-MR<F)CQ
M]1Z&MZPU6TU%?W+XD'WHWX8?A_A39HDE&&%85]HX+>9$2K Y!'!!H ZRBN0A
MUO5-.PEP@NHQW;A_S[_C6M;>)]-GP))&MW/\,JX'Y]* -FBHXIXITWPRI(I_
MB1@1^E24 %%%% !12$A1EB !U)K.NM>TRTR'NT9A_#'\Y_3I^- &E45Q<P6D
M)FN)5CC'=CC_ /6:YFY\57-P2FGVFP'_ ):3<G\A_C5%=/NKZ837LSROZL>G
MT'0?A0!<OO$%SJ!,&G*\,)X,QX=OIZ?7K]*6PTQ( "1S5NWLXX%  %6J!B 8
M&!2T44 %%%% !1110 4444 :E%%% @HHHH **** "BBB@ H[44=J $HHHIB"
MBBB@ HHHH **** "D-+2&@!**** "BBB@ HHHH **** "D-+10 E%%%(8444
M4 %%%% !1110 4444 %%%% !1110 4444 %-[TZ@T -HH[44 %%%% !1110
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MN]M>W^9Z#J^HKI.E3WSIY@B'"9QN/IFDT?4&U;2H+YH/)\T9";MV!]<"N/\
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MYZTA-(30!#+ DG4"LZXTB&3/RBM4FDH YM]"*/OB8JWJIP:58=6A_P!7?W(
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M-)FDHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&L:;3J;0(**** "BBB@ HHHH **** "DI:2@ HHHIB"BBB@ HHHH **** "F
MTZF]Z "BBB@ HHHH **** "BBB@ I*6DI#"BBB@ HHHH **** "BBB@ [T44
M4 %%%% !1110 4444 (:2E/2DH .U%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH *#110 E%%%(84444 %%%% !1110 4444 %&*=BEQ3
M;13\4F*!#**=BFTAA2'K2TAH 2BBB@ HHHH **** "BBB@ HHHH ****  =:
M=3:7- #@:=FF4H-,0^C-(#1FD,6BDS29H 7--)HS2$T (:0]**0F@!*2EI*
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M444 %%%% !1110 48I<<4M "8-)3J* &T4II* %S2TVB@!U%-S1F@!U%-HH
M4FDHI":  FDHHH *2EHH 2BBB@ HHHH **** "BBE'6@!**?1B@!E)3B*2@
MHHHH **** $-%*:* "E I!UIXH 7%+2XXIU " 48%.Q1BF(9BDQ3Z:10,C(I
MM2&F$4@&GI3:<::>M !1110,**** %%/'6F"G"@1*.E**8#3J 'T4@-+3$%%
M%% !29H)XIM  ::QI2:832&)FHS3S3*!C:**!0(**** "BBB@ HHHH 4&G9I
ME% $F:,TS-)F@"3=3<TW-% "D\TE%+B@!*2G8I* $HI:2@!:<M-I10!*#4@J
M(=*<#0!)130:4F@!:C/2E)II- #&IE*U-H 2BBB@ HHHH **** $HH-% !11
M10 4444 %%%% !1110 4444 (124ZD[4#$HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#6HHHIDB'I24ZFTAA1110 4
M444 %%%% !1110 4E+24 %%%%,04444 %%%% !1110 'I3:=VIM !1110 44
M44 %%%% !1110 4E+2&@84444@"BBB@ HHHH .].%-I1UIB'TZF4N: '44F:
M3-  :::4TTF@!****0Q#24ZF]Z "BBB@ HHHH *.]%'>@!U%%** %Q0:6D/6
MF(;3:=3:0PHHHH *#110 W)HHHH **** "BBB@ HHHH 2BBB@ HHHH ****
M%IU-IU "XI:** &TVGGK330 VBBB@ HHHH *3O2TE #A3QTIJ\T^@!PZ4X4G
M:EIB"BBBD,*0TM(: &4P]*>:;VH CI#2FD/6@!****!A1110 4HIII0: '@T
MX&F TM B4&BF TN: '4N:9FC- #J0FD)XII-  332:"::30 $TS-*:2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHI1UH <!3@*!3@* $Q32M28IIH B(I
M*<:;0 E+244 /!IP:HZ7- $N:,U%FEW4 /+4QC29I*  TE%)0 4444 %%%%
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MM8Q)&>5EC7/!_O*<?CUJMJ(5)+NYA:2\MH;R))IK@@?;+O<L:*=H \N/()
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M10!(#2YJ//%.!H D!HR*9FEIB'9IIHHH 0TW&:?6+XIN[VRT"=["VGGN'(C
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MM8C+(L0G)./3)'\Z[33IWN],M+F0 /- DC!>@)4$X_.@98IV* *=B@0E+BG
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M(-:5% 7*5CI-CIFG_8;&W6WM\$;8R0>>IW=<^^<T#2+!=)72A:I]A5!&(N<
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M(UF5I^(O^1FU7_K[E_\ 0C697G'Y_B/XTO5_F%%%%!B%%%% !16AHD]S;ZO
MUG!#/<L=D23*"NX]^2!GZUW>O?VD/ 4W_"21(^H&7]PR1@E!D=2HVCC-5R^Z
MY';AL(J\)2NU9-[::=W?2YYI17K^D)>3Z7HLN@O!!IH7_3(WB^9_7MR>O(_6
MO-?$DMK-XAO7LX3%!YA 0IMP>_';GM3G'D=B\3@?8T55YKWMT[J^FNMNNQE4
M5Z3H%W=R>#M.LM'UFPL]0\U]T<\B[B,G@*03G\*IZ;)>6'B35?[9N[:WUF2
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M% #N]+24M,04444 %%%% !33TIU--(8QNM1L:D/6HFH 8:*#10 M/6F"G T
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ME^I+12@4M=)]()BC%+13$-Q28I])B@",BDI^*0BD,8:2G4TT %%%% !1110
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MI- "TH-,W4H- $H-+48-.!XH ?1244 +1249H *:QH+4PF@!":C)YIS&HS0
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M110 4444 %%%% !1110 VBBB@04444 % ZT4HH <*<!2 4\#-  !3MM*!2T
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MM-'6G4 /I:8#3\TQ"DTE%)FD,0TPTXTTT )33UIQIM "4444 %%%% !1110
M4444 %%%% !1110 4444 .'2G 4@IU !BF]*=2'K0 E)FD-)0 _-&:910 _-
M)FFT4 *33:6F]* %)IM%% SF?B)_R3K7_P#KS;^E;&B_\@#3?^O2+_T 5C_$
M0?\ %NM?_P"O-OZ5LZ(/^)#IO_7I%_Z *!%[MTI,4[%% #<4&G4&@!E%+2=Z
M!A1110 4444 %%%% "&DIU(.: $I:7%% "4HHI: '"GK3!TIZT"'BEI!2TP
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M$^Y4 ?C7?:)_R --_P"O2+_T 5C?$;_DG.O_ /7FW]*V]#'_ !(--_Z](O\
MT 4@+V*7;3L4N* &8I,<5)2$4 1&FU(W6FXH 910:*!A1110 444M !13@*7
M% "8HQ3L4X+0(CQ1BI,4;: &4X48I: %!I<TVDS0 _--)IN:0F@ S49-*3S3
M: $[T444 %%%% !1110 44H%.VT ,HJ3;2;: &4E/*TWI0 E%%% !1110 4E
M+10 E+24X=: '**>!Q2+3P*  "EQ3@*6@"/%,(XJ4BF$4 0D4AI["F&@!*2E
MI* "E%)0* 'BI%J,5** )%IU-%.H **** &'I4;4\]*8U $1IAI[4TT --%!
MZT4#"BBB@ HHHH **** "BBB@ HHHH **** #O1110 4444 :U%%%,D****
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M_0!0!H4[%(*=3$)BFT^FF@!C#FF5(>M1GK2&,-)2FDH&%%%% "BE H'6G4"
M"G@4 4X4 &**7%+B@!*2G8HQ3$-I"*=24AC#3:<13: $SQ32:#TI#0,0FDHH
MH$%%%% !1110 4H% IX% "@4X"@"G@4 -VTA%28HQ0!$13&%3$5&10!$:2GF
MFF@!**** "BBB@!/6GCK3:4=: )5J1:C%/!H ?2TE%  :C;M3R:8U $;5'4C
M&HZ $I#2T4 )1110 X5(IYJ*G T 3@TX&H0U/!H DS29IN:7- "-4;5)3&%
M$1IIIYIM #**4CFDH&%%&*=B@!M%.Q2X- #**?BDQ0 VBEQ1B@!***#0 444
M4 %%%% !1110!K4444R0HHHH **** "BBB@ K"\0V-Y-<Z7J-E;I=2:?.TAM
MF<)Y@9"N5)X##((S[UNUS?BZ>YC&EP+?26%C<W7E7=U"0KH"K;0&/W06P,^X
M]:3&C 73M=CUM-2?1"L:Z@VHO#%/&># (=B\\R=7/0>A.:Z;PO:7-MIMQ)=P
MM!)=7D]R(&()C5W) ..,XY/N352UT*R@O894\2:K,R.&$4FI%U<^A7N/:NF-
M-:+^O+_(3U_KU_S"BBBD,**** "BBB@ HHHH 2BEI*8@HHHH !UKA/@[_P D
MRTW_ *ZW'_HYZ[L=:X3X._\ ),M-_P"NMQ_Z.>@9W=%%% @HHHH ;THI324
M>$^(O^1FU7_K[E_]"-9E:?B+_D9M5_Z^Y?\ T(UF5YQ^?XC^-+U?YA11108A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (WW&^E?0MO_P >T7^X
M/Y5\]-]QOI7T+;_\>T7^X/Y5O0W9]'P_O4^7ZDE%%%=)](%%%% !12'K24 +
MFDH[44 %%%% !1110 4444 %%%% !1110 4444 %-IU(: $HHHH **** "E
MH I1S0 4N*4"EQ0 F*,4[%+B@!F*,4_%)B@"/%)BI"*:10 RDIQI#0 E%%%
M!112=Z %HHHH **** $HH-% !1110 4444 %%%% "&E%%(* .:^(W_).=?\
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M&XRKHP(8>H(I]<_X'1H_ ^C(P(86J9!%=!525G82=U<****0PHHHH *2EI*
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MS/Q%_P"2<Z__ ->;?TK:T3_D :;_ ->D7_H K$^(G_).M?\ ^O-OZ5M:(?\
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M4AH 9333C3: &TE*:2@ HHHH **** "BBB@ I#2T4 )1110 4444 '>BBB@
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M24 %%%% !1110 4444 %%%% "&B@T4 %%%% !1110 4444 %%%% !2=Z6@T
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M 4444 %-HHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM-- !3J;2CI0
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M%_Y)UK__ %YM_2MC1?\ D :;_P!>D7_H H NT4=J*!A111B@ J*Z_P"/.?\
MZYM_(U+@U%=?\><__7-OY&D]B9?"SP-?NCZ4M(OW1]*6O/6Q^<A1113 ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /0U[GIG_((L?^O:/_ -!%
M>&'H:]STS_D$6/\ U[1_^@"MZ&[/H<@^.?R+5%%%=)],%%%% !1110 4444
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MBI*0]* (6'%1FIB*B8<T --)2TE !1110 444M !BC%*!3@M #<48J3;2[:
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MD"BBB@ HHHH **** &T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]:B4U(M $E+31TI: %IIZ4M(30 QJB:I341ZT ,I*6B@!**6B@ I0**>HH
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MM5_Z^Y?_ $(UF5I^(O\ D9M5_P"ON7_T(UF5YQ^?XC^-+U?YA11108A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 (WW&^E?0MO_ ,>T7^X/Y5\]
M-]QOI7T+;_\ 'M%_N#^5;T-V?1\/[U/E^I)2=Z6BND^D"BBB@ HHHH ****
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M\DZU_P#Z\V_I6SHG_( TW_KTB_\ 0!6-\1?^2=:__P!>;?TK9T3_ ) &F_\
M7I%_Z * +].!IM% $H-&:9FESQ0 ^J][_P >-Q_UR;^1J7-07A_T*X_ZY-_(
MTGL3+X6?/Z_='TI:1?NCZ4M>>MC\Z"BBBF 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%%  >AKW/3/^018_\ 7M'_ .@"O##T->YZ9_R"+'_KVC_]
M!%;T-V?0Y!\4_D6J***Z3Z8**** "BBB@ HHHH **** "DI:* $I:4#D5R\_
MB.\BN9HUB@*I(RC*GH"1ZT =/2BN4_X2>]_YY6__ 'RW^-'_  E%[_SRM_\
MOEO\: .LI<UR7_"47O\ SRM_^^6_QH_X2>]_YY6__?+?XT#.LS3:Y3_A)[W_
M )Y6_P#WR?\ &C_A)KW_ )Y6_P#WR?\ &@1U=%<I_P )->_\\K?_ +Y/^-'_
M  DU[_SRM_\ OD_XT =:*DKC_P#A)[W_ )Y6_P#WRW^-+_PE-]_SRM_^^6_Q
MH ["DKD/^$JOO^>5O_WRW^-'_"57W_/*W_[Y;_&@#KZ<*X[_ (2J^_YY6_\
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M:K_U]R_^A&LRM/Q%_P C-JO_ %]R_P#H1K,KSC\_Q'\:7J_S"BBB@Q"BBB@
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M@#F/B+_R3K7_ /KS;^E;.B?\@#3?^O2+_P! %8WQ%_Y)UK__ %YM_2MG1/\
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M** *U[_QX7/_ %Q?_P!!->;K]T?2O2+[_CPNO^N+_P#H)KS=?NCZ4 +1110
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MK_\ UYM_2MG1/^0!IO\ UZ1?^@"L;XB_\DZU_P#Z\V_I6SHG_( TW_KTB_\
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MIAZT\]*8: (3UIAIYIAH 8>M%.I/PH&)10:* ->BBB@04444 %%%% !24M%
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M%>=7G_'_ '7_ %W?_P!"- $-%%% !1110 4444 %%%% !1110 4444 %%%%
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M 07W_(/NO^N+_P#H)KS5?NCZ5Z5??\@^Z_ZXO_Z":\U7[H^E "T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5)!_Q\P_\ 71?YBHZD@_X^
M8?\ KHO\Q0!Z2>II*4]324 %%%% !1110 E%%% !3A3:6@!PIU,'2ES0 ZD-
M)FB@!II*** "BBB@ HHHH **** .7^(W_).M?_Z\V_I6SHG_ " --_Z](O\
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M$:]!/!%>?7G_ !_W7_79_P#T(T 0T444 %%%% !1110 4444 %%%% !1110
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M_K[E_P#0C696GXB_Y&;5?^ON7_T(UF5YY^?8C^-+U?YA11108A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (WW&^E?0MO\ \>T7^X/Y5\]-]QOI
M7T+;_P#'M%_N#^5;T-V?1\/[U/E^I)11172?2!1110 4444 %%%% !10.E%
M!1110!!??\@^Z_ZXO_Z":\U7[H^E>E7W_(/NO^N+_P#H)KS5?NCZ4 +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4D'_'S#_UT7^8J.I(
M/^/F'_KHO\Q0!Z2>II*4_>-)0 4444 %%%% "44M)0 4444 +FES3:* '9I,
MTE% !1110 4444 %%'>B@ HHHH YCXC?\DYU_P#Z\V_I6QHG_( TW_KTB_\
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M10 4444 07W_ "#[K_KB_P#Z":\U7[H^E>E7W_(/NO\ KB__ *":\U7[H^E
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)!_P ?,/\
MUT7^8J.I(/\ CYA_ZZ+_ #% 'I)^]24I^\:2@ HHHH **** "DI:2@ HHHH
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M I0:2B@!<^M.S3** 'YIN:2B@!1U%>?WG_'_ '7_ %V?_P!"->@#J*\_O/\
MC_NO^NS_ /H1H AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH [CP^?^)%:_1__0VK4SQ61H)_XD=K]'_]#:M,-0!)F@FF;J0M0 ,:
M832DTTT )WI*** #O3A3:<* 'BGBHP:<&XH <:;2$TF:!CQ3UJ('FI :!$HZ
M44U33J "BBB@ HHHH **** )Z*** "BBB@ HHHH **** "BBB@!**6D- !11
M13$%%%% !1110 5R&JRW>M^,?^$?AU&YL;.VLQ<SO:/LE=V;"KNQP !GWS77
MUQVK)>:%XT_MZ+3;J_L[JS%O,MHF^6-U;*G;W!!Q^%+JK_UH_P!1ZV=OZU_R
M,EM4U33_ .V-!>_N+B.PNK7-ZS?O4M92"^YNN0,Y;J <\8XTK36KBVBOK:PE
M:^\^[\G2&FE:0./+4NQ<\M&C%LG)Z8!Z58\.V]TNHZ[XFOK*>U%[L\JV*%I1
M%&N 2HR=QY^7K574-+U*]TV35[FW<W5S-");502T-F) 6B '5B.6 ^]R.0 *
M:[/R_3^OO#3I_7]?Y'5Z=9M86$5O)<S7,B+\\TS%F=CR3[<]AP.@JUVK \,V
MSV[:FT5N]MITMR&LH'C,>Q-BAL(<%07#'&!ZXYK?H8D ZUPGP=_Y)EIO_76X
M_P#1SUKZGX!\,ZSJ<VHZAIGG7<^WS)//D7=A0HX# = *X?X:^!_#FO\ @6RU
M+4].\^[EDF#R>?(N0LK*.%8#H!VI#/7**X__ (5=X-_Z _\ Y-3?_%T?\*N\
M&_\ 0'_\FIO_ (N@#L**X_\ X5=X-_Z _P#Y-3?_ !='_"KO!O\ T!__ ":F
M_P#BZ .PHKC_ /A5W@W_ * __DU-_P#%T?\ "KO!O_0'_P#)J;_XN@#S;Q'_
M ,C/JO\ U]R_^A&LRO7/^%7>#?\ H#_^34W_ ,71_P *N\&_] ?_ ,F9O_BZ
MY_8>9\]4R+GFY>TW\O\ @GD=%>N?\*N\&_\ 0'_\FIO_ (NC_A5W@W_H#_\
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MU%<C_P *P\'?] ?_ ,F9O_BZ3_A6'@[_ * __DS-_P#%T =?17(_\*P\'?\
M0'_\F9O_ (NC_A6'@[_H#_\ DS-_\70!T]]_R#[K_KB__H)KS5?NCZ5T?_"L
M/!W_ $!__)F;_P"+H_X5AX._Z __ ),S?_%T <[171?\*P\'?] ?_P F9O\
MXND/PQ\&@9_L?_R9F_\ BZ .>HK>_P"%9^#O^@/_ .3,W_Q='_"L_!W_ $!_
M_)F;_P"+H P:*WO^%9^#O^@/_P"3,W_Q='_"L_!W_0'_ /)F;_XN@#!HK>_X
M5GX._P"@/_Y,S?\ Q='_  K/P=_T!_\ R9F_^+H P:*WO^%9^#O^@/\ ^3,W
M_P 71_PK/P=_T!__ "9F_P#BZ ,&BM[_ (5GX._Z _\ Y,S?_%T?\*S\'?\
M0'_\F9O_ (N@#!HK>_X5GX._Z __ ),S?_%T?\*S\'?] ?\ \F9O_BZ ,&BM
M[_A6?@[_ * __DS-_P#%T?\ "L_!W_0'_P#)F;_XN@#!HK?'PR\''_F#_P#D
MS-_\72_\*P\'?] ?_P F9O\ XN@#GZD@_P"/F'_KHO\ ,5N?\*P\'?\ 0'_\
MF9O_ (ND/PQ\'_\ 0(_\F9O_ (N@#KCU-)7(_P#"L?!__0(_\F9O_BZ/^%8^
M#_\ H$?^3,W_ ,70!UU%<C_PK'P?_P! C_R9F_\ BZ/^%8^#_P#H$?\ DS-_
M\70!UU%<C_PK'P?_ - C_P F9O\ XNC_ (5CX/\ ^@1_Y,S?_%T ==25Y7X[
M\&>'] T6SO=,L/(N/[1MDW^=(WREQD89B*]5/4T )1110 4444 %%%% !111
M0 #DUQ5K!?>+)-2OAK5]9107#P6L5I)L4;>[\?-DUVHX.:XBRN+_ ,*2ZEIX
MT6^O4GN'GM)K:/<AW]G/\.#2'T(K379M3T_2'U2[>VM-TT5W<QRF$-*G"_,I
M!&>N,C-7[*_U'4=,LM*661+V52]S<='B@W':?]]AC'YU8T>UNO#7A&.,VK3W
M[LSF&(%AYCG."1_".YJG=Z*;.>PDU"!]0MY&DDO]D+2[YBORG8 25'0<<=>*
MI[B6QV"*$14!8A0 "QR?Q)ZFEK+\.P75MH-K%>;O.4-PQR57<=H/N!BM&6))
MX9(I!NCD4JPSU!&#0]Q(YOXC?\DYU_\ Z\V_I6SHG_( TW_KTB_] %<#XS\
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MKHKU3_A6?A#_ *!'_DS+_P#%T?\ "L_"'_0(_P#)F7_XNCV'F'^KW_3S\/\
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M_P *R\)_] C_ ,F9?_BZ3_A6OA+_ *!/_DS+_P#%4 8]%;'_  K7PC_T"?\
MR9E_^*H_X5KX1_Z!/_DS+_\ %4 ;FA?\@.U^C_\ H;5H5R?_  K7PC_T"?\
MR9E_^*H_X5KX1_Z!/_DS+_\ %4 =9FBN3_X5KX1_Z!/_ ),R_P#Q5'_"M?"/
M_0)_\F9?_BJ .LI*Y3_A6OA'_H$_^3,O_P 51_PK7PC_ - G_P F9?\ XJ@#
MJJ*Y7_A6OA'/_()_\F9?_BJJ?#2".UT[Q#;0KMA@U^[BC7).U5"*HR>>@% '
M:THI** '"ES3:* %HS244 .!J1340IPH F!IX-1#I3@: )**:#2YH 6BDS29
MH =32:0FFDT 7**** "BBB@ HHHH **** "BBB@ I#UI:0T %% HIB"BBB@
MHHHH **** "BBB@!#24ZFTAA4%G8VFG6JVMC:P6MNI)6*",(@R<G ''))-3T
M4 %%%% !1110 4444 %)2T4 )1113$%%%<_+XW\.PRO%)J.'0E6'D2<'_OFD
MY);LBI5ITU><DO70Z"BJ6F:M8ZQ;-<6$_G1*VPML9>?Q J[3'&<9KFB[H***
M*"A#TI*=3: "BBB@ HK,U'7;/39/+E):3 )4.B8STR791GVSGVJY:7<-[ )H
M6)7)4@C!4CJ"/6DFGL0JD7+EOJ3T444RPHHHH *2EI*0!1110,**** "FR1Q
MS1/%*BR1NI5T89# \$$=Q3J* (K>W@M+:.WMH8X((E"QQ1*%5 .@ ' %2T44
M %)2T4 %%%% !1110 4U_N_C3J:_W?QH CHHHH ***J:?J$6I6[30JZ;9&C9
M)  RD'!SB@"W156UOXKNYNH8U?-M)Y;L0-I;&>.:M#DXH **S]'U/^U;22?R
M?*V2M'MW;L[3C/05:EN/*N((?)F?SB1O1<JF/[Q[4 34452CO]^LSZ?Y6/*A
M67S-W7)Z8Q0!=HHHH **** '+WIU-7O3J "D-+1VH ;1110 4444 %%%% $%
MU96M]$L5Y;0W$:N'"31AP&'(.#W'K4]%% "4444 %%%% !1110 4444 %%%%
M !1110 4444 17-M!>6TEM=01SP2#:\4J!E8>A!X(IZ(D4:QQJJ(@"JJC  '
M0 4ZB@!#12TE !1110 4444 %%%% !2&EH/- #:**RM1\2:3I5S]GO;ORI=H
M;;Y;MP?H#2;2W)G4A37--V7F:M%9>F^(M*U>=H+&Z\V15W%?+9>/Q K4IIWV
M"%2%1<T&FO(****"PHHHH 2B@]:* "ES[54OM0@T^(23M][[JC&3Z]< #W)
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M*** $HI:2D,**** "BBB@ HHHH **** #M11VHH **** "FO]W\:=37^[^-
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M)K'BU31[;6=#DCO3*L(F:ZG,;@M(X'.,9Y/Y#%4U[UB5\-SL-5U6WTBT^T7
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MNO)KS_P_%+K?C277H+)[6P$9 9UQYA(Q^)]<>E:UIX$TJSU2/4(Y[PRQR>8
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M10 4444 %%%% !1110 4444 %)WI:#TH ;1110 4444 %%%% !1110 4444
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M->E2+0 ZEIHIU !1113$%%%% "&D-*:0TAD9[U$W6IFZU"W6@!A[TE*>])0
@4444 %%%% !BE[4HI10 F*,4X4M #<4F*?2'I0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image3.jpg
<TEXT>
begin 644 image3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,4!B@# 2(  A$! Q$!_\0
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MHH **** %I13:6@"04M-'2ES0 $TPTI--H 2BBEH 2EI0*4"@!M+@T[;2XH
MB(HQ4A%-(H 9BDQ3Z0CB@!E%+BDH&%%%% !0>E%!Z4 (*>*8*<* )!3Q40-/
M!H$244W-&: %-1D\4XFF$T (:C-/)XIA]* $HHHH **** "BBB@ HHHH ***
M* 'J:D!J$5(.E $HIU,!IU "T444Q!1110 4T]*6FDTAC3UJ-NM.)J-CS0 T
MT444 %+BE%. H ;BC%28HQ0!'@TX+3MM+0 @6EV^U. IV* (\>U-*U-BFD4
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MUIU(!2B@ Q3J*<!0 VBG8HQ3 9BFD5(:::0#*2G'K3: "BBB@ HHHH ****
M"BBB@!#12TE !1110 4444 %%%%  .M+2"E[T *.E24T=:<.M #A2T44Q!12
MT4AB44M)3$-(IIZ4\TP]*0QAZTPT\TTT ,HI324#"BBB@ IM.IM @HHHH 7-
M&:2B@!<TE%% !12]J2@ HHHH ***4"@!**?BC;0 RBGXI"* &T44HH <!3A2
M+3Z $HI:2@ I,TTFFYH DW4FZF9-)0 [=3<T4E !2=Z6D- !1110 M.S3:*
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MVJ/1]4@UK2H=0MDD2&7.U9  PP<<X)JEXV_Y$K5O^O<U5^'_ /R)&G_\#_\
M0C0M;@WL:6NZ]:^'-.%[=QS/$7"8A4$Y/U(KG/\ A:VA?\^FH_\ ?M/_ (NN
MVS7)?$L_\41<_P#76+_T(4F[#M<K_P#"UM"_Y]-1_P"_:?\ Q==9I6IPZSI=
MOJ%NLB13C*B088<XYP3Z53\,'_BE=+_Z]EK4S5-6;1,7=)G'ZA\1]'T_4+BR
MEMKXR0.4<I&F"?;+57_X6GH?_/KJ'_?M/_BZ[>O/-%_Y+!K'_7,_^@K26]AO
M:YMZ+X[TO7=4CT^U@O$FD#,#(BA>!GLQKIFW%&V8W8^7/3-+10P.<\)^(KC6
MDOK;4(HH=0LIBDJ1 A2.@(R2>H_E71UY_*W]B_%Z,K\L.IP@..Q8C'\PM>@4
M;I,-FT%%%% "4444 %%%% !1110 9I:2B@!^:,TW-&: '9--)HS2&@ I***
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M,4=17C^F7&NVWCOQ V@V4%U.96$BS, %7<<$?,M>P#J*\W\%?\E&\3?[Q_\
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M? OQ"TVZLHS%I]R A7<6P#PPR>>N#7K'49'(-5NDR=FT>:_%A2W]AHK%2T[
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M&BEI* "BBB@ HHHH **** "BBB@ HHHH 2BBB@ HHHH **** "BBB@ HHHH
M*<*:*<* 'J*D IBBI!TH >!2T44 (>165.YT^_2Z _=GY9!_LG_#K6M5>[@$
MT1!':@"\"& (((/(([TM8VD79BD.GSD[ER82>X]/P_E]*V: &NH=&1AD,,&F
MP0I;PK&@X Z^M245'LX\_/;78+] HHHJP"BBB@ HHHH **** "BBB@ HHHH
M***PM?U A1IUNW[Z4?O"/X$_Q/\ +\* *<D_]J:LTZG,$7R1>X[G\3^@%:(&
M!BJUE;B"$ #'%6J!A1110 4444 :E%%% @HHHH **** "BBB@ -)2TE !111
M3$%%%% !1110 4444 (>M)3J;0 4444 %%%% !1110 4444 %)2TE(84444
M%%%% !1110 4444 %'>CO10 4444 %%%% !1110 AI*<:;0 4444 %%%% !1
M110 4444 %4)M#TFYF\Z?2[*64_QR6Z,WYD5?HH :B+&@1%"JHP%48 IU%%
M#)8HYXS'-&DD;=5=<@_A5*'0M'MI1+!I5C%(.CQVZ*1^(%:%% !33UIU!H ;
M0*7%+0 F*KPZ?9V]S+<PVD$<\W^ME2,*S_4CD_C5FEQ0 E%+BC% $4]O#=0/
M!<0QS0N,-'(H96^H/6E@AAM8$@MXHXH4&$CC4*JCV Z4_%% $%W96FH1"*]M
M8+F,'(2:,. ?7!%3* J!5 50,  8 %+FFT 17=G:7\/D7EM#<19SY<T8=<^N
M#4JA41410JJ,  8 %%'>@!'C26-DD571@596&01Z&H[6SM;& 06=M#;Q Y$<
M*!%S]!4]*!0!6NK"SOO+^V6D%QY9W)YT8?:?49Z&I\"GT8H J+86B7K7BVD"
MW3C:TXC&\CT+=:LTN*6@"M::?96'F?8[2WM_,.Y_)B";CZG'6K0%*!2BF(K7
M>G6.H!!>V=O<B,Y031!]I]1GI5@*%& , < "G44AE:[T^RO_ "_MEI!<>6VY
M/.C#[3ZC/0U/BG44 4Y=.LIKN.[EL[>2YB_U<SQ*73Z-C(J8BI33#0!$Z*ZL
MCJ&5A@@C((J"ULK2QA\FSM8;>,G.R&,(,^N!5HTR@!**** "F2Q13Q-%-&DD
M3C#(Z@AA[@T^B@#-_P"$;T+_ * NG?\ @*G^%36NCZ78SB:TTVSMY0,"2*!5
M;'U JY2T /!J#[#9_;OMWV2#[7MV^?Y8\S'INQG%24N: ),U6ETZQN+N.[FL
MK:2YC^Y,\2EU^A(R*FS2YH =FH+JVM[V P75O%/"3DI*@93^!J3-)F@#,_X1
MW0L_\@73O_ 5/\*OQQQPQA(T5$'15& *?24 -/O364.I5@&5A@@C@BG'K24#
M(+6SM;&'R;.VAMXLYV0QA%SZX%3T44 %%%% %:[TZQOP/MEG;W&WIYT2OC\Q
M1:Z?96((L[.WMP>HAB"9_(59HH 0]*2G4G>@"M'8VD-U)=16L"7$O$DRQ@._
MU/4U8HHH$036-I<7$5Q-:P23P\Q2/&"R?0GD?A4]%% %:ZT^ROBAN[.WN/+.
M4\Z(/M/MD<59HHH !44]C9W4T4UQ:032Q',;R1AF3Z$]*EIPH DS3U-1@TH-
M $N:6F T9H X7XE6$T<-AXAM%)GTV4,^/[F>OX&NRLKV+4+"WO(3^[GC#K[9
M[58)II.:%HK ][D4T,5Q \,\:2Q.,.CJ&5AZ$'K4<%O!:P+!;0QPPI]V.-0J
MCZ 5,324 -Q45Q:6]Y T%U!%/"W6.5 RG\#5@"EQ0,ABACAB2*)%CC085%&
MH] *?C%2 4N*!$.VJZV%I'>/>):P+=.,/,(P'8>[=35W%)B@"*FLRHC.YPJC
M)/H!4I%-Q0!P7@J)M9\0ZMXHE4^7*YAM<_W>F1^ 'YUW=+2=J.B0=;A1110
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MBZ9%96V2J<LQZNQZDU?K7H;X6%2G1C&H[R6X4PBGTAH.@B(J(CFICU-1-UH
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M!M%%% !1110 4444 %%%% !1110 E%!HI#"BBB@ HHHH **** "BBB@ I<4
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M>U.IM PHHHH$%%%% "@T\&HZ4&@"8&G U"&I^: ),T9IF:-U #\TA--S29H
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M'%/'2@!XI>](M**8A:***0PI#2T&@!AIAZT]J8>M ##UI.U./6F'I0 E%%%
MPHHHH ***2@!XIP-1YIP- B0&G5$#3LT /S1FFY%&10 ZD)INX4W- "DUSGC
MC_D5+K_>3^==#5:^L;?4K1[6[C\R%\97<1G'N.:BI%RBTC.K!SIRBNJ9BZ]9
M&^\&A4_UL4$<L?U4 US-UJLVI7UCK4+;H=.2+S?0LQPV?3IFO1! H@$( \L)
ML"^V,8K.@\.Z9;6-Q90VJK;W'^M3>QW?CG(_"IG!N?,O7YG)7PDZEN5VTL_E
MJOQ.9CT\>(K77[]3N,S[+9NHPG(Q^-)8WA\3:GHD)^[9Q^;<KZ.O !^M=E9:
M?;Z=:I:VD0CA3.%R3^IYK*\/Z!)I5SJ%S,(!+=2[E$1)"KUQR!25.TDNGZK_
M (<AX6=XWZ_%]_-^>GHS#L](M=5O?$1NS*ZQ392,2%5#8)W8'4_6JLVI7W_"
M!:?B21C)/Y+N'VL5'0;NV>F:[F#2[6U>Z>&(*UTVZ8[B=QZ=^GX5''HEA'IO
M]G+;(;3)/E,2P_7FDJ34;>2_ <L'+5Q=F^;7U=U]W_#'+Z/9W^G:VK0Z7_9U
MK)"^^$WJS"1@,A@,Y_*JEI86>I^&[S6K^>0ZBC.?.\UE,)'0 9P*Z_3O#NF:
M3*TME:)%(1C?N+'\"2<5%-X4T6>\^U2:?$9B=Q.2 3[KG!_*FZ;:MY?=Z$1P
M4U!)I/5Z/;IVBMO3KOU*=C9RZUX>TZYN)"MWY7+.I(<9Z, 03T!ZBM+3=+33
M][EP\K]2 0JC).%!)(&3GJ:T!'M4*H 4#  Z 4NP^U:V5[G;3H1BDWJTEJ-H
MIVP^U(5(&:9N)1110 4444 . I^!35J04 )BC%/Q32.* (V%,J1J8>M #>]+
M244 +3@:92T 2;J7-1YHS0 \M32>*:310 4E%)0 4444 %.3[XIM.3[XH EH
MHHH *P[?&F^*;R%R%@OXOM*9/ =.''Y8-;E9>MZ-_;$,*K<&WDB8D2*NX[2"
MK+U[@T 9<-^VF^&;[7C'NGO)#,H;^Z3LC!]L8/XU5T[Q')_:UE =7CU%;J3R
MY(UM3$82>A4XY&>.:Z>[TVVO-+;3G0BW,8C 4\J!TQ[C JG::7J,5S&]WK4U
MS#$<K$(ECSZ;B.6IJUP>QA:;%JL@UM["]BM8XKV5\F(.SMZ'/ 'OUK0.M75Q
MI7AZ\C(B:]NHXYE !!!R".>G2M*PTG[#%J">?O\ MD[S9V8V;AC'7FJT7A[R
M],TBS^U9_LZ=9M_E_P"LQGC&>.OO273Y?\$'N_G_ , @$^K:Q?WPL+Z.SMK.
M7R5_<B0RN!DYST';BI%:2/Q;$]QM\Q=))DV=,AUSCVS3Y]"N5O[BXT[5)+)+
MD[IXQ$K@MTRN?NFK<6E^7JD5Z9VDV6?V4JXR6Y!W$^O'IWI=/Z[,??\ KJ<A
M_P )?<-;_P!H#581)G<--^S'!7/0R8ZX_"N]1Q)&KJ"%90PSUY&:PH_#UY;)
M]EM-:G@T\$[8%B4N@)S@/U K?]JKH+J%%%%(".7^&HZDE_AJ.@!M%!ZT4#"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH UJ*
M**9(4AZ4M% #:*#1VI#"BBB@ HHHH **** "BBB@!**6DIB"BBB@ HHHH **
M** "BBB@!M%'2B@ HHHH **** "BBB@ IDG:GTR3M0!'1112&%%175Q':6DU
MS*<1PH7;'H!FH]/EN)]/@FNE19I$#,J @+GG'-*^MB>9<W*6:***9045FZEJ
M%[;2K%8Z5+>R%=Q/F+&@'IN/4^PJ*W\06TNB3ZG+')"+<LL\3<LC XV_R_.I
MYUKY&?M8*7*]_P"NNQKT5@6_B&Z^V6T5_H\MG#=MM@E,RODXS\P'*\5-J7B"
M.PO(;:.VDG+7"02.#M2,MTY[GO@?I1SHA8BFXN5]%Y,V:*HZM>OIL$5P AA$
MRI.6SD*W&1]#C\*O?2FG<VYES<O4****8R1/NTZFI]VG4 %%%% #:*** "BB
MB@ HHHH 44M-I<T +124E #C3:** "BBB@ HHHH *;3J,4 -IO>GFF=Z "BB
MB@ HJA?7LD%Y8VD 0RW#G.X9"HH^8_7I5^@ HHHH **QO^$@CDUFWL8;=WCF
M++]H)VKE>NT8^;ZUI7MW'8V<MS+]U!P!U8]@/<FCI<.MB>BLG3-;:_TN>\:R
MD1X79#!&=[$CTX%16^N7/]HP6>H:6]F;G/D/YJN&([''0T ;=%4(KY_[:N-/
MF51B-986 ^\O0Y]P:OT %'>BCO0!,1333J* (S25(13"* $HHHH **** "GB
MF4X&@"0&G4RG TQ#J*2BD,6D[T4A-,0A-,/6G4PTAC>]-/2G=Z2@!M%*124#
M"BBB@ I#UI:#0 E**2EH 4&G4T"G4""BBDQ0 4444 %%%% !15&UOGNM4O($
M">1;!4+?Q&0\G\ *O4D[JXHR4M@HHJ&ZG-M;23+#),RCB.(99O84-V&W97)J
M*Q;+7+I]3CL=1TN2QDF!,#&99%?'8D=#[5#<>([CS9S8Z1->6MLQ6:=957!'
M7:#RV*7/$P^L4^7FU^YW^ZUSH**R+K7HH[.SELX'NYKT9MX4(!;UR3P .YI=
M,UB:^FN+.YLFLK^)-_E.XD4J>A##KS1S*]BO;T^913W^[[]C6HJCI%\VH:>L
MTBA9E9HY5 ( =3@XSVJ]5;ZEQDI*Z"FO]VG4U_NT%#**** "BBB@!XIXJ(&G
M@T 2 TA--R*3=Q0 &H^]*324 (:*.]% !1110 4444 !I*6C% "44M+0 F*2
MG44 -IR??%)BE3[XH EHHHH **/K7/Z5?1QZ1J.NSJS"6623Y1R8T^50,_0_
MG0!T%%8D'BFPGN+>,1W217#!(KAXL1,Y_A#>OZ>]2WFN?8[M[?\ LK4Y]F/W
MD-ON0\=CF@#6HK.CN[K4M/9[.&6RE,FS_3(L,HXRP7OUX]ZI^%)9Y;"\$\\L
M[1WTL8>5LG QC_\ 4* -VBN0\2:A=RB2>SN)8;6SGCA+1L5\V5F&X<=0HX^I
M]JW]:NI8D2SLSB\NV,<1_N#^)S[*/UQ1TN'6QH45S>A1/J?AF_M+J:6?-Q/
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M-)3CUIM !1110 4HZTE% #P:<#40.*<#0!)FES3,T9H ?FDI**8!3>].HQ2
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MX_Y*'_Y18/\ &@#M:*XG_A&?'/\ T4/_ ,HL'^-'_",^.?\ HH?_ )18/\:
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M_P I4% 'KIJ)OO'ZUY/]K\<_]#I_Y2H*3[3XX_Z'/_RE04 >L45Y-]H\;_\
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M#3_Y3X?\*/:P[A_:^#_G_!_Y'NM%>%?\)3XW_P"AI_\ *?#_ (4G_"4^-_\
MH:?_ "GP_P"%'M8=P_M?!_S_ (/_ "/=J*\)_P"$I\;_ /0TG_P7P_X4?\)3
MXW_Z&D_^"^'_  H]K#N']KX/^?\ !_Y'NU%>$_\ "4^-_P#H:3_X+X?\*/\
MA*?&_P#T-)_\%\/^%'M8=P_M?!_S_@_\CW:BO"?^$I\;_P#0TG_P7P_X4?\
M"4^-_P#H:3_X+X?\*/:P[A_:^#_G_!_Y'NU%>$_\)3XW_P"AI/\ X+X?\*/^
M$I\;_P#0T_\ E/A_PH]K#N']KX/^?\'_ )'NU%>%?\)3XW_Z&G_RGP_X4?\
M"5>-_P#H:?\ RGP_X4>UAW#^U\'_ #_@_P#(]UI",BO"_P#A*O&__0T_^4^'
M_"C_ (2KQO\ ]#3_ .4^'_"CVL.X?VO@_P"?\'_D>XD4E>'?\)1XW_Z&G_RG
MP_X4?\)/XV_Z&G_RGP_X4>UAW#^U\'_/^#_R/<:*\._X2?QM_P!#3_Y3X?\
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M'(H [_%&*X[_ (1GQO\ ]% _\HT/^-'_  C7C;_H?_\ RC0_XT =C3P*XO\
MX1KQM_T4#_RC0_XTX>&?&_\ T4'_ ,HT/^- ': 5(!7$CPSXX_Z*#_Y18?\
M&G?\(SXY_P"BA_\ E%@_QH [7 I:XK_A&?'/_10__*+!_C63K%IXYTF2%/\
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MJ* /G9OO'ZTE*WWC]:2O-6Q^=2W84444Q!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'H'PK_X_M4_ZYQ_S:O3J\Q^%?\ Q_:I_P!<X_YM
M7IU==#X#[3*/]SA\_P V%(>M+FFUL>F-/6FTXTVD AI*=CBD(H 2BBB@ HHH
MH 4=*<M-!I: 'BN-\8?\A2W_ .N'_LQKL0:X[QA_R$[?_KC_ .S&@#GJ***
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M?^:TQ'-T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;J]TR.2<G+.K,A8^^TC/XUK6EI;V%K';6D*0P1C"1QK@"DMALFHHHH ****
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M*FH?]A>[_P#0Z[ZN ^$G_(JW_P#V%[O_ -#I@=YVIAIQZ4PFD E-/2EIIZT
M%%%% S)\4?\ (K:G_P!>[5XK7M7BC_D5M3_Z]VKQ6N6O\1\KG_\ &AZ?J%%%
M%8G@A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>AHH/0
MT >YZ9_R"+'_ *]H_P#T$5:JKIG_ ""+'_KVC_\ 015JN^.R/T2G\""E%)13
M+)%IXJ(&G T 2@TN:C!I<F@!^::32$TTF@!:*9FC- $H-/S4(-.!YH DKD_&
M/_'S9?[C_P UKJ\URGC#_CXLO]Q_YK0!S=%%% !1110 4444 %%%% !1110
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MWWC]:2E;[Q^M)7FK8_.I;L****8@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#O_A;_P ?FJ?]<X_YM7I@KS3X6?\ '[JG_7./^;5Z8*ZZ
M/P'VF4?[G'Y_FQU%% K8](**** "BBB@ IIIU(: (R*2G&FTAC>]%*:2@ KD
M/%O_ "$;?_KC_P"S&NOKD/%O_(1M_P#KC_[,: ,"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ J2#_CYA_P"NB_S%1U)!_P ?,/\
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MBK-=\=D?HE/X$%%%%,L*4&DHH ?NHS3** 'YII-)29H 6BDHH >#3P:BI<T
M39KEO%_,]E_N/_-:Z0-7->+#F6R_W7_FM '.T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &UX8_Y"4W_ %[G_P!"6NHQ7,>%
M_P#D)S?]>Y_]"6NI(H 8:2G$4V@84444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %20?\?,/_71?YBHZD@_X^8?^NB_S% 'I!ZFDI3U-)0
M4444 %%)FEH 44\"FBG"@!:0CO2T'I0 VDS0>E-H =FC--HH =FC--HH 4'D
M5P?PH_Y%:^_["]W_ .AUW8ZBN$^%'_(JWW_87N__ $90!W1--HHH&%%**,4
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M:***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 :U%%%,D****
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M!-)D<1CNHYRW3/2MJCH'4**** "BBB@ HHHH 2B@T4Q' ^,/^2H_#S_KK?\
M_H@5WU<#XP_Y*C\//^NM_P#^B!7?4 %%%% !1110 4=Q]:*!UH ^=6^\?K24
MK?>/UI*\U;'YU+=A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 =]\+O\ C\U3_KG'_-J]*KS7X7?\?FJ?]<X_YM7I5=='X#[7*/\
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MS_-A1116IZ04444 %&:0TE "YI*7%&* $HHHH **** "N0\6_P#(1M_^N/\
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MEBBGK4=2"@!XJ0=*C%/% #J***8A*::=49I#&MTJ,T]NE,- #:YOQ5_K;/\
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MB@ HHHH **** "BBB@ H/0T4'H: /<],_P"018_]>T?_ *"*M55TS_D$6/\
MU[1_^@BK5=\=D?HE/X$%%%%,L*<#3:44 2@T\&H5-/!H ES1FH\T$T .)IA-
M!-,)XH &-,I2<TE "5S?BK_6V?\ NO\ S6NDKF_%7^ML_P#=?^:T <_1110
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M^/F'_KHO\Q3*?!_Q\P_]=%_F* /3VZTPT]NM,- #33:<:;0 4444 %%%'>@
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MK_S6NDKF_%7^ML_]U_YK0!S]%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@ HHHH *#T-%!Z&@#W/3/^018_P#7M'_Z"*M55TS_ )!%C_U[1_\
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M='X#[7*/]SA\_P V%%%%:GI!1110 4444 %-IU(: $HHHH **** "N0\6_\
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MW$/2D[TX]*;4E!1110 4444 %%%% ' ^,/\ DJ7P\_ZZW_\ Z(%=]7 ^,/\
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MIS6B*"=[DLI&>.@">O5C7053_K[_ .F2E;^O(*:>M.I#ZTAB44=C12&%%%%
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M ,(E?_\ /:V_[Z;_  H_X1*__P">UM_WTW^%=G13$<9_PB5__P ]K;_OIO\
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M#[7*/]SA\_S84445J>D%%%% !1110 4444 %(12T'I0 VBBB@ HHHH ****
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M444 %%%% !1110 A%)3J;0 4444 %%%% !1110 4444 %%%% !1110 4444
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MM%%% @HHHH **** "B@=:4]: $HHHH **** "BBB@ HHI10 X"I *:*>* '
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M /(JWW_87N__ $.@#N:*#UHH **** "BBB@ HHHH 0TE.Q24 )1110,****
M"BBB@ HHH- "4444 %%%% !1110 4444 -[T4II#UH$%%%% !1110 4II**
M"BBB@ HHHH **** "E%)2K0!(.E2+48Z5(M #A2CK2"E[TQ"FDI324 %%%%
M!24M)0 P]*C:I#TJ-J0R,]:2E[TE "&BEI* "BBB@ I:2B@!U+DTRES0 [)H
MR:;10 M(:*2@!**** "BBB@ HHHH 44X"FBI%'- #@*D"T@ZT\4 &*6BEH 2
MDQ3J2@!A'-,(J4]*810! 1@TTU(XYIAH C-%*?ZTE PHHHH UZ***!!1110
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M1110 4444 %%%% '??"[_C\U3_KG'_-J]*KS7X7?\?FJ?]<X_P";5Z5771^
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MA2-R @;K@# S3JV<M//[C3'SI2H+DE_+97\M=.FOWF511169XH4444 %%%%
M!1110!WWPN_X_-4_ZYQ_S:O2J\U^%W_'YJG_ %SC_FU>E5UT?@/M<H_W.'S_
M #84445J>D%%%% !1110 4444 %%%% !1110 4VG4WH: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ;12GK24 %%%% !1110 4444 %)2TE !1
M110 4444 %+B@4[% #<<4E/I,<T -HHHH **** %'45PGPG_ .15OO\ L+W?
M_H==V.HKA/A/_P BK??]A>[_ /0Z .ZI#2T4 )1110 M**2G"@!0*7% IP%
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MYS36P/<NT4=Z*!!1110 4444 %%%% !0:** &T44=J0S@?&'_)4OAY_UUO\
M_P!$"N^K@?&'_)4OAY_UUO\ _P!$"N^H **** "BBB@ H'6B@=: /G1OO'ZT
ME*WWC]:2O.6Q^<RW84444Q!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '??"[_ (_-4_ZYQ_S:O2J\U^%W_'YJG_7./^;5Z5771^ ^URC_
M '.'S_-A1116IZ04444 %%%% "&EH%% !1110 4444 %'6BB@!M%!ZT4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "&DIU-[T %%%'>@ HHHH ****
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MR*9NI: '9HQ2"G4 )BC%.Q2XH 9MHVT^B@"(BBI,44 6**** "BBB@ HHHH
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M$D-!YPEP.QW#CFKE%% !1110 4AZ4M!H ;1110 4444 %%%% !1110 4444
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M&G@U%2YH ES1GBH]U&Z@!Q/%,)H)IIZ4 (:2E-)0 4O>DI: 'CK3P:C!IP-
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MHH **** "BBB@ HHHH **#10 4444 %(>M+2&@!**** "BBB@ HHHH ****
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M%,6I!0 \4ZD%** %I*6D-,0TTP]*D/2HZ0R(TE*U)0 E%%% !1110 4E+0:
M$HHHH **** "ES244 +FC-)10 M)110 AHI:2@ HHHH 6ES3:6@!<T9I*2@!
MU.!YIM*.U $P-.!J)>M/% $N:*9FES0 ZBFYH)H =FBF$T4 6J*** "BBB@
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M4M8>G&I[1*SM8****9L%(:6CM0 VBCM10 4444 %%%% !1110 4444 %%%%
M!1110 4444 (:2G4V@ HHHH **** "BBB@ I*6B@!**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!**#10 4444 %%%% !1110 'I3:<>E-H&%%%%
M !1110 4444 %)2T4 )1110 4444 %%%% !45Q&\UM+%'(8W="JN.JGUJ6BD
MU=6 XV7P_P"*[R)K*ZUR!K)QM8A/G(_[Y!_\>K4U'PM'<^%H]&M9?+,)#1R/
MW8')S]:WZ>*ETXM-/J<D<'2C>]W=6U;>G8YI/#NIZAX:N-,UG4(Y9F*^2\:Y
M"!>F>!FLN;P=XAOM)^Q7NL0ND( MX5R$X_O';DX'UKO%-.H=.+>I,L#2DDG?
M16W>J\^YR^N>%;C4K+39+2Z6#4+%%5'.=IP!WZCD>E4SX3UJYU+3M1U'5(KF
MY@F#.N-J*@[* O)_ 5VM(:;IQOS>=PE@J4W=WZ=7TVT.)^)-O'_9EK>+)LN8
MY=L>.I!Z@?SK>\/:>-,\/V5J  PC#N<?Q-R?\/PJUJ.D6&J^2;V#SO);<@+L
M #] >?QJVU*$.5R?<J.'MB77?9+_ #_0P_$N@KKU@D(E\F:)]\4F,X/O6-!X
M8U>^OK:;Q!J4=S%:MNCBB'WC[G _J:[.DVT<BO<=3"4JL^>7YZ/U74YG5M.\
M1M?RSZ3JT44,A!,4RYV\=CM;^E2>'O#IT9KBYN;@W-]<_P"LDQP.^!^/>NA*
M\4W%-02=Q_5:?M/:.[?J[+T0QU5T9&&588(]17%#PGK=DL]EIFK1Q:;.Q+(X
M^8 ]<<'MZ$9KM\4E*4%)W8ZV'A6MS7NNJ=F82:!-8^'HM.TN]:WGC<2>?M^^
MW?(]#^-9@\+ZSJMU"WB#5(YH(6W+% N-W_CJX_(UV%%-P3=R)X.E)).]EI:[
MM\UU) ?;'M2YJ/-&:HZB3=1FF9I,T .+4TG-)24 %%%% "TH%)3U%  %IV*4
M"G@4 ,VTA6I<4A% $!6FU,149% #*2EI* "BBB@ HHHH **** "BBB@!****
M "BBB@ IW>FTX=: )%IXJ(=*E% "XIIZ&ES2-TH C:FFE;K3: $-&:0_UI*
M%S1244#->BBB@04444 %%%% !1110 4444 %%%% !24M(: "BBBF(**** "B
MBB@ HHHH **** $(I*<>E-I#"BBB@ HHHH **** "BBB@ I*6DH ****8@HH
MHH **** "BBB@!#24IZ4E !1110 4444 %%%% !1110 4E+24AA1110 4444
M %%%% !1110 =Z3O2T4 %%%% !1110 4444 (:2G4V@ [T444 %%%% !1110
M 4444 %%%% !1110 4444 %(>M+2&@!**** #M11VHH **** "BBB@!****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#12TE !1110 4444 %%%%
M!2=Z6D/6@!****!A1110 4444 %%%% "44M** &T4[%+B@!E%.Q24 )1110
MM*#3:6@"0&G U&#2YH$2YHJ,&G4 *:2E'-+0 S%)MJ2C'M0!'MI,5+CVI,4
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MT444 %%%% !2&EHH ;1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-,-*3S3* "BBB@ HHHH **** "DI:* $HHHH **** "BBB@ HHHH *.U%+0
MHJ4"HQUJ4#F@!P%.H I10 4444Q!1110 E-(I]-/2D,B(J-AS4QJ)NM $=)2
MFD[T %%%% !1110 4444 %%%+B@!**7%% &I1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 (:***8@HHHH **** "BBB@ HHHH **** &T444AA11
M10 4444 %%%% !1110 E%%% !1113$%%%% !1110 4'I110 VBBBD,****8@
MHHHH **** "BBB@!****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M0]*** $HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $-)110 4444
M %%%% !1110 4AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!**** "BBB@ HHHH **** $-)110,**** "BBB@ I<T44 +3>]%% @I***!A
M1110 4444 %%%% ""E%%% #Q2T44"%!IU%% "'I2$FBB@!*::** &'K2444
M%%%% !1110 4444 %%%% "4444 %%%% !1110 4444 %+110!(M2+UHHH ?2
MBBB@ HHHIB"BBB@ I***0R-JC?O110!&:;110 4444 %%%% !2T44 *****
'%HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image4.jpg
<TEXT>
begin 644 image4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,5!B@# 2(  A$! Q$!_\0
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MHH *2EI* "BBBF(**** "BBB@ HHHH 0TE.IM !1110 4444 %%%% !1110
M4E+24@"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 (:2G4V@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *0]*6B@!M%%% !1110 4444 %%
M%% "44M)0 4444 %%%% !1110 4444 %%%% !11WHH **** "DI:2@ HHHH
M*!110 O>GBF4H.* )!TI#3<T$T (:::6B@!*6BE H 2EP:<!2XH 9BC;4F!1
M@4 18I,5(13<4 ,Q3:DIN* &T444#"BBB@ I.]+2&@!PIXJ.G"@"44ZH@:=D
M4"'T4W-)D4 !--H/6FDT -/6FTIZ4E !1110 4444 %%%% !1110 4HZTE%
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M@!U/'6HZ>#0 ^CM110 5&>M/-1DT ,?I49I[=*8: &]Z*.]% !1110 4444
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MZ>6W\JRH#F)3[5JWI L+@GH(F_E63;?ZA?I0!-1110,**** -2BBB@04444
M%%%% "&BE-)3$%%%% !1110 4444 %%%% #>]%*>M)0 4444 %%%% !1110
M4444 )10:*0PHHHH **** "BBB@ HHHH ***!0 4444 %%%% !28I:* &T4I
MZTE !1110 4444 %%%% !1110 4444 %%%% !1110 'I3:=3: "BBB@ HHHH
M ***44 +0!13J "EQ0!3J8AN*0BI,4TT 1FD(IYIII#&44M)0 4444 %%%%
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MD\A%)89;>?Z=*Z+7=-.HZ+<VD(57=<KV&:Y&>'7-5TRWT-M.:%8F7?,W3 H
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M% !24M)WH&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0TE.IM
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MN.*\\\.?\E8U_P#W&_\ 9:]")J5\,?0?VF<6VF?$,ROLU[3@A8[08QP,\?\
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M&F3,<L(O+/\ P$D?R K;JI*SL2G=!2'K2T&D,2BBB@ HHHH **** "E%)10
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M==@_WCR?Z#\*M#I6?IL3",R2',CDLQ]2>36A0,**** "BBB@#4HHHH$%%%%
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MB*,*JC  ]!3J* L4-;MC>:#?VZC+20,!^5<C\*;M'\/W-ED":"<LRGKAA_\
M6KO:X74?!FHZ?K3ZQX7ND@ED),EO)PISUQV(/H?SH6C?F-ZKT.ZKS/QL!K'C
M[1M+@^9XL>9C^'+9_D*TC>?$6Y7R1IMA:EACSPRDK[_?;^5:/A;PA_8MQ+J-
M_<?;-4GSOEYPF>N,\D^]-?$GV$]FEU.H/WC7GOQ3_P"/?1O^OH_RKT'O7'^/
MM#U'6X=,&GV_G&"XWR#>JX&.O)%+JAG7I_JT_P!T?RK!\;?\B5JW_7 UO*,(
MH] !65XHLKC4O#&H6=JF^XFB*HN0,GZGBE/9BCT*?@A5D\#Z:CJ&1HF# ]QN
M-<KIK/X*\87FCRMC3;]"T!/0'!V_ETKL_"EC<Z9X7L+.[C\NXB0ATW X.3W'
M%4_&GAMO$.DJ+<*+ZW;?"2<9]5S[U4W[S81VL9'PL_Y!&I?]?7]#7>5R7@#1
M=0T32;J/4H?*FFGWA=X8XQU)!(KK:)?Y?D)?Y_F8WC'_ )$W5_\ KV:JGPY_
MY$BR_P!Y_P"=:7B2SGU'PUJ-G;('GF@9(UR!D_4U!X+TZ[TGPM:V=[%Y5PA8
MLFX-C)]02*4>HY=#H13Z8*?0 M>=_%U2=$TY_P"%;KG_ +Y->B5RGQ%TUM1\
M&7809D@Q,OK\IY_2E+17''>QT&G$-I=F1R# A'_?(J<]16'X+U :EX/TZ?(+
M+%Y38[%>/Y8K;/6KG\3(C\*/-_#?_)6?$'^XW_LM>@]ZY#1=!U*S^(6L:I/;
MA;*X4B*7>IW?=[9R.AZBNO/6I7PQ]"NK]11UKSOX=?\ (P>)/^NQ_P#0S7H@
MZUQG@S0=2TC6-;GO;?RXKF4M"V]6W#<3V/'![T+XOD$OA^:.RI*6B@#@/BK_
M ,@?3?\ K[_]E-=U;?\ 'I!_UR7^0KEOB!HFH:YIEE%IT FDBN-[KO5<+@C/
M)%=5"A2WB0_>5%!^H%"V?J#W7H/K"\:$#P9JV3UMV%;M<=\2[S[/X4-LI_>7
M<RQJ,]0#D_RJ9;6''<M?#Y2O@JRS_$SD?3=73UGZ%8?V9H-A9$8:*%0P_P!H
M\G]2:T*TEN1'8****DH;2T&B@ HHHH **** "BBB@ HHHH *2EHH 2BBB@ H
MHHH **** "BBB@ HHHH 6GBF5(M $@%2+3!UIXZ4 +1110!!<Q"6)@15;1[D
MH6L)3\\?,9/=?3\*T*R=2MG5UN(#MEC.5(H W:*J:??)?VPD7Y77B1/[I_PJ
MW0 F!G..3WI:** "BBB@ HHHH **** "BBB@ HHHH **** "N9U:Z_M#4EM(
MCF&W;+D?Q/\ _6_GGTJ_KFJ&SB%M;D&[F'R_["_WO\/_ *QK/TVT$$(XY[T
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M>M<# Q2*H48%.H&%%%% !1110 4444 :E%%% @HHHH **** "BBB@ I*6@T
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M1X8,0;#3RJH]P.36WHFF1Z/I%O9)C,:_.1_$QZFN0^(DRRZCI5BSJJ%M[,Q
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M:AHH EW+ZTFY?6HZ* )-R^M)N&>M,HH ?N'K1N'K3** 'Y%+3!U%/H ****
M"BBB@ HHHH **** #O3J;10 \&ES3<BB@"2BF9HR: 'TF:;DTE "DTE)FDH
M0D4A(I&ZTE "YHI** %HI** %HI** %HI** %HI** %HI** %HI** %HHHH
M*0TM% "4444 %+12@4 &*7%.Q2XH ;BC%/P:,4 18I*EQ32* (Z0BG$8I#0
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MBB@"K10.E% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@8)YR.OXU3JI?C\[%K&PMS6]WO\ +F_KS.[HKB[B/4H=9T/2O[4NHVEM")Y
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MD,**** "BBB@ HHHH **** #M24M)0 4444Q!1110 4444 %%%% "&DIU-H
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M&(06\4(.1&BH#]!BJ@FKI]E]_7]#HH1<6D^WZNP^BBBM#K"BBB@ I1249Q0
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M.4L;3:Q_VY#T_P"^1FMJET7]=6'5_P!=$%%%% %4=**7M24#"BBB@ HH%.H
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M1^;[?K1YOM^M $E%1^;[?K1YOM^M $7:DIW:FT#"BBE% "@4X4@IX% A0M/
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MBBBF(**** "BBB@ K$\9?\B-X@_[!ES_ .BFK;K$\9?\B-X@_P"P9<_^BFH
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M./\ H=/_ "EPT?:/''_0Z?\ E+AJ_10!0^T>./\ H=/_ "EPT?:/''_0Z?\
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M?\+"_P"I/\6_^"S_ .RK:\(?\BEIO_7-O_0VK:KHB[I,^DI3YZ<9OJDSC/\
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MG_T+7B7_ , 1_P#%T?\ "T;/_H6O$O\ X C_ .+JO10!8_X6C9_]"UXE_P#
M$?\ Q='_  M&S_Z%KQ+_ . (_P#BZKT4 6/^%HV?_0M>)?\ P!'_ ,73?^%H
M6?\ T+7B7_P!'_Q=0T4 3?\ "T+/_H6O$O\ X C_ .+J6'XDPS[O)\*^*9-N
M,[-.!Q_X]52NB\+?=O?K'_[-0!G#XA?]2?XM_P#!9_\ 94]?B'C_ )D[Q=_X
M+/\ [*NO6I%H X\?$7_J3?%__@K_ /LJ?_PL;_J3/&'_ (*__LJ[(4\=* .*
M_P"%C?\ 4F>,/_!7_P#94'XC<?\ (F>,/_!7_P#95VU(>E 'D7Q!\2W?BGP1
MJ&CV/A#Q3'<W!B*--II"#;(KG)!)Z*>U>K2<NWUJ1JB:@",TT]:<::>M "44
M44#"BBB@ HHHH **** "BBB@#6HHHIDA1110 4TTZD- "&BCM12&%(S;49L$
MX&<#J:6D)"J6)P ,DTGL".,T:SUGQ'H]OK4GB.YM9;M/-BAMD3RH0>BD$?,1
MWS6YX7U.XU;0H[F[\O[0DDL$C1_==HW9"P]CMS^-8>F>'-/UO3H]3L;C5M,M
M+S=,MG;WA2-U8DABH!V[NN!TS6YX7GLYO#]N+"T^R00EX/LY.?+9&*L,]_F!
MY[]:H1L4444AA1110 E%%%,04444 %%%% !6)XR_Y$;Q!_V#+G_T4U;=8GC+
M_D1O$'_8,N?_ $4U %?P!_R3KPW_ -@RW_\ 1:UT1%<[X _Y)UX;_P"P9;_^
MBUKHCTH 2BBB@ HHHH *\K^)W_(PVO\ UZ#_ -#>O5*\K^)W_(PVO_7H/_0W
MK&O\)Y><_P"Z/U1Q5%%%<A\:%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %6]+_P"0S8?]?,7_ *&*J5;TK_D,V'_7S%_Z&*#2E_$CZH^@
MC33TI:0UZ!^AC*/:@T4 -HIU)B@!**** "@=:** '4[-,%+F@"2ES3,TM,1F
M^(C_ ,2"[_W1_P"A"O/J] \0G_B07?\ NC_T(5Y_2&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7>:+_P @2S_ZY"N#KO-%_P"0
M)9_]<A0!?I0.:2E'6@!V*"*44&@!F* *=10 #K3Q3>U/6@!:6BB@ HHHH *2
MEH/2@!*:>M.I#3$,(IAJ3M49I#.$\#_\CCX\_P"PG'_Z+KN:X;P/_P CCX\_
M["<?_HJNYH 6G TREH ES1FF9HS0 _-<I\0CGPC+_P!=H_\ T*NHS7+?$ Y\
M)3?]=8__ $*HJ? SEQW^[5/1GD=%%%<1\$%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'L?A#_D4M-_ZYM_Z&U;8%8GA#_D4M-_ZY
MM_Z&U;JBNZ'P(_0,+_ AZ+\A0*<!0*D%4;C=M!6GT4 1X-)BI,4E #0*>!24
MX=* "EI!2TQ!1110 V3_ %;?[IKRZ/\ U:_05ZC)_JV_W37ET?\ JU^@I#'4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=#X7X6]
M^L?_ +-7/5T/A?[M[]8__9J .B%/!J.E!H F4T_-0 T\-0!-FFYXIFZ@M0 K
M'%1$\TI-,H 2FGK3J;0 4444#"BBB@ HHHH **** "BBB@#6HHHIDA1110 4
M444 -HHHI#"CKP:*0D*I8G  R30]M0.63PIJ=BHMM(\27%EIX)VVS6R2F,$_
M=5SR .W7%;FD:5;Z+I<-A:EVCCR2TC;F=B268GU))/XUAVOB;6M3MDO-,\,M
M-8S#=!+->I$TB]FVX. :Z#3I[NXL4EOK,6=P2=T(E$FWDX^8 9R,'\:>H%JB
MBBD 4444 )12FDIB"BBB@ HHHH *Q/&7_(C>(/\ L&7/_HIJVZQ/&7_(C>(/
M^P9<_P#HIJ *_@#_ ))UX;_[!EO_ .BUKHCTKG? '_).O#?_ &#+?_T6M='0
M VBE-)0 4444 %>5_$[_ )&&U_Z]!_Z&]>J5Y7\3O^1AM?\ KT'_ *&]8U_A
M/+SG_='ZHXJBBBN0^-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "K>E?\AFP_Z^8O_0Q52K>E?\AFP_Z^8O\ T,4&E+^)'U1] FDI>]%>
M@?H8TBDI^*,4Q$=%/Q2$4AC:;3J* &T4'K10 4ZFT4 .I<TW)HS0!G>(/^0#
M=_[H_P#0A7 UWNOG_B0W?^X/_0A7!4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7>:+_R!+/\ ZY"N#KO-%_Y EG_US% %^E%)
M10 ^BFYHS0 I- Z4F: : 'CI3UI@IZT .HI*6@ HHHH *#THH- "4AI:0]:8
MAO:HS3STIAI#.$\#_P#(X^//^PG'_P"BZ[@]:X?P/_R./CS_ +"<?_HNNW[T
M +FES3:*!CLBEIF:,T"'9KF/'YSX2F_ZZQ_^A5TN:YCQ\?\ BDYO^NL?_H51
M4^!G+CO]VJ>C/)J***XCX(**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /8_"'_(IZ;_US;_T-JWEK!\(?\BEIO_7-O_0VK=!KNA\"
M/T#"_P "'HOR)!UIXZ4P4\51N.I#113 *;3B:832 6E'2F9IP- #A2TE+3$%
M%%% #9/]6W^Z:\NC_P!6OT%>HR?ZMO\ =->71_ZM?H*0QU%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !70^%_NWGUC_\ 9JYZNA\+
M_=O/K'_[-0!OTZFT4#'YI<TS-+F@0[-&:;FC- "YI,TF:2@ HH[44#"BBB@
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M=.: .A\ ?\DZ\-_]@RW_ /1:UT=<YX _Y)WX;_[!EO\ ^BUKHZ $-)3J0]:
M$HHHH *\K^)W_(PVO_7H/_0WKU2O*_B=_P C#:_]>@_]#>L:_P )Y><_[H_5
M'%4445R'QH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5;
MTK_D,V'_ %\Q?^ABJE6]+_Y#-A_U\Q?^AB@TI?Q(^J/H&G8HHKT3]""BBCF@
M!,4A%.H- $9%-J2FF@!IIM.IIZTAA1110 4444 9NO\ _("N_P#<'_H0K@Z[
MS7_^0%=_[@_]"%<'0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMOH:\OC_ -6OT%>GR']VWT->81_ZM?H* '4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %=#X7^[>?6/\ ]FKGJZ'PM]V]^L?_ +-0
M!OT4=J*!A1110 4444 %%%% !1110 4444 %%%% !12FDH **** "BBB@#6H
MHHIDA1110 4444 %(:6D- "53N7U$:C9K;10-9MO^U.[$.O'R[1WR>N:N4C
ME2 <$C&1VJ7L,XZ[AUB5A>W^@>'&=/\ EO--DK_P(I74:=)>2V$;WT4$=P<[
ME@<NF,\8) [8KD-*\-ZE<C2=,UFQ@32](C((\P2+>RXVJY7'  W'#<Y:MWPE
M8W.G>'8K:ZB,+++*R0LP8Q1F1BBY!(X4@50&Y1112 **** "@T44 )1113$8
M&HZ+K%Q?R3Z?XDGLH)2"\!MTE X ^0GE>GOR<UH:/I-MHFF1V-KO9$)9GD.6
M=B<LS'N23FK]%"T *Q/&7_(C>(/^P9<_^BFK;K$\9?\ (C>(/^P9<_\ HIJ
M*_@#_DG7AO\ [!EO_P"BUKHZYSP!_P DZ\-_]@RW_P#1:UT= !2'K2TA% "4
M444 %>5_$[_D8;7_ *]!_P"AO7JE>5_$[_D8;7_KT'_H;UC7^$\O.?\ ='ZH
MXJBBBN0^-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K>
ME_\ (9L/^OF+_P!#%5*MZ7_R&;#_ *^8O_0Q0:4OXD?5'T'0:*6O1/T,2BBB
M@04444 (:::>>E,/2@!E(:6@]*0QM%%% !1110!FZ_\ \@*[_P!P?^A"N#KO
M-?\ ^0%=_P"X/_0A7!T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7>:+_R!+/_ *Y"N#KO-%_Y EG_ -<A0!?HHHH **** "EQ
M2XI<4 (*6C%% #LTN:91F@"3-&:9FC- #\UEZSH.F:_'%'J=MYZQ,60>8RX)
MX_A(K1S2$T 8=U>+X7M;6UL]%O;FP1-H^QCS6C.>!M)R1[YJEX=M+F77]4UR
M6RDL(;M$CCMY0 [8ZNP'0G\ZZ<FDS1?6X>05F7WA[1-1N3<W^C:?=3D!3+/:
MH[$#H,D9Q6E3<T <%\/[:"S\4>.+:UAC@@CU&-4BB0*JCR^@ X%=[7#^"/\
MD<?'?_83C_\ 15=Q0,****  TE+24 %<SX^_Y%.;_KK'_P"A5TU<SX^_Y%.;
M_KK'_P"A5%3X&<N._P!VJ>C/)J***XCX$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /8_"'_ "*6F_\ 7-O_ $-JVJQ?"'_(I:;_
M -<V_P#0VK:KNA\"/T#"_P "'HOR"ES2451N+NHS3<T4 .S24E% "T4E% #P
MW%/W5%1F@";-&:BR:7=]: 'L?E;Z&O,T_P!6OT%>D$\'Z5YNG^K7Z"@!U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !71>%ONWOUC
M_P#9JYVNB\*_=O?K'_[-0!O44I%)0,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH UJ***9(4444 %%%% !1110 VD;=M;: 6QP#ZTN.*RM
M3FUV.X4:99V4T&S+-/.R,&R>, 'C&*E]AHX70]2T^TUG1=0OM3VZA):W(U4W
M5P04F!C^0J3A0#O"@ 9 XS77^"I)I?#$,LOF[))IG@\W.[R3*QCSGG[N/PJC
M<6>N7=PMQ<^'- FG7I))(68?B4S72:>UZ]DC:A##%<Y.Y(7+*!GC!(';%5T$
M6J***0PHHHH **** $HI:2F(**** "L3QE_R(WB#_L&7/_HIJVZQ/&7_ "(W
MB#_L&7/_ **:@"OX _Y)UX;_ .P9;_\ HM:Z.N<\ ?\ ).O#?_8,M_\ T6M=
M'0 4444 -HI324 %>5_$[_D8;7_KT'_H;UZI7E?Q._Y&&U_Z]!_Z&]8U_A/+
MSG_='ZHXJBBBN0^-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "K>E_P#(9L/^OF+_ -#%5*MZ7_R&;#_KYB_]#%!I2_B1]4?0=+24M>@?
MH8@HHHIB"BBB@ /2F&G&FF@!E!Z44AI#$HHHH **** ,W7_^0%=_[@_]"%<'
M7>:]_P @*\_W!_Z$*X.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *[S1?^0)9_]<A7!UWFB_\ ($L_^N0H OT44AH 6E%)2B@!
MPZTZF@TZ@ IIZTZFDT -)HS2=Z* %S1FDHH 7-)244 !I,TM-/6@ HHH% SA
M_!'_ "./CO\ ["<?_HJNYQ7#^!_^1Q\>?]A./_T77<T"#%&*6EP: &XII%28
MI#0 S%<QX^_Y%.;_ *ZQ_P#H5=1BN8\??\BG-_UUC_\ 0JBI\#.7'?[M4]&>
M2T445Q'P04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 >Q^$/^12TW_KFW_H;5M5B^$/\ D4M-_P"N;?\ H;5M5W0^!'Z!A?X$/1?D
M%%%%4;B44M)0 4444 %%%% !1110 M%)10 'H?I7G*?<7Z"O1NQ^E><I]Q?I
M0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KH_"
MGW;[ZQ_^SUSE='X4^[??6/\ ]GH WZ;3S33R: $HH[T4#"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH UJ***9(4444 %%%% !1110 'I3>U.II^
M4$^@S2>PT<_#XNL$D6'58KC29R<!;U-J,?:090_G6\CI(BO&RLC#(93D&N5@
MMM:\46"S7>JVMKIUPN1#IP$A=3ZRL,?]\BKVE^$=-T2Y@ETV2[MUC!WQ+.QC
MFR,9=3D9[Y&.E/U#T+VNW-S9^']1NK)-]U#;220KC.6"DCCOS7.:=H6I#2;7
M5-*\1WD]Y+$LI%Y)YEO/D9QMZJ#V(Y'O76W5S%96<]U.Q6&"-I)& )PH&3P.
M>E<Y'X]\,I$JQ7,BQX^4+:2 8]OEI+J!4T?5VU7Q\?,@EM;B'2S'<VLAYBD$
MOKT8$$$,.H(KM*Y;2O$UEK7BUK>P2*2);'>T[0,DN[?C;EL?+@YZ=:ZFG]E?
MUU8?:?R_)!1112 *2EI* "BBBF(*Q/&7_(C>(/\ L&7/_HIJVZQ/&7_(C>(/
M^P9<_P#HIJ *_@#_ ))UX;_[!EO_ .BUKHZYSP!_R3KPW_V#+?\ ]%K71T %
M%%% "&DIU-H *\K^)W_(PVO_ %Z#_P!#>O5*\K^)W_(PVO\ UZ#_ -#>L:_P
MGEYS_NC]4<51117(?&A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !5O2O^0S8?]?,7_H8JI5O2O^0S8?\ 7S%_Z&*#2E_$CZH^@\T4W/-+
MFO1/T(6BC(I,T +2$T9I":  TPTI--H *:>M*324AA1110 4444 9NO?\@*\
M_P!P?^A"N#KO-?\ ^0%=_P"X/_0A7!T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7>:+_R!+/_ *Y"N#KO-%_Y MG_ -<A0!?H
MHHH **** %S3@:92T .S3<T9I* "DHHH **** "BBB@ I#2T'I0 VE I*<*!
MG#>!O^1Q\>?]A./_ -%UW8%<+X%_Y'+QY_V$X_\ T77>B@0@%+BEIV#0 PBF
MD5)BD(H A(KE_'__ "*<W_76/_T*NJ/6N6^('_(I3?\ 76/_ -"J*GP,Y<=_
MNU3T9Y)1117$?!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!['X0_P"12TW_ *YM_P"AM6U6+X0_Y%+3?^N;?^AM6U7=#X$?H&%_
M@0]%^0444H%4;ABC%/ IV* (]M)BI<48H AHJ0BF$<T -HI:2@ HHHH .Q^E
M><I]Q?I7HW8_2O.4^XOTH =1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#HIJ *_@#_ ))UX;_[!EO_ .BUKHZYSP!_R3KPW_V#+?\ ]%K71T %%%%
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M^XOTH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#0WK&O\)Y><_[H_5'%4445R'QH4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5;TK_D,V'_7S%_Z&*J5;TK_D,V'_ %\Q?^AB@TI?Q(^J
M/?>]%'>BO0/T,**** $S29I<48H 0T4[%)B@!**** "BBB@ HHHH S=?_P"0
M%=_[@_\ 0A7!UWFO_P#("N_]P?\ H0K@Z "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KO-%_P"0)9_]<A7!UWNB_P#($L_^N8H
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M !1110 4444 %%%% !1110 4444 %=[HG_(#L_\ KF*X*N^T3_D!6?\ US%
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MXR2.#S[FNCJEI^CZ;I*%-/L8+8$88QH 6^IZG\:NTV)!1112&%%%% !0:**
M$K$\9?\ (C>(/^P9<_\ HIJVZQ/&7_(C>(/^P9<_^BFIB*_@#_DG7AO_ +!E
MO_Z+6NCKG/ '_).O#?\ V#+?_P!%K71T %%%% !1110 5Y5\3O\ D8K7_KT'
M_H;UZK7E7Q._Y&*U_P"O0?\ H;UC7^$\O.?]T?JCB:***Y#XT**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *MZ5_R&;#_KYB_]#%5*MZ5_
MR&;#_KYB_P#0Q0:4OXD?5'OO>BCO17H'Z&%%%%  *<.M-I:8AU--&:2@ IM.
M--I#"BBB@ HHHH S=?\ ^0%=_P"X/_0A7!UWFO\ _("N_P#<'_H0K@Z "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KOM$_Y 5G_
M -<Q7 UWVB?\@*S_ .N8H O&DI324 %%%% !1110 4444 %(:6B@!**** "B
MBB@ HHHH **** .%\$?\CCX\_P"PG'_Z+KN*X?P1_P CCX[_ .PG'_Z*KN*!
MA1110 4=Z** "N9\??\ (I3?]=8__0JZ:N9\??\ (I3?]=8__0JBI\#.3'?[
MM4]&>2T445Q'P04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >Q^$/^12TW_KFW_H;5M5B^$/^12TW_KFW_H;5M5W0^!'Z!A?X$/1?
MD%%%%4;BYH!I** 'Y--)I** "BDHH **** "BBB@ ['Z5YRGW%^E>C=C]*\Y
M3[B_2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG/\ NC]4<31117(?&A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+_D1O$'_ &#+G_T4U;E8?C+_ )$;Q#_V#+G_ -%-0!7\ ?\ )._#?_8,M_\
MT6M='7.> /\ DG7AO_L&6_\ Z+6NCIB"BBB@ HHHH *\J^)W_(Q6O_7H/_0W
MKU6O*OB=_P C%:_]>@_]#>L:_P )Y><_[H_5'$T445R'QH4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5;TK_D,V'_ %\Q?^ABJE6]*_Y#
M-A_U\Q?^AB@TI?Q(^J/?>]%'>BO0/T,**** "BBB@!"*2G4V@ HHHH ****
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M2B@!XJ4&H13@>: )P:<#40:G;J )**9N]Z7=0 ZC--W4W=0 XGFHR:":C)H
M">:8:4FFGI0 AI***!A1110 4444 :]%%% A****8@HHHH **** "D8!E*G.
M",'%+5*YL9;C4;.Z2]N(4M]^^",C9-N&!N^G44FKJP'+>'KW6-$T.WTQO"]Z
MZVP,<;K)$"R _*6&[[V.OOSWKK-/N9KRR2>XLY+.1B<PRL"RX..H)'/7\:YV
M329X;^WL)/%NJBYN$=XDVI\RIC<<[,<;A^==%I]K)96202W<UVZDYFFQN;)S
MS@ <=/PI[ZAZ%JN.\91>&))ECU>_FL[N:$Q9M6;S'B)/RLJ@Y7.>HQU]Z[&N
M3O?[0TOQC<ZA9Z-<7T%U:1QRNC(-K(6QMR>A#<CCH*3&AOA.3P[]JN$TN\N[
MV^>-3-<7:R&1D' &YE P,]!765E:9JE[?7#QW.C7-BBKN$DKHP)ST^4FM4TV
M)!1112&%%%% !1110 5B>,O^1&\0_P#8,N?_ $4U;=8GC+_D1O$/_8,N?_13
M4 5O '_).O#?_8,M_P#T6M='7.> /^2=>&_^P9;_ /HM:Z.F(**** "BBB@
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M_P ^W_C[?XTO]@Z;_P ^W_D1O\:TPM/ H RO^$?TW_GV_P#(C?XT?\(_IO\
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M\"/T#"_P(>B_(****HW"BBB@ HHHH **** $-%+24 %.%-I: )13Q42FI :
M)*6F@TN10 4AZT$TPF@!#41IY-1T )1BEHQ0 E&*7%% !3@* *>!0 X"G 4
M4Z@!,4M+10 W%&*=24 1D4TBI<"F$<4 0D4P]:E85&: &T4M)0 444M "4M%
M+B@!*2E[4AH ,TF:3M10,7-)110 4444 %%%% !1110 44HZ44"-:BBB@ I#
M2T4 )VHHHIB"BBB@ I&)",5&2!P/6EHS@9-)[ <%X?T2T\1:!#K.I:I?27\Z
MEYI$NVC^S/W10#A=O3GTK?\ !U_<:CX:@GN9OM#K)+$L^,><J2,JO^( /XUS
M%T?"NLWC:A%X2U34 [$BZMK<B*8]V^^H;ZD5W&D3QW&EP/%8SV,8!1+::,1L
M@!P!M!( XX]J?0&7:Y?Q#X=M];N;R.VU8V-Y/:"&[10KB2$EMI=#R/X@&!!Z
MUU%<5XHT^6._O&36M.T^VU:!+>Y:[DV2*J[@3%S@DJQ&#TZTF-%KPK#ITUY=
M7Z:ZNLZB(U@DF 51'&"2 J+T!.3GG.*ZGO7+Z3#ITOBQ;G3+_3I+6WTU;5(;
M:=7<_/G+ =   !]374=Z;V7]=?Z8E_7W!1112&5[^S34-/N+*222-)XVC9XS
MA@",'!]:YZS\$16)MQ#X@U\10%2D/VP;,*1A=H7[O&,>E=311UN!@ZKX3L]4
MU#^T$N[ZPNV01R36,_E-(HZ!N#G%:6EZ79Z-I\=C8Q>5!'G SDDGDDGN2:N4
M4 %8GC+_ )$;Q#_V#+G_ -%-6W6)XR_Y$;Q#_P!@RY_]%-0!7\ ?\DZ\-_\
M8,M__1:UT5<[\/\ _DG7AO\ [!EO_P"BUKHS0 E%%%,04444 %>5?$[_ )&*
MU_Z]!_Z&]>JUY5\3O^1BM?\ KT'_ *&]8U_A/+SG_='ZHXFBBBN0^-"BBB@
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M7P/_ ,CCX\_["<?_ *+KNJ '"GU&*>* 'BEIE.R:8A:Y/XB?\BC+_P!=H_\
MT*NJS7*?$/\ Y%&7_KM'_P"A5G5^!G+C?]VJ>C/(:***XCX,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /8_"'_(I:;_ -<V_P#0
MVK:K%\(?\BEIO_7-O_0VK:KNA\"/T#"_P(>B_(****HW"BBB@ HHHH ****
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M110 4444 %8GC+_D1O$/_8,N?_135MUB>,O^1&\0_P#8,N?_ $4U %?X?_\
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M *%73Y-<M\0/^12F_P"NL?\ Z%45/@9RX[_=JGHSR2BBBN(^""BBB@ HHHH
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M1112.8**** "BBB@ HHHH ]C\(?\BEIO_7-O_0VK:K%\(?\ (I:;_P!<V_\
M0VK:KNA\"/T#"_P(>B_(****HW"BBB@ HHHH ***44  %2 4@%/ H ,4[''2
ME I: $Q1BG44 -Q32*?10!$13"*F(IF* (C24YA3: "BDI* '44VEH >#4@-
M0T\&@"8&G5$#3P: 'T4W-+0 M)129H 6HR:"::3B@!K&F&E)R:8>M "4444
M%+244 .S2YIM+0 M)12XH ;BDQ3\4;: &8H(I^*3% #,4E/Q33TH 2BE-)0,
M**** %%%)10(UZ*** "BBB@ I.]+10 E%)WI:8@I&.U2V"<#/%+12>V@'(Z=
MJ?BW6]/AU.RBT:VM+E1)#'<>:\@0]-Q4@9]JZ33OMXL4_M,VQN\G>;8,(^IQ
MC=STQ7$>3I.B3/I__"<W-LXD9GB#Q (Q.6S\N%YYQQ7;:9;M;:?%$][+>GEA
M/*06<$Y'0 =Z?30'N6ZX'Q!_8<OCAXO$MV/LZV:-9Q^>R+&VX^9NVD$$_+C/
M4#VKOJYO5=5NY-:;2M(TNWN[J*%9;B:Y?;'$&)VKT))."?;\:3W0ULR/PU#X
M2COY3H$T;W)B^<+<R2'9GT8D=<5U%<_HNJS/JDVE:EIT5EJ"1"93"P:.:,G&
M5. 1@\$'V]:Z"JZ(740]*3M3J::0PHH-%( HHHH *Q/&7_(C>(?^P9<_^BFK
M;K$\9?\ (C>(?^P9<_\ HIJ *_P__P"2=>&_^P9;_P#HM:Z.N<^'_P#R3KPW
M_P!@RW_]%K71T %)2TE !1113$%>5?$[_D8K7_KT'_H;UZK7E7Q._P"1BM?^
MO0?^AO6-?X3R\Y_W1^J.)HHHKD/C0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ JWI7_(9L/\ KYB_]#%5*MZ5_P AFP_Z^8O_ $,4&E+^
M)'U1[[WHH[T5Z!^AA1110 4444 %%%% !1110 AI*<>E-H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "D-+10 VBBB@ HHHH **** "BBB@!**** "B
MBB@ HHHH **** "BBD% "T444 %%%% !1110 AZ44M(>M !1110!PW@?_D<?
M'G_83C_]%UW-<-X'_P"1Q\>?]A./_P!%UW- !1110 4AI:#TH ;45Q;07<)A
MN88YHR<E)$# _@:EHH!I-69G_P!A:/\ ] FQ_P# =/\ "C^PM'_Z!-C_ . Z
M?X5H44K(S]C3_E7W&?\ V#H__0)L?_ =/\*/[!T?_H$V/_@.G^%:%%%D'L:?
M\J^XS_["T?\ Z!-C_P" Z?X4?V%H_P#T";'_ ,!T_P *T**+(/8T_P"5?<9W
M]A:/G_D%6/\ X#I_A1_86C_] JQ_\!T_PK1I*+(/8T_Y5]QG_P!A:/\ ] JQ
M_P# =/\ "C^PM'_Z!5C_ . Z?X5H4460>QI_RK[C/_L+1_\ H%6/_@.G^%']
MA:/_ - JQ_\  =/\*T**+(/8T_Y5]QG_ -A:/_T"K'_P'3_"C^PM'_Z!5C_X
M#I_A6A119![&G_*ON,_^PM'_ .@58_\ @.G^%(="T?\ Z!5C_P" Z?X5HTAH
ML@]C3_E7W&=_86D?] JQ_P# =/\ "C^PM(_Z!5C_ . Z?X5H4460>QI_RK[C
M/_L+2/\ H%6/_@.G^%']A:1_T"K'_P !T_PK0HHL@]C3_E7W&?\ V%I'_0*L
M?_ =/\*/["TC_H%6/_@.G^%:%%%D'L:?\J^X9#!%;PK%#&D42C"HB@ ?0"GT
MO:DIFEK:(**** "BBB@ HHHH *>*8.M/6@!XIXIHIXZ4 +2T4O:F(2BBB@ H
MHHH 0]*C(J0TTTAD35'4IJ,T -I.]*:* $HHHH 6ES3:6@"0-3@U0T[- $VZ
MC=4>?>C=[T 2;J"U1[J0F@!Q-,)I,TV@!2:;110 4444 %%%% "THH%. H
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MI>U)2]J8A**** "BBB@ IAZTXTUJ0QAZU$U2-49H ::*#10 E%*:2@ HHHH
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M . S_P"%%F'L:G\K^XSJ*T?^$?UK_H$7_P#X#/\ X4?\(_K7_0(O_P#P&?\
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M4]I'W7NNA[;WHHHKO/OPHHHH **** "BBB@ HHHH **** $-)3C3: "BBB@
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MH CHIV*;0(**** "BBB@ HHHH **** "BBE H ,48IX%+B@"/!%'O4A6FD4
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M4 -HI3UI* "BBB@ HHHH **** "BBB@!**4TE(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% #:*.]% !1110 4444 %%%% !1110 4444 %%%%
M!1110 &FTZD/6@!**** "BBB@ HHHH *2EHH 2BBB@ I>E)2T .I<TW-+D4
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M HHI: "BEQ2T )2TF*4=: 'ITJ04Q>E2+T_&@!PI:** "BBB@ HHHH ****
M)Z*** "BBB@ HHHH **** "FL,JPR1D=1U%.IKL$0L>BC)I.UM0/.?#EUH=A
MH<%I?>'[B2ZBRDD[:8SF<@_ZS)7/S=<'D=*[G2)K2XTR.2QMFMK<EML30>41
MR<_+@8YR:Y&U\2^*=2ETMK6#2((=5ADN+99A(S*B[2 Y! R0PZ#UKIO#>HW.
MJ:)%<WHA6[#R1S)"I"HZ.5*\D]",9SSUJ]>HC6HHHI %%%% !1110 4444 (
M>E)3J;2&%8GC+_D1O$/_ &#+G_T4U;=8GC+_ )$;Q#_V#+G_ -%-0!7^'_\
MR3KPW_V#+?\ ]%K71USGP_\ ^2=>&_\ L&6__HM:Z.@ HHHH **** "DI:2@
M HHHIB"BBB@ HHHH **** $-)3J;0 4444 %%%% !1110 4444 %)2TE PHH
MHI %%%% !1110 4444 %(:6B@ HHHH **** "BBB@!#24ZFT %%%% !1110
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M^SM#OKW=M,$#N#[@<?KBN'DM-0T72-(U)?$&IRZG<RPJ;2>X\R.7<1N 0C/
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M>ARJD4AF3X&_Y''QY_V$X_\ T77<FN ^&]U%J>M>,-6M"\EA>:BC6\YC95D
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M[M+=A*Z!CD%<8W<UV-% ''Z<+V_\07OB:72[BVBAL_(M;>==LTN,L<KSMR<
M4W5UU"_MO#_B2/2YQ<6;F6:P_P"6H5EP0,@$D>F*[*BCTZ <0;2Z\7:VU[)I
MUSI]C#92VT9O(]DCN_&=N> *H"76'\(CPD-!OEOO*%J;ED'V<(#]_?GGCM7H
MU)WH\NG]?YA=WOU.4\33/IWADZ+;Z9J%V\UH84>TMS(B'&/F/:KWA&]DN-#@
MMY=/OK.2UC6)A=P^7O('5?45O44[[WZBLM$N@4444AA0>E%% #:*4BDH ***
M* "BBB@ HHHH **** "BBB@ HHHH ****  ]*;3J;0 4444 %%%% !1110 4
M&BB@!**** "BBB@ HHHH **** "N6O=-\67D,^GMJ&F&RF!5KCR7$X4]MOW<
MXXKJ:*+!<Q+JQUFRM+.'0;BSV6\0B:*]1MK8Z-N7D'VHT31KFTO;O5-2GBFU
M&["H_DJ5CC1>BKGD_4UMT4[ZW"W0****0!1110 G>B@]:* "BBB@ HHH[T %
M%%% "&DIU-[T %%%% PHHHH **** "D[TM%  #3@:92T /S1FF9]Z7/'6@0[
M-)FFYHH ":2BB@8T]:*4TG6@0HI:*<!0,3%. I0*7;0(XP>&;7Q!XEUF\UG3
MW>*-HX+0LSQAE"Y8C!&1D]:U[[PQIEYIUO9"#[/':OYEN8/E,;_W@.A_$&MS
M;2$4=+!UN<\EMKA,FG7[6UY93Q.GVM!Y<B?*<;DY![#*_E7-I-JZ^$SX5_L.
M\-]Y1M?M&S%N5)(W[\^G.*]#(IM _0QX7ET^YTW1$LY);4VA5[M?N1E%  /'
M\7U_.N:L;C4]!T2?PZNAWMQ<(TB6L\: P.C$E2SY^7KR*[RDH>N_42TV.(_L
M>Z\+RZ#?06DM]'9VC6MU';+N?YN=RCOSFK^D)=7OB&^\1W%A/:0_9%MK>&9<
M2N =Q8KV] *ZBBFVWKZ_B%NG]:'!VFL3MXVEU4Z!K:6]Q9I;*'LR"K;\Y;G
M'XUWN.<>E)0.M+I8.I**>M1BI%H ?2TE+0(*0]*6DS0,C/6HVJ0]:C8T ,I*
M6D[T %%%% !1110 4E+24 %%%% !1110 4444 %%%% !1110 E%%% !1110
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M+MH 92$5)MII% #**7%)0 4444 %%%% !1110 4444 %)2TE !1110 4444
M%.%)3A0 H%. -*HXIU "8Q29IU,:@ W4;J8329H DWTTM3<TF: '$T4W-% &
MI1110 4444 %%%% !1110 4444 %%%% "4444Q!1110 4444 %%%% !1110
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MMU;>,K'1TCA-O<1[F8@[P>>ASCMZ50O/%6K7&MSZ?H.FQW7V4_OFD;&?7'(
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M*** "BBB@ HHHH *2EI* "BBB@ HHHH **** "CO110 4444 %%%% !1110
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MD<_G2=FM>_WZ'%!4Y49QO%1]W51T[V:Z_P!7*_A.7P]*L[:+"T,A \V.0L7
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M(.E #Z6DI: $I#3J:>E #&J%JF-1-UH 924M)0 4444 %%%% !1110 4444
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M!Z]*?35IU API:04M,04444 %%%% #333TIQIIZ4AD9J,U(W6F'K0 RBBB@
MHHHH *2EHH 2BBB@!:7--HS0!(&I=U1T4 2;J0MQ3** %S33110 E%*:2@ I
M:*4"@!,4N*<%IX% $>VC;4N*7% $.TTA%38I"* (2*0BI"*810 VB@T4 %%%
M% !1110 4444 %%%% !1110 VB@]:*!FO1110(**** "BBB@ HHHH **** "
MBBB@ HHHH 0T4M)3 ****!!1110 4444 %%%% !1110 VB@]:*0PHHHH ***
M* "BBB@ HHHH 2BE-)3$%%%% !1110 4444 %':BB@!M%*>M)0 4444 %%%%
M !1110 4444 )1112&%%%% !1110 4444 %!Z444 %%%% !1110 4444 %%%
M% #:*** "BBB@ HHHH **** "BBB@ H-%% !1110 4444 !IM.IO>@ HHHH
M**** "BBB@ I*6@T )1110 4444 %%%% !1110 4444 %%%% !1110 4444
M)10:* "BBB@ HHHH **** $-)3J;WH ****!A2]Z2B@!PIPIH-+0(D%.S48-
M.S0 _-(33<T9H #TIAZTI--H ::;3CUIM PHHHH *<*;2CK0!*.E/%1"G@T"
M)!2TRG9IB%HHHH **,TV@!#32:<:832&--1FGDU&: $HHHH **** "BBB@!*
M*#10 4444 %%%% !1110 4444 !H%%% "@4\+2**D H  *<!2@4Z@!,48I:6
M@!N*;BGT4 1$5&1Q4Y%1GI0!":;4C"F4 )1110 4444 %%%% !1110 4444
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M %%%% !1110 444M "44N*7% #:*=BB@#3HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $HHHIB"BBB@ HHHH **** "BBB@ I#UHHH 2BBBD,***
M* "BBB@ HHHH **** $HHHH$%%%%, HHHH **** "D[T44 )1110,****!!1
M110 4444 %%%% "4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4A
MHHH 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;1110 4444 %%
M%% !1110 4E%% !1110 4444 %%%% !2"BB@!:*** "BBB@ HHHH *0]:**
M"BBB@ HHHH **** "BBB@!O:BBB@84444 %%%% !1110 'I2444 %%%% !11
M10 4444 %(>E%% "BEHHH <*6BB@0N31DT44 )2444 -)I***!C:***!!111
M0 4444 %%%% !1110 E%%% !1110 4444 %%%% "]J<M%% $@J0=*** %%+1
M13$%%%% !1110 G>FGK112&1MTJ(]:** &4444 %%%% !1110 [%&*** ' 4
+8HHH&&**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image5.jpg
<TEXT>
begin 644 image5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *N R # 2(  A$! Q$!_\0
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MQ=6K,4SM(88*GT-<WHMC!I?@BXOGC4S3P.[,1S@@A1].GYU8\!VYB\/&4_\
M+:9F'T&!_0U5:C24).%]'8RPN)Q,JE.-2WO1O:VVWYG07]P+33[FX)QY<;-^
M0KD?!<D>G^']0U2Y)"F3)/J%'^)-;'C*Y^S^&K@ \RE8Q^)Y_3-8%];O:?#2
MV1?^6C*[_1B2/Z4\/!.C9_:DD&,J..)4E_R[A*7S>@^R@U/QC))=75W):Z:&
M*K%$<;O;W^IS5X>"1931S:7J-S"ZNI<.WWAGG[H%6M'MOMW@NVM[*[-L[1@&
M6,9*MG+=".<Y[UBZ%_:"^,Y+&35;JZAM@Q??(V&XQT)/<_I6O/-N:A+E4;Z6
MZ(YO9TU&E*M%S<[>]?9OMKT\M#K=8U*/2=+FNWP2HPB_WF/05Y[8Q75AK^D:
MA=L3)>OYASU 8X_D<UH>)]0EU778[.VM9KRWLV#2Q0@G>W?H#@=OSJGXDU:\
MO)+&>?1Y[#[.WR-)G#=#@94>E:86C*$4K?%>_I;0QS+$PJ3D[_P[6T>KNKN^
MVBTU/3:IZCJ=II5M]HO)0B9P!C)8^@%6D8.BL.C#(KB]8 U3Q]9:?.-UO$H;
M8>AX+'\\ 5YU"DJD[2V2N_D>YB\0Z-+FAJVTEZLOIX[T=K>24BX5D(Q&4&YO
MISC]:A\4^)4MM,2"V,\5U=1+(C#@HI/<YX/TJGXW,%UJ&FZ=$$^T%\,0.5!(
M %2^.R733-.CZR2<#\E'\Z[*5*DYTY*.]^O8\NOB<1&G6BYI\J2NEU?SWZ&A
MX0UI-1L%M2;F2X@3,LLW())/?))_'TJ]XG7=X:OQ_P!,L_D:TXHUBA2-1A44
M*/H*I:XGF:#?IZP/_*N1SC*LIQ5E<]*%*<,+[.;N[6_ R?"MU':>#([B4XCA
M$C$_1B:YCPY<W%SXVM[N?<&N2[_4%6Q^''Z4074ESX:T[0[=OWMU.V_'\*[O
M\>?PK2U%8-(\;:81\EO!; ?0 ,*]%1495%UES?=_P6>$YNI2HV?NT^2_J[?D
MOS+GBV1]6UBPT"!B-S"28CL/_K#)_*MC4?$^DZ!LLY&=WC4*(H5!*CMG) _6
ML7PPLDW]J>);A<R2!_*![*.3_(#\*R/#;>(";C4-.T^VN7GD(>XF8;E/4@?,
M/7TK+V,6N23TAYVNWYG2\3.,O:P6M1NVC=HQVT\]SO-&U^PUR)VM'8,GWXY!
MAE_S[51U/QII&F7+6[-+/(IPP@4$*?J2!63#I5[X>TO6-8NIHS?31D 1?=3)
MZ_7/\JSO#D7B2'3,Z;IUH8KHDFZE(+'MS\W3CIBH6'HMRFG[J\[:^IK+&XE*
M%-QM)W;TOI?32_7UT.ZTW6;+5;%KNTEW1KG>&&"I]"*Y+P;<Q1_VUK=VX2)I
M.7/U)/\ ,5:@TF3PMX1U.2>97N9D);9]U2> !^=<C#$\%OI,.H%ETNYD,K!.
M,G=M))^@'X&M*-&$E-0>C:7ZLQQ.*JP=*56/O)-M=-?=3?;?4].T;6H-;MGN
M+>"XCB5MH:90-WTP35B_>Z2QF:RC62Y"_NU8X!/O4T,<4$*10HJ1H %51@ 4
MZO-DX\UXK0]RG&?L[3>O='F<MKJ$_CBQM=2N_M$P=9'"_=3'S;1^ KOM2ANK
MFQDAL[@6\SX EQG:,\D>^*Y+0O\ B8>/]3O#\RPAE4^G(4?H#74ZMJUKH]F;
MFY? Z*@ZN?05V8ER<X12U26GGZ'F8",(PK5)/1R>K?1:7O\ ><'XIT1-"%M=
MP7]U)=2.0SR/\W Z@CFNZTJ6:?2+.6XSYSPJSY'4D5RVG:7=^*-175]639:+
M_J8/[P[?A[]_I7:]!@4L54]R-.3O);_Y#R^C^]G7@N6#V7?S$HHHKA/7"BBB
M@ IP--HH ?2YI@-+F@!]+FF T;J 'DTE-W49H 7-)FDS29H #2444 )1110
M4M)10 [-&:2B@!<TE%% #3UI*<128H&)11BB@"Y1110(**** "BBB@ HHHH
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M^.2?TQ74BG 41Q%57L]PE@</)KFCMZ_T_F<YJ?AFYO;^2[M-9NK,R ;T3)'
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M]/\ O&^Y#'\SM]!_4X%:<$HGMXY@K*)%#!6ZC(S@^] $E+24M #J<.E-I10
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M6\!@  8 HMH[_P!?U<=]K?U_5CCTU1?#<>G^&+. 7.H" ;3+((HO<[CR><\
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M?B#_ +=__0#6[0 E%%%,04444 %%%% !1110 4AI:* &T444 %%%% !1110
M4444 %%%% "4444AA1110 4444 %%%% !1110 4444 %%%% !113A0  4N*4
M"G4Q#,5A^%[#P]8:9)%X:>W>S,Q9S!<F9?,PN?F+'G 7C-;]>:?!+_D3+S_L
M(/\ ^BXZSE*TTO4ZZ5-RPU2?,U9QTZ.]]_0]&(I*<:;5G*(:2E-)0 4444 %
M%%%  *=2"G"@  IU%.%,0F*3%/I#0!&1BFFI#3*0QM-IU)0 E%%% !1110 4
ME+24 %%%% !3A3:<.M #A3AUIHIU #Z*0&EH 2FFE)IM,0UJ;3CTIE(84444
M %%%% !1110 N:=3*<* 'BBD'2G4 %+BEHIB'T444 -HI324AA1110 4444
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M !1112&%+13J8A,4N*4"EQ0 S%!'%.Q24 ,HI2*2D,**** "E%)10 \&ES3
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MH >.E.IHZ4Z@04444#'4444Q!2&EH- #:***0PHHHH **** ,+2O^1K\0?\
M;O\ ^@&MVL+2O^1K\0?]N_\ Z :W: "BBB@!****8@HHHH **** "BBB@ I#
M2T4 -HHHH **** "BBB@ HHHH **** $I124M(8ZE%(*<*8A:*6BD,2D(IU(
M>E $9%-IYIAH **** "BBB@ I:2G"@!:YOP3XL_X3'1IM1^Q?8_+N&@\OS?,
MSA5;.<#^]T]JZ6N2^'?A6^\(^'Y[#4);>262Z:8&!F*[2B#N!SE34/FYE;8Z
M::I>PFY?%=6_&_Z'6XI<4M%:'*-Q1BG44 ,(IIIY%)B@!E(:<124AC:*#10
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M.REMQ51V X^45#4N9-;'13G35"<9+WFU;\;_ *&[24M)5G.%%%% @H/2BD-
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MAH/+\WS,X56SG _O?I6<DN=7WU.NE*HL-445[MXW?;>WWG24445H<@48HHH
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M2&@!*44E.% 'A5%%%?7GYD%%%% !1110 4444 %%%% !1110!N^#O^1JLO\
M@?\ Z U>K&O*?!W_ "-=E_VT_P#0&KU8UX6:?QEZ?JS[#A__ '67^)_DA***
M*\T]T**** "BBB@ HHHH 2BEI* +E%%%,04444 %%%% !1110 =J;VIU)0,P
M=*_Y&OQ!_P!N_P#Z :W:PM*_Y&OQ!_V[_P#H!K=I %%%% !1110 4444 %)2
MT4 )1113$%%%% !1110 4444 %-IU(: $HHHH **** *&N?\@#4O^O67_P!!
M->+5[3KG_( U+_KUE_\ 037BU>UE?P2]3Y3B'^+#T"BBBO4/G@HHHH ****
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MM7M97\$O4^4XA_BP] HHHKU#YX**** "BBB@ HHHH **** "N[^&_P#S$_\
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MN:@L]*NA<6TEY)"5M4VQ)%GGW.:V** "BBB@ HHHH **** "BBB@ I#TI:*
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M #V_\=/^%<W10!TG]J67_/;_ ,=/^%(=4LO^>W_CI_PKG** .B_M2S_Y[?\
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M35#:?\><'_7-?Y5-0 4444 %%%% !1110!X51117UY^9!1110 4444 %%%%
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M_BP] HHHKU#YX**** "BBB@ HHHH **** "N[^&__,3_ .V7_L]<)7=_#?\
MYB?_ &R_]GKCQ_\ N\OE^:/3R;_?8?/\F=Y1117SA]T%>;_!3_D3;S_L(/\
M^BXZ](K$\+WWA_4-,DE\-I;K9B8JX@MS"OF87/RE1S@KSBLY*\T_4ZZ51QPU
M2'*]7'7HK7W]3;HHHK0Y K!UO_C]3_KF/YFMZL'6_P#C]3_KF/YF@#-HHHH
M**** "BBB@ I*6DH **** "BBB@#J;3_ (\X/^N:_P JFJ&T_P"/.#_KFO\
M*IJ "BBB@ HHHH **** /"J***^O/S(**** "BBB@ HHHH **** "BBB@#=\
M'?\ (U67_ __ $!J]5KRKP=_R-5E_P #_P#0&KU6O"S3^,O3]6?8</\ ^ZR_
MQ/\ )!1117FGNA1110 4444 %%%% !1110!<HHHH **** $HI:2F(**** "B
MBB@#!TK_ )&SQ!_V[?\ H!K>K!TK_D;/$'_;M_Z :WJ "BBB@#F-6_Y"<W_
M?_015*KNK?\ (3F_X#_Z"*I4#"BBBD 4444 %%%% !1110 4444 )795QM=E
M3 ****!!1110 4444 4-<_Y%_4O^O67_ - ->*5[7KG_ "+^I?\ 7K+_ .@&
MO%*]K*_@EZGRG$/\6'H%%%%>H?/!1110 4444 %%%% !1110 5W?PW_YB?\
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MHHH YC5O^0G-_P !_P#015*KNK?\A.;_ (#_ .@BJ5 PHHHH ****0!1110
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M0 4444 >%4445]>?F04444 %%%% !1110 4444 %%%% &[X._P"1JLO^!_\
MH#5ZM7E/@[_D:K+_ ('_ .@-7JU>%FG\9>GZL^PX?_W67^)_D@I*6DKS3W0H
MHHH 6C-)10 [-&:;10 M)110!<HHHH **** "BBB@!#12TE !1113$8.E?\
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M .@BJ57=6_Y"<W_ ?_015*@84444 %%%%( HHHH **** "BBB@ KLJXVNRH
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MY-QT?9M?_P"@)_Y-QT 25V5<3]FU_P#Z G_DW'6S_:NO_P#0M_\ D]'_ (4
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M .18_P#XJCZ_A_YOP?\ D']C8W^3\5_F<_16_P#\(7KW_/C_ .14_P#BJ/\
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MU_#_ ,WX/_(^%_L;&_R?BO\ ,P**W_\ A#-=_P"?+_R*G_Q5'_"&:[_SY?\
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M6_S/I,GPU7#T'"JK.]_P78VZ*Q/[3UW_ *%W_P G4_PH_M/7?^A=_P#)U/\
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M'*T@"N6X4 YP<Y&/7- $YZTE1375O!+#'-/%').VR)7< R-@G"@]3@$X'I5
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M?6"D6^EV#6EW,H^625V#+'GN5 R?3<!5OPO)Y7B;Q9IZD^7%>QSJ#T4R1*6
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MHH ***3O0 M%%% !1110 4444 -HI>])0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %-IU(>M "4444 %%%% !1110 4444 )1110 4444 7**** "B
MBB@ HHHH **** "BBB@ I#2T&@!****8@HHHH **** "BBB@ HHHH #3:=33
M2&%%%% !1110 4444 %%%% !24M% "4444Q!1110 4444 %%%% "&DIU(>M
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MCR%-OT&,GW_.M2EB*L9U+QV7_#O\1X/#RI46I;O_ (9?@D<+ML-2\2Z;+H$
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,@ HHHH 2BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image6.jpg
<TEXT>
begin 644 image6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *I N # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W"BBB@844
M44 %)2TE !1110 4H% IP% "TH%*!3@*!"8I<4M+B@!N*3%/Q28H 9BD(J3%
M(10!$133UJ0BFD4 1TE.(IM !1110 4444 +BI!TKCKV]NI_'5I90W,J0Q@%
MT1R < L<@=>PKHCK6G)=3VSW2++ NZ4," HX[].XK:="44K:W5SEIXN$Y23T
MY7;7J[&DO2GBLW3M:T[5'=+*Z65TY9<$''KR.17*^,/$$5Q-#IMI>%(Q(5NG
M4,-O.,>XZ]*=+#SJ5.2UB<1C:-&BZUTUTLUJSO:=7FFM6UAIWA:&+2[B:>&^
MG#[I.IV@C@8'?':N[$]IHFD6ZW4Z110QK'N8]<#MZU52ARQ33O=M;=B:&,]I
M-QDDK)-N]UKM^&MS0I#6/_PE>A_9?M']H)Y8;:?D;=G_ '<9[>E7;[5;+3EA
M-U-Y?G-MC^4G<?P%9.E-.SBSH6(HM<RDK+S1:HK+;Q%I"7PLC?Q>>6V[1DC/
MINZ _C1<^(](L[H6T]]&LV<%>3M/N0,#\:?LJCTY7]PGB**3;FM--UN:9J-J
M@O\ 4[/3+87%Y,(XF(4-M+9)^F:J7/B+2+:Y6WFOHUE)QCDX^IQ@?C4QISEL
MFRIUZ4/BDE\R^U1FJ5]KVEV$PAN;R-)#_" 6(^N,X_&K0EC:+SA(IB*[@^>,
M>N:3A))-K<J-6$FXIIM;CJ*RX_$>D2S-$E]&74$G@@''H<8/X43>(-.CTO[>
MMP#"Q*(=C?,P[8QFJ]C4O;E?W&:Q-!J_.OO73<U**Y3POXC:]+0:A=A[J23$
M2"+'&,]0,?GZ5NWVLZ=IK;;NZ2-C_#RS?D.:JIAZD)^S:NR*.-HUJ7MD[+SM
MIZEVBJMEJ-GJ,1DM)TE4=<<$?4'D5%)K6G17$]O)<JLD"[I 00%''?&.XJ/9
MSO:VIM[:GRJ7,K/K<OT5F1>(-+FEMXX[H%[C_5#8PW<X]..1WJQ?ZI9Z6B/>
M3"(.<+\I.?R%'LIWY;.XE7I.+DI*RZW1;HH'(R.]<G'>75WX\>!+B5;:!3NC
M#G:<+Z=.IJJ5)U+^2N17Q"H\MU?F:7WG644A(4$D@ <DFLL^)M&%QY)OX]V<
M9P=O_?6,?K41A*?PJYI4JTZ?QR2OW=C6IRU!-=06T!GGF2.(#[[-@55L->TO
M4+CR+6[627LI4J3],CFA0DTY):()5:<9*,I)-[:[FL*D KE1;65[XV\\:D[W
M-LG_ !ZB,X7 Q][IWZ5M7VN:9I;;;R\2-S_!RS?D,FKE2=THZMKL9PQ$6I2G
M9).U[K^EZ&C152PU.RU.(R65PDRCKC@CZ@\BHFUO34NY[9[M$EMUW2A@0%''
M?&.X[U/LYWM;5&GMJ?*I<RL]M30-1M5/3]<TW5'=+*Z65TY9<$''KR!D5<:E
M*,HNTE8<*D*BYH.Z\B-ZC-<I?ZWJ&L:PVEZ,XBCC.);CZ=3[#^=6+31]:T^^
M@<:O)=P,V)DESP/;)/Z8K=X?EC><DGV.18WGFU2@Y).S:M;_ ()T-%4+[6]-
MTY]EU=HC_P!T L1^ S4UG?VNH0^;:3K*@ZXZCZCJ*Q=.:CS-:'4JU-SY%)7[
M7U+-%4XM4LY[^2QBFW7,0RZ;3QT[XQW%!U2R&I#3_._THC(CVGTSUQCI1[.?
M;S^0>VIVOS+>V_7MZ^1>S2@UG-K&GI=36[W2K+ NZ0," HX[].XI;#6=/U)W
M2TN5E=.2N"#CUY'2CV<[7L["]O2YN7F5_4T@U.W5Q.K^*]FLVL-E>!+5' N6
M\O/\7(Y&>GI75VEY!?6R7%L^^)\[6P1G!QWJZE"=.*E);F5'&4:U25.#UCZ?
MAZ%S=[T9%19HS6)U$FZFEJ9FC-  324F:3- !FDQ110,:4![4GE)Z"GT4 1^
M2GH*<(U'84ZB@!,#TI:** "BBB@ HHHH **** "BBB@"Q1110 4444 %%%%
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MI7%^(SE4D)"_CDFNEHK:%>I"/+%G-5P=&K/GG&[^?Y;!2YI**Q.D7-&3244
M+FDHI10 E+BG 4[% $>*2I<4TK0!'12TE "TX&FTH- $H-/!J$-3LT 2YHS3
M,TF: '$TPFC=49;-  >M-HHH 2BBB@ HHHH **** $HHHH **** "BBB@ HH
MHH **** "BBB@!#2&G4V@84444 %%%% !1110 4444 %%%% !1110 4>]%%
M!1110 4444 %%%% &@:8>E.-,:@0TTVG&F]J "BBB@84444 '>E!I*2@!X-.
M!J,4[- B3-+FHZ7)H ?FC-,R:3- #R::329II- "DTW-(32$T !I*** "BBB
M@ HHHH **** "BBB@ HHHH **** "G+3:>* 'BE I!3LT &*8>E2&F&@"(TE
M*:2@!*6DHH 6ES3:6@!^[WI-U-I* '9I*3-)0 M)110 4444 %%%% !1110
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M/ %<M;ZWI6EW_C"]DLS;"PEC>[G$I<W!\E2"%/"G&%P.M0^);W5KKP+KYO\
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MHHYR WMCFMOQ*[6+^&M1,H:6*_B@=UZ2+*I1OPR5/X4EK;UL-Z?F=712TN*
M&XHIVVN=\<:=->^%;F2U4F\LBM[;8Z^9$=X'XX(_&BZ6XTF]$=!17(:O>P^)
M1X9L+9@]OJ3I?RX/_+"(!^?JYC'XFK<_B:[=M0FTW3$N['39'CN96N?+=F0
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M(H 8:2GTTT )113A0,YCQIX<U#7;.TDT>ZAM-3M)2T4TN=NQU*.. 3]ULCW
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MC_Y%?_XJ@#='6GBL$>$="_Y\?_(S_P#Q59^J^&M(MO)\FTV[LY_>.?3WH [
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MGM=%>*;F]:-S>M']EUNZ_'_(/]8,+_++[E_F>UT5XIN;UHW-ZT?V76[K\?\
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M"G#I0 \&G4P49H 4TUNE+FF$T >5^+_^1IO/^ ?^@+6)6WXN_P"1HO/^ ?\
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M $-:VJQ?%O\ R+%Y_P  _P#0UK;#_P :'JOS.7&_[K4_PO\ (\PHHHKZD_/
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M* $HHHH *2EHH 2I;;_CZA_WU_G452VW_'U#_OK_ #H Z.BBE% !2XH%. H
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M&OJ</_!AZ+\C\[QO^\U/\3_,****V.8**** "BBB@ HHHH **** "O7M&_Y
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MM;8?^-#U7YG+C?\ =:G^%_D>34445]2?G@4444 %%%% !1110 4444 %%%%
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MXI2]_P"V?_H:UMA_XT/5?F<N-_W6I_A?Y'D]%%%?4GYX%%%% !1110 4444
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M110!:HHHH$%%%% !1110 'I6)J7_ ",^A?\ ;Q_Z *VZQ-3_ .1HT+_MX_\
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M_P +_(\OHHHKZD_/ HHHH **** "BBB@ HHHH **** .K^'W_(>G_P"O5O\
MT):]&(KSKX>_\A^?_KU;_P!"2O1S7S^8_P ?Y'VN1?[HO5D)'-,-3,*B-<![
M P\4E*:2@9:HHHH$%%%% !1110 5B:G_ ,C1H7_;Q_Z *VZQ-3_Y&C0O^WC_
M - % &U[4E.--H&%9.M?\L/^!?TK6K)UK_EA_P "_I0!E4444""BBB@ I*6D
MH *44E% QU%)2T"%%+3:7- '0:'_ ,>;_P#70_R%:>:RM$/^AO\ ]=#_ "%:
M>: '9I*3-)F@!::30332: $)IIH)I#0!Y7XO_P"1IO/^ ?\ H"UB5M^+O^1H
MO/\ @'_H"UB5]3A_X,/1?D?G>._WJI_B?YA1116QS!1110 4444 %%%% !11
M10 5Z_HW_(#T_P#Z]H__ $$5Y!7K^C?\@/3_ /KVC_\ 017E9K\$?4^BX=_B
MS]"[2445XI]6%8VC66@VNI:I+I#P->3S;KX17!D829;[PR=IR6XX[^E;->>?
M#S_D;_&__7^/_1DU9R=I11UT*;E0JR4FK):=]4M?S/0Z***T.0*Y:NIKEJ "
MBBB@ HHHH **** "BBB@ HHHH *EMO\ CZA_WU_G452VW_'U#_OK_.@#HZ2E
MHH 2BBB@ HHHH *Q?%O_ "+%Y_P#_P!#6MJL7Q;_ ,BQ>?\  /\ T-:VP_\
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M >R%%%% &I1124"$--/2G$TPT -/2FTII* $K$U/_D:-"_[>/_0!6W6)J?\
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MD%+0 4444 %3VG_'Y!_UT7^=05/9_P#'[!_UT7^= '5TM)2TQ!1110 4444
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M >G_ /7M'_Z"*\@KU_1O^0'I_P#U[1_^@BO*S7X(^I]#P[_%GZ%VBBBO%/K
MKA/ E_>WGBGQA#<W=Q/%;WNV%)9"RQC?*,*">!P.GH*[P"L?1;'0+;4M5ETA
M[=KR:;=?B*X,C"3+?>&3M.2_&!W]*B2;DF=5&I&-&I%J[:5O+5&QBE"T_%*%
MJSE&[:Q/[%N/[\7YG_"M[;1MH P?[%N/[\7YG_"D_L:X_OQ?F?\ "M_%-(H
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M: )@:=40-/!XH =129HS0 M%)FD)H 4FN?\ &1_XI6]_X!_Z&M;I-8'C _\
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MG:9J<5_<:GK.K30,6MAJEZTZVYZ91<  X[G)KK*;=UJ)*VQ!=RSPVKR6UO\
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MQ_Z * -NBBB@ HHHH ***6@!M)3L4F*!B4444 %%%% !1110 4E+24 %%%%
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M=311]<K_ ,S#^S,)_P ^T<M_P@>E_P#/>\_[[7_XFE_X0/2_^?B\_P"^U_\
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M&F&GGK28K@/8(B*3;4V*,4 !I*4TE !1110 4444 %8FI_\ (T:%_P!O'_H
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M-5%4U0<I1UV6KU?_  #.HZ[Q2ITZFF[5EHNU[7U-VL#7/%,.D3B". W,H&9
M'VA!VR<'FK'B+6#H^F^8@!FD;9'GH#ZGZ5Q>I7.F?V7#;6UX9[B:827<Y1@3
M^8Z<U6$PW.U*:NB,QQWL8N%.24DK]/DDGNW^"^1Z+9SM=64%PT?EF6-7*9SM
MR,XS4U16TD4MK%) <Q,@*'&,C''6I:XI;L]2'PJ[N%%%. XI%"8I=M/ I<4
M18K%T;PS9Z%J6JWUK+</+J<WG3"5@54Y8_+@# ^<]<]JWB*\X^'G_(X>./\
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MSP**** "BBB@ HHHH **** "BBB@#J_A_P#\AZ?_ *]6_P#0EKTE:\V^'_\
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M5']J4>S_  _S#_5_%?S1^]_Y'E5%>J'P?H/_ #X_^1G_ /BJ3_A$-"_Y\?\
MR,__ ,51_:E'L_P_S#_5[%?S1^]_Y'+_  __ .0]/_U[-_Z$M>EK63IV@Z9I
M<[3V=MY4C+L+>8S<9![D^@K5%>7BZT:U3GB?0Y;A9X6A[.;5[]!U%%%<QWA1
M110!%1110 4444 %%%% !6)J?_(T:%_V\?\ H K;K$U/_D:-"_[>/_0!0!MT
M444 )1110 4444 %%%% !1110 AI*4TE PHHHH *.U%':@ HHHH *44E% #Q
M3@:8*4&@1+13-U+NH =32:3-(30 AIIZTI--H :>M)110 444N* $HIV*,4
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MA?\ ;Q_Z *VZQ-3_ .1HT+_MX_\ 0!0!MT444 %)2TE !1110 4444 %%%%
M!2&EHH ;1110,**** "BBB@ HHHH 2BBB@ HHHH **** "BBB@ H%%+0 HIX
M%-%/6@0[%+13L4 -I"*?BFT 1D4PBI#3#TH C-)3J;0 5ROA7Q->ZYKOB*QN
M8H$BTVY\F$Q*0S#=(/FR3D_(.F.]=57.^'O"W]@ZQKE_]L\_^U+CSMGE;?*^
M9SC.3G[_ +=*B7-S*VQTT725*HI_%96^]7_ Z*@=:**LYB133P:A!IX- $P-
M+FHLTN: 'YII-)FFDT !-1FE)IM !2444 %+12@4 )13PM+MH CI#4NVF$4
M,HIV*2@!**** "BBB@ HHHH **** "DI:2@ HHHH **** %IPI*<M "@<4_%
M '%.H ;2$TZF-0 FZC=3:0F@">BBB@ HHHH **** "L34_\ D:-"_P"WC_T
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MU)+D^4^%1?PYY],UW%C>V^HV<=W:2>9!(,HVTKGMT/-);,;W+%%%% !1110
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MDY8@<GD]?4U;I#18:;2LAIIA%2&F,*0$9%1FI"*8: &T444 %%%% !24M)0
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ME'HGZ/0B->2C3;G]IKIJO>L_P1UE%%%<)ZX4444 %%%)F@"0&G U'FG T")
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MCN8+WQR;RWF22VM;,^;*ARH//&1]?T-.-*/L]KZ/7S6Q,\1-UM';6*2\GO\
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?4)J5JB- #310:* "BBB@ I124X4 %*!0.M/% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image7.jpg
<TEXT>
begin 644 image7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +\ \ # 2(  A$! Q$!_\0
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MBBB@ HHHH **** "BBB@!**** "BBB@ HHHH **** %[444HH <!3A2"G+0
MHZ4M%%,044M%(8E(12T4Q#*8PJ0TPTAC*8:?WIIZT -HHHH&%%%% "'I24IZ
M4E A<T9I** %S1FDHH 7-)110 44IZTE !1110 444N* $HIV*-OM0 VBG$4
MF* $I124HH <!3A0.E+0 44M)0 4F:;FDW4 /S1NJ/-&: '$\4TTE)F@ S24
MM)0 4M)10 ZG!J92T /W49]Z910!(#3@:BS3@: )@:7-1YI<T /)XIA-(332
M: $8U&:4FFF@!**** +U%%% !1110 AI*=VIM !1110 4444 %%%% !1110
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MXB6'VOPK)<IQ-9.LZ-Z<\_TK:\/:C_:WA^QOCC=)$-_^\.#26J8WNC2HHHH
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M0>/=6.D>$+QT;;-<_P"C1GT+9W'\%#&N8\/^ M6_L2UG@\27>G"XC6=K>%&
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M/7GKBND)S24HHZ6#K<S]:T:VU_29=.O#(L,A4EHR P*D$8SGN*Y7_A4^A?\
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M4X]*;0 44"B@ HHHH **** "BBB@ HHHH **#10 4444 %%%+B@!*=BBG8H
M;13P*7% $=%28IN* &$4E/(I"* (Z*4BDQQ0 4HIO>G"@!PI::*=0 4444 %
M**2G"@!U%%% !1110 4444 (:8:D-1GK0 PTVGFF4 )1110 4444 %%&*,4
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M,]:>:8: $-,-.-,H 2BBCO0 M%%*!0 E%/I#0 RD/!IQIIZ4 )1110,****
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M^IQO@*/S%U'4&!_>RX!/<=:9X15KWQ!K&HL.K%%/H2?\*[6BB>)YG-V^*R]
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MF: %SQ3":7--SB@ )I#THI#0 E)2TE !1110 4444 %%%% "TE%% !2YI**
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MO,9(]<\\4[!?2YU5%<EK'C&\AU6?2?#OA^XUV^M0OVG;<);PPY&=ID?@MC'
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M3BVF):BFF,:4FF$U(Q#3#3C3*!B&BDI1UH$)1110 4444 %%%% "@T[-,HH
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MPC&/F)Y[C&* -X&GBO._^$\O7\0BR@A@9#!]H6V* LT>"0QD\S*Y"Y_U14<
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MU+3$%%%%(84AI:0T ,IAZ4\TWM0!'2&E-(>M "4444#"BBB@ KD_$(.D^,M
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MY?\ <;^5 '#BUN<?\A?4_P#P)-+]EN?^@OJ?_@2:M#I10!5^RW/_ $%]3_\
M DT?9;G_ *"^J?\ @2:M44 5?LMS_P!!?5/_  )-'V6Y_P"@OJ?_ ($FK5%
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M,6M:"4JL4^Z_,PQ4G"A.4=TG^1YS_;FJ_P#02N_^_P"W^-']NZM_T$KS_O\
MO_C6?17T/U.A_*CX?^T\7_S\9H?V[JW_ $$KS_O^_P#C1_;NK?\ 03O/^_[_
M .-9]%'U.A_*@_M/%_\ /QFA_;NK?]!.\_[_ +_XT?V[JW_03O/^_P"_^-9]
M%'U.A_*@_M/%_P#/QFA_;NK?]!*\_P"_[_XT?VYJW_02N_\ O^W^-9]%'U.A
M_*@_M/%_\_&:']N:K_T$KO\ [_M_C1_;FJ_]!*[_ ._[?XUGT4?4Z'\J#^T\
M7_S\9H?VYJO_ $$KO_O^W^-']N:K_P!!*[_[_M_C6?11]3H?RH/[3Q?_ #\9
MH?VYJO\ T$KO_O\ M_C1_;NK?]!*\_[_ +_XUGT4?4Z'\J#^T\7_ ,_&:']N
MZM_T$[S_ +_O_C6QX:N=0UG65L[C5M02,QLV8[A@<CZYKEZZ7P)_R,Z?]<7_
M *5CB,+1C2DU'6QU8',,5/$PC*;:;.W_ .$:_P"HWK7_ (%__6I?^$:'_0<U
MK_P+_P#K5LYI:^?/M3$_X1K_ *C>M?\ @7_]:D_X1K_J-ZS_ .!?_P!:MRB@
M#C;G39H?$MCIJZQJIAG@DD9C<G<"O3'&/TK4_P"$:_ZC6L?^!7_UJGBNM'U#
MQ#(D;^9J=@A1AAQY:MC/^R>WK6MBDFGL.47%V:,#_A&_^HUK'_@5_P#6H_X1
MS_J-:Q_X%?\ UJWL4A%,1@_\(W_U&=8_\"O_ *U4-1TF2T>(1ZOJIW@D[KGZ
M>U=9BL;6_P#66_\ NM_,4 <_]EN/^@MJ?_@2:/LMQ_T%M3_\"35NDH J_9;C
M_H+:G_X$FC[+<?\ 06U+_P "35JB@"K]EN/^@MJ7_@2:7[)<?]!;4_\ P)-6
MJ* *OV6X_P"@MJ?_ ($FC[+<_P#06U/_ ,"35NEH I_9+G_H+:G_ .!)H^RW
M'_06U/\ \"35RDQ0!4^R7'_06U/_ ,"32?9;C_H+:E_X$FK=(: *GV6X_P"@
MMJ7_ ($&C[+<?]!74O\ P(-6J* *OV6X_P"@KJ7_ ($&KFGZ3)=F7S-7U0;-
MN-MSZY]O:FUJ:+UN/HG_ +-0!'_PCW_48U?_ ,"?_K4?\(]_U&-7_P# G_ZU
M;-% &-_PCW_48U?_ ,"?_K4?\(]_U&-7_P# G_ZU;-% '*6NFRSZ]J5@VK:H
M(K5(60BY.X[U).>*TO\ A'O^HQJ__@3_ /6K22S@BO9[M(\3SA1(V3\P48''
M0?A4] &-_P (]_U&-7_\"?\ ZU'_  CW_48U?_P)_P#K5M8HQ0!B_P#"/?\
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M4F* ("*2IB*85H 924ZDH N4444 %%%% !1110 4444 %%%% %/5O^0+?_\
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MUF_W&_E4QJ&Y_P"/6;_<;^5(9QXZ"EI!T%+0 E%+24 %%%% !1110 M+244
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ME%% PK4T7K<?1/\ V:LNM31>MQ]$_P#9J!&K1110 4=Z*4=:  4\4P=:<#0
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MS2U'2YH ?7EWC;_D:)_^N<?_ *"*].S7F'C7_D:)_P#KG'_Z"*]'+/XS]/\
M(\3/_P#=5ZK]3GZ***]X^-"BBB@ HHHH **** "BBB@ HHHH **** "O7/"/
M_(JZ?_N-_P"A-7D=>M^$?^15T_\ W&_]":O-S3^$O7_,][A[_>)>GZHW*6DI
M:\(^O"BBBF(**** "DI:2D,C:F-3VJ-J +@IV*04HH **6B@!I%,-2'I3#3$
M,H[T'K12&%%%% %/5O\ D"W_ /U[2?\ H)JKX8_Y%;2_^O9/Y5:U;_D"W_\
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M!;2W4\EO$/W<3R$JG(Z#H*[6LX6MH=.(4U-<[OHOR"CM12&K.<*PM>_U]O\
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M]O\ ]=5_G0!U%.S3:* '4N:92YH =FDS1FFYH =3:*0F@!#UK"\9?\BE??\
M;/\ ]&+6[6%XR_Y%*^_[9_\ HQ:VP_\ &AZK\SFQO^[5/\+_ "/*:***^I/S
ML**** "BBB@ HHHH **** "BBB@ HHHH *Z7P)_R,Z?]<7_I7-5TO@7_ )&9
M?^N+_P!*PQ7\&7H=F7?[W3]4>I9II-)FD-?+GZ"(:**2@"E;ZO8W>I7.GP3[
MKJV_UT>QAM_$C!Z]JNUR&@V=U#X]U^YEMID@E \N5HR%?D=#T-=?4Q;:U-J]
M.,))1?1?D%%%%48A6/K?^LM_]UOYBMBL?6_]9!_NM_,4 95%%% "T444 %&*
M=BB@!N**=24 )24M% #:*6DH&%%%% !6KHG6X^B?^S5E5K:)]ZX_X!_[-0!K
M44H%.Q0 W%+BG8I0M AF*,5)MHVT ,I1UIV** %!KROQQ_R-5Q_USC_]!%>I
MUY7XW_Y&FX_ZYQ_^@BO1RS^,_3_(\3/_ /=5ZK]3GJ***]X^-"BBB@ HHHH
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M 4444 %%%% !4]E_Q_V__75?YU!4]E_Q_P!O_P!=5_G0!U%%%% "9YI:0TE
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M4VGD4VO"/KQ**** "BBB@ [THI*44 2#K4JU$#4BF@!]%!HH **** "BBB@
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M2_\ KV3^5 &L**** "HY_P#CWE_W&_E4E1S_ /'O+_N-_*@#DAT%+2#H*6@
MHHHI@+24M)0 4E+24@"BBB@ HHHH **** "I[+_C_M_^NJ_SJ"I[+_C_ +?_
M *ZK_.@#J**** "BBB@!IZT4II*  =:=2"EH 45A>-/^10OO^V?_ *,6MZL+
MQI_R*%__ -L__1BUMA_XT/5?F<V-_P!VJ?X7^1Y+1117U)^=A1110 4444 %
M%%% !1110 4444 %%%% !72>!?\ D9E_ZXO_ $KFZZ3P+_R,R_\ 7%_Z5ABO
MX,O0[,N_WNGZH].HHHKY<_00I#2T4 <?H-Y=3>/=?MI;F9X(@/+B:0E4Y'0=
M!77U1MM(L;34;G4((-EU<_ZZ3>QW?@3@=.U7JF*:6IM7J1G).*Z+\@HHHJC$
M.]8^M_ZR#_=;^8K8K'UO_60?[K?S% &71110 E%+24 %+244 +2444 %%%%
M!24M)0 4444#%K7T/[US_P  _P#9JR*U]#ZW/T3_ -FH$;0-.J,&G@\4 /S2
MTRES3$.HI,TF: %)IM%(32&(37E?C?\ Y&FX_P"N<?\ Z"*]2)KRWQM_R-,_
M_7./_P!!%>CEG\9^G^1XF?\ ^ZKU7ZG/4445[Q\:%%%% !1110 4444 %%%%
M !1110 4444 %>J^%_\ D6-/_P!QO_0FKRJO5?"__(L:?_N-_P"A-7FYI_"7
MK^C/>X>_WB7I^J->DHHKPCZ\**** "BBB@ HHHH 0T4&B@"]1113$)10:*0P
MHHHH **** "BBB@"GJW_ "!;_P#Z]I/_ $$U5\,?\BMI?_7LG\JM:M_R!;__
M *]I/_0357PQ_P BMI?_ %[)_*@#6HHHH *CG_X]Y?\ <;^525'/_P >\O\
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M8^M_ZR#_ '6_F*V*Q];_ -9!_NM_,4 9=%%% !24M)0 4444 %%%% !1110
M4444 )1110,*UM$ZW'_ /_9JR:U=$ZW'T3_V:@#9!IP-1T[- B3-+FH\TN:
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M_?!H @-%3_9+G_GWE_[X-)]DN?\ GWE_[X- $-%3?9+G_GWE_P"^#1]DN?\
MGWE_[X- $-%3?9+G_GWE_P"^#1]DN?\ GWE_[X- $-%3?9+G_GWE_P"^#1]D
MN?\ GWE_[X- $-%3?9+G_GWE_P"^#1]DN?\ GWE_[X- $-3V7_'_ &__ %U7
M^=)]DN?^?>7_ +X-36EM<+>P,T$@42*22AXYH Z.B@T4 %%%% !2&EHH ;2]
M#244 .K"\9_\BC??]L__ $8M;@K#\9?\BC??]L__ $8M;8?^-#U7YG-C?]VJ
M?X7^1Y/1117U)^=A1110 4444 %%%% !1110 4444 %%%% !72>!?^1F7_KB
M_P#2N;KI? O_ ",R_P#7%_Z5ABOX,O0[,N_WNGZH].Q2XI0*7%?+GZ"-Q1BG
MXHQ0!PGAS_DHWB3_ '1_-:[;%9UEK]I?ZW?:3%',MQ9C,C,HVGITYSW]*U,5
M$$DM#HQ,I2FG)6T7Y#*2G$4E6<XE8^M_ZR#_ '6_F*V*Q];_ -9!_NM_2@#+
MHHHH *0TM% "4444 %%%% !1110 4444 )12TE PK5T3K<?1/_9JRJU=$ZW'
MT3_V:@#6I<\TE% #LT9-)24 .S29-)10 4444 )FO,O&O_(SS_\ 7./_ -!%
M>FXKS+QK_P C//\ ]<X__017HY9_&?I_D>'G_P#NJ]5^3.?HHHKWCXT****
M"BBB@ HHHH **** "BBB@ HHHH *]4\+_P#(L6'^XW_H35Y77JOA?_D6-/\
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M6MOZ_KO\NP-WU_X;3^K+_@GLU%%,FB2>"2&5=T<BE&&<9!&#4@5M6_Y M_\
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M6YY]C5!?(UR::ZO[N*V"96- 0&QZG/)J[X?ODMM+N#<,J6\,F%D"8W9^G6A
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M5:NB=;CZ)_[-0,UJ*** "BBB@ %/%-IPH 6GTRG T"$->6^-O^1IG_ZYQ_\
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M***0PHHHH IZM_R!;_\ Z]I/_0357PQ_R*VE_P#7LG\JM:M_R!;_ /Z]I/\
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M7IIKS+QK_P C//\ ]<X__017HY9_&?I_D>'G_P#NJ]5^3.?HHHKWCXT****
M"BBB@ HHHH **** "BBB@ HHHH *]5\+_P#(L6'^XW_H35Y57JOA?_D6-/\
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MHIB"BBB@!"*8PJ2F$4ACZ***8@HHHH **** "D/6EHH 2BBBD,IZM_R!;_\
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M *\Q\:_\C//_ -<X_P#T$5Z=7F/C7_D9Y_\ KG'_ .@BO1RS^,_3_(\//_\
M=5ZK]3GZ***]X^-"BBB@ HHHH **** "BBB@ HHHH **** "O5_"G_(L:?\
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M1110 E%%% !1110 4444 %>8^-?^1GG_ .N<?_H(KTZO,?&O_(SS_P#7./\
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MFD)II- %FBBBF(**** "BBB@ HHHH *0TM% %+5O^0+?_P#7M)_Z":J^&/\
MD5M+_P"O9/Y5:U;_ ) M_P#]>TG_ *":J^&/^16TO_KV3^5(9K4444 %%%%
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M\JMZO_R!;_\ Z]I/_0353PQ_R*VE_P#7LG\J0S6HHHH **** "BBB@ HHHH
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M!IV:C!I<T /S24W-!-  33#2FFT !Z4VE-)0,**** "BCM10 4444 )1110
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M/^$,T#_GP_\ (TG_ ,52?\(9H'_/A_Y&D_\ BJZ$]*95_6*W\[^]F/U+#?\
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M24[!HQ0 VBG8-&#0!=I#2TAZ4Q"4444 %%%% !1110 4444 4]7_ .0+?_\
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MG/?TK4J()):'1B)2E-.2MHOR"BBBK.<**** "BBB@ I*6B@!**.U% !1110
M4444 %%%% #313CTIM PHHHH **** "BBB@ H%%% #J>*9FE!Q0(EI0:8#Q3
MJ '$\4TT4A- "$U&:JZKJ<&DV+7=P':-2%P@R236(_BJWO\ 1-1N+.*X0P1_
M>D4#D\<8)K6%&<US):&%3%4J<N24M;7L+>^*TCNY+73[&?4)8_O^5G:/Q /\
MJLKKB1:+_:-_;2V>#M,+CYB?;I7+V46OZ;X<6^M9[6*VQYS#&9'R>IR#_.KN
MLB^UOP]I=_%;>:RMYDL29Y^@[UVRP])-1TM>S=]?\CRJ>-KN,IN]^6ZC;3Y/
M=V+,?C BYA6ZTNXMK>9L1S.3SGVP/T)KJ*X+6-0OM8N--LI=,:SW3 HKMEF_
M @$"N[=EBC9F.$1<GZ"L,32C!1:5F[Z7N=> KSJ2FI2YDK:M6W^XJZGJ,&EV
M37,Y)QPJ#J[=@*H:+XA_M:"[FDM#;);?>_>;B?T%<^FNZ??WLVHZA<[3""MG
M;;&(4_WB0,9J]X,%O=Z'>0,Q,TKMYP .0#TY_.M)894Z+<T[Z:F,,<ZV)C&G
M-<KOII=V[]M=EVU)X/$&H//83RVL"V-]+Y<0#$RC_:/;\*TKS4I?MZ:=IZ)+
M=?>E9\[(E]3COZ"L&:PET^YMK6.^:[N;=";=&C"I:IW=R.I':I]'U6.S^S1+
M8S?9KR8H+V1QNFD_O%>N/QISI0:YH*_]>?E]XJ>(J1?)5DU>U^MMKVMIO]RW
MU9U=**2BO//8%IV:910 _/O3<TE% !1110 4X"D%/ H  *7%. S3@* (\"C:
M*DQ28XH FHHHIB&T4'K10 4444 %%%% !1110!3U?_D"W_\ U[2?^@FJOA?_
M )%;2_\ KV3^56M7_P"0+?\ _7M)_P"@FJOA?_D5M+_Z]D_E0!JT444AA111
M0 4444 %%%% !1110 444E "T444 %%%% !0>E%% #:*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ IM.IO>@ HHHH **** "BBB@ I*6B@!****
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MYS0M7_7]?\&_83T_K^O^&]3N***9-*D$$DTK;8XU+L<9P ,FD!6U?_D"W_\
MU[2?^@FJOA?_ )%;2_\ KV3^59^H^+-#GTJ\BCOLO) ZJ/*<9)4@=JTO#<;P
M^&M-CE1D=;= RL,$'% &I24M)2&%%%% !1110 4444 %%%% !24M% !1110
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M?^O07]??N%%%%( HHHH *2EH/2@!****0PHHHH **** "BBB@ HHHH ****
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MHH **** $HHHI#"BBB@ HHHH **** "BBB@ [44=J* "BBB@ HHHH *0BEK
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MZ[/,<[-N[.,XYQ7;S6\-S;M;SPQRPN-K1NH96'H0>,5G_P#"-Z%_T!--_P#
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MH7_X2?Q>=0LSOT_2[=XH)L?++.PY*^H'2J_@S7](TCP@L5]>PV\]O)+YT,C
M2;MQ/"]3GVKMXHHX8UCB14C4855& !["H&TK3I+L7DEA:M= Y$S0J7!_WL9I
M;:('W.>\+@65A?:]J[I9OJ=R9L3N$\M.B*2?;G%5=.U?3;OXB:C=OJ%IY45O
M';6K&9?WA/+!>>>?2NQNK.VOH?)N[:&XBR#LE0.N?7!JM%X>T6&59(](L$D0
MY5EMD!!]0<4UN#V+^*,5)BC%(".FD5(132* &4E.--H&%&>:*0T .!IP-1BG
M"@!XIPIM/% APZ444X4 )BEQ2T4Q#<4E/I"* (R*:14E-(I#(B.*9BI34;4
M-HHHH **** +U%%%,04444 %-IU(>E "4444#"BBB@04444 %%%% !2&EHH
M2BBBD,**** "BBB@ HHHH ***.] !12'K2T %%%% !1110 4VG4A]: $HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** $/6DI324 %%%% !1110 44
M44 %)2TE !1110 4444 %%%% !2=Z6B@ HHHH **** "BBB@ H-%% "4444
M%%%% !1110 4444 -HI3TI*!A1110 4OI24OI0 M+24HH$/ IU(.E.'6@ Q1
M3J0TQ#2*813S332&1FFFGTPT )1110,04X4E** )!UIXIB]:D'2@0HIU-IU,
M04444 %%%% #:0TXTV@9&:C-2MT-1-2 9WHI3UI* "BBB@"]1113$%%%% !2
M&EHH ;12FDH **** "BBB@ HHHH **** $HHHI#"BBB@ HHHH **** "BBB@
M!*6CM10 4444 9NH:_I>ERB*\NTCD(SL"ECCW !Q5K[?:>1%.;J$13$"-RX
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M\WGT_P S9HHHKG.T**** "BBB@ /2FTZFGK0 444=Z "BBB@ HHHH *2EHH
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M;K>WJ:1K5'74-&FK^:[7]?D;AIII<TPFN<[!#3#3CTIIH 2BBB@84HI*4<4
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M44 %%%% !1110 4444 %%%% !333J0]* $HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** &GK12FDH **** "BBB@ HHHH *2EI* "BBB@ HHHH **
M** "D[TM)WH 6BBB@ HHHH **** "@T4&@!**** "BBB@ HHHH **** $[FD
MH/6B@84444 %%%% !FES244 .S3<T4E "YHS244 %%%% !1110 4444  -*#
M3*4&@1)FG9J/-*": ),TN?>HZ6@!Y:FYI*0F@!<TTFD)I*!B'-)0:*!!1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>zk2125664slide1.jpg
<TEXT>
begin 644 zk2125664slide1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (< \ # 2(  A$! Q$!_\0
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MZC_V'M0_]'&@#UW7M4_L/0]1U'RO.^QVTEQY>[;OV*6QG!QG'7%8OPS\:?\
M"R/ .B>)?L?]G?VE;B?[+YOF^7DD8W;5ST]!5SQY_P B-XB_[!UQ_P"BFKC?
MV8_^2!^"?^P>O_H34 8?B;]I*S\(_&RV\!ZEHLD5E/Y$?]N+<9CCFF4F-'39
MP"01G=[XX..O^*GQ*_X5G9^'I_[._M+^UM9MM(V^?Y7E>;N_>?=;=C;]WC.>
MHKR#Q7\/;/XI?'+XI>&;U@BW?AVQ,,Q&?(F4DQR >JG\P2.]<IXB^(5[XS^&
M_@/2]>!B\7>'?'&G:9JT+9W%T,@27GJ'49ST)#8XH ^LM>U3^Q-#U'4?*\[[
M';27'E[MN_8I;&<'&<=<5X_X1^-WQ*\:^&[#7-)^$4$^FWT?FP2-XHA0LN2,
M[3#D=.]>I>//^1'\1?\ 8.N/_135X3^S[)\7A\)O"(TB#P2^@_9E\EKV:\6Z
M\K<?O!4*[NO0XH ^DK.]=='BO-1B6PE6 2W$6_S!"=N77<!\V.1D#G%>/Z1^
MT-XK\66+:]X6^%6HZ[X.WN(M4&J00W-PB,RL\5JPW-RIP-P)KV2ZM(=0L9[2
MX02V\\;12QG^)6!!'Y&OG.UM_B+^RCH<T=I!;>/OAC8.\JQAC#JFFP%BS?[,
MB+DGN3S]Q>C$?2UC=?;K&WN3#+;^=&LGDSKMDCR =K#L1G!%$O450\+^*+#Q
MCX;TS7=,D:33]0MTN8&==K;6&1D=CZBKLK9Z4!U/%?%7Q.\8ZY\3M2\$> +'
M1!=:+:Q7.IZAXA:8Q RC*1QI%AB<$'<3CJ.,#.A\$_B=J_CY?$FF>(M/M+#Q
M!X=U V%VVG.SVLQQD/&6Y'0_*22.,]<#P_XF7GBSQQX_\2^/?A=:7-E!X?B;
M0]5OK>=?M&JJC RK;Q%&&Z,='/)^7:"1BNP\'_$#PWX/T3X=:9\,?LVHP^*=
M9*:B^H,TMZ0$W7,LI# B9?ER6!49X&,4AGT9110.: .%T/XG?VQ\6O$?@G^S
M?)_L>S@N_MWG[O-\P#Y=FT;<9Z[CFCXK?$__ (5C%X;?^S?[2_MG6+?2<>?Y
M7D^;G]Y]UMV,?=XSZBN*\#Q-_P -:?$7((!T:Q(SW&!1^U9 QM_AHJJ69O&-
M@  .?XZ /8->U/\ L70]1U'R_.^R6\EQY>[;OV*6QG!QG'7%>(:3^T5XUU#P
M?;>+Y?A/,?"\D)N9+JQUV&>=(1G+B QJS8QTR#7L_CR'_BA_$7_8.N/_ $4U
M?-OPLUCXG:]\ =$\->'O EM;6MWIK6D/B/4-8A\A8VW*9?(4&3.#P,=?7H0#
MZ0\*>*-/\:>&].UW2IO/TZ_A6>%\8.#V([$'(([$&O/O&'QUEL?&-QX1\&^%
MKSQQXDM$62]AM[A+6VM 02%DG?*AR,?+COC.>*['X9>!X_AOX T/PU%<&[&G
M6PB:<KM\Q\EF8#L"Q.!V&*\I_9#6*ZT+QUJ4A#ZK=^*+PW;,!OR-I53WP-S$
M9]30!Z#\/?B5?^*]1O-'U[PIJ'A'7[2)9WM;ITG@EC)QNBG3Y9,' / QD4[X
MF?%W3OAJVEV)L;S7?$&K.T>GZ-IJ!IYR!EF.3A4'=CT]#@X[FO"]+C2\_;*U
MEKT;I;/PM%]@#'HC2C>0/JS#\: +MU^T5XE\$K%??$#X7ZCX5\/.ZQMJUIJ4
M.HI 6. 94C *+DCGDY. ":]XL;N&_LX;FVE2>WF19(I8V#*ZD9# CJ"#FN%^
M,$5K=?"/QG%>X^RG2+K?N'3$3'/U! -4_P!FN2X;X$>!_M)8R?V9$!OZ[<?)
M^&W;30C!T']IJ#5/CE??#R[\/36$,=U-8VNL_:0\<]Q'&)"C)L&S*YQ\Q[>O
M'L&N:U:>'-%O]5OY1#8V,#W,\A_A1%+,?R%?(&O>$[OQ!#\;M6T@;?$'AKQ5
M#KFG2*FYO,ACW,H'?*;N.Y KT+XK>.8?C1X/^'OA/1)"H\>O'<WGEMDP6$0$
MMP"?7(V=N01[4 =;\!/CY+\;6U]+CPU+X;ETLV[+'-="=I8YT+HQ^1=IVA3C
MG[W6NA^(7Q+_ .$'\3^"M'_LW[;_ ,))?O8^=Y_E_9\)NW;=IW^F,CZUP?P/
MMXK'XY?&FW@18H(;K38XXUZ*HMB !] *?\?F_P"+G_!?_L/2_P#HFGT#J>J^
M)-4_L70]1U'R_.^R6\EQY>[;OV*6QG!QG'7%>5_ GX_6?QPTR_;^RI-!U6Q9
M&ET^:;S<Q.-T<JMM7*L,_P /IUR#7H?Q ;_BB?$/_8.N/_135\H:)8W/P[^&
M_P +?BYI432#3[!-.U^"-"3/8.Y <XZF,XQ_P'LN*DH^B?#?Q(_X2#XF>+O"
M/]G?9_[ CM9/MGG[O/\ .CWXV;1MV].IS[5<^(_Q)T3X6Z#_ &KK4DNR258+
M>UMH_,GN96^['&G=C@^@]Z\W^%-_;ZI^T5\4[VTF6XM;BRTF6*5#E71K?*L/
M8@BJWQ)\N_\ VJOA?::B UE#8WES:K(1M-SM;D#^\-B'\!0,TU^-7CR&'^T;
MWX-ZS#H.-YG@U&":]">OV3 ?=_LYR*]4T/6+;Q!HUCJEF7-I>0)<1&1"C;&4
M,,J>0<'H:X;XH?$KQAX!_M*]T_P%%KN@6-J;J74CK<=LV%4LX\HQLW&/QKKO
M!GB+_A,/!^AZ]]G^R?VG90WGV??O\OS$#;=V!G&<9P/I0)FS7CGBS]HR#P?\
M8K7P5=Z#,]A*UM%+K27 VPR3Y$8:/9]W(QNW>O'K['7S/XV\#+\1OC!\5="X
M%Q/X<LGM9,<I.C;XV'I\P'X$T"/I=F"*6)V@#)/I7D'PK_:&C^*7CW5- @T&
M2PL8+:2\LM3DN=_VR%9_)#B/8-H)#$?,>E<GJWQAO?%G[.>CI9-CQ?XBD3PW
MY71X[LGRYF(Q\N%#/VQN6KO@#PS:>#/VDO["L5Q:Z?X)M[=/4[;C!8^Y.3^-
M 'IOQ4^(O_"L?#UIJO\ 9W]I_:-0M['R?.\K;YK;=^=K9QZ8Y]17=Q15XG^U
M4/\ BW>D?]C!I_\ Z-KW6->:!G%?"'XA?\+2\,7&K_V=_9?DW]Q9>3Y_G9\I
M]N[=M7KUQCCU-=3K]Y_8>A:CJ/E>=]CMI+CR]VW?L4MC.#C..N*\J_9#'_%L
M-1_[#VH?^CC7J'CY?^*%\1_]@VY_]%-3$>->%_C1\2/&WAVPUW2OA)#-IU]'
MYL$C>*(4++DC.##D=.]>O0WCQ:5'=W\*V$H@$MQ%O\P0G;EEW ?,!SR!SBO!
M/@"WQ>'PC\(?V3!X);0?LJ^2UY->"Z\K<?O!4*[NO0XKZ$U2SAOK.>VN$\V"
M>-HI$/1E88(_(TAGC>D_M!>*/%%DVM^&?AAJ&N>$=[B+4QJ<,-Q.B%@SQVS#
M<W*G R":]3U[Q!JEKX1DU31M"DU?5#"DL.D37"VCN6QE&=\JA )SGTQ7@-M;
M_$#]E_1I4M8+?QS\.+%WE$88Q:EI\!8L?]EU7)/<GG[@Z>]>&?$EGXN\/:=K
M6G2-)87\"7$+,NT[6&1D=C0!XQJ7[0GQ$L?%.F^';GX/^5K.HQ23VMM_PD]N
M?,2,9<[A'M&/<CVKU+P'K_B/Q!I,UQXF\+?\(E?+,8TL_P"T([W?'M4B3?&
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MD!1110 4R3[U/IK#B@!E%%% PHHHH$%-:G4E(8VBBBI*"BBB@ HHHH ****
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M&#N!^8J"<<=@:=K7P_M/%7PS;PCK"I)%-IZ6DCH-P1U0 2+D=58!A]!76T4
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M1FGNY27EFD.6=CR23W- R_I.FQZ78Q6\2A548XJY1104%%%% ';44K?>I*"
MHHHH **** &D8I*5J2J)"BBBF(**** (CP:*5_O4E PHHHH$%%%% #**<U-J
M2@HHHI#"BBB@ HHHH **** $;[IJ.L/Q-X^T/P?<0PZK<S0R2PR7 $-I-/B-
M,;W8QHVU1N&2V!S6XK++&KQL'1AN5E.00>XH **** "BF2R+#&\CG:B LQ]
M*K:;J]IJ^DVVIVDPDL;F%;B*8@J&C8;@V" 1P>] %L4M9GAO7H/%&BVFJVL<
MT5K=)YD7GJ%9DS\K8R>&&&'L1TK3H 2EHHH 55W5+''2(O:K*I[4Q#5B%.V"
MI57UI=H]*8BNT8J&1*NLOI4,B[J0R@Z?-[5&.#4\S"-2[<*HR37&6/Q4\,:H
MJO;ZA( S0!!-9SQ,XF?9$RAT!96;C<,KZD4AG9*U2;AZU55SZT[>?6@"QD&I
M8ZRM4UJST.U6ZO9O(@:6.$-M+?.[A$& #U9@/QK4C/2FA,L4444AA1110!7E
M^]5*;K5R8U3E.:; AHHI](!NV@C%3"/UJIK&H6NAZ7=:A>2>3:6L3332;2VU
M%&2< $GCT% #]WS4;JYS3_B#H.L3P06UY(+F:X-JMO/:RPR"3RC+AD= RY0%
M@2 #V-;] QV\TT\]:*I:CK-GI,MG'=3>4]Y*88!M8[W",^.!Q\JL>?2@9</-
M)VJMI.J6NN:;;:A92^=:7,8EBDVE=RD9!P0"/QJR:!B444Y5S0 FTTY4S4JI
MZU.D)-!-RHT-)Y/TK0\D>E(8?:@#.:'VJ,IZ5HM"15>2.@"I3E?UHDVQHSMP
M%&37)Z?\4/#6IH&@OY &, 036DT1<3/LB90Z LK-QN&1ZF@#L/.V_2E^T$]Z
M@HH G5BQZU8BCK+OM5M-$MQ<WLWDPF6.$-M+?.[A$& #U9@/QIVD^+M(U2^B
ML[:[\VYE-P$3RW&?(<)+R1CY6('OGC- &['&/2I OM3E&<5(%"U1%R$K3'B#
M5.X[TTT6 SYHN*HR)M-:\R@K6?<+WJ2RH>*2E:DH$(U-IS=*;0 445GZ]X@L
M?#6GF]U"5XK<.D>8XGE8LS!54*@+$DD#@=Z -"BL9O%VFQ6JW$QNK:%C$H:Y
ML9XN9'\M%PR#DMVZC()P"#6VO- #E6K4-OZBJ&F:K::AJ%]:02^9<6+K'<)M
M(V,R!P,D8/RL#QGK6Y @- R,6P]*;);CTJ]39%W"@1BRQ[3BJ[#%:5THVGCF
MJ$E $=2(V*CH!Q0!IP3=*NQS9KD]0\4:=HNH:=97ET(+K4',=LA1CO88SR!@
M=0,G R0.IK;CNMO6@9J[AZT;AZUBVGB"SO&MA;3&YCN(S+%/ C20LH(&?, *
M \\ G)YQG!J:358X[N.V(E,CHSAEA<I@$ Y<#:#R, G)YQT- BY=+'/&R.H9
M3V-<!J_@V?3[YM1T"]DTR^(Y:(_*_LR]&'L179R7'85G+J$%Q-/#%/')+ P6
M6-'!:,D @,.Q((//8T <]:?%W6=!81>(=$:ZC7@W>G<,?<QL<?DP^E=%I_QH
M\(7ZC=JGV*3O'>1/$1]21M_(U0UBZL['3KF\O2$M;>-II9"I;:B@DG &3P#T
MKE]9?PI%?Z59WICCN=5S]D4PL1)T[@87[P^\1UH'8]._X6)X5_Z&;1__  /B
M_P#BJK7GQ4\(V(S)XAL9/^O>43'_ ,<S7DZZ3X.NM6O]/A5I[VQ>-+F&&VE<
MQESA>0I!'J1PO.<8K8T/PQX=OX7GL84FCCED@9MA&'1BK#D#H010%C;U#X[Z
M?)NCT/2K[5YNBNR>1$?Q;YO_ !VN>O5\4^/<KK-V+'36ZV%GE$8>C'JWT)Q[
M5T;6^G:+!YLGD6D0*KYDA"+DD!1D]R2 /<U?Z4#,[1]!M-%MUBMHE0 =A6C1
M10,**** "BBB@#N9.E,J6HCP:;,T%>._%OXK>(/!_C.TT72+GPS8P2::]\]Q
MXBDDC5F5ROEHRL,L1T&.>>:]BKR'XJ?"[Q!XI\=6&O:19^%]3A@T]K-[3Q-%
M)+'N,A;>J*IY XSGN>*0S+\0?&SQ)#X5\!W]K;:)H-YXA$IG;Q"\B6T&Q<JV
M\,I4,.1G/WE^M:_AGXT7=Y\+/$?B;5;2S-SH\TUJDE@[-:7LBX"-$QY*L[!1
MUJAIOP"GM]/\"Z?J,NGZQ8:-<W<]]!<1DQ.)@=J11D,"JL1]XCIGVJ&;X(>(
M[GPVO@]M8A@\*QZU]LAFAN7^V160RR0+F,J&5\$')''MB@#H?!WQ*UK5/!?B
MN;6K2RM?$WA\RK/;6ZOY)Q%YD;89BV"#CKS@XKEM)^/FL77PMU?5[RQLK7Q1
MI_V68VIC?R)+>X>/RY5&_)!5R/O<,OX5IZ?\#M4\,Z_K\^FZ_<ZM8ZWH\EG=
M2:]=M+<_:,$1/N6/E #CGD9.,]*J>-/@/JFM^"?#-GIMY96NNV&GP:9?22,X
M@N8$V,5R$+$K)&&7('4YZTQ&CK7C?X@ZA\0=>T+PK:^'9;;2;>WG<:H)UEE\
MQ"VU61MN<@CD =*QM<^/NK77A_PE>Z-'HNC7.K7%S:WG_"12N+>TDA'S R(R
MX!.<''.5Z5LZUX(^(&G_ !!U[7?"MUX=BM=6M[>!SJAG:6+RT*[E5%VYR2>2
M>U8VN? +5K7P_P"$K+19-%UFYTFXN;J\_P"$BB<V]W),/F)C16R >@SQA>M,
M1J:Y\0O&]K8^";/39/"E_K>ORW"/=1-/)IY5 64QLK;ON]>O-='\.O'FKZUK
MFL^&O$UA:V/B'2ECE=]/=FMKB)\[73=\PZ8(/J/H.:UKX>^.;JR\%WFGQ^$[
M#6] FN'-K"L\>GA77:H157=]WKTYKI?AWX#U?1=<UGQ+XFO[6^\0ZJL<3I81
MLMM;Q)G:B;OF/7))]!]2 <]#\1O'/C+5M7G\'Z+H\N@:3>/9.VJ3R)<7LB'Y
M_)*_*@YP"V1T/J OC;XP:EX;\>0:?;6=I)H%D]I%K-U+N,D#W#$($((4;0 Q
MR#]X4EK\.O'O@S5]:@\(:QHD>@:K>/>D:I#*]Q9/)]_R@ORL.X#'' XZDXVI
M?LY7OB:U\37.L^)]1@U35[F6?[)IUV18-C_4"5#'E]H"Y^G'3- S;^)7Q=U3
MP'X_TO3TL;>X\/\ V07FISE',\$1F$1D7#8PI92?E/&:9XL^+NJZ+!\1);."
MQF7P]'9/9-(CL)?.168OAQD<\8Q^-:&C_#?5;CQ#IFH>(7L+V%/#;:+?1QN[
M^=(9%)8 H,J5!SG!R>G>N3MO@/XAM?"?CG1CJ=C=-JR6UOIT\TDFY883A!-\
MG#! H^7.<4".AT7XA>,-"\3:)I7C6PT8V^N!ELK[1'EVQR*N[RY%DYY'<?KV
MP+3XQ>,M?\-^!I=(M=#36?$-Q>0O]MCF%N@A9L$;7+#(7GKSZ5OZ-\/?&&N^
M)M$U7QK?Z.(-##-96.B)+L>1EV^9(TG/ Z ?IWP+3X.^,M \-^!HM(NM#?6?
M#UQ>3/\ ;9)C;N)F; &U QP&YZ<^M '7>#_B7J#W/B/2?%]G::;K&@P+=W$U
MC(S6T\!4L)$W?,,8Y!]OH,3P'\3O%WC6SUFR:QTC3O$7V6WU'2XK@2B![:4G
M!EP2Q( P2N!DCBH+[X.^*=:T;Q-<:EJ^GOXE\1^1:W4ELKQVUK9HWS1Q9!9B
M5R/FQU_$V]'^!]WX/\>:%KVD>(=1U6*WBDL[V/7KPS/]F*_(L)5.,-SM/'TI
M#,_PE\1/B+JT'B:^U"#PNNGZ#)>6EPMLER)7GAC+ IN;!0L5ZX.,]*=X#^+/
MBG7/#^I:[?S>%-5M[;2GOETO09Y3?I( "J2JQ8(,;@>ISCK72^'OAWJ6D^'_
M ![8S3VK3:]J%[=VK([%429 JA\KP01SC/XUSOPZ^&_C;P;I<]BL/@S2G%AY
M$.J:7:2&[DF7&QIBR@.IYSWR<BD,U_@[\0O$7CY6NM1;P]=:;) )4DT6X<RV
MKDC$,\;G(8@GD<?*?45Z?7E'@3X8^(+'X@2>+/$!T"QNOLKVWD>'(9(UN2S
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M+EI7W,P8G*G ))YZXZU@Q_!_6%NO$$GV^-9M0ANXH[U9U#2"9]RK,BVX<@#
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MU0+;* HC;=&!QP$8Y7T/(KX^HH_U?C_S\_#_ ((?ZYS_ .?/_DW_ -J?8?\
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M/]7U_P _/P_X(?ZYR_Y\_P#DW_VI]QC6)O[J?D?\:7^V)?[J?D?\:^&Z*/\
M5]?\_/P_X(?ZYR_Y\?\ DW_VI]QMJTW]U/R/^-12:M+TVI^1_P :^(:*/]7U
M_P _/P_X(?ZYR_Y\?^3?_:GVL^J2_P!U?R/^-5Y-4E;^%/R/^-?&-%'^K\?^
M?GX?\$/]<Y?\^?\ R;_[4^R_[2E_NI^1_P :/[2E_NI^1_QKXTHH_P!7X_\
M/S\/^"'^N<_^?/\ Y-_]J?9?]I2_W4_(_P"-+_:<O]U/R/\ C7QG11_J_'_G
MY^'_  0_USG_ ,^?_)O_ +4^S?[4E]%_(_XT[^UI?[J_D?\ &OC"BC_5^/\
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M_@D_Z\+_ )]?^3__ &I]I3WTG7:GY'_&JS:A(/X5_(_XU\:'Q!8C_EJ3_P
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M/X5T&Q-KHVL^1_Q,AI<-H)][?ZK"MMVYQUYSC-?'%?:_A7_D5]'_ .O.'_T
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MUV 8=XHA_P !I=R_\\H_^^:/[0G_ #/[V']GX;^2/W(XK_A7?A7_ *%G1_\
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M0?\ /&/_ +YJNS#_ )XQG_@-3_:$_P"9_>Q_V=AOY(_<CC/^%>^%O^A:T?\
M\ (O_B:/^%?>%O\ H6M'_P# "+_XFNO9Q_SQC_[YIN\#_EE'_P!\T?VA/^9_
M>P_L[#?R1^Y')?\ "OO"W_0M:/\ ^ $7_P 32-\/O"W_ $+6D?\ @!%_\376
M>8/^>4?_ 'S2>8/^>4?_ 'S1_:$_YG]['_9V&_DC]R.47X?^%O\ H6M'_P#
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M3_X Q?\ Q-'_  @/AC_H7-)_\ 8O_B:ZHR ?\LH_^^:3S1_SRC_[YH_M"?\
M,_O8?V=A_P#GW'[D<I_P@7AG_H7-)_\  &+_ .)H_P"$"\,_]"YI/_@#%_\
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MLG_Q5'_"<>(_^@_JG_@;)_\ %5G?V;-Z ?C2_P!FS?[(_&CZW/\ Y^/[V/\
MVCN_Q+__  FWB+_H/ZI_X&2?_%4?\)KXA_Z#VI_^!DG_ ,55'^RY?[R?F?\
M"E_LN3^^OZTOKD_^?C^]C_VCN_O+G_":>(?^@[J?_@9)_P#%4?\ ":>(?^@[
MJ?\ X&2?_%54_LI_[ZTO]E-_ST'Y4OKD_P#GX_O8^7$=W]Y:_P"$U\0_]![4
M_P#P,D_^*I(_&.OPM(R:YJ2-(VYRMW("S8 R>>3@ ?0"J_\ 9/\ TU_\=_\
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ME<=:Q+Q?^*PTS'_/A=_^C+>E_JO3_P"?S^Y#_L>AW/F?_A7>N?\ 0)U+_P
MY/\ "E_X5UK?_0'U/_P$?_"OJVE5L&E_JM3_ .?S^Y%?V/0[GRG_ ,*YUO\
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M!7I4OB"#PG\+X=8N"!%9Z5'-@G&XB(;5^I.!^-=S(PQ7.^%O^15T7_KRA_\
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MC_WR*/MUM_SR/_?(KXK_ .%[>.O^@\W_ (#0_P#Q%'_"]O'7_0>;_P !H?\
MXBBR&?;*7UOWB/\ WR*E6^MO^>)_[Y%?$7_"^/'?_0>;_P !H?\ XBG?\+[\
M>#_F/M_X#0__ !%/05C[>%Y:]XC_ -\BD:\M>T)_[Y%?$7_"_/'G_0?;_P !
MH?\ XBC_ (7YX\_Z#[?^ T/_ ,11IV%8^V7O+;_GB?\ OD?XUS]Y>6__  FF
ME'RCC^S[S^$?\]+:OD8_'KQX>NOM_P" T/\ \15=_C9XUDNX[EM;8SQHT:/]
MFAX5BI8?<[E%_*BR'8^UGO;;KY1_[Y%-^WVW_/(_]\BOC#_A>WCG_H.M_P"
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M:%%R\AR@V;3Q@G)ZUN>$_B5X:\<7$\&B:HE[-"N]X_+>-@N<9 =1D9]/6BR
M[C[=;?\ /(_]\BL>UOK?_A,-3/EG'V"T_A'_ #TN*Y5O'D&F:YXI35;^QBTS
M2%MF_<Q3&:'S%Y,IV[3DXQLS@=<5%X1\>:#XP\8:PNCZE'>M%:6Z,%5ER5DF
MW$;@-P&]>1D?,*+(#TE+RWD=5$1RQQ]T5:\E/[B_E6+;_P#'Q%_O#^=;M%D
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M"=A2**U8_A7_ )!D_P#U_7G_ *4RUL5C^%?^09/_ -?UY_Z4RT"-BD)Q2TE
M";J,FC;1M- !FG*V.AIE% $ZS,.]*;@D=:@R:,F@![2D]349:FFG(* $VDTN
MVIXX=U6%MP!0,H;::1BKTEO5:2/:: (&K'\(?\BGHG_7C!_Z+6MEA6-X0_Y%
M/1/^O&#_ -%K0(UZD5:8M6;=<GF@"2*WW=:F^RCT_2K$$=3[!0!FR6WIUJI)
M&0>E;4L8-9]S'CF@#,==M,J:9:B-!2$HHHH&%%%% !1110 444M "4444 =W
M1115F(4444 %%%% $?MTI*<WWJ;4%A1110 5!=V-MJ$:1W5O%<HCK*JS(' =
M2&5@#W! (/8BIZ* &FDI6I*HD****8@HHHH B/!HISCO3:!A1110(**** &5
M\]?'CX5ZU\1_B%%)I,]A"MII<"R?;)70DM-/C&U&]*^AVKE?-@_X3C51*C,5
MT^S''_72Y/K[U)9\O-^R[XU/34-!7_MM-_\ &JC;]ECQNW_,5T0?2:7_ .-5
M]<^99?\ /)_S_P#KT>99?\\G_/\ ^O2 ^06_90\:-UU;1C_V\3?_ !JF?\,D
M^,/^@EHG_?\ F_\ C5?8/F67_/)_S_\ KT>99?\ /)_S_P#KT ?'O_#)/C#_
M *"6B?\ ?^;_ .-4?\,D^,/^@EHG_?\ F_\ C5?87F67_/)_S_\ KT@FL_\
MGB_Y_P#UZ /C\?LC^,#_ ,Q+0_\ O_-_\:IP_9#\8'_F)Z'_ -_YO_C5?7_G
M6?\ SQ?\_P#Z]2+<67_/%_S_ /KTQ'Q]_P ,@^,?^@GH?_?^;_XU1_PR#XQ_
MZ">A?^!$W_QJOL3[18_\\7_/_P"O0;BQ_P">+_G_ /7H ^.F_9#\8K_S$]#_
M ._\W_QJJ<O[*_BR'4H+$ZCHQEFADF5A/-M"HR @_NNN9%_(U]FM<61Z0O\
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MB\5?] _1_P#OS+_\=KQZBD,]A_X:B\5?] _1_P#OS+_\=H_X:B\5?] _1_\
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MZU(L6>U3(G'2G[?:F(KF'VK!MH_^*VU7M_Q+[/\ ]&W-=/M]JP;50?'&K_\
M8.LO_1MU0!=>/FH67%79(_6J\B]?6D,AHI#UI: $%+24M "4VGTUJ $HHHH
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MTXR::^JW-G;B>YC7S+1)W52Y4Y7>H;H<C=C.171ZMX1T+7+R"\U+1=/U"[@
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MVDO@8[8VSB(O&3%^])9@0K*@XY[9OV?Q(OUO)+"*V_M'49[Z.TA%]=)! O\
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M\9952'(.P(#MQD#M6M10!SDGP[\/S6=Y:OI^8+R^_M*=/.D^>XR#OSNR.5'
MXXZ5->>!M"U&XU::YT])Y-6B2&]\QV(E1!A1C.!CU&#6[10!Q^C?!OP?H*7"
MV&C);?:;62RF*SRDO"Y!922V3G YZCL167KWPE\)ZMXET"UO-'CG@M=,FBB5
MI9!A(G@6,$ALM@.WWL]:]'4UC7C ^,-+_P"O"[_]&6U4(@_X57X6UA-'%WI*
M3#0Q&M@3+(#"%QM&0V6 VKPV>E7KSX7^%]0TK4]-N=)CGLM2NVO[J.21SOG;
M&9 =V4/'\)&.U;NFGB7\/ZU=J1G':?\ !_P?I7AN^T"TT6.#2[X@W,2RR;Y<
M'(S)NW\'I\W'/K6W'X5TN+Q!'KBVN-4CM/L"S^8_$&[=LVYV]><XS[UK44 %
M)2T4 %%%% #''>F]O>I&&14?0\T 2*,"K$:U O6K$76F(LJN:<_:D0TYAD4"
M(SUK"L_^1XU;_L'67_HVZK=K"L_^1XU?_L'67_HVZI%&S(HQ561:MR?=JI)3
M%U*S4E*U)2&%%%(* %I#2T4 ,HHHH **** $8;A3 Q6I*C88H&AZR9K'T%O^
M)IXCY_Y?T_\ 26WK4K&T+_D*>(O^O]?_ $E@H'8W&DSTIE':B@!II*5J2@98
MC-7(6J@CU8CDQ]*"311ATIU55D%2B2J(L2TQG'3K3&D]:C:0"@+#9GQ5&9NU
M32254D:I+(F^\:2BB@05C^%?^09/_P!?UY_Z4RUL5C^%?^09/_U_7G_I3+0!
ML5/%,5R#4%% %])O>B2?'>J*L10S[J!DLLQ;@5 QI-U)0(**** "BBB@!E+D
MT4E "Y-)110 M8_@_P#Y%+1/^O&#_P!%K6O61X/_ .12T3_KQ@_]%K0!K-24
MXTV@ I5:DHH F60COBGF8_WJK9-+N- $N[=4]N@9LU56KUK0,NPQCK4]-C'%
M.H$%%%% $<J;A6?<1YYK3;[IJC<]Z!F5(.#4%690*KT A***6@H[VFFG4UJ:
M,Q****HD**** "@\T44 1^U)2MD-25!84444 %%%% #324K5\]_M:^$=?\1V
M_A2ZMM%OO%?A&PNI)==\/Z;<M#-=1X78P"D,^TAN%YR1[D42?0=%?'6K_$30
MK#X%Z1HOPJU'5M M-<\31Z+.+Z1_M6B^9S)$I8DKPHQAC]YL-GIH-X3^%7PC
M^+GAS1HO"?CG3O$<FH6]O;^*5ED^RZA*VQF#2/-MD4[L.%C_ +V!0!]:T5\=
M>+/V;?AS9?M*^#/#$/AW9H>IZ7=W5W:_;KD^9*FXJVXR;AC X! KWG1?BY\.
M?"_BJP^%VGZM]FUJQ6.PM]*^S7+[ L09$\UD*G" <ES]<T >CG@T5\'6_@73
M_@MJD.M_$WX17,MM)KKR1^*K?7]QBW2EXB;:*3;@8S\Q&?KQ7JO[:GA>%O#&
MC^(6U#499?[6LK:*R:Y(M(E+.6<1# +MQEFR>!C% 'TY17S[^T5$WC+XI_##
MX?7MQ-%X:UN:ZN-2MX9VB^UK#&&6)BI!VDYXSW'< U#^S_IZ?#[XV?$SX?Z2
M]POA;3X[.]L;.:5I5M6EC#.JLQ)P2W?.=OUR ?1%<J@MI/'.KEY&!^P68.!W
M\RY'I755\N_%7XTZ[X'^*>O6>GV]C)&B00@W$3L=H0R#HXYS,WX8H ^C##9_
M\]7_ "_^M2>79?\ /5_R_P#K5\G?\-/^+?\ GTTG_OQ)_P#'*/\ AI[Q9_SZ
M:3_WXD_^.5)1]8^79?\ /5_R_P#K4>79?\]7_+_ZU?)W_#3WBS_GTTG_ +\2
M?_'*/^&GO%G_ #Z:3_WXD_\ CE 'UCY=E_SU?\O_ *U'EV7_ #U?\O\ ZU?)
M<G[4GBF%<O;:2H_ZX2?_ !ROJB@"YY=E_P ]7_+_ .M1Y=E_SU?\O_K53- H
M N>79?\ /5_R_P#K4>79?\]7_+_ZU4Z* +GEV?\ SV?\O_K5BW:V?_"9:7^]
M?;]@N^W_ $TMO:KU8=XN/&&F?]>-W_Z,MZ .MLS &98G9B1D@C_ZWO5JLO2_
M^/AO]W^HK4H **** "BBB@ HI*6@ J)LYYJ6F.O>@!4/%3QMTJNK 8J16 H
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M?>@#XND_9W^(TK9?0"Q][ZW_ /CE,_X9S^(G_0O?^3MO_P#'*^[?[)_Z:_\
MCO\ ]>D.D_\ 37_QW_Z]*P[GPG_PSG\0_P#H7O\ R=M__CE'_#.?Q#_Z%[_R
M=M__ (Y7W5_9/_37_P =_P#KT?V3_P!-?_'?_KTAGPK_ ,,Y_$/_ *%[_P G
M;?\ ^.5]M5H?V3_TU_\ '?\ Z]']D_\ 37_QW_Z] &?2>M:/]D_]-?\ QW_Z
M]']D_P#37_QW_P"O0!GT5H?V3_TU_P#'?_KT?V3_ --?_'?_ *] &?6-=?\
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M'_GQ#_P%?Y#_ +4S#_H(G_X%+_,]E_X;%^,#=?%__E,L_P#XS2_\-B?%\_\
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M?^4ZT_\ C5*/VL?BO_T-7_E.M/\ XU7DRQT[%+^SL%_SXA_X"O\ (I9GC_\
MH(G_ .!2_P SUH?M7_%;_H:O_*=:?_&JR;S]H7XBWVH2WLGBN\2YD18W>W5(
M057.T810,#<W;N?4UYX%-/6.I_L[!?\ /B/_ ("O\BO[4Q__ #_G_P"!2_S.
M]_X7]\1O^AQU7_O_ $Y?CW\1F_YG'5?^_P#7!A:>JU/]GX+_ )\1_P# 5_D'
M]IX__G_/_P "?^9WG_"^/B+W\8ZI_P!_S2_\+W^(G_0X:I_W_-<,%IZQU/\
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M_P#@3_S.P'QI\??]#9JG_@0:</C/X^_Z&S5/_ @UR 6G8J?[/P?_ #YC_P"
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M_P# EJYQ8Z=@#WJ?J.$_Y]1_\!7^0_[1QW_/^?\ X$_\SI%^*'C3_H9]2_\
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M61BG!34_4\+_ ,^H_<BO[0QG_/Z7_@3_ ,S6_P"$Z\5_]#%J/_@4_P#C3O\
MA.?%?_0PZC_X%/\ XUE+'3PE+ZGAO^?4?N0_[0QG_/Z7_@3_ ,S4'CCQ5_T,
M.H_^!3_XTX>-?%7_ $,.H_\ @4_^-9>*=MJ?J>&_Y]1^Y#_M#&?\_I?^!/\
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M=U.VT^RB\^\N9!%%'N"[F/09) 'XFIE)15WL7&+DTENRCBG!*WM5\&:IH?\
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MU_QK+ZG1M;VCZ=5T-UC\1>_LEUZ/J[]SL_\ A(M$N=#\U)=+T_4/M\CW$?\
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M+^X9K%K0->98N/M*2JKL\TC$!0PSN/)X !P/-QX=O_\ GW_\?7_&E_X1^_\
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M%J;CL1+'4@2GA*>L=(9&%IZQU*$IV*FY5ABQT[:*<%-/6.IN,CIVTFI0M+M
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M><8?-QY&<;QT^]@]*R)OBIXDN-1;4#<V<=^\<T4EU#IEK%+*LJE9/,=8P7+
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MW_H'6O\ WX7_  H_L+3?^@=:_P#?A?\ "O1%T>R7I;)^(S4BZ=:KTMH1_P
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MGA;P?>+XAM5L?#UO';F&9[?RK:VE1V4J9. "00-IR/O$<YI-H>AR$6KZ_8^
M]=UM_$5[=W5K<W%K$DT%L(U"7/EA\+"I+;1W..3QTQT=YXJNO#6I>*8K]FN8
M[>U34=/4HH+(5*&$$ 9(D4=>?WJ\]*M:EX=\/:?X?E\/WVK"SAU>ZDDC\ZYC
M266227S"L>1S\S   $X(J;Q1HOA[7O$NA1:CJ$<.JVSF>VLEN41[E00Q!0_,
MZ!HU;CNGUJ;ICT?0YF]U;5[+6=/TS5-=UBTF7289YVT72ENB]P78.6 MY=J\
M8'0<=ZZGQIJ%[9:9I^FZ7>-!K&I3I:P73QJ[( -\DA4KMR$5NV,D<5#J]GIF
MH:TVJ6_BZ31[D%=*D^QS6K*TH8LL1$L;XDR_W1@\CBK.K>%?#GB+Q%90ZS);
M:O?VMFQBTR^,4@V,RAIS"1URH7=C R0,9I76C8]-&<]JGC2>;P+H6H2ZJ- E
MFOH[+4;O]T/(92R3#,JL@^=#R1TJA-XQODT%Y6\2^7I(UN.SA\2,MNAFMRF7
M;<R>20K[D#A0#M]<D]/H?A/PL+J[L=&OH0MEJ4>H2Z;8S1%+.8+MV>6H_=JV
MTDJ>^<8JY<>(?"7BR:VCB\2Z;<RZ?,+_ &6E_"Q7RP<E@"?E&>3Q]:5UV*T[
M'%77C+55T56AUN\N=.;78[*WUNRLXYKB[MS&6<HBQ,CD/N4,D>"%Z9!)T]-\
M5ZS>:#8V]OJ#2R:IK$FGV6K7<$:S"!5=V=X@%42 QR(%91R%+)U!ZW69-!UR
M'0;F?5K=(3>QW%A)'<QA+F4!@JJ3G?D$\+R<5E:EH?A9=4N=)GUQ+'5K^\74
MK:U6]CCN(+C9M\R!#S\VUB00P8E\@@D4N9=AZ=BO??\ "0Z1K#Z'!KUQ?R:G
MIMS-97EU;P>=:W$10#.R-49&\P<%<@J>3GBQI7C"]\3W7A*.Q_T;[7;/?ZDI
M0%HT1=GE'/0F9L>O[MJN>'[31+3Q5/'+XE_M[Q/'"83'=W,'VB"$E6*B&)4"
M@G:2=N3\N3@#%[1? .G^'[W6[NSEN8[C56+.Q<'R,EFQ$,?*-[N_.>6/TJ6U
MU#0YW0_%^HW7C42SW ?PYJ5Q<6&GQ^6HV30 9;=C)WE+CJ2/D7'4UTW@S4KK
M5;74WNI?-:'4KJWC.T#$:2%5' [ =>M<QHO@/X=W0AL-$DTO^U]'DBD>^T^2
M!K^-XW&3*X!;+%2'W=<L*U?"=GI,MY?:EHGC634--%S+<W-G;SV<ULCOEF#,
ML1=1SG[_ &]*4K=!M+H=F%IX2LQ_%>APZ*FL/K.GII+G"W[748@)SC DSMZ\
M=>M7]-U"SU>RBO+"ZAOK249CN+>021N,XR&!P>16.HK$P6G;:=BEVU-QV$Q2
M[:>%IVT"IN588%IVWUIV#]*<%I%<HSZ"G;?6GA:7%258:%IVVG;33@E*Y5AF
M*<$IX6G;:5RK#0M.VTN*<%J;E6/SZ"T\)4@6G!:_5KGYE88L=."U(L=2+'4E
M$2QU(L=/VT[::5QV&A12XIZQT\+4W&1A*>L=2!:<%J;C&!:<%IX2GA*0[$86
MG>74H6EVU-P(UCJ0+BG;32A:5QV&XIVVGA:<%J;E%_PNL'_"2:3]J_X]?M<7
MF_[F\;OTS7U'=>,;#35\1:+>:Q'::G=ZQKRBVN;Y([4EHP(Q=1'[R-R$8D ,
M!UKY/"_A5J^OKK5+N2ZO+B:\NI#EY[B0N[<8Y8\G@"O+Q>#6*E%R>B/6P>/E
M@X245=NQ[_;WEO#\1O#^N6VN:3!;GPPMC%<KJ]LCQ7(L&4*P\P-&0^!N8 9Q
MSFL#Q?-I>M>'H%UJ\TK7/%MCH<IN]0?5<L93<+Y(62/<MU,L1(*[B,'KE:\:
M6.GA*RC@5&49<VUO+:_6_GK\C668N4)1Y/BN^ZUMTMOIH^USV+P+J&G7OPFN
M=&UC6(]"TV.26Y:?3=3$=Q<,6C7R)[3&Z8%1N5P"% YZ,*U[KPC\.EU(Q.NB
MP3K/?#3H;;6C);WT*1 VS74GG'R2SY_BBSR,+7A&*<%S1+!OF<HU&KMO3S_K
M_*VXHY@E",9TU*R2U\OE_76ZT/>[6S\'"RNM$BOM%T^&\O=)DO+:2]:>TCE\
MF;SPCB8,\:LRC<)< M@OBGWGASX8Z7JT&(=)OXKJ]TRWDC_M1U2UCD1Q=.-E
MP_"LH.3(ZJ6'S$8SX(L=/" =:S^HRN[59:_\#7\#3^TH62=&+MY>NFUNI[?9
MZ=X%O--\/)<V6@&UM+745N9AJ!BN)IHS,8!(!*&8. AW;<$D*I PM9UYIWAG
M2_AK!XATRZTJP\5))!<P1Z;<OYJ!GD62)DDN9&;:-A.8TXQRX)->1?04]4)-
M7]3DG_$=KWMWU;M\[_<9O'1:_A*]K7ZIV2OMTM=>;/1=:U&?5O@W;7FH327%
M]-XBF9)'[K]GCWX]L[.!Q7G84FK;WEU-9P6LEQ-):P%FB@9R4C+8W%5Z G S
MCKBHPHKII0]DFO-LXZU7VTE+LDB-8Z>$I^*<$K4PL,Q3@IJ18ZD6.D,B6.GK
M'4F!]:7:3[4K@-VA:=SV%/6.GK'4W&1B.GK'4FT"G8/TJ;CL," 4[Z"GK'3@
MM*Y5A@0GK3@E2;:7%24?2/[.]C+??#.\CBB:3=JEPIPF\#,,'45U=G\*;RWL
MXK6/4M5MK>,86"R6&TB7)R=JQQC R37AGAWQA>>$_ASIWV6]OK/[1JM[N^QR
MLF[;#:8W889^\?S-/'QBU?\ Z#>M_P#@6_\ \77R5;!8BK5G.FU9MGVU#'X6
MC1A3JIW27Y'JT?[,^G0:E/J-F;VQU"<,LMU&+5I'### EXFR""0?4&I)O@CX
MQMULUT_Q18R0V)#6D&KZ';3+ 1P"AA\K;]17DW_"XM7_ .@UK7_@6_\ \73A
M\8M6_P"@UK7_ (%/_P#%U'U/'=9)^JO^9NLRR_\ EE]YU7C;X&_%#Q1>V<EY
MI_@+5K..[CN;ZW3[1:G4Q&I6-)@4?<%SD L1[$<5@Z?\'_B)X=^(3Z_I?PJ\
M,V=BVG/I[:;INK16\,F]PS/+^Z_>< #&T?CBJO\ PN#5_P#H-:U_X%/_ /%T
MO_"WM7_Z#6M?^!3_ /Q=;QHXV,>5\MMMG^C1#Q^7R=[2^]?JCU#X:_#?QOI.
MO1--X7\%^#/#\FYKN#2-TEY*VT[,%$1/O8R3GC.*]=7PFG>Y8_1<?UKY4'Q=
MU?\ Z#6M?^!3_P#Q=+_PMW5O^@UK/_@4_P#\77!6RW%5I<S:7HG^MV=E+-L!
M3C;D;]6?5R^%;;^*64_0@?TJ1?#%FO4R-]6_^M7R=_PMW5C_ ,QG6?\ P*?_
M .+IR_%K5O\ H,ZS_P"!3_\ Q=<_]CXK^<Z%GF!_Y]GUFOAVQ7K$6^KG_&I%
MT.Q7I;K^))_K7R6/BUJO_09UG_P*?_XNG?\ "W-5_P"@QK'_ (%/_P#%U']C
MXG^?\RUGV#6U/\CZV72[->EM%^*@U(ME;K]V")?H@KY&_P"%M:K_ -!C6/\
MP*?_ .+K9T+XF:G<Z9XAD;5=58V]BLBEKAB5)N8%ROS<'#$?0FLY9/7BKN1M
M3S["R=E#OVZ*Y]2+&B_=15^@I]?(8^*VJ_\ 08UC_P "G_\ BZ7_ (6OJO\
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M_L>KW'_;]#^5GT_17S$OQ(U'_H*:I_X$-_\ %4__ (6-J/\ T%-3_P# AO\
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MC5'_ &;1/(O"/@F]L?%6BW,J3I%#>PR,S6[* !(I))["LL?#V_\ ^>5S_P"
MS5[C14?7ZG,Y%_V?2Y5'M_P/\CQ#_A7]_P#\\KC_ ,!FI1X O_\ GE<_^ S5
M[>JLWW5)^@J5;.=ONP2-]$-/^T:@EEE-['AO_"!7_P#SRN?_  &:G#P%?_\
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MFI3><@V2P!LQA"=Q$C+$20*T5\)ZEI_Q8\4:U/X?UR_LKZ2S:SN-)U5+>/\
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M!R0RKO+')'J<UY/H5GJOPL.H^*%\*C25FT^QTQ/#Z7$*OJ.H&3!E!A+J,[B
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M_P *2L/^?O\ \A-_\73O^%*6'_/W_P"0V_\ BZ7UW"?TA_4<9_3/+1XDNO\
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MZIBN_P")P'_"07']R(_@?\:=_;UR?X(A^!_QKOO^%6V?_/?_ ,</_P 52_\
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M(E%^Q@I)-/7ROYHLV?B[P-9ZA SVVCW#M=Z>E[-_9 ,,L:Q.+J2)#%\BEMG
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MC<%)!&<=J98^-M;NOAGXAU35O%C:+)X>O;ZQ?4+:T@,EV\3;8BRNC)SD HB
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MI.+!"/G/'^E05E/*J,5=>7YFM//,1)V?9]/(]S_X7!HW_/M??]^T_P#BZ/\
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M^>\G_?9H_LNB']N8C^D>^?\ "UM)_P"?:]_[X3_XNE_X6II/_/O>_P#?"?\
MQ5>"BZG_ .>TG_?9I?M4_P#SWD_[[-3_ &72'_;F(_I'T!9?$G3+Z\@MHX+L
M232+&I9%P"3@9^;WJ'_A:FD_\^]Y_P!\)_\ %5XYX3N9F\5:,#+(0;V'(+'_
M )Z"LL7$_P#SVD_[[-1_9M+F:_KJ:O.J_(I>;_0]W_X6II/_ #[WG_?"?_%4
MO_"TM*_Y][S_ +X3_P"*KPH7,_\ SVD_[Z-.^U3_ //:3_OHT_[,I$?VWB#W
M3_A:&E?\^]Y_WPG_ ,52_P#"SM+_ .?>\_[X3_XJO#!<3_\ /:3_ +[-/%Q/
M_P ]I/\ OLTO[-I!_;>(_I'N'_"SM+_Y][S_ +X3_P"*I?\ A9NE_P#/"\_[
MX3_XJO$/M,__ #VD_P"^C2_:IO\ GM)_WT:/[-I%?VU7/;O^%F:7_P ^]Y_W
MPG_Q5+_PLS2_^>%W_P!\+_\ %5XC]IG_ .>TG_?1IPN)O^>TG_?1I?V;2'_;
M5<]L_P"%E:9_SPN_^^%_^*I?^%E:9_SPN_\ OA?_ (JO%!<3_P#/:3_OHT[[
M5-VED/\ P(TO[.I#_MFN>U?\+(TS_GA=_P#?"_\ Q59OB+QM8ZOH]Q:0Q7"R
M2;<&15 X8'LWM7E'VB<_\MI/^^C3A<3?\]I/^^C3C@*<6I+H*6;5IQ<7U.@V
MUS(6K'VB;_GM)_WT:9BN^,>4\FI)3L5K[3X-3L;BSNH5GM;B-HI8G&0Z,,$'
MV(-<Q9_#:"&2R2\UK5M6T^QD66UT^]DB,43H<QDLL:R2;,#'F.W(!.2 1V(4
MT\+6O,UL9HY/5/AOI>L>']8T>X:Y-OJ=R]X\BR!9896(8/&P'RE64$9STYS4
M?B#X8V/B;POI_ARZU"_CT:UCBBEM8C%_I:1E"HD8QEAR@^X4ZGVQV06EQ2YV
MNI1QVK?#.VOO$%SK6GZMJ?A_4;NW6UNI=-:'%PB_<W++&X#+R R@'D\U)IWP
MOT31Y/#'V%9[6+P\LRVD*R JWFKM<N6!+'DGJ.377[:4+2YY;7&>7?\ #//A
MI+'Q39V]SJ5K;>(9(I)XXI8]MOY<IE40@H=J[F/!W=>,5W>@Z'=Z1#,EUKNH
M:R7QM>^2W4Q8'1?*BC'_ 'T#TK9"4X**4IRENRC@M!^%)T#7M9UBW\4ZY)?:
MLJB[>5;,AF5"D;@"W !4'C'!(^8&LE_@SJ&B>'=8TWP[XKU6*76+T7-U<74L
M4;PL\BM--$T,*-YA5=H7<%Y[5ZKBG!/6CVLAG.^,O!\/C;PK=Z#/J%_I]M=(
M(Y9["54F9.Z[F5N&'!XY!([UB2?"*"XTW3K6;Q!JSOI<T<^F7*1V<+V!12N(
MUCMU0J5.TJZL,=,5WX6EX^M2IR2LAGF<WP&TIK71(;?6M8M/[)N9+Y&1K>43
MW4A):XE66%U:0$G:=H"Y^4"K6N?!73_$4LDU]KFL-/=6@L-1EC:WC.HP!]X2
M4+" ,9*[HPC8)&:]#P?I3@M'M9=RK$-M;QVEO%!!&(X8E"(@Z*H& !^%2[?6
MGA:=BL;CL-"TNVG!2:<$I%V&XIP2GA:=MJ;E6&!:=MIV*4+2N.PW%.VT[;3@
MM258:%I0M/"T[;2N589MIP6GA?PI<4BK#0M.VTX*33ECI7'89BG!*DV@>]+^
ME258;M ZTOTIP6G!*5RK'P=]!3@I-2+'3MHK]1N?E-ABQT\+3L&G+'4CL,Q3
M@E2K'3PE(9&L=/6.G_2G;2>M*X#=H'O2X)]JD6.GK'4W&1+'4BQT_ ^M.VDU
M-QV&;:4+4BQT\+2N5RD0C-/6.I-M+BIN.PU8Z-OI4@6GA:5RK$6PFG".I=M.
M"U-QD02G!*F6.GA*5RK$(C-.$53!:7%3<JQ&$IVVI-IIRQTAV(MIIZQFI0M.
MQ4W*L,$=/Q3@AIZQU-RK$84T]8ZE"4N*0[#%CI^T4[;3@M*XQF*<%IX2G8J;
ME6&!*<% IX4FG+'2N,9BG!*D"T[%3<=A@2G8IX6G!:FXQ@4FG!*D"TN />D5
M8W+&ZTJZ\/V^GZA<WEH]O=33JUM:),&$B1+@[I4QCRO?K1]A\-#_ )BVJ_\
M@KB_^2*Q<$^U*%K#D?237W?Y'3[1/XHI_?\ YFU]C\-]M5U7_P %<7_R12_8
M?#??5M5_\%D7_P D5CA:<$I<LOYW^'^0^>/\B_'_ #-@6/AO_H*ZI_X+(_\
MY(IXL?#G_05U3_P61_\ R16.%IP6ERR_F?X?Y%<\?Y%^/^9L"R\.?]!75/\
MP61__)%+]B\.?]!75/\ P61__)%9 2GA0.M+E?\ ,_P_R'[2/\B_'_,UQ8^'
M?^@IJG_@LC_^2*<+'P[_ -!34_\ P6Q__)%9'T%+M]:GEE_,_P /\A\\?Y%^
M/^9L"S\._P#04U/_ ,%L?_R12_8_#Y_YBFI_^"V/_P"2*R M/V^M+E?\S_#_
M "'SQ_D7X_YFL+/P]_T$]3_\%L?_ ,?IZV>@<XU34P#U_P")='_\?K'^@IVT
MFERR_F?X?Y#YX_R+\?\ ,UOL?AX?\Q/4C_W#H_\ X_3OL>@?]!/4O_!='_\
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M1/\ H(:A_P" "?\ QZG"TT3_ *"%_P#^ *?_ !ZL[;2XI<K_ )G^'^0^:/\
M(OQ_S-+[+HO_ $$+_P#\ 4_^/4[[-HO_ #_W_P#X I_\>K,VT\+4\K_F?X?Y
M%<T?Y%^/^9H_9=%_Z"%__P" *?\ QZE%KHW_ #_W_P#X I_\>K.V@4[!^E+E
M?\S_  _R'S1_D7X_YFC]ET8=;^^_\ 4_^/4X6^C=K^^_\ 4_^/5G!:<%J>5_
MS/\ #_(OFC_(OQ_S-#[+H_>_OO\ P"3_ ./4X6NC_P#/]??^ 2?_ !ZL[%.V
MFERO^9_A_D5S1_E7X_YFA]FT?_G_ +[_ , D_P#CM.^SZ/\ \_U]_P" 2?\
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M[:>PGKTL-"T[;3MM."T!8:%I0M/VTN*FY5ANVG8IRQT\*!UI7*L1A:>(Z?\
M2C;^-(JPGT%+BGA*<% J;CL,"TX+3L4X)4W*L-Q3@IIX6G;:1=CX/"FG+'4J
MQT_ ^M?J1^3$:QT_:!3MI/M3UCJ;@,^@I1'4JQT\*!4W'8L_V#J*V<=VUA="
MUD!9)S"VQ@,Y(;&".#^5+>:/>Z9'$]Y9W%JDPW1M-$R!Q@'(R.>"/SKH[3QQ
M&NEQZ?<Z<9+=(/(W02K$YX<$EMAW??XW9VX./O&HM6\16.K6\T0LKFV$A64Y
MN%DS*J!$_@7"XW$CDG@9'6N)5*W-:4=/Z\ST'2P_)>,]?Z\OU.8^@J>XLIK2
M14G0HY57VD\X(R,^G!'YUTVG^-GLK=(#!(RI;+;KMFQCDEN"I&ULC*XYVKGI
MBM";XE3W"VQEMYG>$H<FYR&*J &(*G#<'Y@1Q@>N252M?2&GJ.-+#\MW4U]#
MA@E/"UUL?CV>*U@2..9+B*)D$RW'1V!S(OR[E8GYCAN3SZ8N2_$*.1IS%I\U
MNLH*K%'=#RXP220J&/&&S\P.=Q Z#BI=6M_S[_$:HT&OXOX,XZ.QGDMVN$A=
MX5.UG49 .,\_A3/*=45RC!&SM8C@XZXK=T+Q$-'LY;<VWG"1R^X. 1E=O0J1
M^?Y5MR?$:2:>*0V]U^[,A3=?,S*SJN64E3ALJ>?1BN!UHE4K*5E"Z]0A2H2B
MG*I9^AQ:VLC6[3A"8E8(SXX#$$@?B%/Y4Z2UDA6)G0JLJ[T)'WER1D?B"/PK
MIKWQBEY8VUM]B;RX;B*?R9)@8/DWY"QA %W;\M@\GL.@O77Q!>Z:V'D7+QH?
MWOGW>]Y5S(<$[ ./,XX.-HXJ/:5OY/Q+]E0_Y^?@SB=M/"UW6J>+=,U#PO%8
M1PW5N08]\*SY#A%VC/R[<X .X#.>,8&:XL+5TZDIIN4;&=6E"FTH2YABQT\+
M3MM+BM+F-A-M+BGB.GA*15B,*:>L=/Q2A32N58;M%.P:>L=2+'4W'8B$=/6.
MI-N*7;4C&A13L4X+3@E*Y5AFVG!:D"BEQ2N,:%IV*<L=/"5-QD84T]8Z?BG!
M34W*L-VBEVDT\+3PM(9&$IX6G[0*7GL*FX[#0OK3OI3MOK3@M(JPS:3UIP6I
M E."TKE6&!*<%IX6GA:5QV&;:<%J18Z7CL*FY0Q8Z?M IVTFG!:0[#,'Z4X+
M3PM.P/K4W&,"T[:!UI^"?:G+'2N.PSZ"G".I%CIV*FY5ABQT\**<%-/6.D.Q
M'BGB.I M.VU-RK# E."T[%."DTKCL-VTN*>$IX6I*(PE/"TX+3PE*X[#-M."
MT\+3MM(=A@6GA?PIV*7;4W*L-Q3MM."T[:!UI7'88%IP7UI_T%+M]:FY=AN!
MVYI=I-/"T[;2*L,"T_;2XIP2I*L-Q2A34@6G;:5RK# M."T[%+MI7'83%+MI
MP6GA*DJQ&%IX2GXI0II7*L-VBG8-/"4[;^%(8P)3@M.^E+M)ZTAV&_K3L$^U
M."T[;2N588%IX6EQ3@M3<JPW%*%-2!:=MI7*L,"4X+3L4NVIN583;2XIP6G!
M?QI#L,"T[;3]M."U-RK# M."T\+2[:15ANVG!:=BG!<TKE6&8IP4T\)3OH*0
M[#%CI^!]:7%."U-RK#>?I2A:>%IV*5RK# E.Q3PM."U)5A@4TX)3]M.Q2N58
M:%I=M.VTX+2*L-Q2A:>$IVW%3<JQ\)[2:>L==2/A?XP'_,J:Y_X+IO\ XFG?
M\*R\8=O">N?^"Z;_ .)K]*^L4OYU]Z/RSZK7_D?W,YA8Z=@=N:Z;_A6/C#OX
M5UO_ ,%TW_Q-/'PQ\7_]"KK?_@NF_P#B:GZQ2_G7WHKZK7_D?W,Y<*33UCKI
MQ\,_%_\ T*NM_P#@NF_^)I?^%9^+O^A5UO\ \%TW_P 32]O2_G7WHKZM6_D?
MW,Y5)%;)P0O9CC!I_G1+C,B^O6NC'PM\78P/#.N@ Y'_ !+I>/\ QRE7X4^*
MUV_\4OKG'_4/E]"/[OO2^L4OYE]Z']6K_P C^YG.K(A) =21UYI5DC/_ "T7
MUZUT2_"GQ:,C_A&=<QV_XE\O'3_8]J?'\+/%:8_XI?6SSGG3Y??_ &?>I]O2
M_G7WH?U:M_(_N9SXVX)R,#K0LD9( =<^F:Z*+X7>+5@\L^&=:'J1I\V?_0:<
MGPK\4J,?\(QK9YS_ ,@^7W_V?>E]8I?S+[Q_5J_\C^YG-K.A21E^8)UQ],T]
M)$(Y8*>>&(SQUKI5^%WBKRW0^&=;8-U)T^7TQ_<IQ^&'BDK@>&-908P NGRC
M'.?[M3[>E_,OO*^JUOY']S.;,T:A3N!R<#!]\5+N11DLH'UK>'PO\59S_P (
MWKF<Y/\ Q+Y>><_W*</A;XJSG_A'-;!SD?Z!)QR?]CW-+V]+^9?>5]6K?R/[
MF<^LL9. PSG'6AI@C8*L0/O,.BY]:Z/_ (5?XI9LGPYK7WMW_'A)_P#$4]_A
MEXI=B3X;UH!L;E%A+@X_X#2]O2_F7WC^K5OY']S.>W1K@EUQ]:<LD?.'4XZX
M(K>_X5=XG.?^*:UKEB>=/D/7MRG2G_\ "K_$QV9\-ZS\N?\ EQEYS_P&I]O2
M_F7WE?5ZW\C^YF LT9P-R@^F14B8DY4AA[&MS_A5OB4J1_PCFLX/_3A)D?CL
M]JL0?#;Q-;J57PWK!!.>;&7_ .)J?;T_YE]X_J];^1_<SGHP'W8'W3@T+-%L
M5BX4$9^8XXKHD^'7BE=X_P"$<U<;CG(L)>/_ !VH_P#A5_B7Y<^'M:(48 ^P
MR>F/[M+VU+^9?>/ZO6_D?W,Q5D1N0RD?7WQ09HE^](HYQR:WC\,_$S,#_P (
M]K*\Y(%C)SSG^[ZTZ/X9^)(Y"_\ PCVL,?\ :L9/?_9]Z7MZ?\R^\KZO6_D?
MW,P^-I*C<1V'6DAF68@ $'!)![8./\?RK?A^&_BB.V\K_A'M8!(Y9;&7/_H-
M.A^''B6)EQX>U?(7;_QXR=,_[M3[:G_,OO']7K?R/[F8N*<%-="OP_\ $W_0
MNZM_X R__$T[_A ?$O\ T+NK?^ ,O_Q-+VU/^9?>/ZO6_D?W,YY8Z>%%;_\
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M  #D_P#B:7MJ?\R^\?U>K_(_N9A!:<%K='@?Q%_T -4_\ Y/_B:<O@?Q#_T
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M+_S\S?\ ?QO\:/[-E_Y^9O\ OXW^-:5% &;_ &;+_P _,W_?QO\ &C^S9?\
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M;_&C^S9?^?F;_OXW^-:5% &;_9LO_/S-_P!_&_QH_LV7_GYF_P"_C?XUI44
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8_P!_&_QH_LV7_GYF_P"_C?XUI44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703890003016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SOL-GEL TECHNOLOGIES LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001684693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">23,000,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703890233544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,122<span></span>
</td>
<td class="nump">$ 9,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestBearingDepositsInBanks', window );">Bank deposits</a></td>
<td class="nump">21,400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">21,652<span></span>
</td>
<td class="nump">40,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables from collaborative arrangements</a></td>
<td class="nump">2,153<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,074<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">53,401<span></span>
</td>
<td class="nump">55,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted long-term deposits and cash</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,817<span></span>
</td>
<td class="nump">2,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,896<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">754<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">5,760<span></span>
</td>
<td class="nump">5,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">59,161<span></span>
</td>
<td class="nump">61,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
<td class="nump">4,088<span></span>
</td>
<td class="nump">4,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating leases</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">5,964<span></span>
</td>
<td class="nump">6,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating leases liabilities</a></td>
<td class="nump">1,299<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
<td class="nump">2,348<span></span>
</td>
<td class="nump">2,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">8,312<span></span>
</td>
<td class="nump">8,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, NIS 0.1 par value - authorized: 50,000,000 as of December 31, 2019 and 2020, respectively; issued and outstanding: 20,402,800 and 23,000,782 as of December 31, 2019 and December 31, 2020, respectively</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">231,577<span></span>
</td>
<td class="nump">203,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(181,363)<span></span>
</td>
<td class="num">(152,073)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">50,849<span></span>
</td>
<td class="nump">52,465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 59,161<span></span>
</td>
<td class="nump">$ 61,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestBearingDepositsInBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For banks and other depository institutions (including Federal Reserve Banks, if applicable): Interest-bearing deposits in other financial institutions for relatively short periods of time including, for example, certificates of deposits, which are presented separately from cash on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117340910&amp;loc=d3e59706-112781<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestBearingDepositsInBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703888905720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value per share</a></td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">23,000,782<span></span>
</td>
<td class="nump">20,402,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">23,000,782<span></span>
</td>
<td class="nump">20,402,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703888641432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">COLLABORATION REVENUES</a></td>
<td class="nump">$ 8,771<span></span>
</td>
<td class="nump">$ 22,904<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">27,913<span></span>
</td>
<td class="nump">40,578<span></span>
</td>
<td class="nump">28,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
<td class="nump">11,091<span></span>
</td>
<td class="nump">8,276<span></span>
</td>
<td class="nump">5,504<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">TOTAL OPERATING LOSS</a></td>
<td class="nump">30,233<span></span>
</td>
<td class="nump">25,950<span></span>
</td>
<td class="nump">33,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_FinancialIncomeExpensesNet', window );">FINANCIAL INCOME, net</a></td>
<td class="num">(943)<span></span>
</td>
<td class="num">(1,374)<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="nump">29,290<span></span>
</td>
<td class="nump">24,576<span></span>
</td>
<td class="nump">32,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAXES</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">LOSS FOR THE YEAR</a></td>
<td class="nump">$ 29,290<span></span>
</td>
<td class="nump">$ 24,609<span></span>
</td>
<td class="nump">$ 32,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER ORDINARY SHARE</a></td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</a></td>
<td class="nump">22,574,688<span></span>
</td>
<td class="nump">19,534,562<span></span>
</td>
<td class="nump">17,867,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_FinancialIncomeExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial expenses (income), net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_FinancialIncomeExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703888949000">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th" colspan="2"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 42,480<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (95,261)<span></span>
</td>
<td class="num">$ (52,699)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,290,244<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(32,203)<span></span>
</td>
<td class="num">(32,203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(66)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Stock split, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of loans from the Controlling shareholder</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 160<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">65,178<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of loans from the Controlling shareholder, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,444,825<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts', window );">Issuance of shares through an initial public offering, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">78,564<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares', window );">Issuance of shares through an initial public offering, net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,187,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Exercise of options granted to employee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Exercise of options granted to employee, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,399<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,654<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,654<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">190,853<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(127,464)<span></span>
</td>
<td class="nump">63,909<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,949,968<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(24,609)<span></span>
</td>
<td class="num">(24,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted share units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted share units, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,332<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares through public offering, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,572<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares through public offering, net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,437,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,552<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">203,977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(152,073)<span></span>
</td>
<td class="nump">$ 52,465<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,402,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,402,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(29,290)<span></span>
</td>
<td class="num">$ (29,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts', window );">Issuance of shares and warrants through public offering, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares', window );">Issuance of shares and warrants through public offering, net of issuance costs, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,091,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder', window );">Issuance of shares and warrants through private placement from the controlling shareholder</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,987<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares', window );">Issuance of shares and warrants through private placement from the controlling shareholder, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">454,628<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted share units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted share units, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">151<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,447<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 635<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 231,577<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (181,363)<span></span>
</td>
<td class="nump">$ 50,849<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,000,782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,782<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than 1,000.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants through private placement from the controlling shareholder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants through private placement from the controlling shareholder, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_IssuanceOfSharesAndWarrantsThroughPrivatePlacementFromControllingShareholderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants through public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants through public offering, net of issuance costs, shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_IssuanceOfSharesAndWarrantsThroughPublicOfferingNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares through an initial public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares through an initial public offering, net of issuance costs, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_IssuanceOfSharesThroughInitialPublicOfferingNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703890240488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
<td class="num">$ (29,290)<span></span>
</td>
<td class="num">$ (24,609)<span></span>
</td>
<td class="num">$ (32,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expenses</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">2,552<span></span>
</td>
<td class="nump">4,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_NetChangesInOperatingLeases', window );">Net changes in operating leases</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ChangesInFairValueOfMarketableSecurities', window );">Changes in fair value of marketable securities</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_FinanceExpensesNet', window );">Finance expenses, net</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating asset and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables from collaborative arrangements</a></td>
<td class="nump">1,967<span></span>
</td>
<td class="num">(4,120)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other</a></td>
<td class="num">(542)<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="nump">3,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent', window );">Long term receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,241)<span></span>
</td>
<td class="num">(22,500)<span></span>
</td>
<td class="num">(23,467)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(449)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
<td class="num">(1,052)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_BankDeposits', window );">Bank deposits</a></td>
<td class="num">(21,400)<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments', window );">Restricted long-term deposits</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investments in marketable securities</a></td>
<td class="num">(32,322)<span></span>
</td>
<td class="num">(38,702)<span></span>
</td>
<td class="num">(71,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturity of marketable securities</a></td>
<td class="nump">51,498<span></span>
</td>
<td class="nump">54,333<span></span>
</td>
<td class="nump">15,092<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(2,694)<span></span>
</td>
<td class="nump">16,024<span></span>
</td>
<td class="num">(54,735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options granted to employees</a></td>
<td class="nump">151<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of shares and warrants through public offering, net of issuance costs</a></td>
<td class="nump">21,306<span></span>
</td>
<td class="nump">10,613<span></span>
</td>
<td class="nump">78,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from issuance of shares and warrants to the controlling shareholder through private placement</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">26,457<span></span>
</td>
<td class="nump">10,613<span></span>
</td>
<td class="nump">78,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(1,490)<span></span>
</td>
<td class="nump">4,087<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESRICTED CASH AT BEGINNING OF THE YEAR</a></td>
<td class="nump">9,762<span></span>
</td>
<td class="nump">5,675<span></span>
</td>
<td class="nump">5,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR</a></td>
<td class="nump">8,272<span></span>
</td>
<td class="nump">9,762<span></span>
</td>
<td class="nump">5,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash equivalents</a></td>
<td class="nump">7,122<span></span>
</td>
<td class="nump">9,412<span></span>
</td>
<td class="nump">5,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</a></td>
<td class="nump">8,272<span></span>
</td>
<td class="nump">9,762<span></span>
</td>
<td class="nump">5,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities', window );">Recognition of new operating lease ROU and liabilities</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of loans from the controlling shareholder</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">65,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest received</a></td>
<td class="nump">$ 770<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_BankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow and outflow from bank deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_BankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in accrued liability for employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_ChangesInAccruedLiabilityForEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_ChangesInFairValueOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from changes in fair value of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_ChangesInFairValueOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_FinanceExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance expenses, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_FinanceExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_NetChangesInOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net changes in operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_NetChangesInOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognition of operating lease ROU and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_RecognitionOfOperatingLeaseRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due within one year (or one business cycle) of receivables that were originally due beyond one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with funds and investments that are not available for withdrawal or use (such as assets held in escrow or contractually limited as to use or disposition) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892294184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">NOTE 1&#8201;&#8212;&#8201;NATURE OF OPERATIONS</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Sol-Gel Technologies Ltd. (collectively with its subsidiary, the Company) is an Israeli Company incorporated in&#160; 1997.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">The Company is a clinical stage specialty
          pharmaceutical company focused on developing and commercializing topical dermatological drug products. The Company&#8217;s lead product candidates are based upon its proprietary microencapsulation delivery system, consisting of microcapsules made of
          precipitated silica. The most advanced investigational drugs in the Company's product pipeline are: (i) Twyneo<sup style="font: smaller/1 Times New Roman,serif; vertical-align: text-top">&#174;</sup>, which is developed for the treatment of acne vulgaris. The New Drug Application ("NDA") for Twyneo&#174; was accepted by
          the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;), which
          assigned a Prescription Drug User Fee Act ("PDUFA") goal date of August 1, 2021; and (ii) Epsolay<sup style="font: smaller/1 Times New Roman,serif; vertical-align: text-top">&#174;</sup>, a potential treatment for subtype II rosacea. The NDA for Epsolay&#174; was accepted by the FDA, which assigned a PDUFA goal date of April 26, 2021.  In addition to the novel product candidates, the Company&#8217;s products include the generic product Acyclovir and other generic product candidates.</div>
    </div>

    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company has a wholly owned U.S. subsidiary - Sol-Gel Technologies Inc. (the "Subsidiary"). The Subsidiary supports the Company with regard to marketing, regulatory affairs and business development
      relating to its products and technology in the U.S.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Since incorporation through December 31, 2020, the Company has an accumulated deficit of approximately $181,363 thousand and its activities have been funded mainly by its shareholders and collaboration
      revenues. The Company expects to continue to incur significant research and development and other costs related to its ongoing operations and in order to continue its future operations, the Company will need to obtain additional funding until
      becoming profitable.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Management is considering raising additional funding from different sources, such as corporate collaborations, licensing of its branded products or similar arrangements, public or private equity
      offerings and/or debt financings, and/or selling shares under the Company's Open Market Sale Agreement with Jefferies LLC. Management expects that the Company's cash and cash equivalents, deposits and marketable securities as of December 31, 2020
      will allow the Company to fund its operating plan through at least the next 12 months from the financial statement issuance date.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">In December 2019, COVID-19 was identified in Wuhan, China. This virus continues to spread globally and, as of December 2020, has spread to over 50 countries, including the United States and Israel. The
      Company is subject to risks and uncertainties as a result of the COVID-19 pandemic.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">As of December 31, 2020, the main impact on the Company's operations resulting from COVID-19 was the decline in revenues of Acyclovir in the second quarter.&#160; Management believes that such decline was
      mainly attributed to travel restrictions and stay-at-home-orders.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues from collaboration
      arrangements, expenses, reserves and allowances, manufacturing, supply, regulatory approvals, clinical trials, commercial launch of branded and generic product candidates,&#160; research and development costs and employee-related amounts, will depend on
      future developments that are highly uncertain and cannot be predicted. The Company continues to monitor and assess new information related to the COVID-19 pandemic, the actions taken to contain or treat COVID-19, as well as the economic impact on the
      different markets.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Furthermore, the estimation process required to prepare the Company&#8217;s consolidated financial statements requires assumptions to be made about future events and conditions and the impact of COVID-19 on
      its financial results, and while management believes such assumptions are reasonable, they are inherently subjective and uncertain. The Company&#8217;s actual results could differ materially from those estimates.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703898368072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: bold 10pt/1.25 Times New Roman, Times, Serif"><br />
      NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">Basis of presentation</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</div>

<div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">&#160;<br style="line-height: 1.25" /></div>
    <table cellspacing="0" cellpadding="0" id="z79ce61c58f764cd4a9fa64fe81b14829" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">a.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Use of estimates in the preparation of financial statements</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of
      contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the fair value of share-based
compensation and the incremental borrowing rate for leases.&#160;</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>

    <table cellspacing="0" cellpadding="0" id="z324b2b78394744a6be48487dc70d4003" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">b.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Functional and presentation currency</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The U.S. dollar (&#8220;dollar&#8221;) is the currency of the primary economic environment in which the operations of the Company and its subsidiary are conducted. The Company&#8217;s financing has been provided in
      dollars, revenues are primarily in dollars and a significant part of expenses are incurred in dollars. The financial statements are presented in dollars, which is the Company&#8217;s functional and presentation currency.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange
      rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (I) for transactions &#8212; exchange rates at transaction
      dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) &#8212; historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z6c9ffab81e864a618ac4edfe4b6d9c74" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">c.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Cash and cash equivalents</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase
      that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z7f1b6911715048f48107b0c09a6d1af5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">d.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif"><font style="font-weight: bold">Bank deposits</font><br />
              <br />
              Bank deposits with original maturity dates of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an average annual rate of approximately 0.71%-1.87% in 2020. Interest
              accrued on bank deposits was recorded as interest receivable as part of "Prepaid expenses and other current assets" in the company&#8217;s balance sheet. </div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"> <br />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bank deposits with maturity of more than one year are considered long-term.<br />
      <br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="zc761d232035445b7b04ae0b4702e8c23" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">e.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Marketable securities</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"><br />
      Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825,&#160;Financial Instruments as the Company manages its portfolio and
      evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z5ee031687b39499782a8e3367f82326a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">f.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif"><font style="font-weight: bold">Derivatives and hedging</font><br />
              <br />
              The Company carries out transactions involving foreign currency exchange derivative financial instruments. The transactions are designed to hedge the Company&#8217;s exposure in currencies other than the U.S. dollar. The derivative does not meet
              the definition of a cash flow accounting hedge, therefore the changes in the fair value are included in financial expense (income), net.</div>
            <div style="font: 10pt Times New Roman, Times, Serif"><br />
              The currency hedged items are denominated in New Israeli Shekel (NIS).&#160; The counterparties to the derivatives are major banks in Israel.</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>
    <div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt">

    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">As of December 31, 2020, the Company has $1,150 on the Company&#8217;s bank account that is restricted in order to secure the hedging transactions. This amount is presented among Restricted long-term
      deposits and cash.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="za932c38e076d43c9b7a8bedb2974ffe4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">g.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Trade receivables:</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 20.15pt">Trade receivables are initially recognized at the transaction price and subsequently measured at amortized cost less any allowance for expected credit losses.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 20.15pt">&#160;Starting from January 1, 2020, the Company applies ASU 2016-13 &#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;the Standard&#8221;).</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z109d213175f74f7a8c8ca1b35225a9f2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">h.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Property and equipment:</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z59a5ed342ee546a4bd32f4e6f1249a3a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"><br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">1)</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif">Property and equipment are stated at cost, net of accumulated depreciation and amortization.</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z6147f6baec204641b7d368d9e11bcc9b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"><br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">2)</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s property and equipment are depreciated utilizing the straight-line method on the basis of their estimated useful life.</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">Annual rates of depreciation are as follows:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" border="0" align="center" id="z8b2cd7cdce7d403380565b5c928b1fed" style="font: 10pt Times New Roman, Times, Serif; width: 85%; color: #000000; text-align: left">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">%&#8201;&#8199;</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Laboratory equipment</div>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">10 &#8211; 33 (mainly 15 &#8211; 25)</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Office equipment and furniture</div>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">7 &#8211; 15</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Computers and related equipment</div>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">33</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Leasehold improvements are amortized utilizing the straight-line method over the shorter of the expected lease term or the estimated useful life of the improvements.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="zf29af5ff7e744ab7a318efd9f9ceb0f7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">i.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Impairment of long-lived assets</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest
      charges) of the assets is less than the carrying amount of such assets, an impairment loss would be recognized. The assets would then be written down to their estimated fair values.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">For the three years ended December&#160;31, 2020, the Company did not recognize an impairment loss for its long-lived assets.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="za27b9bfab8074ad4ac5345b539fb50df" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">j.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Share-based compensation</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company accounts for employees&#8217; share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an
      expense over the requisite service period.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option award
      approach.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">On January 1, 2019 the Company adopted ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Under
      the provision of the amendment, the Company measures share-based compensation to non-employees in the same manner (except for certain exceptions) as share-based compensation to employees.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>
    <div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt">

    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Prior to January 1, 2019, when options were granted as consideration for services provided by consultants and other non-employees, the grant was accounted for based on the fair value of the
      consideration received or the fair value of the options issued, whichever is more reliably measurable. The fair value of the options granted was measured on a final basis at the end of the related service period and recognized over the related
      service period using the graded vesting schedule method.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 15.7pt"> <br />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company has elected to recognize forfeitures as they occur.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="zf8bf3f8a3cc54154a9fe73d9f16a6983" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">k.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Research and development expenses</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll
      taxes and other employee benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Acquisitions of in-process research and development product candidate, which are not part of business combination, are recognized as an expense as research and development expenses as incurred.<br />
      <br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Grants received from Israel Innovation Authority (hereafter &#8212; &#8220;IIA&#8221;), formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS are recognized when the
      grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and
      development expenses as the applicable costs are incurred. See note 6a(1).</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources its clinical trial activities
      utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs are expensed as
      incurred.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="zb6c579e0afcb47cf80a2422f09d1b739" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">l.<br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Revenue recognition</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">The Company applies ASC 606, Revenue from Contracts with Customers. According to the standard, an entity recognizes revenue when its customer obtains control of promised goods or services, in an
      amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the
      following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
      and (v) recognize revenue when (or as) the performance obligation is satisfied.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">An entity only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
      customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the entity assesses the goods or services promised within each contract and determines those that are performance
      obligations and assesses whether each promised good or service is distinct. The entity then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation
      is satisfied.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt">

    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin: 0px 0px 0px 20pt"><font style="font-family: Times New Roman,Times,serif"><font style="font-style: italic">Collaborative Arrangements</font><br />
      </font><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">The Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC
      808, the Company may analogize to ASC 606 for some aspects of the arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part
      of its ongoing major or central operations. Revenue recognized by analogizing to ASC 606 is recorded as &#8220;collaboration revenues&#8221;.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) royalties on net sales of licensed products; (ii) reimbursements or cost-sharing of R&#38;D
      expenses. Each of these payments results in collaboration revenues or an offset against R&#38;D expense.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">Royalties: For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes collaboration revenue at the
      later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">Under certain collaborative arrangements, the Company has been reimbursed for a portion of its R&#38;D expenses or participates in the cost-sharing of such R&#38;D expenses. Such reimbursements and
      cost-sharing arrangements have been reflected as a reduction of R&#38;D expense in the Company&#8217;s consolidated statements of operations, as the Company does not consider performing research and development services for reimbursement to be a part of
      its ongoing major or central operations.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z0812def152d54fdb9f01feeecdb9dedc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">m.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Income taxes:</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z7defb31d969c43c8980ae9f04b65e866" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"><br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">1)</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif">Deferred taxes</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 36pt">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC&#160;740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and
      liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to
      reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the
      weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt">Uncertainty in income taxes</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 36pt">The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence
      indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being
      realized upon ultimate settlement.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt">

    <table cellspacing="0" cellpadding="0" id="z7945dbca9614463db051890512fb5a4a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">n.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Leases</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">As of January 1, 2019, the Company adopted ASU No. 2016-02, &#8220;Leases (Topic 842)". The Company adopted the standard using the modified retrospective approach with an effective date as of the beginning
      of the Company's fiscal year, January 1, 2019. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts are or contain
      leases, (2) lease classification and (3) initial direct costs.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Right of Use ("ROU") assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the
      lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is
      reasonably certain that the Company will exercise that option.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company uses the implicit rate when readily determinable. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information
      available at commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to not separate lease and non-lease components for the
      leases. The Company elected the practical expedient of the short-term lease recognition exemption for all leases with a term shorter than 12 months.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"> <br />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Additionally, the company applies the portfolio approach to account for operating lease ROU asset and liabilities for certain car leases and incremental borrowing rates.<br />
      <br />
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Upon adoption, the standard resulted in an increase of $1,200 in operating lease ROU assets and corresponding liabilities on the Company&#8217;s consolidated balance sheet and did
        not have a material impact on the Company&#8217;s consolidated statements of operations or consolidated statements of cash flows.&#160; See also note 6b.</div>
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z27d5f92405494446b69a4061f09c078a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">o.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Loss per share</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is based
      upon the weighted average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options, restricted shares and warrants, which are included under the treasury
      stock method when dilutive. The calculation of diluted loss per share does not include 1,119,310, 1,260,984 and 3,271,507 options, restricted shares and warrants for the years ended December&#160;31, 2018, 2019 and 2020, respectively, because their effect
      would be anti-dilutive.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z4d42a1eac37e418b92c66e4e364bc26f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">p.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Fair value measurement</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
      date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are
      described as follows:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt Times New Roman, Times, Serif; clear: both; margin-top: 10pt; margin-bottom: 10pt">

    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers
      counterparty credit risk in its assessment of fair value.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The carrying amount of the cash and cash equivalents, bank deposits, restricted cash, receivables from collaborative arrangements, restricted long-term deposits, accrued expenses (under other account
      payable), operating leases liabilities and other liabilities approximates their fair value.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="zf24ba24f57404740917d2ca20a147269" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">q.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Concentration of credit risks</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, bank deposits and marketable securities and certain
      receivables. The Company deposits cash and cash equivalents with highly rated financial institutions (Israeli banks). In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced any material
      credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" id="z339fd1fa884f49f086d0c0eb4212cb95" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">r.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Newly issued and recently adopted accounting pronouncements</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: italic bold 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Recently adopted accounting pronouncements:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">In June 2016, the FASB issued ASU 2016-13 &#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&#8221;. This guidance replaces the current incurred loss impairment
      methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance became effective for the fiscal year beginning
      on January 1, 2020, including interim periods within that year. This guidance did not have significant impact on the Company&#8217;s financial statements.</div></div></div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703898185064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"></div>
    <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">NOTE 3&#8201;&#8212;&#8201;MARKETABLE SECURITIES</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The following table sets forth the Company&#8217;s marketable securities for the indicated period:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table align="right" cellspacing="0" cellpadding="0" border="0" id="z9e4af40726134ff29da35241ab772cb6" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-left: 9pt; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December 31,</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-left: 9pt; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Level 2 securities:</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">U.S government and agency bonds</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,499</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,192</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Canada government bonds</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">999</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Other foreign government bonds</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,521</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,006</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Corporate bonds*</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">33,947</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">15,454</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 4px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Total</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">40,966</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">21,652</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 1.95pt; margin-left: 36pt; clear: both"> <br />
      </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"><font style="font-family: Times New Roman,Times,serif">* Investments in Corporate bonds
        rated A or higher.</font></div>

<div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"><font style="font-family: Times New Roman,Times,serif">&#160;</font><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company&#8217;s debt securities are classified
      within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The table below sets forth a summary of the changes in the fair value of the Company&#8217;s marketable securities for the
      years ended December 31, 2019 and 2020:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table align="right" cellspacing="0" cellpadding="0" border="0" id="z7ff47d7add744957b075a599acb90947" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December 31,</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Balance at beginning of the year</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">56,662</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">40,966</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Additions</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">38,702</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">32,322</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Sale or maturity</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(54,333</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(51,498</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify">Changes in fair value during the year</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(65</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(138</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify">Balance at end of the year</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">40,966</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">21,652</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">As of December 31, 2020, the Company&#8217;s debt securities had the following maturity dates:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table align="right" cellspacing="0" cellpadding="0" border="0" id="zf17a4cc52f0946eb8e8223ee2e133e79" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center; text-indent: 7pt">Market value</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center; text-indent: 7pt">December 31,</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center; text-indent: 7pt"> 2020</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Due within one year</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">21,652</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 88%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1 to 2 years</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Total</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">21,652</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>

    </table>
    </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892056184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"></div>
    <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">NOTE 4&#8201;&#8212;&#8201;PROPERTY AND EQUIPMENT</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table align="right" cellspacing="0" cellpadding="0" border="0" id="z5b8c8feb5b8048ae96207a1f12d10a94" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December 31</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Cost:</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Laboratory equipment</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,242</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,644</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Office equipment and furniture</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">265</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">265</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Computers and software</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">490</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">530</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Leasehold improvements</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,946</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,953</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5,943</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6,392</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Less:</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Accumulated depreciation and amortization</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(3,629</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(4,575</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Property and equipment, net</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,314</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,817</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Depreciation and amortization expense
        totaled $762, $887 and 946$ for the years ended December&#160;31, 2018, 2019 and 2020, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703905981784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE SEVERANCE BENEFITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE SEVERANCE BENEFITS</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"></div>
    <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">NOTE 5&#8201;&#8212;&#8201;EMPLOYEE SEVERANCE BENEFITS</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company is required to make severance payments upon dismissal of an employee or upon termination of employment in
      certain circumstances. The severance payment liability to the employees (based upon length of service and the latest monthly salary &#8212; one month&#8217;s salary for each year employed) is recorded on the Company&#8217;s balance sheet under &#8220;Liability for employee
      rights upon retirement.&#8221; The liability is recorded as if it was payable at each balance sheet date on an undiscounted basis.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">In accordance with the current employment terms starting in August&#160;2014 with all of its employees (Section 14 of the
      Israeli Severance Pay Law, 1963), the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s retirement benefit obligation. The Company is fully relieved
      from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not
      reflected in the Company balance sheet, as the amounts</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">funded are not under the control and management of the Company and the pension or severance pay risks have been
      irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plan&#8221;).</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">With regard to the period before August&#160;2014, the liability is funded in part from the purchase of insurance policies or
      by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s
      assets.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The amounts of severance payment expenses were $431, $402 and $428 for the years ended December&#160;31, 2018, 2019 and 2020,
      respectively, of which $292, $363 and $408 in the years ended December 2018, 2019 and 2020, respectively, were in respect of the Contribution Plan.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company expects to contribute approximately $408 in the year ending December&#160;31, 2021 to insurance companies in
      connection with its expected severance liabilities for that year.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892381768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">NOTE 6&#8201;&#8212;&#8201;COMMITMENTS:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2206b0aec79c40bb963978da84db12f6" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">a.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Royalty Commitments:</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z96799f1a692b43d0a6f3b5be12a526fa" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 38pt"><br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">1)</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif">The Company is obligated to pay royalties to the IIA on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from the IIA.</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56pt">Under the specific terms of the funding arrangements with the IIA, royalties of 3.5% to 25% are payable on the sale of products developed with funding received from the IIA, which payments shall not
      exceed, in the aggregate, 300% of the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR.<br />
      <br />
      Up to December&#160;31, 2020, the Company had recognized and received grants from the IIA in the aggregate amount of $1,431 (no grants were received in the last three years.). Through December&#160;31, 2020, the Company recorded an accumulated royalty expense
      of&#8201;$2,086 as royalties to the IIA with respect to revenue recognized through December 31, 2020 ($32, $32 and $25 were recorded in 2018, 2019 and 2020 accordingly, as an expense in the consolidated statements of operations).<br />
      <br />
      The Company did not receive any grants from the IIA for the years ended December&#160;31, 2018, 2019 and 2020.<br />
      <br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbf7a8e9a9ae249baa013c9d81cb75b17" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"><br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">2)</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif">The Company has an agreement, that was amended several times (hereafter &#8212; the agreements) with Yissum Research Development Company (hereafter &#8212; &#8220;Yissum&#8221;), the technology-licensing arm of the Hebrew University of Jerusalem.</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>

    <div style="font: 10pt Times New Roman, Times, Serif">
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56.7pt">According to the agreements, the Company received from Yissum an exclusive and a non-exclusive license for the commercialization of certain Yissum patents. According to the agreements the Company
        shall pay Yissum:</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56.7pt"> <br />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56.7pt">Royalties of 1.5% of net sales related to certain patents.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 56.7pt"> <br />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc1742217551248ed9b7f4429a64baf29" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 72pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">i.</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif">1.5%&#8201;&#8211;&#8201;8% of proceeds received by the Company for the sub-license or license of certain patents.<br />
                </div>
              </td>
            </tr>

        </table>
        <div style="font: 10pt Times New Roman, Times, Serif"><br />
        </div>
        <div style="font: 10pt Times New Roman, Times, Serif">
          <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 1.7pt; margin-left: 56.7pt">Royalty expenses in immaterial amounts were recorded in 2018, 2019 and 2020 in respect of
            these agreements</div>
        </div>
        <br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 1.7pt; margin-left: 56.7pt">According to the agreements, the Company may continue commercial use of certain Yissum&#8217;s patents in connection with the products and subject to the obligation to pay Yissum the
        royalties and the sub-license fees.<br />
        <br />
        The Company granted rights to a third party for use and commercialization of certain Yissum patents.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z905397d8e1d84d10b0626edcd3bfaa66" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">b.</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif"><font style="font-weight: bold">Lease Agreements</font><br />
                </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif">The Company leases offices and vehicles under operating leases. For leases with terms greater than 12 months, the Company
          records right of use assets and lease liabilities at the present value of lease payments over the leases term.</div>
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"><u>Offices</u></div>
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt">The Company leases office spaces and research and development facilities under several agreements. These agreements are linked to the change in the Israeli consumer price index and expire in
          December 2023. These agreements are considered as operating leases and presented under operating lease right-of-use assets and operating leases liabilities.&#160;A restricted deposit of $143 has been made in order to secure the agreement. <br />
          <br style="line-height: 1.25" />
        </div>
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"><u>Vehicles</u></div>
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt">The Company has entered into operating lease agreements for vehicles used by its employees for a period of 3 years. These contracts are considered as operating leases and presented under operating
          lease right-of-use assets and operating leases liabilities.</div>
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"><u>Lease Position</u></div>
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"><br />
          The table below presents the lease-related assets and liabilities recorded on the consolidated balance sheet:</div>
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="right" id="za98baf96df3e480f81f6a0b47af646c1" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">As of<br />
                December 31,</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2020</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Assets</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating Leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating lease right-of-use assets</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,040</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,896</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Liabilities</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Current liabilities</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Current maturities of operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">672</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">673</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Long-term liabilities</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Non-current operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,373</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,299</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Weighted Average Remaining Lease Term</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1.66</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1.29</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Weighted Average Discount Rate</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.44</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">%</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.25</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">%</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"><font style="font-family: Times New Roman,Times,serif"><u>Lease Costs</u></font></div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt">The table below present certain information related to lease costs of operating leases the year ended December 31, 2020:</div>
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="right" id="z189bca4764724745a014e2f7301a4530" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year</div>
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Ended</div>
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December 31,</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating lease cost:</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">643</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">685</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt">The table below presents supplemental cash flow information related to leases for the year ended December 31, 2020:</div>
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="right" id="zcf28705bc8f54985bc6fdc8eeb00706b" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year</div>
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Ended</div>
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December 31,</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2020</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Cash paid for amounts included in the measurement of leases liabilities:</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating cash flows from operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">807</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">735</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt"><u>Undiscounted Cash Flows</u><br />
          <br style="line-height: 1.25" />
        </div>
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 36pt">The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the operating lease liabilities recorded on the consolidated balance
          sheet:</div>
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="right" id="zd3bb0ab18d5d49dc9dada56d56d1d045" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Operating</div>
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -8.5pt; margin-left: 11.35pt">&#160;For the year ended December 31, 2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt">2021</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">778</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt">2022</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">714</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt">2023</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">648</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Total minimum lease payments</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,140</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td rowspan="1" colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Less: amount of lease payments representing interest</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(168</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Present value of future minimum lease payments</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,972</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Less:&#160; Current maturities of operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">673</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Long-term operating leases liabilities</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,299</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,972</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z770f468da62e42938aa55590c6d29e43" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">c.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">In June&#160;2008, the Company entered into a Master Clinical Trial Services Agreement with a third party, which was later
                  amended in April&#160;2017, to retain its services as a clinical research organization for certain product candidate subject to task work orders to be issued by the Company. During 2018, the Company entered into six additional task orders. As consideration for its services the Company will pay a total amount of approximately $14,425 during the term of the engagement and based on
                  achievement of certain milestones, out of which $14,354 were recognized as an expense until December&#160;31, 2020.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"><br />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc6c20d410f8f48c7a282d50dec86fcf9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">d.</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif">In 2016 through 2020, the Company entered into twelve collaboration agreements with two third parties for the development, manufacturing and commercialization of ten product candidates (including an agreement assumed by the Company in
                  August 2018, following the transfer of an in-process research and development product candidate from a related party). See detailed information in note 7b.<br />
                </div>
              </td>
            </tr>

        </table>
        <div style="font: 10pt Times New Roman, Times, Serif"><br />
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z35b3af3e3b604c0f917e16d36a6c38b1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">e.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">In October&#160;2017, the Company entered into a Clinical Development Master Services Agreement with a third party, to retain it as
                  clinical research organization for certain product candidate, subject to task work orders to be issued by the Company. As consideration for its services the Company will pay a total amount of approximately $13,955 during the term of the engagement and based on achievement of certain milestones, out of which $13,801 were recognized as an expense until December&#160;31, 2020.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z62610358882041928953182433291290" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">f.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top; text-align: justify">
              <div style="font: 10pt Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">In July&#160;2018, the Company signed on a Master Services Agreement to receive certain clinical research services for certain
                  product candidate subject to task work orders to be issued by the Company. As consideration for the services in the first work order the Company will pay a total amount of approximately $2,234 during the term of the engagement and based
                  on achievement of certain milestones, out of which $2,099 were recognized as an expense until December&#160;31, 2020.</div></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703898199464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif">
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><font style="font-weight: bold">NOTE 7&#8201;&#8212;&#8201;COLLABORATION AGREEMENTS<br />
        </font><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z69f6c9ad58d04439a6a2789d55e7fe8f" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">a.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales,
                royalties are not material.</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt Times New Roman, Times, Serif"><br />
      </div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z27cd88c288d14dcba4faaa3dbbfb4ac5" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">b.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">In 2016 through 2020, the Company entered into several collaboration agreements with two third parties for the development,
                  manufacturing and commercialization of several generic product candidates. Under the agreements, the third parties are obligated to conduct regulatory, scientific, clinical and technical activities necessary to develop the product and
                  prepare and file ANDA, with the FDA and gain regulatory approval. The Company participates in the development of the product candidates, including participation in joint steering committees and is obligated for sourcing the active
                  pharmaceutical ingredient (API) during the development phase.</div>
              </div>
              <div style="font: 10pt Times New Roman, Times, Serif"><br />
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Upon FDA approval, the third parties have exclusive rights and are required to use diligent efforts to commercialize these
                  products in territories defined under the agreements, including all required sales, marketing and distributing activities associated with the agreements. The Company is entitled to 50% of the third parties&#8217; gross profits related to the
                  sale of these products, as such term is defined in the agreements.</div>
                <br />
                As of December 31, 2020, the Company decided not to pursue one of the agreements with one of the third parties collaborators.<br />
                <br />
                In February 2019, the Company announced that a third party has received final approval from the FDA for the first generic version of a drug product.&#160; During
                  the years ended December 31, 2019 and 2020, the Company
                  recognized collaboration revenues related to sales of products in the U.S. under this agreement in the amounts of $22,775 and $8,673, respectively.<br />
              </div>
              <div style="font: 10pt Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br />
                  This Agreement is considered to be within the scope of ASC 808, as the parties are active participants and exposed to the risks and rewards of the collaborative
                    activity.<br />
                    <br style="line-height: 1.25" />
                </div>
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">The Company recognizes collaboration revenues when the related sales occur<font style="font-family: Times New Roman, Times, serif">.</font></div></div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892284264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
      <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">NOTE 8&#8212;&#8201;SHARE CAPITAL</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" id="z8fa77ab4ec544cda8510b95deb82eef6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: bold 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">a.</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: bold 10pt Times New Roman, Times, Serif">Ordinary shares<br />
                  </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" id="z8eb2dd07038b4695834632dcacda22be" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">1)</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif"><font style="font-weight: bold">Rights of the Company&#8217;s ordinary shares</font><br />
                  <br />
                  Each ordinary share is entitled to one vote. The holder of the ordinary shares is also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the
                  Company has not declared any dividends.<br />
                  </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      <br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="zfcc58fdf7aa343d4b9e4a0c228b544d7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">2)</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">On January&#160;19, 2018, the Company executed a 1-for-1.8 share split of the Company&#8217;s shares by way of an issuance of bonus shares for each share. Upon the effectiveness
                of the share split, (i)&#160;0.8 bonus shares were issued for each outstanding share, (ii)&#160;the number of ordinary shares into which each outstanding option to purchase ordinary shares is exercisable was proportionally increased, and (iii)&#160;the
                exercise price of each outstanding option to purchase ordinary shares was proportionately decreased. Unless otherwise indicated, and except for authorized capital, all of the share numbers, loss per share amounts, share prices and option
                exercise prices in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-1.8 share split.</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z60c56e9853dd4a50928dbc17e985ab49" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">3)</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">In January 2018, the Company completed an Initial Public Offering ("IPO") on the NASDAQ
                  Stock Market, in which it issued 6,250,000 Ordinary shares at a price per share of $12. During February 2018 the underwriters exercised their green shoe option and purchased additional 937,500 ordinary shares at the same price per share.&#160;The total proceeds received from the IPO, net of issuance costs, were $78,775.<br />
                  <br />
                </div>
              <div style="font: 10pt Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Immediately prior to the closing of the IPO, the outstanding promissory note received from its current controlling
                  shareholder (the "Controlling Shareholder") were automatically converted into 5,444,825 Ordinary shares of the Company based on the IPO price of&#8201;$12 per ordinary share.</div>
              </div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z4fd0d1b03c6b4f5b9bee3db9b6a2fce7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">4)</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">On August 12, 2019, the Company completed an underwritten follow-on public offering, in which it issued 1,437,500&#160;ordinary shares,&#160;including the full exercise by the
                underwriters of their option to purchase&#160;187,500 additional ordinary shares,&#160;at a&#160;public offering&#160;price of $8.00&#160;per ordinary share.<br />
                The total proceeds received from the offering, net of issuance costs, were approximately $10,613.</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="ze94b55ad01934790acb357e2db6b9a1b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 20pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">5)</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">On February 19, 2020, the Company completed an underwritten public offering, in which it issued 2,091,907 ordinary shares and 2,091,907 warrants to purchase up to
                1,673,525 ordinary shares, at a public offering price of $11.00 per ordinary shares. The warrants are exercisable over a three-years period from the date of
                issuance at a per share exercise price of $14, subject to certain adjustments as defined in the agreement.&#160;The total proceeds received from the offering, net of&#160;issuance costs, were approximately $21,306.</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"> <br />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt">In addition and in parallel to the public offering, the Company signed an agreement for a private placement with its
        controlling shareholder for an additional investment of approximately $5,000 in consideration of 454,628 ordinary shares and 454,628 warrants to purchase up to 363,702 ordinary shares, at the same terms of the underwritten public offering mentioned
        above. The private placement agreement was contingent on certain conditions and was approved by the company&#8217;s shareholders on April 8, 2020.&#160; The total proceeds of $5,000 were received&#160;in April 2020.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="zfda0292c5dc449c5a54c23cb1aeb159c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">b.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Share-based compensation:</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" id="z0b21a8a2fdcb4a3083fe3032d3d5a858" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">1)</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif"><font style="font-weight: bold">Option plan</font><br />
                  </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 38pt">In December, 2014, the Company&#8217;s Board of Directors approved a Share Incentive Plan (hereafter &#8212; the Plan)
        and reserved a pool of 629,025 ordinary shares, par value NIS 0.1 each, or such other number as the Board may determine, subject to certain terms and conditions as defined in the Plan. According to the Plan, the Company may issue shares or
        restricted shares, may grant options or restricted share units and other share-based awards (hereafter &#8212; the awards) to the Company employees, consultants, directors and other service providers.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 38pt">The Plan is designed to enable the Company to grant awards to purchase Ordinary Shares under various and
        different tax regimes including, without limitation: pursuant and subject to Section 102 of the Israeli Tax Ordinance and pursuant and subject to Section 3(i) of the Israeli Tax Ordinance and under Internal revenue Code Section 422.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 38pt">The awards may be exercised after vesting and in accordance with vesting schedules which will be determined
        by the Board of Directors for each grant. The maximum term of the awards is 10 years. The fair value of each option granted under this Plan is estimated using the Black-Scholes option pricing method. Expected volatility is based on the historical
        volatility of comparable peer companies.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt">The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term
        of the options granted in dollar terms. <font style="font-family: Times New Roman, Times, serif">The expected term of the options is estimated based on the simplified method, as its historical experience for options grants as a
          public company is insufficient.</font><font style="font-family: Times New Roman, Times, serif"><br />
        </font><font style="font-family: Times New Roman, Times, serif"><br />
        </font>In December 2019, the Company&#8217;s Board of Directors approved an increase of the ordinary shares that may be issued under the Company&#8217;s Plan by reserving an additional amount of 912,230 ordinary shares.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt"> <br />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 38pt">As of December 31, 2020, 949,415 ordinary shares remain available for future grants under the Plan.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" id="z93a633ddd1db481aacea15e042b9702e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">2)</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif"><font style="font-weight: bold">Options grants</font><br />
                  </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z9005236ad7ae411793e0a26cda0d10a0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">a.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top; text-align: justify">
              <div style="font: 10pt Times New Roman, Times, Serif">Option granted to employees and directors</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z1b8ebecfd9ec453881039d2deb7ffa3e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 85.05pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 21.3pt; vertical-align: top">i.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">In January 2019, the Company granted a total of 80,000 options to an executive officer to purchase ordinary shares at an exercise price of $5.95 per share.</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="za7081ac888d64c28b3e7464a194600e7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 85.05pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 21.3pt; vertical-align: top">ii.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">In May 2019, the Company granted a total of 9,000 options to several employees to purchase ordinary shares at an exercise price of $7.32 per share.</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z3c0e048d8d7a4f5d9e71d3c3b4b6923c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 85.05pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 21.3pt; vertical-align: top">iii.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">In December 2019, the Company granted a total of 6,300 options to several employees to purchase ordinary shares at an exercise price of $8.32 per share.</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt">The options vest over a period of 4 years; 25% of the options vest on the first anniversary of the vesting
        commencement date (as described in each agreement) and the rest vest quarterly over the following three years. The options expire on the tenth anniversary of their grant date.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt">The fair value of options granted to employees and directors in 2018 and 2019 were $878 and $485 respectively. The
        underlying data used for computing the fair value of the options are as follows:</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="zd132b3fd475547dba6e7e8ceae2bfccd" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2018</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2019</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Value of one ordinary share</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">$6.24-$10.40</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">$6.08-$8.59</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Dividend yield</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">0%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">0%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expected volatility</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">70.43 %-73.35%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">74.87%-77.83 %</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Risk-free interest rate</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2.67%-2.83%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">1.82%-2.75%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expected term</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">5.50-7 years</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">6.11 years</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt">The total unrecognized compensation cost of employee options at December&#160;31, 2020 is $271, which is expected to be
        recognized over a period of 2.96 years.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt"><br />
        The following table summarizes the number of options granted to employees under the Plan for the years ended December&#160;31, 2019 and 2020, and related information:</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 76.3pt"> <br />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="z8504eda92ce2497294e9b56e1f571d96" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="22" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year ended December 31</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><font style="line-height: 1.25"> </font></div>
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Number of options</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Number of options</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -9pt; margin-left: 9pt">Options outstanding at the beginning of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">938,090</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.47</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.89</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,031,591</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.74</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.25</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Granted</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">95,300</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.24</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">9.17</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Exercised</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(28,447</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5.27</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expired</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(563</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5.57</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Forfeited</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(1,238</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5.57</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(2,250</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.77</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Options outstanding at the end of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,031,591</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.74</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.25</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,000,894</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.63</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.05</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Options exercisable at the end of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">683,979</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3.60</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.56</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">900,687</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.08</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5.67</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 76.3pt; clear: both"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" id="z060c11d49c1742b1bab4681a407a72f5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">b.</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif">Option granted to non-employees<br />
                  </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt">In March 2018, the Company granted a total of 76,895 options to several consultants to purchase ordinary shares at an
        exercise price of $11.21 per share.<br />
        <br />
        The options vest over a period of 4 years; 25% of the options vest on the first anniversary of the vesting commencement date (as described in each agreement) and the rest vest quarterly over the following three years. The options expire on
        the tenth anniversary of their grant date.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt">The fair value of options granted to non-employees in 2018 was $648. The underlying data used for computing the fair
        value of the options are as follows:</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table align="center" cellspacing="0" cellpadding="0" border="0" id="zb5166ac1be864ad599232c6ce037f683" style="font: 10pt Times New Roman, Times, Serif; width: 80%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2018</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Value of one ordinary share</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">$ 10.40</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Dividend yield</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">0%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expected volatility</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">79.07%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Risk-free interest rate</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2.86%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expected term</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">10 years</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt">The total unrecognized compensation cost of non-employees' options at December&#160;31, 2020 is $25, which is expected to
        be recognized over a period of 1.23&#160;years.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 70.9pt">The following table summarizes the number of options granted to non-employees under the Plan for the year ended
        December&#160;31, 2019 and 2020, and related information:</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="zb2de4e2f65a649efac2a1f4896b9f69f" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="22" rowspan="1" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year ended December 31</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><font style="line-height: 1.25"> </font></div>
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Number of options</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Number of options</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -9pt; margin-left: 9pt">Options outstanding at the beginning of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">198,575</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.48</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">8.81</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">198,575</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.48</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.84</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Granted</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Options outstanding at the end of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">198,575</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.48</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.84</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">198,575</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.70</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.84</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Options exercisable at the end of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">96,588</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.97</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.78</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">137,771</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.34</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.8</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 70.9pt; clear: both"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" id="zb5378c024eca4291a968ee7fce692323" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">c.</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif">The aggregate intrinsic value of the total outstanding and of total exercisable options as of December 31, 2020 is approximately $482 and $413, respectively.<br />
                  </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" id="z6bdd89df0c0d4d09a2903226774a5021" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">d.</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif">Restricted Share Units (RSUs) granted to Directors<br />
                  <br />
                  In February 2018 and September 2018, the board of directors approved and recommended the Company shareholders to approve a total grant of 46,000 and 11,500 RSUs, respectively, to its independent and
                  external directors that vest annually in equal portions over a three-year period. The fair value of shares as of the date of grant was $495 and $105 respectively. As of December 31, 2020, 38,332 RSUs were vested.<br />
                  </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <table cellspacing="0" cellpadding="0" id="zaf6f739ae1274c2497a12e2429df894b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

            <tr style="font: 10pt Times New Roman, Times, Serif">
              <td style="font: 10pt Times New Roman, Times, Serif; width: 54pt"><br />
              </td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">e.</td>
              <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
                <div style="font: 10pt Times New Roman, Times, Serif">The following table illustrates the effect of share-based compensation on the statements of operations:<br />
                  </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="z242876e0ae6a4d3180613b645b513bc5" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year ended<br />
                December 31</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2018</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2019</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Research and development expenses</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,708</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,028</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">431</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">General and administrative expenses</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,946</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,524</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">786</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,654</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,552</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,217</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703898521208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"></div>
      <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">NOTE 9&#8201;&#8212;&#8201;TAXES ON INCOME</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="zafcb5a0dbf77404cbc014740969eb7b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">a.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Tax rates in Israel</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company is taxed in accordance with Israeli tax laws. The corporate tax rates applicable to 2018, 2019 and 2020 is
        23%. Capital gain is subject to capital gain tax according to the corporate tax rate in the year the assets are sold.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z9f68172d194443cf92430c81892fb78e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">b.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Tax rates for the U.S Subsidiary</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The subsidiary is taxed according to U.S. tax laws. The Company&#8217;s income is taxed in the United States
          at the federal rate of 21%.<br />
          <br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z7f798157ebb3419994c9166d9fb8fb9f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">c.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;)</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Under the Investment Law, including Amendment No. 60 to the Investment Law that was published in April&#160;2005, by virtue
        of the Benefited Enterprise program for certain of its facilities; the Company may be entitled to various tax benefits.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The main benefit arising from such status is the reduction in tax rates on income derived from a Benefited Enterprise.
        The extent of such benefits depends on the location of the enterprise. Since the Company&#8217;s facilities are not located in &#8220;national development zone A,&#8221; income derived from Benefited Enterprises will be tax exempt for a period of two years and then
        have a reduced tax rate for a period of up to an additional eight years.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The period of tax benefits, as described above, is limited to 12 years from the beginning of the Benefited Enterprise
        election year (2012). As of December&#160;31, 2020, the period of benefits has not yet commenced.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">In the event of distribution of cash dividends from income, which was tax exempt as above, the amount distributed will
        be subject to the tax rate it was exempted from. The Company is entitled to claim accelerated depreciation in respect of equipment used by the approved enterprises during five tax years.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"> <br />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Entitlement to the above benefits is conditioned upon the Company fulfilling the conditions stipulated by the
        Investment Law and regulations published thereunder.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"> <br />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">In the event of failure to comply with these conditions, the benefits may be canceled and the Company may be required
        to refund the amount of the benefits, in whole or in part, with the addition of linkage differences to the Israeli consumer price index and interest.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Investment Law was amended as part of the Economic Policy Law for the years 2011&#160;&#8211;&#160;2012 (the
          &#8220;Amendment&#8221;), which became effective on January&#160;1, 2011 and was further amended in August 2013 and January 2017.<br />
          <br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Under the 2017 Amendment, and provided the conditions stipulated therein are met, income derived by Preferred
        Companies from &#8216;Preferred Technological Enterprises&#8217; (&#8220;PTE&#8221;) (as defined in the 2017 Amendment), would be subject to reduced corporate tax rates of 7.5% in Development Zone &#8220;A&#8221; and 12% elsewhere, or 6% in case of a &#8216;Special Preferred Technological
        Enterprise&#8217; (&#8220;SPTE&#8221;) as defined in the 2017 Amendment) regardless of the company&#8217;s geographical location within Israel. A Preferred Company distributing dividends from income derived from its PTE or SPTE, would subject the recipient to a 20% tax
        (or lower, if so provided under an applicable tax treaty). The 2017 Amendment further provides that, in certain circumstances, a dividend distributed to a corporate shareholder who is not an Israeli resident for tax purposes would be subject to a
        4% tax (inter alia, if the amount of foreign investors in the distributing company exceeds 90%). Such taxes would generally be withheld at source by the distributing company.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"></div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"><br />
        On June 14, 2017, the Encouragement of Capital Investments Regulations (Preferred Technology Income and Capital Profits for a Technological Enterprise), 2017 (the &#8220;Regulations&#8221;) were published, which adopted Action 5 under the base erosion
        and profit shifting (&#8220;BEPS&#8221;) regulations. The Regulations describe, inter alia, the mechanism used to determine the calculation of the benefits under the PTE and under the SPTE Regime and determine certain requirements relating to documentation of
        intellectual property for the purpose of the PTE. According to these provisions, a company that complies with the terms under the PTE regime may be entitled to certain tax benefits with respect to income generated during the company&#8217;s regular
        course of business and derived from the preferred intangible asset (as determined in the Investments Law), excluding income derived from intangible assets used for marketing and income attributed to production activity. In the event that intangible
        assets used for marketing purposes generate over 10% of the PTE&#8217;s income, the relevant portion, calculated using a transfer pricing study, would be subject to regular corporate income tax. If such income does not exceed 10%, the PTE will not be
        required to exclude the marketing income from the PTE&#8217;s total income. The Regulations set a presumption of direct production expenses plus 10% with respect to income related to production, which can be countered by the results of a supporting
        transfer pricing study. Tax rates applicable to such production income expenses will be similar to the tax rates under the Preferred Enterprise regime, to the extent such income would be considered as eligible. In order to calculate the preferred
        income, the PTE is required to take into account the income and the research and development expenses that are attributed to each single preferred intangible asset. Nevertheless, it should be noted that the transitional provisions allow companies
        to take into account the income and research and development expenses attributed to all of the preferred intangible assets they have.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Under the transitional provisions of the law, a company is allowed to continue to enjoy the tax benefits available
        under the law prior to its amendment until the end of the period of benefits, as defined in the law. In each year during the period of benefits as a Benefited Enterprise, the Company will be able to opt for application of the amendment, thereby
        making available the tax rates discussed above. The Company&#8217;s election to apply the amendment is irrecoverable.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">As of December&#160;31, 2020, the Company&#8217;s management decided not to adopt the application of the Amendment.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">There is no assurance that future taxable income of the Company will qualify as Benefited or Preferred income or that
        the benefits described above will be available to the Company in the future.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="za6788c86eeaa4adda5a5cca049c2b07d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">d.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Tax assessments</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Tax assessments filed by the Company through the year 2015 are considered to be final.</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="zadebd1412dd84e49ac50920812a568ad" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">e.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Losses for tax purposes carried forward to future years</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">As of December&#160;31, 2020, the Company had approximately $151.4 million of net carry forward tax losses
          which are available to reduce future taxable income with no limited period of use.<br />
          <br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z0356fe2a933a4536a0e14eecb1af6ec9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">f.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Deferred income taxes:</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="z48e34922d0dc4e97a12bd3715a9a8159" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December, 31</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">In respect of:</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Net operating loss carry forward</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">25,879</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">34,835</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Research and development expenses</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7,842</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7,133</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Other</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,226</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,085</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Less&#8201;&#8211;&#8201;valuation allowance</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(34,947</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(43,053</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Net deferred tax assets</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#8212;</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#8212;</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z3d861b0c288b4988b8d969b13b072614" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">g.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Reconciliation of theoretical tax expenses to actual expenses</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Actual tax expenses are in respect of the U.S. subsidiary. The primary reconciling items between the
          statutory tax rate of the Company and the effective rate are the full valuation allowance of deferred tax assets and nondeductible expenses in relation to the operations in Israel.<br />
          <br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z46e47d0cd1f6456f88d75a17f843be40" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">h.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Roll forward of valuation allowance</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="z7da7b359ed9d4f239f9f2621cf1bb85b" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Balance at January 1, 2018</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">21,982</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Additions</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,184</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Balance at December 31, 2018</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">26,166</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Additions</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">8,781</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Balance at December 31, 2019</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">34,947</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Additions</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">8,106</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Balance at December 31, 2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">43,053</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z30097f43e4894caf9a50737470e45e3d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">i.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: bold 10pt Times New Roman, Times, Serif">Provision for uncertain tax positions</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">As of December&#160;31, 2019, and 2020, the Company does not have a provision for uncertain tax positions.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703898228184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"></div>
      <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">NOTE 10&#8201;&#8212;&#8201; &#160;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -21.3pt; margin-left: 39.3pt">Other accounts payables and accruals</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="za1f580f57fe44685a5e67f5546f31902" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December, 31</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Accrued expenses</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,249</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,250</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Employees payables</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">841</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">812</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Other</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">33</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">26</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,123</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,088</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          </tr>

      </table>
      </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892226360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; clear: both"></div>
      <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">NOTE 11&#8201;&#8212;&#8201;RELATED PARTIES</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="zf003d7e6af31422597f9239a41dc021d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">a.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">Related parties include the Controlling Shareholder and companies under his control, the Board of Directors and the Executive Officers of the Company.</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="z66b62cc7c3624fe7a98fdf038818bee0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">b.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">As to options and restricted shares granted to directors and executive officers, see note 8b.</div>
            </td>
          </tr>

      </table>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table cellspacing="0" cellpadding="0" id="zb5477391df374a25a6630398886bec9d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><br />
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 18pt; vertical-align: top">c.</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
              <div style="font: 10pt Times New Roman, Times, Serif">As to issuance of shares and warranted to the controlling shareholder in a private placement for a total consideration of $5,000, see note 8a (4).</div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703889224888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif">Basis of presentation</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z79ce61c58f764cd4a9fa64fe81b14829" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">a.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Use of estimates in the preparation of financial statements</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of
      contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the fair value of share-based compensation and the incremental borrowing rate for
      leases.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional and presentation currency</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z324b2b78394744a6be48487dc70d4003" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"><tr style="font: 10pt Times New Roman, Times, Serif"><td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">b.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Functional and presentation currency</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The U.S. dollar (&#8220;dollar&#8221;) is the currency of the primary economic environment in which the operations of the Company and its subsidiary are conducted. The Company&#8217;s financing has been provided in
      dollars, revenues are primarily in dollars and a significant part of expenses are incurred in dollars. The financial statements are presented in dollars, which is the Company&#8217;s functional and presentation currency.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange
      rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (I) for transactions &#8212; exchange rates at transaction
      dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) &#8212; historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6c9ffab81e864a618ac4edfe4b6d9c74" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">c.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Cash and cash equivalents</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase
      that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_BankDepositsPolicyTextBlock', window );">Bank deposits</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7f1b6911715048f48107b0c09a6d1af5" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">d.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif"><font style="font-weight: bold">Bank deposits</font><br />
              <br />
              Bank deposits with original maturity dates of more than three months but less than one year are included in short-term deposits. Such short-term deposits bear interest at an average annual rate of approximately 0.71%-1.87% in 2020. Interest
              accrued on bank deposits was recorded as interest receivable as part of "Prepaid expenses and other current assets" in the company&#8217;s balance sheet. </div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"> <br />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bank deposits with maturity of more than one year are considered long-term.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc761d232035445b7b04ae0b4702e8c23" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">e.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Marketable securities</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"><br />
      Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825,&#160;Financial Instruments as the Company manages its portfolio and
      evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives and hedging</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"></div>
    <table cellspacing="0" cellpadding="0" id="z5ee031687b39499782a8e3367f82326a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">f.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif"><font style="font-weight: bold">Derivatives and hedging</font><br />
              <br />
              The Company carries out transactions involving foreign currency exchange derivative financial instruments. The transactions are designed to hedge the Company&#8217;s exposure in currencies other than the U.S. dollar. The derivative does not meet
              the definition of a cash flow accounting hedge, therefore the changes in the fair value are included in financial expense (income), net.</div>
            <div style="font: 10pt Times New Roman, Times, Serif"><br />
              The currency hedged items are denominated in New Israeli Shekel (NIS).&#160; The counterparties to the derivatives are major banks in Israel.</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>

    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">As of December 31, 2020, the Company has $1,150 on the Company&#8217;s bank account that is restricted in order to secure the hedging transactions. This amount is presented among Restricted long-term
      deposits and cash.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy', window );">Trade receivables</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"></div>
    <table cellspacing="0" cellpadding="0" id="za932c38e076d43c9b7a8bedb2974ffe4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">g.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Trade receivables:</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 20.15pt">Trade receivables are initially recognized at the transaction price and subsequently measured at amortized cost less any allowance for expected credit losses.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 20.15pt">&#160;Starting from January 1, 2020, the Company applies ASU 2016-13 &#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;the Standard&#8221;).</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z109d213175f74f7a8c8ca1b35225a9f2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">h.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Property and equipment:</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z59a5ed342ee546a4bd32f4e6f1249a3a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"><br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">1)</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif">Property and equipment are stated at cost, net of accumulated depreciation and amortization.</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6147f6baec204641b7d368d9e11bcc9b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"><br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">2)</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s property and equipment are depreciated utilizing the straight-line method on the basis of their estimated useful life.</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">Annual rates of depreciation are as follows:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" border="0" align="center" id="z8b2cd7cdce7d403380565b5c928b1fed" style="font: 10pt Times New Roman, Times, Serif; width: 85%; color: #000000; text-align: left">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">%&#8201;&#8199;</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Laboratory equipment</div>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">10 &#8211; 33 (mainly 15 &#8211; 25)</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Office equipment and furniture</div>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">7 &#8211; 15</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Computers and related equipment</div>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">33</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Leasehold improvements are amortized utilizing the straight-line method over the shorter of the expected lease term or the estimated useful life of the improvements.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf29af5ff7e744ab7a318efd9f9ceb0f7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">i.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Impairment of long-lived assets</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest
      charges) of the assets is less than the carrying amount of such assets, an impairment loss would be recognized. The assets would then be written down to their estimated fair values.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">For the three years ended December&#160;31, 2020, the Company did not recognize an impairment loss for its long-lived assets.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Share-based compensation</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za27b9bfab8074ad4ac5345b539fb50df" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">j.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Share-based compensation</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company accounts for employees&#8217; share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an
      expense over the requisite service period.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option award
      approach.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">On January 1, 2019 the Company adopted ASU 2018-07 (Topic 718) that expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Under
      the provision of the amendment, the Company measures share-based compensation to non-employees in the same manner (except for certain exceptions) as share-based compensation to employees.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Prior to January 1, 2019, when options were granted as consideration for services provided by consultants and other non-employees, the grant was accounted for based on the fair value of the
      consideration received or the fair value of the options issued, whichever is more reliably measurable. The fair value of the options granted was measured on a final basis at the end of the related service period and recognized over the related
      service period using the graded vesting schedule method.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 15.7pt"> <br />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company has elected to recognize forfeitures as they occur.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf8bf3f8a3cc54154a9fe73d9f16a6983" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">k.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Research and development expenses</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll
      taxes and other employee benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Acquisitions of in-process research and development product candidate, which are not part of business combination, are recognized as an expense as research and development expenses as incurred.<br />
      <br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Grants received from Israel Innovation Authority (hereafter &#8212; &#8220;IIA&#8221;), formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS are recognized when the
      grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and
      development expenses as the applicable costs are incurred. See note 6a(1).</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources its clinical trial activities
      utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs are expensed as
      incurred.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb6c579e0afcb47cf80a2422f09d1b739" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">l.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Revenue recognition</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">The Company applies ASC 606, Revenue from Contracts with Customers. According to the standard, an entity recognizes revenue when its customer obtains control of promised goods or services, in an
      amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the
      following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
      and (v) recognize revenue when (or as) the performance obligation is satisfied.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">An entity only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the
      customer, after considering any price concession expected to be provided to the customer, when applicable. At contract inception, the entity assesses the goods or services promised within each contract and determines those that are performance
      obligations and assesses whether each promised good or service is distinct. The entity then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation
      is satisfied.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>

    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin: 0px 0px 0px 20pt"><font style="font-family: Times New Roman,Times,serif"><font style="font-style: italic">Collaborative Arrangements</font><br />
      </font><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">The Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC
      808, the Company may analogize to ASC 606 for some aspects of the arrangements. The Company analogizes to ASC 606 for certain activities within the collaborative arrangement for the delivery of a good or service (i.e., a unit of account) that is part
      of its ongoing major or central operations. Revenue recognized by analogizing to ASC 606 is recorded as &#8220;collaboration revenues&#8221;.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">The terms of the Company&#8217;s collaborative arrangements typically include one or more of the following: (i) royalties on net sales of licensed products; (ii) reimbursements or cost-sharing of R&#38;D
      expenses. Each of these payments results in collaboration revenues or an offset against R&#38;D expense.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">Royalties: For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes collaboration revenue at the
      later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">Under certain collaborative arrangements, the Company has been reimbursed for a portion of its R&#38;D expenses or participates in the cost-sharing of such R&#38;D expenses. Such reimbursements and
      cost-sharing arrangements have been reflected as a reduction of R&#38;D expense in the Company&#8217;s consolidated statements of operations, as the Company does not consider performing research and development services for reimbursement to be a part of
      its ongoing major or central operations.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0812def152d54fdb9f01feeecdb9dedc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">m.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Income taxes:</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7defb31d969c43c8980ae9f04b65e866" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt"><br />
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">1)</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: 10pt Times New Roman, Times, Serif">Deferred taxes</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: justify; margin-left: 36pt">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC&#160;740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and
      liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to
      reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized, based on the
      weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt">Uncertainty in income taxes</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: 36pt"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 36pt">The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence
      indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being
      realized upon ultimate settlement.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7945dbca9614463db051890512fb5a4a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">n.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Leases</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">As of January 1, 2019, the Company adopted ASU No. 2016-02, &#8220;Leases (Topic 842)". The Company adopted the standard using the modified retrospective approach with an effective date as of the beginning
      of the Company's fiscal year, January 1, 2019. The Company elected the package of transition provisions available for expired or existing contracts, which allowed it to carryforward its historical assessments of (1) whether contracts are or contain
      leases, (2) lease classification and (3) initial direct costs.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Right of Use ("ROU") assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the
      lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is
      reasonably certain that the Company will exercise that option.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The Company uses the implicit rate when readily determinable. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information
      available at commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company elected to not separate lease and non-lease components for the
      leases. The Company elected the practical expedient of the short-term lease recognition exemption for all leases with a term shorter than 12 months.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"> <br />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Additionally, the company applies the portfolio approach to account for operating lease ROU asset and liabilities for certain car leases and incremental borrowing rates.<br />
      <br />
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Upon adoption, the standard resulted in an increase of $1,200 in operating lease ROU assets and corresponding liabilities on the
        Company&#8217;s consolidated balance sheet and did not have a material impact on the Company&#8217;s consolidated statements of operations or consolidated statements of cash flows.&#160; See also note 6b.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z27d5f92405494446b69a4061f09c078a" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">o.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Loss per share</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is based
      upon the weighted average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options, restricted shares and warrants, which are included under the treasury
      stock method when dilutive. The calculation of diluted loss per share does not include 1,119,310, 1,260,984 and 3,271,507 options, restricted shares and warrants for the years ended December&#160;31, 2018, 2019 and 2020, respectively, because their effect
      would be anti-dilutive.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4d42a1eac37e418b92c66e4e364bc26f" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">p.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Fair value measurement</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
      date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are
      described as follows:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers
      counterparty credit risk in its assessment of fair value.</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The carrying amount of the cash and cash equivalents, bank deposits, restricted cash, receivables from collaborative arrangements, restricted long-term deposits, accrued expenses (under other account
      payable), operating leases liabilities and other liabilities approximates their fair value.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf24ba24f57404740917d2ca20a147269" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">q.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Concentration of credit risks</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, bank deposits and marketable securities and certain
      receivables. The Company deposits cash and cash equivalents with highly rated financial institutions (Israeli banks). In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced any material
      credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued and recently adopted accounting pronouncements</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif">
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z339fd1fa884f49f086d0c0eb4212cb95" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: bold 10pt Times New Roman, Times, Serif; width: 20.15pt; vertical-align: top">r.</td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top">
            <div style="font: bold 10pt Times New Roman, Times, Serif">Newly issued and recently adopted accounting pronouncements</div>
          </td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: italic bold 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">Recently adopted accounting pronouncements:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">In June 2016, the FASB issued ASU 2016-13 &#8220;Financial Instruments Credit Losses Measurement of Credit Losses on Financial Instruments&#8221;. This guidance replaces the current incurred loss impairment
      methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance became effective for the fiscal year beginning
      on January 1, 2020, including interim periods within that year. This guidance did not have significant impact on the Company&#8217;s financial statements.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_BankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bank deposits [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_BankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI http://asc.fasb.org/topic&amp;trid=2196771<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892026872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ScheduleOfDepreciationRatesTableTextBlock', window );">Schedule of Annual Depreciation Rates</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20.15pt">Annual rates of depreciation are as follows:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table align="center" cellspacing="0" cellpadding="0" border="0" id="z8b2cd7cdce7d403380565b5c928b1fed" style="font: 10pt Times New Roman, Times, Serif; width: 85%; color: #000000; text-align: left">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">%&#8201;&#8199;</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Laboratory equipment</div>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">10 &#8211; 33 (mainly 15 &#8211; 25)</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Office equipment and furniture</div>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">7 &#8211; 15</div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; width: 72.22%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Computers and related equipment</div>
          </td>
          <td style="font: 10pt Times New Roman, Times, Serif; width: 27.78%; vertical-align: top; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">33</div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_ScheduleOfDepreciationRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of annual depreciation rates for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_ScheduleOfDepreciationRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892184696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt">The following table sets forth the Company&#8217;s marketable securities for the indicated period:</div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
    </div>
    <table align="right" cellspacing="0" cellpadding="0" border="0" id="z9e4af40726134ff29da35241ab772cb6" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-left: 9pt; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December 31,</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-left: 9pt; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Level 2 securities:</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">U.S government and agency bonds</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,499</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,192</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Canada government bonds</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">999</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Other foreign government bonds</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,521</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,006</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Corporate bonds*</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">33,947</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">15,454</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 4px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Total</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">40,966</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">21,652</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
        </tr>

    </table>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 1.95pt; margin-left: 36pt; clear: both"> <br />
      </div>
    <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 20pt"><font style="font-family: Times New Roman,Times,serif">* Investments in Corporate bonds
        rated A or higher.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock', window );">Summary of Changes in Fair Value of Marketable Securities</a></td>
<td class="text"><div><div style="margin-left: 20pt; line-height: 1.25">The table below sets forth a summary of the changes in the fair value of the Company&#8217;s marketable securities for the
      years ended December 31, 2019 and 2020:</div>
    <div style="line-height: 1.25"><br style="line-height: 1.25" />
    </div>
    <table align="right" cellspacing="0" cellpadding="0" border="0" id="z7ff47d7add744957b075a599acb90947" style="font: 10pt Times New Roman, Times, serif; width: 95%; color: #000000; text-align: left">

        <tr>
          <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
            <div style="line-height: 1.25">
              <div style="text-align: center; line-height: 1.25">December 31,</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
            <div style="line-height: 1.25">
              <div style="text-align: center; line-height: 1.25"> 2019</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
            <div style="line-height: 1.25">
              <div style="text-align: center; line-height: 1.25">2020</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">Balance at beginning of the year</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">56,662</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">$</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">40,966</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: top; width: 76%">
            <div style="line-height: 1.25">Additions</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="line-height: 1.25">38,702</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="line-height: 1.25">32,322</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">Sale or maturity</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">(54,333</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">)</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">(51,498</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">)</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px">
            <div style="text-align: justify; line-height: 1.25">Changes in fair value during the year</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">(65</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">)</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">(138</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">)</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
            <div style="text-align: justify; line-height: 1.25">Balance at end of the year</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">$</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">40,966</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">$</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">21,652</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Debt Securities</a></td>
<td class="text"><div><div style="margin-left: 20pt; line-height: 1.25">As of December 31, 2020, the Company&#8217;s debt securities had the following maturity dates:</div>
    <div style="line-height: 1.25"><br style="line-height: 1.25" />
    </div>
    <table align="right" cellspacing="0" cellpadding="0" border="0" id="zf17a4cc52f0946eb8e8223ee2e133e79" style="font: 10pt Times New Roman, Times, serif; width: 95%; color: #000000; text-align: left">

        <tr>
          <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
            <div style="line-height: 1.25">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 7pt">Market value</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; vertical-align: bottom">
            <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 7pt">December 31,</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
            <div style="line-height: 1.25">
              <div style="text-align: center; line-height: 1.25; font-weight: bold; text-indent: 7pt"> 2020</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25; font-family: &#38;quot">Due within one year</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">21,652</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: middle; width: 88%; padding-bottom: 2px">
            <div style="line-height: 1.25; font-family: &#38;quot">1 to 2 years</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: right; width: 9%">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">-</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; vertical-align: middle; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25; font-family: &#38;quot">Total</div>
          </td>
          <td colspan="1" style="vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="line-height: 1.25">
              <div style="line-height: 1.25">21,652</div>
            </div>
          </td>
          <td colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703898181880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><table align="right" cellspacing="0" cellpadding="0" border="0" id="z5b8c8feb5b8048ae96207a1f12d10a94" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"><tr style="font: 10pt Times New Roman, Times, Serif"><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px"><div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December 31</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#160;</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
            <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Cost:</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Laboratory equipment</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,242</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,644</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Office equipment and furniture</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">265</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">265</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Computers and software</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">490</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">530</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Leasehold improvements</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,946</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,953</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5,943</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6,392</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Less:</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Accumulated depreciation and amortization</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(3,629</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(4,575</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </div>
          </td>
        </tr>
        <tr style="font: 10pt Times New Roman, Times, Serif">
          <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 9pt">Property and equipment, net</div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,314</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </div>
          </td>
          <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
            <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,817</div>
            </div>
          </td>
          <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703890475208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Lease-related Assets And Liabilities</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt">The table below presents the lease-related assets and liabilities recorded on the consolidated balance sheet:</div>
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="za98baf96df3e480f81f6a0b47af646c1" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">As of<br />
                December 31,</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2020</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Assets</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating Leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating lease right-of-use assets</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,040</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,896</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Liabilities</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Current liabilities</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Current maturities of operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">672</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">673</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Long-term liabilities</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Non-current operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,373</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,299</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Weighted Average Remaining Lease Term</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1.66</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1.29</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Weighted Average Discount Rate</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.44</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">%</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.25</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">%</div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><table align="right" cellspacing="0" cellpadding="0" border="0" id="z189bca4764724745a014e2f7301a4530" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left"><tr style="font: 10pt Times New Roman, Times, Serif"><td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"></td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year</div>
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Ended</div>
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December 31,</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating lease cost:</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">643</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">685</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 38pt">The table below presents supplemental cash flow information related to leases for the year ended December 31, 2020:</div>
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="zcf28705bc8f54985bc6fdc8eeb00706b" style="font: 10pt Times New Roman, Times, Serif; width: 93%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year</div>
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Ended</div>
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December 31,</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2020</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Cash paid for amounts included in the measurement of leases liabilities:</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: middle; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-right: 2.55pt">Operating cash flows from operating leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">807</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">735</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>

      </table>
      </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Reconciles Undiscounted Cash Flows</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 36pt">The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining
          years to the operating lease liabilities recorded on the consolidated balance sheet:</div>
      </div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
        <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
        </div>
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="zd3bb0ab18d5d49dc9dada56d56d1d045" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Operating</div>
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -8.5pt; margin-left: 11.35pt">&#160;For the year ended December 31, 2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt">2021</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">778</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt">2022</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">714</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 8.15pt">2023</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">648</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Total minimum lease payments</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,140</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
            <td colspan="1" rowspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Less: amount of lease payments representing interest</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(168</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Present value of future minimum lease payments</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,972</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Less:&#160; Current maturities of operating
                leases</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">673</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Long-term operating leases liabilities</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,299</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,972</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease-related assets and liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_ScheduleOfSupplementalCashFlowInformationRelatedToLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703888658888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Effect of Share-based Compensation Statements of Operations</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif"><table cellspacing="0" cellpadding="0" id="zaf6f739ae1274c2497a12e2429df894b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: left; color: #000000"><tr style="font: 10pt Times New Roman, Times, Serif"><td style="font: 10pt Times New Roman, Times, Serif; width: auto; vertical-align: top"><div style="font: 10pt Times New Roman, Times, Serif">The following table illustrates the effect of share-based compensation on the statements of operations:<br />
                  </div>
              </td>
            </tr>

        </table>
        <br style="line-height: 1.25" />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="z242876e0ae6a4d3180613b645b513bc5" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year ended<br />
                December 31</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2018</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2019</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Research and development expenses</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,708</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,028</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">431</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">General and administrative expenses</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,946</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,524</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">786</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,654</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">2,552</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,217</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SLGL_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt">The fair value of options granted to employees and directors in 2018 and 2019 were $878 and $485 respectively. The
        underlying data used for computing the fair value of the options are as follows:</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="zd132b3fd475547dba6e7e8ceae2bfccd" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2018</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2019</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Value of one ordinary share</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">$6.24-$10.40</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">$6.08-$8.59</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Dividend yield</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">0%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">0%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expected volatility</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">70.43 %-73.35%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">74.87%-77.83 %</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Risk-free interest rate</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2.67%-2.83%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">1.82%-2.75%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 46.21%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expected term</div>
            </td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.06%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">5.50-7 years</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.83%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25.12%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">6.11 years</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 1.78%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt">The following table summarizes the number of options granted to employees under the Plan for the years ended December&#160;31, 2019 and 2020, and related information:</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 76.3pt"> <br />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="z8504eda92ce2497294e9b56e1f571d96" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="22" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year ended December 31</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><font style="line-height: 1.25"> </font></div>
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Number of options</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Number of options</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -9pt; margin-left: 9pt">Options outstanding at the beginning of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">938,090</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.47</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.89</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,031,591</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.74</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.25</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Granted</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">95,300</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.24</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">9.17</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Exercised</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(28,447</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5.27</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expired</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(563</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5.57</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Forfeited</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(1,238</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5.57</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(2,250</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.77</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Options outstanding at the end of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,031,591</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.74</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.25</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,000,894</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.63</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.05</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Options exercisable at the end of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">683,979</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3.60</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.56</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">900,687</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4.08</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">5.67</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>

      </table>
      </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SLGL_NonEmployeesMember', window );">Non Employees Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 72pt">The fair value of options granted to non-employees in 2018 was $648. The underlying data used for computing the fair
        value of the options are as follows:</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table align="center" cellspacing="0" cellpadding="0" border="0" id="zb5166ac1be864ad599232c6ce037f683" style="font: 10pt Times New Roman, Times, Serif; width: 80%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top">&#160;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2018</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Value of one ordinary share</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">$ 10.40</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Dividend yield</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">0%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expected volatility</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">79.07%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Risk-free interest rate</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2.86%</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; width: 71%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Expected term</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; width: 25%; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-align: center">10 years</div>
            </td>
            <td style="font: 10pt Times New Roman, Times, Serif; width: 2.42%; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt/1.25 Times New Roman, Times, Serif; margin-left: 70.9pt">The following table summarizes the number of options granted to non-employees under the Plan for the year ended
        December&#160;31, 2019 and 2020, and related information:</div>
      <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><br style="line-height: 1.25" />
      </div>
      <table align="right" cellspacing="0" cellpadding="0" border="0" id="zb2de4e2f65a649efac2a1f4896b9f69f" style="font: 10pt Times New Roman, Times, Serif; width: 90%; color: #000000; text-align: left">

          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="22" rowspan="1" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Year ended December 31</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="10" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif"><font style="line-height: 1.25"> </font></div>
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Number of options</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Number of options</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average exercise price</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">Weighted average remaining contractual life</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif; text-indent: -9pt; margin-left: 9pt">Options outstanding at the beginning of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">198,575</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.48</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">8.81</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">198,575</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.48</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.84</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Granted</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">-</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Options outstanding at the end of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">198,575</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.48</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.84</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">198,575</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.70</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.84</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 28%; padding-bottom: 4px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Options exercisable at the end of the year</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">96,588</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.97</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.78</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">137,771</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7.34</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">6.8</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          </tr>

      </table>
      </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SLGL_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SLGL_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SLGL_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SLGL_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703898341688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Taxes</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><table align="right" cellspacing="0" cellpadding="0" border="0" id="z48e34922d0dc4e97a12bd3715a9a8159" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"><tr style="font: 10pt Times New Roman, Times, Serif"><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"></td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December, 31</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">In respect of:</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Net operating loss carry forward</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">25,879</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">34,835</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Research and development expenses</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7,842</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">7,133</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Other</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,226</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">1,085</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Less&#8201;&#8211;&#8201;valuation allowance</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(34,947</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">(43,053</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">)</div>
            </td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Net deferred tax assets</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#8212;</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">&#8212;</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          </tr>

      </table>
      </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Roll Forward of Valuation Allowance</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><table align="right" cellspacing="0" cellpadding="0" border="0" id="z7da7b359ed9d4f239f9f2621cf1bb85b" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"><tr style="font: 10pt Times New Roman, Times, Serif"><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; background-color: rgb(204, 238, 255)"><div style="font: 10pt/1.25 Times New Roman, Times, Serif">Balance at January 1, 2018</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">21,982</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Additions</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,184</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Balance at December 31, 2018</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">26,166</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Additions</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">8,781</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Balance at December 31, 2019</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">34,947</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 2px">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Additions</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">8,106</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Balance at December 31, 2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
              </div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">
                <div style="font: 10pt/1.25 Times New Roman, Times, Serif">43,053</div>
              </div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703898188632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accounts Payables and Accruals</a></td>
<td class="text"><div style="font: 10pt Times New Roman, Times, Serif"><div style="font: 10pt Times New Roman, Times, Serif"><table align="right" cellspacing="0" cellpadding="0" border="0" id="za1f580f57fe44685a5e67f5546f31902" style="font: 10pt Times New Roman, Times, Serif; width: 95%; color: #000000; text-align: left"><tr style="font: 10pt Times New Roman, Times, Serif"><td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px"></td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="6" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">December, 31</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center"> 2019</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
            <td colspan="2" style="border-bottom: #000000 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">
              <div style="font: bold 10pt/1.25 Times New Roman, Times, Serif; text-align: center">2020</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom">&#160;</td>
            <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Accrued expenses</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,249</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">3,250</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Employees payables</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">841</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">812</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">Other</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">33</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 2px solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">26</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255)">&#160;</td>
          </tr>
          <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: top; width: 76%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,123</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; width: 1%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">$</div>
            </td>
            <td colspan="1" style="border-bottom: rgb(0, 0, 0) 4px double; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
              <div style="font: 10pt/1.25 Times New Roman, Times, Serif">4,088</div>
            </td>
            <td colspan="1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 4px">&#160;</td>
          </tr>

      </table>
      </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703895493480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 181,363<span></span>
</td>
<td class="nump">$ 152,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703889254856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">3,271,507<span></span>
</td>
<td class="nump">1,260,984<span></span>
</td>
<td class="nump">1,119,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_RestrictedBankDeposit', window );">Restricted bank deposit</a></td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities', window );">Increase in Operating lease ROU assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ShorttermDepositsBearInterest', window );">Short-term deposits bear interest</a></td>
<td class="nump">0.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ShorttermDepositsBearInterest', window );">Short-term deposits bear interest</a></td>
<td class="nump">1.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in Operating lease ROU assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_IncreaseInOperatingLeaseRouAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_RestrictedBankDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted bank deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_RestrictedBankDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_ShorttermDepositsBearInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term deposits bear interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_ShorttermDepositsBearInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703889166376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Annual Depreciation Rates) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PropertyAndEquipmentDepreciationPercentage', window );">Annual rate of depreciation</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Minimum [Member] | Mainly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PropertyAndEquipmentDepreciationPercentage', window );">Annual rate of depreciation</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PropertyAndEquipmentDepreciationPercentage', window );">Annual rate of depreciation</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_LaboratoryEquipmentMember', window );">Laboratory equipment [Member] | Maximum [Member] | Mainly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PropertyAndEquipmentDepreciationPercentage', window );">Annual rate of depreciation</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_OfficeFurnitureAndEquipmentMember', window );">Office equipment and furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PropertyAndEquipmentDepreciationPercentage', window );">Annual rate of depreciation</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_OfficeFurnitureAndEquipmentMember', window );">Office equipment and furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PropertyAndEquipmentDepreciationPercentage', window );">Annual rate of depreciation</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PropertyAndEquipmentDepreciationPercentage', window );">Annual rate of depreciation</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_PropertyAndEquipmentDepreciationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The annual rate by which the asset depreciates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_PropertyAndEquipmentDepreciationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=SLGL_MainlyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=SLGL_MainlyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703888967592">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Level 2 securities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,652<span></span>
</td>
<td class="nump">$ 40,966<span></span>
</td>
<td class="nump">$ 56,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S government and agency bonds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Level 2 securities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,192<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember', window );">Canada government bonds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Level 2 securities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=SLGL_OtherForeignGovernmentBondsMember', window );">Other foreign government bonds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Level 2 securities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,006<span></span>
</td>
<td class="nump">3,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate bonds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Level 2 securities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 15,454<span></span>
</td>
<td class="nump">$ 33,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Investments in Corporate bonds rated A or higher.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=SLGL_OtherForeignGovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=SLGL_OtherForeignGovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703889247368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Summary of Changes in Fair Value of Company's Marketable Securities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 40,966<span></span>
</td>
<td class="nump">$ 56,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Additions</a></td>
<td class="nump">32,322<span></span>
</td>
<td class="nump">38,702<span></span>
</td>
<td class="nump">$ 71,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale or maturity</a></td>
<td class="num">(51,498)<span></span>
</td>
<td class="num">(54,333)<span></span>
</td>
<td class="num">(15,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ChangesInFairValueOfMarketableSecurities', window );">Changes in fair value during the year</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Balance at end of the period</a></td>
<td class="nump">$ 21,652<span></span>
</td>
<td class="nump">$ 40,966<span></span>
</td>
<td class="nump">$ 56,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_ChangesInFairValueOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from changes in fair value of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_ChangesInFairValueOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703893791384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 21,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">1 to 2 years</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Total</a></td>
<td class="nump">$ 21,652<span></span>
</td>
<td class="nump">$ 40,966<span></span>
</td>
<td class="nump">$ 56,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in two fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892098216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 946<span></span>
</td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703888972280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,392<span></span>
</td>
<td class="nump">$ 5,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(4,575)<span></span>
</td>
<td class="num">(3,629)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,817<span></span>
</td>
<td class="nump">2,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,644<span></span>
</td>
<td class="nump">3,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_OfficeFurnitureAndEquipmentMember', window );">Office equipment and furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,953<span></span>
</td>
<td class="nump">$ 1,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=SLGL_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703889155736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE SEVERANCE BENEFITS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Amount of severance payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 363<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution Plan</a></td>
<td class="nump">$ 408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703887336680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expire</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Expense recognized</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted deposit</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted deposit</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease agreements period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=SLGL_MasterClinicalTrialServicesAgreementMember', window );">Master Clinical Trial Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Consideration for services payment</a></td>
<td class="nump">$ 14,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Expense recognized</a></td>
<td class="nump">14,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=SLGL_ClinicalDevelopmentMasterServicesAgreementMember', window );">Clinical Development Master Services Agreement [Member] | Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Consideration for services payment</a></td>
<td class="nump">13,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Expense recognized</a></td>
<td class="nump">13,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=SLGL_ClinicalDevelopmentMasterServicesAgreementMember', window );">Clinical Development Master Services Agreement [Member] | Agreement Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Consideration for services payment</a></td>
<td class="nump">2,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Expense recognized</a></td>
<td class="nump">$ 2,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SLGL_IsraelInnovationAuthorityMember', window );">IIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived', window );">Percentage of royalties payments shall not exceed aggregate rant received</a></td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant received</a></td>
<td class="nump">$ 1,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Accumulated royalty expense</a></td>
<td class="nump">$ 2,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SLGL_YissumMember', window );">Yissum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_RoyaltiesPayForNetSalesRelatedToPatents', window );">Royalties pay for net sales related to patents</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | IIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped', window );">Royalties payable on the sale of products developed</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Yissum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PercentageOfProceedsReceivedForSubLicence', window );">Percentage of proceeds received for sub licence</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | IIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped', window );">Royalties payable on the sale of products developed</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Yissum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PercentageOfProceedsReceivedForSubLicence', window );">Percentage of proceeds received for sub licence</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_PercentageOfProceedsReceivedForSubLicence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of proceeds received for sub licence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_PercentageOfProceedsReceivedForSubLicence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties payments shall not exceed aggregate rant received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_PercentageOfRoyaltiesPaymentsShallNotExceedAggregateRantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_RoyaltiesPayForNetSalesRelatedToPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties pay for net sales related to patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_RoyaltiesPayForNetSalesRelatedToPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties payable on the sale of products developed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_RoyaltiesPayableOnSaleOfProductsDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383193&amp;loc=d3e16207-108621<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=SLGL_MasterClinicalTrialServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=SLGL_MasterClinicalTrialServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementByArrangementAxis=SLGL_ClinicalDevelopmentMasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementByArrangementAxis=SLGL_ClinicalDevelopmentMasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=SLGL_AgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=SLGL_AgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=SLGL_AgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=SLGL_AgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SLGL_IsraelInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SLGL_IsraelInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SLGL_YissumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SLGL_YissumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703887700680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS (Schedule of Lease-related Assets And Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,896<span></span>
</td>
<td class="nump">$ 2,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating leases</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating leases</a></td>
<td class="nump">$ 1,299<span></span>
</td>
<td class="nump">$ 1,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted Average Remaining Lease Term Operating leases</a></td>
<td class="text">1 year 3 months 15 days<span></span>
</td>
<td class="text">1 year 7 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average Discount Rate Operating leases</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="nump">7.44%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703895440312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Schedule of Lease Costs) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 685<span></span>
</td>
<td class="nump">$ 643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892042760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Schedule of Supplemental Cash Flow Information Related to Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of leases liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 735<span></span>
</td>
<td class="nump">$ 807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703889278120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS ( Schedule of Reconciles Undiscounted Cash Flows) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>For the year ended December 31, 2020</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">2,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_AmountOfLeasePaymentsRepresentingInterest', window );">Less: amount of lease payments representing interest</a></td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PresentValueOfFutureMinimumLeasePayments', window );">Present value of future minimum lease payments</a></td>
<td class="nump">1,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current maturities of operating leases</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating leases liabilities</a></td>
<td class="nump">1,299<span></span>
</td>
<td class="nump">$ 1,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PresentValueOfFutureMinimumLeasePayments', window );">Total</a></td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_AmountOfLeasePaymentsRepresentingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments representing interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_AmountOfLeasePaymentsRepresentingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_PresentValueOfFutureMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of future minimum lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_PresentValueOfFutureMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703900173128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AGREEMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_PercentageOfGrossProfitsRelatedToSaleProducts', window );">Percentage of gross profits related to sale products</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues recognized</a></td>
<td class="nump">$ 8,673<span></span>
</td>
<td class="nump">$ 22,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_RoyaltiesMaturity', window );">Royalties Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_RoyaltiesMaturity', window );">Royalties Maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_PercentageOfGrossProfitsRelatedToSaleProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross profits related to sale products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_PercentageOfGrossProfitsRelatedToSaleProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_RoyaltiesMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_RoyaltiesMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703813025064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Narrative) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 19, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 19, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value per share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_AdditionalOrdinarySharesPurchased', window );">Additional ordinary shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Procceds from Initial public offering, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,306<span></span>
</td>
<td class="nump">$ 10,613<span></span>
</td>
<td class="nump">$ 78,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Share split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_BonusShare', window );">Bonus share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=SLGL_FPOMember', window );">FPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,091,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Per share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,673,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=SLGL_FPOMember', window );">FPO [Member] | Underwriter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds | $</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Per share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Procceds from Initial public offering, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Outstanding promissory note converted into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,444,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Promissory note conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Option vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants [Member] | FPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,091,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=SLGL_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Maximum term of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">949,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition', window );">Compensation costs weighted average period to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value per share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Odinary share issued under share incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">912,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=SLGL_ConsultantMember', window );">Consultant Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=SLGL_NonEmployeesOneMember', window );">Non Employees Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition', window );">Compensation costs weighted average period to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value outstanding option | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value exercisable option | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_AdditionalOrdinarySharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional ordinary shares purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_AdditionalOrdinarySharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_BonusShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bonus share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_BonusShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_ShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SLGL_FPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SLGL_FPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SLGL_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SLGL_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SLGL_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SLGL_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SLGL_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SLGL_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SLGL_NonEmployeesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SLGL_NonEmployeesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703887789016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Schedule of Assumptions Used to Estimate Fair Value) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SLGL_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SLGL_EmployeesMember', window );">Employees [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of one ordinary share</a></td>
<td class="nump">$ 6.08<span></span>
</td>
<td class="nump">$ 6.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">74.87%<span></span>
</td>
<td class="nump">70.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.82%<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SLGL_EmployeesMember', window );">Employees [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of one ordinary share</a></td>
<td class="nump">$ 8.59<span></span>
</td>
<td class="nump">$ 10.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.83%<span></span>
</td>
<td class="nump">73.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SLGL_NonEmployeesMember', window );">Non Employees Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of one ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.07%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.86%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SLGL_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SLGL_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SLGL_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SLGL_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703887146776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Schedule of Stock Option Activity) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SLGL_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">1,031,591<span></span>
</td>
<td class="nump">938,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">95,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(28,447)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(2,250)<span></span>
</td>
<td class="num">(1,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of year</a></td>
<td class="nump">1,000,894<span></span>
</td>
<td class="nump">1,031,591<span></span>
</td>
<td class="nump">938,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at the end of the year</a></td>
<td class="nump">900,687<span></span>
</td>
<td class="nump">683,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of year</a></td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">5.27<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">7.77<span></span>
</td>
<td class="nump">5.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding at end of year</a></td>
<td class="nump">4.63<span></span>
</td>
<td class="nump">4.74<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at the end of the year</a></td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">7 years 2 months 30 days<span></span>
</td>
<td class="text">7 years 10 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at the end of the year</a></td>
<td class="text">5 years 8 months 2 days<span></span>
</td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SLGL_NonEmployeesMember', window );">Non Employees Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">198,575<span></span>
</td>
<td class="nump">198,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of year</a></td>
<td class="nump">198,575<span></span>
</td>
<td class="nump">198,575<span></span>
</td>
<td class="nump">198,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at the end of the year</a></td>
<td class="nump">137,771<span></span>
</td>
<td class="nump">96,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of year</a></td>
<td class="nump">$ 7.48<span></span>
</td>
<td class="nump">$ 7.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding at end of year</a></td>
<td class="nump">7.70<span></span>
</td>
<td class="nump">7.48<span></span>
</td>
<td class="nump">$ 7.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at the end of the year</a></td>
<td class="nump">$ 7.34<span></span>
</td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">6 years 10 months 3 days<span></span>
</td>
<td class="text">7 years 10 months 3 days<span></span>
</td>
<td class="text">8 years 9 months 22 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at the end of the year</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">7 years 9 months 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option grant awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SLGL_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SLGL_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SLGL_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SLGL_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703893818200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Schedule of Effect of Share-based Compensation Statements of Operations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 1,217<span></span>
</td>
<td class="nump">$ 2,552<span></span>
</td>
<td class="nump">$ 4,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">2,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">$ 1,524<span></span>
</td>
<td class="nump">$ 1,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703900058696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rates</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_TaxBenefitPeriod', window );">Tax benefit period</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net carry forward tax losses</a></td>
<td class="nump">$ 151,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rates</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_TaxBenefitPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefit period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_TaxBenefitPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703893813944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>In respect of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 34,835<span></span>
</td>
<td class="nump">$ 25,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
<td class="nump">7,133<span></span>
</td>
<td class="nump">7,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less - valuation allowance</a></td>
<td class="num">(43,053)<span></span>
</td>
<td class="num">(34,947)<span></span>
</td>
<td class="num">$ (26,166)<span></span>
</td>
<td class="num">$ (21,982)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703892311768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Roll Forward of Valuation Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract', window );"><strong>Taxes On Income Roll Forward Of Valuation Allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance</a></td>
<td class="nump">$ 43,053<span></span>
</td>
<td class="nump">$ 34,947<span></span>
</td>
<td class="nump">$ 26,166<span></span>
</td>
<td class="nump">$ 21,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Additions</a></td>
<td class="nump">$ 8,106<span></span>
</td>
<td class="nump">$ 8,781<span></span>
</td>
<td class="nump">$ 4,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SLGL_TaxesOnIncomeRollForwardOfValuationAllowanceDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SLGL_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703890559304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Accounts Payables and Accruals) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="nump">$ 3,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent', window );">Employees payables</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payables and accruals</a></td>
<td class="nump">$ 4,088<span></span>
</td>
<td class="nump">$ 4,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to underwriters, promoters, and employees excluding salaries, wages and amount to related party, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139703890555944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 19, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M.[MQ:XDZHCQ?8("-^U/<KFM  P;DCB:V9K*=Q;:"X8JXP]*F E#<J?=VQJ*
M"2VK0"L0+G3$)FCC^13WZF8[V+@$0H6+'7,)VA@]Q1VZQOID]1C9_W1\?^]\
M9TW<G6(UB>Q"+H]Z]=/ZI'Q5G@^;YN4Q^R>S-4"3C*\@-#B[ *-2Y<FUO#%R
MXTZ++]+ V=-=)G#:Y\HV@/<K*<WNQG90__]@_"]02P,$%     @ 6CUD4NK>
M69$<!@  O1<  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RE6&UOZC84
M_BL6NM(VJ13;>2-=BT0+=T6BT '=M(]N,"5J$N<Z3EOVZV>'E$#BN&S[T)+
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MCAYFL($9&&'>Y/FJ7%T%R&JUX8N,K>8+0%+1[423$2UEN7J.HU#(S&@F,)^
M5)!-H1&]:8<LYUK8@9(E!*5%=!0HKGF^X]I2EG12GM?B/K1J6F#];P$PY:^"
MT< /?<^QK!8/MH@--'HP^D&S,,I+#]BR( 4YF&<D+;HX9X FRYC]I%0+"JJ3
M2$I.);*-VY87=IU,2]^!==>'YK:_IUO&F",%%_)P6W>&=7N&YOX\*4;L%D\2
M4Y'X1#Q>Y:0 J*5Q:F.V74<N[EU23:!U\X;F[MU"G7QML&RE%APD+ZA0[>$P
ML'Q'JHAKC5P7(L]69K5&T,6!U9:BFA1 ,RO80:'T$5") /0#.PC<EEX ZS8.
MS2UX+QI5V6@$#=GN5C"JF.V4:Z*L.S,TM^:O-.=%2Q(S3L2,9U%83+8R@F E
M5D+])#/:W(M'E(:&.\#I6<SH6,-_.FCX\1&&;R:KYA?03#!V)LNX,JIT @K.
M@UHJJ&83\& Z<3B'@"J)L)4VI=(#:#D>DJ>.3LR%+8\@J&81Z& 6\7'J@%3J
M &W<3AU031V0F3J\IY$AM<DCQY$#O$NJ"71K"^"@/8! &R[UH=R1']Q'2$,-
M+!QXGKP/H,IUH>B+GLR!=*.*1;F%GZ*::Z /[07H(Z"R"639%O(M2T:]AV03
M>,T]T!%V#I"&)Z  !0I.E9Q(<DV4-4] 9IZ@F;@DG8)7DA54\QBK%]+L0"C5
MJ#(/!)'MR%'0B6'+;0E"S4Z0F9T<-PC&I4RE+L@*!(7T6GRHN0LR]^>]?<BB
M%\(I6,:B*R<TY?53>;C_Y@/2[#Y@.:GJOH(=^)Z<4U5*+.QM=5VS V1F!_]=
M.(SI56F%[=@N:N'/J.85R,PK#F*F9IOO8*8[P+4PTV,-/SZ"H>8V=$UKL)G6
M?(AC8I6V(-Q:VK@F+?C=^QW:X8U6WI']'7!:LH]5(@0=^?7!#J%F@&JRA-^]
M<V+,DX8*^;;=LB+CK9<8Q]LEP2H/@0C*:^4NJ2;0FJG@0W9)BKT/3;!4(N)B
MJ4^/-$((0T<AEQJY+O0A=F5RJ1%T+-]N>\U4LQ_\D5V2E@AH2$@QK3WY3=MX
M'\DF\(*Q-*_4_1\?\GQ^M4/KEN9%+R0I@"<"V:ENU>QMO71.:#8O/T#(14FO
M4KY^3;6YNOG(X:K\%D"Z/H!G0]WU$3S[I+M^B=VS:^QJ[@BWQ)WR37JOAK3^
M"N,SR>91FH.8S@0\Z]03\<_6'S:L3SA;EJ_)GQGG+"D/%Y2(SEX(B/LSQOC;
M23' YO.2_K]02P,$%     @ 6CUD4E"%%_7>"   OR4  !@   !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6RM6EUSXK@2_2LJ:A]FJH;!DOP!J215!)P)50EP
M@63N/CI&@'>,Q<J&)/]^)=NQ09(5LCL/"<8<R3JM5O=1RY<OE/U*-X1DX'4;
M)^E5:Y-ENXM.)PTW9!NDW^F.)/R7%67;(.-?V;J3[A@)EGFC;=Q!EN5VMD&4
MM*XO\WM3=GU)]UD<)63*0+K?;@/V=D-B^G+5@JWW&[-HO<G$C<[UY2Y8DSG)
M'G=3QK]UJEZ6T98D:403P,CJJM6'%T,;B08YXBDB+^G1-1!4GBG]);Z,EE<M
M2XR(Q"3,1!<!_SB0 8ECT1,?Q]]EIZWJF:+A\?5[[[<Y>4[F.4C)@,8_HV6V
MN6IU6V!)5L$^SF;TY8Z4A!S17TCC-/\/7DJLU0+A/LWHMFS,1["-DN(S>"T-
M<=0 N@T-4-D R0WLA@:X;(#/;6"7#>S<,@65W [#( NN+QE] 4R@>6_B(C=F
MWIK3CQ(Q[_.,\5\CWBZ['DS&\\G]:-A?^$,P7_"/!W^\F(/)+1CTYW?@]G[R
M<P[:X'$^!%_^^ K^ %$"%ANZ3X-DF5YV,CX&T5,G+)]W4SP/-3P/(O! DVR3
M C]9DN5I!QT^^(H!>F=P@XP]#DGX'6#X#2 +69H!#<YN#GN:YL/SFW<-;' U
M'SCO#S?-1VWTV]GD 4RF_JR_&(U_@/Y@,7H:+4;^_,+P'+MZCIT_QVYXSCU-
MM;-7M'+S5B)F'*[;J(=ZW+"'8YOJ8+9K]4YA0PT,(V3A"G8R=J<:NV.T47_Y
M%U\8//AD*0\]?^\C1I8@H_PZI$D8Q03$G)VXD_# &0;I!NQ3#N&>R^,E"[(H
M61<!)\HBDIK,Z59#<HWF'!(>=<,H$+%,9]:BM7-DB)[M2C95,=VN)QE4Q7@N
MTEO3JX;N&8<^V 3)FJ3".D$8LCTW5!P%SU$<96^ )Q9 MKN8OA$"F(BA*=CO
M\I"?<;.+.=#1]91A(BBQ52&X*Y%5(=!R]62[%=FND>Q\$S#2%HEB"4*ZY=DS
MS><,D%=Q3;1KHJN. T%I9@8J"#D.DABI(-MU;#VE7D6I9Z0T%CY>SV'MX3$)
M&@CU5"^2IT>%.!(7XZB$7+E(=T%(KEI\9:2$'4CK&AA6&K3JC&6=Z["K(&+@
M$,1[ NB*IT7VBV3!,P\ *0GW+%_=VA1EJ3,J>]]  W)E&V@PJ*>?3GB4D:&1
MWVV4!$E(*I?\)L*8E@;4.*;,0L4XELQ"Q;1Q@U="5-- YDRF\\D@3;F[<NE0
MQ9@/ C"L$R?$1K/-2$BB@YC]%*P8W?+U'<?!,Q5//A 0,";&DV<-K3&Q:LR>
M*Z]R#:IM0Z18U#C4?[$XZK0.S7E]RL@NB):5\^2VIMF&,*XF&>/LBSG0V\#6
MQ.V>; (5!-V>+5M 1;6A[39D?EBG?N@8^?7#D.Y%XM\%;V*NOU5)2V6LI>BH
MXW)L9=6HJ)Z2GC0@;#4N_UI)0+.4N*=\G62$;86>>?=H+15C/V<Y6<GV-W4T
MA*H\@:[3-.>U0(%FA3(^1\5I+:0JB#9RD"TG.RT..9:RK'4X;!]%B5.&M2J!
MW4^I_M'XR9]_0O7#6BQ LUJ8[AD7"VF>+W=,&)*K/+%BA([>->DYJ,J!MFTK
MD4&#<GJRA-6AH.4TJ%A4RP)DE@4W0?*+[_AW-(WTT0VIR;J-H"W/\D"#@Y;B
M"QH4/D:=LJB3/S(G_QE),Q:%F5#A/!"T\T!@9*5)WHK8UH&@PD@%=1OHU"(
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M\;90\26CN_S]F6>:972;7VY(P)>F /#?5Y1F[U_$ ZIWMJ[_ 5!+ P04
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M'U-F6Z8-'[F6VTR%@U!PG]TT]! $NI(F=R7I:'F\&LJZ[\LZ&.(C:ZM@N9]
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M\V<C5(CT)2/?X'TJ?3U8V!!LDRYKE"=R/ '/*VM#?\,;#)^3+O\"4$L#!!0
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MT>".- L:4<G=DP>$<(,P3%K#D?=6IH!(B '-KPAEL-BQZR3[Q(J_\,K&1P!
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MAWQ LLT83\1EW.XZ(;0?,$5JM8]R,BHP3 =^$B!;[DGAJ2Y4 :T%?W5(VY.
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ME3X4F'(,<9A0%D\X!-HC]U=KY.W?DN*G\&B;,]3[K;ADLDAVK*:PK\ZEPBS
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MIST?+CH:^&/>D>D-5QM1:UI"CJ[A^6C@4=415*<8V3A26$N#%./$ CD=E#7
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M@*,%^#ZW-K0WY*#[G#K]%U!+ P04    " !:/612?&K,^;@)  !?&P  &0
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M =4*@R%V#;GOCG@&0&/7"<IFX'BY[L,J*_O';VSE$EF!PWD8*VK.J:F#S 5
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M.3YL^96K^E#HN?L)9:R+0F?N[4QB%S;T .Y/-)@G?" %]6]JY_\%4$L#!!0
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M*PPBI@=D&#:IX0ZF>:3/XP3OMR]#\>[&I"N.J,3Q",BTTLYMF;994V*D(L9
M"73>[;0A-K%'C5L#^^ E,@C\1!Q.W5)6'=> 3DA+F#C(RKJ!,$\E!W IDU/V
M7APS%0E9:,G^[W(C=&'"H"9%#&6L:Y&PDYZ8=/3$3"DDZ7+\ L&YHY&.QO[6
M@A5(%@-^P;1,$%@KW,6 [#"\@QYCLSND>L@A.'A6KIU_.,R.^2(BL*!!778V
M(5#8$ND-O1BG;5TUW&I4]9O9=KV]:ROR =V(4IWT9PWH) JGP!I&FNSRC4!A
ME@]3:=[:\/-\DQZH)FCE7J@D L7#4VSI3XQ(U!8.CF#I3M]KA]#V\&G:*32
M>#A(RYZ)F6(7VZ24W\F$+@H[PX^CY&2-<^T,>?C4UTV$!+2:^OG.9I03C6+/
MH,#2'K\S+>ZK+V75'O5RE#15*M4";9:3LW%BVG>VJU$VVJI00W0^QM$Q'"(D
MU:_G440^LO>1:J**G1#_:% TRRVEI4\*XMQS62ML676R,[WL#>-]UOK FYT]
M(VB"?:,D#P=C.MT[QP=<L7^-(:X?(5LU?FU-LUKW[PC 7V?<6&E803!MJ!28
M K#*8I1@LT^&U/[,+)FT5A,#&[M!(R"Y&+\PC/R1M&+RS\. ^ZA+8 QH^65R
M-AF=BI*&T)"_BDX%V&S;;T7O'=BL)$PPY,).\$+K?2*A/-$A^^WY9W#*HL/I
M<I1\V,LB,]FKI'4FA3<)O=%)R"/,P8,I_E7R!?::FL9]*B:R<]?\Y)=D>I;.
M+R[Q8W::SF=GR3<,N]*2(]0)!O. >L1AF/R\2.>G4_R=S&;)5ZK79)).I^?X
M.YZ?)9^0]^$[L$G[#NQ!%DTH!"9"@GIRC$TO3R^2E\GQZ2P=G\WPBVS.6Z=]
MQ))WL#"^4QO\6HU@+P!#)^QAD:%=>&[UX<05#.?*S'Q#Q]7VUG6XWEE&&=P]
M#<4W4Z/!NZAXRK6:7H-32P]&(,K(8^F 6[]1BFLEX=<6Z%K;_O2V5\CMF:&?
M>WD561**#45Y('Y\$OTY5*RN,C04TPL2@EOG'#L6CD5M94> 4._JAZ%DC= :
M;-L"'5L=RN [6; EH*S=.7U.V)JDE_-I<AU/*RXY32?STZ',7DT&J?-T<GX^
MD)JG%_/)<U(1OH2DH=1D?/Z,%*KEER2B3H^2V[:#,[TT53LF,=$8%P\#!YED
M<IEV[U-W.24W*@Q(\=U*_4<V&1UZF7TR^#R D]R*/X+0 1J-/WPIZ.YVWUFN
MP^>%?GGX2/-9VI6&+X5:0G0\NC@[$C9\^ @7WM3\L6%AO#<E_UPK"4JF!7B^
M-,:W%[1!]_7I[?\ 4$L#!!0    ( %H]9%+U2F1I@ (  ' %   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;+5436_;, R]^U<(WK!34-NRF[EM8L!I
M4RQ \X$DW3 ,.R@V$QN5+$]2FO;?3Y(=-P/6 #OL8HH4^?A(F1P<N'B2!8!"
M+XQ6<N@62M77GB>S AB1%[R&2M]LN6!$:57L/%D+(+D-8M3#OM_W&"DK-QE8
MVT(D [Y7M*Q@(9#<,T;$ZP@H/PS=P#T:EN6N4,;@)8.:[& %ZK%>"*UY'4I>
M,JADR2LD8#MTT^!Z%!E_Z_"UA(,\.2-3R8;S)Z-,\J'K&T) (5,&@6CQ#+=
MJ0'2-'ZUF&Z7T@2>GH_H][9V7<N&2+CE]%N9JV+HQB[*84OV5"WYX0NT]5P:
MO(Q3:;_HT/A&?1=E>ZDX:X,U U96C20O;1]. F+_G0#<!F#+NTED6=X119*!
MX <DC+=&,P=;JHW6Y,K*/,I*"7U;ZCB5K!X7BX?Q=#Q;I\OOZ'XR2V>WD_0!
MK=;IVIK19'8_7T[3]60^&WA*IS2!7M;"CQIX_ Y\@-&45ZJ0:%SED/\)X&FN
M'6%\)#S"9Q'O(+M 8=!#V,?^&;RP:T!H\<)W\!;DE6PH2$2J'*59)O:$2O0C
MW4@E]"_S\TR*J$L1V131_^KQ67@SMM>R)AD,73V7$L0SN,ELOAZCP/_T(<9^
M<&-$@&]:#?T3(317!0@]/AG?5TJB^K1AI&V8HY\%V 9$3[^-HY-<.>9]'-M0
MR!&\Z"TB03H?G;"'HZM&7OK.F-64OP*\X3IQ%#AQ@!V;UPE#!_>U>]0+<&BE
M'\?H;Z_BG4P! [&SLRZ1I=T,1&?MUDG:3-&;>[.+ID3LRDHB"EL=ZE]\OG21
M:.:[412O[4QMN-(3:H^%7HD@C(.^WW*NCHI)T"W9Y#=02P,$%     @ 6CUD
M4L!JGTK+ @   08  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULG511
M;]HP$'[G5YRR:=HD1$*@&VH!"0K3*JTK K8]3'LPR858<^S,=DK[[W=V0DJG
ME8>]Q+[S?=]]=XYO?%#ZE\D1+3P40II)D%M;7H:A27(LF.FI$B6=9$H7S)*I
M]Z$I-;+4@PH1QE'T/BP8E\%T['TK/1VKR@HN<:7!5$7!].,<A3I,@GYP=*SY
M/K?.$4[')=OC!NW7<J7)"EN6E!<H#5<2-&:38-:_G ]=O _XQO%@3O;@*MDI
M]<L9-^DDB)P@%)A8Q\!HN<=K%,(1D8S?#6?0IG3 T_V1_:.OG6K9,8/72GSG
MJ<TGP2B %#-6";M6AT_8U'/A^!(EC/_"H8X=4'!2&:N*!DP*"B[KE3TT?3@!
MC*(7 '$#B+WN.I%7N6"63<=:'4"[:&)S&U^J1Y,X+MVE;*RF4TXX.UTO/\^V
MRP6L9NOMS7(S#BV1NJ,P:0CF-4'\ D$_AELE;6Y@*5-,GQ.$I*:5%!\ES>.S
MC M,>C#H=R&.XN@,WZ M<>#Y!B^5B()93&'%M'V$K6;2,/]+&/@QVQFKR?IY
M)L^PS3/T>8;_W\KS!%_NMDOH]]^\&L51_\HM_?BJL?XB[[!>YUA7275Q-,!E
M(JH4P>8(UW0E6@G*L(=-SC3F2J2H@<D4$E643#I$)9TOYX9\/K[KP7/%= HJ
M@P77]'B4-A[GCI8/F%3N'<%=EO$$Z8CBZHR.];'7V?4Z,P-6@2KK)CNL1NHS
M3YQ<X^08V-,].),"TV=IL$VAFA1=,(@@E448$7MR3,"-J9A,7."1U1$<F'[B
M=M*2DV:8DV9P&@I0:GY/;812L 1IVEB@24=^JRP3#FHXQ3(_0BC/ZXMN%$6G
MBAB\';[K_>O_"4^>98%Z[X>/ZW4E;?U"6V\[WV;ULWX*KX?C+=-[3KT4F!$T
MZGVX"$#7 Z<VK"K](]\I2R/#;W.:T:A= )UGBL0VADO03OWI'U!+ P04
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M""WHJ/R,7(4\D%R9#@V,[W79\.61?3Q)XV7D8?XOEY3<3+7_.+V5EF)%ZKY
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MSEJ#A-M\_<@;WV(OJJXIS6T6F'MD=Z="T4D>Z KTFJ,[R&D G "F.AIWTB_
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M$DAC@-_70NCSQ 1HWE_C?P%02P,$%     @ 6CUD4B%=6Q7, @  I 4  !D
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M)31VM15S'*,@C0'>9T+HG6((NL$\^0]02P,$%     @ 6CUD4MCLQ>)[!
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M8^PZXY#]/@,N!ELA$Z=19$0^@[;CM""=TI=]AD:Q_V6N*E9[#+6Z&=926;F
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M:IH1/TR=-/5Q$$;&WX/E,^E=/E0@%_:*1>%6KFO=W$-TTNX:9]I<7MRK-W=
M;YC$/56TA#F:>GC<'%'97*LT RU6]BKC2F@M*ONZ!(:P-@KX?2Z$OAN8";K+
MK:-_ %!+ P04    " !:/6121?'X'R8#  #I!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q]5=MNVS ,?==7"-XP=(!17Y.X71(@:3NLPWI!VUV
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M&\T6#T^K>;J9/2W0YPW94E!?AH$VW!8AR%J>2<.#S_!$&,T%UX5"4YY#_C]
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MSQ5(&V#.=T+HHV$)N@=P_!=02P,$%     @ 6CUD4@(9-3,P @  F@0  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULC51-;]LP#/TKA-%#"W21/]JT
M*QP#:=)@/;0)\K$=AAT4FXF%RE(FR4FW7S])=K(,2(9>+)'B>^2C*:4[J=YT
MB6C@O>)"]X+2F,T#(3HOL:*Z(S<H[,E*JHH::ZHUT1N%M/"@BI,X#+NDHDP$
M6>I]$Y6ELC:<"9PHT'554?7K$;G<]8(HV#NF;%T:YR!9NJ%KG*%9;";*6N3
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M_H26BV^>ZSVLT<T<<X[UWMRBFRE(3")QB^[09CU%-Y]NT2=$*'H.62HP#<3
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MG#:,@LEEB[*<:#%W;<%$:--DN.',M'4@[0;S/!9"KR?60=XHMO\ 4$L#!!0
M   ( %H]9%+2'W@P>0,  %\,   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y
M+GAM;*U7VX[:,!#]%2NJU*W4DC@W-@B0EDO55;OJ:MEM'ZH^F&0@T29V:AOH
M_GWM))MP"916O( O<XYGSICQT-\P_BQB (E^9RD5 R.6,N^9I@ACR(CHL!RH
MVEDPGA&IIGQIBIP#B0I0EIJV9?EF1A)J#/O%VCT?]ME*I@F%>X[$*LL(?QE!
MRC8# QNO"P_),I9ZP1SV<[*$&<BG_)ZKF5FS1$D&5"2,(@Z+@7&#>U/<U8#"
MXEL"&[$U1CJ4.6//>G(;#0Q+>P0IA%)3$/6UAC&DJ692?ORJ2(WZ3 W<'K^R
M?RR"5\',B8 Q2[\GD8P'QK6!(EB052H?V.835 %YFB]DJ2@^T::RM0P4KH1D
M6056'F0)+;_)[TJ(+8!W#&!7 'L/@-TC *<"..<"W K@G@OP*D 1NEG&7@@W
M(9(,^YQM$-?6BDT/"O4+M-(KH?JBS"17NXG"R>'=S</GZ>/-Z,L4S:;CIX?;
MQ]OI#%W-U(6,5BD@MD!CEN6$OKP5Z([P9Y!DKM9G$*YX(A,0[]#51"TFJ1I]
M0$^S";IZ\PZ]00E%CS%;"4(CT3>E\E6?:(:57^/2+_N(7Q,(.\C![Y%MV58+
M?'(V' <M\.GY\.M=N*D$KE6V:Y7M@L\YPO<%UI B&XE:M=X)5J=F=0I6]UCN
MFG0TQ&U2ES1^0:,KQWIH8]^S^^9Z6]%#*]<*?'_7:GIHY?F^WW#M1.+6D;@G
M(WGJS-"2K8%358,D4E<&J2I%PQ<T9^KZH!]WD,V!_SPAFE<?Y5TP%7[-ZE\F
M%26-MRTR#O8S<6ADNT'0+G&W]K![TL,QH20BVRJ?+>UU?<3U!:4-:M;@,M*>
MI-$/;D_D)(2!H5Y4 7P-QA"U59;@0/W@F/C8:LJL=3**KS(&CM3#KEXN^E]9
MP%LE'5\P#[@I8MB^3"8JGIT+K!J7O5O>8N5X-CZB=%,4\>FJ.&8\9YQ(^ =I
MFSJ%W4M*VQ0E[%U$VM%?>'[@GZT)\0ZJ-O9<S]W/R*&9XP1N]TA*=''<76F*
M$3Y=C=K]'/T%=4O7(*3^V0C=7NQG6@\C=(,81['J#X%WVG)C;C5+&?!ET:4*
M%+(5E>7;6Z_6G?"H:!@/UOW>1(EPN*/B4#M%\VPV1Y2MM\KT,J$"I;!0QUF=
MKM*<E]UL.9$L+]JU.9.J^2N&L?H' %P;J/T%8_)UH@^H_U,,_P!02P,$%
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MN?ID :X-U/Z:,?DVT0>T'T&3OU!+ P04    " !:/612##!UK8@"  !*!@
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M,[MD">,4J8@9!8Z+GC5H7OD=;6\,GF+<B)TQZ$CFC+WHR4W8LQI:$"882,U
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M$35CWD#\?Y$D?/,E[Z!^I^CD?U!+ P04    " !:/6120Y$M&B,$  "Y$0
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M-!#?;_*<'Q[D ,V%Z?(_4$L#!!0    ( %H]9%+?!SAT'@,  *L)   9
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MUK$AZNNCJ/_"W!![;N>C(!6\.X 9M("NC!@&:T1#>(<H64EBLE+$"-U8>&J
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MST]PBBJJEFTPA)W]!2>D8C?MK >S$6Y69W\VR_,73<'NQ1W] 5!+ P04
M" !:/612EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M!>D6 KL%\18"O17U5@*]%?56 KWUX6>;0&]%O95 ;T6]E4!O1;V50&]%O95
M;T6]E4!O1;V50&]%O95 ;T.]C4!O0[V-0&]#O8U ;WO8+"'0VU!O(]#;4&\C
MT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU%O)]#;46\GT-M1;R?0VU%O)]#;'S:[
M"?1VU-L)]';4VPGT=M3;"?1VU-L)]';4VY^I=\JG74RWGNL:CVZ>274^OQMO
MG[\LKS<1Y^$%YP!'K>^_4$L#!!0    ( %H]9%*<*],/O0$  '<=   3
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M MM[6NNR.>2S[G_K]!-02P$"% ,4    " !:/612!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %H]
M9%+:"-YR[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( %H]9%*97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 6CUD4B>GY:@H
M!   2Q   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( %H]9%+JWEF1' 8  +T7   8              "
M@6L,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !:/612
M9A@'S'L"  "I!@  &               @(&]$@  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ 6CUD4C"()_E!!   T@T  !@
M     ("!;A4  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M %H]9%+J]51V^08  &HB   8              " @>49  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " !:/6124(47]=X(  "_)0  &
M            @($4(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ 6CUD4C8@0 T/"   6A(  !@              ("!*"H  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( %H]9%(_)3I IAD  '5)
M   8              " @6TR  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " !:/612N/B]^C $   H"0  &               @(%)3
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 6CUD4N]R<+K_
M @  ,08  !D              ("!KU   'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " !:/612#,QHI)H%  !:#0  &0
M@('E4P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %H]
M9%)\:LSYN D  %\;   9              " @;99  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ 6CUD4O$!IZB !   )0H  !D
M         ("!I6,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " !:/612OS*(YFT-  "F)0  &0              @(%<:   >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %H]9%+!&6+NK@H  (D:
M   9              " @0!V  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ 6CUD4O5*9&F  @  < 4  !D              ("!Y8
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !:/612P&J?
M2LL"   !!@  &0              @(&<@P  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( %H]9%+:X'H&X1H  )=3   9
M  " @9Z&  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M6CUD4J>NXLB# @  ,@4  !D              ("!MJ$  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " !:/612#T"BAOT#  "+"0  &0
M            @(%PI   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( %H]9%(A75L5S (  *0%   9              " @:2H  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 6CUD4MCLQ>)[!
MZ0L  !D              ("!IZL  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " !:/612_$>,%^H%  #H$@  &0              @(%9
ML   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( %H]9%)%
M\?@?)@,  .D&   9              " @7JV  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ 6CUD4F@^?;AS @  # 4  !D
M     ("!U[D  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M" !:/612 ADU,S "  ":!   &0              @(&!O   >&PO=V]R:W-H
M965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %H]9%(^8EJ?^P(  %@(   9
M              " @>B^  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!
M A0#%     @ 6CUD4L3-7?L] P  - X  !D              ("!&L(  'AL
M+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !:/612TA]X,'D#
M  !?#   &0              @(&.Q0  >&PO=V]R:W-H965T<R]S:&5E=#(Y
M+GAM;%!+ 0(4 Q0    ( %H]9%)CX&,*.@,  ! )   9              "
M@3[)  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 6CUD
M4@PP=:V( @  2@8  !D              ("!K\P  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " !:/612TN[K7'0"  #&!0  &0
M        @(%NSP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( %H]9%+#Z\->40,  /\+   9              " @1G2  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 6CUD4L<:<K#6 @  ?P@
M !D              ("!H=4  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " !:/612#E=[ U<%   C&0  &0              @(&NV
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( %H]9%)(=(B7
MY@(  (0(   9              " @3S>  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ 6CUD4GH-V8Q: @  +P4  !D
M ("!6>$  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !:
M/612Z_,%.X("  "#!0  &0              @('JXP  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %H]9%+*/:</"0,  ,H(   9
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M970T,RYX;6Q02P$"% ,4    " !:/612WP<X=!X#  "K"0  &0
M    @(&S  $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M %H]9%*H..&JQ@(  $<(   9              " @0@$ 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ 6CUD4I#=%QKR @  A@@  !D
M             ("!!0<! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " !:/612E-I"WIL"   =!P  &0              @($N"@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( %H]9%*1YD^%DP(
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( %H]9%)"0LPW000  .8@   /
M      "  ;P5 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !:/612CF$X
M^KT!  !Z'0  &@              @ $J&@$ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !:/612G"O3#[T!  !W'0  $P
M    @ $?' $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .0 Y (8/   -
%'@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>130</ContextCount>
  <ElementCount>319</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/MarketableSecurities</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - EMPLOYEE SEVERANCE BENEFITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/EmployeeSeveranceBenefits</Role>
      <ShortName>EMPLOYEE SEVERANCE BENEFITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/Commitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - COLLABORATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/CollaborationAgreements</Role>
      <ShortName>COLLABORATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ShareCapital</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/TaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/SupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sol-gel.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/MarketableSecuritiesTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sol-gel.com/role/MarketableSecurities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sol-gel.com/role/PropertyAndEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - COMMITMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/CommitmentsTables</Role>
      <ShortName>COMMITMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sol-gel.com/role/Commitments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ShareCapitalTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sol-gel.com/role/ShareCapital</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/TaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sol-gel.com/role/TaxesOnIncome</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/SupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sol-gel.com/role/SupplementaryFinancialStatementInformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - NATURE OF OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/NatureOfOperationsDetails</Role>
      <ShortName>NATURE OF OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/NatureOfOperations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Annual Depreciation Rates) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/SignificantAccountingPoliciesScheduleOfPropertyAndEquipmentAnnualDepreciationRatesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property and Equipment Annual Depreciation Rates) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Schedule of Company's Marketable Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - MARKETABLE SECURITIES (Summary of Changes in Fair Value of Company's Marketable Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/MarketableSecuritiesSummaryOfChangesInFairValueOfCompanysMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Summary of Changes in Fair Value of Company's Marketable Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/MarketableSecuritiesScheduleOfCompanysDebtMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES (Schedule of Company's debt marketable securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - PROPERTY AND EQUIPMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - EMPLOYEE SEVERANCE BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/EmployeeSeveranceBenefitsDetails</Role>
      <ShortName>EMPLOYEE SEVERANCE BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/EmployeeSeveranceBenefits</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - COMMITMENTS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/CommitmentsNarrativeDetails</Role>
      <ShortName>COMMITMENTS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/CommitmentsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - COMMITMENTS (Schedule of Lease-related Assets And Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/CommitmentsScheduleOfLease-relatedAssetsAndLiabilitiesDetails</Role>
      <ShortName>COMMITMENTS (Schedule of Lease-related Assets And Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/CommitmentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - COMMITMENTS (Schedule of Lease Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/CommitmentsScheduleOfLeaseCostsDetails</Role>
      <ShortName>COMMITMENTS (Schedule of Lease Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/CommitmentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - COMMITMENTS (Schedule of Supplemental Cash Flow Information Related to Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/CommitmentsScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>COMMITMENTS (Schedule of Supplemental Cash Flow Information Related to Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/CommitmentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - COMMITMENTS ( Schedule of Reconciles Undiscounted Cash Flows) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/CommitmentsScheduleOfReconcilesUndiscountedCashFlowsDetails</Role>
      <ShortName>COMMITMENTS ( Schedule of Reconciles Undiscounted Cash Flows) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/CommitmentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - COLLABORATION AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/CollaborationAgreementsDetails</Role>
      <ShortName>COLLABORATION AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/CollaborationAgreements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SHARE CAPITAL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ShareCapitalNarrativeDetails</Role>
      <ShortName>SHARE CAPITAL (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/ShareCapitalTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SHARE CAPITAL (Schedule of Assumptions Used to Estimate Fair Value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ShareCapitalScheduleOfAssumptionsUsedToEstimateFairValueDetails</Role>
      <ShortName>SHARE CAPITAL (Schedule of Assumptions Used to Estimate Fair Value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/ShareCapitalTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ShareCapitalScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SHARE CAPITAL (Schedule of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/ShareCapitalTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SHARE CAPITAL (Schedule of Effect of Share-based Compensation Statements of Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/ShareCapitalScheduleOfEffectOfShare-basedCompensationStatementsOfOperationsDetails</Role>
      <ShortName>SHARE CAPITAL (Schedule of Effect of Share-based Compensation Statements of Operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/ShareCapitalTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - TAXES ON INCOME (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/TaxesOnIncomeNarrativeDetails</Role>
      <ShortName>TAXES ON INCOME (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/TaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails</Role>
      <ShortName>TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - TAXES ON INCOME (Roll Forward of Valuation Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/TaxesOnIncomeRollForwardOfValuationAllowanceDetails</Role>
      <ShortName>TAXES ON INCOME (Roll Forward of Valuation Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Accounts Payables and Accruals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/SupplementaryFinancialStatementInformationScheduleOfOtherAccountsPayablesAndAccrualsDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Accounts Payables and Accruals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/SupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="slgl-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - RELATED PARTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sol-gel.com/role/RelatedPartiesDetails</Role>
      <ShortName>RELATED PARTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sol-gel.com/role/RelatedParties</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>slgl-20201231.xml</File>
    <File>slgl-20201231.xsd</File>
    <File>slgl-20201231_cal.xml</File>
    <File>slgl-20201231_def.xml</File>
    <File>slgl-20201231_lab.xml</File>
    <File>slgl-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001178913-21-000909-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-21-000909-xbrl.zip
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MYNG?([FY2_3OLY#= /UK&8/WU\>)R)EO_(FHFK_\Y%G5S^=??\W*[<XVRT@
M2XU(@1#\&86H##UJG&,O;RT'$[>^M\!^N(2Q(=[3(CZ#M"YJ ;IFPE?HH>H
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ME50&R511:G@RFB>F_CJ.E,V1WYN6UCC:(PE9TQMDJ,JICF_XF?[2U,I:L6Q
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M8YY)C<.NU?>DN .'?"AU 097 XI5#^C&NE0;<WOFQ50&L(S:$09/K[<,@!D
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M-X=H, 63 LXF"+UR';7WQ"02GST'VG0"79O63B,5:X+"O"2W!<ZP1?,)_:1
MERC\M*N:UHD@39MIABXH&IY.)5DP#$,V#4%5+6,VU6=38\8@K1E(VUWYM)>0
M-L4NGI'J>!"HXQC7OJ+G%<9=@>9$/GJ@%9V( J3.Q[5+:LO1.D\C3C 4@WM-
MGD_53N3?KY\@+:Y^$-Z_85#9+%3^OIJZ_)B/"/ Y$07+2U)FD?[PS9MP*I_Z
M@_DWXE*'I/[@(IHZ=O 8@^7EPK>=]3J-R//*B)LNN2?;#R.<FXRDH.''6*S@
M]2MR3!S>#S"W\+T''\VI<)D@Y\1)A>>)],T X1P[M''P/E<)<HZ6(*(<D&>'
M3ES,\@GYMA=1*%]);R]\U#8LY)R,83(*X+'; 9GKF>_-P7::C[08&PR5'1=Q
M\[$5F;166Q(=Q/X,_9L:2! CF]3FI V@TDF<Y&:;D$ *9L;80+M< 4I<;#-(
MZ\(YGHGB.G&SY![>59/<G4V"IW"+]5[+!HU)7"^,&XME,X,X+NV E.[,G!;_
MTW,Q=SG*X$\IMV6\!@#-CD/DCPP6_H'G *M$>%%2VY/R\NS1T"F@01OPX.9&
MZ!'1NJ5TZ(G\ID%7L9EH00N=0C0)MCUA@PI:W/C9"GAFH#/Z/B*U4RT<F+X]
M)3[AU'O"(R+FCCVWDZ*W@IC,"YU?6HX60R<NT9 =*)6;/>S@6&%H</P:8G/Q
M3;'^ZAH7UX58PQSE*Y5X!*J)^"YQR,65;TW<C_BZZ:F]CD$!]#2&#HN<T[&G
M48H0)@H>X<LGVZ(80J<P5ML1V:8 G"%&*J.6\%<B!70)8^Y%T/"J59AAHLJY
MN9WB[,H)K?*^6A&);6#<=((0N>B"B%K6)H%[;<]): ("XU-D O3SL6FC%&Z3
M"KZ$-_SOR(ZQ*2)%-,&.4I+3PL@X@S]6Y%- )^>7"'6M8<&V>4HCFA.*RE4\
MSG3 DHFB,[U6*Y@,TW-CV(0!C!:)R4DG:Q8Y,YA]&C/2);#DV0#HM!>10R<L
MGH:<A!1\H[AB]0-YGKZ\=I'@11]3!_K,YJ:HQC-D.Y%/5S-);5AG&:^(PC-!
M=MR3ZN#I_"5.GDF64)VD-'B)$^@3Q0%#FILCZ,G'LRAY(]'[!-[7U@(4\/G1
M([<S^.3S OGA:$7:RN22]T!*_H!P!Z!C-H-)!8J"E:N<K.L"'T$T!X\;E-3$
MM*SX#TJS3307).8L$?U^,Y@@&(J2\NXDI(!13Z?F"@;1F]LF=^LYMKG,Q9RQ
MU09;*V2VAE.'4'B?C4/ QK\N:BV7=0E784\V_DQ-R!2;0%Y2VYA +(C _T%N
M1%;S5IU0FRX(=(()0[/()^J^8HR$1]%#%(3D,8D^EK1!OM".M5K47DQ)N%B'
MCR/*(3%5=EJUOQQ/*2:2W1& @SD.1T6O&_#V%C07^T6-CK6>>/O4ZJ]F7GV_
M>IZ[Q^:CZSG> UDJR7KLF<"!>YV1@]O[JZP$<*^I_SBSW?5J8)Y/(B1>Y%@%
M-R'UX\MV<T"TM8GR$VGO<R8 ^7\D ,F*9#84H3<7B#^!HQG@9S)B(P)1*FT$
M?""ZYHBR8W"W(%Z%PVT9B]Q(9IS:+<-R5QR7%X>%6$#D6PX.5I<7F"4QVP,F
MH?[BD<[/*O0CB+O:G@0_.L-%BO5K1Q"L=:D#F(_;B/T )LBH$6;265M-&0U[
M37MA)^X# H9^(I.6&ZG7\+KC/6,?Q!3B6&\MX/&R&(G+,GMU,.6ACU&X?!-[
MA?DQ6D%$TDA\@00U0NFJAVG[9C0GEPF91!/1BM.<RTK)74M:YE8,8LV(VT."
M">2N+!,8'YM>;T&A%*A<1/ R#61+9!GEAD"FH\*]ID:,E"Y'="SR5A7:!8 B
M#BT!>G(W1B(EN6E+! +\9Q-CF#R#_PD&ZHZL#I#U]Y2:A_BLOD.-.Q&-1PS?
MHA#&/_+!L":.<5G3K5K8(R'L5L-P U8H LP09&IZM%'EE5CN>\8]?5T"$4LN
M3E^BN),V<.M[U V+ER2V0>N;F)B-9=Y,ESDDH?>/K%SDU.0BRZ,1U64<5BN9
M96=RI0"'?2^ 'W+CD1@<LL(5/-HS*@=9$/MX=7N7ZSKCI,?ZF1V6=-5@Q&4E
MG1 P!\[!\ 3S."X##;$P/#$'-(QQ#CEFTDS1P\RP0<"(4+S^AN 2(<%.QGW=
M:@H'B6<;SZ&/21_Q_I;E 4S MVFGN7$A]#MD@8+>0^.3JQ;"Y<J+2E0_I11H
M , M9 /$:[)/=A [Y6BEN709F'KP-ET%2QQE0G>15S]FK&2A-N4NNW 3MY4&
MP^1BGE@>8RR@@7,<\FXS+/'<^KF!((H1<SJ- AC7($C&.6,GZ)"L% *&#KD/
M-KVD@60[)/Y ,B\KVY=5+?!0004 TI(%]5)C5&@VB"6)3 E@P!\X3&^.2UY&
M81;K82K2]5E$_%$[7$ZX7(1%IV7=25Y+MG:X,@+I(,=W%0E@!]?"4;)?.DJL
MIX.?R*U$R4U'HY4>$.M(UYL16$/D!K,D)")?!6%D+;>Y4'0&,X8M&0V0$^ W
M649.A]?#L96+;0DA>K02/;HZ2WZ<YH<B#11);_&$Q0J\'I*D]95D% <@OF8J
M?FH30HC (")-$ 8N4CB(KXO*3F):<(9;.%% AWN+\%.-+\I BI@0%=/@F)A@
M[*_7BTCO3GS)"H(A6]#I<1_RP7'IM !#6S*0Z,AG.$CH6S&2+H<']MPF4UA8
M-\M!PTK7,AM ,5:,TO>2G8/L?*\$A@39X,OX<>@(S@V5>*H/-+D\SG9*!#&O
MW0607(LRD1D[R(E'B/Z@ESYZ-*\@<F./T5X;R62H=U>BC1631#IYC<:([,'
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MH\!+B#+3,WP](B;J-723IF>&;2?EG-!4)24'P;HVT/'3D-S/F>AVJ+L4SJN
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M.=$BP^ ;"S3?A_2I\2#BQ(<Y=]M0RR'4^T90C$PGOY]A@06O+4S *RPB'!.
MQT)< ;Y@$^@++OSNE? 7LD@_L1NS]$7"9"(A(4]\QB@2,$3.A&JLB7K5FC3^
M#5^WYQ)OY0RLPE;TO0!?SC"S=. )%\*O:]^YVW[;R":P7=G0Q:EE&^Y4-0WR
M07,=V\#8$D5=U*RC9!,T<)!BG\-T(O*( $]"X$D(/ F!!V(X#SV7J&J/&0E/
M0N#DPLFEQ=2&<R>7\0G</&K8PZ @.';(:7D.=1Z@.?03B 4OL/T4W =>0!T*
M<XSB-*+N"!B6G;D;*B,3AQ5'[-CWWG&2P*#"(SMQC0'MBZ/6R8_@=*@U7@G5
M@QZYA;,[%MPHG(]DFF!/:&;+=0XD^#JREJ.&J/<22+QU3W_6R2GS%)2I*V-*
M9#AQ-L)!:0:K5>MQC'&A/="+\I+WY\\H22/RWP%6M/<F4T%KR%2(, &C[?GD
M2> A((IUUHT0.S45+HP$C.P9N W@.M>+XH3\^Y%E*<0""B"# ;(<LBNB?/[2
M$C*RRY.07K2D%%9=$71E$3@O0N:\(.NDCDF:+&$A'P4V%N(9QHW9SSP7HN1<
M+>1".(IEB<B2#&?JJ*9CFPYRT%1SR#^2(ZK3 W(AICW-A1B8=Y_'(_:O(SIF
M(D(AYTZ6"O&IOS;X. ,4?7'WM>T)HOCE!0Z&NRZ-J^DB65(]).E*R=U#Y;%\
MW"+'L9?HR3W&)Q=-9^(Q[O:\,]7+,+IU$3,>8%Q).0L@A"T-BK"YAXE[F+;W
M,.E&+X'$VUWOSA=[D.BQCGO*O42P5HL&^\]C1[&;'I<<ZM*Y=K<^7V[;:,L?
MD;GVLRA_CYK6MAR)FPJCC^";:UO]/OEV3J*5;I\;O5L+B\VZ[A@2H%NBL)%R
M[).J"/<TVCCW F^>SK/XX0(]0P2ZGX[M\U JQ[6;'JO(\D12^^DB/S\E^2@3
M3M>Z;7LUIK1C'8ZO^6#ELE?;X$[)P2E=D*?W)JLO*TK("K5+B'#6^092NCS(
M-L!QTDL9=1[JR[AVTV-E[)6DC2GP<V)HOMX3E"/E^$=RC-)G?F7\6WA$?HJ!
MP[MIDD9X9'8V]Y8.8SLG\99*$U/O9Y"5NRZ[Y*E]4*W+$Q'>I5$$G'C.JE^@
M)(*PXZ)B8JU/?\BEM0>?R="9W2F4]9-ONL<ZO:;W,QK<HA08LL]UG/KWIY"\
M*,'1:L.$:G%<+_&2Z]U<[SY,[Y;-S1T(1\!Q.2\]I8['U=B>JK$#J58X.7![
MK"Z?A=OD8$*N<'6_UG*C"KC*Y^K4CYU;9"QWV2B[=;S'+HXB[-RCG]?DL4E\
M'3B?2OUR@)TVVNAPH!I844U9=D3'5K&I(TFV'$67ILA$AC0UC]+AX #I?@QA
MWJC3]$P@CVE4 _O^^'T*\HKLB:#TLV:3]PIHD8![JUOSEB/':.\_>AKFR#M4
MY.UM,Q N?X;3JX8^\P;F[<4+;$/V(N]VSQO,'$[6 ]H71ZV3'P'O7=1>0*&C
M]O;TF5]P4HW AG$LV"B*GJ$3ZA.*-H\1[!M]\Q9&O(71]G6%TXFAC\!4'"C2
M#V6=G#A/09R*.C%X$_O1J"\GMH:_X1BCR)[1[NT.?L1^N*##X?#/!0X&G$D\
M((/@/';3X[P%?6*HX\I;& &^\-WT=S>]IF5)&5?2/G<!G<P%=)O,<-1+9!J9
M*=G;=9XJ#5[6>HEVW/W"U]E7FA$-[A49BT3O:W4V.Q!#%J6W^4>I_$B^A:89
M"*8="LCWPR>84-=+I.1%+'VTV$Z^Z1X;=J\4=6*J8YJKW$<FMV_?)<ZM.+?B
MW*K"K51E(D['Y8@:#[<Z$YU9[;!+!61'.5D)H9"@GP*B182]1/@]<%L]0EL*
M\@[!"5/+QT?L2S&0I(W3P^TT8SIRHU)^VTM*:DMTM$5>G#=PWL!YP_GRAB9%
MKO('NZ1HLK#TP\9^"WLV2UCIN9#.YRAZOG7_GCL'KW/?X/DU6- =I%O*U,2.
MZ:BNK)BNZ<J:+-FN9%G&U.(-%O;M]7\H?_D#^8"2 DJ$OZ$@)1@KT"GL4C_;
MFO?)$]*SW0Q$CI^E8TB6)J;!DPW/R#5S] :BU^15H&6,QAG#>X3V<SLG,8/4
MB62,:S(T[PHQ@-[\%>TX[XDE* /7CWG,M!>Z]9IG=JZQ+[D_NG?,G5P@C?*0
M96TB:9M3A3LYZ5X)2VZ!< N$6R#< CF6!6),=&,$S5"Y!;(+NU3[;('TLU?+
M?K&_GE@@1P[ CU([[9D)<OK<@%&>\A9Y^2.W0=KG6F<B5+D-PFV0P6_G1#:(
M)(ZI1)S;( .W07K:GKT7TKS?"BNW0;@-,O13WJ+:CML@'4ZFVR;%N7D4W;5M
MDS4G\5?T#*^\#ASR391B/H_N/TARIX;H3G47JZIF3-$4:[H[G:J:JTBFN$]?
M_=&E2_-Y=.<S!XC/HZMO<!0V#Q_I=8ZDW-_ %9]'QY'W!>3MK<.#RY]=Y4^O
MJ;45PAPSV'; ]YZLF!]T;PYZ-#RL1Q-%,M<-'R RT-WPXN'^.L^5B:R.P&3B
M5#:RW7">T6N>,1V!J<K[#>R@ G:&3!_F"S]\QN2J!8O5#52]&PH3[ODZ3Y/Z
MIHX@\C.4$^;K' /%2&-J.'3>HKV/O3$&/":--\'@@P/Z9:[QF0$#<Y-P!L(9
M2(\8R*@F1_)^+ZVIB;SE?B]*,WC+_0$9SNI$DL>MCW&NT OLYEQA4%Q!-/K9
M\W/,(SAV+Q);+CA[%\[G87"7D)_N9BC"\4T<0Z92M9;L.KYU(2\]JQ\3TL!C
M/[ [+@0'V]X<^?%O%S=?/E[\3G1.439$L5QQPUOV7TQ1S/;R8A11%'5#WGDQ
MW["/$NQ\15'R?!^A($8V;9WQWHMM/XS3:&"5=_N2]UO!]C&**(W,+I:Q<@EQ
M#THLIP__<GO_09"D=4.EY>I0Z6\?/EW??W@O?+W^=G_SX6Z7->U4FDL>8!7F
MCN\%^'*&@:F2QY G7 B_;B+?^M>L]O&E:D=:XNB*HN+H6$.N(JFR/#5UUY05
M$ZF28XNRY)#;?!03'']_]_7C)R].*)7O7_@HB>(OJY6.R[60J]*CA\9AOB-C
MD51/</F<MA9*ARR@.7<8777X:I0FX8:TY1W$_Q8'E_%)(B\C$#>"%]A^ZF A
MF6'A'7E0%/J$;!X$RFMGA!W@2$ !,/4YD?5P1QK =S,OIGR47#^A-_\1HL@1
M0E=X[T783L(HIO?!3Q]^8CM-O$<LW+JN9V/R$[F.O1&>^GRUIRIRJ. >(J_1
M-$N3;5NW%4U67:PCTW =5U0,0S(LC$7.:P;.:ZS1\)KKF#Q9"!=4$:/<@*AO
M2>39P(!BJLP)#T17@S_)A4Z-<>"":809TY@(,<;$)DBP8%B<96S/,JRIJNN*
M*3FNHJM(GB)-4T3%- Q#L[!M<O5DZ"S#'AG+\(B)1YMT$34AXQ/ $IY05'(+
M4!_LBL(25Q06+Q"0L(B\1Z+J" L?V7B.@T1P0Z++D'L3Y,.ML4>N1<"<X#U_
MF4X(4E9Y#!)>J:_K?*8"Y0H?J?.+%QT".YBJN97K8._-AR#QDN<5<_@V3>*$
M0 =@T([EO=W+5GKAP%7,-G^?1N2"K^100P>ZZ6#ZVRV3 T09C&PO7O(3;###
MRY6GL5-=]J5R\;LT)<RFXKK8>17'VL8_LQ?\LP+3S[0/R/(&@65_#,,$GJ%>
M"#]C[TW@^;]=)%%*>/*O1U]PWH44^5^1Y]P$[]#"(Q2T?O$=G<[=I[]^>G.3
M<85;ER'C=>#\@W&$^'X6A>G#[&MJ^9Y-C P,#_^"DULWO^E=&"=Q*R@G2XJH
MT6VUM*K3;')[A*QO7Y-&M/<#<%N69'7:8U"P^]I$AD;_L2F9HMX:'-A]NT*#
M"?NON:R'K5;<&55O1AL\8,I4V.WWO/7R3KWO?=F"I(P<'@>P"M4T](%!YVC<
M0YVJFFQT )HZ&RDT$$P,F8+52&LV*!GE!LGG+9B!JBQI.?5W[+$$L[*$U3C>
MNB60LVAU";NS1!5BB-LOX3UVO0 [].P\*P7*(H<:P,7?L!T^!-Y_UJJJNQ^/
M;-9AL]6;6UONSD>I:,KIEKO'L8O&"9<KP1*SY4I+S.@NM6+\[Y0PB0^/Y%];
M,>I#-D,YV+?P&?D06,EB_+?!'8+0_]<H=%([B=\3JO##Q?966!PE__SL!=X\
MG;,=_--.XR2<__,FCA#V;X(@?*0^C.LTF841,=I7-KI(([S"=\4K49EF;'?K
M11]AJ^AG!UN5#]LIL5*A;QIZ(%=6GP ""-15W_\2)A]^VA@[UP\/$7X@$NH;
M$5H$1[#WN#T VMFN<E6H&H<N?)E._TI%,?N5N9\;'4Z[;V:=4KDL6I<7L)(%
M0C?Y_($U[ND,[NNDC&AHM:76E])(.1_#B)A @(5QYA>\#[^2_P3;&[/9\O\$
MK^E\:^J7UM'$AM4T4@2A'4"@.$<:\@S">C]YY )[UR.H[F&5]>VRJZU7>*)]
M5?G<%OLR]MU6CHZ?,(HQ04:/>;S?DT/=6N_[O?Q<XO>Z!ZZ^-(XQOEU0-WOP
M0&^YQ]'\UJ4B%=G))@Z2"_*_XYEG$XS,@/7[5^7/ZC)>>L5JIMB#%R=LU1DO
MO 8;XX$:%-G!? T!Z3WDOZO%"5[F=Y]1G.#H'3%&(%IR'Y%'W.'HD1Q*?$TX
M+'O'5JQ/E:=UAK+_NH\+@GSSF3!ECP2H-  BOZ_X^C; V[D<S.FY@NC^*=Q*
M*LF*VA6$[C UN9ME[>ZFFK)LQ5;?L/O[=[>]6GW_'J&%:=?O;Y]-*5/U6(L^
M'F,QQ&673G\WM2TK$$USASW5)6J>H/[\)0SL-(H@FKY5SOE:Z.IU#\>+KVIC
M;5N&D^4E(!VXMG_0[!YB78$O[ %_PW-$3KNBIDB;P/C[5^E/_;-LO&]:S\N/
M[V!YI5I(EJ=\EJ;'6A[D1T#]Q#=P #,]>#LD;%*J=57=<NEK7MW!TM?@:-/2
M-7!I=+-T\&ZU(DTU=1.=PVOV6LCN8E4SI@<M)/>8M (50]0W+"9_U=X+VATZ
MNK().DT+6F=W%>PQO^E]BK^0Y=T_8?\1?R9KG<5[LV9=K_MF]UW OAOY$Z.(
MB-K]UR^I>ZT_>^]!RYX156'OA6OJ?H OWKSOTO=>L4Q!O<>2:[Z@ZSFPS5NW
M1@;?\"+",5A'P<,-C-+ \0':AF:48>&M7U=W6+&?:0;5K?LQ38B\R'QFS9QB
MIS6:NEPN<MO7K7=W?D;D>@+Q-6Q+U$NV13[7'4!U)R#19"5MV7>9/[KE%]>\
M=. &4[=Z<=5+]]<HC..O4>AZ2>E3!0]K'G/8G8DW* 73=6[_%U^_ZOAXQ$&*
MB\ ZLI-_>,GL';4Z<'1#ZX4(.EX3DB+_./?H9RMR499U?=F;L_-*NMG,[C+5
MT)9LG!;V0A,:_B!$YD#5%+'96)"B]-[\\5Q>DOMVGE#D5,MF;P*6<KGNR-3*
MD:E+E$"KNV[=HK;KW0QYT1P%VZ9Y:+(I5E765C=S=$BM06[JU3\42J8DRXIX
M3"A9+S_<6G[X1[(I*@&N(:B19^PN,)3UK!J-S;[ W)-!C.FB*7/AXY?$/Y?@
MT,E2>PN4)8BL"8;]_G7ZI_99?,_!M RFNM3^JI\!)JWC2.M!1 "B_2E]-L>/
M-YN\KDM D55=4W5=5$[,>?;A]5]2V$&1,OF(/!]2(SZ&$<V6V"(:M8PA+\LI
MU52E-J3Y"VMO#49970E+'\D%(E6-&_B-4O(;\KGBK2=/2?T$K8F.-,!*UPRS
M#5 U;^%$4-J!Y;R,4%-%;$/O&1*0UJ@]JW!ZL?KK%-L@GS.%M^CLD#5VV/:\
MC;I_9E3G/:T :GH048P41H2ERA7V*E_*1F%G?BL:!- J@N\!N"WNOF]=3:"-
M%V9F!6;FI2*V!3-)FHX29CNH?[UEO)OV,"SY4>3I'ZPK:$-3%2I%\TNQV;S.
M^2LAWW7ACBT\)26XOM^]_]JD@UZI1GL@VW(__07C7C!4KU3]O&&XK2&T 8B2
M="5+YPS%76P 3M#;@G%/@M95#L,F&$J2)$M36325[:!I7"GR>4-S!ZMX QRG
M5VUZBP8)Q^V,YHW<\:QQ\45?MT%-/G%;-JDI')@M2&R]1:MEB& 4Y4O)S,'X
M\>OM3GKC@"4U_=??<9P4_:Y:#%:IR[&JEE;8H]U7*:XLX#CRUO<) 5:?_0T0
M+2X3L]K"@*U*WSO=21_!M1YE1@2KC)7!:\H$GR+DW$Y;&V,IX;JKQ?8,*-OB
MT!:9TF.$V.ZMB9:*+\8(E#8B6FO[AIT%Z X.;*U+6Q=/ [J<963%F^OU$L):
M'NGSZ!OB>VA(7/T=*I*^A,F?.&GH?K1K&L^Z=&N]7N':V<+[!*$]>/I227;G
M8*()_.T]-L/7,,J^@NO:LS[D/R6)%8 >8=G]A5"3A2+]*7^6E>-"IP,K^0:Z
MGP6Q9U.6UPV9J8;<:N9&X_+;EG69SP"R%NLOVE0Z?0B@)*55P=:\_K60VC/$
MNK&7TP:_CW8E+WM^FITS!ZVMH1_3)I^4>*4N'\3AB]O7O]C2:C8'A?8_1G$Y
M7-G1VG8_1N-J:FZ]MGTXTJ9,\/?>H^?@P('B_,,J'[;H&= &>]UV,WV'WD8R
MXP \),7[;*#W]] GCX$2\B,AH$[;[!]Q3_T'XRX"J@FJHMI&@'/T4-VM8Z6N
M*&WD,0P.JMNSS+UP537.D@/L"M4=<54W1L0!OGGQCX\1QGF_D&-I1[*A=03$
M=3OJ.PA;('91UKHB]M% =,<VRG)GA-Y;B'8KD,@IM9%J-VJ([HJC>E>*4Z<0
M776\LN+N0WU>3?XNTYBV JBF=?<!,+N7C"J&:';C1C\A5/8IG#X+=#FTE$X2
M%6EJ=E.0<SJP[)'_W @?433,;G)/^P.?LZ"G<E)%O&MGKWVI:]IFXOR:]9\&
M1/TNJ_X81B[VH"WET8Y9DI46:_'6;. T,#KLG)=GQ,K3%K62(\"H$A;O5"\Q
MM:G1(O:L++L/<-F]PM]03'TY*#MTJ+2GE9BBJ+7B!NXS>/922A1=UUO49@\'
M3+Q3]XFM:ZH.D6*[9=L<9W/#@>O6Z3D'*SJ=;G$_X3Z._?7G"/-=G(X!]'Z+
MAR/J2GV]O(OH;'5_'4!WQ6([M0R97DW;A>]..^PAA ? :M?84R-#HQUWV$,(
MM\X(]2M]2!#>7E4_44LF[<KLQB8;)ACW@J%RI;7H)AH<#-MNW+*2='_.P-R_
M<8O28@#H$#!:+[_6>CF\TC24,1]+DR(?^M/+!Y8CP-@%2?PL2VW,&=A_%\,#
MY-II*,:?YF=9YJ \=/*%_J?\66EE9,HYP7$M2E+R5C@H#U/581B+^%DR.!P/
M=N+1N3:]0<FRY+N=]U-WZ-'XI$GXI%0K7#_!+CHLU=YR"6V,6M+:U8'VV,3P
MX-@@<,S/$@?EP0)G^J?QN4U5\BS V"!OS'9%=PN@_."ZV(;>PS>!'<[Q/?H)
M6=[0*"2P/=]C"TH^8H<\UK]+4)(F8?1<NWCW[G%-_?0J^6\MK.M(6]W<X6Q,
M6]UOS/!HMDJK,^Y2*_8<#T7>]J5NU1$&+4* *EODNS]P@%TOV2DS#[H-R7]F
M"MOR,Y9!7 Y"#^/X'8JB9S>,:/NA_<>$3]G,]8K[MODMR^MYCUT<173H,<P_
M3N*=%KCE>.FIH=<':NWPUG87O!U$%=50IITM^";X&H4VCN-O.,8HLF?7@?,>
M/V(_7(!0VAO,NJ'*FQ?]PIL[6/EV\-8E1>EVY;?);&.^Y L4)LO:"^@ S]][
M%5O2N6B\A)1;K0)*TQAO]/WP"07K8TKZ5I0MF<8+.+?ZMI86N%4C75F3M!>.
MKK,%;H5:BFJJ^FD6N!W6J8HX?8$X]UC@)P]94))/)/\7O O+>RDA8_<W-8'A
MI3>5>D1-X7@W X/C)MCU3/9M%:U*AEH[GL/7=9R=[MS-V- -:8@[?4'57[=3
M2=0ZWNFU;1.T=BK4\2XECSA _5!DM:[D-;[BD+5LJ<#1UK%[KB5,@R3^BI[!
M%? ](,;#4^0E.(J)!C(/X0/1/<K6D2!R[\DYW"&?&C+DQW^@A\/!::C2\@Y:
M7=@)-KXM\LM'W3B]O@-RJ O-S6\Y>$W;@79)B]UM3>]\%)-W_0.!2RVYC>B
MA6*(/+;3B-V-?!\[?SQGU\79A0W&V(N#:9K*331=F59G1ARXNB-N-GO%/[]&
MWB-*\%<?V=0_N>W6%4W117E .P=);U3\N<4QYU]42'KK\S?TVN3DEH%PJ#.9
MM:POWD_WL*UG+,>/ T=+*X:R,HFMY1TM0XV:Z-B)87,W<9R"WG'K+N-Y*QH2
M%>]5!-CNW8WZ'B;BQ7.6#83M=?*MC86-+]I")6[E1;O#6U^OCA8O60J]AU%"
MB'G^'B_"F*#M'QA%>>.;71S$NS9$$J$"\>4E=+38'7L-25!'NN-BKQV'=IQ'
M_FWD> &*&-'&7]/(G@'E[HZ^386N"F.PV[UVU0JWDIN \*\4J.X=]-F/$H]H
M;^QC3)Y%<RW7-6HODO)R1GBSX[PZN>JJV'(=*P+ GF$G]0D+V6KJ!)A9-OUT
MZR[/"H I O$]V>,?Y)H?6\<4_H^?O'6\1R%.GGW\VX5+;GLC2.(B$>Z].9$F
M7_"3\"V<HV#"OI@(9(6>>_%_'I*WG=S[JW0E3[=\0 *:NF!CWX\7R/:"A]\N
MQ OZ]P(Y3OZWY_QV\1_D:JZNF A+LJ[:Q(;4D21C695-QS5,U2*W@6S_[>+]
MW=>/G[PXN8=G7^RZM[?"D^<D,[A4_.6M $=PB7SO(7@C^-A-WI)S\</HC? _
M3+"4.XGVAF+B[+U(E";A6X$BJXW\?*%)N#CX>.]G6'!#\ J04Q#8.7F^3Q2Q
MB C*6" F@8!I7$T(72$&;+^T,LY2XKM _H$KXX3<1$M4X.J0Q42(MO &EFA%
MPJ]TN?\C*6^%E?_!);^2;31<0G].G+6_LM^B-;_5_F27P197KLS6ET'0]P)\
M.:-1?P)(@N87*RMO6&V)[/2,?KN(X"$7+Z*^%49$YRVI@."[H6M81%A#JJ-(
MAJA)BJ6I4VM*_FM/]\=W$]"]CMRKZ'^Q"J EN!Y "NM.;Q_:6"8'*TR(];"6
M3-X*&; OV45O!'GQDZT&S1=O_T?2Q+<O(5@"* ^'2$Y5V@/^VRXW_[[E%8O%
MDAFN%<_-D ">+\2A[SEOA4[.8/WALY6N<"\K])UMI4P=?6&\(U$-X&5_$K5)
MP,28=%YD/^^Q354*09$V\J%3(<G3C%C#E\!!\!LA")\BM.@&<S:P4D[RPR)Y
M^?PH7@!SX;P)F&/N(#$7/#P<<3GB#A!Q9?&\$7=$*E-F(VHJL1$M9/]XB,(T
M<"XS<S%ZL%[)HCH19,4@_YI.7^^$;KLXC?*T/@$%CN!44@KQ3W ZX+B7*->(
MBIFK:2>H]I9E[K6;#G#D+X/"@2K[I$ZATB-S:D#*$UT<@=;,J6QDN^$\H[\\
M0YJ(,N<9/<,7OAO.,WK,,]0Q.->[HK&16I&-AG4'^/57'$!E)[49D3/W H]&
ML;U'/'BSL2O'VI*;"O!7G CPS^MN?54K>QP4^SXYV#9Q^0YU/E/5>DE!^W+P
MX?FK.4_@/*%?/&$JJYPG<)[ >4(?P782GJ ;7$NH[W7T9IVZ^#DVG]-IM[B)
M<Y"5"$Z86CX^"L<=H?OM]-#MLYMNHDW'K=)Q;L6Y%>=6X^!6\F0ZE3FWXMQJ
M2/3$N=69<BMI(DLZYU8OD'+%9O9K)9M5P%4^5]I:=%6GO5(0#CTX9J%/4#W^
M\._42YZ_A FFW]XM?&^+OA'D<Z7["_2^Q?].<9!\>"R;O_PN7;IA="E=5:='
MO?#F6H. /\(@C>G>VUG05A7W(BQWZ?7+\/N"8#[=K7M;U @?IQ(^)ZFU#]DE
M(9X^[LOM_0=!8DAL$""^S3]*\MO*MU^N[[]_^R#<?A1NOW[X=GU_<_OE;BT3
M.)B_P -VJ&-N?1%OA3F*'KS@$JJ(WP@RN8NNZR[T+_^*?>$>V[. <(0'CSSC
M4^)<":\(@_!9VV;_F3"69"9X22S$>2_HYPFM+ >J1<'S:\&+!10(-W&$L._E
M7PM>8(?1(H2:=8?\4;(503)-_>J\@+U4CW[0'N]+V%/0"S;9)X@$J/5_P$*\
M(+2/_.1Y25@M"-'/B2Q)J?R@S0+@$6YHI] \( SRK'YH.P )&^2*.73<)Y+F
M/[05 ?D)[B1L;HX2BC+TSRA]$!91Z*1V$E\)E>45I*>_C04?(R>_3+!AX(E#
MVQD (V3M"](%60-@&KEJ$7DX(:@FS#T["G%@HT6<^I0MD??[!#7);_%SG.#Y
M!-A4[,70ZAEZ'- [V/7D\7/D8/+M,BPB J.%EU#DC#V?;(2M?$Y$C("<1VA.
M!&C[B,ES'Q!KK4*W&I-OJ_C_?^-B5PMO@0'G8$]OA%?>:^'^Z3G (1QYG"[J
M1Q[/H=-5]*NT<N3Q>K6 ZE!%01$C)UUE4I<\';Z=@,Y@SP MLK,DFR#BBJXW
MB3!*:,4& 1*RR3(?4_\!15YV:+" ]W"6UXL% (3"^M7%E_?7%Z_I0[+-%&\6
MGA Y/MO&"X"BM8QO\,[O5W=7)>5_#$.'8A9[324?"-X$U^<8(Y.+WU\7?TEO
M7V=;6WH'BF,"&_)V)'PE<L^./-H+B[W@.P&D\!%CX9J<S:N+K^^_?X2M/(1P
MDM (G\#A.GU(R8E+1 $2R6OHZEYYY.0^+.+01\]'/#HD+(C6$"2$WBIG!8 G
MG#=Y7F#AYD:(PIB0<(:LY&CH[_E:&T^&G@4!:(X?5; !5)9@0HC/%V2-P>1*
M$&X" 67]A0@3H \+0H)>:\BY)AIJ])]S"! ,?DJ($BY\@/PPSRX>=&T_VW[X
MZ$7T($+:C'OYFO)ES4)DZ<M.>7N5'\\ [@3(1( ^"^$3@!A(H"([A4MAK>2]
M">PK1@,7Q="%YXO7[*#+;\B3%D2H)G$5SDQ&1Y@0LP,'1-;Y P,[G,"7P#9#
M<B=R7>1%,86LE<:$3\5QM9"K0EH1!E9+67[.D-G9P;U)ONSGG!-2*C\K>7[G
M02/A4L6AE#$CYM7#K-JX@E*06*,)AB(!4&<ZAZ/!4$WG>K;'^/*"P/HG4=T3
MT+W^(AG21-$4\H PC6D2)?D_G @"]8PV3"0/?"02%.- <%/HK"' +!QR,R%[
MJK:!KI\9)YE8]WUD9:NN'3JQ*E)<%^$T31-.GF "6 ,>N8)B16"GY%P(%_'(
MVA%A5%%3?6!)R3;8;PRYL)/C5A@\A%1REV8'W60@4*]%[<5PO9N"F5*Y?+)$
M"KXO!)@]/[02 HN">1$>!R""MZ7DB7YE\Q8Q->?P P&_ZU'S]LQ0^C,*$.LS
M">H#5:D(^ $D$?)BJA.N@M$E1J'@>*Z+:=?;.$PC&]X4IU3*"(4)4,<Z<@71
M,(C)GZEL<*Y6A"CV%KP&!)\W]WQ$A$%ETOI$6*06N1M^7[#FD0*F1G?E.$-8
M$7DXQ:5?R94.MH@L]0*BU\'7D_S[&/L^+")F#4"!@*(E[8[8PX'PF;)4X0[Y
M1)UXB# #%.6[?\/T96 ]?7IW)53@6-#.#"5+#[51S"B%?H#U/Y)'T^TY68M!
M^C-CY;1]55ST2 7($JBM,)H* "@9(&@B5J,.0A-P=(SP\ODHPL)')?LB2R6J
M>LP6'!#%19!DHA8'R2QFQPW?9Y!D-D>28PWKZ4GUB#,C'J(A%:<!?2,FPKO;
MO]^\OY1,JHH12B+\QO6H22'\(YW!<]_-"!"!V1)R(QI/&A=\CG+;F-@HQ&)Z
M\$,+@39!L&&R?/!,NH!$R:X&GD>43V$J"K0E-Z#E)-.XJ#P':1UXP'YAVA)F
M2,9,=\KW*RA4L3&)^O(OZ#=''D_,A1_LKI2<=03\-4=)!#(@]:D<HTB7@V !
ME$W,LC-#BNOU5,KD%0AIP2,0AC9^RP9E118RD!:\MH96<).#;6IRDJ?E ISJ
M\(4BG>EH,8PE<(1_IRA*<%0QRJH,RR+F*WE(QK$H$\^?3]Y7P8U,Q4 )P3 K
MS:0YL>3 *(BRKLB%*"<LXOD2)9>S<(XOJ5#?H+F/$A-H2\>4<&3"3@'.!%C,
M$%M+)HQY.UY$2 [,"#C#XJ\,9>KXDJOSDPQ=EGH]TE,H638@ A7D5<Y0( ]%
MLR8=L2Z(\Q(>^EH</6;L!.43+<@/!$2I"P,9(VJ.@/7B/]?-$M!XB? C%Q>.
M+((_[(O" R7XB/";&>PK5Q3@5<VVX:2"X8VJ*5-(X5N<Q28N<^T4S>E(@TEV
M&)CL%'QD%5ADBFCE>1G=@$=K1K".G%;!(S-9'P0A4!GXGQS:.+RN;-<$ )&Y
M'H$0 VD<@[46$+3S F+RSYG)45&EUV(28S4HH\4$_<!!KD\CJF S1T-Q(Q4P
M3QA4AZS/*+DT!)2L<:H*$$K=CVDJYT;9'],(3)MY&&$&;/ 79J>S8//0R"D1
M]2YBQT0.?@'XT>0E ;T;,I#IL:[1LHJG@<2-T_DB.]H0L(KZ.@G9IDF.G$#4
M26[V952?6?%D ?FANB7FU#"<FEO%&C+60E5G8%\^O'!5=&2J?[DVV"[!LI@8
M#D2-I5!ZIE]ZP8RBCO^<*QA0%UA3+9K=R6S(:\'OB+;C.QDV"F ] P<A#\XT
MUC N3F;9;;0V:+D:"UL9PD!8DT===/%[+R:R-B8WM-1#>K^@E_9BT.O=[>?/
M-_>?/WRYOWO3;S+=KCOU^K;3K%NO+&J6B+"MF[8J6I:I*:9N.,A0'4N27>TX
MW:DK49^JW[J]//-]L\RSO93Q*;^Q&^OF1/H#7BX9BZ2Y8QJZZNS%+[3N7I?B
MT4RB6YS9M_ 9PG%"A66L)[_- %]?MU"GI=56VH>3=#T?I!-J-37=-%T)::9L
MJ8HC(LU5K*F%)1E-9<U%G%IA+XK16VJ57O>:6G?HO%_Q>H26#Z'?3'%#ST)$
M"=ECZCDH4#<WUT*NZ&&GXA^+P4](]*K"F5D)Q\(US<[RTJ]/;8DGHB%E?OT)
M64.44+5F L[]!SH?J7PG6<QZY;N?;*5?"OU4RVCK>^$!IGD4+K%]8.Y+G#NU
M<L]WU1)F?N#L#"85-"'W*%?37P!=9/(?4'H7;$9>,9ZA&5'H0_/7$>L?$^W8
MJ1UW'LY=L&%0--8#T8^P&LO#/P$W)[D?"#T\0* P(8JX0GACOBUF[N9_4=0J
MW_G* 7= ))!3^H&=UP01_13BN-D$'C!Y@X!JX^",9\D<9'^?;OZX_7;5P*P:
MOOZ^ &#E/K-2]C3%TAQ8998D2(FI6/0:\EB!067;?Y$FJB()KX(POY.27O&X
M[%:?><8CC(5G0L'Q%8W0U@-_+ZT:5APQ#T8M#!AE>D+F5JF%,RI:_%_DB6AH
M8*&OY4=9+!BPESELF6.G"J?&2*7PZB^*/!'(OR@L_T*(*(<"6S&! B0F3JB3
MFUY#;R.["&'LT .P)A;?S#:1PZUFUS;-)'F]([)4^;7C.8#X^8$)\-TZ%,BS
M8>CIL5$$C0>WLM$7UG=ZL\=R=61@$YD(RZII(21*BFTZAF1;^M22=*Y(445*
MZZTB)8].D<KS'?*@Z213;.#K.:._F+ HZ!*5T >_ J\0<HEP$2INC(QQ9P^)
M7S,^]R<$'>="T9OX?465RA?0\+Q*JAE[2CW;C&;,%9DNEV6X&D7S7$S^?]B*
M"!2^!QZ=5$98-_GA;SA*0:K/ST@9>WDEN]%XJXK=E9['XW(IE8O+$IU6!'1%
MV<IPC,HTFR@^N9,2$7D37);?,13!A82IIL\RAS#!CCP<D#UT@2 >%%\)&]96
M\Q57D85I>V"8L*<U.16Z@6:34#[J(KY556T)5&WRWP G5*^NI1KE@,\A/E98
MK3+S5A0+6])5PAGUZ52250,[IJ6[JBJ;2%,MY,KFL16+%>6B706C!7&KRR\K
M&9M$02N+V*QL>!M\K"V\?$>%XU#Y >2_+@0B54,@QB^9M<T<-@6GSW*DWQ5%
M$9D/(+4N<[X>1@6+KS#R*C_9.,]L@S;P$AJLUPI62*!!.S@4KHT[:]Q12UK
MQD?MPH^C7)71@1HVRY+"_*9U'MX\CR7F"0';&<0T&X>9X"NU)[0R(JY*^(V
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M=C@UTS^"4D0WEE9@LAKQ9@L[T\P*K2&S(L)V&-B>G_5+2*O0K:J<821@9,_
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M2*2:I.)X__JM=]1%43XB)_$A8'K@2&)5L>K5N]_G29K\2S *?1^^V+HA+9?
M-Y =#'6O\!-K?S9<@M[MR01.VW/*!6#L3<8' UZ%M7X OPDP CMF*;#"M^V'
M!A;VV/C2L2HV6;0UE\:F6WT/PWZ(&_P+?5?$+TD##+/]730($//T<;?#:3XN
MYF'LC^-Y',>3=#)/8G\2%/X\\Z>SO2?B'IZ(^AEY(@!"5]Y*0O38>R1V%8<_
M2=4G(V!BO:N@,&747V.P-1XFU&HL8TY-!#PPN3B%R :?4F@';!A)'V#35VM
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MDD_;%9=N#7QNRU?\N?7VO0<=56!0)+ R\+4Y:# ^GC*A>8-94]]%&$,IW*!
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MQ0/%/%BZ%?)(N'Z%O'S>NLI5086K<<S\V<C;OI\.ZA;"A/LS!W#+^Y_+$B4
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M%$'-!@%-HFX:2I=N-LBRK#!>W4LE--Q[D+ E8=AFTQW(^]A#::@#DG#Q>Q?
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M]#X%#BV_^>MK6&;Y!OY?_O/_ %!+ P04    " !:/612@+4APM<0  "]GP
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MT"8;U);E+WCC+5VN.5!DT<V$HF3G2'JS&07<)CM.&LYVZQ'8<V-+[,#%C30
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M7)*#=($B):7.%/H][IA@:7 \D1 :N0+%=Y.85<X;Q@Q6F9@6=?>S\F8Y3B1
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M4=:"(F-N--2K:I''1'J&>SQ/Y:Q05BRM3%UU47X>'UW;B!^OF79 C)9@S3V
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MOCPB+EI?O[AY5SN:K/H;3E5K?RXZ+@- B<298T#STP2Q)(Z\.\I&02Y*+N-
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M^#GA5#OYG/Y#+X.33_X?4$L#!!0    ( %H]9%*4WIO'@UP  )?T!  5
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MIY"Y6 %H=QU&NS#BVPLQN-_/-' ]&B^IFT9>XFGV&@^2-"3@#C"UBL@>8M!
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M9'!LGAAIZJ^;B"'AW,>X6LJW#OQHX-Q#:>DDY?YZ,9TLI^2/-U/QIS^1V5E
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M?-2?IXO)_?647$WOI[<S-)?KPNW6$UX[N.0AW]RA 6SM=!EKN\@8&+?=S6L
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M$Q4)$#9% H2X2("  S^W842]YT"LO=WZVB=8\[_ZXHZ^W2!W@+PA47FPV54
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M[ZP5.%WVM,4XE<U@,=^P\7++=' =WQP6:Z1&U@P6JDIM GT$<E=S+I[<"4.
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M]@?$:%\CV2PJ&S?#BWA#NE,>VWC7=WTBDJ[M[9=H!4-+?:1&")@BCVXJQ/Z
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M68_L!-1VK$.0VI!G=HH=N#V.GA%.W1+AQ-XQ[Q:QT\B/<&Q[8!5K_],M7-8
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M%3$/-(+#I*1+%M15@(4'B$)#(!2?S(.BDF*-",R>R0J:7O&+ #AN!SZ^F0=
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M,"G%KDMH-T!11 %/PLB]]Z6((DGDGO6G;+S_N@7Q-4'*G1VZX7A9F-TN^3]
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M7SO3GM7M3 ;SSM#ZTWX4,P(59U'@?'T./"(L(:TJ23U2$2!23]9/YZ'K\+*
MHG=GA]SDW^'=[M F2P7]8N.%[ C=W"=,.7Y Q*!XY&N."Z:<UV5T\,B G.\;
M&-L086E:P8IRU0"G-+H>KJ7$;6LP2ZOB:O!LW*KBFE45EW.6ZJTW7K!#@A+>
MM%FIE4Z?R8EE;ROIT>U:N0N(;H^7]RY&#ADV[#[;+E[;OLC7(NNC+8BOD=+$
M,([H0ZSWBIR8'CL 1:-Y;;6%YC2"D)@#+?E^:#[MV(ML/Q(N6.5F^DJT-+-D
M\0AOB<^CP-\ODF.??T5!&W/:ZBO]T0S'A2RX_!"CQ)PD7^%8TVF[0K,KMZ2K
MB<ZY_DP^2W-)/9#C+R:>[8_L->*:W= S8ZVOF2$^E:*O>F:N17\;UZ(U?.U9
MU2GFI7KTZ17![)&[QN_]SL)NVDNAM*D?W+I= @Z:<;'R.W6/"ZREM%VA&?0R
MI+7G?V<$LY)#9H WBY]"=^':>)=4OF+2)MZO!5W,6'Q;=W;R&9#S2N@$]3 M
M*IOCY9P0'-H.JP\NVY4!?0V!62:Z1=@ E+7C NM/QL+C3>[WVHOMP&4G?Y(I
M46C&ZC;![I;F-O1L)RD4*]FC>.VAJ+3V7%4=%0E%)J$T$*A'VF:@K"$?VPNC
MJ(M%B4XSV)_&[K Z63E2R-:8_XW8)E 9PY#=HV4C084CN2!%0^1 9B54M34#
M5W5I%@#7KEGPZ)-17[ ;"7S[M&%%.^@BV%JX(%]8\F8!ET(S5C[Z="SPV4K.
M%#SLQ-%S@#G%+'/OS;B==$?3-A8,4\Q/*>>4<9 2V1QC%O.X8&_[)@BSN8.@
MY7?6'JA[!HQEK#,#Z]J<2$1X$(8Q6@Q\0IP;"!2^X<]HCP)N2WY:@<,@27N2
MD_94)*UONYAI4(=0M]XP2X26#::.74FYBC:_J3OU6KLRV"I0!@ED'0:.8FJ&
MI8>>L+.U78\>8OH!_DQ=U"VL@M(OZDX$9]Z"" 3IPD5QG&@9(RG,UGWVJ*@%
M*11]3'<N.O,$4 Z-0;)79[E/"?P-A61]/U:W%G9DX==TY\8S;R\&@&.0^)V@
M7^,X"B/;IT_I"I69>J\(.VZ()MAU1(^:SC4!W0G]C%TB%2&\<+EE_Z-Z2<A-
M-@79 ::QK^A.,FB>! K ,$C,ZFP ><I8^>WP\.Z\A>U9_#G=20W-VY\A\%RX
M!!Z9()D!O/<1M.&UD7Y1>TI%\P01B)(9LIA%^L\0WA*+H)J;H\#?,FH8?>&<
MYH?,_Y[6!AP%T1<4T;)**U]\5=7B)[6G?6Q-&EO'J:7W-,U---6C *<_HNTX
M5]-M?U3?FZK6Q.P<;#-IW6OPA#7P(^SZH>NP]?TLQ^+B)Z$">:%7)VWB9) X
MGF!LI,=ZZH\_)K-%HU#T37UO($TW"^5(&221Z?6W1(;VK:"H7^B=18$;YN'$
MG'KR@")!%RB"%^KW%_&I)0.XLU@P\\?VQICL0O1=")O)),;.,R6"8\,"^IG_
M\K"6&0KFF"$*2$/3$KFZC_'>ZYG,>81>V*^$Z;IA_:%H7Z"O68F#EY^!8((#
M!Z%%2#-94MILWR&V )%YVYO$3Y[KC)>$+,('OM H# &5F\MS%2OS4:?HB/PC
MARA#&?S[8SJWB_ZG>NWY)B1\,F,_Z'IV&(Z7Z>OJ,69W$?MX >303-$N"KNV
MYZ'%W2YM%Z8-!1O%R0-#1>/RO*,-\=P, :I:UL;+7!R\VK90Z H5@@OR7<*)
M-PGF+O6KXI#0GC[;3):XY,<1$L4P +J:G\BB_H,0(-_,@/D>/44#/XQP3"E,
M9^D^>>A !SN."N!6& (*^^7YW93Y: ;\U?FP$[G=>*YR8O1\3_WO_UL]$0*X
MUI+/YB[PXY#G1*,M\@V@*%R0RZQ((I?9&HLH'%[*Y][&/(:TVD<OC-RU':%]
MS(6PSL)'29V%[$-6L+1RG[+HMZPHL+*O6?1S%OO>K2+#K2+#K2+#K2+#K2+#
MY51D4#^FISGVQ"EHCEM]&R ?T]Q**8;::,E2R)B9N+5*UCA,O^2R":TY'L7Y
M,%NLC #(,@Y.,:[*3(W<Y-.GKW#!Q17R;;%J3KD&<+,YOF\U@*^K!G#S2\FM
M!G!K&77TU !N\)0&>5ZL]@+X<EQO%30:AT\=@D69;.YIJ1+D+Z9VU$;X//S3
MNLU4\Z+H56&[8BG]+:!%=#PWVFF0T^+';^G:3H?N"F5UZH9?^QC1EP6(2$1T
M1DFM_O1UIW0[!VP&26F=5R^7G6KP\L(DV@>JX2!:(ZZ0V1U9\D"KXT3$KHEV
MPCOC'Q3NC-G85C*XE8U^NR&^W1#?;HAO-\2W&^+;#?'MAOAV0WR[(;[=$)_]
MAKBUTXUQ%\3GLP7*:4>F@>?U TQ_V8)](/G>5=^/M(;/U<E@\A3N+.*7?4KW
M@MZRA+0FCL=0U7:V;)(G])&-(_T/WD]ES\4DXS?OOD6'-,,2]%]H\@9ALHJ<
M'S%+]"3,GE1CK(N]4:DEB;69K2YHGQ)!\]&*%A@S0-!.9'3O=>-BUB=LL9J8
MZ&.ZCR$7M6@*X+K),F']$KE13%. M"[+E1^[V&H\.F19 -=-EG4>R_[X<,&5
M?8PXF%$.-G(TZ_E7(,NY9*9MRW+%IRZV_(\>^X(#U4V.P?62*$K+,[IRP7.Y
ME2%J'-BK\P%?1RTW\[)4GBYIIM1^NV8/,S=,H=)GV9*N-#F)RRV\=':%:1[[
M"]D<9(1GM.F6>\5Y:'\ ?SVB7TL"KD;Z2QY7;?*O.)/++4!EH ;4DH(KT8$*
M3ZTF'5">R>76O#).!VI*P87HP)4<D15\]P:6U;K04_+-W<_Q(>M1%? $+K<2
MF6F*HHCY34W\\%# ZO!&- 2\JFSWLU=>VJUMO PR=I[DI#XI+RM31-]JD)]W
M Y\1'ML>???]02*PYY[,Y1:]4Y*V9HN.G@![FW7!FZ&(N6]/D.9]>2DMT[G<
MLGYUY%DOK_7'H+>O#>E9'A5/\!HUHL:4+K=HH0%:45L$KN!UQHE<Y)]V>,P[
M3X%U^&0NM_ZC1OOH!-A-K8K36RZ1$Z4)'-Z4>#,CGTY\P^/EF)R]DQL08=*C
M'Q62'B5?9^F/#M^W\A.P#C.@S0YSN*5&:CTU4O;T?H;PUG401V,]-A>7UMF;
M(B=8^>Z_B?(P-TTW"*,0G":IT<^9D6[CQ)1)C7+$D/1)S=!4\O64!:OQ#QDB
M4FVJ9T$2&V>A(1F7!C[9%=%^9QFF\Q<G8!)V^O9D0\@.,U(U<:8HR]PDZ68&
MU  1A@'64)JG9A";$E82-CQW_,4]VB(OV-"ITORB?LBO 9+V!G76G6\$)),%
MY!2X8L;UPV?D$S/=(_/M+-;D6$3-G<C=(B"0P.ZZDVW4@5*),V: 6;UWJ-Y/
M:L\QU9+=";IC-,<),+=?43CV$]$=V3B1/N%Y_J?B>7[>^6=O9HU'UF#4'3_T
MK#_MQS'C3)X01R@]S%I^(!=VTF[#D'E1QY+KKY#O["0G:D$7DVP7(4"5MDLE
M288<:^G<,%JX49<HPRZ-M0&<4F7]#$.,)X4%O&14M7,.!%7H(A205=%=T"P1
M/4),Y**07^Z/W_K"@!'2TLIQK38:W/,9AP9##F9"#H/ :/,H!D)C%C^%[L*U
ML2O()DL:5K73EL5)PLP2Y_E$FF%O)W<BQ)K:ZS:M\T*M4=]Q/3=A:-1'"WJ0
MH*>/F$QD=]18X!1M8G#-ECQLJRVZ,IOC:DNA3N0K=^1TN'0C;N8JVJ[<3+=+
M0PV/:AI,4L#TCM%?#8,PS-,D,.-$?73[*6KIBYP)AAUF#[[O^S0D9:^\2'QA
M_6?I 3=_99V-;B7#6VS\V\&W<6(R/I.9=<(01>$(17)JQ+TT;USJYUX($\Q8
M-$LSK;.**@VB>]L#82.!L]8J:P*Z W^" P>%8?7=A +$TI%T;Y]-X QDU^4'
M5I8E/'H67?7PVNM.7]V(<N=)-U2/:2G'_<W'B^V+7F6".NM.YMP$<'RF7'Y:
MVA*Q0]=^HC6/7419I8!^L:/NU,=-(%_-C-K+<A1$MJ>WD.G1&2F7/G2\+$NY
M\)3TL_241$>WTN'I26G_ 6O_A5//27S7B2J1@J-$ZJ&H/Z))ZJUK@6]<RT]&
MI<&UWX3[X&/79?>9/F$8^"?AW\38VDYE[<A'<^R^\'K8\6;CL3 G&^_ZKD\H
M<Q,_.?OAP"?GUG7R8F3OAV/V;\=Q@MB/PHF]H]>2(8U\<AP<VY[8*?>I](KD
M<3(9]AYZHWEG^L7J#T:=47?0&5JS>6?.?DSVH?YX^M"9#\B>=.2R8Q.QLIE8
MV50LVU]8V63,\.!5<$GN\Q)VTKA4L<D0(3_85-T88Z%W0-!%L^\.@$QAZ9"2
M;\:&4E#01[(FX!?L1@B'$\*$@/Z%$+TOP\F4:4[6OYGML3M4\LO?[14,W(:_
MI-L%6$LH6N&V&;*4K?BJ:B_KI]L%J(XSC!.7[^\KR#,C6W4A..ZDV_-WLDY7
M\>"2/0A3Y%'7U<3&+*Q&8+3]^*YHM$U[0V*=W5N3SG0^Z,V,L+%R].SFV/9#
M@BQ[4"XUM.0]C7BVRYOFW>[H-]!GN4K#F1$5"868^_!6B69#(I Y<Q[*8Y#E
M/<V ]201+[VIDM%LR%O5?;CBCIB A'3VI%S\4E70Y?J %!!KQBO4W+1&]IK\
M-4>G["DJI*\AD,K$M @;@#(CGJ1.L+LE@CCQ;(>YNF2/%WGM=9]5X6)80$K,
M #,.GBRZ BW"/J&:UH&FCM?QLANLUS2%#2%9A)>TJV;7$W1C+^$&Y(E2(&?Z
M&_H_FJR'_.3_ U!+ 0(4 Q0    ( %H]9%)"=C?0@/D  ,?U#@ 1
M      "  0    !S;&=L+3(P,C Q,C,Q+GAM;%!+ 0(4 Q0    ( %H]9%*
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M '-L9VPM,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( %H]9%+(*TU6+3P
M -[= P 5              "  6*@ 0!S;&=L+3(P,C Q,C,Q7W!R92YX;6Q0
52P4&      8 !@"* 0  PMP!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
